FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Mayer, DK Gerstel, A Walton, AL Triglianos, T Sadiq, TE Hawkins, NA Davies, JM AF Mayer, Deborah K. Gerstel, Adrian Walton, AnnMarie Lee Triglianos, Tammy Sadiq, Teresa E. Hawkins, Nikki A. Davies, Janine M. TI Implementing Survivorship Care Plans for Colon Cancer Survivors SO ONCOLOGY NURSING FORUM LA English DT Article DE survivorship care plans; colon cancer; communication; transitions; survivorship ID COLORECTAL-CANCER; FOLLOW-UP; BREAST-CANCER; PRACTICE GUIDELINE; PREVENTIVE CARE; PROVIDERS; PHYSICIANS; ONCOLOGY; PERSPECTIVES; KNOWLEDGE AB Purpose/Objectives: To evaluate the feasibility, usability, and satisfaction of a survivorship care plan (SCP) and identify the optimum time for its delivery during the first 12 months after diagnosis. Design: Prospective, descriptive, single-arm study. Setting: A National Cancer Institute-designated cancer center in the southeastern United States. Sample: 28 nonmetastatic colon cancer survivors within the first year of diagnosis and their primary care physicians (PCPs). Methods: Regular screening identified potential participants who were followed until treatment ended. An oncology certified nurse developed the Journey Forward (TM) SCP, which then was delivered to the patient by the oncology nurse practitioner (NP) during a routine follow-up visit and mailed to the PCP. Main Research Variables: Time to complete, time to deliver, usability, and satisfaction with the SCP. Findings: During one year, 75 patients were screened for eligibility, 34 SCPs were delivered, and 28 survivors and 15 PCPs participated in the study. It took an average of 49 minutes to complete a surgery SCP and 90 minutes to complete a surgery plus chemotherapy SCP. Most survivors identified that before treatment ended or within the first three months was the preferred time to receive an SCP. Conclusions: The SCPs were well received by the survivors and their PCPs, but were too time and labor intensive to track and complete. Implications for Nursing: More work needs to be done to streamline processes that identify eligible patients and to develop and implement SCPs. Measuring outcomes will be needed to demonstrate whether SCPs are useful or not. C1 [Mayer, Deborah K.; Gerstel, Adrian] Univ N Carolina, Sch Nursing, Chapel Hill, NC 27599 USA. [Walton, AnnMarie Lee] Univ Utah, Coll Nursing, Salt Lake City, UT 84112 USA. [Triglianos, Tammy; Sadiq, Teresa E.] Univ N Carolina, Canc Hosp, Chapel Hill, NC USA. [Hawkins, Nikki A.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Davies, Janine M.] British Columbia Canc Agcy, Vancouver, BC, Canada. RP Mayer, DK (reprint author), Univ N Carolina, Sch Nursing, Chapel Hill, NC 27599 USA. EM dmayer@unc.edu FU Centers for Disease Control and Prevention [5U48DP001944] FX Deborah K. Mayer, PhD, RN, AOCN (R), FAAN, is a professor and Adrian Gerstel, BA, is a project manager, both in the School of Nursing at the University of North Carolina in Chapel Hill; AnnMarie Lee Walton, RN, MPH, OCN (R), CHES, is a student in the College of Nursing at the University of Utah in Salt Lake City; Tammy Triglianos, MS, APRN, AOCNP (R), is a nurse practitioner and Teresa E. Sadiq, FNP, is a clinical instructor and nurse practitioner, both at the University of North Carolina Cancer Hospital in Chapel Hill; Nikki A. Hawkins, PhD, is a behavioral scientist for the Centers for Disease Control and Prevention in Atlanta, GA; and Janine M. Davies, MD, BN, MSc, is a medical oncologist at the British Columbia Cancer Agency in Vancouver. This study was supported, in part, by a cooperative agreement (No. 5U48DP001944) from the Centers for Disease Control and Prevention. Mayer can be reached at dmayer@unc.edu, with copy to editor at ONFEditor@ons.org. (Submitted July 2013. Accepted for publication October 4, 2013.) NR 56 TC 9 Z9 9 U1 3 U2 11 PU ONCOLOGY NURSING SOC PI PITTSBURGH PA 125 ENTERPRISE DR, PITTSBURGH, PA 15275 USA SN 0190-535X EI 1538-0688 J9 ONCOL NURS FORUM JI Oncol. Nurs. Forum PD MAY PY 2014 VL 41 IS 3 BP 266 EP 273 DI 10.1188/14.ONF.266-273 PG 8 WC Oncology; Nursing SC Oncology; Nursing GA AH3EX UT WOS:000336007600009 PM 24769591 ER PT J AU Nahid, P Bliven-Sizemore, E Jarlsberg, LG De Groote, MA Johnson, JL Muzanyi, G Engle, M Weiner, M Janjic, N Sterling, DG Ochsner, UA AF Nahid, Payam Bliven-Sizemore, Erin Jarlsberg, Leah G. De Groote, Mary A. Johnson, John L. Muzanyi, Grace Engle, Melissa Weiner, Marc Janjic, Nebojsa Sterling, David G. Ochsner, Urs A. TI Aptamer-based proteomic signature of intensive phase treatment response in pulmonary tuberculosis SO TUBERCULOSIS LA English DT Article DE Tuberculosis; Treatment response; Biomarkers; Proteomics; Multiplex analysis; SOMAscan; Logistic regression model ID DRUG DEVELOPMENT; MYCOBACTERIUM-TUBERCULOSIS; RESISTANT TUBERCULOSIS; CULTURE CONVERSION; SURROGATE MARKERS; SPUTUM; BIOMARKERS; CHALLENGES; SELECTION; REGIMENS AB Background: New drug regimens of greater efficacy and shorter duration are needed for tuberculosis (TB) treatment. The identification of accurate, quantitative, non-culture based markers of treatment response would improve the efficiency of Phase 2 TB drug testing. Methods: In an unbiased biomarker discovery approach, we applied a highly multiplexed, aptamer-based, proteomic technology to analyze serum samples collected at baseline and after 8 weeks of treatment from 39 patients with pulmonary TB from Kampala, Uganda enrolled in a Centers for Disease Control and Prevention (CDC) TB Trials Consortium Phase 2B treatment trial. Results: We identified protein expression differences associated with 8-week culture status, including Coagulation Factor V, SAA, XPNPEP1, PSME1, IL-11 R alpha, HSP70, Galectin-8, alpha 2-Antiplasmin, ECM1, YES, IGFBP-1, CATZ, BGN, LYNB, and IL-7. Markers noted to have differential changes between responders and slow-responders included nectin-like protein 2, EphA1 (Ephrin type-A receptor 1), gp130, CNDP1, TGF-b RIII, MRC2, ADAM9, and CDON. A logistic regression model combining markers associated with 8-week culture status revealed an ROC curve with AUC = 0.96, sensitivity = 0.95 and specificity = 0.90. Additional markers showed differential changes between responders and slow-responders (nectin-like protein), or correlated with time-to-culture-conversion (KLRK1). Conclusions: Serum proteins involved in the coagulation cascade, neutrophil activity, immunity, inflammation, and tissue remodeling were found to be associated with TB treatment response. A quantitative, non-culture based, five-marker signature predictive of 8-week culture status was identified in this pilot study. (C) 2014 Elsevier Ltd. All rights reserved. C1 [Nahid, Payam; Jarlsberg, Leah G.] Univ Calif San Francisco, San Francisco Gen Hosp, San Francisco, CA 94110 USA. [Bliven-Sizemore, Erin] Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA 30333 USA. [De Groote, Mary A.] Colorado State Univ, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA. [De Groote, Mary A.; Janjic, Nebojsa; Sterling, David G.; Ochsner, Urs A.] SomaLogic Inc, Boulder, CO 80301 USA. [Johnson, John L.] Case Western Reserve Univ, Div Infect Dis, TB Res Unit, Cleveland, OH 44106 USA. [Johnson, John L.; Muzanyi, Grace] Uganda Case Western Reserve Univ Res Collaborat, Kampala, Uganda. [Engle, Melissa; Weiner, Marc] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Infect Dis, San Antonio, TX 78229 USA. RP Nahid, P (reprint author), Univ Calif San Francisco, San Francisco Gen Hosp, 1001 Potrero Ave,5K1, San Francisco, CA 94110 USA. EM pnahid@ucsf.edu; uochsner@somalogic.com FU National Institutes of Health through National Institute of Allergy and Infectious Diseases [1R01AI104589]; Centers for Disease Control and Prevention TB Trials Consortium; SomaLogic, Inc. FX Funding for recruitment, enrollment, and clinical and laboratory follow-up of TBTC Study 29 participants was provided by the United States Centers for Disease Control and Prevention. The work of P.N. is supported by the National Institutes of Health through National Institute of Allergy and Infectious Diseases funding (1R01AI104589), and by the Centers for Disease Control and Prevention TB Trials Consortium. The entire sample analysis was funded by SomaLogic, Inc. No additional external funding was received for this study. NR 48 TC 20 Z9 21 U1 3 U2 21 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 1472-9792 J9 TUBERCULOSIS JI Tuberculosis PD MAY PY 2014 VL 94 IS 3 BP 187 EP 196 DI 10.1016/j.tube.2014.01.006 PG 10 WC Immunology; Microbiology; Respiratory System SC Immunology; Microbiology; Respiratory System GA AH1WY UT WOS:000335913700001 PM 24629635 ER PT J AU Joloba, ML Johnson, JL Feng, PJI Bozeman, L Goldberg, SV Morgan, K Gitta, P Boom, HW Heilig, CM Mayanja-Kizza, H Eisenach, KD AF Joloba, Moses L. Johnson, John L. Feng, Pei-Jean I. Bozeman, Lorna Goldberg, Stefan V. Morgan, Karen Gitta, Phineas Boom, Henry W. Heilig, Charles M. Mayanja-Kizza, Harriet Eisenach, Kathleen D. TI What is the most reliable solid culture medium for tuberculosis treatment trials? SO TUBERCULOSIS LA English DT Article DE Solid media; Mycobacterium tuberculosis; Drug trials; LCA ID LATENT CLASS ANALYSIS; PULMONARY TUBERCULOSIS; MYCOBACTERIA; DRUGS AB We conducted a prospective study to determine which solid medium is the most reliable overall and after two months of therapy to detect Mycobacterium tuberculosis complex (MTB). MTB isolation and contamination rates on LJ and Middlebrook 7H10 and 7H11 agar with and without selective antibiotics were examined in a single laboratory and compared against a constructed reference standard and MGIT 960 results. Of 50 smear positive adults with pulmonary TB enrolled, 45 successfully completed standard treatment. Two spot sputum specimens were collected before treatment and at week 8 and one spot specimen each at weeks 2, 4, 6, and 12. The MTB recovery rate among all solid media for pre-treatment specimens was similar. After 8 weeks, selective (S) 7H11 had the highest positivity rate. Latent class analysis was used to construct the primary reference standard. The 98.7% sensitivity of 7H11S (95% Wilson confidence interval 96.4%-99.6%) was highest among the 5 solid media (P = 0.003 by bootstrap); the 82.6% specificity of 7H10S (95% CI 75.7%-87.8%) was highest (P = 0.098). Our results support 7H11S as the medium of choice. Further studies in different areas where recovery and contamination are likely to vary, are recommended. (C) 2014 Elsevier Ltd. All rights reserved. C1 [Joloba, Moses L.] Makerere Univ, Coll Hlth Sci, Dept Med Microbiol, Kampala, Uganda. [Joloba, Moses L.; Johnson, John L.; Morgan, Karen; Gitta, Phineas; Boom, Henry W.; Mayanja-Kizza, Harriet] Uganda Case Western Reserve Univ Res Collaborat, Kampala, Uganda. [Johnson, John L.; Boom, Henry W.; Eisenach, Kathleen D.] Case Western Reserve Univ, Sch Med, Dept Med, TB Res Unit, Cleveland, OH 44106 USA. [Feng, Pei-Jean I.; Bozeman, Lorna; Goldberg, Stefan V.; Heilig, Charles M.] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis & TB Prevent, Div TB Eliminat, Atlanta, GA USA. [Eisenach, Kathleen D.] Univ Arkansas Med Sci, Dept Pathol, Little Rock, AR 72205 USA. RP Joloba, ML (reprint author), Makerere Univ, Coll Hlth Sci, Dept Med Microbiol, POB 7072, Kampala, Uganda. EM moses.joloba@case.edu; jlj@case.edu; ewc6@cdc.org; llb1@cdc.gov; ssg3@cdc.gov; kammorg@gmail.com; pgitta@mucwru.or.ug; whb@case.edu; cqh9@cdc.gov; hmk@chs.mak.ac.ug; EisenachKathleenD@uams.edu OI Mayanja-Kizza, Harriet/0000-0002-9297-6208; Joloba, Moses/0000-0002-0334-9983; Heilig, Charles/0000-0003-1075-1310 FU Tuberculosis Trials Consortium; Centers for Disease Control and Prevention [200-2009-32598]; Tuberculosis Research Unit at Case Western Reserve University; National Institute of Allergy and Infectious Diseases; National Institutes of Health and Human Services [HHSN266200700022C/NO1-AI-70022] FX This work was supported by the Tuberculosis Trials Consortium (sponsored by the Centers for Disease Control and Prevention under contract 200-2009-32598) and the Tuberculosis Research Unit at Case Western Reserve University (established with funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health and Human Services under contract HHSN266200700022C/NO1-AI-70022). The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the funders (CDC and TBRU). NR 22 TC 2 Z9 2 U1 0 U2 5 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 1472-9792 J9 TUBERCULOSIS JI Tuberculosis PD MAY PY 2014 VL 94 IS 3 BP 311 EP 316 DI 10.1016/j.tube.2014.03.002 PG 6 WC Immunology; Microbiology; Respiratory System SC Immunology; Microbiology; Respiratory System GA AH1WY UT WOS:000335913700017 PM 24698569 ER PT J AU Heilig, CM Feng, PJI Joloba, ML Johnson, JL Morgan, K Gitta, P Boom, WH Mayanja-Kizza, H Eisenach, KD Bozeman, L Goldberg, SV AF Heilig, Charles M. Feng, Pei-Jean I. Joloba, Moses L. Johnson, John L. Morgan, Karen Gitta, Phineas Boom, W. Henry Mayanja-Kizza, Harriet Eisenach, Kathleen D. Bozeman, Lorna Goldberg, Stefan V. TI How we determined the most reliable solid medium for studying treatment of tuberculosis SO TUBERCULOSIS LA English DT Article DE Middlebrook agar culture media; Lowensteine-Jensen culture medium; Composite reference standard; Latent-class model; Mycobacterium tuberculosis ID LATENT CLASS ANALYSIS; DIAGNOSTIC-TEST; GOLD STANDARD; CLASS MODELS; TESTS; PERFORMANCE; DEPENDENCE; AGREEMENT; ACCURACY; ERROR AB Phase 2 clinical trials for tuberculosis (TB) treatment require reliable culture methods to determine presence or absence of Mycobacterium tuberculosis (Mtb) over the course of therapy, as these trials are based primarily on bacteriological endpoints. We evaluate which of 5 solid media is most reliable: Lowenstein-Jensen (LJ) egg-base medium and 4 Middlebrook agar media (nonselective 7H10 and 7H11 and selective 7H10 and 7H11). We analyze 393 specimens from 50 HIV-negative Ugandan adults with newly-diagnosed, pulmonary TB and high acid-fast bacillus smear grade. Specimens were collected every 2-4 weeks during the first 12 weeks of therapy. We compare the results for each culture to 2 composite reference standards-one that was deemed positive if any solid culture was positive for Mtb and another based on latent-class analysis. Both reference standards established that the 2 selective Middlebrook media most reliably determine the presence or absence of Mtb (P < 0.003), largely because of their lower contamination rates. We also showed that results on Middlebrook media were similar to each other, while LJ was most frequently discordant. Contaminated results appeared more likely to be truly negative than to harbor undetected Mtb. Published by Elsevier Ltd. C1 [Heilig, Charles M.; Feng, Pei-Jean I.; Bozeman, Lorna; Goldberg, Stefan V.] Ctr Dis Control & Prevent, Div TB Eliminat, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30329 USA. [Joloba, Moses L.] Makerere Univ, Coll Hlth Sci, Dept Med Microbiol, Kampala, Uganda. [Joloba, Moses L.; Johnson, John L.; Morgan, Karen; Gitta, Phineas; Boom, W. Henry; Mayanja-Kizza, Harriet] Uganda Case Western Reserve Univ Res Collaborat, Kampala, Uganda. [Johnson, John L.; Boom, W. Henry; Eisenach, Kathleen D.] Case Western Reserve Univ, Sch Med, Dept Med, TB Res Unit, Cleveland, OH 44106 USA. [Eisenach, Kathleen D.] Univ Arkansas Med Sci, Dept Pathol, Little Rock, AR 72205 USA. RP Heilig, CM (reprint author), Ctr Dis Control & Prevent, Div TB Eliminat, 1600 Clifton Rd NE,MS E-10, Atlanta, GA 30329 USA. EM cqh9@cdc.gov OI Mayanja-Kizza, Harriet/0000-0002-9297-6208; Joloba, Moses/0000-0002-0334-9983; Heilig, Charles/0000-0003-1075-1310 FU Tuberculosis Trials Consortium; U.S. Centers for Disease Control and Prevention [200-2009-32598]; Tuberculosis Research Unit at Case Western Reserve University; U. S. National Institutes of Health [HHSN266200700022C/NO1-AI-70022] FX This work was supported by the Tuberculosis Trials Consortium (sponsored by the U.S. Centers for Disease Control and Prevention under contract 200-2009-32598) and the Tuberculosis Research Unit at Case Western Reserve University (established with funds from the U. S. National Institutes of Health under contract HHSN266200700022C/NO1-AI-70022). NR 24 TC 1 Z9 2 U1 0 U2 4 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 1472-9792 J9 TUBERCULOSIS JI Tuberculosis PD MAY PY 2014 VL 94 IS 3 BP 317 EP 322 DI 10.1016/j.tube.2014.02.006 PG 6 WC Immunology; Microbiology; Respiratory System SC Immunology; Microbiology; Respiratory System GA AH1WY UT WOS:000335913700018 PM 24661816 ER PT J AU Pavkov, ME Nelson, RG AF Pavkov, Meda E. Nelson, Robert G. TI Improved Early Risk Stratification With Cystatin C-Based Estimated GFR SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Editorial Material ID GLOMERULAR-FILTRATION-RATE; SERUM CREATININE; COLLABORATIVE METAANALYSIS; ESTIMATING EQUATIONS; POPULATION COHORTS; MORTALITY; ALBUMINURIA; ASSOCIATION C1 [Pavkov, Meda E.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Nelson, Robert G.] NIH, Phoenix, AZ 85014 USA. RP Nelson, RG (reprint author), NIH, 1550 E Indian Sch Rd, Phoenix, AZ 85014 USA. EM rnelson@nih.gov NR 27 TC 0 Z9 0 U1 0 U2 2 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 EI 1523-6838 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD MAY PY 2014 VL 63 IS 5 BP 745 EP 748 DI 10.1053/j.ajkd.2014.02.006 PG 4 WC Urology & Nephrology SC Urology & Nephrology GA AG5JZ UT WOS:000335456600416 PM 24602780 ER PT J AU Banerjee, T Davidson, L Steffick, D Saran, R Burrows, N Saydah, S Powe, N AF Banerjee, Tanushree Davidson, Lauren Steffick, Diane Saran, Rajiv Burrows, Nilka Saydah, Sharon Powe, Neil CA CDC CKD Surveillance Team TI TRACKING PROGRESS TOWARDS ACHIEVING HEALTHY PEOPLE (HP) 2020 OBJECTIVES FOR CHRONIC KIDNEY DISEASE (CKD) SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Meeting Abstract CT Spring Clinical Meeting of the National-Kidney-Foundation (NKF) CY APR 22-26, 2014 CL Las Vegas, NV SP Natl Kidney Fdn C1 [Banerjee, Tanushree; Davidson, Lauren; Powe, Neil] UCSF, San Francisco, CA USA. [Burrows, Nilka; Saydah, Sharon] CDC, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 EI 1523-6838 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD MAY PY 2014 VL 63 IS 5 MA 48 BP A30 EP A30 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA AG5JZ UT WOS:000335456600050 ER PT J AU Bragg-Gresham, JL Han, SW Morgenstern, H Tilea, A Yi, JH Ko, YS Pavkov, ME Williams, DE Banerjee, T Powe, N Saran, R AF Bragg-Gresham, J. L. Han, S. W. Morgenstern, H. Tilea, A. Yi, J. H. Ko, Y. S. Pavkov, M. E. Williams, D. E. Banerjee, T. Powe, N. Saran, R. TI COMPARISON OF PREVALENCE AND RISK FACTORS FOR LOW GLOMERULAR FILTRATION RATE IN US AND KOREAN ADULTS SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Meeting Abstract CT Spring Clinical Meeting of the National-Kidney-Foundation (NKF) CY APR 22-26, 2014 CL Las Vegas, NV SP Natl Kidney Fdn C1 [Bragg-Gresham, J. L.; Morgenstern, H.; Tilea, A.; Saran, R.] Univ Michigan, Ann Arbor, MI 48109 USA. [Han, S. W.; Yi, J. H.; Ko, Y. S.] Hanyang Univ, Seoul 133791, South Korea. [Pavkov, M. E.; Williams, D. E.] CDC, Atlanta, GA 30333 USA. [Banerjee, T.; Powe, N.] UCSF, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 EI 1523-6838 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD MAY PY 2014 VL 63 IS 5 MA 60 BP A33 EP A33 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA AG5JZ UT WOS:000335456600062 ER PT J AU Creanga, AA Bateman, BT Kuklina, EV Callaghan, WM AF Creanga, Andreea A. Bateman, Brian T. Kuklina, Elena V. Callaghan, William M. TI Racial and ethnic disparities in severe maternal morbidity: a multistate analysis, 2008-2010 SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY LA English DT Article DE ethnicity; race; severe maternal morbidity ID PREGNANCY-RELATED MORTALITY; UNITED-STATES; DELIVERY; FETAL; HOSPITALIZATIONS; PREVALENCE; INFANTS; RACE AB OBJECTIVE: The purpose of this study was to examine racial and ethnic disparities in severe maternal morbidity during delivery hospitalizations in the United States. STUDY DESIGN: We identified delivery hospitalizations from 20082010 in State Inpatient Databases from 7 states. We used International Classification of Diseases, 9th Revision, codes to create severe maternal morbidity indicators during delivery hospitalizations. We calculated the rates of severe maternal morbidity that were measured with and without blood transfusion for 5 racial/ethnic groups: non-Hispanic white, non-Hispanic black, Hispanic, Asian/Pacific Islander, and American Indian/Alaska Native women. Poisson regression models were fitted to explore the associations between race/ethnicity and severe maternal morbidity after we controlled for potential confounders. RESULTS: Overall, severe maternal morbidity rates that were measured with and without blood transfusion were 150.7 and 64.3 per 10,000 delivery hospitalizations, respectively. Non-Hispanic black, Hispanic, Asian/Pacific Islander, and American Indian/Alaska Native women had 2.1, 1.3, 1.2, and 1.7 times (all P < .05), respectively, higher rates of severe morbidity that were measured with blood transfusion compared with non-Hispanic white women; similar increased rates were observed when severe morbidity was measured without blood transfusion. Other significant positive predictors of severe morbidity were age <20 and >= 30 years, self-pay or Medicaid coverage for delivery, low socioeconomic status, and presence of chronic medical conditions. CONCLUSION: Severe maternal morbidity disproportionally affects racial/ ethnic minority women, especially non-Hispanic black women. There is a need for a systematic review of severe maternal morbidities at the facility, state, and national levels to guide the development of quality improvement interventions to reduce the racial/ ethnic disparities in severe maternal morbidity. C1 [Creanga, Andreea A.; Callaghan, William M.] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Kuklina, Elena V.] Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Bateman, Brian T.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Pharmacoepidemiol & Pharmacoecon,Dept Med, Boston, MA 02115 USA. [Bateman, Brian T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesiol Crit Care & Pain Med, Boston, MA USA. RP Creanga, AA (reprint author), Natl Ctr Chron Dis Prevent & Hlth Promot, Div Reprod Hlth, 4770 Buford Hwy NE,Mail Stop K-23, Atlanta, GA 30341 USA. EM acreanga@cdc.gov NR 24 TC 10 Z9 12 U1 2 U2 5 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9378 EI 1097-6868 J9 AM J OBSTET GYNECOL JI Am. J. Obstet. Gynecol. PD MAY PY 2014 VL 210 IS 5 AR 435.e1 DI 10.1016/j.ajog.2013.11.039 PG 8 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA AG6EF UT WOS:000335510700011 PM 24295922 ER PT J AU Parise, ME Hotez, PJ Slutsker, L AF Parise, Monica E. Hotez, Peter J. Slutsker, Laurence TI Neglected Parasitic Infections in the United States: Needs and Opportunities SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Editorial Material ID TOXOPLASMA-GONDII INFECTION; TOXOCARA C1 [Parise, Monica E.] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA 30333 USA. [Hotez, Peter J.] Baylor Coll Med, Natl Sch Trop Med, Houston, TX 77030 USA. [Slutsker, Laurence] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA 30333 USA. RP Parise, ME (reprint author), Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Ctr Global Hlth, 1600 Clifton Rd NE,Mailstop A06, Atlanta, GA 30333 USA. EM mparise@cdc.gov; hotez@bcm.edu; lslutsker@cdc.gov OI Hotez, Peter/0000-0001-8770-1042 NR 13 TC 7 Z9 8 U1 0 U2 7 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 EI 1476-1645 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD MAY PY 2014 VL 90 IS 5 BP 783 EP 785 DI 10.4269/ajtmh.13-0727 PG 3 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA AG8ZN UT WOS:000335707600001 PM 24808243 ER PT J AU Jones, JL Parise, ME Fiore, AE AF Jones, Jeffrey L. Parise, Monica E. Fiore, Anthony E. TI Neglected Parasitic Infections in the United States: Toxoplasmosis SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID TO-CHILD TRANSMISSION; CONGENITAL TOXOPLASMOSIS; OCULAR TOXOPLASMOSIS; PRENATAL TREATMENT; GONDII INFECTION; HEALTH-EDUCATION; IMMUNOGLOBULIN-M; MOOD DISORDERS; RISK-FACTORS; PREGNANCY AB Toxoplasma gondii is a leading cause of severe foodborne illness in the United States. Population-based studies have found T. gondii infection to be,,more prevalent in racial/ethnic minority and socioeconomically disadvantaged groups. Soil contaminated with cat feces, undercooked meat, and congenital transmission are the principal sources of infection. Toxoplasmosis-associated illnesses include congenital neurologic and ocular disease; acquired illness in immunocompetent persons, most notably ocular disease; and encephalitis or disseminated disease in immunosuppressed persons. The association of T. gondii infection with risk for mental illness is intriguing and requires further research. Reduction of T. gondii in meat, improvements in hygiene and food preparation practices, and reduction of environmental contamination can prevent toxoplasmosis, but more research is needed on how to implement these measures. In addition, screening and treatment may help prevent toxoplasmosis or reduce the severity of disease in some settings. C1 [Jones, Jeffrey L.; Parise, Monica E.; Fiore, Anthony E.] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA 30333 USA. RP Jones, JL (reprint author), Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Ctr Global Hlth, 1600 Clifton Rd NE,Mailstop A-06, Atlanta, GA 30333 USA. EM jlj1@cdc.gov; mep0@cdc.gov; abf4@cdc.gov NR 85 TC 25 Z9 25 U1 3 U2 27 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 EI 1476-1645 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD MAY PY 2014 VL 90 IS 5 BP 794 EP 799 DI 10.4269/ajtmh.13-0722 PG 6 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA AG8ZN UT WOS:000335707600005 PM 24808246 ER PT J AU Secor, WE Meites, E Starr, MC Workowski, KA AF Secor, W. Evan Meites, Elissa Starr, Michelle C. Workowski, Kimberly A. TI Neglected Parasitic Infections in the United States: Trichomoniasis SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID SEXUALLY-TRANSMITTED INFECTION; TRANSCRIPTION-MEDIATED AMPLIFICATION; HUMAN-IMMUNODEFICIENCY-VIRUS; VAGINALIS INFECTION; RISK-FACTORS; CLINICAL-MANIFESTATIONS; GENETIC DIVERSITY; PRETERM DELIVERY; HIV TRANSMISSION; HIGH PREVALENCE AB Trichomonas vaginaLis is one of the most common human parasitic infections in the United States, as well as the most prevalent non-viral sexually transmitted infection. However, it has long received much less consideration than other parasitic and sexually transmitted diseases. Much of this inattention can be attributed to a poor understanding of the public health impact of trichomoniasis. Increasing recognition of the sequelae of infection, including increased risk of infection with human immunodeficiency virus and adverse outcomes of pregnancy, has led to increased interest in T. vagina/is. Recent innovations include development of diagnostic tests that could improve detection of the parasite. A number of important questions, such as the epidemiology among men and women, the true public health burden of symptomatic and asymptomatic T vaginalis infections, and whether current treatments will be adequate to reduce the substantial health disparities and costs associated with trichomoniasis, need consideration to remedy neglect of this important disease. C1 [Secor, W. Evan] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA 30333 USA. [Meites, Elissa; Workowski, Kimberly A.] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA 30333 USA. [Starr, Michelle C.] Seattle Childrens Hosp, Seattle, WA USA. Emory Univ, Sch Med, Dept Med, Atlanta, GA USA. RP Secor, WE (reprint author), Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, 1600 Clifton Rd NE,Mailstop D-65, Atlanta, GA 30333 USA. EM was4@cdc.gov; emeites@cdc.gov; michelle.starr@seattlechildrens.org; kgw2@cdc.gov OI Meites, Elissa/0000-0002-0077-2591; Starr, Michelle/0000-0001-9412-8950 NR 65 TC 22 Z9 22 U1 0 U2 15 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 EI 1476-1645 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD MAY PY 2014 VL 90 IS 5 BP 800 EP 804 DI 10.4269/ajtmh.13-0723 PG 5 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA AG8ZN UT WOS:000335707600006 PM 24808247 ER PT J AU Cantey, PT Coyle, CM Sorvillo, FJ Wilkins, PP Starr, MC Nash, TE AF Cantey, Paul T. Coyle, Christina M. Sorvillo, Frank J. Wilkins, Patricia P. Starr, Michelle C. Nash, Theodore E. TI Neglected Parasitic Infections in the United States: Cysticercosis SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID TAENIA-SOLIUM TAENIASIS; LOS-ANGELES-COUNTY; ORTHODOX JEWISH-COMMUNITY; EXTRAPARENCHYMAL NEUROCYSTICERCOSIS; CLINICAL-MANIFESTATIONS; DIAGNOSIS; DISEASE; SEROPREVALENCE; TAPEWORM; SEIZURES AB Cysticercosis is a potentially fatal and preventable neglected parasitic infection caused by the larval form of Taenia solium. Patients with symptomatic disease usually have signs and symptoms of neurocysticercosis, which commonly manifest as seizures or increased intracranial pressure. Although there are many persons living in the United States who emigrated from highly disease-endemic countries and there are foci of autochthonous transmission of the parasite in the United States, little is known about burden and epidemiology of the disease in this country. In addition, despite advances in the diagnosis and management of neurocysticercosis, there remain many unanswered questions. Improving our understanding and management of neurocysticercosis in the United States will require improved surveillance or focused prospective studies in appropriate areas and allocation of resources towards answering some of the key questions discussed in this report. C1 [Cantey, Paul T.; Wilkins, Patricia P.] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA 30333 USA. [Coyle, Christina M.] Albert Einstein Coll Med, Dept Med, Bronx, NY 10467 USA. [Starr, Michelle C.] Univ Washington, Dept Pediat, Seattle, WA 98195 USA. [Sorvillo, Frank J.] Univ Calif Los Angeles, Sch Publ Hlth, Dept Epidemiol, Los Angeles, CA 90024 USA. [Nash, Theodore E.] NIAID, Gastrointestinal Parasites Sect, Parasit Dis Lab, NIH, Bethesda, MD 20892 USA. RP Cantey, PT (reprint author), Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, 1600 Clifton Rd NE,Mailstop A-06, Atlanta, GA 30333 USA. EM pcantey@cdc.gov; christina.coyle@einstein.yu.edu; franksorvillo@yahoo.com; pwilkins@cdc.gov; michelle.starr@seattlechildrens.org; tnash@niaid.nih.gov FU National Institute of Allergy and Infectious Diseases, U.S. National Institutes of Health FX This study was supported in part by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases, U.S. National Institutes of Health. NR 60 TC 18 Z9 18 U1 1 U2 10 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 EI 1476-1645 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD MAY PY 2014 VL 90 IS 5 BP 805 EP 809 DI 10.4269/ajtmh.13-0724 PG 5 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA AG8ZN UT WOS:000335707600007 PM 24808248 ER PT J AU Woodhall, DM Eberhard, ML Parise, ME AF Woodhall, Dana M. Eberhard, Mark L. Parise, Monica E. TI Neglected Parasitic Infections in the United States: Toxocariasis SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID VISCERAL LARVA MIGRANS; OCULAR TOXOCARIASIS; RISK-FACTORS; PREVALENCE; CHILDREN; POVERTY; AMERICA AB Toxocariasis is a preventable parasitic disease that is caused by the dog and cat roundworms Toxocara cani and T call, respectively. Humans become infected when they accidently ingest infectious Toxocara eggs commonly found in contaminated soil; children are most often affected. Clinical manifestations of Toxocara infection in humans include ocular toxocariasis and visceral toxocariasis. Although infection with Toxocara can cause devastating disease, the burden of toxocariasis in the United States population remains unknown. In addition, risk factors for acquiring infection need to be better defined, and research needs to be conducted to better understand the pathophysiology and clinical course of toxocariasis. Development of diagnostic tests would enable clinicians to detect active infection, and determination of optimal drug regiments would ensure patients were appropriately treated. Addressing these public health gaps is necessary to understand and address the impact of toxocariasis in the United States. C1 [Woodhall, Dana M.; Eberhard, Mark L.; Parise, Monica E.] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA 30333 USA. RP Woodhall, DM (reprint author), Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, 1600 Clifton Rd NE,Mailstop MS A-06, Atlanta, GA 30333 USA. EM dqw6@cdc.gov; mle1@cdc.gov; mep0@cdc.gov NR 32 TC 23 Z9 23 U1 1 U2 11 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 EI 1476-1645 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD MAY PY 2014 VL 90 IS 5 BP 810 EP 813 DI 10.4269/ajtmh.13-0725 PG 4 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA AG8ZN UT WOS:000335707600008 PM 24808249 ER PT J AU Montgomery, SP Starr, MC Cantey, PT Edwards, MS Meymandi, SK AF Montgomery, Susan P. Starr, Michelle C. Cantey, Paul T. Edwards, Morven S. Meymandi, Sheba K. TI Neglected Parasitic Infections in the United States: Chagas Disease SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID TRYPANOSOMA-CRUZI INFECTION; POLYMERASE-CHAIN-REACTION; AUTOCHTHONOUS TRANSMISSION; AMERICAN TRYPANOSOMIASIS; MYOCARDITIS; PREVALENCE; DNA AB Chagas disease, which is caused by the protozoan parasite Trypanosoma cruzi, can lead to severe cardiac and gastrointestinal disease. Most persons acquire this infection through contact with vector bugs carrying T. cruzi in endemic areas of Latin America. Infection can also be acquired by congenital, transfusion, transplantation, and foodborne transmission. Although an estimated 300,000 persons with Chagas disease live in the United States, little is known about the burden of chagasic heart disease. It is not known how often congenital or vector-borne transmission of T. cruzi occurs in the United States, although it is known that infected mothers and infected vector bugs are found in this country. Better diagnostic tests and treatment drugs are needed to improve patient care, and research is needed to define transmission risks and develop strategies to prevent new infections and reduce the burden of disease. C1 [Montgomery, Susan P.; Cantey, Paul T.] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA 30333 USA. Seattle Childrens Hosp, Seattle, WA USA. [Starr, Michelle C.] Univ Washington, Dept Pediat, Seattle, WA 98195 USA. [Edwards, Morven S.] Baylor Coll Med, Dept Pediat, Infect Dis Sect, Houston, TX 77030 USA. [Meymandi, Sheba K.] Univ Calif Los Angeles, Olive View UCLA Med Ctr, David Geffen Sch Med, Sylmar, CA USA. Olive View UCLA Med Ctr, Ctr Excellence Chagas Dis, Sylmar, CA 91342 USA. RP Montgomery, SP (reprint author), Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, 1600 Clifton Rd NE,Mailstop A-06, Atlanta, GA 30333 USA. EM smontgomery@cdc.gov; michelle.starr@seattlechildrens.org; pcantey@cdc.gov; morvene@bcm.edu; smeymandi@dhs.lacounty.gov NR 33 TC 25 Z9 25 U1 0 U2 10 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 EI 1476-1645 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD MAY PY 2014 VL 90 IS 5 BP 814 EP 818 DI 10.4269/ajtmh.13-0726 PG 5 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA AG8ZN UT WOS:000335707600009 PM 24808250 ER PT J AU Sridaran, S Rodriguez, B Soto, AM De Oliveira, AM Udhayakumar, V AF Sridaran, Sankar Rodriguez, Betzabe Mercedes Soto, Aida Macedo De Oliveira, Alexandre Udhayakumar, Venkatachalam TI Molecular Analysis of Chloroquine and Sulfadoxine-Pyrimethamine Resistance-Associated Alleles in Plasmodium falciparum Isolates from Nicaragua SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID THYMIDYLATE SYNTHASE GENE; DIHYDROFOLATE-REDUCTASE; DIHYDROPTEROATE SYNTHASE; DRUG-RESISTANCE; POINT MUTATIONS; CENTRAL-AMERICA; MALARIA; PFCRT; CYCLOGUANIL; VENEZUELA AB Chloroquine (CQ) is used as a first-line therapy for the treatment of Plasmodium falciparum malaria in Nicaragua. We investigated the prevalence of molecular markers associated with CQ and sulfadoxine-pyrimethamine (SP) resistance in P. falciparum isolates obtained from the North Atlantic Autonomous Region of Nicaragua. Blood spots for this study were made available from a CO and SP drug efficacy trial conducted in 2005 and also from a surveillance study performed in 2011. Polymorphisms in P. faciparum CQ resistance transporter, dihydrofolate reductase, and dihydropteroate synthase gene loci that are associated with resistance to CQ, pyrimethamine, and sulfadoxine, respectively, were detected by DNA sequencing. In the 2005 dataset, only 2 of 53 isolates had a CO resistance allele (CVIET), 2 of 52 had a pyrimethamine resistance allele, and 1 of 49 had a sulfadoxine resistance allele. In the 2011 dataset, none of 45 isolates analyzed had CO or SP resistance alleles. C1 Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA 30333 USA. Atlanta Res & Educ Fdn, Decatur, GA USA. [Sridaran, Sankar] Case Western Univ, Sch Med, Cleveland, OH USA. [Rodriguez, Betzabe] Minist Hlth, Natl Reference & Diag Ctr, Managua, Nicaragua. [Mercedes Soto, Aida] Pan Amer Hlth Org, Managua, Nicaragua. [Macedo De Oliveira, Alexandre; Udhayakumar, Venkatachalam] Ctr Dis Control & Prevent, Malaria Branch, Atlanta, GA 30333 USA. RP Udhayakumar, V (reprint author), Ctr Dis Control & Prevent, Malaria Branch, 1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM sxs973@case.edu; parasitologia@minsa.gob.ni; sotoa@nic.ops-oms.org; acq7@cdc.gov; vxu0@cdc.gov RI maria, ana /G-8106-2014 FU United States Agency for International Development under the Amazon Malaria Initiative; Pan American Health Organization; Network for Surveillance of Antimalarial Drug Resistance; Ministry of Health of Nicaragua; Atlanta Research and Education Foundation (Decatur, GA); Centers for Disease Control and Prevention Emerging Infectious Diseases Fellowship FX This study was supported by the United States Agency for International Development under the Amazon Malaria Initiative, the Pan American Health Organization, the Network for Surveillance of Antimalarial Drug Resistance, the Ministry of Health of Nicaragua, and the Atlanta Research and Education Foundation (Decatur, GA). Sankar Sridaran was also partly supported by the Centers for Disease Control and Prevention Emerging Infectious Diseases Fellowship. NR 33 TC 2 Z9 2 U1 0 U2 4 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 EI 1476-1645 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD MAY PY 2014 VL 90 IS 5 BP 840 EP 845 DI 10.4269/ajtmh.13-0214 PG 6 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA AG8ZN UT WOS:000335707600014 PM 24615126 ER PT J AU Harvey, K Jentes, ES Charles, M Johnson, KJ Petersen, B Lamias, MJ Blanton, JD Sotir, MJ Brunette, GW AF Harvey, Kira Jentes, Emily S. Charles, Myrna Johnson, Katherine J. Petersen, Brett Lamias, Mark J. Blanton, Jesse D. Sotir, Mark J. Brunette, Gary W. TI Possible Rabies Exposures in Peace Corps Volunteers, 2011 SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID TRAVELERS AB We surveyed Peace Corps Medical Officers (PCMOs) to determine the frequency of and responses to possible rabies exposures of U.S. Peace Corps volunteers (PCVs). Surveys were sent to 56 PCMOs serving in countries with moderate or high rabies vaccine recommendations from the U.S. Centers for Disease Control and Prevention (CDC), of which 38 (68%) responded. Thirty-seven PCMOs reported that, of 4,982 PCVs. 140 (3%) experienced possible rabies exposures. Of these, 125 (89%) had previously received rabies vaccination, 129 (92%) presented with adequately cleansed wounds, and 106 (76%) were deemed to require and were given post-exposure prophylaxis (PEP). Of 35 respondents, 30 (86%) reported that rabies vaccine was always accessible to PCVs in their country within 24 hours. Overall, the Peace Corps is successful at preventing and treating possible rabies exposures. However, this study identified a few gaps in policy implementation. The Peace Corps should continue and strengthen efforts to provide education, preexposure vaccination, and PEP to PCVs. C1 [Harvey, Kira; Jentes, Emily S.; Johnson, Katherine J.; Sotir, Mark J.; Brunette, Gary W.] Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, Atlanta, GA 30333 USA. Peace Corps, Off Med Serv, Washington, DC USA. [Petersen, Brett; Blanton, Jesse D.] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Atlanta, GA 30333 USA. Ctr Dis Control & Prevent, Off Informat, Atlanta, GA 30333 USA. [Charles, Myrna] Peace Corps Headquarters, Off Med Serv, Washington, DC USA. [Lamias, Mark J.] Ctr Dis Control & Prevent, Off Director, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. RP Harvey, K (reprint author), Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, 1600 Clifton Rd,MS E-03, Atlanta, GA 30333 USA. EM jii3@cdc.gov; ejentes@cdc.gov; myrna.charles@redcross.org; kate.j.johnson@gmail.com; Ige3@cdc.gov; Bnz6@cdc.gov; Asi5@cdc.gov; mps6@cdc.gov; fvd3@cdc.gov NR 9 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 EI 1476-1645 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD MAY PY 2014 VL 90 IS 5 BP 902 EP 907 DI 10.4269/ajtmh.13-0521 PG 6 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA AG8ZN UT WOS:000335707600024 PM 24639304 ER PT J AU Imanishi, M Kweza, PF Slayton, RB Urayai, T Ziro, O Mushayi, W Francis-Chizororo, M Kuonza, LR Ayers, T Freeman, MM Govore, E Duri, C Chonzi, P Mtapuri-Zinyowera, S Manangazira, P Kilmarx, PH Mintz, E Lantagne, D AF Imanishi, Maho Kweza, Patience F. Slayton, Rachel B. Urayai, Tanaka Ziro, Odrie Mushayi, Wellington Francis-Chizororo, Monica Kuonza, Lazarus R. Ayers, Tracy Freeman, Molly M. Govore, Emmaculate Duri, Clemence Chonzi, Prosper Mtapuri-Zinyowera, Sekesai Manangazira, Portia Kilmarx, Peter H. Mintz, Eric Lantagne, Daniele CA Zimbabwe Typhoid Fever Outbreak TI Household Water Treatment Uptake during a Public Health Response to a Large Typhoid Fever Outbreak in Harare, Zimbabwe SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID POINT-OF-USE; SAFE STORAGE; DIARRHEA PREVENTION; SALMONELLA; COUNTRIES; KENYA AB Locally manufactured sodium hypochlorite (chlorine) solution has been sold in Zimbabwe since 2010. During October 1, 2011-April 30, 2012, 4,181 suspected and 52 confirmed cases of typhoid fever were identified in Harare. In response to this outbreak, chlorine tablets were distributed. To evaluate household water treatment uptake, we conducted a survey and water quality testing in 458 randomly selected households in two suburbs most affected by the outbreak. Although 75% of households were aware of chlorine solution and 85% received chlorine tablets, only 18% had reportedly treated stored water and had the recommended protective level of free chlorine residuals. Water treatment was more common among households that reported water treatment before the outbreak, and those that received free tablets during the outbreak (P < 0.01), but was not associated with chlorine solution awareness or use before the outbreak (P > 0.05). Outbreak response did not build on pre-existing prevention programs. C1 [Imanishi, Maho; Slayton, Rachel B.; Ayers, Tracy; Freeman, Molly M.; Mintz, Eric] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30329 USA. [Imanishi, Maho; Slayton, Rachel B.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Sci Educ & Profess Dev Program Off, Atlanta, GA 30329 USA. [Kweza, Patience F.; Kuonza, Lazarus R.] Natl Inst Communicable Dis, Field Epidemiol & Lab Training Program, Johannesburg, South Africa. [Urayai, Tanaka] Populat Serv Int Zimbabwe, Harare, Zimbabwe. [Ziro, Odrie] Welthungerhilfe Zimbabwe, Harare, Zimbabwe. [Mushayi, Wellington; Francis-Chizororo, Monica] United Nations Childrens Funds Zimbabwe, Collaborating Ctr Operat Res & Evaluat, Harare, Zimbabwe. [Govore, Emmaculate; Duri, Clemence; Chonzi, Prosper] City Harare Hlth Serv Dept, Harare, Zimbabwe. [Mtapuri-Zinyowera, Sekesai] Minist Hlth & Child Welf, Natl Microbiol Reference Lab, Harare, Zimbabwe. [Manangazira, Portia] Minist Hlth & Child Welf, Harare, Zimbabwe. [Kilmarx, Peter H.] Ctr Dis Control & Prevent Zimbabwe, Harare, Zimbabwe. [Kilmarx, Peter H.] Ctr Dis Control & Prevent, Div Global HIV AIDS, Atlanta, GA 30329 USA. [Lantagne, Daniele] Tufts Univ, Medford, MA 02155 USA. RP Imanishi, M (reprint author), Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, 1600 Clifton Rd NE MSC-09, Atlanta, GA 30329 USA. EM m.imanishi@gmail.com; Patiencek@nicd.ac.za; via3@cdc.gov; turayai@psi-zim.co.zw; Odrie.Ziro@welthungerhilfe.de; wmushayi@unicef.org; mchizororo@unicef.org; LazarusK@nicd.ac.za; eyk6@cdc.gov; evy7@cdc.gov; echotogovore@yahoo.com; kireduri@gmail.com; chonziprosper@yahoo.com; zinyoweras@nmrl.org.zw; directoredc@gmail.com; pbk4@cdc.gov; emintz@cdc.gov; daniele.lantagne@tufts.edu OI Slayton, Rachel/0000-0003-4699-8040; Kilmarx, Peter/0000-0001-6464-3345; Ayers, Tracy/0000-0003-4140-3263 FU U.S. Centers for Disease Control and Prevention Division of Global Disease Detection and Emergency Response; U.S. Agency for International Development's Office of U.S. Foreign Disaster Assistance; United Nations Children's Fund-Zimbabwe; Welthungerhilfe-Zimbabwe; Population Services International-Zimbabwe FX This investigation was supported by the U.S. Centers for Disease Control and Prevention Division of Global Disease Detection and Emergency Response, the U.S. Agency for International Development's Office of U.S. Foreign Disaster Assistance, the United Nations Children's Fund-Zimbabwe, Welthungerhilfe-Zimbabwe, and Population Services International-Zimbabwe. NR 27 TC 7 Z9 7 U1 0 U2 8 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 EI 1476-1645 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD MAY PY 2014 VL 90 IS 5 BP 945 EP 954 DI 10.4269/ajtmh.13-0497 PG 10 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA AG8ZN UT WOS:000335707600030 PM 24664784 ER PT J AU Tsang, BL Sullivan, KM Ruth, LJ Williams, TN Suchdev, PS AF Tsang, Becky L. Sullivan, Kevin M. Ruth, Laird J. Williams, Thomas N. Suchdev, Parminder S. TI Nutritional Status of Young Children with Inherited Blood Disorders in Western Kenya SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID SOLUBLE TRANSFERRIN RECEPTOR; SICKLE-CELL TRAIT; PLASMODIUM-FALCIPARUM MALARIA; VITAMIN-A-DEFICIENCY; IRON-DEFICIENCY; ALPHA(+) THALASSEMIAS; EARLY-CHILDHOOD; ANEMIA; ALPHA(+)-THALASSEMIA; COAST AB To determine the association between a range of inherited blood disorders and indicators of poor nutrition, we analyzed data from a population-based, cross-sectional survey of 882 children 6-35 months of age in western Kenya. Of children with valid measurements, 71.7% were anemic (hemoglobin < 11 g/dL), 19.1% had ferritin levels < 12 mu g/L, and 30.9% had retinol binding protein (RBP) levels < 0.7 mu mol/L. Unadjusted analyses showed that compared with normal children, homozygous alpha(+)thalassemia individuals had a higher prevalence of anemia (82.3% versus 66.8%, P = 0.001), but a lower prevalence of low RBP (20.5% versus 31.4%, P = 0.024). In multivariable analysis, homozygous alpha(+)-thalassemia remained associated with anemia (adjusted odds ratio [aOR] = 1.8, P = 0.004) but not with low RBP (aOR = 0.6, P = 0.065). Among young Kenyan children, alpha(+)-thalassemia is associated with anemia, whereas G6PD deficiency, haptoglobin 2-2, and HbS are not; none of these blood disorders are associated with iron deficiency, vitamin A deficiency, or poor growth. C1 [Tsang, Becky L.] Ctr Dis Control & Prevent, Prevent Res Branch, Atlanta, GA 30341 USA. [Sullivan, Kevin M.] Emory Univ, Hubert Dept Global Hlth, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Ruth, Laird J.; Suchdev, Parminder S.] Ctr Dis Control & Prevent, Nutr Branch, Atlanta, GA 30341 USA. [Williams, Thomas N.] Kenya Govt Med Res Ctr, Ctr Geog Med Res Coast, Kilifi, Kenya. RP Suchdev, PS (reprint author), Ctr Dis Control & Prevent, Nutr Branch, 4770 Buford Hwy NE,MS-F77, Atlanta, GA 30341 USA. EM woh3@cdc.gov; cdckms@sph.emory.edu; lruth@cdc.gov; twilliams@kilifi.kemri-wellcome.org; dvo8@cdc.gov OI Suchdev, Parmi/0000-0002-0350-3469 FU U. S. Centers for Disease Control and Prevention (CDC); Wellcome Trust, UK [091758] FX This work was supported by the U. S. Centers for Disease Control and Prevention (CDC) through a cooperative agreement between CDC and the Kenya Medical Research Institute (KEMRI) and a senior fellowship from the Wellcome Trust, UK (091758). NR 46 TC 2 Z9 2 U1 1 U2 5 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 EI 1476-1645 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD MAY PY 2014 VL 90 IS 5 BP 955 EP 962 DI 10.4269/ajtmh.13-0496 PG 8 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA AG8ZN UT WOS:000335707600031 PM 24639300 ER PT J AU Ram, PK Dutt, D Silk, BJ Doshi, S Rudra, CB Abedin, J Goswami, D Fry, AM Brooks, WA Luby, SP Cohen, AL AF Ram, Pavani K. Dutt, Dhiman Silk, Benjamin J. Doshi, Saumil Rudra, Carole B. Abedin, Jaynal Goswami, Doli Fry, Alicia M. Brooks, W. Abdullah Luby, Stephen P. Cohen, Adam L. TI Household Air Quality Risk Factors Associated with Childhood Pneumonia in Urban Dhaka, Bangladesh SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; PNEUMOCOCCAL DISEASE; PARTICLE DEPOSITION; PARTICULATE MATTER; CHILDREN; POLLUTION; VENTILATION; ENVIRONMENT; MORTALITY; EXPOSURE AB To inform interventions to reduce the high burden of pneumonia in urban settings such as Kamalapur, Bangladesh, we evaluated household air quality risk factors for radiographically confirmed pneumonia in children. In 2009-2010, we recruited children < 5 years of age with pneumonia and controls from a population-based surveillance for respiratory and febrile illnesses. Piped natural gas was used by 85% of 331 case and 91% of 663 control households. Crowding, a tin roof in the living space, low socioeconomic status, and male sex of the child were risk factors for pneumonia. The living space in case households was 28% less likely than in control households to be cross-ventilated. Particulate matter concentrations were not significantly associated with pneumonia. With increasing urbanization and supply of improved cooking fuels to urban areas, the high burden of respiratory illnesses in urban populations such as Kamalapur may be reduced by decreasing crowding and improving ventilation in living spaces. C1 [Ram, Pavani K.] SUNY Buffalo, Dept Epidemiol & Environm Hlth, Buffalo, NY 14260 USA. [Dutt, Dhiman; Abedin, Jaynal; Brooks, W. Abdullah; Luby, Stephen P.] Icddr B, Ctr Communicable Dis, Dhaka, Bangladesh. [Silk, Benjamin J.] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA USA. [Doshi, Saumil; Fry, Alicia M.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. [Rudra, Carole B.] SUNY Buffalo, Sch Publ Hlth & Hlth Profess, Buffalo, NY 14260 USA. [Goswami, Doli] ICDDR B Hlth Syst & Infect Dis, Dhaka, Bangladesh. [Brooks, W. Abdullah] Johns Hopkins Univ, Bloomberg Sch Publ Hlth Int Hlth, Baltimore, MD USA. [Luby, Stephen P.] Stanford Univ, Stanford, CA USA. [Cohen, Adam L.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. RP Ram, PK (reprint author), Rm 270 Farber Hall,3435 Main St, Buffalo, NY 14214 USA. EM pkram@buffalo.edu; dhiman@icddrb.org; ekg3@cdc.gov; hgj3@cdc.gov; cbrudra@buffalo.edu; jaynal@icddrb.org; drdolly@icddrb.org; agf1@cdc.gov; abrooks@icddrb.org; sluby@stanford.edu; acohen@sa.cdc.gov OI Luby, Stephen/0000-0001-5385-899X FU U.S. Centers for Disease Control and Prevention [5U51CI000298-05] FX We sincerely thank the large number of Kamalapur households who allowed us into their homes numerous times for the data collection for this study. None of the work would have been possible without the diligent effort of our numerous field research assistants, and Moarrita Begum, Gazi Salahuddin, Iffat Sharmin, and Moshtaq Ahmed. Daniel Feikin, Wolf-Peter Schmidt, and Stephanie Schrag provided thoughtful reviews of the study protocol and we are grateful for their collective wisdom. Emily Gurley provided valuable advice during the study planning and implementation. Funding for this project was provided by the U.S. Centers for Disease Control and Prevention by a cooperative agreement to the International Centre for Diarrhoeal Disease Research, Bangladesh (Cooperative agreement no. 5U51CI000298-05). NR 34 TC 4 Z9 6 U1 1 U2 9 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 EI 1476-1645 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD MAY PY 2014 VL 90 IS 5 BP 968 EP 975 DI 10.4269/ajtmh.13-0532 PG 8 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA AG8ZN UT WOS:000335707600033 PM 24664785 ER PT J AU Santos, GM Coffin, PO Vittinghoff, E DeMicco, E Das, M Matheson, T Raiford, JL Carry, M Colfax, G Herbst, JH Dilley, JW AF Santos, Glenn-Milo Coffin, Phillip O. Vittinghoff, Eric DeMicco, Erin Das, Moupali Matheson, Tim Raiford, Jerris L. Carry, Monique Colfax, Grant Herbst, Jeffrey H. Dilley, James W. TI Substance use and drinking outcomes in Personalized Cognitive Counseling randomized trial for episodic substance-using men who have sex with men SO DRUG AND ALCOHOL DEPENDENCE LA English DT Article DE MSM; Behavioral interventions; Methamphetamine; Alcohol; Substance use; HIV risk; Risk reduction counseling; Personalized cognitive counseling ID BEHAVIORAL SURVEILLANCE SYSTEM; HIV RISK; UNITED-STATES; METHAMPHETAMINE USERS; AMPHETAMINE USERS; TESTING BEHAVIORS; BINGE DRINKING; SAN-FRANCISCO; DRUG-USE; INTERVENTIONS AB Background: Non-dependent alcohol and substance use patterns are prevalent among men who have sex with men (MSM), yet few effective interventions to reduce their substance use are available for these men. We evaluated whether an adapted brief counseling intervention aimed at reducing HIV risk behavior was associated with secondary benefits of reducing substance use among episodic substance-using MSM (SUMSM). Methods: 326 episodic SUMSM were randomized to brief Personalized Cognitive Counseling (PCC) intervention with rapid HIV testing or to rapid HIV testing only control. Both arms followed over 6 months. Trends in substance use were examined using GEE Poisson models with robust standard errors by arm. Reductions in frequency of use were examined using ordered logistic regression. Results: In intent-to-treat analyses, compared to men who received rapid HIV testing only, we found men randomized to PCC with rapid HIV testing were more likely to report abstaining from alcohol consumption (RR= 0.93; 95% CI= 0.89-0.97), marijuana use (RR= 0.84; 95% CI= 0.73-0.98), and erectile dysfunction drug use (EDD; RR= 0.51; 95% CI= 0.33-0.79) over the 6-month follow-up. PCC was also significantly associated with reductions in frequency of alcohol intoxication (OR= 0.58; 95% CI= 0.36-0.90) over follow-up. Furthermore, we found PCC was associated with significant reductions in number of unprotected anal intercourse events while under the influence of methamphetamine (RR= 0.26; 95% Cl= 0.08-0.84). Conclusion: The addition of adapted PCC to rapid HIV testing may have benefits in increasing abstinence from certain classes of substances previously associated with HIV risk, including alcohol and EDD; and reducing alcohol intoxication frequency and high-risk sexual behaviors concurrent with methamphetamine use. (C) 2014 Elsevier Ireland Ltd. All rights reserved. C1 [Santos, Glenn-Milo; Coffin, Phillip O.; DeMicco, Erin; Das, Moupali; Matheson, Tim; Colfax, Grant] Substance Use Res Unit, San Francisco Dept Publ Hlth, San Francisco, CA USA. [Santos, Glenn-Milo; Coffin, Phillip O.; Vittinghoff, Eric; Das, Moupali; Dilley, James W.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Herbst, Jeffrey H.] Natl Ctr HIVAIDS Viral Hepatitis STD & TB Prevent, Ctr Dis Control & Prevent CDC, Div HIVAIDS Prevent, Prevent Res Branch, Atlanta, GA USA. RP Santos, GM (reprint author), Univ Calif San Francisco, Dept Publ Hlth Epidemiol & Biostat, 25 Van Ness Ave,Suite 200, San Francisco, CA 94102 USA. EM glenn-milo.santos@sfdph.org OI Coffin, Phillip/0000-0002-3891-6570 FU Intramural CDC HHS [CC999999]; NCHHSTP CDC HHS [UR6 PS000684] NR 36 TC 5 Z9 5 U1 4 U2 11 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0376-8716 EI 1879-0046 J9 DRUG ALCOHOL DEPEN JI Drug Alcohol Depend. PD MAY 1 PY 2014 VL 138 BP 234 EP 239 DI 10.1016/j.drugalcdep.2014.02.015 PG 6 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA AG7SN UT WOS:000335618800034 PM 24641808 ER PT J AU Manco-Johnson, MJ Dudley, B Recht, M Byams, V Kapica, S Cooke, B Oakley, M Aschman, DJ AF Manco-Johnson, Marilyn J. Dudley, Becky Recht, Michael Byams, Vanessa Kapica, Suzanne Cooke, Brandi Oakley, Meredith Aschman, Diane J. TI Community counts: A national surveillance system for bleeding and clotting disorders SO HAEMOPHILIA LA English DT Meeting Abstract C1 [Manco-Johnson, Marilyn J.] Childrens Hosp Colorado, Aurora, CO USA. [Manco-Johnson, Marilyn J.] Univ Colorado, Aurora, CO USA. [Recht, Michael; Aschman, Diane J.] Amer Thrombosis & Hemostasis Network, Riverwood, OR USA. [Recht, Michael] Orgeon Hlth & Sci Univ, Portand, OR USA. [Byams, Vanessa; Cooke, Brandi; Oakley, Meredith] Ctr Dis Control & Prevent, Atlanta, GA USA. [Kapica, Suzanne] Hemophilia Fdn Michigan, Ypsilanti, MI USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1351-8216 EI 1365-2516 J9 HAEMOPHILIA JI Haemophilia PD MAY PY 2014 VL 20 SU 3 SI SI BP 35 EP 36 PG 2 WC Hematology SC Hematology GA AF9BH UT WOS:000335009500142 ER PT J AU Ullman, M Zhang, QC Grosse, SD Recht, M Soucie, JM AF Ullman, Megan Zhang, Qing C. Grosse, Scott D. Recht, Michael Soucie, J. Michael TI Factors associated with prophylaxis use in persons with hemophilia in the United States SO HAEMOPHILIA LA English DT Meeting Abstract C1 [Ullman, Megan] Univ Texas Hlth Sci Ctr Houston, Gulf States Hemophilia & Thrombophilia Ctr, Houston, TX 77030 USA. [Zhang, Qing C.; Grosse, Scott D.; Soucie, J. Michael] Ctr Dis Control & Prevent, Portland, OR USA. [Recht, Michael] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1351-8216 EI 1365-2516 J9 HAEMOPHILIA JI Haemophilia PD MAY PY 2014 VL 20 SU 3 SI SI BP 98 EP 98 PG 1 WC Hematology SC Hematology GA AF9BH UT WOS:000335009500391 ER PT J AU Soucie, JM Miller, CH AF Soucie, J. Michael Miller, Connie H. TI Surveillance for hemophilia inhibitors in the United States SO HAEMOPHILIA LA English DT Meeting Abstract C1 [Soucie, J. Michael; Miller, Connie H.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1351-8216 EI 1365-2516 J9 HAEMOPHILIA JI Haemophilia PD MAY PY 2014 VL 20 SU 3 SI SI BP 120 EP 121 PG 2 WC Hematology SC Hematology GA AF9BH UT WOS:000335009500486 ER PT J AU Soucie, JM Grosse, SD Siddiqi, AEA Byams, V Thierry, J Zack, M Shapiro, A Duncan, N AF Soucie, J. Michael Grosse, Scott D. Siddiqi, Azfar-E-Alam Byams, Vanessa Thierry, Joann Zack, Matthew Shapiro, Amy Duncan, Natalie CA Hemophilia Treatment Ctr Network TI The effect of an inhibitor on health-related quality of life among persons with severe hemophilia A in the United States SO HAEMOPHILIA LA English DT Meeting Abstract C1 [Soucie, J. Michael; Grosse, Scott D.; Siddiqi, Azfar-E-Alam; Byams, Vanessa; Thierry, Joann; Zack, Matthew] Ctr Dis Control & Prevent, Atlanta, GA USA. [Shapiro, Amy; Duncan, Natalie] Indiana Hemophilia & Thrombosis Ctr, Indianapolis, IN USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1351-8216 EI 1365-2516 J9 HAEMOPHILIA JI Haemophilia PD MAY PY 2014 VL 20 SU 3 SI SI BP 168 EP 169 PG 2 WC Hematology SC Hematology GA AF9BH UT WOS:000335009500701 ER PT J AU Srivaths, LV Byams, VR Zhang, QC Dietrich, JE James, AH Kouides, PA Kulkarni, R AF Srivaths, Lakshmi V. Byams, Vanessa R. Zhang, Qing C. Dietrich, Jennifer E. James, Andra H. Kouides, Peter A. Kulkarni, Roshni CA Hemophilia Treatment Ctr Network I TI Bleeding phenotype and provider interventions for menorrhagia in postmenarchal adolescents with congenital bleeding disorders (CBD) when compared to adult women - A surveillance report of the female Universal Data Collection (UDC) project in United States (US) hemophilia treatment centres (HTCs) SO HAEMOPHILIA LA English DT Meeting Abstract C1 [Srivaths, Lakshmi V.] Baylor Coll Med, Dept Pediat, Sect Hematol Oncol, Houston, TX 77030 USA. [Byams, Vanessa R.; Zhang, Qing C.] Ctr Dis Control & Prevent, Div Blood Disorders, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Dietrich, Jennifer E.] Baylor Coll Med, Dept Obstet & Gynecol, Houston, TX 77030 USA. [James, Andra H.] Univ Virginia, Div Maternal Fetal Med, Charlottesville, VA USA. [Kouides, Peter A.] Mary M Gooley Hemophilia Treatment Ctr, Rochester, MN USA. [Kulkarni, Roshni] Michigan State Univ, Dept Pediat & Human Dev, E Lansing, MI 48824 USA. NR 0 TC 0 Z9 0 U1 1 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1351-8216 EI 1365-2516 J9 HAEMOPHILIA JI Haemophilia PD MAY PY 2014 VL 20 SU 3 SI SI BP 184 EP 184 PG 1 WC Hematology SC Hematology GA AF9BH UT WOS:000335009500769 ER PT J AU Reves, R Heilig, CM Tapy, JM Bozeman, L Kyle, RP Hamilton, CD Bock, N Narita, M Wing, D Hershfield, E Goldberg, SV AF Reves, R. Heilig, C. M. Tapy, J. M. Bozeman, L. Kyle, R. P. Hamilton, C. D. Bock, N. Narita, M. Wing, D. Hershfield, E. Goldberg, S. V. CA TB Trials Consortium TI Intermittent tuberculosis treatment for patients with isoniazid intolerance or drug resistance SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE LA English DT Article DE tuberculosis; anti-tuberculosis agents; mycobacterial infections ID SHORT-COURSE CHEMOTHERAPY; PULMONARY TUBERCULOSIS; MONORESISTANT TUBERCULOSIS; CLINICAL-TRIAL; PYRAZINAMIDE; THERAPY; TWICE; HEPATOTOXICITY; REGIMEN AB SETTING: Twenty tuberculosis (TB) clinics in the United States and Canada. OBJECTIVE: To evaluate the efficacy and safety of a 6-month intermittent regimen of rifampin (RMP), pyrazinamide (PZA) and ethambutol (EMB) in human immunodeficiency virus (HIV) negative patients with culture-confirmed pulmonary or extra-pulmonary tuberculosis and either isoniazid (INH) resistance or INH intolerance. DESIGN: Patients were enrolled in a single-arm clinical trial to receive intermittent dosing after at least 14 initial daily doses of RMP+PZA+EMB. Treatment was continued twice (BIW) or thrice weekly (TIW) per physician/patient preference for a total of 6 months, with 2 years of follow-up for relapse after treatment. RESULTS: From 1999 to 2004, 98 patients were enrolled, 78 with reported INH resistance and 20 with INH intolerance. BIW dosing was used in 77 and TIW in 21. Study treatment was completed in 73 (74%). Reasons for discontinuation were hepatic adverse events (n = 12), other adverse effects (n = 3) and other reasons (n=10). Failure (n= 1) and relapse (n=2) occurred in 3 (3.5%, 95%CI 1.2-9.8) of 86 patients eligible for efficacy analysis, all occurring in patients with cavitary, acid-fast bacilli smear-positive pulmonary TB. CONCLUSIONS: Intermittent RMPA-PZA-EMB appears to be effective in HIV-negative patients, but the regimen is poorly tolerated, possibly due to the prolonged use of PZA. Alternative regimens of lower toxicity are needed. C1 [Reves, R.; Tapy, J. M.] Denver Publ Hlth Dept, Denver, CO 80204 USA. [Heilig, C. M.; Bozeman, L.; Kyle, R. P.; Bock, N.; Goldberg, S. V.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Hamilton, C. D.] Family Hlth Int 360, Durham, NC USA. [Hamilton, C. D.] Duke Univ, Durham, NC USA. [Narita, M.] Univ Washington, Seattle, WA 98195 USA. [Wing, D.] South Texas Audie Murphy VA Hosp Res Collaborat, Harlingen, TX USA. [Hershfield, E.] Univ Manitoba, Winnipeg, MB, Canada. RP Reves, R (reprint author), Denver Publ Hlth Dept, 605 Bannock St, Denver, CO 80204 USA. EM rreves@dhha.org RI Kyle, Ryan/E-5718-2014; OI Kyle, Ryan/0000-0001-5829-9867; Heilig, Charles/0000-0003-1075-1310 FU CDC FX Supported by the CDC. ClinicalTrials.gov Identifier: NCT00023374 NR 31 TC 5 Z9 5 U1 1 U2 4 PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D) PI PARIS PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE SN 1027-3719 EI 1815-7920 J9 INT J TUBERC LUNG D JI Int. J. Tuberc. Lung Dis. PD MAY PY 2014 VL 18 IS 5 BP 571 EP 580 DI 10.5588/ijtld.13.0304 PG 10 WC Infectious Diseases; Respiratory System SC Infectious Diseases; Respiratory System GA AG7VV UT WOS:000335627800015 PM 24903795 ER PT J AU Lee, X Coyle, DR Johnson, DKH Murphy, MW Mcgeehin, MA Murphy, RJ Raffa, KF Paskewitz, SM AF Lee, Xia Coyle, David R. Johnson, Diep K. Hoang Murphy, Matthew W. Mcgeehin, Michael A. Murphy, Robert J. Raffa, Kenneth F. Paskewitz, Susan M. TI Prevalence of Borrelia burgdorferi and Anaplasma phagocytophilum in Ixodes scapularis (Acari: Ixodidae) Nymphs Collected in Managed Red Pine Forests in Wisconsin SO JOURNAL OF MEDICAL ENTOMOLOGY LA English DT Article DE blacklegged tick; coinfection; Lyme disease; anaplasmosis; Anaplasma phagocytophilum variant 1 ID EASTERN UNITED-STATES; WHITE-TAILED DEER; LYME-DISEASE; NEW-JERSEY; HABITATS; SURVIVAL; TICKS; INFECTION; STRAIN; RISK AB Changes in the structure of managed red pine forests in Wisconsin caused by interacting root-and stem-colonizing insects are associated with increased abundance of the blacklegged tick, Ixodes scapularis Say, in comparison with nonimpacted stands. However, the frequency and variability of the occurrence of tick-borne pathogens in this coniferous forest type across Wisconsin is unknown. Red pine forests were surveyed from 2009 to 2013 to determine the prevalence of Borrelia burgdorferi and Anaplasma phagocytophilum in questing I. scapularis nymphs. Polymerase chain reaction analysis revealed geographical differences in the nymphal infection prevalence (NIP) of these pathogens in red pine forests. In the Kettle Moraine State Forest (KMSF) in southeastern Wisconsin, NIP of B. burgdorferi across all years was 35% (range of 14.5-53.0%). At the Black River State Forest (BRSF) in western Wisconsin, NIP of B. burgdorferi across all years was 26% (range of 10.9-35.5%). Differences in NIP of B. burgdorferi between KMSF and BRSF were statistically significant for 2010 and 2011 and for all years combined (P < 0.05). NIP of A. phagocytophilum (human agent) averaged 9% ( range of 4.6-15.8%) at KMSF and 3% (range of 0-6.4%) at BRSF, and was significantly different between the sites for all years combined ( P < 0.05). Differences in coinfection of B. burgdorferi and A. phagocytophilum were not statistically significant between KMSF and BRSF, with an average of 3.4% (range of 1.7-10.5%) and 2.5% (range of 0-5.5%), respectively. In 2013, the density of infected nymphs in KMSF and BRSF was 14 and 30 per 1000m(2), respectively, among the highest ever recorded for the state. Differences in the density of nymphs and NIP among sites were neither correlated with environmental factors nor time since tick colonization. These results document significant unexplained variation in tick-borne pathogens between coniferous forests in Wisconsin that warrants further study. C1 [Lee, Xia; Coyle, David R.; Raffa, Kenneth F.; Paskewitz, Susan M.] Univ Wisconsin, Dept Entomol, Madison, WI 53706 USA. [Johnson, Diep K. Hoang] Wisconsin Dept Hlth Serv, Div Publ Hlth, Madison, WI 53701 USA. [Murphy, Matthew W.; Mcgeehin, Michael A.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. [Murphy, Robert J.] Wisconsin Dept Nat Resources, Madison, WI 53707 USA. RP Paskewitz, SM (reprint author), Univ Wisconsin, Dept Entomol, Madison, WI 53706 USA. EM paskewit@entomology.wisc.edu FU CDC; National Center for Environmental Health FX We thank Scott Larson and University of Wisconsin-Madison undergraduate students Justin Berg, Amanda Maegli, Colin Sinnot, Karli Reifschneider, Charles Opitz, Oliver MacDonald, and Elizabeth Hemming for their assistance with tick collecting and PCR analysis. We also thank Mike Sieger and Peter Bakken, site managers for KMSF and BRSF, respectively, for their cooperation in this project. Funding for this project was provided by the CDC, National Center for Environmental Health. NR 27 TC 5 Z9 5 U1 2 U2 33 PU ENTOMOLOGICAL SOC AMER PI ANNAPOLIS PA 3 PARK PLACE, STE 307, ANNAPOLIS, MD 21401-3722 USA SN 0022-2585 EI 1938-2928 J9 J MED ENTOMOL JI J. Med. Entomol. PD MAY PY 2014 VL 51 IS 3 BP 694 EP 701 DI 10.1603/ME13140 PG 8 WC Entomology; Veterinary Sciences SC Entomology; Veterinary Sciences GA AG8IB UT WOS:000335660900025 PM 24897864 ER PT J AU Hughes, TH Richardson, AG Hoel, DF Mejeoumov, T Farooq, M Stoops, CA AF Hughes, Tony H. Richardson, Alec G. Hoel, David F. Mejeoumov, Tracy Farooq, Mohammad Stoops, Craig A. TI Suppression of Amblyomma americanum (Ixodida: Ixodidae) for Short-Term Field Operations Utilizing Cypermethrin and Lambda-Cyhalothrin SO JOURNAL OF MEDICAL ENTOMOLOGY LA English DT Article DE Amblyomma americanum; cypermethrin; lambda-cyhalothrin; military ID IXODES-SCAPULARIS; ACARI IXODIDAE; AREA CONTROL; TICK ACARI; NYMPHS; NOOTKATONE AB Tick-borne diseases pose risks to U. S. military personnel who conduct operations, both domestic and abroad. To determine the feasibility of protecting personnel from tick vectors during short-term field deployments, acaricides cypermethrin (Demon WP, Syngenta, Greensboro, NC) and lambda-cyhalothrin (Surrender Pestabs, CSI, Pasadena, TX) were applied to plots within two separate field sites on Camp Blanding Joint Training Center in Starke, FL, from May to June 2011. We analyzed their effectiveness in reducing tick counts for 6 wk after application. In total, 8,193 ticks were identified and counted, of which >99% were a mix of nymphs and adult-stage Amblyomma americanum (L.). Our results indicate that both cypermethrin and lambda-cyhalothrin were effective in significantly reducing tick numbers and preventing entry into treated plots for 6 wk after application. Thus, these two acaracides can be used to effectively suppress tick populations and provide residual protection in small geographic areas of recreation or public health significance. C1 [Hughes, Tony H.; Richardson, Alec G.; Mejeoumov, Tracy; Farooq, Mohammad] Navy Entomol Ctr Excellence, Operat Assessment Dept, Naval Air Stn Jacksonville, Jacksonville, FL 32212 USA. [Hoel, David F.] US Ctr Dis Control & Prevent, Navy & Marine Corps Publ Hlth Ctr Detachment CDC, Atlanta, GA 30329 USA. [Stoops, Craig A.] USDA ARS, Navy & Marine Corps Publ Hlth Ctr Detachment, Ctr Med Agr & Vet Entomol, Gainesville, FL 32608 USA. RP Hughes, TH (reprint author), Navy Entomol Ctr Excellence, Operat Assessment Dept, Naval Air Stn Jacksonville, Bldg 937, Jacksonville, FL 32212 USA. EM tony.hughes@med.navy.mil FU Deployed War fighter Protection Research Program (DWFP) FX We thank Rosa Ergas of the Navy and Marine Corps Public Health Center for providing tick-borne disease data to the Department of Defense. We gratefully acknowledge the staff of the Navy Entomology Center of Excellence for their assistance with the fieldwork. We also thank Carl Doud, Peter Obenauer, and Graham White for a thorough review of the manuscript. This work was supported by the Deployed War fighter Protection Research Program (DWFP). NR 17 TC 2 Z9 2 U1 0 U2 7 PU ENTOMOLOGICAL SOC AMER PI ANNAPOLIS PA 3 PARK PLACE, STE 307, ANNAPOLIS, MD 21401-3722 USA SN 0022-2585 EI 1938-2928 J9 J MED ENTOMOL JI J. Med. Entomol. PD MAY PY 2014 VL 51 IS 3 BP 709 EP 712 DI 10.1603/ME13034 PG 4 WC Entomology; Veterinary Sciences SC Entomology; Veterinary Sciences GA AG8IB UT WOS:000335660900027 PM 24897866 ER PT J AU Wu, QZ Mcfee, WE Goldstein, T Tiller, RV Schwacke, L AF Wu, Qingzhong McFee, Wayne E. Goldstein, Tracey Tiller, Rebekah V. Schwacke, Lori TI Real-time PCR assays for detection of Brucella spp. and the identification of genotype ST27 in bottlenose dolphins (Tursiops truncatus) SO JOURNAL OF MICROBIOLOGICAL METHODS LA English DT Article DE Bottlenose dolphins; IS711; Real-time PCR; Brucella spp.; Lung; Brain ID MARINE MAMMAL BRUCELLA; ZOONOTIC INFECTION; SOUTH-CAROLINA; PINNIPEDIALIS; IS711; STRAINS; TOOL; SEA AB Rapid detection of Brucella spp. in marine mammals is challenging. Microbiologic culture is used for definitive diagnosis of brucellosis, but is time consuming, has low sensitivity and can be hazardous to laboratory personnel. Serological methods can aid in diagnosis, but may not differentiate prior exposure versus current active infection and may cross-react with unrelated Gram-negative bacteria. This study reports a real-time PCR assay for the detection of Brucella spp. and application to screen clinical samples from bottlenose dolphins stranded along the coast of South Carolina, USA. The assay was found to be 100% sensitive for the Brucella strains tested, and the limit of detection was 0.27 fg of genomic DNA from Brucella ceti B1/94 per PCR volume. No amplification was detected for the non-Brucella pathogens tested. Brucella DNA was detected in 31% (55/178) of clinical samples tested. These studies indicate that the real-time PCR assay is highly sensitive and specific for the detection of Brucella spp. in bottlenose dolphins. We also developed a second real-time PCR assay for rapid identification of Brucella ST27, a genotype that is associated with human zoonotic infection. Positive results were obtained for Brucella strains which had been identified as ST27 by multilocus sequence typing. No amplification was found for other Brucella strains included in this study. ST27 was identified in 33% (18/54) of Brucella spp. DNApositive clinical samples. To our knowledge, this is the first report on the use of a real-time PCR assay for identification of Brucella genotype ST27 in marine mammals. (c) 2014 Elsevier B.V. All rights reserved. C1 [Wu, Qingzhong; Schwacke, Lori] Natl Ocean Atmospher Adm, Hollings Marine Lab, Natl Ctr Coastal Ocean Sci, Natl Ocean Serv, Charleston, SC 29412 USA. [McFee, Wayne E.] Natl Ocean & Atmospher Adm, Ctr Coastal Environm Hlth & Biomol Res, Natl Ctr Coastal Ocean Sci, Natl Ocean Serv, Charleston, SC 29412 USA. [Goldstein, Tracey] Univ Calif Davis, Sch Vet Med, Hlth Inst 1, Davis, CA 95616 USA. [Tiller, Rebekah V.] Ctr Dis Control & Prevent, Zoonoses & Select Agent Lab, Atlanta, GA 30333 USA. RP Wu, QZ (reprint author), NOAA Natl Ctr Coastal Ocean Sci, Hollings Marine Lab, 331 Ft Johnson Rd, Charleston, SC 29412 USA. EM qingzhongwu@yahoo.com FU NOAA's Oceans and Human Health Initiative; National Marine Fisheries Service Marine Mammal Health and Stranding Response Program FX We would like to thank Brian Thompson, for providing non-Brucella bacteria. We would like to thank Christine Quance of the National Veterinary Services Laboratories in Ames, Iowa, USA for analyzing the samples with the culture methods. Funding for this research was provided by NOAA's Oceans and Human Health Initiative and the National Marine Fisheries Service Marine Mammal Health and Stranding Response Program. This publication does not constitute an endorsement of any commercial product or intend to be an opinion beyond scientific or other results obtained by the NOM. NR 34 TC 4 Z9 4 U1 2 U2 14 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0167-7012 EI 1872-8359 J9 J MICROBIOL METH JI J. Microbiol. Methods PD MAY PY 2014 VL 100 BP 99 EP 104 DI 10.1016/j.mimet.2014.03.001 PG 6 WC Biochemical Research Methods; Microbiology SC Biochemistry & Molecular Biology; Microbiology GA AG7XD UT WOS:000335631200016 PM 24632518 ER PT J AU Park, J Rajasingham, R Smith, RM Boulware, DR AF Park, J. Rajasingham, R. Smith, R. M. Boulware, D. R. TI Update on the global burden of cryptococcosis SO MYCOSES LA English DT Meeting Abstract C1 [Park, J.; Smith, R. M.] US Ctr Dis Control & Prevent, Atlanta, GA USA. [Rajasingham, R.] Beth Israel Deaconness Hosp, Boston, MA USA. [Boulware, D. R.] Univ Minnesota, Minneapolis, MN USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0933-7407 EI 1439-0507 J9 MYCOSES JI Mycoses PD MAY PY 2014 VL 57 SU 1 SI SI BP 6 EP 6 PG 1 WC Dermatology; Mycology SC Dermatology; Mycology GA AG0FL UT WOS:000335090600005 ER PT J AU Lockhart, SR Iqbal, N Bolden, CB Grossman, NT Ottinger, EA Garvey, EP Brand, SR Hoekstra, WJ Moore, WR Schotzinger, RJ AF Lockhart, S. R. Iqbal, N. Bolden, C. B. Grossman, N. T. Ottinger, E. A. Garvey, E. P. Brand, S. R. Hoekstra, W. J. Moore, W. R. Schotzinger, R. J. TI Susceptibility testing of VT-1129, a novel fungal CYP51 inhibitor, against Cryptococcus neoformans and Cryptococcus gattii SO MYCOSES LA English DT Meeting Abstract C1 [Lockhart, S. R.; Iqbal, N.; Bolden, C. B.; Grossman, N. T.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Ottinger, E. A.] NIH, Bethesda, MD 20892 USA. [Garvey, E. P.; Brand, S. R.; Hoekstra, W. J.; Moore, W. R.; Schotzinger, R. J.] Viamet Pharmaceut Inc, Durham, NC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0933-7407 EI 1439-0507 J9 MYCOSES JI Mycoses PD MAY PY 2014 VL 57 SU 1 SI SI BP 43 EP 43 PG 1 WC Dermatology; Mycology SC Dermatology; Mycology GA AG0FL UT WOS:000335090600094 ER PT J AU Bonfietti, LX Pham, CD Szeszs, MW Silva, DC Martins, MA Lockhart, SR Melhem, MSC AF Bonfietti, L. X. Pham, C. D. Szeszs, M. W. Silva, D. C. Martins, M. A. Lockhart, S. R. Melhem, M. S. C. TI Suceptibility profile of a Brazilian collection of clinical Cryptococcus gattii isolates SO MYCOSES LA English DT Meeting Abstract C1 [Bonfietti, L. X.; Szeszs, M. W.; Silva, D. C.; Martins, M. A.; Melhem, M. S. C.] Adolfo Lutz Inst, Arac Atuba, Brazil. [Pham, C. D.; Lockhart, S. R.] Ctr Dis Control & Prevent, Atlanta, GA USA. RI MELHEM, MARCIA/D-4477-2012 OI MELHEM, MARCIA/0000-0002-1335-8808 NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0933-7407 EI 1439-0507 J9 MYCOSES JI Mycoses PD MAY PY 2014 VL 57 SU 1 SI SI BP 48 EP 48 PG 1 WC Dermatology; Mycology SC Dermatology; Mycology GA AG0FL UT WOS:000335090600104 ER PT J AU Engelthaler, DM Hicks, N Gillece, J Roe, C Schupp, JM May, RC Voelz, K Fisher, MC Firacative, C Trilles, L Thompson, GR Lockhart, SR Keim, PS Meyer, W AF Engelthaler, D. M. Hicks, N. Gillece, J. Roe, C. Schupp, J. M. May, R. C. Voelz, K. Fisher, M. C. Firacative, C. Trilles, L. Thompson, G. R. Lockhart, S. R. Keim, P. S. Meyer, W. TI A whole population comparative genomics approach to understanding the emergence of Cryptococcus gattii in the American Pacific Northwest SO MYCOSES LA English DT Meeting Abstract C1 [Engelthaler, D. M.; Hicks, N.; Gillece, J.; Roe, C.; Schupp, J. M.; Keim, P. S.] Translat Genom Res Inst, Phoenix, AZ USA. [May, R. C.; Voelz, K.] Univ Birmingham, Birmingham, W Midlands, England. [Fisher, M. C.] Univ London Imperial Coll Sci Technol & Med, London, England. [Firacative, C.; Trilles, L.; Meyer, W.] Unvers Sydney, Sydney, NSW, Australia. [Thompson, G. R.] Univ Calif Davis, Davis, CA 95616 USA. [Lockhart, S. R.] Ctr Dis Control & Prevent, Atlanta, GA USA. RI Voelz, Kerstin/A-8888-2011 OI Voelz, Kerstin/0000-0003-0973-4353 NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0933-7407 EI 1439-0507 J9 MYCOSES JI Mycoses PD MAY PY 2014 VL 57 SU 1 SI SI BP 67 EP 67 PG 1 WC Dermatology; Mycology SC Dermatology; Mycology GA AG0FL UT WOS:000335090600143 ER PT J AU Sreenivasan, MV He, HH Park, SY AF Sreenivasan, Meera V. He, Hua H. Park, Sarah Y. TI Administration Time Between Seasonal Live-Attenuated Influenza Vaccine and Trivalent Influenza Vaccine During the "Stop Flu at School" Campaign-Hawaii, 2009 SO PUBLIC HEALTH REPORTS LA English DT Article ID CHILDREN; SCHOOLCHILDREN; EFFICACY; RECOMMENDATIONS; METAANALYSIS; RESPONSES AB Objectives. We determined whether the administration time differed between seasonal intranasal live-attenuated influenza vaccine (LAIV) and seasonal injectable trivalent inactivated influenza vaccine (TIV) during Hawaii's 2009 school-located influenza vaccination clinics. This information is useful for public health response and allows further investigation into possible differences between the two vaccines. Methods. We conducted a prospective cohort study in 15 public schools to determine mean times to administer LAIV and TIV to students. We performed group analyses to control for various clinic characteristics and conducted a stratified, weighted analysis. Results. A total of 4,701 students were enrolled in the study, and administration time was obtained for 3,869 (82%) students (1,492 [39%] LAIV and 2,377 [61%] TIV). The mean administration time for LAIV was 62 seconds and for TIV was 90 seconds, a difference of 28 seconds (p<0.01). This finding remained significant in the stratified analysis. Conclusions. Although results indicated that both LAIV and TIV can be administered rapidly among school-aged populations, LAIV was faster to administer. This finding, in addition to the greater immunogenicity of LAIV compared with TIV among children, may be an important consideration for public health administrators in planning school-located mass vaccination clinics and encouraging patient acceptance of this vaccine. C1 [Sreenivasan, Meera V.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. [He, Hua H.; Park, Sarah Y.] Hawaii Dept Hlth, Dis Outbreak Control Div, Honolulu, HI USA. RP Sreenivasan, MV (reprint author), Kaiser Permanente, Hawaii Med Grp, 2828 Paa St,Ste 2055, Honolulu, HI 96819 USA. EM meera.v.sreenivasan@kp.org NR 24 TC 1 Z9 1 U1 0 U2 0 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1900 M ST NW, STE 710, WASHINGTON, DC 20036 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD MAY-JUN PY 2014 VL 129 IS 3 BP 229 EP 236 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AG4XH UT WOS:000335423200004 PM 24791020 ER PT J AU Courtney-Long, E Stevens, A Caraballo, R Ramon, I Armour, BS AF Courtney-Long, Elizabeth Stevens, Alissa Caraballo, Ralph Ramon, Ismaila Armour, Brian S. TI Disparities in Current Cigarette Smoking Prevalence by Type of Disability, 2009-2011 SO PUBLIC HEALTH REPORTS LA English DT Article ID AGED GREATER-THAN-OR-EQUAL-TO-18 YEARS; UNITED-STATES; ADULTS; HEALTH; OLDER; MORTALITY; HISTORY AB Objectives. Smoking, the leading cause of disease and death in the United States, has been linked to a number of health conditions including cancer and cardiovascular disease. While people with a disability have been shown to be more likely to report smoking, little is known about the prevalence of smoking by type of disability, particularly for adults younger than 50 years of age. Methods. We used data from the 2009-2011 National Health Interview Survey to estimate the prevalence of smoking by type of disability and to examine the association of functional disability type and smoking among adults aged 18-49 years. Results. Adults with a disability were more likely than adults without a disability to be current smokers (38.8% vs. 20.7%, p<0.001). Among adults with disabilities, the prevalence of smoking ranged from 32.4% (self-care difficulty) to 43.8% (cognitive limitation). When controlling for sociodemographic characteristics, having a disability was associated with statistically significantly higher odds of current smoking (adjusted odds ratio = 1.57, 95% confidence interval 1.40, 1.77). Conclusions. The prevalence of current smoking for adults was higher for every functional disability type than for adults without a disability. By understanding the association between smoking and disability type among adults younger than 50 years of age, resources for cessation services can be better targeted during the ages when increased time for health improvement can occur. C1 [Courtney-Long, Elizabeth; Stevens, Alissa; Armour, Brian S.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Div Human Dev & Disabil, Atlanta, GA 30333 USA. [Caraballo, Ralph] Ctr Dis Control & Prevent, Off Smoking & Hlth, Epidemiol Branch, Atlanta, GA 30333 USA. [Ramon, Ismaila] Ctr Dis Control & Prevent, Assoc Univ Ctr Disabil, Atlanta, GA 30333 USA. RP Courtney-Long, E (reprint author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Div Human Dev & Disabil, 1600 Clifton Rd NE,MS E-88, Atlanta, GA 30333 USA. EM ECourtneyLong@cdc.gov NR 33 TC 8 Z9 8 U1 1 U2 2 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1900 M ST NW, STE 710, WASHINGTON, DC 20036 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD MAY-JUN PY 2014 VL 129 IS 3 BP 252 EP 260 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AG4XH UT WOS:000335423200007 PM 24791023 ER PT J AU Johnson, MG Williams, J Lee, A Bradley, KK AF Johnson, Matthew G. Williams, Jean Lee, Anthony Bradley, Kristy K. TI Completeness and Timeliness of Electronic vs. Conventional Laboratory Reporting for Communicable Disease Surveillance-Oklahoma, 2011 SO PUBLIC HEALTH REPORTS LA English DT Article ID SYSTEM AB Objectives. The Health Information Technology for Economic and Clinical Health (HITECH) Act encourages the meaningful use of certified electronic health record technology. A HITECH-compliant core component is nationwide electronic laboratory reporting (ELR) implementation for communicable disease surveillance. In Oklahoma, laboratories with >= 400 positive tests/year for reportable diseases must use ELR. Of 18 such laboratories, two have adopted ELR. We compared completeness and timeliness of ELR reports from these two laboratories with conventional reports from all other Oklahoma laboratories. Methods. We retrospectively reviewed confirmed reportable disease cases for January 1-December 31, 2011, excluding tuberculosis, hepatitis, sexually transmitted infections, diseases without laboratory diagnoses, and immediately reportable diseases. Probable reportable tickborne disease cases were included. We compared ELR with conventional reporting (i.e., mail, fax, telephone, and Internet). We assessed data completeness based on eight demographic and two laboratory fields in each disease report and timeliness by percentage of cases reported in <= 1 business day. Results. Overall, 1,867 reports met the inclusion criteria; 24% of these reports had been submitted by ELR. Data completeness was 90% for ELR and 95% for conventional reporting. Patient addresses accounted for 97% of the missing data fields for ELR reports. Timeliness was 91% for ELR and 87% for conventional reports. Conclusions. Although early in the transition to ELR compliance in Oklahoma, ELR has already yielded improved timeliness for communicable disease surveillance. However, ELR did not yield more complete reports than conventional reporting. Requiring specific demographic data fields for ELR reports can improve the completeness of ELR. C1 [Johnson, Matthew G.; Williams, Jean; Lee, Anthony] Oklahoma Dept Hlth, Acute Dis Serv, Oklahoma City, OK USA. [Johnson, Matthew G.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. [Bradley, Kristy K.] Oklahoma Dept Hlth, Off State Epidemiologist, Oklahoma City, OK USA. RP Johnson, MG (reprint author), Duke Univ, Med Ctr, Div Infect Dis, 315 Trent Dr, Durham, NC 27710 USA. EM matthew.g.johnson@dm.duke.edu NR 10 TC 0 Z9 0 U1 0 U2 4 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1900 M ST NW, STE 710, WASHINGTON, DC 20036 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD MAY-JUN PY 2014 VL 129 IS 3 BP 261 EP 266 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AG4XH UT WOS:000335423200008 PM 24791024 ER PT J AU Pouget, ER West, BS Tempalski, B Cooper, HLF Hall, HI Hu, XH Friedman, SR AF Pouget, Enrique R. West, Brooke S. Tempalski, Barbara Cooper, Hannah L. F. Hall, H. Irene Hu, Xiaohong Friedman, Samuel R. TI Persistent Racial/Ethnic Disparities in AIDS Diagnosis Rates Among People Who Inject Drugs in US Metropolitan Areas, 1993-2007 SO PUBLIC HEALTH REPORTS LA English DT Article ID SEXUALLY-TRANSMITTED-DISEASES; UNITED-STATES; SOCIAL DETERMINANTS; HEALTH DISPARITIES; RACIAL DISPARITIES; VIRAL-HEPATITIS; HIV DIAGNOSIS; USERS; PREVALENCE; INFECTION AB Objectives. We estimated race/ethnicity-specific incident AIDS diagnosis rates (IARs) among people who inject drugs (PWID) in U.S. metropolitan statistical areas (MSAs) over time to assess the change in disparities after highly active antiretroviral therapy (HAART) dissemination. Methods. We compared IARs and 95% confidence intervals (CIs) for black/African American and Hispanic/Latino PWID with those of white PWID in 93 of the most populous MSAs. We selected two three-year periods from the years immediately preceding HAART (1993-1995) and the years with the most recent available data (2005-2007). To maximize stability, we aggregated data across three-year periods, and we aggregated data for black/African American and Hispanic/Latino PWID for most comparisons with data for white PWID. We assessed disparities by comparing IAR 95% CIs for overlap. Results. IARs were significantly higher for black/African American and Hispanic/Latino PWID than for white PWID in 81% of MSAs in 1993-1995 and 77% of MSAs in 2005-2007. MSAs where disparities became non-significant over time were concentrated in the West. Significant differences were more frequent in comparisons between black/African American and white PWID (85% of MSAs in 1993-1995,79% of MSAs in 2005-2007) than in comparisons between Hispanic/Latino and white PWID (53% of MSAs in 1993-1995,56% of MSAs in 2005-2007). IARs declined modestly across racial/ethnic groups in most MSAs. Conclusions. AIDS diagnosis rates continue to be substantially higher for black/African American and Hispanic/Latino PWID than for white PWID in most large MSAs. This finding suggests a need for increased targeting of prevention and treatment programs, as well as research on MSA-level conditions that may serve to maintain the disparities. C1 [Pouget, Enrique R.; West, Brooke S.; Tempalski, Barbara; Friedman, Samuel R.] Natl Dev & Res Inst Inc, New York, NY 10010 USA. [Cooper, Hannah L. F.] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Hall, H. Irene; Hu, Xiaohong] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Pouget, ER (reprint author), Natl Dev & Res Inst Inc, 71 West 23rd St,8th Fl, New York, NY 10010 USA. EM pouget@ndri.org OI Tempalski, Barbara/0000-0002-6128-2510 FU NIDA NIH HHS [R01 DA013336, P30 DA121041] NR 53 TC 3 Z9 3 U1 2 U2 4 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1900 M ST NW, STE 710, WASHINGTON, DC 20036 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD MAY-JUN PY 2014 VL 129 IS 3 BP 267 EP 279 PG 13 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AG4XH UT WOS:000335423200009 PM 24791025 ER PT J AU Kempe, A Daley, MF Pyrzanowski, J Vogt, T Fang, H Rinehart, DJ Morgan, N Riis, M Rodgers, S McCormick, E Hammer, A Campagna, EJ Kile, D Dickinson, M Hambidge, SJ Shlay, JC AF Kempe, Allison Daley, Matthew F. Pyrzanowski, Jennifer Vogt, Tara Fang, Hai Rinehart, Deborah J. Morgan, Nicole Riis, Mette Rodgers, Sarah McCormick, Emily Hammer, Anne Campagna, Elizabeth J. Kile, Deidre Dickinson, Miriam Hambidge, Simon J. Shlay, Judith C. TI School-Located Influenza Vaccination With Third-Party Billing: Outcomes, Cost, and Reimbursement SO ACADEMIC PEDIATRICS LA English DT Article DE cost of care; influenza immunization; reimbursement; school-based health care; school-located immunization ID SEASONAL INFLUENZA; CHILDREN; COMMUNITY; SCHOOLCHILDREN; ATTITUDES; CLINICS; H1N1; FAMILIES; DELIVERY; ILLNESS AB OBJECTIVE: To assess rates of immunization; costs of conducting clinics; and reimbursements for a school-located influenza vaccination (SLIV) program that billed third-party payers. METHODS: SLIV clinics were conducted in 19 elementary schools in the Denver Public School district (September 2010 to February 2011). School personnel obtained parental consent, and a community vaccinator conducted clinics and performed billing. Vaccines For Children vaccine was available for eligible students. Parents were not billed for any fees. Data were collected regarding implementation costs and vaccine cost was calculated using published private sector prices. Reimbursement amounts were compared to costs. RESULTS: Overall, 30% of students (2784 of 9295) received influenza vaccine; 39% (1079 of 2784) needed 2 doses and 80% received both. Excluding vaccine costs, implementation costs were $24.69 per vaccination. The percentage of vaccine costs reimbursed was 62% overall (82% from State Child Health Insurance Program (SCHIP), 50% from private insurance). The percentage of implementation costs reimbursed was 19% overall (23% from private, 27% from Medicaid, 29% from SCRIP and 0% among uninsured). Overall, 25% of total costs (implementation plus vaccine) were reimbursed. CONCLUSIONS: A SLIV program resulted in vaccination of nearly one third of elementary students. Reimbursement rates were limited by 1) school restrictions on charging parents fees, 2) low payments for vaccine administration from public payers and 3) high rates of denials from private insurers. Some of these problems might be reduced by provisions in the Affordable Care Act. C1 [Kempe, Allison; Daley, Matthew F.; Pyrzanowski, Jennifer; Dickinson, Miriam] Childrens Hosp, Childrens Outcomes Res Program, Aurora, CO USA. [Kempe, Allison; Daley, Matthew F.; Hambidge, Simon J.] Univ Colorado, Dept Pediat, Aurora, CO USA. [Kempe, Allison; Campagna, Elizabeth J.; Kile, Deidre] Univ Colorado, Colorado Hlth Outcomes Program, Aurora, CO USA. [Fang, Hai] Univ Colorado, Dept Hlth Syst Management & Policy, Aurora, CO USA. [Dickinson, Miriam; Shlay, Judith C.] Univ Colorado, Dept Family Med, Aurora, CO USA. [Daley, Matthew F.; McCormick, Emily] Kaiser Permanente, Inst Hlth Res, Denver, CO USA. [Vogt, Tara] Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [McCormick, Emily] Ctr Dis Control & Prevent, Publ Hlth Prevent Serv, Atlanta, GA USA. [Rinehart, Deborah J.] Denver Hlth, Hlth Serv Res, Denver, CO USA. [Morgan, Nicole] Denver Hlth, Physician Billing, Denver, CO USA. [Riis, Mette; Rodgers, Sarah; McCormick, Emily; Hammer, Anne; Shlay, Judith C.] Denver Hlth, Denver Publ Hlth, Denver, CO USA. [Hammer, Anne; Hambidge, Simon J.] Denver Hlth, Community Hlth Serv, Denver, CO USA. RP Kempe, A (reprint author), 13199 E Montview Blvd,Suite 300, Aurora, CO 80045 USA. EM Allison.Kempe@childrenscolorado.org FU Centers for Disease Control and Prevention [1U01P000199] FX This investigation was supported and funded by Cooperative Agreement 1U01P000199 from the Centers for Disease Control and Prevention. NR 39 TC 9 Z9 9 U1 2 U2 9 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1876-2859 EI 1876-2867 J9 ACAD PEDIATR JI Acad. Pediatr. PD MAY-JUN PY 2014 VL 14 IS 3 BP 234 EP 240 PG 7 WC Pediatrics SC Pediatrics GA AG4CX UT WOS:000335368000004 PM 24767776 ER PT J AU Kempe, A Daley, MF Pyrzanowski, J Vogt, TM Campagna, EJ Dickinson, LM Hambidge, SJ Shlay, JC AF Kempe, Allison Daley, Matthew F. Pyrzanowski, Jennifer Vogt, Tara M. Campagna, Elizabeth J. Dickinson, L. Miriam Hambidge, Simon J. Shlay, Judith C. TI School-Located Influenza Vaccination With Third-Party Billing: What Do Parents Think? SO ACADEMIC PEDIATRICS LA English DT Article DE immunization delivery; influenza vaccination; school-located immunization delivery ID HEALTHY-YOUNG CHILDREN; SEASONAL INFLUENZA; AGED CHILDREN; ATTITUDES; IMMUNIZATION; SCHOOLCHILDREN; PERSPECTIVES; PROGRAMS; DELIVERY; RATES AB OBJECTIVE: School-located influenza vaccination (SLIV) may be instrumental in achieving high vaccination rates among children. Sustainability of SLIV programs may require third-party billing. This study assessed, among parents of elementary school students, the attitudes about SLIV and billing at school, as well as factors associated with being supportive of SLIV. METHODS: We conducted a survey (April 2010 to June 2010) of parents of 1000 randomly selected primarily low-income children at 20 elementary schools at which SLIV with billing had occurred. RESULTS: Response rate was 70% (n = 699). Eighty-one percent agreed (61% strongly) they "would be okay" with SLIV for their child. Many agreed it was better to get vaccinated at their child's doctor's office because they could take care of other health issues (72%) and the doctor knows the child's medical history (65%). However, an equal percentage (47%) thought the best place for influenza vaccination was the child's doctor's office and the child's school. Twenty-five percent did not want to give health insurance information necessary for billing at school. Factors independently associated with strongly supporting SLIV included parental education of high school or less (relative risk 1.30; 95% confidence interval 1.09-1.58), Hispanic ethnicity (1.25; 1.08-1.45); believing the vaccine is efficacious (1.49; 1.23-1.84); and finding school delivery more convenient (2.37; 1.82-3.45). Having concerns about the safety of influenza vaccine (0.80; 0.72-0.88) and not wanting their child to be vaccinated without a parent (0.74; 0.64-0.83) were negatively associated. CONCLUSIONS: The majority of parents were supportive of SLIV, although parental concerns about not being present for vaccination and about the safety and efficacy of the vaccine will need to be addressed. C1 [Kempe, Allison; Daley, Matthew F.; Pyrzanowski, Jennifer; Campagna, Elizabeth J.; Dickinson, L. Miriam] Childrens Hosp, Childrens Outcomes Res Program, Aurora, CO USA. [Kempe, Allison; Hambidge, Simon J.] Univ Colorado, Dept Pediat, Aurora, CO USA. [Dickinson, L. Miriam; Shlay, Judith C.] Univ Colorado, Dept Family Med, Aurora, CO USA. [Daley, Matthew F.] Kaiser Permanente, Inst Hlth Res, Denver, CO USA. [Vogt, Tara M.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Hambidge, Simon J.] Denver Hlth, Community Hlth Serv, Denver, CO USA. [Shlay, Judith C.] Denver Hlth, Denver Publ Hlth, Denver, CO USA. RP Kempe, A (reprint author), 13199 E Montview Blvd,Suite 300, Aurora, CO 80045 USA. EM Allison.Kempe@renscolorado.org FU Centers for Disease Control and Prevention [U01 IP000199]; Denver public schools personnel,; MSN; CNS; RN FX This investigation was supported and funded by Cooperative Agreement 1 U01 IP000199 from the Centers for Disease Control and Prevention. This investigation would not have been possible without the strong support of Denver public schools personnel, including Donna Shocks, MSN, CNS, RN, manager of nursing and student health; Jean Lyons, BSN, RN, nursing supervisor; Scott Romero, MS, coordinated school health specialist; and school principals, nurses, and staff at each of the participating schools. NR 32 TC 9 Z9 9 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1876-2859 EI 1876-2867 J9 ACAD PEDIATR JI Acad. Pediatr. PD MAY-JUN PY 2014 VL 14 IS 3 BP 241 EP 248 PG 8 WC Pediatrics SC Pediatrics GA AG4CX UT WOS:000335368000005 PM 24767777 ER PT J AU Vosburgh, DJH Ku, BK Peters, TM AF Vosburgh, Donna J. H. Ku, Bon Ki Peters, Thomas M. TI Evaluation of a Diffusion Charger for Measuring Aerosols in a Workplace SO ANNALS OF OCCUPATIONAL HYGIENE LA English DT Article DE diffusion charger; nanoparticles; surface area monitor ID SURFACE-AREA; ENGINEERED NANOMATERIALS; ULTRAFINE PARTICLES; EXPOSURE; MASS; ASSOCIATION; DEPOSITION; MORTALITY; BATTERY; NUMBER AB The model DC2000CE diffusion charger from EcoChem Analytics (League City, TX, USA) has the potential to be of considerable use to measure airborne surface area concentrations of nanoparticles in the workplace. The detection efficiency of the DC2000CE to reference instruments was determined with monodispersed spherical particles from 54 to 565.7nm. Surface area concentrations measured by a DC2000CE were then compared to measured and detection efficiency adjusted reference surface area concentrations for polydispersed aerosols (propylene torch exhaust, incense, diesel exhaust, and Arizona road dust) over a range of particle sizes that may be encountered in a workplace. The ratio of surface area concentrations measured by the DC2000CE to that measured with the reference instruments for unimodal and multimodal aerosols ranged from 0.02 to 0.52. The ratios for detection efficiency adjusted unimodal and multimodal surface area concentrations were closer to unity (0.931.19) for aerosols where the majority of the surface area was within the size range of particles used to create the correction. A detection efficiency that includes the entire size range of the DC2000CE is needed before a calibration correction for the DC2000CE can be created. For diesel exhaust, the DC2000CE retained a linear response compared to reference instruments up to 2500mm(2) m(3), which was greater than the maximum range stated by the manufacturer (1000mm(2) m(3)). Physical limitations with regard to DC2000CE orientation, movement, and vibration were identified. Vibrating the DC2000CE while measuring aerosol concentrations may cause an increase of similar to 35mm(2) m(3), whereas moving the DC2000CE may cause concentrations to be inflated by as much as 400mm(2) m(3). Depending on the concentration of the aerosol of interest being measured, moving or vibrating a DC2000CE while measuring the aerosol should be avoided. C1 [Vosburgh, Donna J. H.] Univ Wisconsin, Dept Occupat & Environm Safety & Hlth, Whitewater, WI 53190 USA. [Ku, Bon Ki] NIOSH, Div Appl Res & Technol, Cincinnati, OH 45226 USA. [Peters, Thomas M.] Univ Iowa, Dept Occupat & Environm Hlth, Iowa City, IA 52242 USA. RP Vosburgh, DJH (reprint author), Univ Wisconsin, Dept Occupat & Environm Safety & Hlth, 800 West Main St, Whitewater, WI 53190 USA. EM vosburgd@uww.edu FU National Institute for Occupational Safety and Health [K01OH009255]; University of Iowa Executive Council of Graduate and Professional Students FX National Institute for Occupational Safety and Health (K01OH009255); University of Iowa Executive Council of Graduate and Professional Students. NR 28 TC 0 Z9 0 U1 0 U2 19 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0003-4878 EI 1475-3162 J9 ANN OCCUP HYG JI Ann. Occup. Hyg. PD MAY PY 2014 VL 58 IS 4 BP 424 EP 436 DI 10.1093/annhyg/met082 PG 13 WC Public, Environmental & Occupational Health; Toxicology SC Public, Environmental & Occupational Health; Toxicology GA AF8YB UT WOS:000335000600003 PM 24458322 ER PT J AU Evans, DE Turkevich, LA Roettgers, CT Deye, GJ AF Evans, Douglas E. Turkevich, Leonid A. Roettgers, Cynthia T. Deye, Gregory J. TI Comment on Comparison of Powder Dustiness Methods SO ANNALS OF OCCUPATIONAL HYGIENE LA English DT Letter C1 [Evans, Douglas E.; Turkevich, Leonid A.; Roettgers, Cynthia T.; Deye, Gregory J.] NIOSH, Chem Exposure & Monitoring Branch, Div Appl Res & Technol, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. RP Evans, DE (reprint author), NIOSH, Chem Exposure & Monitoring Branch, Div Appl Res & Technol, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. EM dje3@cdc.gov NR 8 TC 0 Z9 0 U1 1 U2 7 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0003-4878 EI 1475-3162 J9 ANN OCCUP HYG JI Ann. Occup. Hyg. PD MAY PY 2014 VL 58 IS 4 BP 524 EP 528 DI 10.1093/annhyg/met086 PG 5 WC Public, Environmental & Occupational Health; Toxicology SC Public, Environmental & Occupational Health; Toxicology GA AF8YB UT WOS:000335000600011 PM 24477891 ER PT J AU Raphael, BH Bradshaw, M Kalb, SR Joseph, LA Luquez, C Barr, JR Johnson, EA Maslanka, SE AF Raphael, Brian H. Bradshaw, Marite Kalb, Suzanne R. Joseph, Lavin A. Luquez, Carolina Barr, John R. Johnson, Eric A. Maslanka, Susan E. TI Clostridium botulinum Strains Producing BoNT/F4 or BoNT/F5 SO APPLIED AND ENVIRONMENTAL MICROBIOLOGY LA English DT Article ID GENES; DIVERSITY AB Botulinum neurotoxin type F (BoNT/F) may be produced by Clostridium botulinum alone or in combination with another toxin type such as BoNT/A or BoNT/B. Type F neurotoxin gene sequences have been further classified into seven toxin subtypes. Recently, the genome sequence of one strain of C. botulinum (Af84) was shown to contain three neurotoxin genes (bont/F4, bont/F5, and bont/A2). In this study, eight strains containing bont/F4 and seven strains containing bont/F5 were examined. Culture supernatants produced by these strains were incubated with BoNT/F-specific peptide substrates. Cleavage products of these peptides were subjected to mass spectral analysis, allowing detection of the BoNT/F subtypes present in the culture supernatants. PCR analysis demonstrated that a plasmid-specific marker (PL-6) was observed only among strains containing bont/F5. Among these strains, Southern hybridization revealed the presence of an approximately 242-kb plasmid harboring bont/F5. Genome sequencing of four of these strains revealed that the genomic backgrounds of strains harboring either bont/F4 or bont/F5 are diverse. None of the strains analyzed in this study were shown to produce BoNT/F4 and BoNT/F5 simultaneously, suggesting that strain Af84 is unusual. Finally, these data support a role for the mobility of a bont/F5-carrying plasmid among strains of diverse genomic backgrounds. C1 [Raphael, Brian H.; Kalb, Suzanne R.; Joseph, Lavin A.; Luquez, Carolina; Barr, John R.; Maslanka, Susan E.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Bradshaw, Marite; Johnson, Eric A.] Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA. RP Raphael, BH (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. EM BRaphael@cdc.gov OI Kalb, Suzanne/0000-0002-8067-136X; Raphael, Brian/0000-0003-2778-2623 FU Centers for Disease Control and Prevention Office of Public Health Preparedness and Response; Pacific Southwest RCE (NIH) [U54-AI-065359]; NIH/NIAID Regional Center for Excellence for Biodefense and Emerging Infectious Diseases Research (RCE) Program FX This publication was supported by funds made available from the Centers for Disease Control and Prevention Office of Public Health Preparedness and Response. The work in the laboratory of E.A.J. was sponsored by the NIH/NIAID Regional Center for Excellence for Biodefense and Emerging Infectious Diseases Research (RCE) Program. E.A.J. and M.B. acknowledge membership in and support from the Pacific Southwest RCE (NIH award U54-AI-065359). The findings and conclusions in this report are ours and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 16 TC 6 Z9 6 U1 0 U2 3 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0099-2240 EI 1098-5336 J9 APPL ENVIRON MICROB JI Appl. Environ. Microbiol. PD MAY PY 2014 VL 80 IS 10 BP 3250 EP 3257 DI 10.1128/AEM.00284-14 PG 8 WC Biotechnology & Applied Microbiology; Microbiology SC Biotechnology & Applied Microbiology; Microbiology GA AG4JQ UT WOS:000335386200032 PM 24632257 ER PT J AU Cancelliere, C Hincapie, C Keightley, M Godbolt, A Cote, P Kristman, V Stalnacke, BM Carroll, L Hung, R Borg, J Nygren-de Boussard, C Coronado, V Donovan, J Cassidy, JD AF Cancelliere, Carol Hincapie, Cesar Keightley, Michelle Godbolt, Alison Cote, Pierre Kristman, Vicki Stalnacke, Britt-Marie Carroll, Linda Hung, Ryan Borg, Jorgen Nygren-de Boussard, Catharina Coronado, Victor Donovan, James Cassidy, J. David TI A systematic review of prognosis and return-to-play after sport concussion: Results of the International Collaboration on MTBI Prognosis (ICoMP) SO BRAIN INJURY LA English DT Meeting Abstract C1 [Cancelliere, Carol; Hincapie, Cesar; Donovan, James] Univ Toronto, Toronto, ON, Canada. [Keightley, Michelle] Bloorview Res Inst, Toronto, ON, Canada. [Godbolt, Alison; Borg, Jorgen; Nygren-de Boussard, Catharina] Karolinska Inst, Stockholm, Sweden. [Cote, Pierre] Univ Inst Technol, Oshawa, ON, Canada. [Kristman, Vicki] Lakehead Univ, Thunder Bay, ON P7B 5E1, Canada. [Stalnacke, Britt-Marie] Umea Univ, Umea, Sweden. [Carroll, Linda] Univ Alberta, Edmonton, AB, Canada. [Hung, Ryan] Holland Bloorview Kids Rehabil Hosp, Toronto, ON, Canada. [Coronado, Victor] Ctr Dis Control & Prevent, Atlanta, GA USA. [Cassidy, J. David] Univ Southern Denmark, Odense, Denmark. NR 0 TC 0 Z9 0 U1 0 U2 3 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0269-9052 EI 1362-301X J9 BRAIN INJURY JI Brain Inj. PD MAY PY 2014 VL 28 IS 5-6 MA 0337 BP 636 EP 637 PG 2 WC Neurosciences; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA AF9EA UT WOS:000335017000295 ER PT J AU Haarbauer-Krupa, J Lionbarger, M McGuire, L AF Haarbauer-Krupa, Juliet Lionbarger, Michael McGuire, Lisa TI Review of concussion guidelines for children and youth SO BRAIN INJURY LA English DT Meeting Abstract C1 [Haarbauer-Krupa, Juliet; Lionbarger, Michael; McGuire, Lisa] CDC, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0269-9052 EI 1362-301X J9 BRAIN INJURY JI Brain Inj. PD MAY PY 2014 VL 28 IS 5-6 MA 0471 BP 688 EP 688 PG 1 WC Neurosciences; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA AF9EA UT WOS:000335017000420 ER PT J AU Harrison-Felix, C Pretz, C Hammond, FM Cuthbert, J Bell, J Corrigan, J Miller, AC Haarbauer-Krupa, J AF Harrison-Felix, Cynthia Pretz, Christopher Hammond, Flora M. Cuthbert, Jeffrey Bell, Jeneita Corrigan, John Miller, A. Cate Haarbauer-Krupa, Juliet TI Life expectancy following inpatient rehabilitation for traumatic brain injury in the US SO BRAIN INJURY LA English DT Meeting Abstract C1 [Harrison-Felix, Cynthia; Pretz, Christopher; Cuthbert, Jeffrey] Craig Hosp, Englewood, CO USA. [Hammond, Flora M.] Indiana Univ Sch Med, Indianapolis, IN 46202 USA. [Bell, Jeneita; Haarbauer-Krupa, Juliet] CDC, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA. [Corrigan, John] Ohio State Univ, Columbus, OH 43210 USA. [Miller, A. Cate] US DOE, Natl Inst Disabil & Rehabil Res, Washington, DC 20585 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0269-9052 EI 1362-301X J9 BRAIN INJURY JI Brain Inj. PD MAY PY 2014 VL 28 IS 5-6 MA 0481 BP 693 EP 693 PG 1 WC Neurosciences; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA AF9EA UT WOS:000335017000430 ER PT J AU Cuthbert, J Harrison-Felix, C Whiteneck, G Pretz, C Bell, J Haarbauer-Krupa, J Corrigan, J AF Cuthbert, Jeffrey Harrison-Felix, Cynthia Whiteneck, Gale Pretz, Chris Bell, Jeneita Haarbauer-Krupa, Juliet Corrigan, John TI US population characteristics and age-related trends of late teens and adults receiving inpatient rehabilitation for a primary diagnosis of TBI between 2001 and 2010 SO BRAIN INJURY LA English DT Meeting Abstract C1 [Cuthbert, Jeffrey; Harrison-Felix, Cynthia; Whiteneck, Gale; Pretz, Chris] Craig Hosp, Englewood, CO USA. [Bell, Jeneita; Haarbauer-Krupa, Juliet] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA. [Corrigan, John] Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0269-9052 EI 1362-301X J9 BRAIN INJURY JI Brain Inj. PD MAY PY 2014 VL 28 IS 5-6 MA 0507 BP 704 EP 704 PG 1 WC Neurosciences; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA AF9EA UT WOS:000335017000455 ER PT J AU Cuthbert, J Corrigan, J Harrison-Felix, C Bell, J Pretz, C Haarbauer-Krupa, J Whiteneck, G Miller, C AF Cuthbert, Jeffrey Corrigan, John Harrison-Felix, Cynthia Bell, Jeneita Pretz, Christopher Haarbauer-Krupa, Juliet Whiteneck, Gale Miller, Cate TI US population-based 2-and 5-year employment, health and social outcomes for individuals receiving inpatient rehabilitation for a primary diagnosis of TBI between 2001-2010 SO BRAIN INJURY LA English DT Meeting Abstract C1 [Cuthbert, Jeffrey; Harrison-Felix, Cynthia; Pretz, Christopher; Whiteneck, Gale] Craig Hosp, Res Dept, Englewood, CO USA. [Corrigan, John] Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA. [Bell, Jeneita; Haarbauer-Krupa, Juliet] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA. [Miller, Cate] Natl Inst Disabil & Rehabil Res, Dept Educ, Washington, DC USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0269-9052 EI 1362-301X J9 BRAIN INJURY JI Brain Inj. PD MAY PY 2014 VL 28 IS 5-6 MA 0512 BP 706 EP 707 PG 2 WC Neurosciences; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA AF9EA UT WOS:000335017000460 ER PT J AU Haarbauer-Krupa, J Parks, S AF Haarbauer-Krupa, Juliet Parks, Sharyn TI Abusive head trauma in young children: Descriptive factors and outcomes SO BRAIN INJURY LA English DT Meeting Abstract C1 [Haarbauer-Krupa, Juliet; Parks, Sharyn] CDC, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0269-9052 EI 1362-301X J9 BRAIN INJURY JI Brain Inj. PD MAY PY 2014 VL 28 IS 5-6 MA 0720 BP 784 EP 784 PG 1 WC Neurosciences; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA AF9EA UT WOS:000335017000649 ER PT J AU Hung, R Carroll, L Cancelliere, C Cote, P Rumney, P Keightley, M Coronado, V Stalnacke, BM Cassidy, JD AF Hung, Ryan Carroll, Linda Cancelliere, Carol Cote, Pierre Rumney, Peter Keightley, Michelle Coronado, Victor Stalnacke, Britt-Marie Cassidy, J. David TI A systematic review of the clinical course, natural history and prognosis for paediatric MTBI: Results of the International Collaboration on MTBI Prognosis (ICoMP) SO BRAIN INJURY LA English DT Meeting Abstract C1 [Hung, Ryan; Rumney, Peter; Keightley, Michelle] Holland Bloorview Kids Rehabil Hosp, Toronto, ON, Canada. [Carroll, Linda] Univ Alberta, Edmonton, AB, Canada. [Cancelliere, Carol; Cote, Pierre; Cassidy, J. David] Univ Toronto, Toronto, ON, Canada. [Coronado, Victor] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA. [Stalnacke, Britt-Marie] Umea Univ, Umea, Sweden. NR 0 TC 0 Z9 0 U1 0 U2 2 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0269-9052 EI 1362-301X J9 BRAIN INJURY JI Brain Inj. PD MAY PY 2014 VL 28 IS 5-6 MA 0779 BP 806 EP 807 PG 2 WC Neurosciences; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA AF9EA UT WOS:000335017000704 ER PT J AU Edwards, BK Noone, AM Mariotto, AB Simard, EP Boscoe, FP Henley, SJ Jemal, A Cho, H Anderson, RN Kohler, BA Eheman, CR Ward, EM AF Edwards, Brenda K. Noone, Anne-Michelle Mariotto, Angela B. Simard, Edgar P. Boscoe, Francis P. Henley, S. Jane Jemal, Ahmedin Cho, Hyunsoon Anderson, Robert N. Kohler, Betsy A. Eheman, Christie R. Ward, Elizabeth M. TI Annual Report to the Nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer SO CANCER LA English DT Editorial Material DE survival; North American Association of Central Cancer Registries (NAACCR); Surveillance; multiple chronic conditions; comorbidity; Epidemiology; trends; mortality; incidence; multiple health conditions; National Program of Cancer Registries (NPCR); and End Results (SEER)-Medicare ID ONCOLOGY SPECIALTY CARE; ADJUSTED LIFE-YEARS; QUALITY-OF-CARE; UNITED-STATES; SURVIVORSHIP CARE; SURVEILLANCE DATA; INCIDENCE RATES; SPECIAL SECTION; GLOBAL BURDEN; MEDICARE DATA AB BACKGROUND The American Cancer Society (ACS), the Centers for Disease Control and Prevention (CDC), the National Cancer Institute (NCI), and the North American Association of Central Cancer Registries (NAACCR) collaborate annually to provide updates on cancer incidence and death rates and trends in these outcomes for the United States. This year's report includes the prevalence of comorbidity at the time of first cancer diagnosis among patients with lung, colorectal, breast, or prostate cancer and survival among cancer patients based on comorbidity level. METHODS Data on cancer incidence were obtained from the NCI, the CDC, and the NAACCR; and data on mortality were obtained from the CDC. Long-term (1975/1992-2010) and short-term (2001-2010) trends in age-adjusted incidence and death rates for all cancers combined and for the leading cancers among men and women were examined by joinpoint analysis. Through linkage with Medicare claims, the prevalence of comorbidity among cancer patients who were diagnosed between 1992 through 2005 residing in 11 Surveillance, Epidemiology, and End Results (SEER) areas were estimated and compared with the prevalence in a 5% random sample of cancer-free Medicare beneficiaries. Among cancer patients, survival and the probabilities of dying of their cancer and of other causes by comorbidity level, age, and stage were calculated. RESULTS Death rates continued to decline for all cancers combined for men and women of all major racial and ethnic groups and for most major cancer sites; rates for both sexes combined decreased by 1.5% per year from 2001 through 2010. Overall incidence rates decreased in men and stabilized in women. The prevalence of comorbidity was similar among cancer-free Medicare beneficiaries (31.8%), breast cancer patients (32.2%), and prostate cancer patients (30.5%); highest among lung cancer patients (52.9%); and intermediate among colorectal cancer patients (40.7%). Among all cancer patients and especially for patients diagnosed with local and regional disease, age and comorbidity level were important influences on the probability of dying of other causes and, consequently, on overall survival. For patients diagnosed with distant disease, the probability of dying of cancer was much higher than the probability of dying of other causes, and age and comorbidity had a smaller effect on overall survival. CONCLUSIONS Cancer death rates in the United States continue to decline. Estimates of survival that include the probability of dying of cancer and other causes stratified by comorbidity level, age, and stage can provide important information to facilitate treatment decisions. Cancer 2014;120:1290-1314. (c) 2013 American Cancer Society. C1 [Edwards, Brenda K.; Noone, Anne-Michelle; Mariotto, Angela B.; Cho, Hyunsoon] NCI, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA. [Simard, Edgar P.; Jemal, Ahmedin; Ward, Elizabeth M.] Amer Canc Soc, Surveillance Res Program, Atlanta, GA 30329 USA. [Boscoe, Francis P.; Kohler, Betsy A.] North Amer Assoc Cent Canc Registries, Springfield, IL USA. [Henley, S. Jane; Eheman, Christie R.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Anderson, Robert N.] Ctr Dis Control & Prevent, Div Vital Stat, Natl Ctr Hlth Stat, Hyattsville, MD USA. RP Edwards, BK (reprint author), NCI, Div Canc Control & Populat Sci, 9609 Med Ctr Dr,Room 4E338, Bethesda, MD 20892 USA. EM edwardsb@mail.nih.gov OI Henley, S Jane/0000-0002-2420-306X FU Intramural NIH HHS [Z99 CA999999] NR 113 TC 240 Z9 251 U1 8 U2 53 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0008-543X EI 1097-0142 J9 CANCER-AM CANCER SOC JI Cancer PD MAY 1 PY 2014 VL 120 IS 9 BP 1290 EP 1314 DI 10.1002/cncr.28509 PG 25 WC Oncology SC Oncology GA AF4BT UT WOS:000334657100005 PM 24343171 ER PT J AU Yu, GQ Gail, MH Shi, JX Klepac-Ceraj, V Paster, BJ Dye, BA Wang, GQ Wei, WQ Fan, JH Qiao, YL Dawsey, SM Freedman, ND Abnet, CC AF Yu, Guoqin Gail, Mitchell H. Shi, Jianxin Klepac-Ceraj, Vanja Paster, Bruce J. Dye, Bruce A. Wang, Guo-Qing Wei, Wen-Qiang Fan, Jin-Hu Qiao, You-Lin Dawsey, Sanford M. Freedman, Neal D. Abnet, Christian C. TI Association between Upper Digestive Tract Microbiota and Cancer-Predisposing States in the Esophagus and Stomach SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION LA English DT Article ID SQUAMOUS-CELL CARCINOMA; HELICOBACTER-PYLORI INFECTION; INFLAMMATORY BOWEL DISEASES; SERUM PEPSINOGENS; GUT MICROBIOME; GASTRIC-CANCER; PERNICIOUS-ANEMIA; HIGH-RISK; POPULATION; CHINA AB Background: The human upper digestive tract microbial community (microbiota) is not well characterized and few studies have explored how it relates to human health. We examined the relationship between upper digestive tract microbiota and two cancer-predisposing states, serum pepsinogen I/pepsinogen II ratio (PGI/II; predictor of gastric cancer risk) and esophageal squamous dysplasia (ESD; the precursor lesion of esophageal squamous cell carcinoma; ESCC) in a cross-sectional design. Methods: The Human Oral Microbe Identification Microarray was used to test for the presence of 272 bacterial species in 333 upper digestive tract samples from a Chinese cancer screening cohort. Serum PGI and PGII were determined by ELISA. ESD was determined by chromoendoscopy with biopsy. Results: Lower microbial richness (number of bacterial genera per sample) was significantly associated with lower PGI/II ratio (P = 0.034) and the presence of ESD (P = 0.018). We conducted principal component (PC) analysis on a beta-diversity matrix (pairwise difference in microbiota), and observed significant correlations between PC1, PC3, and PGI/II (P = 0.004 and 0.009, respectively), and between PC1 and ESD (P = 0.003). Conclusions: Lower microbial richness in upper digestive tract was independently associated with both cancer-predisposing states in the esophagus and stomach (presence of ESD and lower PGI/II). Impact: These novel findings suggest that the upper digestive tract microbiota may play a role in the etiology of chronic atrophic gastritis and ESD, and therefore in the development of gastric and esophageal cancers. (C) 2014 AACR. C1 [Yu, Guoqin; Gail, Mitchell H.; Shi, Jianxin; Dawsey, Sanford M.; Freedman, Neal D.; Abnet, Christian C.] NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA. [Dye, Bruce A.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD USA. [Klepac-Ceraj, Vanja; Paster, Bruce J.] Forsyth Inst, Cambridge, MA USA. [Klepac-Ceraj, Vanja] Wellesley Coll, Wellesley, MA 02181 USA. [Paster, Bruce J.] Harvard Univ, Sch Dent Med, Boston, MA 02115 USA. [Wang, Guo-Qing; Wei, Wen-Qiang; Fan, Jin-Hu; Qiao, You-Lin] Chinese Acad Med Sci, Inst Canc, Beijing 100021, Peoples R China. RP Yu, GQ (reprint author), NCI, Div Canc Epidemiol & Genet, Genet Epidemiol Branch, 9609 Med Ctr Dr,Room 6E518,MSC 9704, Bethesda, MD 20892 USA. EM yug3@mail.nih.gov RI Qiao, You-Lin/B-4139-2012; Abnet, Christian/C-4111-2015; Freedman, Neal/B-9741-2015; OI Qiao, You-Lin/0000-0001-6380-0871; Abnet, Christian/0000-0002-3008-7843; Freedman, Neal/0000-0003-0074-1098; Klepac-Ceraj, Vanja/0000-0001-5387-5706 FU Intramural Research Program of the NIH, National Cancer Institute FX This study was supported by the Intramural Research Program of the NIH, National Cancer Institute. NR 33 TC 14 Z9 15 U1 0 U2 25 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1055-9965 EI 1538-7755 J9 CANCER EPIDEM BIOMAR JI Cancer Epidemiol. Biomarkers Prev. PD MAY PY 2014 VL 23 IS 5 BP 735 EP 741 DI 10.1158/1055-9965.EPI-13-0855 PG 7 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA AG0ZU UT WOS:000335145300005 PM 24700175 ER PT J AU Cuzick, J Myers, O Hunt, WC Robertson, M Joste, NE Castle, PE Benard, VB Wheeler, CM AF Cuzick, Jack Myers, Orrin Hunt, William C. Robertson, Michael Joste, Nancy E. Castle, Philip E. Benard, Vicki B. Wheeler, Cosette M. CA New Mexico HPV Pap Registry Steeri TI A Population-Based Evaluation of Cervical Screening in the United States: 2008-2011 SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION LA English DT Article ID HUMAN-PAPILLOMAVIRUS VACCINATION; AMERICAN-CANCER-SOCIETY; PREPAID HEALTH PLAN; YOUNG-WOMEN; OLDER WOMEN; MORTALITY; CYTOLOGY; NETHERLANDS; TRENDS; SMEAR AB Background: Cervical screening consumes substantial resources, but little is known about utilization in the United States or compliance with guideline recommendations. Methods: To describe population screening coverage, utilization, and outcomes and examine time trends from 2008 to 2011, cervical cytology reports from women residing in New Mexico (981,063 tests from 511,381 women) were evaluated. Results: From 2008 to 2011 cervical screening utilization decreased at all ages, but especially in younger women, with a two-third reduction at ages 15 to 20 years. Ninety-four percent of women ages 25 to 29 years were screened within 48 months but coverage decreased at older ages to 69% at 45 to 49 years and 55% at 60 to 64 years. Intervals between screening tests were significantly longer in 2011 compared with 2008 [HR = 1.23; 95% confidence intervals (CI), 1.22-1.24], although the commonest rescreening interval was 13 months. In 2011, 91.9% of screening tests for women ages 21 to 65 years were negative, 6.6% showed minor abnormalities, and 1.0% high-grade abnormalities. High-grade abnormality rates were relatively constant over time, but minor abnormalities and atypical cells cannot rule out high-grade (ASC-H) were increasing. Conclusions: This population-based evaluation of cervical screening shows high coverage under the age of 40 years, but lower levels in older women. Screening under age 21 years is becoming less common and screening intervals are lengthening, reflecting updates in national screening guidelines. Impact: Assessment of cervical screening intervals and population outcomes is essential for accurately estimating the impact and effectiveness of changing recommendations and vaccination against human papilloma virus infections. (C) 2013 AACR. C1 [Cuzick, Jack] Queen Mary Univ London, Wolfson Inst Prevent Med, Ctr Canc Prevent, London, England. [Myers, Orrin] Univ New Mexico, Hlth Sci Ctr, House Prevent Epidemiol HOPE, Div Epidemiol,Dept Internal Med, Albuquerque, NM 87131 USA. [Hunt, William C.; Robertson, Michael; Joste, Nancy E.; Wheeler, Cosette M.] Univ New Mexico, Hlth Sci Ctr, House Prevent Epidemiol HOPE, Dept Pathol, Albuquerque, NM 87131 USA. [Castle, Philip E.] Global Canc Initiat, Chestertown, MD USA. [Benard, Vicki B.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA USA. RP Wheeler, CM (reprint author), House Prevent Epidemiol HOPE, Dept Pathol, MSC 02-1670,1816 Sigma Chi Rd NE, Albuquerque, NM 87131 USA. EM cwheeler@salud.unm.edu FU U.S. National Institute of Allergy and Infectious Diseases (NIAID); U.S. National Cancer Institute (NCI) [U19AI084081, U54CA164336] FX ~The study was funded by the U.S. National Institute of Allergy and Infectious Diseases (NIAID) and the U.S. National Cancer Institute (NCI) under cooperative agreements U19AI084081 and U54CA164336 to C. Wheeler. NR 42 TC 19 Z9 19 U1 0 U2 6 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1055-9965 EI 1538-7755 J9 CANCER EPIDEM BIOMAR JI Cancer Epidemiol. Biomarkers Prev. PD MAY PY 2014 VL 23 IS 5 BP 765 EP 773 DI 10.1158/1055-9965.EPI-13-0973 PG 9 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA AG0ZU UT WOS:000335145300008 PM 24302677 ER PT J AU Rosen, JB Rota, JS Hickman, CJ Sowers, SB Mercader, S Rota, PA Bellini, WJ Huang, AJ Doll, MK Zucker, JR Zimmerman, CM AF Rosen, Jennifer B. Rota, Jennifer S. Hickman, Carole J. Sowers, Sun B. Mercader, Sara Rota, Paul A. Bellini, William J. Huang, Ada J. Doll, Margaret K. Zucker, Jane R. Zimmerman, Christopher M. TI Outbreak of Measles Among Persons With Prior Evidence of Immunity, New York City, 2011 SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE measles; outbreak; immunity; vaccine failure; waning immunity ID HIGHLY VACCINATED POPULATION; UNITED-STATES; NEUTRALIZATION TEST; VIRUS-INFECTION; MMR VACCINE; FAILURE; TRANSMISSION; ELIMINATION; ANTIBODIES; RESPONSES AB Background. Measles was eliminated in the United States through high vaccination coverage and a public health system able to rapidly respond to measles. Measles may occur among vaccinated individuals, but secondary transmission from such individuals has not been documented. Methods. Suspected patients and contacts exposed during a measles outbreak in New York City in 2011 were investigated. Medical histories and immunization records were obtained. Cases were confirmed by detection of measles-specific immunoglobulin M and/or RNA. Tests for measles immunoglobulin G (IgG), IgG avidity, measurement of measles neutralizing antibody titers, and genotyping were performed to characterize the cases. Results. The index patient had 2 doses of measles-containing vaccine; of 88 contacts, 4 secondary patients were confirmed who had either 2 doses of measles-containing vaccine or a past positive measles IgG antibody. All patients had laboratory confirmation of measles infection, clinical symptoms consistent with measles, and high-avidity IgG antibody characteristic of a secondary immune response. Neutralizing antibody titers of secondary patients reached >80 000 mIU/mL 3-4 days after rash onset and that of the index was <500 mIU/mL 9 days after rash onset. No additional cases of measles occurred among 231 contacts of secondary patients. Conclusions. This is the first report of measles transmission from a twice-vaccinated individual with documented secondary vaccine failure. The clinical presentation and laboratory data of the index patient were typical of measles in a naive individual. Secondary patients had robust anamnestic antibody responses. No tertiary cases occurred despite numerous contacts. This outbreak underscores the need for thorough epidemiologic and laboratory investigation of suspected cases of measles regardless of vaccination status. C1 [Rosen, Jennifer B.; Doll, Margaret K.; Zucker, Jane R.; Zimmerman, Christopher M.] New York City Dept Hlth & Mental Hyg, Bur Immunizat, New York, NY USA. [Rota, Jennifer S.; Hickman, Carole J.; Sowers, Sun B.; Mercader, Sara; Rota, Paul A.; Bellini, William J.; Zucker, Jane R.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Huang, Ada J.] Westchester Cty Dept Hlth, New Rochelle, NY USA. RP Rosen, JB (reprint author), NYC DOHMH, Bur Immunizat, 42-09 28th St,5th Fl,CN 21, Queens, NY 11101 USA. EM jrosen4@health.nyc.gov OI Doll, Margaret/0000-0002-2125-7820 NR 39 TC 24 Z9 24 U1 0 U2 15 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD MAY 1 PY 2014 VL 58 IS 9 BP 1205 EP 1210 DI 10.1093/cid/ciu105 PG 6 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA AF9AJ UT WOS:000335006900001 PM 24585562 ER PT J AU Tempia, S Walaza, S Viboud, C Cohen, AL Madhi, SA Venter, M McAnerney, JM Cohen, C AF Tempia, Stefano Walaza, Sibongile Viboud, Cecile Cohen, Adam L. Madhi, Shabir A. Venter, Marietjie McAnerney, Johanna M. Cohen, Cheryl TI Mortality Associated With Seasonal and Pandemic Influenza and Respiratory Syncytial Virus Among Children < 5 Years of Age in a High HIV Prevalence Setting-South Africa, 1998-2009 SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE influenza; respiratory syncytial virus; HIV; mortality; South Africa ID UNITED-STATES; EXCESS MORTALITY; TRACT INFECTIONS; BURDEN; HOSPITALIZATIONS; EPIDEMIOLOGY; PNEUMONIA; ADULTS; SEVERITY; DEATHS AB Background. There are few published data describing the mortality burden associated with influenza and respiratory syncytial virus (RSV) infection in children in low- and middle-income countries and particularly from Africa and settings with high prevalence of human immunodeficiency virus (HIV). Methods. We modeled the excess mortality attributable to influenza (seasonal and pandemic) and RSV infection by applying Poisson regression models to monthly all-respiratory and pneumonia and influenza deaths, using national influenza and RSV laboratory surveillance data as covariates. In addition, we estimated the seasonal influenza- and RSV-associated deaths among HIV-infected and -uninfected children using Poisson regression models that incorporated HIV prevalence and highly active antiretroviral therapy coverage as covariates. Results. In children <5 years of age, the mean annual numbers of seasonal influenza- and RSV-associated all-respiratory deaths were 452 (8 per 100 000 person-years [PY]) and 546 (10 per 100 000 PY), respectively. Infants <1 year of age experienced higher mortality rates compared with children 1-4 years of age for both influenza (22 vs 5 per 100 000 PY) and RSV (35 vs 4 per 100 000 PY). HIV-infected compared with HIV-uninfected children <5 years of age were at increased risk of death associated with influenza (age-adjusted relative risk [aRR], 11.5; 95% confidence interval [CI], 9.6-12.6) and RSV (aRR, 8.1; 95% CI, 6.9-9.3) infection. In 2009, we estimated 549 (11 per 100 000 PY) all-respiratory influenza A(H1N1) pdm09-associated deaths among children aged <5 years. Conclusions. Our findings support increased research efforts to guide and prioritize interventions such as influenza vaccination and HIV prevention in low- and middle-income countries with high HIV prevalence such as South Africa. C1 [Tempia, Stefano; Cohen, Adam L.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. [Tempia, Stefano; Cohen, Adam L.] Ctr Dis Control & Prevent, Influenza Div, Pretoria, South Africa. [Tempia, Stefano; Walaza, Sibongile; Madhi, Shabir A.; Venter, Marietjie; McAnerney, Johanna M.; Cohen, Cheryl] Natl Hlth Lab Serv, Natl Inst Communicable Dis, Ctr Resp Dis & Meningitis, Johannesburg, South Africa. [Viboud, Cecile] NIH, Fogarty Int Ctr, Bethesda, MD 20892 USA. [Madhi, Shabir A.] Univ Witwatersrand, Fac Hlth Sci, Resp & Meningeal Pathogens Res Unit, Johannesburg, South Africa. [Madhi, Shabir A.] Univ Witwatersrand, Natl Res Fdn Vaccine Preventable Dis, Dept Sci & Technol, Johannesburg, South Africa. [Venter, Marietjie] Univ Pretoria, Dept Med Virol, Zoonoses Res Unit, Johannesburg, South Africa. [Cohen, Cheryl] Univ Witwatersrand, Sch Publ Hlth, Johannesburg, South Africa. RP Tempia, S (reprint author), Natl Inst Communicable Dis, Ctr Resp Dis & Meningitis, Private Bag X4, ZA-2131 Johannesburg, Gauteng, South Africa. EM stefanot@nicd.ac.za RI Venter, Marietjie/P-9604-2016 OI Venter, Marietjie/0000-0003-2696-824X NR 46 TC 22 Z9 23 U1 0 U2 7 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD MAY 1 PY 2014 VL 58 IS 9 BP 1241 EP 1249 DI 10.1093/cid/ciu095 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA AF9AJ UT WOS:000335006900007 PM 24567249 ER PT J AU Wortham, JM Zell, ER Pondo, T Harrison, LH Schaffner, W Lynfield, R Thomas, A Reingold, A Bennett, NM Petit, S Aragon, D Bareta, J Juni, BA Farley, MM Beall, B Moore, MR AF Wortham, Jonathan M. Zell, Elizabeth R. Pondo, Tracy Harrison, Lee H. Schaffner, William Lynfield, Ruth Thomas, Ann Reingold, Arthur Bennett, Nancy M. Petit, Susan Aragon, Deborah Bareta, Joseph Juni, Billie A. Farley, Monica M. Beall, Bernard Moore, Matthew R. TI Racial Disparities in Invasive Streptococcus pneumoniae Infections, 1998-2009 SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE pneumocccal vaccines; continental population groups; Streptococcus pneumoniae ID PNEUMOCOCCAL DISEASE; CONJUGATE VACCINE; UNITED-STATES; AIR-POLLUTION; RISK-FACTORS; CHILDREN; SMOKING; ADULTS; ERA AB Background. Before the introduction of 7-valent pneumococcal conjugate vaccine (PCV7), invasive pneumococcal disease (IPD) rates among blacks were twice the rates in whites. We measured the effects of trends in PCV7-type and non-PCV7-type IPD rates on racial disparities in overall IPD and estimated the proportion of IPD caused by serotypes included in the 13-valent pneumococcal conjugate vaccine (PCV13). Methods. We analyzed data from the Active Bacterial Core surveillance system, which performs active, laboratory- and population-based surveillance for IPD for 29.2 million people in the United States, for the period 1998-2009. For patients with unknown race, we multiplied imputed race to calculate age-, race-, and serotype-specific IPD incidence rates. Results. During 1998-2009, 47 449 IPD cases were identified; race was unknown for 5419 (11%). After multiple imputation, 31 981 (67%) patients were considered white and 13 750 (29%) black. PCV7-type IPD rates in all ages in both races decreased to <1 case per 100 000, whereas there were no decreases in overall IPD rates after 2002. By 2009, PCV13 serotypes caused 71% of cases among whites aged <5 years compared with 58% among blacks (P < .01). PCV13 serotypes caused 50% of IPD cases in whites aged >= 5 years compared with 43% among blacks (P < .01). Conclusions. Despite near elimination of PCV7-type IPD in both races, overall disparities in IPD rates persisted because non-PCV7-type IPD rates are higher among blacks. Whereas PCV13 introduction may reduce racial disparities in IPD, higher valency conjugate vaccines and strategies to directly address underlying causes are needed to eliminate IPD disparities. C1 [Wortham, Jonathan M.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Zell, Elizabeth R.; Pondo, Tracy; Beall, Bernard; Moore, Matthew R.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Harrison, Lee H.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA. [Schaffner, William] Vanderbilt Univ, Sch Med, Dept Prevent Med, Nashville, TN 37212 USA. [Lynfield, Ruth; Juni, Billie A.] Minnesota Dept Hlth, St Paul, MN USA. [Thomas, Ann] Oregon Publ Hlth Div, Portland, OR USA. [Thomas, Ann] Oregon Emerging Infect Program, Portland, OR USA. [Reingold, Arthur] Calif Emerging Infect Program, Oakland, CA USA. [Bennett, Nancy M.] Univ Rochester, Sch Med & Dent, New York, NY USA. [Petit, Susan] Connecticut Dept Publ Hlth, Hartford, CT USA. [Aragon, Deborah] Colorado Dept Publ Hlth & Environm, Denver, CO USA. [Bareta, Joseph] New Mexico Dept Hlth, Emerging Infect Program, Santa Fe, NM USA. [Farley, Monica M.] Emory Univ, Atlanta, GA 30322 USA. [Farley, Monica M.] Atlanta Vet Affairs Med Ctr, Atlanta, GA USA. RP Wortham, JM (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE MS E-10, Atlanta, GA 30333 USA. EM vij5@cdc.gov FU CDC Emerging Infections Program FX This work was supported by the CDC Emerging Infections Program. NR 29 TC 6 Z9 6 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD MAY 1 PY 2014 VL 58 IS 9 BP 1250 EP 1257 DI 10.1093/cid/ciu108 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA AF9AJ UT WOS:000335006900008 PM 24585565 ER PT J AU Bard, JD Hindler, JA Gold, HS Limbago, B AF Bard, Jennifer Dien Hindler, Janet A. Gold, Howard S. Limbago, Brandi TI Rationale for Eliminating Staphylococcus Breakpoints for beta-Lactam Agents Other Than Penicillin, Oxacillin or Cefoxitin, and Ceftaroline SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE beta-lactams and Staphylococcus; Staphylococcus susceptibility; CLSI breakpoints ID COAGULASE-NEGATIVE STAPHYLOCOCCI; IN-VITRO ACTIVITY; RESISTANT HETERORESISTANT STAPHYLOCOCCI; ANTIMICROBIAL-SURVEILLANCE-PROGRAM; DISK DIFFUSION METHOD; METHICILLIN-RESISTANT; AUREUS BACTEREMIA; BINDING PROTEINS; UNITED-STATES; 3RD-GENERATION CEPHALOSPORINS AB Due to the ongoing concern about the reliability of Staphylococcus breakpoints (interpretive criteria) for other beta-lactam agents, the Clinical and Laboratory Standards Institute recently approved the elimination of all breakpoints for antistaphylococcal beta-lactams except for penicillin, oxacillin or cefoxitin, and ceftaroline. Routine testing of penicillin and oxacillin or cefoxitin should be used to infer susceptibility for all beta-lactams with approved clinical indications for staphylococcal infections. It is critical for laboratories to reject requests for susceptibility testing of other beta-lactams against staphylococci and to indicate that susceptibility to these agents can be predicted from the penicillin and oxacillin or cefoxitin results. This article reviews beta-lactam resistance mechanisms in staphylococci, current antimicrobial susceptibility testing and reporting recommendations for beta-lactams and staphylococci, and microbiologic data and clinical data supporting the elimination of staphylococcal breakpoints for other beta-lactam agents. C1 [Bard, Jennifer Dien] Univ So Calif, Keck Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90027 USA. [Bard, Jennifer Dien] Childrens Hosp Los Angeles, Los Angeles, CA USA. [Hindler, Janet A.] Univ Calif Los Angeles, Los Angeles Hlth Syst, Los Angeles, CA USA. [Gold, Howard S.] Beth Israel Deaconess Med Ctr, Dept Med, Div Infect Dis, Boston, MA 02215 USA. [Gold, Howard S.] Harvard Univ, Sch Med, Boston, MA USA. [Limbago, Brandi] Ctr Dis Control & Prevent, Clin & Environm Microbiol Branch, Div Healthcare Qual Promot, Atlanta, GA USA. RP Bard, JD (reprint author), Univ So Calif, Keck Sch Med, Dept Pathol & Lab Med, 4650 Sunset Blvd,Mailstop 32, Los Angeles, CA 90027 USA. EM jdienbard@chla.usc.edu NR 79 TC 7 Z9 7 U1 0 U2 7 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD MAY 1 PY 2014 VL 58 IS 9 BP 1287 EP 1296 DI 10.1093/cid/ciu043 PG 10 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA AF9AJ UT WOS:000335006900015 ER PT J AU Masur, H Brooks, JT Benson, CA Holmes, KK Pau, AK Kaplan, JE AF Masur, Henry Brooks, John T. Benson, Constance A. Holmes, King K. Pau, Alice K. Kaplan, Jonathan E. TI Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents: Updated Guidelines From the Centers for Disease Control and Prevention, National Institutes of Health, and HIV Medicine Association of the Infectious Diseases Society of America SO CLINICAL INFECTIOUS DISEASES LA English DT Editorial Material DE opportunistic infections; HIV/AIDS; guideline; revision; online ID RECONSTITUTION INFLAMMATORY SYNDROME; ACTIVE ANTIRETROVIRAL THERAPY; HUMAN-IMMUNODEFICIENCY-VIRUS; RISK-FACTORS; UNITED-STATES; TRENDS; COHORT; MORTALITY; RECOMMENDATIONS; TUBERCULOSIS AB In May 2013, a revised and updated version of the Centers for Disease Control and Prevention/National Institutes of Health/HIV Medicine Association Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents was released online. These guidelines, since their inception in 1989, have been widely accessed in the United States and abroad. These guidelines have focused on the management of HIV/AIDS-related opportunistic infections that occur in the United States. In other parts of the world, the spectrum of complications may be different and the resources available for diagnosis and management may not be identical to those in the United States. The sections that have been most extensively updated are those on immune reconstitution inflammatory syndrome, tuberculosis, hepatitis B, hepatitis C, human papillomavirus, and immunizations. The guidelines will not be published in hard copy form. This document will be revised as needed throughout each year as new data become available. C1 [Masur, Henry; Pau, Alice K.] NIH, Bethesda, MD 20892 USA. [Brooks, John T.; Kaplan, Jonathan E.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Benson, Constance A.] Univ Calif San Diego, San Diego, CA 92103 USA. [Holmes, King K.] Univ Washington, Seattle, WA 98195 USA. RP Masur, H (reprint author), NIH, Dept Crit Care Med, Ctr Clin, 10 Ctr Dr,Rm 2C145, Bethesda, MD 20892 USA. EM hmasur@nih.gov NR 37 TC 28 Z9 30 U1 0 U2 15 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD MAY 1 PY 2014 VL 58 IS 9 BP 1308 EP 1311 DI 10.1093/cid/ciu094 PG 4 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA AF9AJ UT WOS:000335006900017 PM 24585567 ER PT J AU Marks, SM Flood, J Seaworth, B Hirsch-Moverman, Y Armstrong, L Mase, S Salcedo, K Oh, P Graviss, EA Colson, PW Armitige, L Revuelta, M Sheeran, K AF Marks, Suzanne M. Flood, Jennifer Seaworth, Barbara Hirsch-Moverman, Yael Armstrong, Lori Mase, Sundari Salcedo, Katya Oh, Peter Graviss, Edward A. Colson, Paul W. Armitige, Lisa Revuelta, Manuel Sheeran, Kathryn CA TB Epidemiologic Studies Consortiu TI Treatment Practices, Outcomes, and Costs of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis, United States, 2005-2007 SO EMERGING INFECTIOUS DISEASES LA English DT Article ID NEW-YORK-CITY; METAANALYSIS; CALIFORNIA AB To describe factors associated with multidrug-resistant (MDR), including extensively-drug-resistant (XDR), tuberculosis (TB) in the United States, we abstracted inpatient, laboratory, and public health clinic records of a sample of MDR TB patients reported to the Centers for Disease Control and Prevention from California, New York City, and Texas during 2005-2007. At initial diagnosis, MDR TB was detected in 94% of 130 MDR TB patients and XDR TB in 80% of 5 XDR TB patients. Mutually exclusive resistance was 4% XDR, 17% pre-XDR, 24% total first-line resistance, 43% isoniazid/rifampin/rifabutin-plus-other resistance, and 13% isoniazid/rifampin/rifabutin-only resistance. Nearly three-quarters of patients were hospitalized, 78% completed treatment, and 9% died during treatment. Direct costs, mostly covered by the public sector, averaged $134,000 per MDR TB and $430,000 per XDR TB patient; in comparison, estimated cost per non-MDR TB patient is $17,000. Drug resistance was extensive, care was complex, treatment completion rates were high, and treatment was expensive. C1 [Marks, Suzanne M.; Armstrong, Lori; Mase, Sundari; TB Epidemiologic Studies Consortiu] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Flood, Jennifer; Salcedo, Katya; Oh, Peter] Calif Dept Publ Hlth, Richmond, CA USA. [Seaworth, Barbara; Armitige, Lisa; Sheeran, Kathryn] Texas Dept State Hlth Serv, Tyler, TX USA. [Seaworth, Barbara; Armitige, Lisa; Sheeran, Kathryn] Univ Texas Hlth Ctr Tyler, Tyler, TX USA. [Hirsch-Moverman, Yael; Colson, Paul W.; Revuelta, Manuel] Columbia Univ, ICAP, New York, NY USA. [Graviss, Edward A.] Methodist Hosp, Res Inst, Houston, TX 77030 USA. RP Marks, SM (reprint author), Ctr Dis Control & Prevent, Mailstop E10,1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM smarks@cdc.gov FU Tuberculosis Epidemiologic Studies Consortium of CDC; CDC National Center for HIV; Viral Hepatitis; STD and TB Prevention; Division of Tuberculosis Elimination FX This work was supported by the Tuberculosis Epidemiologic Studies Consortium of CDC. The CDC National Center for HIV, Viral Hepatitis, STD and TB Prevention and the Division of Tuberculosis Elimination supported CDC and contract staff and the analytical resources used during the project. NR 21 TC 28 Z9 29 U1 0 U2 10 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD MAY PY 2014 VL 20 IS 5 BP 812 EP 820 DI 10.3201/eid2005.131037 PG 9 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA AG0SC UT WOS:000335124900010 PM 24751166 ER PT J AU Henry, R AF Henry, Ronnie TI Papillomavirus SO EMERGING INFECTIOUS DISEASES LA English DT Editorial Material C1 Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Henry, R (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop E03, Atlanta, GA 30333 USA. EM boq3@cdc.gov NR 3 TC 1 Z9 1 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD MAY PY 2014 VL 20 IS 5 BP 821 EP 821 DI 10.3201/eid2005.ET2005 PG 1 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA AG0SC UT WOS:000335124900011 ER PT J AU Steinau, M Saraiya, M Goodman, MT Peters, ES Watson, M Cleveland, JL Lynch, CF Wilkinson, EJ Hernandez, BY Copeland, G Saber, MS Hopenhayn, C Huang, YJ Cozen, W Lyu, C Unger, ER AF Steinau, Martin Saraiya, Mona Goodman, Marc T. Peters, Edward S. Watson, Meg Cleveland, Jennifer L. Lynch, Charles F. Wilkinson, Edward J. Hernandez, Brenda Y. Copeland, Glen Saber, Maria S. Hopenhayn, Claudia Huang, Youjie Cozen, Wendy Lyu, Christopher Unger, Elizabeth R. CA HPV Typing Canc Workgrp TI Human Papillomavirus Prevalence in Oropharyngeal Cancer before Vaccine Introduction, United States SO EMERGING INFECTIOUS DISEASES LA English DT Article ID SQUAMOUS-CELL CARCINOMA; NECK-CANCER; HPV INFECTION; ORAL-CAVITY; HEAD; WORLDWIDE; SURVIVAL; BURDEN AB We conducted a study to determine prevalence of HPV types in oropharyngeal cancers in the United States and establish a prevaccine baseline. for monitoring the impact of vaccination. HPV DNA was extracted from tumor tissue samples from patients in whom cancer was diagnosed during 1995-2005. The samples were obtained from cancer registries and Residual Tissue Repository Program sites in the United States. HPV was detected and typed by using PCR reverse line blot assays. Among 557 invasive oropharyngeal sguannous cell carcinomas, 72% were positive for HPV and 62% for vaccine types HPV16 or 18. Prevalence of HPV-16/18 was lower in women (53%) than in men (66%), and lower in non-Hispanic Black patients (31%) than in other racial/ethnic groups (68%-80%). Results indicate that vaccines could prevent most oropharyngeal cancers in the United States, but their effect may vary by demographic variables. C1 [Steinau, Martin; Saraiya, Mona; Watson, Meg; Cleveland, Jennifer L.; Unger, Elizabeth R.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Goodman, Marc T.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. [Peters, Edward S.] Louisiana State Univ, New Orleans, LA USA. [Lynch, Charles F.] Univ Iowa, Iowa City, IA USA. [Wilkinson, Edward J.] Univ Florida, Gainesville, FL USA. [Hernandez, Brenda Y.] Univ Hawaii, Honolulu, HI 96822 USA. [Copeland, Glen] Michigan Canc Surveillance Program, Lansing, MI USA. [Saber, Maria S.; Cozen, Wendy] Los Angeles Canc Registry, Los Angeles, CA USA. [Hopenhayn, Claudia] Univ Kentucky, Lexington, KY USA. [Huang, Youjie] Florida Dept Hlth & Rehabil Serv, Tallahassee, FL 32399 USA. [Lyu, Christopher] Battelle Mem Inst, Durham, NC USA. RP Steinau, M (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop G41, Atlanta, GA 30333 USA. EM MSteinau@cdc.gov OI Campbell-Thompson, Martha/0000-0001-6878-1235; /0000-0003-4928-6532 FU CDC intramural funds; Vaccine For Children Funds; CDC [5U58DP000810-5, 5U58DP000844-5, 5U58DP000812-5, 5U58DP000769-5, 1U58DP000807-3]; National Cancer Institute SEER Population-based Registry Program, National Institutes of Health, Department of Health and Human Services [N01-PC-35139, N01-PC-35143, N01-PC-35137]; California Department of Health Services [103885]; National Cancer Institute, National Institutes of Health, Department of Health and Human Services [N01-PC-2010-00035]; Merck and Co., Inc. FX The collection of original specimens from nonrepositories (Kentucky, Florida, Michigan, Louisiana), coordination of genotyping data from both the Surveillance, Epidemiology, and End Results (SEER) program and the National Program of Cancer Registries (NPCR) was largely supported by CDC intramural funds and Vaccine For Children Funds. This project has been supported in part with federal funds by CDC under grant nos. 5U58DP000810-5 (Kentucky), 5U58DP000844-5 (Florida), 5U58DP000812-5 (Michigan), and 5U58DP000769-5 (Louisiana); and with federal funds for Residual Tissue Repositories from the National Cancer Institute SEER Population-based Registry Program, National Institutes of Health, Department of Health and Human Services, under contract nos. N01-PC-35139 (Los Angeles), N01-PC-35143 (Iowa), and N01-PC-35137 (Hawaii).; The collection of data from California used in this publication was largely supported by the California Department of Health Services as part of the statewide cancer reporting program mandated by California Health and Safety Code Section 103885; by the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under contract no. N01-PC-2010-00035; and grant no. 1U58DP000807-3 from CDC.; B.Y.H. has received consultation and speaker fees from Merck and Co., Inc. NR 33 TC 25 Z9 26 U1 0 U2 4 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD MAY PY 2014 VL 20 IS 5 BP 822 EP 828 DI 10.3201/eid2005.131311 PG 7 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA AG0SC UT WOS:000335124900012 PM 24751181 ER PT J AU Birdsell, DN Johansson, A Ohrman, C Kaufman, E Molins, C Pearson, T Gyuranecz, M Naumann, A Vogler, AJ Myrtennas, K Larsson, P Forsman, M Sjodin, A Gillece, JD Schupp, J Petersen, JM Keim, P Wagner, DM AF Birdsell, Dawn N. Johansson, Anders Ohrman, Caroline Kaufman, Emily Molins, Claudia Pearson, Talima Gyuranecz, Miklos Naumann, Amber Vogler, Amy J. Myrtennas, Kerstin Larsson, Par Forsman, Mats Sjodin, Andreas Gillece, John D. Schupp, James Petersen, Jeannine M. Keim, Paul Wagner, David M. TI Francisella tularensis subsp tularensis Group A.I, United States SO EMERGING INFECTIOUS DISEASES LA English DT Article ID MOLECULAR EPIDEMIOLOGY; PHYLOGEOGRAPHY; TULAREMIA; EVOLUTION AB We used whole-genome analysis and subsequent characterization of geographically diverse strains using new genetic signatures to identify distinct subgroups within Francisella tularensis subsp. tularensis group A.I: A.I.3, A.I.8, and A.I.12. These subgroups exhibit complex phylogeographic patterns within North America. The widest distribution was observed for A.I.12, which suggests an adaptive advantage. C1 [Birdsell, Dawn N.; Kaufman, Emily; Pearson, Talima; Naumann, Amber; Vogler, Amy J.; Keim, Paul; Wagner, David M.] No Arizona Univ, Ctr Microbial Genet & Genom, Flagstaff, AZ 86011 USA. [Johansson, Anders] Umea Univ, Umea, Sweden. [Ohrman, Caroline; Myrtennas, Kerstin; Larsson, Par; Forsman, Mats; Sjodin, Andreas] Swedish Def Res Agcy, Umea, Sweden. [Molins, Claudia; Pearson, Talima] Ctr Dis Control & Prevent, Ft Collins, CO USA. [Gyuranecz, Miklos] Hungarian Acad Sci, Agr Res Ctr, Budapest, Hungary. [Gillece, John D.; Schupp, James; Keim, Paul] Translat Genom Res Inst, Flagstaff, AZ USA. RP Wagner, DM (reprint author), No Arizona Univ, Ctr Microbial Genet & Genom, Flagstaff, AZ 86011 USA. EM dave.wagner@nau.edu RI Forsman, Mats/A-1426-2016; Johansson, Anders/D-2928-2012; OI Forsman, Mats/0000-0002-4466-5325; Johansson, Anders/0000-0003-0548-5943; Sjodin, Andreas/0000-0001-5350-4219 FU US Department of Homeland Security Science and Technology Directorate [HSHQDC-10-C-00139]; Swedish Civil Contingencies Agency through TA [014-2010-01]; Laboratory for Molecular Infection Medicine Sweden; Vasterbotten County Council; Lendulet program of the Hungarian Academy of Sciences FX This work was supported in part by the US Department of Homeland Security Science and Technology Directorate through award HSHQDC-10-C-00139, the Swedish Civil Contingencies Agency through TA#014-2010-01, the Laboratory for Molecular Infection Medicine Sweden, and Vasterbotten County Council. M.G. was supported by the Lendulet program of the Hungarian Academy of Sciences. NR 15 TC 4 Z9 4 U1 0 U2 11 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD MAY PY 2014 VL 20 IS 5 BP 861 EP 865 DI 10.3201/eid2005.131559 PG 5 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA AG0SC UT WOS:000335124900021 PM 24755401 ER PT J AU Saborio, GG Clara, A Garcia, A Quesada, F Palekar, R Minaya, P Cervantes, M Lopez, M Lara, J Jara, J Blanco, N Bresee, J Marc-Alain-Widdowson Azziz-Baumgartner, E AF Guzman Saborio, Guiselle Clara, Alexey Garcia, Antonio Quesada, Fabio Palekar, Rakhee Minaya, Percy Cervantes, Marvin Lopez, Mariel Lara, Jenny Jara, Jorge Blanco, Natalia Bresee, Joseph Marc-Alain-Widdowson Azziz-Baumgartner, Eduardo TI Influenza-associated Hospitalizations and Deaths, Costa Rica, 2009-2012 SO EMERGING INFECTIOUS DISEASES LA English DT Article ID A H1N1 VIRUS AB Data needed to guide influenza vaccine policies are lacking in tropical countries. We multiplied the number of severe acute respiratory infections by the proportion testing positive for influenza. There were approximate to 6,699 influenza hospitalizations and 803 deaths in Costa Rica during 2009-2012, supporting continuation of a national influenza vaccine program. C1 [Guzman Saborio, Guiselle; Garcia, Antonio; Quesada, Fabio; Cervantes, Marvin] Caja Costarricense Seguro Social, San Jose, Costa Rica. [Clara, Alexey] US Ctr Dis Control Cent Amer Reg, Guatemala City, Guatemala. [Palekar, Rakhee] Pan Amer Hlth Org, Washington, DC USA. [Palekar, Rakhee; Bresee, Joseph; Marc-Alain-Widdowson; Azziz-Baumgartner, Eduardo] Ctr Dis Control & Prevent, Atlanta, GA USA. [Minaya, Percy] Training Epidemiol & Publ Hlth Intervent Network, Guatemala City, Guatemala. [Lopez, Mariel; Lara, Jenny] Inst Costarricense Invest & Ensenanza Nutr & Salu, San Jose, Costa Rica. [Jara, Jorge; Blanco, Natalia] Univ Valle Guatemala, Guatemala City, Guatemala. RP Saborio, GG (reprint author), Caja Costarricense Seguro Social, San Jose, Costa Rica. EM gguzmans@ccss.sa.cr FU Centers for Disease Control and Prevention FX This investigation has been funded in part by the Centers for Disease Control and Prevention. NR 14 TC 3 Z9 3 U1 0 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD MAY PY 2014 VL 20 IS 5 BP 878 EP 881 DI 10.3201/eid2005.131775 PG 4 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA AG0SC UT WOS:000335124900026 PM 24750897 ER PT J AU Pabbaraju, K Tellier, R Wong, S Li, Y Bastien, N Tang, JW Drews, SJ Jang, YH Davis, CT Fonseca, K Tipples, GA AF Pabbaraju, Kanti Tellier, Raymond Wong, Sallene Li, Yan Bastien, Nathalie Tang, Julian W. Drews, Steven J. Jang, Yunho Davis, C. Todd Fonseca, Kevin Tipples, Graham A. TI Full-Genome Analysis of Avian Influenza A(H5N1) Virus from a Human, North America, 2013 SO EMERGING INFECTIOUS DISEASES LA English DT Article ID RECEPTOR-BINDING SPECIFICITY; CONTRIBUTE; VIRULENCE; PROTEIN; MICE; ANTIGENICITY; MUTATION; MUTANTS; FERRETS; PB2 AB Full-genonne analysis was conducted on the first isolate of a highly pathogenic avian influenza A(H5N1) virus from a human in North America. The virus has a hemagglutinin gene of clade 2.3.2.1c and is a reassortant with an H9N2 subtype lineage polymerase basic 2 gene. No mutations conferring resistance to adamantanes or neuraminidase inhibitors were found. C1 [Pabbaraju, Kanti; Tellier, Raymond; Wong, Sallene; Tang, Julian W.; Drews, Steven J.; Fonseca, Kevin; Tipples, Graham A.] Prov Lab Publ Hlth, Calgary, AB T2N 4W4, Canada. [Li, Yan; Bastien, Nathalie] Publ Hlth Agcy Canada, Winnipeg, MB, Canada. [Jang, Yunho; Davis, C. Todd] Ctr Dis Control & Prevent, Atlanta, GA USA. [Tellier, Raymond; Drews, Steven J.; Fonseca, Kevin] Univ Calgary, Calgary, AB, Canada. [Li, Yan] Univ Manitoba, Winnipeg, MB, Canada. [Tang, Julian W.; Tipples, Graham A.] Univ Alberta, Edmonton, AB, Canada. RP Fonseca, K (reprint author), Prov Lab Publ Hlth, 3030 Hosp Dr NW, Calgary, AB T2N 4W4, Canada. EM kevin.fonseca@albertahealthservices.ca NR 16 TC 20 Z9 21 U1 0 U2 11 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD MAY PY 2014 VL 20 IS 5 BP 887 EP 891 DI 10.3201/eid2005.140164 PG 5 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA AG0SC UT WOS:000335124900028 PM 24755439 ER PT J AU Fulghieri, C Bloom, S AF Fulghieri, Carl Bloom, Sharon TI Who Is This Person? Sarah Elizabeth Stewart SO EMERGING INFECTIOUS DISEASES LA English DT Editorial Material C1 [Fulghieri, Carl] Carrboro High Sch, Carrboro, NC USA. [Bloom, Sharon] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Bloom, S (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop E41, Atlanta, GA 30333 USA. EM sbloom@cdc.gov NR 9 TC 1 Z9 1 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD MAY PY 2014 VL 20 IS 5 BP 893 EP 895 DI 10.3201/eid2005.131876 PG 3 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA AG0SC UT WOS:000335124900029 PM 24751102 ER PT J AU Rickert-Hartman, R Folster, JP AF Rickert-Hartman, Regan Folster, Jason P. TI Ciprofloxacin-Resistant Salmonella enterica Serotype Kentucky Sequence Type 198 SO EMERGING INFECTIOUS DISEASES LA English DT Letter C1 [Rickert-Hartman, Regan; Folster, Jason P.] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. RP Folster, JP (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop G29, Atlanta, GA 30329 USA. EM gux8@cdc.gov NR 6 TC 8 Z9 8 U1 0 U2 3 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD MAY PY 2014 VL 20 IS 5 BP 910 EP 911 DI 10.3201/eid2005.131575 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA AG0SC UT WOS:000335124900038 PM 24751334 ER PT J AU Li, ZN Ip, HS Trost, JF White, CL Murray, MJ Carney, PJ Sun, XJ Stevens, J Levine, MZ Katz, JM AF Li, Zhu-Nan Ip, Hon S. Trost, Jessica F. White, C. LeAnn Murray, Michael J. Carney, Paul J. Sun, Xiang-Jie Stevens, James Levine, Min Z. Katz, Jacqueline M. TI Serologic Evidence of Influenza A(H1N1) pdm09 Virus Infection in Northern Sea Otters SO EMERGING INFECTIOUS DISEASES LA English DT Letter C1 [Li, Zhu-Nan; Trost, Jessica F.; Carney, Paul J.; Sun, Xiang-Jie; Stevens, James; Levine, Min Z.; Katz, Jacqueline M.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Ip, Hon S.; White, C. LeAnn] US Geol Survey, Natl Wildlife Hlth Ctr, Madison, WI USA. [Murray, Michael J.] Monterey Bay Aquarium, Monterey, CA USA. RP Katz, JM (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop G16, Atlanta, GA 30333 USA. EM jmk9@cdc.gov NR 10 TC 2 Z9 2 U1 0 U2 7 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD MAY PY 2014 VL 20 IS 5 BP 915 EP 917 DI 10.3201/eid2005.131890 PG 3 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA AG0SC UT WOS:000335124900041 PM 24751396 ER PT J AU Bloom, S AF Bloom, Sharon TI Courage Unmasked SO EMERGING INFECTIOUS DISEASES LA English DT Editorial Material C1 [Bloom, Sharon] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Bloom, S (reprint author), Ctr Dis Control & Prevent, Ctr Global Hlth, 1600 Clifton Rd NE,Mailstop E41, Atlanta, GA 30333 USA. EM sbloom@cdc.gov NR 3 TC 0 Z9 0 U1 0 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD MAY PY 2014 VL 20 IS 5 BP 920 EP 921 DI 10.3201/eid2005.AC2005 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA AG0SC UT WOS:000335124900043 ER PT J AU Krueger, AL Greene, SA Barzilay, EJ Henao, O Vugia, D Hanna, S Meyer, S Smith, K Pecic, G Hoefer, D Griffin, PM AF Krueger, Amy L. Greene, Sharon A. Barzilay, Ezra J. Henao, Olga Vugia, Duc Hanna, Samir Meyer, Stephanie Smith, Kirk Pecic, Gary Hoefer, Dina Griffin, Patricia M. TI Clinical Outcomes of Nalidixic Acid, Ceftriaxone, and Multidrug-Resistant Nontyphoidal Salmonella Infections Compared with Pansusceptible Infections in FoodNet Sites, 2006-2008 SO FOODBORNE PATHOGENS AND DISEASE LA English DT Article ID TYPHIMURIUM DT104 INFECTIONS; ACTIVE SURVEILLANCE NETWORK; RAW-MILK CHEESE; SEROTYPE TYPHIMURIUM; UNITED-STATES; ANTIMICROBIAL RESISTANCE; OUTBREAKS; ILLNESS; HUMANS; PATHOGENS AB Background: Nontyphoidal Salmonella causes an estimated 1.2 million infections, 23,000 hospitalizations, and 450 deaths annually in the United States. Most illnesses are self-limited; however, treatment with antimicrobial agents can be life-saving for invasive infections. Methods: The Foodborne Diseases Active Surveillance Network and the National Antimicrobial Resistance Monitoring System collaborated on a prospective cohort study of patients with nontyphoidal Salmonella bloodstream and gastrointestinal infections to determine differences in the clinical outcomes of resistant compared with pansusceptible infections. Interviews were conducted within 85 days of specimen collection date. Results: Of 875 nontyphoidal Salmonella isolates, 705 (81%) were pansusceptible, 165 (19%) were resistant to at least 1 agent, and 5 (0.6%) had only intermediate resistance. The most common pattern, found in 51 (31%) of resistant isolates, was resistance to at least ampicillin, chloramphenicol, streptomycin, sulfisoxazole, and tetracycline (ACSSuT); 88% of isolates with this pattern were serotype Typhimurium or Newport. Fourteen (52%) of the 27 ceftriaxone-resistant isolates were also ACSSuT resistant. Adjusted for age and serotype, bloodstream infection was significantly more common among patients infected with strains resistant to only two, only three, or only five antimicrobial classes, to ACSSuT with or without other agents, to ACSSuT only, or to nalidixic acid with or without other agents than among patients with pansusceptible isolates. Adjusted for age, serotype, and bloodstream infection, hospitalization was significantly more common among patients infected with strains resistant to only three agents or to ceftriaxone (all ceftriaxone-resistant isolates were resistant to other agents) than among patients with pansusceptible isolates. Conclusion: This study extends evidence that patients with antimicrobial-resistant nontyphoidal Salmonella infections have more severe outcomes. Prevention efforts are needed to reduce unnecessary antimicrobial use in patient care settings and in food animals to help prevent the emergence of resistance and infections with resistant nontyphoidal Salmonella. C1 [Krueger, Amy L.; Greene, Sharon A.; Barzilay, Ezra J.; Henao, Olga; Pecic, Gary; Griffin, Patricia M.] Ctr Dis Control & Prevent, Enter Dis Epidemiol Branch, Atlanta, GA 30333 USA. [Vugia, Duc] Calif Dept Publ Hlth, Richmond, CA USA. [Hanna, Samir] Tennessee Dept Hlth, Nashville, TN USA. [Meyer, Stephanie; Smith, Kirk] Minnesota Dept Hlth, Minneapolis, MN USA. [Pecic, Gary] Int Hlth Resources Consulting, Atlanta, GA USA. [Hoefer, Dina] New York State Hlth Dept, Albany, NY USA. RP Krueger, AL (reprint author), Ctr Dis Control & Prevent, Enter Dis Epidemiol Branch, 1600 Clifton Rd NE,Mailstop E-59, Atlanta, GA 30333 USA. EM Frf7@cdc.gov; PMG1@cdc.gov FU U.S. Food and Drug Administration; U.S. Department of Agriculture's Food Safety and Inspection Service FX We thank FoodNet and NARMS-participating public health department epidemiology and laboratory groups for sending isolates, interviewing patients, and reviewing charts; Felicita Medalla and Jason Folster for suggestions; the U.S. Food and Drug Administration for contributing funding support for NARMS; and the U.S. Department of Agriculture's Food Safety and Inspection Service and the U.S. Food and Drug Administration for contributing funding support for FoodNet. NR 27 TC 9 Z9 9 U1 1 U2 6 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1535-3141 EI 1556-7125 J9 FOODBORNE PATHOG DIS JI Foodborne Pathog. Dis. PD MAY 1 PY 2014 VL 11 IS 5 BP 335 EP 341 DI 10.1089/fpd.2013.1642 PG 7 WC Food Science & Technology SC Food Science & Technology GA AG4TH UT WOS:000335412700001 PM 24617446 ER PT J AU Lanzieri, TM Dollard, SC Bialek, SR Grosse, SD AF Lanzieri, Tatiana M. Dollard, Sheila C. Bialek, Stephanie R. Grosse, Scott D. TI Systematic review of the birth prevalence of congenital cytomegalovirus infection in developing countries SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE Cytomegalovirus; Congenital infection; Prevalence; Developing countries ID NEWBORN-INFANTS; HEARING-LOSS; CMV INFECTION; DIAGNOSIS; POPULATION; MOTHERS; RISK; MORTALITY; CHILDREN; COHORT AB Background: Congenital cytomegalovirus (CMV) infection is the leading infectious cause of congenital hearing loss and neurodevelopmental disability in developed countries. Information on congenital CMV infection in developing countries appears to be lacking. Methods: We conducted a systematic literature review to identify studies from developing countries with population-based samples of at least 300 infants that used laboratory methods established as reliable for the diagnosis of congenital CMV infection. Results: Most studies were excluded due to biased samples or inadequate diagnostic methods; consequently the search identified just 11 studies that were from Africa, Asia, and Latin America. The number of newborns tested ranged from 317 to 12 195. Maternal CMV seroprevalence ranged from 84% to 100%. CMV birth prevalence varied from 0.6% to 6.1%. CMV-associated impairments were not documented in most studies. Conclusions: Birth prevalence ranges were higher than for Europe and North America, as expected based on the higher maternal CMV seroprevalence. With very limited data available on sequelae, the disease burden of congenital CMV in developing countries remains largely unknown at this time. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. C1 [Lanzieri, Tatiana M.; Dollard, Sheila C.; Bialek, Stephanie R.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Grosse, Scott D.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. RP Dollard, SC (reprint author), Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM sdollard@cdc.gov FU Intramural CDC HHS [CC999999] NR 42 TC 16 Z9 16 U1 1 U2 6 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1201-9712 EI 1878-3511 J9 INT J INFECT DIS JI Int. J. Infect. Dis. PD MAY PY 2014 VL 22 BP 44 EP 48 DI 10.1016/j.ijid.2013.12.010 PG 5 WC Infectious Diseases SC Infectious Diseases GA AG6AM UT WOS:000335500700012 PM 24631522 ER PT J AU Pfeiffer, CM Hughes, JP Cogswell, ME Burt, VL Lacher, DA LaVoie, DJ Rabinowitz, DJ Johnson, CL Pirkle, JL AF Pfeiffer, Christine M. Hughes, Jeffery P. Cogswell, Mary E. Burt, Vicki L. Lacher, David A. LaVoie, Donna J. Rabinowitz, Daniel J. Johnson, Clifford L. Pirkle, James L. TI Urine Sodium Excretion Increased Slightly among US Adults between 1988 and 2010 SO JOURNAL OF NUTRITION LA English DT Article ID BLOOD-PRESSURE; UNITED-STATES; DIETARY-INTAKE; INTERSALT; TRENDS; POPULATIONS; POTASSIUM; INTERMAP; FOODS; SALT AB Little information is available on temporal trends in sodium intake in the U.S. population using urine sodium excretion as a biomarker. Our aim was to assess 1988-2010 trends in estimated 24-h urine sodium (24hUNa) excretion among U.S. adults (age 20-59 y) participating in the cross-sectional NHANES. We used subsamples from a 1988-1994 convenience sample, a 2003-2006 one-third random sample, and a 2010 one-third random sample to comply with resource constraints. We estimated 24hUNa excretion from measured sodium concentrations in spot urine samples by use of calibration equations (for men and women) derived from the International Cooperative Study on Salt, Other Factors, and Blood Pressure study. Estimated 24hUNa excretion increased over the 20-y period 11988-1994, 2003-2006, and 2010; means SEMs (n): 3160 +/- 38.4 mg/d (1249), 3290 +/- 29.4 mg/d (1235), and 3290 +/- 44.4 mg/d (525), respectively; P-trend = 0.022]. We observed significantly higher mean estimated 24hUNa excretion in each survey period (P < 0.001) for men compared with women (31-33%) and for persons with a higher body mass index (BMI; 32-35% for obese vs. normal weight) or blood pressure (17-26% for hypertensive vs. normal blood pressure). After adjusting for age, sex, and race-ethnicity, temporal trends in mean estimated 24hUNa excretion remained significant (P-trend = 0.004). We observed no temporal trends in mean estimated 24hUNa excretion among BMI subgroups, nor after adjusting for BMI. Although several limitations apply to this analysis (the use of a convenience sample in 1988-1994 and using estimated 24hUNa excretion as a biomarker of sodium intake), these first NHANES data suggest that mean estimated 24hUNa excretion increased slightly in U.S. adults over the past 2 decades, and this increase may be explained by a shift in the distribution of BMI. C1 [Pfeiffer, Christine M.; LaVoie, Donna J.; Rabinowitz, Daniel J.; Pirkle, James L.] CDC, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. [Hughes, Jeffery P.; Burt, Vicki L.; Lacher, David A.; Johnson, Clifford L.] CDC, Natl Ctr Hlth Stat, Hyattsville, MD USA. [Cogswell, Mary E.] CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP Pfeiffer, CM (reprint author), CDC, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. EM cpfeiffer@cdc.gov FU Intramural CDC HHS [CC999999] NR 30 TC 15 Z9 15 U1 0 U2 2 PU AMER SOC NUTRITION-ASN PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-3166 EI 1541-6100 J9 J NUTR JI J. Nutr. PD MAY PY 2014 VL 144 IS 5 BP 698 EP 705 DI 10.3945/jn.113.187914 PG 8 WC Nutrition & Dietetics SC Nutrition & Dietetics GA AF8MQ UT WOS:000334970700018 PM 24623847 ER PT J AU Nielsen, SJ Kit, BK Aoki, Y Ogden, CL AF Nielsen, Samara Joy Kit, Brian K. Aoki, Yutaka Ogden, Cynthia L. TI Seafood consumption and blood mercury concentrations in adults aged >= 20 y, 2007-2010 SO AMERICAN JOURNAL OF CLINICAL NUTRITION LA English DT Article ID NUTRITION EXAMINATION SURVEY; FISH CONSUMPTION; NATIONAL-HEALTH; DIETARY-INTAKE; FATTY-ACIDS; EXPOSURE; RISK; CHILDREN; WOMEN; HYPERTENSION AB Background: Seafood is part of a healthy diet, but seafood can also contain methyl mercury a neurotoxin. Objective: The objective was to describe seafood consumption in US adults and to explore the relation between seafood consumption and blood mercury. Design: Seafood consumption, obtained from a food-frequency questionnaire, and blood mercury data were available for 10,673 adults who participated in the 2007-2010 NHANES a cross-sectional nationally representative sample of the US population. Seafood consumption was categorized by type (fish or shellfish) and by Frequency of consumption (0, 1-2, 3-4, or >= 5 times/mo). Linear trends in geometric mean blood mercury concentrations by frequency of seafood consumption were tested. Logistic regression analyses examined the odds of blood mercury concentrations >= 5.8 mu g/L (as identified by the National Research Council) based on frequency of the specific type of seafood consumed (included in the model as continuous variables) adjusted for sex, age, and race/Hispanic origin. Results: In 2007-2010, 83.0% +/- 0.7% (+/- SE) of adults consumed seafood in the preceding month. In adults consuming seafood, the blood mercury concentration increased as the frequency of seafood consumption increased (P < 0.001). In 2007-2010, 4.6% +/- 0.39% of adults had blood mercury concentrations >= 5.8 mu g/L. Results of the logistic regression on blood mercury concentrations >= 5.8 mu g/L showed no association with shrimp (P = 0.21) or crab (P = 0.48) consumption and a highly significant positive association with consumption of high-mercury fish (adjusted OR per unit monthly consumption: 4.58; 95% CI: 2.44, 8.62; P < 0.001), tuna (adjusted OR: 1.14; 95% Cl: 1.10, 1.17: P < 0.001), salmon (adjusted OR: 1.14; 95% Cl: 1.09, 1.20; P < 0.001), and other seafood (adjusted OR: 1.12; 95% Cl: 1.08, 1.15; P < 0.001). Conclusion: Most US adults consume seafood, and the blood mercury concentration is associated with the consumption of tuna, salmon, high-mercury fish, and other seafood: C1 [Nielsen, Samara Joy; Kit, Brian K.; Aoki, Yutaka; Ogden, Cynthia L.] CDC, Div Hlth & Nutr Examinat Surveys, Natl Ctr Hlth Stat, Hyattsville, MD USA. [Kit, Brian K.] US PHS, Rockville, MD USA. RP Nielsen, SJ (reprint author), 3311 Toledo Rd,Room 4414, Hyattsville, MD 20782 USA. EM wjf7@cdc.gov OI Nielsen, Samara Joy/0000-0002-5777-6542 NR 32 TC 6 Z9 6 U1 1 U2 26 PU AMER SOC NUTRITION-ASN PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0002-9165 EI 1938-3207 J9 AM J CLIN NUTR JI Am. J. Clin. Nutr. PD MAY PY 2014 VL 99 IS 5 BP 1066 EP 1070 DI 10.3945/ajcn.113.077081 PG 5 WC Nutrition & Dietetics SC Nutrition & Dietetics GA AF7LD UT WOS:000334895700015 PM 24522443 ER PT J AU Patel, SM Gunn, JP Tong, X Cogswell, ME AF Patel, Sheena M. Gunn, Janelle P. Tong, Xin Cogswell, Mary E. TI Consumer Sentiment on Actions Reducing Sodium in Processed and Restaurant Foods, ConsumerStyles 2010 SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID PUBLIC-HEALTH; DISEASE; POLICY AB Background: Current recommendations target sodium reduction in the food supply and intake; however, information is limited on consumer readiness for these actions. Purpose: Prevalence and determinants of consumer agreement for government restriction of manufacturers and restaurants putting excess salt in food and support for policies limiting sodium content of quick service restaurant (QSR) foods were examined. Methods: Data were analyzed from 9,579 adults aged >= 18 years who responded to consumer readiness for sodium reduction questions in the 2010 ConsumerStyles survey. Responses were collapsed into three categories. Consumer agreement was determined and logistic regression was used to estimate ORs. Analyses were conducted in 2012. Results: The majority of consumers agree that it is a good idea for government to restrict food manufacturers (55.9%) from putting excess salt in foods. About half agreed that it is a good idea for government to restrict restaurants from putting excess salt in foods and 81.5% supported sodium reduction policies in QSRs. Odds of agreementsupport were higher for non-Hispanic blacks compared with non-Hispanic whites, and those with incomes <$40,000 compared with >=$60,000. Those reporting "neutral" or "yes" to wanting to eat a diet low in sodium were more likely to agree/ support government action compared to those answering "no." Conclusions: Nearly half of consumers agree with government actions to reduce sodium in manufactured and restaurant foods, with even greater support for QSRs. These findings could inform industry and public health partners about consumer preferences to lower the sodium content of the food supply. (C) 2014 American Journal of Preventive Medicine. All rights reserved. C1 [Patel, Sheena M.] Oak Ridge Inst Sci & Educ, Oak Ridge, TN USA. [Patel, Sheena M.; Gunn, Janelle P.; Tong, Xin; Cogswell, Mary E.] CDC, Div Heart Dis & Stroke Prevent, Atlanta, GA 30333 USA. RP Patel, SM (reprint author), 4770 Buford Highway,NE,Mailstop F-72, Atlanta, GA 30341 USA. EM isp7@cdc.gov FU Research Participation Program for the CDC FX This project was supported by an appointment to the Research Participation Program for the CDC administered by the Oak Ridge Institute for Science and Education through an agreement between the Department of Energy and the CDC. No financial disclosures were reported by the authors of this paper. NR 21 TC 1 Z9 1 U1 2 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD MAY PY 2014 VL 46 IS 5 BP 516 EP 524 DI 10.1016/j.amepre.2013.12.012 PG 9 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA AF5QQ UT WOS:000334768400012 PM 24745642 ER PT J AU Scales, D Brownstein, JS Khan, K Cetron, MS AF Scales, David Brownstein, John S. Khan, Kamran Cetron, Martin S. TI Toward a County-Level Map of Tuberculosis Rates in the US SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Letter ID UNITED-STATES C1 [Scales, David; Brownstein, John S.] Harvard Univ, Boston Childrens Hosp, Childrens Hosp Informat Program, Sch Med, Boston, MA 02163 USA. [Khan, Kamran] Univ Toronto, Dept Med, Div Infect Dis, Toronto, ON, Canada. [Cetron, Martin S.] CDC, Div Global Migrat & Quarantine, Atlanta, GA 30333 USA. RP Scales, D (reprint author), Harvard Univ, Boston Childrens Hosp, Childrens Hosp Informat Program, Sch Med, Boston, MA 02163 USA. EM david.scales@aya.yale.edu FU NLM NIH HHS [R01 LM010812, R01 LM010812-04] NR 7 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD MAY PY 2014 VL 46 IS 5 BP E49 EP E51 DI 10.1016/j.amepre.2014.02.001 PG 3 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA AF5QQ UT WOS:000334768400001 PM 24745646 ER PT J AU Li, Z Romanoff, LC Trinidad, DA Pittman, EN Hilton, D Hubbard, K Carmichael, H Parker, J Calafat, AM Sjodin, A AF Li, Zheng Romanoff, Lovisa C. Trinidad, Debra A. Pittman, Erin N. Hilton, Donald Hubbard, Kendra Carmichael, Hasan Parker, Jonathan Calafat, Antonia M. Sjoedin, Andreas TI Quantification of 21 metabolites of methylnaphthalenes and polycyclic aromatic hydrocarbons in human urine SO ANALYTICAL AND BIOANALYTICAL CHEMISTRY LA English DT Article DE Polycyclic aromatic hydrocarbon; PAH; Methylnaphthalene; Human exposure; Biomonitoring; Biomarker ID PULMONARY TOXICITY; MASS-SPECTROMETRY; PETROGENIC PAHS; EXPOSURE; 1-HYDROXYPYRENE; 2-METHYLNAPHTHALENE; MICE; NAPHTHALENE; BIOMARKERS; CHILDREN AB Polycyclic aromatic hydrocarbons (PAHs) and their alkylated derivatives, such as methylnaphthalenes (MeNs), are harmful pollutants ubiquitously present in the environment. Exposure to PAHs has been linked to a variety of adverse health effects and outcomes, including cancer. Alkyl PAHs have been proposed as petrogenic source indicators because of their relatively high abundance in unburned petroleum products. We report a method to quantify 11 urinary methylnaphthols (Me-OHNs), metabolites of 1- and 2-methylnaphthalenes, and 10 monohydroxy PAH metabolites (OH-PAHs), using automated liquid-liquid extraction and isotope dilution gas chromatography tandem mass spectrometry (GC-MS/MS). After spiking urine (1 mL) with C-13-labeled internal standards, the conjugated target analytes were hydrolyzed enzymatically in the presence of ascorbic acid. Then, their free species were preconcentrated into 20 % toluene in pentane, derivatized and quantified by GC-MS/MS. The 11 Me-OHNs eluted as 6 distinct chromatographic peaks, each representing 1 -aEuro parts per thousand 3 isomers. Method detection limits were 1.0- 41 pg/mL and the coefficients of variation in quality control materials were 4.7 -aEuro parts per thousand 19 %. The method was used to analyze two National Institute of Standards and Technology's Standard Reference MaterialsA (R) and samples from 30 smokers and 30 non-smokers. Geometric mean concentrations were on average 37 (Me-OHNs) and 9.0 (OH-PAHs) fold higher in smokers than in non-smokers. These findings support the usefulness of Me-OHNs as potential biomarkers of non-occupational exposure to MeNs and sources containing MeNs. C1 [Li, Zheng; Trinidad, Debra A.; Pittman, Erin N.; Hilton, Donald; Hubbard, Kendra; Carmichael, Hasan; Parker, Jonathan; Calafat, Antonia M.; Sjoedin, Andreas] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Sci Lab, Atlanta, GA 30341 USA. [Romanoff, Lovisa C.] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div STD Prevent, Atlanta, GA 30341 USA. RP Li, Z (reprint author), Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Sci Lab, 4770 Buford Highway F-53, Atlanta, GA 30341 USA. EM ZJLi@cdc.gov RI Sjodin, Andreas/F-2464-2010 FU Intramural CDC HHS [CC999999] NR 57 TC 12 Z9 12 U1 4 U2 61 PU SPRINGER HEIDELBERG PI HEIDELBERG PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY SN 1618-2642 EI 1618-2650 J9 ANAL BIOANAL CHEM JI Anal. Bioanal. Chem. PD MAY PY 2014 VL 406 IS 13 BP 3119 EP 3129 DI 10.1007/s00216-014-7676-0 PG 11 WC Biochemical Research Methods; Chemistry, Analytical SC Biochemistry & Molecular Biology; Chemistry GA AF4LY UT WOS:000334685400013 PM 24714969 ER PT J AU Pereira, LE Clark, MR Friend, DR Garber, DA McNicholl, JM Hendry, RM Doncel, GF Smith, JM AF Pereira, Lara E. Clark, Meredith R. Friend, David R. Garber, David A. McNicholl, Janet M. Hendry, R. Michael Doncel, Gustavo F. Smith, James M. TI Pharmacokinetic and Safety Analyses of Tenofovir and TenofovirEmtricitabine Vaginal Tablets in Pigtailed Macaques SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID HIV-UNINFECTED WOMEN; IMMUNODEFICIENCY VIRUS-INFECTION; PREEXPOSURE PROPHYLAXIS; PHASE-I; RHESUS MACAQUES; ACCEPTABILITY; PREVENTION; TRIALS; INDIA; PUNE AB Vaginal rapidly disintegrating tablets (RDTs) containing tenofovir (TFV) or TFV and emtricitabine (FTC) were evaluated for safety and pharmacokinetics in pigtailed macaques. Two separate animal groups (n = 4) received TFV (10 mg) or TFV- FTC (10 mg each) RDTs, administered near the cervix. A third group (n = 4) received 1 ml TFV gel. Blood plasma, vaginal tissue biopsy specimens, and vaginal fluids were collected before and after product application at 0, 0.5, 1, 4, and 24 h. A disintegration time of < 30 min following vaginal application of the RDTs was noted, with negligible effects on local inflammatory cytokines, vaginal pH, and microflora. TFV pharmacokinetics were generally similar for both RDTs and gel, with peak median concentrations in vaginal tissues and vaginal secretions being on the order of 104 to 105 ng/ g (147 to 571 = M) and 106 ng/ g (12 to 34 mM), respectively, at 1 to 4 h postdose. At 24 h, however, TFV vaginal tissue levels were more sustained after RDT dosing, with median TFV concentrations being approximately 1 log higher than those with gel dosing. FTC pharmacokinetics after combination RDT dosing were similar to those of TFV, with peak median vaginal tissue and fluid levels being on the order of 104 ng/ g (374 = M) and 106 ng/ g (32 mM), respectively, at 1 h postdose with levels in fluid remaining high at 24 h. RDTs are a promising alternative vaginal dosage form, delivering TFV and/ or FTC at levels that would be considered inhibitory to simian- human immunodeficiency virus in the macaque vaginal microenvironment over a 24-h period. C1 [Pereira, Lara E.] LifeSource BioMed LLC, Moffett Field, CA USA. [Clark, Meredith R.; Friend, David R.; Doncel, Gustavo F.] Eastern Virginia Med Sch, Dept Obstet & Gynecol, CONRAD, Arlington, VA 22209 USA. [Garber, David A.; McNicholl, Janet M.; Hendry, R. Michael; Smith, James M.] Ctr Dis Control & Prevent, Branch Lab, Div HIV AIDS Prevent, Atlanta, GA USA. RP Clark, MR (reprint author), Eastern Virginia Med Sch, Dept Obstet & Gynecol, CONRAD, Arlington, VA 22209 USA. EM mclark@conrad.org; ajo9@cdc.gov FU U.S. Agency for International Development (USAID) [GPO-A-00-08-00005-00] FX We thank the U.S. Agency for International Development (USAID) for funding support under cooperative agreement GPO-A-00-08-00005-00. NR 36 TC 8 Z9 8 U1 1 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 EI 1098-6596 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD MAY PY 2014 VL 58 IS 5 BP 2665 EP 2674 DI 10.1128/AAC.02336-13 PG 10 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA AE9XF UT WOS:000334364300021 PM 24566178 ER PT J AU Suda, KJ Hicks, LA Roberts, RM Hunkler, RJ Taylor, TH AF Suda, Katie J. Hicks, Lauri A. Roberts, Rebecca M. Hunkler, Robert J. Taylor, Thomas H. TI Trends and Seasonal Variation in Outpatient Antibiotic Prescription Rates in the United States, 2006 to 2010 SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID PNEUMOCOCCAL CONJUGATE VACCINE; INFECTIOUS-DISEASES SOCIETY; ANTIMICROBIAL CONSUMPTION; STREPTOCOCCUS-PNEUMONIAE; AMBULATORY-CARE; HEALTH-CARE; RESISTANCE; EUROPE; IMMUNIZATION; COMMUNITY AB Antibiotic-resistant bacteria are an increasing threat to the effectiveness of antibiotics. The majority of antibiotics are prescribed in primary care settings for upper respiratory tract infections. The purpose of this study was to describe seasonal trends in outpatient antibiotic prescriptions (Rx) in the United States over a 5-year period. This study was a retrospective, cross-sectional observation of systemic antibiotic prescriptions in the outpatient setting from 2006 to 2010. Winter months were defined as the first and fourth quarters of the calendar year. Antibiotic prescribing rates were calculated (prescriptions/ 1,000 population) using annual U. S. Census Bureau population data. Over 1.34 billion antibiotic prescriptions were dispensed over the 5-year period. The antibiotic prescription (Rx) rate decreased from 892 Rx/ 1,000 population in 2006 to 867 Rx/ 1,000 population in 2010. Penicillins and macrolides were the primary antibiotic classes prescribed, but penicillin prescribing decreased while macrolide prescribing increased over the study period. Overall, antibiotic prescriptions were 24.5% higher in winter months than in the summer, with the largest difference (28.8%) in 2008 and the smallest (20.4%) in 2010. This seasonality was consistently drug class dependent, driven by 75% and 100% increases in penicillin and macrolide prescriptions, respectively, in the winter months. The mean outpatient antibiotic prescription rate decreased in the United States from 2006 to 2010. More antibiotic prescribing, predominately driven by the macrolide and penicillin classes, in the outpatient setting was observed in the winter months. Understanding annual variability in antibiotic use can assist with designing interventions to improve the judicious use of antibiotics. C1 [Suda, Katie J.] Univ Tennessee, Dept Clin Pharm, Hlth Sci Ctr, Memphis, TN 38163 USA. [Hicks, Lauri A.; Roberts, Rebecca M.; Taylor, Thomas H.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Div Bacterial Dis, Atlanta, GA USA. [Hunkler, Robert J.] IMS Hlth, Dept External Affairs, Danbury, CT USA. RP Suda, KJ (reprint author), Univ Tennessee, Dept Clin Pharm, Hlth Sci Ctr, Memphis, TN 38163 USA. EM katiesuda@gmail.com NR 31 TC 18 Z9 21 U1 1 U2 12 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 EI 1098-6596 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD MAY PY 2014 VL 58 IS 5 BP 2763 EP 2766 PG 4 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA AE9XF UT WOS:000334364300033 PM 24590486 ER PT J AU Paulish-Miller, TE Augostini, P Schuyler, JA Smith, WL Mordechai, E Adelson, ME Gygax, SE Secor, WE Hilbert, DW AF Paulish-Miller, Teresa E. Augostini, Peter Schuyler, Jessica A. Smith, William L. Mordechai, Eli Adelson, Martin E. Gygax, Scott E. Secor, William E. Hilbert, David W. TI Trichomonas vaginalis Metronidazole Resistance Is Associated with Single Nucleotide Polymorphisms in the Nitroreductase Genes ntr4(Tv) and ntr6(Tv) SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID POPULATION-STRUCTURE; MYCOPLASMA-HOMINIS; IN-VITRO; TINIDAZOLE AB Metronidazole resistance in the sexually transmitted parasite Trichomonas vaginalis is a problematic public health issue. We have identified single nucleotide polymorphisms (SNPs) in two nitroreductase genes (ntr4(Tv) and ntr6(Tv)) associated with resistance. These SNPs were associated with one of two distinct T. vaginalis populations identified by multilocus sequence typing, yet one SNP (ntr6(Tv) A238T), which results in a premature stop codon, was associated with resistance independent of population structure and may be of diagnostic value. C1 [Paulish-Miller, Teresa E.; Schuyler, Jessica A.; Smith, William L.; Mordechai, Eli; Adelson, Martin E.; Gygax, Scott E.; Hilbert, David W.] Femeris Womens Hlth Res Ctr, Med Diagnost Labs, Hamilton, NY USA. [Augostini, Peter; Secor, William E.] Ctr Dis Control & Prevent, Div Parasit Dis, Atlanta, GA USA. RP Hilbert, DW (reprint author), Femeris Womens Hlth Res Ctr, Med Diagnost Labs, Hamilton, NY USA. EM dhilbert@mdlab.com NR 16 TC 6 Z9 6 U1 1 U2 7 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 EI 1098-6596 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD MAY PY 2014 VL 58 IS 5 BP 2938 EP 2943 DI 10.1128/AAC.02370-13 PG 6 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA AE9XF UT WOS:000334364300057 PM 24550324 ER PT J AU Gordon, SC Lamerato, LE Rupp, LB Li, J Holmberg, SD Moorman, AC Spradling, PR Teshale, EH Vijayadeva, V Boscarino, JA Henkle, EM Oja-Tebbe, N Lu, M AF Gordon, Stuart C. Lamerato, Lois E. Rupp, Loralee B. Li, Jia Holmberg, Scott D. Moorman, Anne C. Spradling, Philip R. Teshale, Eyasu H. Vijayadeva, Vinutha Boscarino, Joseph A. Henkle, Emily M. Oja-Tebbe, Nancy Lu, Mei CA CHeCS Investigators TI Antiviral Therapy for Chronic Hepatitis B Virus Infection and Development of Hepatocellular Carcinoma in a US Population SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY LA English DT Article DE Liver Cancer; Fibrosis; Alanine Aminotransferase; Tumor ID ADVANCED LIVER-DISEASE; RISK-FACTORS; C VIRUS; LAMIVUDINE; MORTALITY; CARE AB BACKGROUND & AIMS: Antiviral therapy could reduce the risk of hepatocellular carcinoma (HCC) among persons with chronic hepatitis B virus (HBV) infection. We evaluated the relationship between therapy for chronic HBV infection and HCC incidence using data from a longitudinal study of patients at 4 US healthcare centers. METHODS: We analyzed electronic health records of 2671 adult participants in the Chronic Hepatitis Cohort Study who were diagnosed with chronic HBV infection from 1992 through 2011 (49% Asian). Data analyzed were collected for a median of 5.2 years. Propensity-score adjustment was used to reduce bias, and Cox regression was used to estimate the relationship between antiviral treatment and HCC. The primary outcome was time to event of HCC incidence. RESULTS: Of study subjects, 3% developed HCC during follow-up period: 20 cases among the 820 patients with a history of antiviral HBV therapy and 47 cases among the 1851 untreated patients. In propensity-adjusted Cox regression, patients who received antiviral therapy had a lower risk of HCC than those who did not receive antiviral therapy (adjusted hazard ratio, 0.39; 95% confidence interval, 0.27-0.56; P < .001), after adjusting for abnormal level of alanine aminotransferase. In a subgroup analysis, antiviral treatment was associated with a lower risk of HCC after adjusting for serum markers of cirrhosis (adjusted hazard ratio, 0.24; 95% confidence interval, 0.15-0.39; P < .001). In a separate subgroup analysis of patients with available data on HBV DNA viral load, treated patients with viral loads >20,000 IU/mL had a significantly lower risk of HCC than untreated patients with viral loads >20,000 IU/mL. CONCLUSIONS: In a large geographically, clinically, and racially diverse US cohort, antiviral therapy for chronic HBV infection was associated with a reduced risk for HCC. C1 [Gordon, Stuart C.; Lamerato, Lois E.; Rupp, Loralee B.; Li, Jia; Oja-Tebbe, Nancy; Lu, Mei] Henry Ford Hlth Syst, Detroit, MI 48202 USA. [Holmberg, Scott D.; Moorman, Anne C.; Spradling, Philip R.; Teshale, Eyasu H.] Ctr Dis Control & Prevent, Div Viral Hepatitis, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. [Vijayadeva, Vinutha] Kaiser Permanente Hawaii, Ctr Hlth Res, Waipahu, HI USA. [Boscarino, Joseph A.] Geisinger Hlth Syst, Ctr Hlth Res, Danville, PA USA. [Henkle, Emily M.] Kaiser Permanente Northwest, Ctr Hlth Res, Portland, OR USA. RP Gordon, SC (reprint author), Henry Ford Hlth Syst, 2799 West Grand Blvd K-7, Detroit, MI 48202 USA. EM sgordon3@hfhs.org FU CDC Foundation; AbbVie; Genentech, a Member of the Roche Group; Janssen Pharmaceutical Companies of Johnson Johnson; Vertex Pharmaceuticals; Bristol-Myers-Squib FX The CHeCS project is funded by the CDC Foundation, which receives grants from AbbVie; Genentech, a Member of the Roche Group; Janssen Pharmaceutical Companies of Johnson & Johnson; and Vertex Pharmaceuticals. Past funders include Bristol-Myers-Squib. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 19 TC 57 Z9 58 U1 0 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1542-3565 EI 1542-7714 J9 CLIN GASTROENTEROL H JI Clin. Gastroenterol. Hepatol. PD MAY PY 2014 VL 12 IS 5 BP 885 EP 893 DI 10.1016/j.cgh.2013.09.062 PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AF1ZL UT WOS:000334512300031 PM 24107395 ER PT J AU Mahamud, A Leung, J Masunu-Faleafaga, Y Teshale, E Williams, R Dulski, T Thieme, M Garcia, P Schmid, DS Bialek, SR AF Mahamud, A. Leung, J. Masunu-Faleafaga, Y. Teshale, E. Williams, R. Dulski, T. Thieme, M. Garcia, P. Schmid, D. S. Bialek, S. R. TI uVaricella zoster virus in American Samoa: seroprevalence and predictive value of varicella disease history in elementary and college students SO EPIDEMIOLOGY AND INFECTION LA English DT Article DE American Samoa; chickenpox; seroprevalence; varicella; varicella-zoster virus ID UNITED-STATES; VACCINATION PROGRAM; SEROEPIDEMIOLOGY; EPIDEMIOLOGY; REGION; IMPACT; AGE; US AB The epidemiology of varicella is believed to differ between temperate and tropical countries. We conducted a varicella seroprevalence study in elementary and college students in the US territory of American Samoa before introduction of a routine varicella vaccination programme. Sera from 515 elementary and 208 college students were tested for the presence of varicella-zoster virus (VZV) IgG antibodies. VZV seroprevalence increased with age from 76.0% in the 4-6 years group to 97.7% in those aged >= 23 years. Reported history of varicella disease for elementary students was significantly associated with VZV seropositivity. The positive and negative predictive values of varicella disease history were 93.4% and 36.4%, respectively, in elementary students and 97.6% and 3.0%, respectively, in college students. VZV seroprevalence in this Pacific island appears to be similar to that in temperate countries and suggests endemic VZV circulation. C1 [Mahamud, A.; Leung, J.; Thieme, M.; Garcia, P.; Schmid, D. S.; Bialek, S. R.] Ctr Dis Control & Prevent, NCIRD, Atlanta, GA 30333 USA. [Mahamud, A.; Williams, R.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Masunu-Faleafaga, Y.] LBJ Trop Med Ctr, Amer Samoa Dept Hlth, Immunizat Program, Pago Pago, AS USA. [Teshale, E.; Williams, R.] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Dulski, T.] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA. [Dulski, T.] CDC Fdn, CDC Experience Appl Epidemiol Fellowship, Atlanta, GA USA. RP Leung, J (reprint author), Ctr Dis Control & Prevent, NCIRD, 1600 Clifton Rd,Mail Stop A-34, Atlanta, GA 30333 USA. EM JLeung@cdc.gov FU CDC Experience Applied Epidemiology Fellowship program; External Medical Affairs, Pfizer Inc. FX T.D. was funded through the CDC Experience Applied Epidemiology Fellowship program, a public/private partnership supported by a grant to the CDC Foundation from External Medical Affairs, Pfizer Inc. NR 22 TC 0 Z9 0 U1 0 U2 0 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0950-2688 EI 1469-4409 J9 EPIDEMIOL INFECT JI Epidemiol. Infect. PD MAY PY 2014 VL 142 IS 5 BP 1002 EP 1007 DI 10.1017/S095026881300174X PG 6 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA AD9BZ UT WOS:000333560900012 PM 23890292 ER PT J AU Mody, RK Meyer, S Trees, E White, PL Nguyen, T Sowadsky, R Henao, OL Lafon, PC Austin, J Azzam, I Griffin, PM Tauxe, RV Smith, K Williams, IT AF Mody, R. K. Meyer, S. Trees, E. White, P. L. Nguyen, T. Sowadsky, R. Henao, O. L. Lafon, P. C. Austin, J. Azzam, I. Griffin, P. M. Tauxe, R. V. Smith, K. Williams, I. T. TI Outbreak of Salmonella enterica serotype I 4,5,12: i:- infections: the challenges of hypothesis generation and microwave cooking SO EPIDEMIOLOGY AND INFECTION LA English DT Article DE Food safety; foodborne infections; outbreaks; Salmonella enterica ID LISTERIA-MONOCYTOGENES; UNITED-STATES; DESTRUCTION; CHICKEN; FOODS; TYPHIMURIUM; MINNESOTA; PRODUCTS; ENERGY; OVENS AB We investigated an outbreak of 396 Salmonella enterica serotype I 4,5,12:i:- infections to determine the source. After 7 weeks of extensive hypothesis-generation interviews, no refined hypothesis was formed. Nevertheless, a case-control study was initiated. Subsequently, an iterative hypothesis-generation approach used by a single interviewing team identified brand A not-ready-to-eat frozen pot pies as a likely vehicle. The case-control study, modified to assess this new hypothesis, along with product testing indicated that the turkey variety of pot pies was responsible. Review of product labels identified inconsistent language regarding preparation, and the cooking instructions included undefined microwave wattage categories. Surveys found that most patients did not follow the product's cooking instructions and did not know their oven's wattage. The manufacturer voluntarily recalled pot pies and improved the product's cooking instructions. This investigation highlights the value of careful hypothesis-generation and the risks posed by frozen not-ready-to-eat microwavable foods. C1 [Mody, R. K.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Div Appl Sci, Sci Educ & Profess Dev Program Off, Atlanta, GA 30333 USA. [Mody, R. K.; Trees, E.; Nguyen, T.; Henao, O. L.; Lafon, P. C.; Austin, J.; Griffin, P. M.; Tauxe, R. V.; Williams, I. T.] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Meyer, S.; Smith, K.] Minnesota Dept Hlth, Foodborne Vectorborne & Zoonot Dis Unit, St Paul, MN USA. [White, P. L.] US Food Safety & Inspect Serv, Appl Epidemiol Staff, Off Publ Hlth Sci, USDA, Omaha, NE USA. [Sowadsky, R.; Azzam, I.] Nevada Div Publ & Behav Hlth, Carson City, NV USA. RP Mody, RK (reprint author), Ctr Dis Control & Prevent, Mailstop C-09,1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM rmody@cdc.gov NR 38 TC 5 Z9 5 U1 2 U2 6 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0950-2688 EI 1469-4409 J9 EPIDEMIOL INFECT JI Epidemiol. Infect. PD MAY PY 2014 VL 142 IS 5 BP 1050 EP 1060 DI 10.1017/S0950268813001787 PG 11 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA AD9BZ UT WOS:000333560900018 PM 23916064 ER PT J AU Slayton, RB Newton, AE Depaola, A Jones, JL Mahon, BE AF Slayton, R. B. Newton, A. E. Depaola, A. Jones, J. L. Mahon, B. E. TI Clam-associated vibriosis, USA, 1988-2010 SO EPIDEMIOLOGY AND INFECTION LA English DT Article DE Clams; epidemiology; shellfish; Vibrionaceae; vulnificus ID RAW OYSTERS; UNITED-STATES; VULNIFICUS; PARAHAEMOLYTICUS; SEPTICEMIA; PATHOGENS AB Infections with Vibrio spp. have frequently been associated with consumption of bivalve molluscs, especially oysters, but illness associated with clams has also been well documented. We describe the 2312 domestically acquired foodborne Vibrio infections reported to the Cholera and Other Vibrio Illness Surveillance system from 1988 to 2010. Clams were associated with at least 4% (93 persons, only clams') and possibly as many as 24% (556 persons, any clams') of foodborne cases. Of those who consumed only clams', 77% of infections were caused by V. parahaemolyticus. Clam-associated illnesses were generally similar to those associated with other seafood consumption. Clams associated with these illnesses were most frequently harvested from the Atlantic coastal states and eaten raw. Our study describes the contribution of clams to the overall burden of foodborne vibriosis and indicates that a comprehensive programme to prevent foodborne vibriosis need to address the risks associated with clams. C1 [Slayton, R. B.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Slayton, R. B.; Newton, A. E.; Mahon, B. E.] Ctr Dis Control & Prevent, Enter Dis Epidemiol Branch, Div Foodborne Waterborne & Environm Dis, Atlanta, GA USA. [Depaola, A.; Jones, J. L.] US FDA, Div Seafood Sci & Technol, Gulf Coast Seafood Lab, Dauphin Isl, AL USA. RP Slayton, RB (reprint author), US Ctr Dis Control & Prevent, 1600 Clifton Rd,MS A-31, Atlanta, GA 30333 USA. EM via3@cdc.gov OI Slayton, Rachel/0000-0003-4699-8040 FU Intramural CDC HHS [CC999999] NR 17 TC 5 Z9 5 U1 0 U2 12 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0950-2688 EI 1469-4409 J9 EPIDEMIOL INFECT JI Epidemiol. Infect. PD MAY PY 2014 VL 142 IS 5 BP 1083 EP 1088 DI 10.1017/S0950268813001830 PG 6 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA AD9BZ UT WOS:000333560900021 PM 23920418 ER PT J AU Jackson, BR Zegarra, JA Lopez-Gatell, H Sejvar, J Arzate, F Waterman, S Nunez, AS Lopez, B Weiss, J Cruz, RQ Murrieta, DYL Luna-Gierke, R Heiman, K Vieira, AR Fitzgerald, C Kwan, P Zarate-Bermudez, M Talkington, D Hill, VR Mahon, B AF Jackson, B. R. Alomia Zegarra, J. Lopez-Gatell, H. Sejvar, J. Arzate, F. Waterman, S. Sanchez Nunez, A. Lopez, B. Weiss, J. Quintero Cruz, R. Lopez Murrieta, D. Y. Luna-Gierke, R. Heiman, K. Vieira, A. R. Fitzgerald, C. Kwan, P. Zarate-Bermudez, M. Talkington, D. Hill, V. R. Mahon, B. CA GBS Outbreak Invest Team TI Binational outbreak of Guillain-Barre syndrome associated with Campylobacter jejuni infection, Mexico and USA, 2011 SO EPIDEMIOLOGY AND INFECTION LA English DT Article DE Campylobacter; Guillain-Barre syndrome; outbreaks; water (safe) ID UNITED-STATES; FISHER-SYNDROME; WATER; POPULATION; CHILDREN AB In June 2011, a cluster of suspected cases of Guillain-Barre syndrome (GBS), which can follow Campylobacter jejuni infection, was identified in San Luis Rio Colorado (SLRC), Sonora, Mexico and Yuma County, Arizona, USA. An outbreak investigation identified 26 patients (18 from Sonora, eight from Arizona) with onset of GBS 4 May-21 July 2011, exceeding the expected number of cases (n=1-2). Twenty-one (81%) patients reported antecedent diarrhoea, and 61% of 18 patients tested were seropositive for C. jejuni IgM antibodies. In a case-control study matched on age group, sex, ethnicity, and neighbourhood of residence, all Arizona GBS patients travelled to SLRC during the exposure period vs. 45% of matched controls (matched odds ratio 8.1, 95% confidence interval 1.5-infinity). Exposure information and an environmental assessment suggested that GBS cases resulted from a large outbreak of C. jejuni infection from inadequately disinfected tap water in SLRC. Binational collaboration was essential in investigating this cross-border GBS outbreak, the first in mainland North America since 1976. C1 [Jackson, B. R.; Sejvar, J.; Waterman, S.; Luna-Gierke, R.; Heiman, K.; Vieira, A. R.; Fitzgerald, C.; Kwan, P.; Zarate-Bermudez, M.; Talkington, D.; Hill, V. R.; Mahon, B.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Alomia Zegarra, J.; Quintero Cruz, R.] Unidad Vigilancia Epidemiol, Hermosillo, Sonora, Mexico. [Lopez-Gatell, H.] Inst Nacl Salud Publ, Ctr Invest Enfermedades Infecciosas, Cuernavaca, Morelos, Mexico. [Arzate, F.; Lopez Murrieta, D. Y.] Direcc Gen Epidemiol, Mexico City, DF, Mexico. [Sanchez Nunez, A.] Serv Salud, San Luis Rio Colorado, Sonora, Mexico. [Lopez, B.] Yuma Cty Hlth Dept, Yuma, AZ USA. [Weiss, J.] Arizona Dept Hlth Serv, Phoenix, AZ 85007 USA. [Luna-Gierke, R.; Heiman, K.] Atlanta Res & Educ Fdn, Decatur, GA USA. RP Jackson, BR (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS A38, Atlanta, GA 30333 USA. EM brjackson1@cdc.gov RI Hill, Vincent/G-1789-2012 OI Hill, Vincent/0000-0001-7069-7737 NR 36 TC 7 Z9 8 U1 0 U2 13 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0950-2688 EI 1469-4409 J9 EPIDEMIOL INFECT JI Epidemiol. Infect. PD MAY PY 2014 VL 142 IS 5 BP 1089 EP 1099 DI 10.1017/S0950268813001908 PG 11 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA AD9BZ UT WOS:000333560900022 PM 23924442 ER PT J AU Favaloro, EJ Verbruggen, B Miller, CH AF Favaloro, E. J. Verbruggen, B. Miller, C. H. TI Laboratory testing for factor inhibitors SO HAEMOPHILIA LA English DT Review DE diagnostic accuracy; assay variation; low titre inhibitors; haemophilia; factor inhibitors; fluorescence immunoassay ID FACTOR-VIII INHIBITORS; EXTERNAL QUALITY ASSESSMENT; NIJMEGEN MODIFICATION; IMMUNE TOLERANCE; BETHESDA ASSAY; HEMOPHILIA; EXPERIENCE AB Inhibitor assays are performed when patients present with unexplained prolonged routine coagulation test times and unexpected and/or unusual bleeding (potential for acquired haemophilia) as well as being a part of normal congenital haemophilia management and monitoring, particularly when bleeding occurs on therapy, or when increments in factor levels post-factor replacement remain lower than expected. In this article, we will describe the assays used, as well as their development, pitfalls in testing such as inter-laboratory variability and false negative/positive results, as well as some strategies for overcoming these pitfalls and potential alternative test approaches. The inter-laboratory coefficient of variation often approaches (and sometimes exceeds) 50%, as evidenced by various external quality assessment groups, and this variability has not improved over recent years. Additional important considerations include appropriate interpretation of test results, repeat testing for confirmation, and assessment of recovery as part of the diagnostic process. C1 [Favaloro, E. J.] Westmead Hosp, Inst Clin Pathol & Med Res ICPMR, Dept Haematol, Westmead, NSW 2145, Australia. [Verbruggen, B.] ECAT Fdn, Leiden, Netherlands. [Verbruggen, B.] Jeroen Bosch Hosp, Lab Clin Chem & Haematol, Shertogenbosch, Netherlands. [Miller, C. H.] Ctr Dis Control & Prevent, Div Blood Disorders, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. RP Favaloro, EJ (reprint author), Westmead Hosp, Inst Clin Pathol & Med Res ICPMR, Dept Haematol, Westmead, NSW 2145, Australia. EM emmanuel.favaloro@health.nsw.gov.au OI Miller, Connie H/0000-0002-3989-7973 NR 15 TC 11 Z9 11 U1 0 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1351-8216 EI 1365-2516 J9 HAEMOPHILIA JI Haemophilia PD MAY PY 2014 VL 20 SU 4 SI SI BP 94 EP 98 DI 10.1111/hae.12408 PG 5 WC Hematology SC Hematology GA AF9BK UT WOS:000335009800017 PM 24762283 ER PT J AU Ullman, M Zhang, QC Brown, D Grant, A Soucie, JM AF Ullman, M. Zhang, Q. C. Brown, D. Grant, A. Soucie, J. M. CA Hemophilia Treatment Ctr Network TI Association of overweight and obesity with the use of self and home-based infusion therapy among haemophilic men SO HAEMOPHILIA LA English DT Article DE self-infusion; obesity; overweight; haemophilia; BMI; home infusion ID BODY-MASS INDEX; RISK-FACTORS; YOUNG MALES; CHILDREN; PREVALENCE; ADOLESCENTS; PROPHYLAXIS; ADIPOSITY; ADULTS; TRENDS AB An elevated body mass index (BMI) may make venipuncture more difficult, potentially impacting the use of home infusion (HI) and self-infusion (SI). We sought to determine whether above-normal BMI is associated with decreased use of HI treatment and SI of clotting factor concentrate among haemophilic persons. We analysed data from 10814 male patients with haemophilia A and B (45% with severe disease) aged 6-79years enrolled in the Centers for Disease Control and Prevention Universal Data Collection surveillance project between 1998 and 2008. Associations between the use of HI and SI and BMI were evaluated using logistic regression. Fifty per cent of haemophilic men were overweight or obese, similar to rates reported among the general US population by the 2007-2008 National Health and Nutrition Examination Survey [Flegal, KM etal., JAMA 2010;303:235-241;]. Twenty per cent of children and 22% of teens were obese, as were 28% of adults [Ogden, CL et al., JAMA 2010;303:235, 242]. Overall, 70% of the study sample used HI; 44% of those who used HI also used SI. Overweight and obese men were each less likely to use HI than those of normal weight [odds ratio (OR) 0.8; 95% confidence interval (CI) 0.7-1.0 and OR 0.7; 95% CI 0.6-0.8 respectively]. Obese teens and adult men were also less likely to practice SI than teens and adults of normal weight (OR 0.8; 95% CI 0.7-0.9 for each). We conclude that overweight and obese haemophilic men are less likely to use HI and obese men are less likely to use SI than their normal-weight counterparts. C1 [Ullman, M.; Brown, D.] Univ Texas Hlth Sci Ctr Houston, Gulf States Hemophilia & Thrombophilia Ctr, Houston, TX 77030 USA. [Zhang, Q. C.; Grant, A.; Soucie, J. M.] CDC, Div Blood Disorders, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. RP Ullman, M (reprint author), Gulf States Hemophilia & Thrombophilia Ctr, 6655 Travis St,Suite 400, Houston, TX 77030 USA. EM megan.m.ullman@uth.tmc.edu RI Kerlin, Bryce/E-3369-2011 OI Kerlin, Bryce/0000-0002-1756-8271 FU CDC; Haemophilia Treatment Center Network (HTCN); Division of Blood Disorders, National Center on Birth Defects and Developmental Disabilities, CDC; Gulf States Haemophilia & Thrombophilia Center, University of Texas Health Science Center at Houston FX The UDC Project was funded by a cooperative agreement between the CDC and the Haemophilia Treatment Center Network (HTCN) comprised of 135 comprehensive care clinics located throughout the United States and its territories. The authors also acknowledge the staff of the HTCN for patient recruitment and data collection and the patients for their participation in the study. The authors thank Rodney Presley, Meredith Oakley and Michael Recht for their contributions to this manuscript. This study was supported by the Division of Blood Disorders, National Center on Birth Defects and Developmental Disabilities, CDC and by the Gulf States Haemophilia & Thrombophilia Center, University of Texas Health Science Center at Houston. NR 24 TC 2 Z9 2 U1 1 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1351-8216 EI 1365-2516 J9 HAEMOPHILIA JI Haemophilia PD MAY PY 2014 VL 20 IS 3 BP 340 EP 348 DI 10.1111/hae.12303 PG 9 WC Hematology SC Hematology GA AE9RQ UT WOS:000334346900019 PM 24261637 ER PT J AU Iglesias, AI Mihaescu, R Ioannidis, JPA Khoury, MJ Little, J van Duijn, CM Janssens, ACJW AF Iglesias, Adriana I. Mihaescu, Raluca Ioannidis, John P. A. Khoury, Muin J. Little, Julian van Duijn, Cornelia M. Janssens, A. Cecile J. W. TI Scientific reporting is suboptimal for aspects that characterize genetic risk prediction studies: a review of published articles based on the Genetic RIsk Prediction Studies statement SO JOURNAL OF CLINICAL EPIDEMIOLOGY LA English DT Review DE Genetic; Risk prediction; GRIPS; Reporting guideline; Epidemiology; Review ID RANDOMIZED CONTROLLED-TRIALS; SINGLE NUCLEOTIDE POLYMORPHISMS; CORONARY-ARTERY-DISEASE; TYPE-2 DIABETES RISK; BEFORE-AND-AFTER; DIAGNOSTIC-ACCURACY; PROSPECTIVE COHORT; PERSONALIZED MEDICINE; CLINICAL INFORMATION; STROBE STATEMENT AB Objectives: Our main objective was to raise awareness of the areas that need improvements in the reporting of genetic risk prediction articles for future publications, based on the Genetic Risk Prediction Studies (GRIPS) statement. Study Design and Setting: We evaluated studies that developed or validated a prediction model based on multiple DNA variants, using empirical data, and were published in 2010. A data extraction form based on the 25 items of the GRIPS statement was created and piloted. Results: Forty-two studies met our inclusion criteria. Overall, more than half of the evaluated items (34 of 62) were reported in at least 85% of included articles. Seventy-seven percentage of the articles were identified as genetic risk prediction studies through title assessment, but only 31% used the keywords recommended by GRIPS in the title or abstract. Seventy-four percentage mentioned which allele was the risk variant. Overall, only 10% of the articles reported all essential items needed to perform external validation of the risk model. Conclusion: Completeness of reporting in genetic risk prediction studies is adequate for general elements of study design but is suboptimal for several aspects that characterize genetic risk prediction studies such as description of the model construction. Improvements in the transparency of reporting of these aspects would facilitate the identification, replication, and application of genetic risk prediction models. (C) 2014 Elsevier Inc. All rights reserved. C1 [Iglesias, Adriana I.; Mihaescu, Raluca; van Duijn, Cornelia M.] Erasmus Univ, Dept Epidemiol, Med Ctr, NL-3015 GE Rotterdam, Netherlands. [Ioannidis, John P. A.] Stanford Univ, Stanford Prevent Res Ctr, Dept Med, Sch Med, Stanford, CA 94305 USA. [Ioannidis, John P. A.] Stanford Univ, Stanford Prevent Res Ctr, Dept Hlth Res & Policy, Sch Med, Stanford, CA 94305 USA. [Ioannidis, John P. A.] Stanford Univ, Dept Stat, Sch Humanities & Sci, Stanford, CA 94305 USA. [Khoury, Muin J.] Ctr Dis Control & Prevent, Off Publ Hlth Genom, Atlanta, GA 30333 USA. [Khoury, Muin J.] NCI, Epidemiol & Genom Res Program, Bethesda, MD 20892 USA. [Little, Julian] Univ Ottawa, Dept Epidemiol & Community Med, Ottawa, ON K1H 8M5, Canada. [Janssens, A. Cecile J. W.] Emory Univ, Dept Epidemiol, Atlanta, GA 30322 USA. RP Janssens, ACJW (reprint author), Emory Univ, Dept Epidemiol, Atlanta, GA 30322 USA. EM cecile.janssens@emory.edu OI Janssens, A Cecile/0000-0002-6153-4976 FU ERACOL program; Centre for Medical Systems Biology [CMSB 1-2]; ENGAGE Consortium [HEALTH-F4-2007-201413]; Netherlands Organization for Scientific Research (NWO) FX A.I.I. was a recipient of the ERACOL program, which gives her the opportunity to perform this research in the Netherlands. J.L. holds a Tier 1 Canada Research Chair in Human Genome Epidemiology. C.M.v.D. was supported by the Centre for Medical Systems Biology (CMSB 1-2) and the ENGAGE Consortium, grant agreement HEALTH-F4-2007-201413. A.C.J.W.J. was supported by a Vidi grant from the Netherlands Organization for Scientific Research (NWO). NR 70 TC 2 Z9 2 U1 0 U2 8 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0895-4356 EI 1878-5921 J9 J CLIN EPIDEMIOL JI J. Clin. Epidemiol. PD MAY PY 2014 VL 67 IS 5 BP 487 EP 499 DI 10.1016/j.jclinepi.2013.10.006 PG 13 WC Health Care Sciences & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA AF8OG UT WOS:000334974900002 PM 24411311 ER PT J AU Al-Awadi, AR Al-Kuhlani, A Breman, JG Doumbo, O Eberhard, ML Guiguemde, RT Magnussen, P Molyneux, DH Nadim, A AF Al-Awadi, Abdul R. Al-Kuhlani, Abdulhakim Breman, Joel G. Doumbo, Ogobara Eberhard, Mark L. Guiguemde, Robert T. Magnussen, Pascal Molyneux, David H. Nadim, Abolhassan TI Guinea worm (Dracunculiasis) eradication: update on progress and endgame challenges SO TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE LA English DT Editorial Material DE Dracunculiasis; Dracunculus medinensis Guinea worm; Eradication ID INSIGNIS NEMATODA; DRACUNCULOIDEA; CERTIFICATION; DISEASE AB The International Commission for the Certification of Dracunculiasis Eradication (ICCDE) met in December to review progress towards eradication. The status of the programme was presented by WHO and The Carter Center, Atlanta. The Commission received reports from international certification teams that Cote dIvoire, Niger and Nigeria were free of transmission and should be certified, while four countries, namely Chad, Ethiopia, Mali and South Sudan, remained endemic. The Commission certified that Somalia and South Africa were free of transmission. During 2013, there was a decline of about 78 in the numbers of cases reported in South Sudan. A report of the perplexing dracunculiasis epidemiology in Chad was also discussed, where dogs have been found to be infected with Dracunculus medinensis. C1 [Al-Awadi, Abdul R.] Islamic Org Med Sci, Sulibikhat 90803, Kuwait. [Al-Kuhlani, Abdulhakim] Minist Publ Hlth & Populat, Sect PHC, Sanaa, Yemen. [Breman, Joel G.] NIH, Fogarty Int Ctr, Bethesda, MD 20892 USA. [Doumbo, Ogobara] Univ Mali, Fac Med, Dept Epidemiol Affect Parasitaires, Bamako, Mali. [Eberhard, Mark L.] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA 30333 USA. [Guiguemde, Robert T.] Univ Bobo Dioulasso, Burkina Natl Acad Sci, Bobo Dioulasso 01, Burkina Faso. [Magnussen, Pascal] Univ Copenhagen, Inst Vet Dis, Biol Sect Parasitol & Aquat Dis, DK-1781 Frederiksberg C, Denmark. [Molyneux, David H.] Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England. RP Molyneux, DH (reprint author), Univ Liverpool, Liverpool Sch Trop Med, Pembroke Pl, Liverpool L3 5QA, Merseyside, England. EM david.molyneux@liv.ac.uk NR 11 TC 12 Z9 12 U1 13 U2 44 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0035-9203 EI 1878-3503 J9 T ROY SOC TROP MED H JI Trans. Roy. Soc. Trop. Med. Hyg. PD MAY PY 2014 VL 108 IS 5 BP 249 EP 251 DI 10.1093/trstmh/tru039 PG 3 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA AF5LE UT WOS:000334754200002 PM 24699360 ER PT J AU Le, M Ravin, K Hasan, A Clauss, H Muchant, DG Pasko, JK Cipollina, G Abanyie, F Montgomery, SP Loy, M Ahmed, M Mathur, M Mani, BC Mehr, J Kotru, A Varma, C Maksimak, M Schultz, M Obradovic, G Alvarez, R Toyoda, Y Birkenbach, M Brunner, E Nelson, J AF Le, M. Ravin, K. Hasan, A. Clauss, H. Muchant, D. G. Pasko, J. K. Cipollina, G. Abanyie, F. Montgomery, S. P. Loy, M. Ahmed, M. Mathur, M. Mani, B. Chokkalingam Mehr, J. Kotru, A. Varma, C. Maksimak, M. Schultz, M. Obradovic, G. Alvarez, R. Toyoda, Y. Birkenbach, M. Brunner, E. Nelson, J. TI Single Donor-Derived Strongyloidiasis in Three Solid Organ Transplant Recipients: Case Series and Review of the Literature SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Article DE Donor screening; donor-to-host transmission; heart transplantation; renal and pancreas transplantation; renal transplant; Strongyloides; strongyloidiasis; survivors; transplant infectious diseases ID KIDNEY-TRANSPLANT; STERCORALIS INFECTION; HYPERINFECTION; TRANSMISSION; ALLOGRAFT AB Donor-derived Strongyloides stercoralis infections in transplant recipients are a rare but recognized complication. In this case series, we report donor-derived allograft transmission of Strongyloides in three solid organ transplant recipients. Following detection of infection in heart and kidney-pancreas recipients at two different transplant centers, a third recipient from the same donor was identified and diagnosed. S. stercoralis larvae were detected in duodenal aspirates, bronchial washings, cerebrospinal fluid, urine and stool specimens. Treatment with ivermectin and albendazole was successful in two of the three patients identified. The Centers for Disease Control and Prevention was contacted and performed an epidemiologic investigation. Donor serology was strongly positive for S. stercoralis antibodies on retrospective testing while all pretransplant recipient serum was negative. There should be a high index of suspicion for parasitic infection in transplant recipients and donors from endemic regions of the world. This case series underscores the need for expanded transplant screening protocols for Strongyloides. Positive serologic or stool tests should prompt early treatment or prophylaxis in donors and recipients as well as timely notification of organ procurement organizations and transplant centers. This case series of suspected donor-derived strongyloidiasis highlights the epidemiology of Strongyloides stercorals and draws attention to the importance of diligent screening in all at-risk recipients and donors, as well as high index of suspicion and timely notification of possible donor-derived infections. (Also see special article by Levi et al on page 1003.) C1 [Le, M.; Cipollina, G.; Kotru, A.; Varma, C.] Geisinger Med Ctr, Dept Transplantat & Liver Surg, Danville, PA 17822 USA. [Ravin, K.] Geisinger Med Ctr, Dept Pediat, Div Infect Dis, Danville, PA 17822 USA. [Hasan, A.] Geisinger Med Ctr, Dept Med, Div Infect Dis, Danville, PA 17822 USA. [Clauss, H.] Temple Univ, Dept Med, Div Infect Dis, Philadelphia, PA 19122 USA. [Muchant, D. G.] Geisinger Med Ctr, Dept Pediat, Div Nephrol, Danville, PA 17822 USA. [Pasko, J. K.; Brunner, E.; Nelson, J.] Geisinger Med Ctr, Dept Internal Med Pediat, Danville, PA 17822 USA. [Abanyie, F.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. [Abanyie, F.; Montgomery, S. P.] Ctr Dis Control & Prevent, Parasit Dis Branch, Atlanta, GA USA. [Loy, M.] Edward Via Coll Osteopath Med, Dept Pediat Infect Dis, Blacksburg, VA USA. [Ahmed, M.; Mathur, M.; Mani, B. Chokkalingam; Alvarez, R.] Temple Univ, Dept Med, Div Cardiol, Philadelphia, PA 19122 USA. [Mehr, J.; Schultz, M.; Obradovic, G.] Geisinger Med Ctr, Dept Med, Div Nephrol, Danville, PA 17822 USA. [Maksimak, M.] Geisinger Med Ctr, Dept Pediat, Div Gastroenterol, Danville, PA 17822 USA. [Toyoda, Y.] Temple Univ, Dept Cardiothorac Surg, Philadelphia, PA 19122 USA. [Birkenbach, M.] Temple Univ, Dept Pathol, Philadelphia, PA 19122 USA. RP Le, M (reprint author), Geisinger Med Ctr, Dept Transplantat & Liver Surg, Danville, PA 17822 USA. EM mele@geisinger.edu NR 20 TC 8 Z9 9 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD MAY PY 2014 VL 14 IS 5 BP 1199 EP 1206 DI 10.1111/ajt.12670 PG 8 WC Surgery; Transplantation SC Surgery; Transplantation GA AF0LG UT WOS:000334404900026 PM 24612907 ER PT J AU Bridges, CB Coyne-Beasley, T AF Bridges, Carolyn B. Coyne-Beasley, Tamera CA ACIP ACIP Adult Immunization Work Grp TI Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older-United States, 2014 SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Reprint ID INFLUENZA VACCINATION; BARRIERS; COVERAGE AB The 2014 adult immunization guideline changes are highlighted in these recommendations. C1 [Bridges, Carolyn B.] CDC, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Coyne-Beasley, Tamera] Univ N Carolina, Div Gen Pediat & Adolescent Med, Chapel Hill, NC USA. RP Bridges, CB (reprint author), CDC, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM cbridges@cdc.gov NR 12 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD MAY PY 2014 VL 14 IS 5 BP 1214 EP 1216 DI 10.1111/ajt.12769 PG 3 WC Surgery; Transplantation SC Surgery; Transplantation GA AF0LG UT WOS:000334404900028 ER PT J AU Xu, S Newcomer, S Nelson, J Qian, L McClure, D Pan, Y Zeng, C Glanz, J AF Xu, Stanley Newcomer, Sophia Nelson, Jennifer Qian, Lei McClure, David Pan, Yi Zeng, Chan Glanz, Jason TI Signal detection of adverse events with imperfect confirmation rates in vaccine safety studies using self-controlled case series design SO BIOMETRICAL JOURNAL LA English DT Article DE Conditional Poisson model; Fixed effects model; Misclassification of adverse events; Screening studies; Self-controlled case series ID INACTIVATED INFLUENZA VACCINE; MISCLASSIFIED COUNTS; DATABASES; CHILDREN; MODEL; DATALINK; QUALITY AB The Vaccine Safety Datalink project captures electronic health record data including vaccinations and medically attended adverse events on 8.8 million enrollees annually from participating managed care organizations in the United States. While the automated vaccination data are generally of high quality, a presumptive adverse event based on diagnosis codes in automated health care data may not be true (misclassification). Consequently, analyses using automated health care data can generate false positive results, where an association between the vaccine and outcome is incorrectly identified, as well as false negative findings, where a true association or signal is missed. We developed novel conditional Poisson regression models and fixed effects models that accommodate misclassification of adverse event outcome for self-controlled case series design. We conducted simulation studies to evaluate their performance in signal detection in vaccine safety hypotheses generating (screening) studies. We also reanalyzed four previously identified signals in a recent vaccine safety study using the newly proposed models. Our simulation studies demonstrated that (i) outcome misclassification resulted in both false positive and false negative signals in screening studies; (ii) the newly proposed models reduced both the rates of false positive and false negative signals. In reanalyses of four previously identified signals using the novel statistical models, the incidence rate ratio estimates and statistical significances were similar to those using conventional models and including only medical record review confirmed cases. C1 [Xu, Stanley; Newcomer, Sophia; Zeng, Chan; Glanz, Jason] Kaiser Permanente Colorado, Inst Hlth Res, Denver, CO 80231 USA. [Nelson, Jennifer] Grp Hlth Res Inst, Seattle, WA USA. [Qian, Lei] Kaiser Permanente So Calif, Dept Res & Evaluat, Pasadena, CA 91101 USA. [McClure, David] Marshfield Clin Res Fdn, Marshfield, WI USA. [Pan, Yi] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Xu, S (reprint author), Kaiser Permanente Colorado, Inst Hlth Res, Denver, CO 80231 USA. EM stan.xu@kp.org FU Centers for Disease Control and Prevention [200-2002-00732]; America's Health Insurance Plans; NIH/NCRR Colorado CTSI [UL1 RR025780] FX This study was supported by the Centers for Disease Control and Prevention via contract 200-2002-00732 (the Vaccine Safety Datalink Project) with America's Health Insurance Plans. S. X. was also supported by NIH/NCRR Colorado CTSI Grant Number UL1 RR025780. NR 18 TC 2 Z9 2 U1 0 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0323-3847 EI 1521-4036 J9 BIOMETRICAL J JI Biom. J. PD MAY PY 2014 VL 56 IS 3 SI SI BP 513 EP 525 DI 10.1002/bimj.201300012 PG 13 WC Mathematical & Computational Biology; Statistics & Probability SC Mathematical & Computational Biology; Mathematics GA AE8LF UT WOS:000334251100011 PM 24402780 ER PT J AU Miller, EA Tarasenko, YN Parker, JD Schoendorf, KC AF Miller, Eric A. Tarasenko, Yelena N. Parker, Jennifer D. Schoendorf, Kenneth C. TI Diabetes and colorectal cancer screening among men and women in the USA: National Health Interview Survey: 2008, 2010 SO CANCER CAUSES & CONTROL LA English DT Article DE Colorectal cancer; Colorectal cancer screening; Diabetes ID GENDER-DIFFERENCES; CARE UTILIZATION; UNITED-STATES; RISK-FACTORS; MELLITUS; METAANALYSIS; SERVICES; RATES; RECOMMENDATION; ASSOCIATIONS AB Adults with diabetes are at increased risk of being diagnosed with and dying from colorectal cancer, but it is unclear whether colorectal cancer screening (CRCS) use is lower in this population. Using the 2008 and 2010 National Health Interview Survey data, we examined whether guideline-concordant CRCS is lower among men and women with self-reported diabetes. We calculated the weighted percentage of guideline-concordant CRCS and unadjusted and adjusted prevalence ratios (PR) comparing adults aged 51-75 years with diabetes (n = 6,514) to those without (n = 8,371). We also examined effect modification by age (51-64 and 65-75), race/ethnicity, and number of medical office visits (0-3, a parts per thousand yen4). The unadjusted prevalence of CRCS among men with diabetes was significantly higher than men without (63.3 vs. 58.0 %; PR = 1.09 95 % CI 1.03-1.16). In adjusted models, this relationship was evident among older [adjusted PR (aPR) = 1.13 95 % CI 1.06-1.21] but not younger men (aPR = 0.99 95 % CI 0.91-1.08; p for interaction term a parts per thousand currency sign0.01). There was no significant association between diabetes and CRCS among women overall (56.6 vs. 57.9 %; PR = 0.98 95 % CI 0.92-1.04) or by age group. Race/ethnicity and the number of medical visits did not significantly modify the association between diabetes and CRCS for men or women. Men and women with self-reported diabetes were not less likely to be up to date with CRCS than those without diabetes. Older men with diabetes were more likely to be up to date with CRCS than those without diabetes. C1 [Miller, Eric A.; Tarasenko, Yelena N.; Parker, Jennifer D.; Schoendorf, Kenneth C.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. [Tarasenko, Yelena N.] Georgia So Univ, Jiann Ping Hsu Coll Publ Hlth, Statesboro, GA 30460 USA. RP Miller, EA (reprint author), Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, 3311 Toledo Rd, Hyattsville, MD 20782 USA. EM bwe6@cdc.gov NR 30 TC 0 Z9 0 U1 2 U2 5 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0957-5243 EI 1573-7225 J9 CANCER CAUSE CONTROL JI Cancer Causes Control PD MAY PY 2014 VL 25 IS 5 BP 553 EP 560 DI 10.1007/s10552-014-0360-z PG 8 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA AF0MU UT WOS:000334409500002 PM 24562970 ER PT J AU Flagg, EW Datta, SD Saraiya, M Unger, ER Peters, E Cole, L Chen, VW Tucker, T Byrne, MJ Copeland, G Silva, W Watson, M Weinstock, H AF Flagg, Elaine W. Datta, S. Deblina Saraiya, Mona Unger, Elizabeth R. Peters, Edward Cole, Lauren Chen, Vivien W. Tucker, Thomas Byrne, Mary Jane Copeland, Glenn Silva, Won Watson, Meg Weinstock, Hillard TI Population-based surveillance for cervical cancer precursors in three central cancer registries, United States 2009 SO CANCER CAUSES & CONTROL LA English DT Article DE Cervical intraepithelial neoplasia; Epidemiology; Public health; Population characteristics; Sexually transmitted diseases ID HUMAN-PAPILLOMAVIRUS INFECTION; AMERICAN SOCIETY; NATURAL-HISTORY; BETHESDA SYSTEM; HPV VACCINE; LESIONS; IMPACT; RECOMMENDATIONS; TERMINOLOGY; PREVALENCE AB The USA has a well-established network of central cancer registries (CCRs) that collect data using standardized definitions and protocols to provide population-based estimates of cancer incidence. The addition of cervical cancer precursors in select CCR operations would facilitate future studies measuring the population-level impact of human papillomavirus (HPV) vaccine. To assess the feasibility of collecting data on cervical cancer precursors, we conducted a multi-site surveillance study in three state-wide CCRs, to obtain annual case counts and compare rates of precursor lesions to those for invasive cervical cancer. We developed standardized methods for case identification, data collection and transmission, training and quality assurance, while allowing for registry-specific strategies to accomplish surveillance objectives. We then conducted population-based surveillance for precancerous cervical lesions in three states using the protocols. We identified 5,718 cases of cervical cancer precursors during 2009. Age-adjusted incidence of cervical cancer precursors was 77 (Kentucky), 60 (Michigan), and 54 (Louisiana) per 100,000 women. Highest rates were observed in those aged 20-29 years: 274 (Kentucky), 202 (Michigan), and 196 (Louisiana) per 100,000. The variable with the most missing data was race/ethnicity, which was missing for 13 % of cases in Kentucky, 18 % in Michigan, and 1 % in Louisiana. Overall rates of cervical cancer precursors were over sixfold higher than invasive cervical cancer rates [rate ratios: 8.6 (Kentucky), 8.3 (Michigan), and 6.2 (Louisiana)]. Incorporating surveillance of cervical cancer precursors using existing CCR infrastructure is feasible and results in collection of population-based incidence data. Standardized collection of these data in high-quality registry systems will be useful in future activities monitoring the impact of HPV vaccination across states. As a result of this study, ongoing surveillance of these lesions has now been conducted in four CCRs since 2010. C1 [Flagg, Elaine W.; Datta, S. Deblina; Weinstock, Hillard] Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Saraiya, Mona; Watson, Meg] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Unger, Elizabeth R.] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Peters, Edward; Cole, Lauren; Chen, Vivien W.] State Univ Hlth Sci Ctr, Sch Publ Hlth, Program Epidemiol, Louisiana Tumor Registry, New Orleans, LA USA. [Tucker, Thomas; Byrne, Mary Jane] Univ Kentucky, Markey Canc Ctr, Markey Canc Control Program, Kentucky Canc Registry, Lexington, KY USA. [Copeland, Glenn; Silva, Won] Michigan Dept Community Hlth, Michigan Canc Surveillance Program, Lansing, MI USA. RP Flagg, EW (reprint author), Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, 1600 Clifton Rd,NE,MS E 02, Atlanta, GA 30333 USA. EM eflagg@cdc.gov OI /0000-0003-4928-6532 FU Centers for Disease Control and Prevention [200-2008-27956] FX Funding for this work was provided by the Centers for Disease Control and Prevention (Contract No. 200-2008-27956). NR 50 TC 4 Z9 4 U1 0 U2 7 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0957-5243 EI 1573-7225 J9 CANCER CAUSE CONTROL JI Cancer Causes Control PD MAY PY 2014 VL 25 IS 5 BP 571 EP 581 DI 10.1007/s10552-014-0362-x PG 11 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA AF0MU UT WOS:000334409500004 PM 24578200 ER PT J AU Siegel, PD Fowler, JF Law, BF Warshaw, EM Taylor, JS AF Siegel, Paul D. Fowler, Joseph F. Law, Brandon F. Warshaw, Erin M. Taylor, James S. TI Concentrations and stability of methyl methacrylate, glutaraldehyde, formaldehyde and nickel sulfate in commercial patch test allergen preparations SO CONTACT DERMATITIS LA English DT Article DE patch test allergens; nickel sulfate; formaldehyde; glutaraldehyde; concentration and stability; methyl methacrylate ID DIPHENYLMETHANE DIISOCYANATE; PETROLATUM; DIPHENYLMETHANE-4,4'-DIISOCYANATE; SENSITIVITY; DEGRADATION AB Background Epicutaneous patch tests are used to reproduce allergy and diagnose allergic contact dermatitis. Reliable allergen test preparations are required. Objectives The purpose of the present study was to measure the actual concentrations of nickel(II) sulfate hexahydrate (NiSO4), methyl methacrylate, formaldehyde, and glutaraldehyde, and to compare them with the labelled concentrations, in commercial patch test allergen preparations found in dermatology clinics where patch testing is routinely performed. Materials and methods The commercial in-date and out-of-date patch test allergen preparations concentrations of NiSO4, methyl methacrylate, formaldehyde and glutaraldehyde from one to three participating clinics were analysed with chromatographic or wet chemical techniques. Results NiSO4 and formaldehyde concentrations were at or above the labelled concentrations; however, formaldehyde loss occurred with storage. NiSO4 particulate was uniformly distributed throughout the petrolatum. 'In-use' methyl methacrylate reagent syringes all contained <= 56% of the 2% label concentration, with no observable relationship with expiration date. Lower methyl methacrylate cocentrations were consistently measured at the syringe tip end, suggesting loss resulting from methyl methacrylate's volatility. The concentrations of glutaraldehyde patch test allergen preparations ranged from 27% to 45% of the labelled (1% in pet.) concentration, independently of expiration date. Conclusions Some false-negative methyl methacrylate, formaldehyde or glutaraldehyde patch test results may be attributable to instability of the test preparations. C1 [Siegel, Paul D.; Law, Brandon F.] NIOSH, Hlth Effects Lab Div, Allergy & Clin Immunol Branch, Morgantown, WV 26505 USA. [Fowler, Joseph F.] Univ Louisville, Div Dermatol, Louisville, KY 40202 USA. [Warshaw, Erin M.] Univ Minnesota, Minneapolis Vet Affairs Hlth Care Syst, Minneapolis, MN 55417 USA. [Taylor, James S.] Cleveland Clin, Cleveland, OH 44195 USA. RP Siegel, PD (reprint author), NIOSH, ACIB, HELD, CDC, 1095 Willowdale Rd, Morgantown, WV 26505 USA. EM psiegel@cdc.gov FU NIOSH intramural research funds FX This work was supported by NIOSH intramural research funds. NR 20 TC 7 Z9 7 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0105-1873 EI 1600-0536 J9 CONTACT DERMATITIS JI Contact Dermatitis PD MAY PY 2014 VL 70 IS 5 BP 309 EP 315 DI 10.1111/cod.12169 PG 7 WC Allergy; Dermatology SC Allergy; Dermatology GA AE7KG UT WOS:000334175900008 PM 24731086 ER PT J AU Vera, DM Hora, RA Murillo, A Wong, JF Torre, AJ Wang, D Boulay, D Hancock, K Katz, JM Ramos, M Loayza, L Quispe, J Reaves, EJ Bausch, DG Chowell, G Montgomery, JM AF Vera, Delphis M. Hora, Ricardo A. Murillo, Anarina Wong, Juan F. Torre, Armando J. Wang, David Boulay, Darbi Hancock, Kathy Katz, Jacqueline M. Ramos, Mariana Loayza, Luis Quispe, Jose Reaves, Erik J. Bausch, Daniel G. Chowell, Gerardo Montgomery, Joel M. TI Assessing the impact of public health interventions on the transmission of pandemic H1N1 influenza a virus aboard a Peruvian navy ship SO INFLUENZA AND OTHER RESPIRATORY VIRUSES LA English DT Article DE Disease outbreak; influenza; military personnel; Peru; ships; transmission ID SEROLOGIC ASSAYS; OUTBREAK; VESSEL AB Background Limited data exist on transmission dynamics and effectiveness of control measures for influenza in confined settings. Objectives To investigate the transmission dynamics of a 2009 pandemic H1N1 influenza A outbreak aboard a Peruvian Navy ship and quantify the effectiveness of the implemented control measures. Methods We used surveillance data and a simple stochastic epidemic model to characterize and evaluate the effectiveness of control interventions implemented during an outbreak of 2009 pandemic H1N1 influenza A aboard a Peruvian Navy ship. Results The serological attack rate for the outbreak was 49.1%, with younger cadets and low-ranking officers at greater risk of infection than older, higher-ranking officers. Our transmission model yielded a good fit to the daily time series of new influenza cases by date of symptom onset. We estimated a reduction of 54.4% in the reproduction number during the period of intense control interventions. Conclusion Our results indicate that the patient isolation strategy and other control measures put in place during the outbreak reduced the infectiousness of isolated individuals by 86.7%. Our findings support that early implementation of control interventions can limit the spread of influenza epidemics in confined settings. C1 [Vera, Delphis M.; Hora, Ricardo A.; Wong, Juan F.; Torre, Armando J.; Ramos, Mariana; Reaves, Erik J.; Bausch, Daniel G.] US Naval Med Res Unit 6, Lima, Peru. [Murillo, Anarina; Chowell, Gerardo] Arizona State Univ, Tempe, AZ USA. [Wang, David; Boulay, Darbi; Hancock, Kathy; Katz, Jacqueline M.; Montgomery, Joel M.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Loayza, Luis; Quispe, Jose] Peruvian Navy, Lima, Peru. [Bausch, Daniel G.] Tulane Univ, New Orleans, LA 70118 USA. [Chowell, Gerardo] NIH, Bethesda, MD 20892 USA. RP Vera, DM (reprint author), US Naval Med Res Unit 6, 3230 Lima Pl, Washington, DC 20521 USA. EM delphisv@gmail.com FU Grant GEIS [I0308_11_LI]; [847705.82000.25GB.B0016] FX This work was supported and funded by work unit No. 847705.82000.25GB.B0016 and Grant GEIS I0308_11_LI entitled "Transmission dynamics of influenza outbreaks in military ships: Assessing the efficacy of control measures." NR 29 TC 6 Z9 6 U1 1 U2 9 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1750-2640 EI 1750-2659 J9 INFLUENZA OTHER RESP JI Influenza Other Respir. Viruses PD MAY PY 2014 VL 8 IS 3 BP 353 EP 359 DI 10.1111/irv.12240 PG 7 WC Infectious Diseases; Virology SC Infectious Diseases; Virology GA AE6PS UT WOS:000334116600011 PM 24506160 ER PT J AU Smith, GJD Donis, RO AF Smith, Gavin J. D. Donis, Ruben O. CA World Hlth Org World Org Anim Hlth Food Agr Org WHO OIE FAO H5N1 Evolution Working Grp TI Revised and updated nomenclature for highly pathogenic avian influenza A (H5N1) viruses SO INFLUENZA AND OTHER RESPIRATORY VIRUSES LA English DT Article DE H5N1; hemagglutinin; highly pathogenic avian influenza; molecular epidemiology; nomenclature; phylogenetics; viral evolution ID MAXIMUM-LIKELIHOOD; EVOLUTION AB The divergence of the hemagglutinin gene of A/goose/Guangdong/1/1996-lineage H5N1 viruses during 2011 and 2012 (807 new sequences collected through December 31, 2012) was analyzed by phylogenetic and p-distance methods to define new clades using the pre-established nomenclature system. Eight new clade designations were recommended based on division of clade 1 center dot 1 (Mekong River Delta), 2 center dot 1 center dot 3 center dot 2 (Indonesia), 2 center dot 2 center dot 2 (India/Bangladesh), 2 center dot 2 center dot 1 center dot 1 (Egypt/Israel), and 2 center dot 3 center dot 2 center dot 1 (Asia). A simplification to the previously defined criteria, which adds a letter rather than number to the right-most digit of fifth-order clades, was proposed to facilitate this and future updates. C1 [Smith, Gavin J. D.] Duke NUS Grad Med Sch, Program Emerging Infect Dis, Singapore 169857, Singapore. [Donis, Ruben O.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30333 USA. RP Smith, GJD (reprint author), Duke NUS Grad Med Sch, Program Emerging Infect Dis, Singapore 169857, Singapore. EM gavin.smith@duke-nus.edu.sg OI Bahl, Justin/0000-0001-7572-4300; Smith, Gavin JD/0000-0001-5031-468X FU Australian Government Department of Health and Ageing FX We thank Justin Bahl, Ian H. Brown, Giovanni Cattoli, Todd Davis, Ruben O. Donis, Ron A.M. Fouchier, Yunho Jang, Samuel Shepard, Gavin J.D. Smith, and Frank Wong for drafting the manuscript on behalf of the H5N1 Evolution Working Group. We also thank Samuel Shepard and Yunho Jang for performing sequence and phylogenetic analyses. We acknowledge the laboratories that provided virus samples and sequence data for access to information deposited into the GISAID database (Table S3). The Melbourne WHO Collaborating Centre for Reference and Research on Influenza is supported by the Australian Government Department of Health and Ageing. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention. This publication contains the collective views of an international group of experts and does not necessarily represent the decisions or the stated policy of the Food and Agriculture Organization of the United Nations (FAO), the World Organisation for Animal Health (OIE), or the World Health Organization (WHO). NR 16 TC 42 Z9 42 U1 1 U2 14 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1750-2640 EI 1750-2659 J9 INFLUENZA OTHER RESP JI Influenza Other Respir. Viruses PD MAY PY 2014 VL 8 IS 3 BP 384 EP 388 DI 10.1111/irv.12230 PG 5 WC Infectious Diseases; Virology SC Infectious Diseases; Virology GA AE6PS UT WOS:000334116600015 ER PT J AU Williams, LO Kupka, NJ Schmaltz, SP Barrett, S Uyeki, TM Jernigan, DB AF Williams, Laurina O. Kupka, Nancy J. Schmaltz, Stephen P. Barrett, Stacey Uyeki, Timothy M. Jernigan, Daniel B. TI Rapid influenza diagnostic test use and antiviral prescriptions in outpatient settings pre- and post-2009 H1N1 pandemic SO JOURNAL OF CLINICAL VIROLOGY LA English DT Article DE Rapid influenza diagnostic testing; Influenza; Influenza testing; Rapid influenza testing; H1N1 ID A H1N1; MANAGEMENT; METAANALYSIS; CHILDREN AB Background: Rapid influenza diagnostic tests (RIDTs) can be used at the point-of-care and are often the only influenza tests readily available in outpatient facilities. Objectives: To determine the use of RIDTs and antiviral prescription practices in outpatient facilities. Study design: Surveys were mailed to U.S. physician's offices, emergency departments, and community health centers in 2008 (pre-2009 H1N1 pandemic) and 2010 (post-2009 H1N1 pandemic). The 2010 survey included questions to evaluate changes in testing and treatment practices among various risk groups subsequent to the 2009 H1N1 pandemic. Results: In both surveys, respondents using RIDTs relied on RIDT results to guide prescribing antiviral medications. Greater than two-thirds of these respondents reported prescribing antiviral medications both pre-and post-pandemic for patients within 48 h of onset of flu-like symptoms with a positive RIDT (69% pre-pandemic; 67% post-pandemic). After the pandemic (2010 survey), outpatient providers also reported prescribing antivirals to those with flu-like symptoms for 31% of children <2 years, 23% of children 2-5 years, 37% of pregnant patients, and 74% of other patients at high risk; while these figures were higher than pre-pandemic, they represent a failure to use CDC guidelines to prescribe antivirals for patients with suspected influenza who are at higher risk for complications. Conclusions: Clinicians in outpatient facilities often relied on RIDT findings to aid in making antiviral treatment decisions; however their treatment practices were not always consistent with CDC guidelines. The use of RIDTs and antiviral medicines were influenced by the 2009 HI NI pandemic. (c) 2014 Elsevier B.V. All rights reserved. C1 [Williams, Laurina O.] Ctr Dis Control & Prevent, Ctr Surveillance Epidemiol & Lab Serv, Atlanta, GA 30333 USA. [Kupka, Nancy J.; Barrett, Stacey] Joint Commiss, Div Healthcare Qual Evaluat, Dept Hlth Serv Res, Oak Brook Terrace, IL 60181 USA. [Schmaltz, Stephen P.] Joint Commiss, Div Healthcare Qual Evaluat, Ctr Data Management & Anal, Oak Brook Terrace, IL 60181 USA. [Uyeki, Timothy M.; Jernigan, Daniel B.] Ctr Dis Control & Prevent, Off Infect Dis, NCIRD, Atlanta, GA 30333 USA. RP Williams, LO (reprint author), Ctr Dis Control & Prevent, Ctr Surveillance Epidemiol & Lab Serv, 1600 Clifton Rd,MS G 25, Atlanta, GA 30333 USA. EM low1@cdc.gov FU Centers for Disease Control and Prevention [1U47CI000581] FX This work was funded by Cooperative Agreement Number 1U47CI000581 from the Centers for Disease Control and Prevention. NR 17 TC 9 Z9 9 U1 0 U2 3 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1386-6532 EI 1873-5967 J9 J CLIN VIROL JI J. Clin. Virol. PD MAY PY 2014 VL 60 IS 1 BP 27 EP 33 DI 10.1016/j.jcv.2014.01.016 PG 7 WC Virology SC Virology GA AF1YW UT WOS:000334510800006 PM 24630481 ER PT J AU Lamson, DM Ramani, R Kleabonas, M Metcalfe, M Humphrey, C St George, K AF Lamson, Daryl M. Ramani, Rama Kleabonas, Matthew Metcalfe, Maureen Humphrey, Charles St George, Kirsten TI An unusual case of influenza-like illness after yellow fever vaccination SO JOURNAL OF CLINICAL VIROLOGY LA English DT Article DE Yellow fever virus vaccine; Influenza-like illness; Electron microscopy ID NEW-YORK-STATE; TRANSCRIPTION-PCR ASSAY; ELECTRON-MICROSCOPY; VIRUS; STRAIN; 17D AB Yellow fever (YF) is an important public health concern in areas where the disease is endemic. For more than 60 years a highly effective live attenuated vaccine has been available, its widespread use resulting in a dramatic decrease in the number of cases. On rare occasions, YF vaccine can cause mild to severe disease and rare adverse vaccine-associated events have been reported. Additionally, an average viremia of 3-5 days after administration of the YF vaccine has been published. Here we present a case where YF vaccine was isolated in cell culture from a respiratory swab collected from a patient presenting with influenza-like illness. To the best of our knowledge, this is the first report finding replicating YF vaccine in the respiratory sample of a post inoculated individual. (c) 2014 Elsevier B.V. All rights reserved. C1 [Lamson, Daryl M.; Ramani, Rama; Kleabonas, Matthew; St George, Kirsten] New York State Dept Hlth, Wadsworth Ctr, Albany, NY 12237 USA. [Metcalfe, Maureen; Humphrey, Charles] Ctr Dis Control & Prevent, Infect Dis Pathol Branch, Atlanta, GA USA. RP Lamson, DM (reprint author), New York State Dept Hlth, Wadsworth Ctr, Albany, NY 12237 USA. EM dml20@health.state.ny.us FU Wadsworth Center FX Funding was provided from within the Wadsworth Center to perform this study. NR 17 TC 1 Z9 1 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1386-6532 EI 1873-5967 J9 J CLIN VIROL JI J. Clin. Virol. PD MAY PY 2014 VL 60 IS 1 BP 67 EP 69 DI 10.1016/j.jcv.2014.01.020 PG 3 WC Virology SC Virology GA AF1YW UT WOS:000334510800014 PM 24594082 ER PT J AU Yang, H Chang, JC Guo, Z Carney, PJ Shore, DA Donis, RO Cox, NJ Villanueva, JM Klimov, AI Stevens, J AF Yang, Hua Chang, Jessie C. Guo, Zhu Carney, Paul J. Shore, David A. Donis, Ruben O. Cox, Nancy J. Villanueva, Julie M. Klimov, Alexander I. Stevens, James TI Structural Stability of Influenza A(H1N1)pdm09 Virus SO JOURNAL OF VIROLOGY LA English DT Article ID HEMAGGLUTININ; SPECIFICITY; ORIGIN AB The noncovalent interactions that mediate trimerization of the influenza hemagglutinin (HA) are important determinants of its biological activities. Recent studies have demonstrated that mutations in the HA trimer interface affect the thermal and pH sensitivities of HA, suggesting a possible impact on vaccine stability (Farnsworth et al., Vaccine 29: 1529-1533, 2011, doi:10.1016/j.vaccine.2010.12.120). We used size exclusion chromatography analysis of recombinant HA ectodomain to compare the differences among recombinant trimeric HA proteins from early 2009 pandemic H1N1 viruses, which dissociate to monomers, with those of more recent virus HAs that can be expressed as trimers. We analyzed differences among the HA sequences and identified intermolecular interactions mediated by the residue at position 374 (HA0 numbering) of the HA2 subdomain as critical for HA trimer stability. Crystallographic analyses of HA from the recent H1N1 virus A/Washington/5/2011 highlight the structural basis for this observed phenotype. It remains to be seen whether more recent viruses with this mutation will yield more stable vaccines in the future. C1 [Yang, Hua; Chang, Jessie C.; Guo, Zhu; Carney, Paul J.; Shore, David A.; Donis, Ruben O.; Cox, Nancy J.; Villanueva, Julie M.; Klimov, Alexander I.; Stevens, James] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Stevens, J (reprint author), Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM fwb4@cdc.gov FU Centers for Disease Control and Prevention; HHS Influenza Vaccine Manufacturing Improvement Initiative; U.S. Department of Energy, Office of Science, Office of Basic Energy Sciences [DE-AC02-06CH11357]; National Institute of General Medical Sciences [GM62116] FX This work was funded by the Centers for Disease Control and Prevention and the HHS Influenza Vaccine Manufacturing Improvement Initiative.; Use of the Advanced Photon Source at Argonne National Laboratory was supported by the U.S. Department of Energy, Office of Science, Office of Basic Energy Sciences, under Contract No. DE-AC02-06CH11357.; Glycan microarray slides were produced under contract for the Centers for Disease Control using a glycan library generously provided by the Consortium for Functional Glycomics funded by National Institute of General Medical Sciences Grant GM62116. NR 38 TC 12 Z9 12 U1 0 U2 6 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X EI 1098-5514 J9 J VIROL JI J. Virol. PD MAY PY 2014 VL 88 IS 9 BP 4828 EP 4838 DI 10.1128/JVI.02278-13 PG 11 WC Virology SC Virology GA AE9TT UT WOS:000334353900020 PM 24522930 ER PT J AU Walstrom, KM Murphy, D Bean, CJ Kelly, WG AF Walstrom, Katherine M. Murphy, Deborah Bean, Christopher J. Kelly, William G. TI RNA helicase A is important for germline transcriptional control, proliferation, and meiosis in C. elegans (vol 122, pg 707, 2005) SO MECHANISMS OF DEVELOPMENT LA English DT Correction ID CAENORHABDITIS-ELEGANS; TRANSPORTERS C1 [Walstrom, Katherine M.; Murphy, Deborah] New Coll Florida, Div Nat Sci, Sarasota, FL 34243 USA. [Bean, Christopher J.; Kelly, William G.] Emory Univ, Dept Biol, Atlanta, GA 30322 USA. [Murphy, Deborah] Benchmark EnviroAnalyt Inc, Palmetto, FL USA. [Bean, Christopher J.] CDC, Div Blood Disorders, Atlanta, GA 30333 USA. RP Walstrom, KM (reprint author), New Coll Florida, Div Nat Sci, 5800 Bay Shore Rd, Sarasota, FL 34243 USA. EM walstrom@ncf.edu NR 4 TC 0 Z9 0 U1 0 U2 3 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0925-4773 EI 1872-6356 J9 MECH DEVELOP JI Mech. Dev. PD MAY PY 2014 VL 132 BP 93 EP 93 DI 10.1016/j.mod.2014.01.002 PG 1 WC Developmental Biology SC Developmental Biology GA AF0LT UT WOS:000334406500009 ER PT J AU Kawai, AT Li, LL Kulldorff, M Vellozzi, C Weintraub, E Baxter, R Belongia, EA Daley, MF Jacobsen, SJ Naleway, A Nordin, JD Lee, GM AF Kawai, Alison Tse Li, Lingling Kulldorff, Martin Vellozzi, Claudia Weintraub, Eric Baxter, Roger Belongia, Edward A. Daley, Matthew F. Jacobsen, Steven J. Naleway, Allison Nordin, James D. Lee, Grace M. TI Absence of associations between influenza vaccines and increased risks of seizures, Guillain-Barre syndrome, encephalitis, or anaphylaxis in the 2012-2013 season SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY LA English DT Article DE vaccine safety; influenza vaccine safety surveillance; Vaccine Safety Datalink; pharmacoepidemiology ID SAFETY DATALINK PROJECT; IMMUNIZATION PRACTICES ACIP; REAL-TIME SURVEILLANCE; PROBABILITY RATIO TEST; FEBRILE SEIZURES; ADVISORY-COMMITTEE; UNITED-STATES; RECOMMENDATIONS; PREVENTION; CHILDREN AB PurposeWe conducted weekly surveillance for pre-specified adverse events following receipt of the 2012-2013 influenza vaccines in the Vaccine Safety Datalink (VSD). MethodsFor each outcome, risk intervals (i.e., period after vaccination with a potentially increased risk) were defined on the basis of biologic plausibility and prior literature. Seizures following inactivated influenza vaccine (IIV) were monitored in children in three age groups (6-23months, 24-59months, and 5-17years) using a self-controlled risk interval design. We also monitored for Guillain-Barre syndrome, encephalitis, and anaphylaxis following IIV in patients 6months of age using a cohort design with historical controls. In the risk intervals following live attenuated influenza vaccine (LAIV), we collected weekly counts of Guillain-Barre syndrome, encephalitis, and anaphylaxis in patients ages 2-49. Among LAIV vaccinees, numbers of expected events based on rates in historical controls were calculated, adjusted for age and site. ResultsAt the end of surveillance, approximately 3.6 million first doses of IIV and 250000 first doses of LAIV had been administered in the VSD. No elevated risks were identified in risk intervals following 2012-2013 IIV, as compared with a self-matched control interval or to historical controls. For each outcome, fewer than three events occurred in the risk interval following 2012-2013 LAIV, and we thus were unable to estimate measures of relative risks. ConclusionsNo increased risk was identified for any of the pre-specified outcomes following 2012-2013 influenza vaccinations in the VSD. Published 2014. This article is a U.S. Government work and is in the public domain in the USA. C1 [Kawai, Alison Tse; Li, Lingling; Kulldorff, Martin; Lee, Grace M.] Harvard Univ, Dept Populat Med, Sch Med, Boston, MA USA. [Kawai, Alison Tse; Li, Lingling; Kulldorff, Martin; Lee, Grace M.] Harvard Pilgrim Hlth Care Inst, Boston, MA 02215 USA. [Vellozzi, Claudia; Weintraub, Eric] Ctr Dis Control & Prevent, Immunizat Safety Off, Atlanta, GA USA. [Baxter, Roger] Kaiser Permanente, Oakland, CA USA. [Belongia, Edward A.] Marshfield Clin Res Fdn, Marshfield, WI USA. [Daley, Matthew F.] Kaiser Permanente, Denver, CO USA. [Jacobsen, Steven J.] Kaiser Permanente, Pasadena, CA USA. [Naleway, Allison] Kaiser Permanente, Portland, OR USA. [Nordin, James D.] Hlth Partners Res Fdn, Minneapolis, MN USA. [Lee, Grace M.] Boston Childrens Hosp, Boston, MA USA. RP Kawai, AT (reprint author), Harvard Pilgrim Hlth Care Inst, Dept Populat Med, 133 Brookline Ave, Boston, MA 02215 USA. EM Alison_Kawai@HPHC.org OI Naleway, Allison/0000-0001-5747-4643; Kulldorff, Martin/0000-0002-5284-2993; Jacobsen, Steven/0000-0002-8174-8533 FU America's Health Insurance Plans (AHIP) from the Centers for Disease Control and Prevention (CDC) [200-2002-00732] FX This study was funded through a subcontract with America's Health Insurance Plans (AHIP) under contract 200-2002-00732 from the Centers for Disease Control and Prevention (CDC). NR 15 TC 14 Z9 14 U1 1 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1053-8569 EI 1099-1557 J9 PHARMACOEPIDEM DR S JI Pharmacoepidemiol. Drug Saf. PD MAY PY 2014 VL 23 IS 5 BP 548 EP 553 DI 10.1002/pds.3575 PG 6 WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy GA AE4JI UT WOS:000333948300012 PM 24497128 ER PT J AU Edison, L Schulte, J Schauben, J Kay, R Rubin, C AF Edison, L. Schulte, J. Schauben, J. Kay, R. Rubin, C. TI Assessment of Human Exposures to Animal Vaccines Using Poison Control Records, 2000-2009 SO ZOONOSES AND PUBLIC HEALTH LA English DT Article DE human medicine; infectious disease; Epidemiology; public health; zoonoses ID VETERINARY VACCINES; SELF-INOCULATION; ADVERSE EVENTS; INFECTION; CONTACT; FUTURE; HEALTH; VIRUS AB To characterize human exposures to vaccines intended for animals, evaluate the human risk due to these exposures and determine whether there is sufficient surveillance in place to monitor them. Retrospective analysis of surveillance data (2000-2009). Information collected by poison specialists during calls reporting human exposure to an animal vaccine product, made to one of the 57 United States Poison Control Centers. Data from the National Poison Data System were analysed to determine the number of calls due to human exposures to animal vaccines, and descriptive statistics were generated to characterize the exposures by age, gender, medical outcome, exposure site, exposure route, vaccine type and intended species, aetiologic agent, call date and exposure reason. Overall, the human health effects were minor, primarily due to unintentional parenteral exposure. Less than 15% of the reports were classified as occupational, and 80% of the exposures took place outside of a workplace or healthcare facility. Almost 60% of calls were due to exposure to the West Nile Virus vaccine; the others distributed among a variety of vaccines. Unintentional exposure to animal vaccines appears to occur almost exclusively among untrained individuals who may benefit from more effective education about the risks and benefits of administering vaccines. Improved reporting of adverse outcomes is essential to adequately define the extent of human exposure and risks associated with availability of new vaccines. C1 [Edison, L.; Rubin, C.] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathogenesis, Hlth Off 1, Natl Ctr Zoonot & Emerging Infect Dis, Atlanta, GA 30333 USA. [Schulte, J.; Kay, R.] Bur Epidemiol, Florida Dept Hlth, Tallahassee, FL USA. [Schauben, J.] Univ Florida, Hlth Sci Ctr Jacksonville, Florida USVI Poison Informat Ctr Jacksonville, Dept Emergency Med, Jacksonville, FL 32209 USA. RP Edison, L (reprint author), Ctr Dis Control & Prevent, Hlth Off 1, Div High Consequence Pathogens & Pathogenesis, Natl Ctr Zoonot & Emerging Infect Dis Edison & Ru, 1600 Clifton Rd NE,Mailstop A30, Atlanta, GA 30333 USA. EM Ledison@cdc.gov NR 21 TC 1 Z9 1 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1863-1959 EI 1863-2378 J9 ZOONOSES PUBLIC HLTH JI Zoonoses Public Health PD MAY PY 2014 VL 61 IS 3 BP 175 EP 180 DI 10.1111/zph.12047 PG 6 WC Public, Environmental & Occupational Health; Infectious Diseases; Veterinary Sciences SC Public, Environmental & Occupational Health; Infectious Diseases; Veterinary Sciences GA AF2JA UT WOS:000334537200003 PM 23551869 ER PT J AU Baron, SL Steege, AL Hughes, JT Beard, SD AF Baron, Sherry L. Steege, Andrea L. Hughes, Joseph T., Jr. Beard, Sharon D. TI Introduction to a special issue: Eliminating health and safety inequities at work SO AMERICAN JOURNAL OF INDUSTRIAL MEDICINE LA English DT Editorial Material C1 [Baron, Sherry L.] CUNY, Queens Coll, Ctr Biol Nat Syst, Flushing, NY USA. [Steege, Andrea L.] Ctr Dis Control & Prevent, Natl Inst Occupat Safety & Hlth, Div Surveillance Hazard Evaluat & Field Studies, Cincinnati, OH USA. [Hughes, Joseph T., Jr.; Beard, Sharon D.] NIEHS, NIH, Res Triangle Pk, NC 27709 USA. RP Baron, SL (reprint author), Queens Coll Remsen 311,65-30 Kissena Blvd, Flushing, NY 11367 USA. EM sbaron@qc.cuny.edu RI Steege, Andrea/H-8900-2016 OI Steege, Andrea/0000-0001-5665-2559 NR 6 TC 0 Z9 0 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0271-3586 EI 1097-0274 J9 AM J IND MED JI Am. J. Ind. Med. PD MAY PY 2014 VL 57 IS 5 SI SI BP 493 EP 494 DI 10.1002/ajim.22321 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AE4NM UT WOS:000333959200001 PM 24687420 ER PT J AU Steege, AL Baron, SL Marsh, SM Menendez, CC Myers, JR AF Steege, Andrea L. Baron, Sherry L. Marsh, Suzanne M. Menendez, Cammie Chaumont Myers, John R. TI Examining occupational health and safety disparities using national data: A cause for continuing concern SO AMERICAN JOURNAL OF INDUSTRIAL MEDICINE LA English DT Article DE ethnicity; injury; fatality; CPS; SOII; CFOI; race; occupation; nativity; industry; occupational health disparities ID UNITED-STATES; INJURIES; WORKERS; FATALITIES; ILLNESSES; SURVEILLANCE AB Background Occupational status, a core component of socioeconomic status, plays a critical role in the well-being of U.S. workers. Identifying work-related disparities can help target prevention efforts. Methods Bureau of Labor Statistics workplace data were used to characterize high-risk occupations and examine relationships between demographic and work-related variables and fatality. Results Employment in high-injury/illness occupations was independently associated with being male, Black, <= high school degree, foreign-birth, and low-wages. Adjusted fatal occupational injury rate ratios for 2005-2009 were elevated for males, older workers, and several industries and occupations. Agriculture/forestry/fishing and mining industries and transportation and materials moving occupations had the highest rate ratios. Homicide rate ratios were elevated for Black, American Indian/Alaska Native/Asian/Pacific Islanders, and foreign-born workers. Conclusions These findings highlight the importance of understanding patterns of disparities of workplace injuries, illnesses and fatalities. Results can improve intervention efforts by developing programs that better meet the needs of the increasingly diverse U.S. workforce. Am. J. Ind. Med. 57:527-538, 2014. Published 2014. This article is a U.S. Government work and is in the public domain in the USA. C1 [Steege, Andrea L.; Baron, Sherry L.] NIOSH, Div Surveillance Hazard Evaluat & Field Studies, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. [Marsh, Suzanne M.; Menendez, Cammie Chaumont; Myers, John R.] NIOSH, Div Safety Res, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA. RP Steege, AL (reprint author), NIOSH, Div Surveillance Hazard Evaluat & Field Studies, Ctr Dis Control & Prevent, CDC, 4676 Columbia Pkwy MS R18, Cincinnati, OH 45226 USA. EM asteege@cdc.gov RI Steege, Andrea/H-8900-2016 OI Steege, Andrea/0000-0001-5665-2559 FU U.S. Government FX Contract grant sponsor: U.S. Government. NR 43 TC 9 Z9 9 U1 0 U2 24 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0271-3586 EI 1097-0274 J9 AM J IND MED JI Am. J. Ind. Med. PD MAY PY 2014 VL 57 IS 5 SI SI BP 527 EP 538 DI 10.1002/ajim.22297 PG 12 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AE4NM UT WOS:000333959200004 PM 24436156 ER PT J AU Baron, SL Beard, S Davis, LK Delp, L Forst, L Kidd-Taylor, A Liebman, AK Linnan, L Punnett, L Welch, LS AF Baron, Sherry L. Beard, Sharon Davis, Letitia K. Delp, Linda Forst, Linda Kidd-Taylor, Andrea Liebman, Amy K. Linnan, Laura Punnett, Laura Welch, Laura S. TI Promoting integrated approaches to reducing health inequities among low-income workers: Applying a social ecological framework SO AMERICAN JOURNAL OF INDUSTRIAL MEDICINE LA English DT Review DE total worker health; disparities; low-income workers; health inequities ID BODY-MASS INDEX; FRANCISCOS CHINATOWN RESTAURANTS; RANDOMIZED CONTROLLED-TRIAL; TIME PHYSICAL-ACTIVITY; PARTICIPATORY RESEARCH; OCCUPATIONAL-HEALTH; RISK-FACTORS; ENVIRONMENTAL-HEALTH; SOCIOECONOMIC-STATUS; BLOOD-PRESSURE AB Background Nearly one of every three workers in the United States is low-income. Low-income populations have a lower life expectancy and greater rates of chronic diseases compared to those with higher incomes. Low- income workers face hazards in their workplaces as well as in their communities. Developing integrated public health programs that address these combined health hazards, especially the interaction of occupational and non-occupational risk factors, can promote greater health equity. Methods We apply a social-ecological perspective in considering ways to improve the health of the low-income working population through integrated health protection and health promotion programs initiated in four different settings: the worksite, state and local health departments, community health centers, and community-based organizations. Results Examples of successful approaches to developing integrated programs are presented in each of these settings. These examples illustrate several complementary venues for public health programs that consider the complex interplay between work-related and non work-related factors, that integrate health protection with health promotion and that are delivered at multiple levels to improve health for low-income workers. Conclusions Whether at the workplace or in the community, employers, workers, labor and community advocates, in partnership with public health practitioners, can deliver comprehensive and integrated health protection and health promotion programs. Recommendations for improved research, training, and coordination among health departments, health practitioners, worksites and community organizations are proposed. Am. J. Ind. Med. 57:539-556, 2014. (c) 2013 Wiley Periodicals, Inc. C1 [Baron, Sherry L.] NIOSH, Div Surveillance Hazard Evaluat & Field Studies, Cincinnati, OH 45226 USA. [Beard, Sharon] NIEHS, Worker Educ & Training Branch, Res Triangle Pk, NC 27709 USA. [Davis, Letitia K.] Massachusetts Dept Publ Hlth, Occupat Hlth Surveillance Program, Boston, MA USA. [Delp, Linda] Univ Calif Los Angeles, Labor Occupat Safety & Hlth Program, Los Angeles, CA USA. [Forst, Linda] Univ Illinois, Sch Publ Hlth, Chicago, IL USA. [Kidd-Taylor, Andrea] Morgan State Univ, Dept Hlth Policy & Management, Baltimore, MD 21239 USA. [Liebman, Amy K.] Migrant Clin Network, Environm & Occupat Hlth Initiat, Quantico, VA USA. [Linnan, Laura] Univ N Carolina, Gillings Sch Publ Hlth, Chapel Hill, NC USA. [Punnett, Laura] Univ Massachusetts Lowell, Dept Work Environm, Lowell, MA USA. [Punnett, Laura] Univ Massachusetts Lowell, Ctr Women & Work, Lowell, MA USA. [Welch, Laura S.] CPWR Ctr Construct Res & Training, Silver Spring, MD USA. RP Baron, SL (reprint author), NIOSH, 4676 Columbia Pkwy R-17, Cincinnati, OH 45226 USA. EM slb8@cdc.gov FU Intramural NIH HHS [Z99 ES999999]; NIEHS NIH HHS [U45 ES006173] NR 124 TC 21 Z9 21 U1 7 U2 48 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0271-3586 EI 1097-0274 J9 AM J IND MED JI Am. J. Ind. Med. PD MAY PY 2014 VL 57 IS 5 SI SI BP 539 EP 556 DI 10.1002/ajim.22174 PG 18 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AE4NM UT WOS:000333959200005 PM 23532780 ER PT J AU Medrano, BA Salinas, G Sanchez, C Miramontes, R Restrepo, BI Haddad, MB Lambert, LA AF Medrano, Belinda A. Salinas, Gloria Sanchez, Connie Miramontes, Roque Restrepo, Blanca I. Haddad, Maryam B. Lambert, Lauren A. TI A Missed Tuberculosis Diagnosis Resulting in Hospital Transmission SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID HEALTH-CARE WORKERS; CONVERSION; RISK AB Objective. To find the source of tuberculin skin test conversions among 38 hospital employees on 1 floor during routine testing January-February 2010. Methods. Record review of patients at a private hospital during September-December 2009 and interviews with hospital employees. Names of patients from the state tuberculosis (TB) registry were cross-referenced with hospital records for admissions. Mycobacterium tuberculosis genotype results in the county and adjacent counties were examined, and contacts were evaluated for TB infection and disease. Results. One of the 38 employees, a nurse, was diagnosed with pulmonary TB with a matching M. tuberculosis genotype and drug resistance pattern (isoniazid monoresistant) to those of a county jail inmate also recently diagnosed with pulmonary TB. The nurse had no known contact with that inmate; however, another inmate in his 20's from the same jail had been hospitalized under that nurse's care in October 2009. That young man died, and a postmortem examination result subsequently confirmed TB, which had not been suspected. Exposure to this man with undiagnosed TB could explain the transmission: 87 (27%) of the 318 hospital-based contacts without previous positive tuberculin skin test results were infected, and 9 contacts had active TB. Conclusions. This investigation demonstrated M. tuberculosis transmission in a hospital due to a missed diagnosis and nonadherence to national TB infection control guidelines. Routine TB screening of employees allowed early detection of this missed TB diagnosis, facilitating prompt evaluation of contacts. Healthcare providers should suspect TB in symptomatic persons and adhere to TB control policies. C1 [Medrano, Belinda A.; Salinas, Gloria; Sanchez, Connie] Hidalgo Cty Hlth Serv, Edinburg, TX USA. [Medrano, Belinda A.; Salinas, Gloria; Sanchez, Connie] Hidalgo Cty Human Serv, Edinburg, TX USA. [Miramontes, Roque; Haddad, Maryam B.; Lambert, Lauren A.] Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA USA. [Restrepo, Blanca I.] Univ Texas Hlth Sci Ctr Houston, Brownsville, TX USA. RP Lambert, LA (reprint author), 1600 Clifton Rd,E-10, Atlanta, GA 30333 USA. EM lal0@cdc.gov OI Miramontes, Roque/0000-0001-9535-460X FU Centers for Disease Control and Prevention (CDC) FX We would like to thank the hospital administrative staff and employees for their support and cooperation. Thank you to Dr. Brian Smith and Dina Sosa from the Texas Department of State Health Services and to all other local, regional, and state public health officials who worked on this investigation. Diana Gomez, Mary Walsh, and Izelda Zarate from the University of Texas Health Science Center School of Public Health, Brownsville, assisted with polymerase chain reaction and interferon-g release assay testing and provided their time and resources. Genotype testing was performed by Francine Arroyo, Laura Cruz, and Steven Yu at the Microbial Disease Laboratory, California Department of Public Health, funded by a contract with the Centers for Disease Control and Prevention (CDC). From the CDC, thank you to Shalom Hernandez, a University of Florida public health student intern, and Mark Miner for programmatic assistance. NR 12 TC 2 Z9 2 U1 1 U2 4 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X EI 1559-6834 J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD MAY 1 PY 2014 VL 35 IS 5 BP 534 EP 537 DI 10.1086/675833 PG 4 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA AE4EI UT WOS:000333933900010 PM 24709722 ER PT J AU Henkle, E Irving, SA Naleway, AL Gaglani, MJ Ball, S Spencer, S Peasah, S Thompson, MG AF Henkle, Emily Irving, Stephanie A. Naleway, Allison L. Gaglani, Manjusha J. Ball, Sarah Spencer, Sarah Peasah, Sam Thompson, Mark G. TI Comparison of Laboratory-Confirmed Influenza and Noninfluenza Acute Respiratory Illness in Healthcare Personnel during the 2010-2011 Influenza Season SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID VACCINATION; METAANALYSIS; OUTCOMES; WORKERS; IMPACT AB Objective. Compare the severity of illnesses associated with influenza and noninfluenza acute respiratory illness (ARI) in healthcare personnel (HCP). Design. Prospective observational cohort. Participants. HCP at 2 healthcare organizations with direct patient contact were enrolled prior to the 2010-2011 influenza season. Methods. HCP who were fewer than 8 days from the start of fever/feverishness/chills and cough were eligible for real-time reverse-transcription polymerase chain reaction influenza virus testing of respiratory specimen. Illness severity was assessed by the sum of self-rated severity (0, absent; 3, severe) of 12 illness symptoms, subjective health (0, best health; 9, worst health), activities of daily living impairment (0, able to perform; 9, unable to perform), missed work, and duration of illness. Results. Of 1,701 HCP enrolled, 267 were tested for influenza, and 58 (22%) of these tested positive. Influenza compared with noninfluenza illnesses was associated with higher summed 12-symptom severity score (mean [standard deviation], 17.9 [5.4] vs 14.6 [4.8]; P < .001), worse subjective health (4.5 [1.8] vs 4.0 [1.8]; P <.05), greater impairment of activities of daily living (4.9 [2.5] vs 3.8 [2.5]; P < .01), and more missed work (12.1 [10.5] vs 7.8 [10.5] hours; P < .01). Differences in symptom severity, activities of daily living, and missed work remained significant after adjusting for illness and participant characteristics. Conclusions. Influenza had a greater negative impact on HCP than noninfluenza ARIs, indicated by higher symptom severity scores, less ability to perform activities of daily living, and more missed work. These results highlight the importance of efforts to prevent influenza infection in HCP. C1 [Henkle, Emily; Irving, Stephanie A.; Naleway, Allison L.] Kaiser Permanente Northwest, Ctr Hlth Res, Portland, OR 97227 USA. [Gaglani, Manjusha J.] Scott & White Healthcare, Temple, TX USA. [Ball, Sarah] Abt Associates Inc, Cambridge, MA USA. [Spencer, Sarah; Peasah, Sam; Thompson, Mark G.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. RP Naleway, AL (reprint author), Kaiser Permanente Northwest, Ctr Hlth Res, 3800 North Interstate Ave, Portland, OR 97227 USA. EM allison.naleway@kpchr.org OI Naleway, Allison/0000-0001-5747-4643; Irving, Stephanie/0000-0001-7437-6797 FU Centers for Disease Control and Prevention [200-2010-F-33396] FX This work was supported by the Centers for Disease Control and Prevention (contract 200-2010-F-33396 to Abt Associates). The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention, Abt Associates, Kaiser Permanente Center for Health Research, or Scott and White Healthcare. NR 18 TC 7 Z9 7 U1 0 U2 0 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X EI 1559-6834 J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD MAY 1 PY 2014 VL 35 IS 5 BP 538 EP 546 DI 10.1086/675832 PG 9 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA AE4EI UT WOS:000333933900011 PM 24709723 ER PT J AU Dore, GJ Ward, J Thursz, M AF Dore, G. J. Ward, J. Thursz, M. TI Hepatitis C disease burden and strategies to manage the burden (Guest Editors Mark Thursz, Gregory Dore and John Ward) SO JOURNAL OF VIRAL HEPATITIS LA English DT Article AB Chronic hepatitis C virus (HCV) infection leads to liver fibrosis, cirrhosis and hepatocellular carcinoma (HCC). The recent Global Burden of Disease project estimated that in 2010 among 170million people living with chronic HCV, an estimated 483100 people died from HCV-related liver failure or HCC. The last two decades has seen progressive improvements in treatment of HCV infection with the most recent therapies offering simple, tolerable, short-duration therapy with extremely high efficacy. The development of public health strategies addressing emerging epidemics requires sound epidemiological data. This study covers epidemiological data collection, detailed expert opinion input and country-specific mathematical modelling of the HCV epidemic and potential impact of improved HCV treatment strategies in 16 countries. The analysis demonstrates that the HCV epidemics vary considerably in terms of age distribution of the infected population across countries. In addition, the burden of advanced liver disease varies widely. This burden is dependent upon factors including chronic HCV prevalence, age distribution (and duration of infection) of those infected, prevalence of cofactors for disease progression (particularly heavy alcohol intake) and uptake and success of therapeutic intervention. Introduction of new therapies with assumed sustained virological response (SVR) rate of >90% will have a modest impact on projected advanced liver disease burden. A combination of enhanced treatment efficacy and improved treatment uptake will have a greater impact on population-level disease burden. However public health advocacy and both public and private sector investment in the HCV response are required to demonstrate significant reduction in HCV disease burden. C1 [Dore, G. J.] UNSW Australia, Kirby Inst, Sydney, NSW, Australia. [Ward, J.] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA USA. [Thursz, M.] Univ London Imperial Coll Sci Technol & Med, Div Med, Dept Hepatol, London, England. RP Dore, GJ (reprint author), UNSW Australia, Kirby Inst, Sydney, NSW, Australia. EM gdore@kirby.unsw.edu.au FU Roche; Merck; Janssen; Gilead; Bristol-Myers Squibb FX Dore - Advisory Board Membership: Roche, Merck, Janssen, Gilead, Bristol-Myers Squibb, Abbvie Honorarium: Roche, Merck, Janssen, Gilead, Bristol-Myers Squibb, Abbvie Research Grants: Roche, Merck, Janssen, Gilead, Bristol-Myers Squibb, Vertex, Boeringher Ingelheim, Abbvie Travel Sponsorship: Roche, Merck, Janssen, Gilead, Bristol-Myers Squibb. NR 5 TC 36 Z9 38 U1 3 U2 12 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1352-0504 EI 1365-2893 J9 J VIRAL HEPATITIS JI J. Viral Hepatitis PD MAY PY 2014 VL 21 SU 1 SI SI BP 1 EP 4 DI 10.1111/jvh.12253 PG 4 WC Gastroenterology & Hepatology; Infectious Diseases; Virology SC Gastroenterology & Hepatology; Infectious Diseases; Virology GA AE3RE UT WOS:000333893200001 PM 24713003 ER PT J AU Pavuk, M Patterson, DG Turner, WE AF Pavuk, Marian Patterson, Donald G., Jr. Turner, Wayman E. TI Serum concentrations of TCDD and other dioxin-like compounds in US Air Force veterans of Operation Ranch Hand SO CHEMOSPHERE LA English DT Article DE PCBs; PCDDs; PCDFs; Ranch Hand; TCDD; Vietnam War veterans ID MASS-SPECTROMETRIC ANALYSIS; TOXIC EQUIVALENCY FACTORS; DIBENZO-P-DIOXINS; VIETNAM VETERANS; AGENT-ORANGE; ADIPOSE-TISSUE; HEALTH-STATUS; POLYCHLORINATED-BIPHENYLS; SOUTHEAST-ASIA; FOLLOW-UP AB We measured serum concentrations of seven dibenzo-p-dioxin congeners (PCDDs), ten dibenzofurans (PCDFs), four non-ortho polychlorinated biphenyls (noPCBs) and six mono-ortho polychlorinated biphenyls (moPCBs) in 1950 veterans of the Vietnam War. The veterans were participants in the Air Force Health Study (AFHS) who attended the final medical examination in 2002. Blood samples were collected from 777 Ranch Hands involved in the aerial spraying of herbicides in Vietnam and a comparison group of 1173 veterans ("Comparisons") who served in Southeast Asia during the same time period. Results for moPCBs were based on a random subsample of 800 veterans. The median 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) concentrations in 2002 were 5.0 pg g(-1) lipid in Ranch Hands and 2.2 pg g(-1) lipid in Comparisons. No substantial differences were found in measured concentrations of other PCDDs, PCDFs, and noPCBs. Similarly, no substantial differences were found for moPCBs in the subsample. The median total dioxin toxic equivalent (TEQ) in Ranch Hands was 18.7 pg g(-1) lipid for PCDDs, 3.4 pg g(-1) lipid for PCDFs, and 3.2 pg g(-1) lipid for noPCBs. Median TEQs in Comparisons were 14.4 pg g(-1), lipid for PCDDs, 3.5 pg g(-1) lipid for PCDFs, and 3.3 pg g(-1) lipid for noPCBs. These TEQs, with the exception of PCDD TEQ in Ranch Hands (primarily due to elevated TCDD), were similar to or lower than those reported for similar age and gender groups in the 2001-2002 National Health and Nutrition Examination Survey (NHANES). These findings support the assumption that the Ranch Hand veterans were not more highly exposed to dioxin-like compounds other than TCDD than were Comparison veterans or the general US population. Published by Elsevier Ltd. C1 [Pavuk, Marian] SpecPro Inc, San Antonio, TX USA. [Pavuk, Marian] Agcy Tox Subst & Dis Registry, Div Toxicol & Human Hlth Sci, Atlanta, GA 30341 USA. [Patterson, Donald G., Jr.] EnviroSolut Consulting, Auburn, GA 30011 USA. [Turner, Wayman E.] Ctr Dis Control & Prevent, Organ Analyt Toxicol Branch, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. RP Pavuk, M (reprint author), ATSDR DHS, 4770 Buford Highway,Mailstop F-58, Atlanta, GA 30341 USA. EM mpavuk@cdc.gov NR 36 TC 5 Z9 6 U1 1 U2 7 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0045-6535 EI 1879-1298 J9 CHEMOSPHERE JI Chemosphere PD MAY PY 2014 VL 102 BP 18 EP 23 DI 10.1016/j.chemosphere.2013.12.004 PG 6 WC Environmental Sciences SC Environmental Sciences & Ecology GA AD8DN UT WOS:000333496800004 PM 24377449 ER PT J AU Schoendorf, KC AF Schoendorf, Kenneth C. TI Individual-Level Influences on Population Data SO PAEDIATRIC AND PERINATAL EPIDEMIOLOGY LA English DT Editorial Material ID DECISION-MAKING; ATTITUDES C1 Ctr Dis Control & Prevent, Infant Child Womens Hlth Stat Branch, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. RP Schoendorf, KC (reprint author), Ctr Dis Control & Prevent, Infant Child Womens Hlth Stat Branch, Natl Ctr Hlth Stat, 3311 Toledo Rd, Hyattsville, MD 20782 USA. EM KSchoendorf@cdc.gov NR 6 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0269-5022 EI 1365-3016 J9 PAEDIATR PERINAT EP JI Paediatr. Perinat. Epidemiol. PD MAY PY 2014 VL 28 IS 3 BP 179 EP 180 DI 10.1111/ppe.12119 PG 2 WC Public, Environmental & Occupational Health; Obstetrics & Gynecology; Pediatrics SC Public, Environmental & Occupational Health; Obstetrics & Gynecology; Pediatrics GA AE2KH UT WOS:000333801300001 PM 24654827 ER PT J AU Cohen, B Bernson, D Sappenfield, W Kirby, RS Kissin, D Zhang, YJ Copeland, G Zhang, Z Macalusof, M AF Cohen, Bruce Bernson, Dana Sappenfield, William Kirby, Russell S. Kissin, Dmitry Zhang, Yujia Copeland, Glenn Zhang, Zi Macalusof, Maurizio CA SMART Collaborative TI Accuracy of Assisted Reproductive Technology Information on Birth Certificates: Florida and Massachusetts, 2004-06 SO PAEDIATRIC AND PERINATAL EPIDEMIOLOGY LA English DT Article DE Assisted Reproductive Technology; validity; birth certificates; data quality ID UNITED-STATES; PERINATAL OUTCOMES; MULTIPLE BIRTHS; SURVEILLANCE; SINGLETON; ASSOCIATION AB Background Assisted Reproductive Technology (ART) includes fertility procedures where both egg and sperm are handled in the lab. ART use has increased considerably in recent years, accounting for 47 090 livebirths in the US in 2010. ART increases the probability of multiple gestation births, which are at higher risks than singletons for adverse outcomes. Additionally, ART is associated with a greater risk of complications during pregnancy, labour, and delivery, and increased risk of adverse perinatal outcomes in singleton births. Methods We merged Florida and Massachusetts birth records from 2004-06 with the National ART Surveillance System (NASS) and using NASS as the gold standard, calculated sensitivity, specificity, and positive predictive value (PPV) of ART reporting on the birth certificates by maternal, infant, and hospital characteristics. We fit random-effects logistic regression models to evaluate simultaneously the association of ART reporting with these predictors while accounting for correlation among births occurring in the same hospital. Results Sensitivity of ART reporting on the birth certificate was 28.9% in Florida and 41.4% in Massachusetts. Specificity was >99% in both states. PPV was 45.5% in Florida and 54.6% in Massachusetts. The odds of ART reporting varied by state and by several maternal and delivery characteristics including age, parity, history of fetal loss, plurality, race/Hispanic ethnicity, delivery payment source, pre-existing conditions, and complications during pregnancy or labour and delivery. Conclusions There was significant under-reporting of ART procedures on the birth certificates. Using data on ART births identified only from birth certificates yields a biased sample of the population of ART births. C1 [Cohen, Bruce; Bernson, Dana] Massachusetts Dept Publ Hlth, Boston, MA 02108 USA. [Sappenfield, William; Kirby, Russell S.] Univ S Florida, Tampa, FL USA. [Kissin, Dmitry; Zhang, Yujia] Ctr Dis Control & Prevent, Atlanta, GA USA. [Copeland, Glenn] Michigan Dept Community Hlth, Lansing, MI USA. [Zhang, Zi] Ctr Hlth Informat & Anal, Boston, MA USA. [Macalusof, Maurizio] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA. RP Cohen, B (reprint author), Massachusetts Dept Publ Hlth, Bur Hlth Informat Stat Res & Evaluat, 250 Washington St,6th Floor, Boston, MA 02108 USA. EM bruce.cohen@state.ma.us RI Macaluso, Maurizio/J-2076-2015 OI Macaluso, Maurizio/0000-0002-2977-9690 NR 19 TC 5 Z9 5 U1 2 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0269-5022 EI 1365-3016 J9 PAEDIATR PERINAT EP JI Paediatr. Perinat. Epidemiol. PD MAY PY 2014 VL 28 IS 3 BP 181 EP 190 DI 10.1111/ppe.12110 PG 10 WC Public, Environmental & Occupational Health; Obstetrics & Gynecology; Pediatrics SC Public, Environmental & Occupational Health; Obstetrics & Gynecology; Pediatrics GA AE2KH UT WOS:000333801300002 PM 24533655 ER PT J AU Canaday, D Oswald, D Hoffman, S Robinson, J Tumpey, T Pearce, M Banks, R Aung, H Burant, C Higgins, P Hornick, T AF Canaday, David Oswald, Douglas Hoffman, Sarah Robinson, Janet Tumpey, Terrence Pearce, Melissa Banks, Richard Aung, Htin Burant, Christopher Higgins, Patricia Hornick, Thomas TI Frailty correlates with age and inflammatory markers but not flu vaccine response in an older veteran cohort SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract C1 [Canaday, David; Banks, Richard; Aung, Htin; Burant, Christopher; Higgins, Patricia; Hornick, Thomas] Cleveland VA, GRECC, Cleveland, OH USA. [Tumpey, Terrence; Pearce, Melissa] CDC, Influenza Branch, Atlanta, GA 30333 USA. [Canaday, David; Oswald, Douglas; Hoffman, Sarah; Robinson, Janet; Aung, Htin] Case Western Reserve Univ, Div Infect Dis, Cleveland, OH 44106 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD MAY 1 PY 2014 VL 192 SU 1 MA VAC2P.937 PG 1 WC Immunology SC Immunology GA V44RB UT WOS:000209765002126 ER PT J AU Liu, F Tumpey, T Sun, XJ Fairman, J Levine, M Katz, J Lu, XH AF Liu, Feng Tumpey, Terrence Sun, Xiangjie Fairman, Jeff Levine, Min Katz, Jacqueline Lu, Xiuhua TI A cationic lipid-DNA complex adjuvant (JVRS-100) enhances the immunogenicity and cross-protective efficacy of influenza pre-pandemic H5N1 vaccine in ferrets SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract C1 [Liu, Feng; Tumpey, Terrence; Sun, Xiangjie; Levine, Min; Katz, Jacqueline; Lu, Xiuhua] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. [Fairman, Jeff] Colby Pharmaceut Co, San Jose, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD MAY 1 PY 2014 VL 192 SU 1 MA VAC2P.931 PG 1 WC Immunology SC Immunology GA V44RB UT WOS:000209765002121 ER PT J AU Long, C Marshall, N Siegel, P Meade, B Lukomska, E Anderson, K Beezhold, D Anderson, S AF Long, Carrie Marshall, Nikki Siegel, Paul Meade, Barbera Lukomska, Ewa Anderson, Katie Beezhold, Donald Anderson, Stacey TI Exploring the role of miRNA 210 and regulatory T cells during TDI sensitization SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract C1 [Long, Carrie] West Virginia Univ, Immunol & Microbial Pathogenesis Grad Program, Morgantown, WV USA. [Long, Carrie; Marshall, Nikki; Siegel, Paul; Meade, Barbera; Lukomska, Ewa; Anderson, Katie; Beezhold, Donald; Anderson, Stacey] NIOSH, Ctr Dis Control & Prevent, Morgantown, WV USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD MAY 1 PY 2014 VL 192 SU 1 MA HYP6P.270 PG 1 WC Immunology SC Immunology GA V44RB UT WOS:000209765002214 ER PT J AU Pals, R Jha, R Omosun, Y He, Q Fujihashi, K Black, C Igietseme, J Eko, F AF Pals, Roshan Jha, Rajneesh Omosun, Yusuf He, Qing Fujihashi, Kohtaro Black, Carolyn Igietseme, Joseph Eko, Francis TI Rectal immunization with an rVCG vaccine protects against genital Chlamydia challenge SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract C1 [Pals, Roshan; Jha, Rajneesh; Omosun, Yusuf; He, Qing; Igietseme, Joseph; Eko, Francis] Morehouse Sch Med, Microbiol Biochem & Immunol, Atlanta, GA 30310 USA. [Black, Carolyn; Igietseme, Joseph] Ctr Dis Control & Prevent, Atlanta, GA USA. [Fujihashi, Kohtaro] Univ Alabama Birmingham, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD MAY 1 PY 2014 VL 192 SU 1 MA VAC7P.962 PG 1 WC Immunology SC Immunology GA V44RB UT WOS:000209765002055 ER PT J AU Forbi, JC Campo, DS Purdy, MA Dimitrova, ZE Skums, P Xia, GL Punkova, LT Ganova-Raeva, LM Vaughan, G Ben-Ayed, Y Switzer, WM Khudyakov, YE AF Forbi, Joseph C. Campo, David S. Purdy, Michael A. Dimitrova, Zoya E. Skums, Pavel Xia, Guo-liang Punkova, Lili T. Ganova-Raeva, Lilia M. Vaughan, Gilberto Ben-Ayed, Yousr Switzer, William M. Khudyakov, Yury E. TI Intra-host diversity and evolution of hepatitis C virus endemic to Cote d'Ivoire SO JOURNAL OF MEDICAL VIROLOGY LA English DT Article DE hepatitis C virus; West Africa; Cote d'Ivoire; molecular epidemiology ID WEST-AFRICA; BLOOD-TRANSFUSIONS; PREGNANT-WOMEN; GENOTYPE 2; INFECTION; CAMEROON; EPIDEMIOLOGY; TRANSMISSION; POPULATION; PREVALENCE AB Hepatitis C virus (HCV) infection presents an important, but underappreciated public health problem in Africa. In Cote d'Ivoire, very little is known about the molecular dynamics of HCV infection. Plasma samples (n = 608) from pregnant women collected in 1995 from Cote d'Ivoire were analyzed in this study. Only 18 specimens (similar to 3%) were found to be HCV PCR-positive. Phylogenetic analysis of the HCV NS5b sequences showed that the HCV variants belong to genotype 1 (HCV1) (n = 12, 67%) and genotype 2 (HCV2) (n = 6, 33%), with a maximum genetic diversity among HCV variants in each genotype being 20.7% and 24.0%, respectively. Although all HCV2 variants were genetically distant from each other, six HCV1 variants formed two tight sub-clusters belonging to HCV1a and HCV1b. Analysis of molecular variance (AMOVA) showed that the genetic structure of HCV isolates from West Africa with Cote d'Ivoire included were significantly different from Central African strains (P = 0.0001). Examination of intra-host viral populations using next-generation sequencing of the HCV HVR1 showed a significant variation in intra-host genetic diversity among infected individuals, with some strains composed of sub-populations as distant from each other as viral populations from different hosts. Collectively, the results indicate a complex HCV evolution in Cote d'Ivoire, similar to the rest of West Africa, and suggest a unique HCV epidemic history in the country. J. Med. Virol. 86:765-771, 2014. Published 2014. This article is a U.S. Government work and is in the public domain in the USA. C1 [Forbi, Joseph C.; Campo, David S.; Purdy, Michael A.; Dimitrova, Zoya E.; Skums, Pavel; Xia, Guo-liang; Punkova, Lili T.; Ganova-Raeva, Lilia M.; Vaughan, Gilberto; Ben-Ayed, Yousr; Khudyakov, Yury E.] Ctr Dis Control & Prevent, Div Viral Hepatitis, Natl Ctr HIV Hepatitis STD & TB Prevent, Atlanta, GA 30333 USA. [Switzer, William M.] Ctr Dis Control & Prevent, Branch Lab, Div HIV AIDS, Natl Ctr HIV Hepatitis STD & TB Prevent, Atlanta, GA 30333 USA. RP Forbi, JC (reprint author), Ctr Dis Control & Prevent, Div Viral Hepatitis, Natl Ctr HIV Hepatitis STD & TB Prevent, 1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM jforbi@cdc.gov RI Campo, David S./C-5072-2011 OI Campo, David S./0000-0002-8970-3436 FU Intramural CDC HHS [CC999999] NR 38 TC 7 Z9 7 U1 0 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0146-6615 EI 1096-9071 J9 J MED VIROL JI J. Med. Virol. PD MAY PY 2014 VL 86 IS 5 BP 765 EP 771 DI 10.1002/jmv.23897 PG 7 WC Virology SC Virology GA AC6ZG UT WOS:000332675600005 PM 24519518 ER PT J AU Nasser, W Beres, SB Olsen, RJ Dean, MA Rice, KA Long, W Kristinsson, KG Gottfredsson, M Vuopio, J Raisanen, K Caugant, DA Steinbakk, M Low, DE McGeer, A Darenberg, J Henriques-Normark, B Van Beneden, CA Hoffmann, S Musser, JM AF Nasser, Waleed Beres, Stephen B. Olsen, Randall J. Dean, Melissa A. Rice, Kelsey A. Long, Wesley Kristinsson, Karl G. Gottfredsson, Magnus Vuopio, Jaana Raisanen, Kati Caugant, Dominique A. Steinbakk, Martin Low, Donald E. McGeer, Allison Darenberg, Jessica Henriques-Normark, Birgitta Van Beneden, Chris A. Hoffmann, Steen Musser, James M. TI Evolutionary pathway to increased virulence and epidemic group A Streptococcus disease derived from 3,615 genome sequences SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE pathogenesis; phylogeography; mobile genetic element; flesh-eating disease; molecular clock ID TOXIC-SHOCK-SYNDROME; SCARLET FEVER TOXIN; STREPTOLYSIN-O; NECROTIZING FASCIITIS; PYROGENIC EXOTOXIN; M1T1 CLONE; CLINICAL-FEATURES; GENETIC ELEMENTS; INVASIVE DISEASE; PYOGENES DISEASE AB We sequenced the genomes of 3,615 strains of serotype Emm protein 1 (M1) group A Streptococcus to unravel the nature and timing of molecular events contributing to the emergence, dissemination, and genetic diversification of an unusually virulent clone that now causes epidemic human infections worldwide. We discovered that the contemporary epidemic clone emerged in stepwise fashion from a precursor cell that first contained the phage encoding an extracellular DNase virulence factor (streptococcal DNase D2, SdaD2) and subsequently acquired the phage encoding the SpeA1 variant of the streptococcal pyrogenic exotoxin A superantigen. The SpeA2 toxin variant evolved from SpeA1 by a single-nucleotide change in the M1 progenitor strain before acquisition by horizontal gene transfer of a large chromosomal region encoding secreted toxins NAD(+)-glycohydrolase and streptolysin O. Acquisition of this 36-kb region in the early 1980s into just one cell containing the phage-encoded sdaD2 and speA2 genes was the final major molecular event preceding the emergence and rapid intercontinental spread of the contemporary epidemic clone. Thus, we resolve a decades-old controversy about the type and sequence of genomic alterations that produced this explosive epidemic. Analysis of comprehensive, population-based contemporary invasive strains from seven countries identified strong patterns of temporal population structure. Compared with a preepidemic reference strain, the contemporary clone is significantly more virulent in nonhuman primate models of pharyngitis and necrotizing fasciitis. A key finding is that the molecular evolutionary events transpiring in just one bacterial cell ultimately have produced millions of human infections worldwide. C1 [Nasser, Waleed; Beres, Stephen B.; Olsen, Randall J.; Dean, Melissa A.; Rice, Kelsey A.; Long, Wesley; Musser, James M.] Houston Methodist Res Inst, Dept Pathol & Genom Med, Ctr Mol & Translat Human Infect Dis Res, Houston, TX 77030 USA. [Nasser, Waleed; Beres, Stephen B.; Olsen, Randall J.; Dean, Melissa A.; Rice, Kelsey A.; Long, Wesley; Musser, James M.] Houston Methodist Hosp, Houston, TX 77030 USA. [Kristinsson, Karl G.; Gottfredsson, Magnus] Landspitali Univ Hosp, Dept Clin Microbiol, IS-101 Reykjavik, Iceland. [Kristinsson, Karl G.; Gottfredsson, Magnus] Landspitali Univ Hosp, Dept Infect Dis, IS-101 Reykjavik, Iceland. [Kristinsson, Karl G.; Gottfredsson, Magnus] Univ Iceland, Sch Hlth Sci, Fac Med, IS-101 Reykjavik, Iceland. [Vuopio, Jaana; Raisanen, Kati] Univ Turku, Natl Inst Hlth & Welf, Antimicrobial Resistance Unit, Turku 20610, Finland. [Vuopio, Jaana; Raisanen, Kati] Univ Turku, Fac Med, Dept Med Microbiol & Immunol, Turku 20610, Finland. [Caugant, Dominique A.; Steinbakk, Martin] Norwegian Inst Publ Hlth, Dept Bacteriol & Immunol, N-0403 Oslo, Norway. [Low, Donald E.; McGeer, Allison] Mt Sinai Hosp, Dept Microbiol, Toronto, ON M5G 1X5, Canada. [Darenberg, Jessica] Publ Hlth Agcy Sweden, S-17182 Solna, Sweden. [Henriques-Normark, Birgitta] Karolinska Inst, Dept Microbiol, SE-17177 Stockholm, Sweden. [Henriques-Normark, Birgitta] Karolinska Univ Hosp, Dept Lab Med, Div Clin Microbiol, SE-17177 Stockholm, Sweden. [Van Beneden, Chris A.] Ctr Dis Control & Prevent, Resp Dis Branch, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Hoffmann, Steen] Statens Serum Inst, Dept Microbiol & Infect Control, Neisseria & Streptococcus Reference Lab, DK-2300 Copenhagen, Denmark. RP Musser, JM (reprint author), Houston Methodist Res Inst, Dept Pathol & Genom Med, Ctr Mol & Translat Human Infect Dis Res, Houston, TX 77030 USA. EM jmmusser@houstonmethodist.org RI Long, S. Wesley/A-9651-2008; mcgeer, allison /H-7747-2014; OI Long, S. Wesley/0000-0003-3043-5307; mcgeer, allison /0000-0001-5647-6137; Gottfredsson, Magnus/0000-0003-2465-0422 FU Knut and Alice Wallenberg Foundation; Swedish Research Council; Houston Methodist Hospital; Fondren Foundation FX We thank Connie Cantu, Chandni Valson, Joseph Ferretti, Alicia Alonso, Anne Ramstad Alme, Gunnhild Roedal, Kirsten Burmeister, Anna Syk, Ingrid Andersson, Christina Johansson, Gunnel Mollerberg, Johanna Makinen, Tuula Siljander, Anna Muotiala, Helena Seppala, the FiRe-Finnish Study Group for Antimicrobial Resistance, and Bernard Beall and the Active Bacterial Core surveillance of the Centers for Disease Control and Prevention's Emerging Infections Programs network. We thank Kathryn Stockbauer for critical comment and editorial assistance and David Morens and Frank DeLeo for suggestions to improve the manuscript. This project was supported in part with funds from the Knut and Alice Wallenberg Foundation, the Swedish Research Council, Houston Methodist Hospital, and the Fondren Foundation. NR 75 TC 70 Z9 70 U1 1 U2 17 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD APR 29 PY 2014 VL 111 IS 17 BP E1768 EP E1776 DI 10.1073/pnas.1403138111 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA AG1TL UT WOS:000335199000015 PM 24733896 ER PT J AU Soyemi, K Medina-Marino, A Sinkowitz-Cochran, R Schneider, A Njai, R McDonald, M Glover, M Garcia, J Aiello, AE AF Soyemi, Kenneth Medina-Marino, Andrew Sinkowitz-Cochran, Ronda Schneider, Amy Njai, Rashid McDonald, Marian Glover, Maleeka Garcia, Jocelyn Aiello, Allison E. TI Disparities among 2009 Pandemic Influenza A (H1N1) Hospital Admissions: A Mixed Methods Analysis - Illinois, April-December 2009 SO PLOS ONE LA English DT Article ID UNITED-STATES; HEALTH DISPARITIES; ETHNIC DISPARITIES; VIRUS-INFECTIONS; RISK-FACTORS; MORTALITY; IMPACT; SURVEILLANCE; VACCINATION; RESPONSES AB During late April 2009, the first cases of 2009 pandemic influenza A (H1N1) (pH1N1) in Illinois were reported. On-going, sustained local transmission resulted in an estimated 500,000 infected persons. We conducted a mixed method analysis using both quantitative (surveillance) and qualitative (interview) data; surveillance data was used to analyze demographic distribution of hospitalized cases and follow-up interview data was used to assess health seeking behavior. Invitations to participate in a telephone interview were sent to 120 randomly selected Illinois residents that were hospitalized during April-December 2009. During April-December 2009, 2,824 pH1N1 hospitalizations occurred in Illinois hospitals; median age (interquartile range) at admission was 24 (range: 6-49) years. Hospitalization rates/100,000 persons for blacks and Hispanics, regardless of age or sex were 2-3 times greater than for whites (blacks, 36/100,000 (95% Confidence Interval ([95% CI], 33-39)); Hispanics, 35/100,000 [95% CI,32-37] (; whites, 13/100,000[95% CI, 12-14); p<0.001). Mortality rates were higher for blacks (0.9/100,000; p<0.09) and Hispanics (1/100,000; p<0.04) when compared with the mortality rates for whites (0.6/100,000). Of 33 interview respondents, 31 (94%) stated that they had heard of pH1N1 before being hospitalized, and 24 (73%) did not believed they were at risk for pH1N1. On average, respondents reported experiencing symptoms for 2 days (range: 1-7) before seeking medical care. When asked how to prevent pH1N1 infection in the future, the most common responses were getting vaccinated and practicing hand hygiene. Blacks and Hispanics in Illinois experienced disproportionate pH1N1 hospitalization and mortality rates. Public health education and outreach efforts in preparation for future influenza pandemics should include prevention messaging focused on perception of risk, and ensure community wide access to prevention messages and practices. C1 [Soyemi, Kenneth; Medina-Marino, Andrew] Illinois Dept Publ Hlth, Div Infect Dis, Off Hlth Protect, Chicago, IL USA. [Medina-Marino, Andrew] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Off Surveillance Epidemiol & Lab Serv, Atlanta, GA USA. [Sinkowitz-Cochran, Ronda; Schneider, Amy] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Njai, Rashid] Ctr Dis Control & Prevent, Off Non Communicable Dis Injury & Environm Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [McDonald, Marian] Ctr Dis Control & Prevent, Off Hlth Dispar, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Glover, Maleeka] Ctr Dis Control & Prevent, Off Director, Ctr Infect Dis, Atlanta, GA USA. [Garcia, Jocelyn] Univ Miami, Miller Sch Med, Dept Obstet & Gynecol, Miami, FL 33136 USA. [Aiello, Allison E.] Univ Michigan, Sch Publ Hlth, Ann Arbor, MI 48109 USA. RP Garcia, J (reprint author), Univ Miami, Miller Sch Med, Dept Obstet & Gynecol, Miami, FL 33136 USA. EM jgarcia10@med.miami.edu NR 44 TC 0 Z9 0 U1 2 U2 2 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD APR 28 PY 2014 VL 9 IS 4 AR e84380 DI 10.1371/journal.pone.0084380 PG 8 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA AW4HM UT WOS:000346241800001 PM 24776852 ER PT J AU Cowan, M Chon, WJ Desai, A Andrews, S Bai, Y Veguilla, V Katz, JM Josephson, MA Wilson, PC Sciammas, R Chong, AS AF Cowan, Michelle Chon, W. James Desai, Amishi Andrews, Sarah Bai, Yaohui Veguilla, Vic Katz, Jacqueline M. Josephson, Michelle A. Wilson, Patrick C. Sciammas, Roger Chong, Anita S. TI Impact of Immunosuppression on Recall Immune Responses to Influenza Vaccination in Stable Renal Transplant Recipients SO TRANSPLANTATION LA English DT Article DE Influenza vaccine; Plasma cells; B cells; T cells; Kidney transplantation; Immunosuppression ID SOLID-ORGAN TRANSPLANTATION; SEROLOGIC ASSAYS; PANDEMIC H1N1; VIRUS; ANTIBODIES; MEMORY; EFFICACY; CELLS AB Background. The recommendation by the American Society of Transplantation for annual trivalent inactivated influenza vaccination greater than 3 to 6 months post-kidney transplantation provides a unique opportunity to test the in vivo impact of immunosuppression on recall T- and B-cell responses to influenza vaccination. Methods. This study took advantage of recent breakthroughs in the single-cell quantification of human peripheral blood B-cell responses to prospectively evaluate both B- and T-cell responses to the seasonal (2010 and 2011) influenza vaccine in 23 stable renal transplant recipients and 22 healthy controls. Results and Conclusion. The results demonstrate that the early B-cell response to influenza vaccination, quantified by the frequency of influenza-specific antibody-secreting cells (ASC) in peripheral blood, was significantly reduced in stable transplant recipients compared to healthy controls. The magnitude of the seroresponse and the rate of sero-conversion were also blunted. The influenza-specific interferon-gamma (IFNF) T-cell response was significantly reduced in transplant recipients; however, there was no correlation between the magnitude of the influenza-specific IgG ASC and IFNF responses. The induction of memory T- and B-cell responses to influenza vaccination supports the recommendation to vaccinate while the blunted responses demonstrate the efficacy of immunosuppression in controlling memory responses individual transplant recipients. C1 [Cowan, Michelle; Sciammas, Roger; Chong, Anita S.] Univ Chicago, Dept Surg, Chicago, IL 60637 USA. [Chon, W. James; Desai, Amishi; Josephson, Michelle A.] Univ Chicago, Dept Med, Chicago, IL 60637 USA. [Andrews, Sarah; Wilson, Patrick C.] Univ Chicago, Dept Pathol, Chicago, IL 60637 USA. [Bai, Yaohui; Veguilla, Vic; Katz, Jacqueline M.] Natl Ctr Immunizat & Resp Dis, Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. [Bai, Yaohui] Atlanta Res & Educ Fdn, Atlanta, GA USA. RP Chong, AS (reprint author), Univ Chicago, 5841 S Maryland Ave, Chicago, IL 60637 USA. EM achong@surgery.bsd.uchicago.edu RI Chon, W. James/K-9860-2013 OI Chon, W. James/0000-0002-3167-8549 FU NIH [P01AI097113, R01AI083452, R01AI072630] FX This work was supported in part by grants from the NIH, P01AI097113, R01AI083452, and R01AI072630, to A.S.C. NR 39 TC 5 Z9 5 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0041-1337 EI 1534-6080 J9 TRANSPLANTATION JI Transplantation PD APR 27 PY 2014 VL 97 IS 8 BP 846 EP 853 DI 10.1097/01.TP.0000438024.10375.2d PG 8 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA AH0XS UT WOS:000335844700013 PM 24366008 ER PT J AU Robbins, CL Zapata, LB Farr, SL Kroelinger, CD Morrow, B Ahluwalia, I D'Angelo, DV Barradas, D Cox, S Goodman, D Williams, L Grigorescu, V Barfield, WD AF Robbins, Cheryl L. Zapata, Lauren B. Farr, Sherry L. Kroelinger, Charlan D. Morrow, Brian Ahluwalia, Indu D'Angelo, Denise V. Barradas, Danielle Cox, Shanna Goodman, David Williams, Letitia Grigorescu, Violanda Barfield, Wanda D. TI Core State Preconception Health Indicators - Pregnancy Risk Assessment Monitoring System and Behavioral Risk Factor Surveillance System, 2009 SO MMWR SURVEILLANCE SUMMARIES LA English DT Article ID GESTATIONAL DIABETES-MELLITUS; NEURAL-TUBE DEFECTS; HIGH BLOOD-PRESSURE; UNITED-STATES; CHRONIC HYPERTENSION; RECOMMENDATION STATEMENT; UNINTENDED PREGNANCY; RACIAL DISPARITIES; ETHNIC DISPARITIES; NONPREGNANT WOMEN AB Problem/Condition: Promoting preconception health can potentially improve women's health and pregnancy outcomes. Evidence-based interventions exist to reduce many maternal behaviors and chronic conditions that are associated with adverse pregnancy outcomes such as tobacco use, alcohol use, inadequate folic acid intake, obesity, hypertension, and diabetes. The 2006 national recommendations to improve preconception health included monitoring improvements in preconception health by maximizing public health surveillance (CDC. Recommendations to improve preconception health and health care-United States: a report of the CDC/ATSDR Preconception Care Work Group and the Select Panel on Preconception Care. MMWR 2006; 55[No. RR-6]). Reporting Period Covered: 2009 for 38 indicators; 2008 for one indicator. Description of Surveillance Systems: The Pregnancy Risk Assessment Monitoring System (PRAMS) is an ongoing state-and population-based surveillance system designed to monitor selected self-reported maternal behaviors, conditions, and experiences that occur shortly before, during, and after pregnancy among women who deliver live-born infants. The Behavioral Risk Factor Surveillance System (BRFSS) is an ongoing state-based telephone survey of noninstitutionalized adults aged >= 18 years in the United States that collects state-level data on health-related risk behaviors, chronic conditions, and preventive health services. This surveillance summary includes PRAMS data from 29 reporting areas (n = 40,388 respondents) and BRFSS data from 51 reporting areas (n = 62,875 respondents) for nonpregnant women of reproductive age (aged 18-44 years). To establish a comprehensive, nationally recognized set of indicators to be used for monitoring, evaluation, and response, a volunteer group of policy and program leaders and epidemiologists identified 45 core state preconception health indicators, of which 41 rely on PRAMS or BRFSS as data sources. This report includes 39 of the 41 core state preconception health indicators for which data are available through PRAMS or BRFSS. The two indicators from these data sources that are not described in this report are human immunodeficiency virus (HIV) testing within a year before the most recent pregnancy and heavy drinking on at least one occasion during the preceding month. Ten preconception health domains are examined: general health status and life satisfaction, social determinants of health, health care, reproductive health and family planning, tobacco and alcohol use, nutrition and physical activity, mental health, emotional and social support, chronic conditions, and infections. Weighted prevalence estimates and 95% confidence intervals (95% CIs) for 39 indicators are presented overall and for each reporting area and stratified by age group (18-24, 25-34, and 35-44 years) and women's race/ethnicity (non-Hispanic white, non-Hispanic black, non-Hispanic other, and Hispanic). Results: This surveillance summary includes data for 39 of 41 indicators: 2009 data for 23 preconception health indicators that were monitored by PRAMS and 16 preconception health indicators that were monitored by BRFSS (one BRFSS indicator uses 2008 data). For two of the indicators that are included in this report (prepregnancy overweight or obesity and current overweight or obesity), separate measures of overweight and obesity were reported. All preconception health indicators varied by reporting area, and most indicators varied significantly by age group and race/ethnicity. Overall, 88.9% of women of reproductive age reported good, very good, or excellent general health status and life satisfaction (BRFSS). A high school/general equivalency diploma or higher education (social determinants of health domain) was reported by 94.7% of non-Hispanic white, 92.9% of non-Hispanic other, 91.1% of non-Hispanic black, and 70.9% of Hispanic women (BRFSS). Overall, health-care insurance coverage during the month before the most recent pregnancy (health-care domain) was 74.9% (PRAMS). A routine checkup during the preceding year was reported by 79.0% of non-Hispanic black, 65.1% of non-Hispanic white, 64.3% of other, and 63.0% of Hispanic women (BRFSS). Among women with a recent live birth (2-9 months since date of delivery), selected PRAMS results for the reproductive health and family planning, tobacco and alcohol use, and nutrition domains included several factors. Although 43% of women reported that their most recent pregnancy was unintended (unwanted or wanted to be pregnant later), approximately half (53%) of those who were not trying to get pregnant reported not using contraception at the time of conception. Smoking during the 3 months before pregnancy was reported by 25.1% of women, and drinking alcohol 3 months before pregnancy was reported by 54.2% of women. Daily use of a multivitamin, prenatal vitamin, or a folic acid supplement during the month before pregnancy was reported by 29.7% of women. Selected BRFSS results included indicators pertaining to the nutrition and physical activity, emotional and social support, and chronic conditions domains among women of reproductive age. Approximately one fourth (24.7%) of women were identified as being obese according to body mass index (BMI) on the basis of self-reported height and weight. Overall, 51.6% of women reported participation in recommended levels of physical activity per U. S. Department of Health and Human Services physical activity guidelines. Non-Hispanic whites reported the highest prevalence (85.0%) of having adequate emotional and social support, followed by other races/ethnicities (74.9%), Hispanics (70.5%), and non-Hispanic blacks (69.7%). Approximately 3.0% of persons reported ever being diagnosed with diabetes, and 10.2% of women reported ever being diagnosed with hypertension. Interpretation: The findings in this report underscore opportunities for improving the preconception health of U. S. women. Preconception health and women's health can be improved by reducing unintended pregnancies, reducing risky behaviors (e. g., smoking and drinking) among women of reproductive age, and ensuring that chronic conditions are under control. Evidence-based interventions and clinical practice guidelines exist to address these risks and to improve pregnancy outcomes and women's health in general. The results also highlight the need to increase access to health care for all nonpregnant women of reproductive age and the need to encourage the use of essential preventive services for women, including preconception health services. In addition, system changes in community settings can alleviate health problems resulting from inadequate social and emotional support and environments that foster unhealthy lifestyles. Policy changes can promote health equity by encouraging environments that promote healthier options in nutrition and physical activity. Finally, variation in the preconception health status of women by age and race/ethnicity underscores the need for implementing and scaling up proven strategies to reduce persistent health disparities among those at highest risk. Ongoing surveillance and research in preconception health are needed to monitor the influence of improved health-care access and coverage on women's prepregnancy and interpregnancy health status, pregnancy and infant outcomes, and health disparities. Public Health Action: Public health decision makers, program planners, researchers, and other key stakeholders can use the state-level PRAMS and BRFSS preconception health indicators to benchmark and monitor preconception health among women of reproductive age. These data also can be used to evaluate the effectiveness of preconception health state and national programs and to assess the need for new programs, program enhancements, and policies. C1 [Robbins, Cheryl L.; Zapata, Lauren B.; Farr, Sherry L.; Kroelinger, Charlan D.; Morrow, Brian; Ahluwalia, Indu; D'Angelo, Denise V.; Barradas, Danielle; Cox, Shanna; Goodman, David; Williams, Letitia; Grigorescu, Violanda; Barfield, Wanda D.] CDC, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP Robbins, CL (reprint author), CDC, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM ggf9@cdc.gov FU NIDA NIH HHS [K01 DA034523] NR 85 TC 36 Z9 38 U1 1 U2 27 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 1545-8636 J9 MMWR SURVEILL SUMM JI MMWR Surv. Summ. PD APR 25 PY 2014 VL 63 IS 3 BP 1 EP + PG 63 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AM9BA UT WOS:000340173200001 PM 24759729 ER PT J AU Gavin, L Moskosky, S Carter, M Curtis, K Glass, E Godfrey, E Marcell, A Mautone-Smith, N Pazol, K Tepper, N Zapata, L AF Gavin, Loretta Moskosky, Susan Carter, Marion Curtis, Kathryn Glass, Evelyn Godfrey, Emily Marcell, Arik Mautone-Smith, Nancy Pazol, Karen Tepper, Naomi Zapata, Lauren TI Providing Quality Family Planning Services Recommendations of CDC and the US Office of Population Affairs SO MMWR RECOMMENDATIONS AND REPORTS LA English DT Article ID RANDOMIZED-CONTROLLED-TRIAL; NURSE HOME VISITATION; ADOLESCENT PREGNANCY PREVENTION; ACTING REVERSIBLE CONTRACEPTION; SEXUALLY-TRANSMITTED-DISEASES; COMPUTER-ASSISTED-INSTRUCTION; REPRODUCTIVE HEALTH-SERVICES; MATERNAL LIFE-COURSE; 15-YEAR FOLLOW-UP; OF-THE-ART AB This report provides recommendations developed collaboratively by CDC and the Office of Population Affairs (OPA) of the U.S. Department of Health and Human Services (HHS). The recommendations outline how to provide quality family planning services, which include contraceptive services, pregnancy testing and counseling, helping clients achieve pregnancy, basic infertility services, preconception health services, and sexually transmitted disease services. The primary audience for this report is all current or potential providers of family planning services, including those working in service sites that are dedicated to family planning service delivery as well as private and public providers of more comprehensive primary care. The United States continues to face substantial challenges to improving the reproductive health of the U.S. population. Nearly one half of all pregnancies are unintended, with more than 700,000 adolescents aged 15-19 years becoming pregnant each year and more than 300,000 giving birth. One of eight pregnancies in the United States results in preterm birth, and infant mortality rates remain high compared with those of other developed countries. This report can assist primary care providers in offering family planning services that will help women, men, and couples achieve their desired number and spacing of children and increase the likelihood that those children are born healthy. The report provides recommendations for how to help prevent and achieve pregnancy, emphasizes offering a full range of contraceptive methods for persons seeking to prevent pregnancy, highlights the special needs of adolescent clients, and encourages the use of the family planning visit to provide selected preventive health services for women, in accordance with the recommendations for women issued by the Institute of Medicine and adopted by HHS. C1 [Gavin, Loretta; Carter, Marion; Curtis, Kathryn; Godfrey, Emily; Pazol, Karen; Tepper, Naomi; Zapata, Lauren] CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Reprod Hlth, Atlanta, GA 30333 USA. [Moskosky, Susan; Glass, Evelyn; Mautone-Smith, Nancy] US Dept HHS, Off Populat Affairs, Rockville, MD USA. [Marcell, Arik] Johns Hopkins Univ, Baltimore, MD USA. [Marcell, Arik] Male Training Ctr Family Planning & Reprod Hlth, Baltimore, MD USA. RP Gavin, L (reprint author), CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Reprod Hlth, Atlanta, GA 30333 USA. EM lcg6@cdc.gov; susan.moskosky@hhs.gov NR 298 TC 73 Z9 73 U1 11 U2 41 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 1057-5987 EI 1545-8601 J9 MMWR RECOMM REP JI MMWR Recomm. Rep. PD APR 25 PY 2014 VL 63 IS 4 BP 1 EP 54 PG 54 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AG6GN UT WOS:000335517200001 PM 24759690 ER PT J AU Socias, CM Menendez, CKC Collins, JW Simeonov, P AF Socias, Christina M. Menendez, Cammie K. Chaumont Collins, James W. Simeonov, Peter TI Workers' Memorial Day - April 28, 2014 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Socias, Christina M.] CDC, Atlanta, GA 30333 USA. [Menendez, Cammie K. Chaumont; Collins, James W.; Simeonov, Peter] CDC, Div Safety Res, Natl Inst Occupat Safety & Hlth, Atlanta, GA 30333 USA. RP Socias, CM (reprint author), CDC, Atlanta, GA 30333 USA. EM csocias@cdc.gov NR 4 TC 0 Z9 0 U1 0 U2 0 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD APR 25 PY 2014 VL 63 IS 16 BP 341 EP 341 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AG4WW UT WOS:000335422100001 ER PT J AU Socias, CM Menendez, CKC Collins, JW Simeonov, P AF Socias, Christina M. Menendez, Cammie K. Chaumont Collins, James W. Simeonov, Peter TI Occupational Ladder Fall Injuries - United States, 2011 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Socias, Christina M.] CDC, Atlanta, GA 30333 USA. [Menendez, Cammie K. Chaumont; Collins, James W.; Simeonov, Peter] CDC, Div Safety Res, Natl Inst Occupat Safety & Hlth, Atlanta, GA 30333 USA. RP Socias, CM (reprint author), CDC, Atlanta, GA 30333 USA. EM csocias@cdc.gov NR 10 TC 0 Z9 0 U1 1 U2 3 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD APR 25 PY 2014 VL 63 IS 16 BP 341 EP 346 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AG4WW UT WOS:000335422100002 ER PT J AU Beaucham, C Page, E Alarcon, WA Calvert, GM Methner, M Schoonover, TM AF Beaucham, Catherine Page, Elena Alarcon, Walter A. Calvert, Geoffrey M. Methner, Mark Schoonover, Todd M. TI Indoor Firing Ranges and Elevated Blood Lead Levels - United States, 2002-2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Beaucham, Catherine; Page, Elena; Alarcon, Walter A.; Calvert, Geoffrey M.; Methner, Mark] CDC, Div Surveillance Hazard Evaluat & Field Studies, Natl Inst Occupat Safety & Hlth, Atlanta, GA 30333 USA. [Schoonover, Todd M.] Washington State Dept Labor & Ind, Washington State ABLES Program, Olympia, WA 98504 USA. RP Beaucham, C (reprint author), CDC, Div Surveillance Hazard Evaluat & Field Studies, Natl Inst Occupat Safety & Hlth, Atlanta, GA 30333 USA. EM cbeaucham@cdc.gov RI Alarcon, Walter/C-4470-2008 OI Alarcon, Walter/0000-0002-4907-4380 NR 10 TC 5 Z9 5 U1 0 U2 4 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD APR 25 PY 2014 VL 63 IS 16 BP 347 EP 351 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AG4WW UT WOS:000335422100003 PM 24759656 ER PT J AU Whitney, CG Zhou, FJ Singleton, J Schuchat, A AF Whitney, Cynthia G. Zhou, Fangjun Singleton, James Schuchat, Anne TI Benefits from Immunization During the Vaccines for Children Program Era - United States, 1994-2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID DISEASES C1 [Whitney, Cynthia G.; Schuchat, Anne] CDC, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Zhou, Fangjun; Singleton, James] CDC, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Whitney, CG (reprint author), CDC, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM cwhitney@cdc.gov NR 9 TC 52 Z9 53 U1 1 U2 14 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD APR 25 PY 2014 VL 63 IS 16 BP 352 EP 355 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AG4WW UT WOS:000335422100004 PM 24759657 ER PT J AU Levitt, A Diop, OM Tangermann, RH Paladin, F Kamgang, JB Burns, CC Chenoweth, PJ Goel, A Wassilak, SGF AF Levitt, Alexandra Diop, Ousmane M. Tangermann, Rudolf H. Paladin, Fem Kamgang, Jean Baptiste Burns, Cara C. Chenoweth, Paul J. Goel, Ajay Wassilak, Steven G. F. TI Surveillance Systems to Track Progress Toward Global Polio Eradication - Worldwide, 2012-2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Levitt, Alexandra] CDC, Off Infect Dis, Atlanta, GA 30333 USA. [Diop, Ousmane M.; Tangermann, Rudolf H.; Paladin, Fem; Chenoweth, Paul J.; Goel, Ajay] World Hlth Org, Polio Eradicat Dept, Geneva, Switzerland. [Kamgang, Jean Baptiste; Wassilak, Steven G. F.] CDC, Global Immunizat Div, Ctr Global Hlth, Atlanta, GA 30333 USA. [Burns, Cara C.] CDC, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Wassilak, SGF (reprint author), CDC, Global Immunizat Div, Ctr Global Hlth, Atlanta, GA 30333 USA. EM swassilak@cdc.gov NR 9 TC 19 Z9 20 U1 0 U2 3 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD APR 25 PY 2014 VL 63 IS 16 BP 356 EP 361 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AG4WW UT WOS:000335422100005 PM 24759658 ER PT J AU MacNeil, A Dietz, V Cherian, T AF MacNeil, Adam Dietz, Vance Cherian, Thomas TI Vaccine preventable diseases: Time to re-examine global surveillance data? SO VACCINE LA English DT Article DE Surveillance; Pertussis; Measles; Vaccine preventable disease; Data ID PERTUSSIS-VACCINE; PROTECTION; MEASLES AB While data driven estimates of the global burden of disease for some vaccine preventable diseases (VPDs) are limited, aggregate case numbers of VPDs are reported annually by country in the Joint Reporting Form (JRF). We examined pertussis surveillance data in the JRF, and vaccine coverage estimates, in comparison to measles, which is a priority disease for elimination and eradication efforts and is supported by the WHO Global Measles and Rubella Laboratory Network. In 2012, highest pertussis case numbers and incidence were reported from high income countries with high vaccine coverage, discordant with countries that had low vaccine coverage. Use of laboratory diagnostics for pertussis cases varied among countries. In contrast, highest reported numbers of measles cases and incidences tended to occur in low income countries. These observations imply poor quality global surveillance data for some VPDs, limiting capacity for monitoring global epidemiology or making vaccination policy decisions. Efforts are needed to improve the availability of quality surveillance data for all VPDs. (C) 2014 Published by Elsevier Ltd. C1 [MacNeil, Adam; Dietz, Vance] Ctr Dis Control & Prevent, Global Immunizat Div, Atlanta, GA 30333 USA. [Cherian, Thomas] WHO, Dept Immunizat Vaccines & Biol, CH-1211 Geneva, Switzerland. RP MacNeil, A (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS A-04, Atlanta, GA 30333 USA. EM aho3@cdc.gov FU World Health Organization [001] NR 20 TC 3 Z9 3 U1 0 U2 2 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD APR 25 PY 2014 VL 32 IS 20 BP 2315 EP 2320 DI 10.1016/j.vaccine.2014.02.067 PG 6 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA AG0JA UT WOS:000335100600009 PM 24625342 ER PT J AU Mereckiene, J Cotter, S Nicoll, A Lopalco, P Noori, T Weber, JT D'Ancona, F Levy-Bruhl, D Dematte, L Giambi, C Valentiner-Branth, P Stankiewicz, I Appelgren, E O'Flanagan, D AF Mereckiene, J. Cotter, S. Nicoll, A. Lopalco, P. Noori, T. Weber, J. T. D'Ancona, F. Levy-Bruhl, D. Dematte, L. Giambi, C. Valentiner-Branth, P. Stankiewicz, I. Appelgren, E. O'Flanagan, D. CA VENICE Project Gatekeepers Grp TI Seasonal influenza immunisation in Europe. Overview of recommendations and vaccination coverage for three seasons: pre-pandemic (2008/09), pandemic (2009/10) and post-pandemic (2010/11) SO EUROSURVEILLANCE LA English DT Article ID CROSS-SECTIONAL ANALYSIS; PREGNANT-WOMEN; RISK-FACTOR; COUNTRIES; OBESITY; DISEASE; IMPACT; RATES AB Since 2008, annual surveys of influenza vaccination policies, practices and coverage have been undertaken in 29 European Union (EU)/European Economic Area (EEA) countries. After 2009, this monitored the impact of European Council recommendation to increase vaccination coverage to 75% among risk groups. This paper summarises the results of three seasonal influenza seasons: 2008/09, 2009/10 and 2010/11. In 2008/09, 27/29 countries completed the survey; in 2009/10 and 2010/11, 28/29 completed it. All or almost all countries recommended vaccination of older people (defined as those aged >= 50, >= 55, >= 59, >= 60 or >= 65 years), and people aged >= 6 months with clinical risk and healthcare workers. A total of 23 countries provided vaccination coverage data for older people, but only 7 and 10 had data for the clinical risk groups and healthcare workers, respectively. The number of countries recommending vaccination for some or all pregnant women increased from 10 in 2008/09 to 22 in 2010/11. Only three countries could report coverage among pregnant women. Seasonal influenza vaccination coverage during and after the pandemic season in older people and clinical groups remained unchanged in countries with higher coverage. However, small decreases were seen in most countries during this period. The results of the surveys indicate that most EU/EEA countries recommend influenza vaccination for the main target groups; however, only a few countries have achieved the target of 75% coverage among risk groups. Coverage among healthcare workers remained low. C1 [Mereckiene, J.; Cotter, S.; O'Flanagan, D.] Hlth Protect Surveillance Ctr, Dublin, Ireland. [Mereckiene, J.; Cotter, S.; D'Ancona, F.; Levy-Bruhl, D.; Dematte, L.; Giambi, C.; Valentiner-Branth, P.; Stankiewicz, I.; Appelgren, E.; O'Flanagan, D.] Vaccine European New Integrated Collaborat Effort, Venice, Italy. [Nicoll, A.; Lopalco, P.; Noori, T.] European Ctr Dis Prevent & Control ECDC, Stockholm, Sweden. [Weber, J. T.] Ctr Dis Control & Prevent, Atlanta, GA USA. [D'Ancona, F.; Giambi, C.; Appelgren, E.] Ist Super Sanita, I-00161 Rome, Italy. [Levy-Bruhl, D.] French Inst Publ Hlth Surveillance, Inst Veille Sanit, InVS, St Maurice, France. [Dematte, L.] CINECA Consortium Univ, Bologna, Italy. [Valentiner-Branth, P.] Statens Serum Inst, DK-2300 Copenhagen, Denmark. [Stankiewicz, I.] Natl Inst Hyg, Natl Inst Publ Hlth, PL-00791 Warsaw, Poland. RP Mereckiene, J (reprint author), Hlth Protect Surveillance Ctr, Dublin, Ireland. EM jolita.mereckiene@hse.ie RI D'Ancona, Fortunato/B-2139-2013 OI D'Ancona, Fortunato/0000-0002-9855-2924 NR 39 TC 40 Z9 41 U1 0 U2 0 PU EUR CENTRE DIS PREVENTION & CONTROL PI STOCKHOLM PA TOMTEBODAVAGEN 11A, STOCKHOLM, 171 83, SWEDEN SN 1560-7917 J9 EUROSURVEILLANCE JI Eurosurveillance PD APR 24 PY 2014 VL 19 IS 16 BP 29 EP 39 AR 20780 PG 11 WC Infectious Diseases SC Infectious Diseases GA AH1WV UT WOS:000335913400006 PM 24786262 ER PT J AU Martin, DL Goodhew, B Czaicki, N Foster, K Rajbhandary, S Hunter, S Brubaker, SA AF Martin, Diana L. Goodhew, Brook Czaicki, Nancy Foster, Kawanda Rajbhandary, Srijana Hunter, Shawn Brubaker, Scott A. TI Trypanosoma cruzi Survival following Cold Storage: Possible Implications for Tissue Banking SO PLOS ONE LA English DT Article ID CHAGAS-DISEASE; TRANSFUSION TRANSMISSION; INFECTED MICE; UNITED-STATES; BLOOD-DONORS; LOS-ANGELES; TRANSPLANTATION; BONE; EXPERIENCE; RECIPIENTS AB While Trypanosoma cruzi, the etiologic agent of Chagas disease, is typically vector-borne, infection can also occur through solid organ transplantation or transfusion of contaminated blood products. The ability of infected human cells, tissues, and cellular and tissue-based products (HCT/Ps) to transmit T. cruzi is dependent upon T. cruzi surviving the processing and storage conditions to which HCT/Ps are subjected. In the studies reported here, T. cruzi trypomastigotes remained infective 24 hours after being spiked into blood and stored at room temperature (N = 20); in 2 of 13 parasite-infected cultures stored 28 days at 4 degrees C; and in samples stored 365 days at -80 degrees C without cryoprotectant (N = 28), despite decreased viability compared to cryopreserved parasites. Detection of viable parasites after multiple freeze/thaws depended upon the duration of frozen storage. The ability of T. cruzi to survive long periods of storage at +4 and -80 degrees C suggests that T. cruzi-infected tissues stored under these conditions are potentially infectious. C1 [Martin, Diana L.; Goodhew, Brook] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Czaicki, Nancy] Univ Calif Berkeley, Berkeley, CA 94720 USA. [Foster, Kawanda] Univ Georgia, Athens, GA 30602 USA. [Rajbhandary, Srijana] Ctr Med Technol Policy, Baltimore, MD USA. [Hunter, Shawn] Ctr Tissue Innovat & Res, Kettering, OH USA. [Brubaker, Scott A.] Amer Assoc Tissue Banks, Mclean, VA USA. RP Martin, DL (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. EM hzx3@cdc.gov FU Scientific and Technical Affairs Committee of the American Association of Tissue Banks (AATB) FX This research was supported by a grant from the Scientific and Technical Affairs Committee of the American Association of Tissue Banks (AATB, www.aatb.org). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 30 TC 5 Z9 5 U1 0 U2 6 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD APR 23 PY 2014 VL 9 IS 4 AR e95398 DI 10.1371/journal.pone.0095398 PG 7 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA AG3EI UT WOS:000335298200054 PM 24759837 ER PT J AU Goodhew, EB Morgan, SMG Switzer, AJ Munoz, B Dize, L Gaydos, C Mkocha, H West, SK Wiegand, RE Lammie, PJ Martin, DL AF Goodhew, Erica Brook Morgan, Sheri Maria G. Switzer, Andrew J. Munoz, Beatriz Dize, Laura Gaydos, Charlotte Mkocha, Harran West, Sheila K. Wiegand, Ryan E. Lammie, Patrick J. Martin, Diana L. TI Longitudinal analysis of antibody responses to trachoma antigens before and after mass drug administration SO BMC INFECTIOUS DISEASES LA English DT Article ID CHLAMYDIA-TRACHOMATIS; SMALLPOX VACCINATION; ALCOHOL-CONSUMPTION; ROCHE AMPLICOR; DURATION; IMMUNITY; MEMORY; TOOLS; ASSAY; ELIMINATION AB Background: Blinding trachoma, caused by the bacteria Chlamydia trachomatis, is a neglected tropical disease targeted for elimination by 2020. A major component of the elimination strategy is mass drug administration (MDA) with azithromycin. Currently, program decisions are made based on clinical signs of ocular infection, but we have been investigating the use of antibody responses for post-MDA surveillance. In a previous study, IgG responses were detected in children lacking clinical evidence of trachoma, suggesting that IgG responses represented historical infection. To explore the utility of serology for program evaluation, we compared IgG and IgA responses to trachoma antigens and examined changes in IgG and IgA post-drug treatment. Methods: Dried blood spots and ocular swabs were collected with parental consent from 264 1-6 year olds in a single village of Kongwa District, central Tanzania. Each child also received an ocular exam for detection of clinical signs of trachoma. MDA was given, and six months later an additional blood spot was taken from these same children. Ocular swabs were analyzed for C. trachomatis DNA and antibody responses for IgA and total IgG were measured in dried bloods spots. Results: Baseline antibody responses showed an increase in antibody levels with age. By age 6, the percentage positive for IgG (96.0%) was much higher than for IgA (74.2%). Antibody responses to trachoma antigens declined significantly six months after drug treatment for most age groups. The percentage decrease in IgA response was much greater than for IgG. However, no instances of seroreversion were observed. Conclusions: Data presented here suggest that focusing on concordant antibody responses in children will provide the best serological surveillance strategy for evaluation of trachoma control programs. C1 [Goodhew, Erica Brook; Wiegand, Ryan E.; Lammie, Patrick J.; Martin, Diana L.] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA 30333 USA. [Morgan, Sheri Maria G.] Ohio State Univ, Coll Optometry, Columbus, OH 43210 USA. [Switzer, Andrew J.] St Olaf Coll, Northfield, MN 55057 USA. [Munoz, Beatriz; West, Sheila K.] Johns Hopkins Univ, Wilmer Eye Inst, Dana Ctr Prevent Ophthalmol, Baltimore, MD 21218 USA. [Dize, Laura; Gaydos, Charlotte] Johns Hopkins Univ, Ctr Infect Dis, Baltimore, MD 21218 USA. [Mkocha, Harran] Kongwa Trachoma Project, Kongwa, Tanzania. RP Martin, DL (reprint author), Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA 30333 USA. EM hzx3@cdc.gov FU U.S. Agency for International Development (USAID) FX The authors acknowledge Jeff Priest and Delynn Moss for helpful conversations regarding the Luminex assay, Kongwa Trachoma Project team members who assisted with sample collection, and the U.S. Agency for International Development (USAID) for funding for this project. USAID played no role in the design or interpretation of this study. The conclusions in this paper are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention. NR 26 TC 7 Z9 7 U1 0 U2 4 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2334 J9 BMC INFECT DIS JI BMC Infect. Dis. PD APR 22 PY 2014 VL 14 AR 216 DI 10.1186/1471-2334-14-216 PG 8 WC Infectious Diseases SC Infectious Diseases GA AG7MH UT WOS:000335601600002 PM 24755001 ER PT J AU Valenzuela, O Gonzalez-Diaz, M Garibay-Escobar, A Burgara-Estrella, A Cano, M Durazo, M Bernal, RM Hernandez, J Xiao, LH AF Valenzuela, Olivia Gonzalez-Diaz, Mariana Garibay-Escobar, Adriana Burgara-Estrella, Alexel Cano, Manuel Durazo, Maria Bernal, Rosa M. Hernandez, Jesus Xiao, Lihua TI Molecular Characterization of Cryptosporidium spp. in Children from Mexico SO PLOS ONE LA English DT Article ID ZIEHL-NEELSEN TECHNIQUE; GIARDIA-DUODENALIS; GENETIC DIVERSITY; PARVUM INFECTION; DAIRY CALVES; HUMANS; EPIDEMIOLOGY; HOMINIS; DIARRHEA; TRANSMISSION AB Cryptosporidiosis is a parasitic disease caused by Cryptosporidium spp. In immunocompetent individuals, it usually causes an acute and self-limited diarrhea; in infants, infection with Cryptosporidium spp. can cause malnutrition and growth retardation, and declined cognitive ability. In this study, we described for the first time the distribution of C. parvum and C. hominis subtypes in 12 children in Mexico by sequence characterization of the 60-kDa glycoprotein (GP60) gene of Cryptosporidium. Altogether, 7 subtypes belonging to 4 subtype families of C. hominis ( Ia, Ib, Id and Ie) and 1 subtype family of C. parvum ( IIa) were detected, including IaA14R3, IaA15R3, IbA10G2, IdA17, IeA11G3T3, IIaA15G2R1 and IIaA16G1R1. The frequency of the subtype families and subtypes in the samples analyzed in this study differed from what was observed in other countries. C1 [Valenzuela, Olivia; Gonzalez-Diaz, Mariana; Garibay-Escobar, Adriana; Burgara-Estrella, Alexel] Univ Sonora, Dept Ciencias Quim Biol, Hermosillo 83000, Sonora, Mexico. [Cano, Manuel; Durazo, Maria] Hosp Infantil Estado Sonora, Serv Infectol, Hermosillo, Sonora, Mexico. [Bernal, Rosa M.] Hosp Infantil Mexico Dr Federico Gomez, Lab Parasitol & Micol, Mexico City, DF, Mexico. [Hernandez, Jesus] Ctr Invest Alimentac & Desarrollo AC, Lab Inmunol, Hermosillo, Sonora, Mexico. [Xiao, Lihua] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Valenzuela, O (reprint author), Univ Sonora, Dept Ciencias Quim Biol, Hermosillo 83000, Sonora, Mexico. EM o_valenzuela@guayacan.uson.mx RI Xiao, Lihua/B-1704-2013 OI Xiao, Lihua/0000-0001-8532-2727 FU University of Sonora funds FX This work has been funded by University of Sonora funds and the funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 64 TC 9 Z9 9 U1 2 U2 11 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD APR 22 PY 2014 VL 9 IS 4 AR e96128 DI 10.1371/journal.pone.0096128 PG 5 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA AG2IS UT WOS:000335240300140 PM 24755606 ER PT J AU Watson, KB Carlson, SA Carroll, DD Fulton, JE AF Watson, Kathleen B. Carlson, Susan A. Carroll, Dianna D. Fulton, Janet E. TI Comparison of accelerometer cut points to estimate physical activity in US adults SO JOURNAL OF SPORTS SCIENCES LA English DT Article DE monitor; device-based assessment; acceleration; NHANES; calibration; public health; objective assessment ID ENERGY-EXPENDITURE; 2-REGRESSION MODEL; ACTIGRAPH ACCELEROMETER; PUBLIC-HEALTH; CALIBRATION; VALIDITY; OUTCOMES; CHILDREN; MONITOR; WALKING AB The purpose of this study was (1) to describe physical activity prevalence, categorised according to the 2008 Physical Activity Guidelines for Americans (2008 Guidelines), using different accelerometer cut points and (2) to examine physical activity prevalence patterns by reported cut points across selected characteristics. Cut points from 9 studies were used to estimate physical activity prevalence in a national adult sample (n=6547). Estimates were stratified by validation study activity protocols used to derive cut points - ambulatory (walking/running) and lifestyle activities (e.g. gardening, housework, walking). Results showed that the prevalence of meeting the 2008 Guidelines ranged from 6.3% to 98.3% overall and was lower for cut points derived from ambulatory (median=11.5%, range=6.3-27.4%) compared to lifestyle (median=77.2%, range=60.6-98.3%) protocols. Prevalence patterns across protocols differed for age, but were similar for other characteristics. In conclusion, prevalence of meeting the 2008 Guidelines varied widely, indicating that choice of cut point had an impact on prevalence. To generate future accelerometer cut points one may consider developing cut points for demographic subgroups using a variety of lifestyle physical activities. C1 [Watson, Kathleen B.; Carlson, Susan A.; Fulton, Janet E.] Ctr Dis Control & Prevent, NCCDPHP DNPAO, Atlanta, GA 30341 USA. [Carroll, Dianna D.] Ctr Dis Control & Prevent, NCBDDD DHDBD, Atlanta, GA 30341 USA. RP Watson, KB (reprint author), Ctr Dis Control & Prevent, NCCDPHP DNPAO, 4770 Buford Highway NE,Mailstop K-46, Atlanta, GA 30341 USA. EM kwatson@cdc.gov FU Intramural CDC HHS [CC999999] NR 38 TC 9 Z9 9 U1 1 U2 17 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 0264-0414 EI 1466-447X J9 J SPORT SCI JI J. Sports Sci. PD APR 21 PY 2014 VL 32 IS 7 BP 660 EP 669 DI 10.1080/02640414.2013.847278 PG 10 WC Sport Sciences SC Sport Sciences GA AB6VV UT WOS:000331928500008 PM 24188163 ER PT J AU Ford, ES Mannino, DM Wheaton, AG Presley-Cantrell, L Liu, Y Giles, WH Croft, JB AF Ford, Earl S. Mannino, David M. Wheaton, Anne G. Presley-Cantrell, Letitia Liu, Yong Giles, Wayne H. Croft, Janet B. TI Trends in the Use, Sociodemographic Correlates, and Undertreatment of Prescription Medications for Chronic Obstructive Pulmonary Disease among Adults with Chronic Obstructive Pulmonary Disease in the United States from 1999 to 2010 SO PLOS ONE LA English DT Article ID CLINICAL-PRACTICE GUIDELINE; PRIMARY-CARE; AMERICAN-COLLEGE; COPD AWARENESS; PHYSICIANS; POPULATION; MANAGEMENT; ADHERENCE; DIAGNOSIS; BARRIERS AB Background: The extent to which patients with COPD are receiving indicated treatment with medications to improve lung function and recent trends in the use of these medications is not well documented in the United States. The objective of this study was to examine trends in prescription medications for COPD among adults in the United States from 1999 to 2010. Methods: We performed a trend analysis using data from up to 1426 participants aged >= 20 years with self-reported COPD from six national surveys (National Health and Nutrition Examination Survey 1999-2010). Results: During 2009-2010, the age-adjusted percentage of participants who used any kind of medication was 44.2%. Also during 2009-2010, the most commonly used medications were short-acting agents (36.0%), inhaled corticosteroids (ICS) (18.3%), and LABAs (16.7%). The use of long-acting beta-2 agonists (LABAs) (p for trend <0.001), ICS (p for trend = 0.013) increased significantly over the 12-year period. Furthermore, the use of tiotropium increased rapidly during this period (p for trend <0.001). For the years 2005-2010, the use of LABAs, ICS and tiotropium increased with age. Compared with whites, Mexican Americans were less likely to use short-acting agents, LABAs, ICS, tiotropium, and any kind of COPD medication. Among participants aged 20-79 years with spirometry measurements during 2007-2010, the use of any medication was reported by 19.0% of those with a moderate/severe obstructive impairment and by 72.6% of those with self-reported COPD and any obstructive impairment. Conclusion: The percentages of adults with COPD who reported having various classes of prescription medications that improve airflow limitations changed markedly from 1999-2000 to 2009-2010. However, many adults with COPD did not report having recommended prescription medications. C1 [Ford, Earl S.; Wheaton, Anne G.; Presley-Cantrell, Letitia; Liu, Yong; Giles, Wayne H.; Croft, Janet B.] Ctr Dis Control & Prevent, Div Adult & Community Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Mannino, David M.] Univ Kentucky, Coll Publ Hlth, Dept Prevent Med & Environm Hlth, Lexington, KY USA. RP Ford, ES (reprint author), Ctr Dis Control & Prevent, Div Adult & Community Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM eford@cdc.gov OI Mannino, David/0000-0003-3646-7828 NR 32 TC 4 Z9 4 U1 1 U2 2 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD APR 21 PY 2014 VL 9 IS 4 AR e95305 DI 10.1371/journal.pone.0095305 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA AG2DX UT WOS:000335227400050 PM 24751857 ER PT J AU Robinson, MK Caudill, SP Koch, DD Ritchie, J Hortin, G Eckfeldt, JH Sandberg, S Williams, D Myers, G Miller, WG AF Robinson, Mary K. Caudill, Samuel P. Koch, David D. Ritchie, James Hortin, Glen Eckfeldt, John H. Sandberg, Sverre Williams, Desmond Myers, Gary Miller, W. Greg TI Albumin adsorption onto surfaces of urine collection and analysis containers SO CLINICA CHIMICA ACTA LA English DT Article DE Urine albumin; Albumin adsorption; Urine containers ID HUMAN SERUM-ALBUMIN AB Background: Adsorption of albumin onto urine collection and analysis containers may cause falsely low concentrations. Methods: We added I-125-labeled human serum albumin to urine and to phosphate buffered solutions, incubated them with 22 plastic container materials and measured adsorption by liquid scintillation counting. Results: Adsorption of urine albumin (UA) at 5-6 mg/l was <0.9%; and at 90 mg/l was <0.4%. Adsorption was generally less at pH 8 than pH 5 but only 3 cases had p < 0.05. Adsorption from 11 unaltered urine samples with albumin 5-333 mg/l was <0.8%. Albumin adsorption for the material with greatest binding was extrapolated to the surface areas of 100 ml and 2 l collection containers, and to instrument sample cups and showed <1% change in concentration at 5 mg/l and <0.5% change at 20 mg/l or higher concentrations. Adsorption of albumin from phosphate buffered solutions (2-28%) was larger than that from urine. Conclusions: Albumin adsorption differed among urine samples and plastic materials, but the total influence of adsorption was <1% for all materials and urine samples tested. Adsorption of albumin from phosphate buffered solutions was larger than that from urine and could be a limitation for preparations used as calibrators. (C) 2014 Elsevier B.V. All rights reserved. C1 [Robinson, Mary K.; Caudill, Samuel P.] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA USA. [Koch, David D.] Grady Mem Hosp, Atlanta, GA USA. [Koch, David D.; Ritchie, James] Emory Univ, Dept Pathol & Lab Med, Atlanta, GA 30322 USA. [Hortin, Glen] Quest Diagnost, Cincinnati, OH USA. [Eckfeldt, John H.] Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA. [Sandberg, Sverre] Haukeland Hosp, Lab Clin Biochem, N-5021 Bergen, Norway. [Sandberg, Sverre] Norwegian Qual Improvement Primary Care Labs, Bergen, Norway. [Williams, Desmond] Ctr Dis Control & Prevent, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Myers, Gary] Amer Assoc Clin Chem, Washington, DC USA. [Miller, W. Greg] Virginia Commonwealth Univ, Dept Pathol, Richmond, VA USA. RP Miller, WG (reprint author), POB 286, Richmond, VA 23298 USA. EM gmiller@vcu.edu FU National Center for Chronic Disease Prevention and Health Promotion at the CDC FX We thank the NKDEP-IFCC joint Working Group for Standardization of Urinary Albumin for developing the framework, the National Center for Chronic Disease Prevention and Health Promotion at the CDC for providing funding, and the Newborn Screening and Molecular Biology Branch at the CDC for use of their radiation laboratory. We thank Elizabeth Monsell for assisting with the experimental design, Theodosia Prater for technical assistance and Pamela Olive for assisting with operation of the Hitachi 912. NR 14 TC 0 Z9 0 U1 1 U2 4 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0009-8981 EI 1873-3492 J9 CLIN CHIM ACTA JI Clin. Chim. Acta PD APR 20 PY 2014 VL 431 BP 40 EP 45 DI 10.1016/j.cca.2014.01.035 PG 6 WC Medical Laboratory Technology SC Medical Laboratory Technology GA AG7QP UT WOS:000335613200007 PM 24513540 ER PT J AU Nakamura, M Kayamori, Y Iso, H Kitamura, A Kiyama, M Koyama, I Nishimura, K Nakai, M Noda, H Dasti, M Vesper, HW Miyamoto, Y AF Nakamura, Masakazu Kayamori, Yuzo Iso, Hiroyasu Kitamura, Akihiko Kiyama, Masahiko Koyama, Isao Nishimura, Kunihiro Nakai, Michikazu Noda, Hiroyuki Dasti, Mahnaz Vesper, Hubert W. Miyamoto, Yoshihiro TI LDL cholesterol performance of beta quantification reference measurement procedure SO CLINICA CHIMICA ACTA LA English DT Article DE Beta quantification; Bottom fraction cholesterol; HDL cholesterol; LDL cholesterol ID DENSITY-LIPOPROTEIN CHOLESTEROL; ADULT TREATMENT PANEL; EDUCATION-PROGRAM; CARDIOVASCULAR-DISEASE; HOMOGENEOUS ASSAYS; PRIMARY PREVENTION; APOLIPOPROTEIN-B; HEART-DISEASE; RISK-FACTORS; SERUM AB Background: Accurate measurement of blood lipids is crucial in cardiovascular disease risk management. The Centers for Disease Control and Prevention (CDC) Cholesterol Reference Method Laboratory Network (CRMLN) has assured the accuracy of these measurements forover 20 years using beta quantification (BQ) method as reference measurement procedure (RMP) for high- and low-density lipoprotein cholesterol (HDL-C, LDL-C). Only limited data exist about the performance of the BQRMP. Methods: Bottom fraction cholesterol (BFC), HDL-C, and LDL-C results after ultracentrifugation from the CDC lipid reference laboratory and the Japanese CRMLN laboratory were compared using 280 serum samples measured over the past 15 years. Data were compared statistically using method comparison and bias estimation analysis. Results: Regression analysis between CDC (x) and Osaka (y) for BFC, HDL-C, and LDL-C were y = 0.988x + 1.794 (R-2 = 0.997), y 0.980x + 1.118 (R-2 = 0.994), and y = 0.987x + 1.200 (R-2 = 0.997), respectively. The Osaka laboratory met performance goals for 90% to 95% of the CDC reference values. Conclusions: The BQ method by the Osaka CRMLN laboratory is highly accurate and has been stable for over 15 years. Accurate measurement of BFC is critical for the determination of LDL-C. (C) 2014 Elsevier B.V. All rights reserved. C1 [Nakamura, Masakazu; Koyama, Isao] Natl Cerebral & Cardiovasc Ctr, Dept Prevent Cardiol, Lipid Reference Lab, Suita, Osaka 5658565, Japan. [Kayamori, Yuzo] Kyushu Univ, Fac Med Sci, Dept Hlth Sci, Fukuoka 812, Japan. [Iso, Hiroyasu; Noda, Hiroyuki] Osaka Univ, Grad Sch Med, Dept Social & Environm Med, Suita, Osaka 565, Japan. [Kitamura, Akihiko; Kiyama, Masahiko] Osaka Ctr Canc & Cardiovasc Dis, Osaka, Japan. [Nishimura, Kunihiro] Natl Cerebral & Cardiovasc Ctr, Dept Prevent Med & Epidemiol Informat, Off Evidence Based Med & Risk Anal, Suita, Osaka 5658565, Japan. [Nakai, Michikazu] Natl Cerebral & Cardiovasc Ctr, Dept Prevent Med & Epidemiol Informat, Suita, Osaka 5658565, Japan. [Noda, Hiroyuki] Minist Hlth Labour & Welf, Hlth Serv Bur, Canc Control & Hlth Promot Div, Tokyo, Japan. [Dasti, Mahnaz; Vesper, Hubert W.] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA USA. [Miyamoto, Yoshihiro] Natl Cerebral & Cardiovasc Ctr, Dept Prevent Cardiol, Dept Prevent Med & Epidemiol Informat, Suita, Osaka 5658565, Japan. RP Nakamura, M (reprint author), Natl Cerebral & Cardiovasc Ctr, Dept Prevent Cardiol, Lipid Reference Lab, 5-7-1 Fujishirodai, Suita, Osaka 5658565, Japan. EM nakamura.masakazu.hp@ncvc.go.jp OI Iso, Hiroyasu /0000-0002-9241-7289 NR 36 TC 3 Z9 3 U1 2 U2 9 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0009-8981 EI 1873-3492 J9 CLIN CHIM ACTA JI Clin. Chim. Acta PD APR 20 PY 2014 VL 431 BP 288 EP 293 DI 10.1016/j.cca.2014.02.018 PG 6 WC Medical Laboratory Technology SC Medical Laboratory Technology GA AG7QP UT WOS:000335613200047 PM 24589772 ER PT J AU Bankamp, B Liu, CY Rivailler, P Bera, J Shrivastava, S Kirkness, EF Bellini, WJ Rota, PA AF Bankamp, Bettina Liu, Chunyu Rivailler, Pierre Bera, Jayati Shrivastava, Susmita Kirkness, Ewen F. Bellini, William J. Rota, Paul A. TI Wild-Type Measles Viruses with Non-Standard Genome Lengths SO PLOS ONE LA English DT Article ID SUBACUTE SCLEROSING-PANENCEPHALITIS; CANINE-DISTEMPER VIRUS; PCR PRIMER DESIGN; FUSION PROTEIN; MESSENGER-RNA; MOLECULAR EPIDEMIOLOGY; UNTRANSLATED REGIONS; NUCLEOTIDE-SEQUENCE; CELLULAR RECEPTOR; GENE-EXPRESSION AB The length of the single stranded, negative sense RNA genome of measles virus (MeV) is highly conserved at 15,894 nucleotides (nt). MeVs can be grouped into 24 genotypes based on the highly variable 450 nucleotides coding for the carboxyl-terminus of the nucleocapsid protein (N-450). Here, we report the genomic sequences of 2 wild-type viral isolates of genotype D4 with genome lengths of 15,900 nt. Both genomes had a 7 nt insertion in the 39 untranslated region (UTR) of the matrix (M) gene and a 1 nt deletion in the 5' UTR of the fusion (F) gene. The net gain of 6 nt complies with the rule-of-six required for replication competency of the genomes of morbilliviruses. The insertions and deletion (indels) were confirmed in a patient sample that was the source of one of the viral isolates. The positions of the indels were identical in both viral isolates, even though epidemiological data and the 3 nt differences in N-450 between the two genomes suggested that the viruses represented separate chains of transmission. Identical indels were found in the M-F intergenic regions of 14 additional genotype D4 viral isolates that were imported into the US during 2007-2010. Viral isolates with and without indels produced plaques of similar size and replicated efficiently in A549/hSLAM and Vero/hSLAM cells. This is the first report of wild-type MeVs with genome lengths other than 15,894 nt and demonstrates that the length of the M-F UTR of wild-type MeVs is flexible. C1 [Bankamp, Bettina; Liu, Chunyu; Rivailler, Pierre; Bellini, William J.; Rota, Paul A.] Ctr Dis Control & Prevent, Measles Mumps Rubella & Herpes Virus Lab Branch, Atlanta, GA 30333 USA. [Liu, Chunyu] Chinese Acad Med Sci, Inst Pathogen Biol, Beijing 100730, Peoples R China. [Liu, Chunyu] Peking Union Med Coll, Beijing 100021, Peoples R China. [Bera, Jayati; Shrivastava, Susmita; Kirkness, Ewen F.] J Craig Venter Inst, Rockville, MD USA. RP Bankamp, B (reprint author), Ctr Dis Control & Prevent, Measles Mumps Rubella & Herpes Virus Lab Branch, Atlanta, GA 30333 USA. EM bbankamp@cdc.gov FU National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services [HHSN272200900007C] FX This project has been funded in part with federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services under contract number HHSN272200900007C. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 51 TC 7 Z9 7 U1 0 U2 6 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD APR 18 PY 2014 VL 9 IS 4 AR e95470 DI 10.1371/journal.pone.0095470 PG 8 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA AG2DP UT WOS:000335226500105 PM 24748123 ER PT J AU Shi, JR Njai, R Wells, E Collins, J Wilkins, M Dooyema, C Sinclair, J Gao, HJ Rainey, JJ AF Shi, Jianrong Njai, Rashid Wells, Eden Collins, Jim Wilkins, Melinda Dooyema, Carrie Sinclair, Julie Gao, Hongjiang Rainey, Jeanette J. TI Knowledge, Attitudes, and Practices of Nonpharmaceutical Interventions following School Dismissals during the 2009 Influenza A H1N1 Pandemic in Michigan, United States SO PLOS ONE LA English DT Article ID PUBLIC-SCHOOLS; CLOSURE; DECISIONS; OUTBREAK AB Background: Many schools throughout the United States reported an increase in dismissals due to the 2009 influenza A H1N1 pandemic (pH1N1). During the fall months of 2009, more than 567 school dismissals were reported from the state of Michigan. In December 2009, the Michigan Department of Community Health, in collaboration with the United States Centers for Disease Control and Prevention, conducted a survey to describe the knowledge, attitudes, and practices (KAPs) of households with school-aged children and classroom teachers regarding the recommended use of nonpharmaceutical interventions (NPIs) to slow the spread of influenza. Methods: A random sample of eight elementary schools (kindergarten through 5th grade) was selected from each of the eight public health preparedness regions in the state. Within each selected school, a single classroom was randomly identified from each grade (K-5), and household caregivers of the classroom students and their respective teachers were asked to participate in the survey. Results: In total, 26% (2,188/8,280) of household caregivers and 45% (163/360) of teachers from 48 schools (of the 64 sampled) responded to the survey. Of the 48 participating schools, 27% (13) experienced a school dismissal during the 2009 fall term. Eighty-seven percent (1,806/2,082) of caregivers and 80% (122/152) of teachers thought that the 2009 influenza A H1N1 pandemic was severe, and >90% of both groups indicated that they told their children/students to use NPIs, such as washing hands more often and covering coughs with tissues, to prevent infection with influenza. Conclusions: Knowledge and instruction on the use of NPIs appeared to be high among household caregivers and teachers responding to the survey. Nevertheless, public health officials should continue to explain the public health rationale for NPIs to reduce pandemic influenza. Ensuring this information is communicated to household caregivers and teachers through trusted sources is essential. C1 [Njai, Rashid; Dooyema, Carrie; Sinclair, Julie; Gao, Hongjiang; Rainey, Jeanette J.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Div Global Migrat & Quarantine, Atlanta, GA USA. [Wells, Eden] Univ Michigan, Sch Publ Hlth, Ann Arbor, MI 48109 USA. [Wilkins, Melinda] Michigan State Univ, Program Publ Hlth, E Lansing, MI 48824 USA. [Collins, Jim] Michigan Dept Community Hlth, Bur Epidemiol, Lansing, MI USA. [Shi, Jianrong] Eagle Med Serv, San Antonio, TX 78257 USA. RP Shi, JR (reprint author), Eagle Med Serv, San Antonio, TX 78257 USA. EM hku3@cdc.gov FU Epidemic Intelligence Service (EIS) Training Program at the United States Centers for Disease Control and Prevention FX This survey was supported by the Epidemic Intelligence Service (EIS) Training Program at the United States Centers for Disease Control and Prevention (http://www.cdc.gov/eis/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 22 TC 2 Z9 2 U1 0 U2 7 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD APR 18 PY 2014 VL 9 IS 4 AR e94290 DI 10.1371/journal.pone.0094290 PG 8 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA AG2DP UT WOS:000335226500022 PM 24747300 ER PT J AU Wilken, JA Marquez, P Terashita, D McNary, J Windham, G Materna, B AF Wilken, Jason A. Marquez, Patricia Terashita, Dawn McNary, Jennifer Windham, Gayle Materna, Barbara TI Coccidioidomycosis Among Cast and Crew Members at an Outdoor Television Filming Event - California, 2012 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID OUTBREAK C1 [Wilken, Jason A.; McNary, Jennifer; Windham, Gayle; Materna, Barbara] California Dept Publ Hlth, Sacramento, CA 95814 USA. [Wilken, Jason A.] CDC, Atlanta, GA 30333 USA. [Marquez, Patricia; Terashita, Dawn] Los Angeles Cty Dept Publ Hlth, Los Angeles, CA USA. RP Wilken, JA (reprint author), California Dept Publ Hlth, Sacramento, CA 95814 USA. EM jwilken@cdc.gov NR 8 TC 5 Z9 5 U1 0 U2 3 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD APR 18 PY 2014 VL 63 IS 15 BP 321 EP 324 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AF1VY UT WOS:000334503200001 PM 24739339 ER PT J AU Bashir, M Umar-Tsafe, N Getso, K Kaita, IM Nasidi, A Sani-Gwarzo, N Nguku, P Davis, L Brown, MJ AF Bashir, Muhammed Umar-Tsafe, Nasir Getso, Kabiru Kaita, Ibrahim M. Nasidi, Abdulsalami Sani-Gwarzo, Nasir Nguku, Patrick Davis, Lora Brown, Mary Jean TI Assessment of Blood Lead Levels Among Children Aged <= 5 Years - Zamfara State, Nigeria, June-July 2012 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Bashir, Muhammed; Umar-Tsafe, Nasir; Getso, Kabiru; Kaita, Ibrahim M.] Zamfara State Minist Hlth, Adebka, Nigeria. [Brown, Mary Jean] CDC, Div Emergency & Environm Hlth Serv, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. RP Brown, MJ (reprint author), CDC, Div Emergency & Environm Hlth Serv, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. EM mjb5@cdc.gov NR 9 TC 4 Z9 4 U1 0 U2 3 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD APR 18 PY 2014 VL 63 IS 15 BP 325 EP 327 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AF1VY UT WOS:000334503200002 PM 24739340 ER PT J AU Crim, SM Iwamoto, M Huang, JY Griffin, PM Gilliss, D Cronquist, AB Cartter, M Tobin-D'Angelo, M Blythe, D Smith, K Lathrop, S Zansky, S Cieslak, PR Dunn, J Holt, KG Lance, S Tauxe, R Henao, OL AF Crim, Stacy M. Iwamoto, Martha Huang, Jennifer Y. Griffin, Patricia M. Gilliss, Debra Cronquist, Alicia B. Cartter, Matthew Tobin-D'Angelo, Melissa Blythe, David Smith, Kirk Lathrop, Sarah Zansky, Shelley Cieslak, Paul R. Dunn, John Holt, Kristin G. Lance, Susan Tauxe, Robert Henao, Olga L. TI Incidence and Trends of Infection with Pathogens Transmitted Commonly Through Food - Foodborne Diseases Active Surveillance Network, 10 US Sites, 2006-2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID UNITED-STATES C1 [Crim, Stacy M.; Iwamoto, Martha; Huang, Jennifer Y.; Griffin, Patricia M.; Tauxe, Robert; Henao, Olga L.] CDC, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Gilliss, Debra] California Dept Publ Hlth, Sacramento, CA USA. [Cronquist, Alicia B.] Colorado Dept Publ Hlth & Environm, Arvada, CO USA. [Tobin-D'Angelo, Melissa] Georgia Dept Publ Hlth, Atlanta, GA USA. [Blythe, David] Maryland Dept Hlth & Mental Hyg, Baltimore, MD 21201 USA. [Smith, Kirk] Minnesota Dept Hlth, Minneapolis, MN 55414 USA. [Lathrop, Sarah] Univ New Mexico, Albuquerque, NM 87131 USA. [Zansky, Shelley] New York State Dept Hlth, Albany, NY 12237 USA. [Cieslak, Paul R.] Oregon Hlth Author, Salem, OR USA. [Dunn, John] Tennessee Dept Hlth, Memphis, TN USA. [Holt, Kristin G.] US Food Safety & Inspect Serv, USDA, Washington, DC 20250 USA. [Lance, Susan] US FDA, Ctr Food Safety & Appl Nutr, Rockville, MD 20857 USA. RP Henao, OL (reprint author), CDC, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. EM ohenao@cdc.gov NR 10 TC 79 Z9 80 U1 3 U2 26 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD APR 18 PY 2014 VL 63 IS 15 BP 328 EP 332 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AF1VY UT WOS:000334503200003 PM 24739341 ER PT J AU Nelson, C Hojvat, S Johnson, B Petersen, J Schriefer, M Ben Beard, C Petersen, L Mead, P AF Nelson, Christina Hojvat, Sally Johnson, Barbara Petersen, Jeannine Schriefer, Marty Ben Beard, C. Petersen, Lyle Mead, Paul TI Concerns Regarding a New Culture Method for Borrelia burgdorferi Not Approved for the Diagnosis of Lyme Disease SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Nelson, Christina; Johnson, Barbara; Petersen, Jeannine; Schriefer, Marty; Ben Beard, C.; Petersen, Lyle; Mead, Paul] CDC, Div Vector Borne Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Hojvat, Sally] US FDA, Div Microbiol Devices, Off In Vitro Diagnost & Radiol Hlth, Ctr Devices & Radiol Hlth, Rockville, MD 20857 USA. RP Nelson, C (reprint author), CDC, Div Vector Borne Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. EM wje1@cdc.gov NR 6 TC 11 Z9 11 U1 0 U2 4 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD APR 18 PY 2014 VL 63 IS 15 BP 333 EP 333 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AF1VY UT WOS:000334503200004 PM 24739342 ER PT J AU Vora, NM Osinubi, M Wallace, RM Aman-Oloniyo, A Gbadegesin, YH Sebastian, YK Saliman, OA Niezgoda, M Davis, L Recuenco, S AF Vora, Neil M. Osinubi, Modupe Wallace, Ryan M. Aman-Oloniyo, Abimbola Gbadegesin, Yemi H. Sebastian, Yennan Kerecvel Saliman, Olugbon Abdullateef Niezgoda, Mike Davis, Lora Recuenco, Sergio TI Assessment of Potential Zoonotic Disease Exposure and Illness Related to an Annual Bat Festival - Idanre, Nigeria SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Vora, Neil M.; Wallace, Ryan M.] CDC, EIS Officer, Atlanta, GA 30333 USA. [Osinubi, Modupe; Niezgoda, Mike; Recuenco, Sergio] CDC, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Aman-Oloniyo, Abimbola; Saliman, Olugbon Abdullateef] Field Epidemiol & Lab Training Program, Abuja, Nigeria. [Gbadegesin, Yemi H.; Sebastian, Yennan Kerecvel] Fed Minist Hlth, Abuja, Nigeria. [Davis, Lora] CDC, Global Immunizat Div, Ctr Global Hlth, Atlanta, GA 30333 USA. RP Vora, NM (reprint author), CDC, EIS Officer, Atlanta, GA 30333 USA. EM nvora@cdc.gov NR 6 TC 0 Z9 0 U1 0 U2 6 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD APR 18 PY 2014 VL 63 IS 15 BP 334 EP 334 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AF1VY UT WOS:000334503200005 PM 24739343 ER PT J AU Newton, AE Garrett, N Stroika, SG Halpin, JL Turnsek, M Mody, RK AF Newton, Anna E. Garrett, Nancy Stroika, Steven G. Halpin, Jessica L. Turnsek, Maryann Mody, Rajal K. TI Increase in Vibrio parahaemolyticus Infections Associated with Consumption of Atlantic Coast Shellfish-2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Newton, Anna E.; Garrett, Nancy; Stroika, Steven G.; Halpin, Jessica L.; Turnsek, Maryann; Mody, Rajal K.] CDC, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging Infect & Zoonot Dis, Atlanta, GA 30333 USA. RP Newton, AE (reprint author), CDC, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging Infect & Zoonot Dis, Atlanta, GA 30333 USA. EM ivz9@cdc.gov NR 3 TC 13 Z9 14 U1 0 U2 5 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD APR 18 PY 2014 VL 63 IS 15 BP 335 EP 336 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AF1VY UT WOS:000334503200006 PM 24739344 ER PT J AU Gregg, EW Li, YF Wang, J Burrows, NR Ali, MK Rolka, D Williams, DE Geiss, L AF Gregg, Edward W. Li, Yanfeng Wang, Jing Burrows, Nilka Rios Ali, Mohammed K. Rolka, Deborah Williams, Desmond E. Geiss, Linda TI Changes in Diabetes-Related Complications in the United States, 1990-2010 SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID LOWER-EXTREMITY AMPUTATIONS; US ADULTS; MYOCARDIAL-INFARCTION; PUBLIC-HEALTH; LONG-TERM; TRENDS; METAANALYSIS; INDIVIDUALS; MELLITUS; DISEASE AB Background: Preventive care for adults with diabetes has improved substantially in recent decades. We examined trends in the incidence of diabetes-related complications in the United States from 1990 through 2010. Methods: We used data from the National Health Interview Survey, the National Hospital Discharge Survey, the U.S. Renal Data System, and the U.S. National Vital Statistics System to compare the incidences of lower-extremity amputation, end-stage renal disease, acute myocardial infarction, stroke, and death from hyperglycemic crisis between 1990 and 2010, with age standardized to the U.S. population in the year 2000. Results: Rates of all five complications declined between 1990 and 2010, with the largest relative declines in acute myocardial infarction (-67.8%; 95% confidence interval [CI], -76.2 to -59.3) and death from hyperglycemic crisis (-64.4%; 95% CI, -68.0 to -60.9), followed by stroke and amputations, which each declined by approximately half (-52.7% and -51.4%, respectively); the smallest decline was in end-stage renal disease (-28.3%; 95% CI, -34.6 to -21.6). The greatest absolute decline was in the number of cases of acute myocardial infarction (95.6 fewer cases per 10,000 persons; 95% CI, 76.6 to 114.6), and the smallest absolute decline was in the number of deaths from hyperglycemic crisis (-2.7; 95% CI, -2.4 to -3.0). Rate reductions were larger among adults with diabetes than among adults without diabetes, leading to a reduction in the relative risk of complications associated with diabetes. When expressed as rates for the overall population, in which a change in prevalence also affects complication rates, there was a decline in rates of acute myocardial infarction and death from hyperglycemic crisis (2.7 and 0.1 fewer cases per 10,000, respectively) but not in rates of amputation, stroke, or end-stage renal disease. Conclusions: Rates of diabetes-related complications have declined substantially in the past two decades, but a large burden of disease persists because of the continued increase in the prevalence of diabetes. (Funded by the Centers for Disease Control and Prevention.) C1 [Gregg, Edward W.; Li, Yanfeng; Wang, Jing; Burrows, Nilka Rios; Ali, Mohammed K.; Rolka, Deborah; Williams, Desmond E.; Geiss, Linda] Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA 30341 USA. [Ali, Mohammed K.] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. RP Gregg, EW (reprint author), Ctr Dis Control & Prevent, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy, Atlanta, GA 30341 USA. EM edg7@cdc.gov NR 41 TC 299 Z9 306 U1 3 U2 31 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD APR 17 PY 2014 VL 370 IS 16 BP 1514 EP 1523 DI 10.1056/NEJMoa1310799 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA AF3HE UT WOS:000334601600008 PM 24738668 ER PT J AU Cummings, JF Guerrero, ML Moon, JE Waterman, P Nielsen, RK Jefferson, S Gross, FL Hancock, K Katz, JM Yusibov, V AF Cummings, James F. Guerrero, Melanie L. Moon, James E. Waterman, Paige Nielsen, Robin K. Jefferson, Stacie Gross, F. Liaini Hancock, Kathy Katz, Jacqueline M. Yusibov, Vidadi CA Fraunhofer USA Ctr Mol Biotechnolo TI Safety and immunogenicity of a plant-produced recombinant monomer hemagglutinin-based influenza vaccine derived from influenza A (H1N1)pdm09 virus: A Phase 1 dose-escalation study in healthy adults SO VACCINE LA English DT Article DE Influenza A; H1N1; Recombinant vaccine; Hemagglutinin; Plant-produced ID H5N1 VACCINE; CLINICAL-TRIAL; H1N1 VACCINE; PANDEMIC INFLUENZA; ALUMINUM-HYDROXIDE; RAPID PRODUCTION; IMMUNE-RESPONSE; AVIAN INFLUENZA; A/H5N1 VACCINE; ELDERLY ADULTS AB Background: Novel influenza viruses continue to pose a potential pandemic threat worldwide. In recent years, plants have been used to produce recombinant proteins, including subunit vaccines. A subunit influenza vaccine, HAC1, based on recombinant hemagglutinin from the 2009 pandemic A/California/04/2009 (HI NI) strain of influenza virus, has been manufactured using a plant virus-based transient expression technology in Nicotiana benthamiana plants and demonstrated to be immunogenic and safe in pre-clinical studies (Shoji et al., 2011). Methods: A first-in-human, Phase 1, single-center, randomized, placebo-controlled, single-blind, dose escalation study was conducted to investigate safety, reactogenicity and immunogenicity of an HAC1 formulation at three escalating dose levels (15 mu g, 45 mu g and 90 mu g) with and without Alhydrogel (R), in healthy adults 18-50 years of age (inclusive). Eighty participants were randomized into six study vaccine groups, a saline placebo group and an approved monovalent H1N1 vaccine group. Recipients received two doses of vaccine or placebo (except for the monovalent HI NI vaccine cohort, which received a single dose of vaccine, later followed by a dose of placebo). Results: The experimental vaccine was safe and well tolerated, and comparable to placebo and the approved monovalent HI NI vaccine. Pain and tenderness at the injection site were the only local solicited reactions reported following vaccinations. Nearly all adverse events were mild to moderate in severity. The HAC1 vaccine was also immunogenic, with the highest seroconversion rates, based on serum hemagglutination-inhibition and virus microneutralization antibody titers, in the 90 mu g non-adjuvanted HAC1 vaccine group after the second vaccine dose (78% and 100%, respectively). Conclusions: This is the first study demonstrating the safety and immunogenicity of a plant-produced subunit HI NI influenza vaccine in healthy adults. The results support further clinical investigation of the HAC1 vaccine as well as demonstrate the feasibility of the plant-based technology for vaccine antigen production. (C) 2014 Published by Elsevier Ltd. C1 [Cummings, James F.; Guerrero, Melanie L.; Moon, James E.; Waterman, Paige; Nielsen, Robin K.] Walter Reed Army Inst Res, Silver Spring, MD 20910 USA. [Jefferson, Stacie; Gross, F. Liaini; Hancock, Kathy; Katz, Jacqueline M.] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Yusibov, Vidadi] Fraunhofer USA Ctr Mol Biotechnol, Newark, DE 19711 USA. RP Cummings, JF (reprint author), Walter Reed Army Inst Res, 503 Robert Grant Ave, Silver Spring, MD 20910 USA. EM james.f.cummings6.mil@mail.mil RI Moon, James/B-6810-2011 OI Moon, James/0000-0002-9274-4554 FU Defense Advanced Research Projects Agency (DARPA); DARPA [HR0011-10-C-0051] FX The HAC1 clinical trial and serologic testing were supported by the Defense Advanced Research Projects Agency (DARPA). The cGMP manufacture of HAC1 was supported by DARPA under contract number # HR0011-10-C-0051. NR 45 TC 21 Z9 23 U1 1 U2 15 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD APR 17 PY 2014 VL 32 IS 19 BP 2251 EP 2259 DI 10.1016/j.vaccine.2013.10.017 PG 9 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA AG7XN UT WOS:000335632200017 PM 24126211 ER PT J AU Killeen, GF Seyoum, A Gimnig, JE Stevenson, JC Drakeley, CJ Chitnis, N AF Killeen, Gerry F. Seyoum, Aklilu Gimnig, John E. Stevenson, Jennifer C. Drakeley, Christopher J. Chitnis, Nakul TI Made-to-measure malaria vector control strategies: rational design based on insecticide properties and coverage of blood resources for mosquitoes SO MALARIA JOURNAL LA English DT Review DE Plasmodium; Anopheles; Vector control; Mosquito; Malaria; Target product profile ID TREATED NETS; BEHAVIORAL RESILIENCE; ANOPHELES-ARABIENSIS; HUMAN EXPOSURE; TRANSMISSION; POPULATIONS; PREVENTION; RESISTANCE; IMPACT; TRIAL AB Eliminating malaria from highly endemic settings will require unprecedented levels of vector control. To suppress mosquito populations, vector control products targeting their blood hosts must attain high biological coverage of all available sources, rather than merely high demographic coverage of a targeted resource subset, such as humans while asleep indoors. Beyond defining biological coverage in a measurable way, the proportion of blood meals obtained from humans and the proportion of bites upon unprotected humans occurring indoors also suggest optimal target product profiles for delivering insecticides to humans or livestock. For vectors that feed only occasionally upon humans, preferred animal hosts may be optimal targets for mosquito-toxic insecticides, and vapour-phase insecticides optimized to maximize repellency, rather than toxicity, may be ideal for directly protecting people against indoor and outdoor exposure. However, for vectors that primarily feed upon people, repellent vapour-phase insecticides may be inferior to toxic ones and may undermine the impact of contact insecticides applied to human sleeping spaces, houses or clothing if combined in the same time and place. These concepts are also applicable to other mosquito-borne anthroponoses so that diverse target species could be simultaneously controlled with integrated vector management programmes. Measurements of these two crucial mosquito behavioural parameters should now be integrated into programmatically funded, longitudinal, national-scale entomological monitoring systems to inform selection of available technologies and investment in developing new ones. C1 [Killeen, Gerry F.] Ifakara Hlth Inst, Environm Hlth & Ecol Sci Themat Grp, Morogoro, Tanzania. [Killeen, Gerry F.; Seyoum, Aklilu] Univ Liverpool, Liverpool Sch Trop Med, Vector Biol Dept, Liverpool L3 5QA, Merseyside, England. [Gimnig, John E.] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA 30333 USA. [Stevenson, Jennifer C.; Drakeley, Christopher J.] London Sch Hyg & Trop Med, Fac Infect & Trop Dis, Dept Immunol & Infect, London WC1E 7HT, England. [Stevenson, Jennifer C.] Johns Hopkins Bloomberg Sch Publ Hlth, Johns Hopkins Malaria Res Inst, Baltimore, MD 21205 USA. [Chitnis, Nakul] Swiss Trop & Publ Hlth Inst, Dept Epidemiol & Publ Hlth, Basel, Switzerland. [Chitnis, Nakul] Univ Basel, Basel, Switzerland. [Chitnis, Nakul] NIH, Fogarty Int Ctr, Bethesda, MD 20892 USA. RP Killeen, GF (reprint author), Ifakara Hlth Inst, Environm Hlth & Ecol Sci Themat Grp, Morogoro, Tanzania. EM gkilleen@ihi.or.tz RI Smith, Thomas/B-5569-2015; Chitnis, Nakul/B-3105-2013 OI Smith, Thomas/0000-0002-3650-9381; FU Bill & Melinda Gates Foundation [45114, 52644, OPP1032350] FX We thank Dr K Aultman for stimulating discussions that led to this manuscript, Dr T Burkot and Dr D Malone for comments upon an early draft, and two anonymous reviewers whose insightful comments significantly improved the final text and figures. This work was funded by the Bill & Melinda Gates Foundation (award numbers 45114, 52644 and OPP1032350). NR 65 TC 13 Z9 13 U1 0 U2 21 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1475-2875 J9 MALARIA J JI Malar. J. PD APR 16 PY 2014 VL 13 AR 146 DI 10.1186/1475-2875-13-146 PG 9 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA AL8AA UT WOS:000339357700001 PM 24739261 ER PT J AU Greig, J Thurtle, N Cooney, L Ariti, C Ahmed, AO Ashagre, T Ayela, A Chukwumalu, K Criado-Perez, A Gomez-Restrepo, C Meredith, C Neri, A Stellmach, D Sani-Gwarzo, N Nasidi, A Shanks, L Dargan, PI AF Greig, Jane Thurtle, Natalie Cooney, Lauren Ariti, Cono Ahmed, Abdulkadir Ola Ashagre, Teshome Ayela, Anthony Chukwumalu, Kingsley Criado-Perez, Alison Gomez-Restrepo, Camilo Meredith, Caitlin Neri, Antonio Stellmach, Darryl Sani-Gwarzo, Nasir Nasidi, Abdulsalami Shanks, Leslie Dargan, Paul I. TI Association of Blood Lead Level with Neurological Features in 972 Children Affected by an Acute Severe Lead Poisoning Outbreak in Zamfara State, Northern Nigeria SO PLOS ONE LA English DT Article ID MU-G/DL; EXPOSURE; ENCEPHALOPATHY; HEALTH; CHINA; PRESSURE; SUCCIMER; CADMIUM; THERAPY; FALL AB Background: In 2010, Medecins Sans Frontieres (MSF) investigated reports of high mortality in young children in Zamfara State, Nigeria, leading to confirmation of villages with widespread acute severe lead poisoning. In a retrospective analysis, we aimed to determine venous blood lead level (VBLL) thresholds and risk factors for encephalopathy using MSF programmatic data from the first year of the outbreak response. Methods and Findings: We included children aged <= 5 years with VBLL >= 45 mu g/dL before any chelation and recorded neurological status. Odds ratios (OR) for neurological features were estimated; the final model was adjusted for age and baseline VBLL, using random effects for village of residence. 972 children met inclusion criteria: 885 (91%) had no neurological features; 34 (4%) had severe features; 47 (5%) had reported recent seizures; and six (1%) had other neurological abnormalities. The geometric mean VBLLs for all groups with neurological features were >100 mu g/dL vs 65.9 mu g/dL for those without neurological features. The adjusted OR for neurological features increased with increasing VBLL: from 2.75, 95%CI 1.27-5.98 (80-99.9 mu g/dL) to 22.95, 95%CI 10.54-49.96 (>= 120 mu g/dL). Neurological features were associated with younger age (OR 4.77 [95% CI 2.50-9.11] for 1-<2 years and 2.69 [95% CI 1.15-6.26] for 2-<3 years, both vs 3-5 years). Severe neurological features were seen at VBLL,105 mg/dL only in those with malaria. Interpretation: Increasing VBLL (from >= 80 mu g/dL) and age 1-<3 years were strongly associated with neurological features; in those tested for malaria, a positive test was also strongly associated. These factors will help clinicians managing children with lead poisoning in prioritising therapy and developing chelation protocols. C1 [Greig, Jane] Med Sans Frontieres, Manson Unit, London, England. [Thurtle, Natalie; Cooney, Lauren; Shanks, Leslie; Dargan, Paul I.] Med Sans Frontieres, Dept Publ Hlth, Amsterdam, Netherlands. [Ariti, Cono] London Sch Hyg & Trop Med, Dept Med Stat, London WC1, England. [Ahmed, Abdulkadir Ola; Ashagre, Teshome; Ayela, Anthony; Chukwumalu, Kingsley; Criado-Perez, Alison; Gomez-Restrepo, Camilo; Meredith, Caitlin; Stellmach, Darryl] Med Sans Frontieres, Nigeria Miss, Sokoto, Niger. [Neri, Antonio] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA. [Stellmach, Darryl] Univ Oxford, Inst Social & Cultural Anthropol, Oxford, England. [Sani-Gwarzo, Nasir] Fed Minist Hlth, Dept Publ Hlth, Abuja, Nigeria. [Nasidi, Abdulsalami] Nigeria Ctr Dis Control, Abuja, Nigeria. [Dargan, Paul I.] Guys & St Thomas NHS Fdn Trust, London, England. [Dargan, Paul I.] Kings Coll London, London, England. RP Greig, J (reprint author), Med Sans Frontieres, Manson Unit, London, England. EM Jane.Greig@london.msf.org OI Stellmach, Darryl/0000-0003-3845-6874; Greig, Jane/0000-0003-2732-0023 NR 48 TC 7 Z9 7 U1 2 U2 7 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD APR 16 PY 2014 VL 9 IS 4 AR e93716 DI 10.1371/journal.pone.0093716 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA AI4VW UT WOS:000336863900025 PM 24740291 ER PT J AU Cauchemez, S Van Kerkhove, MD Archer, BN Cetron, M Cowling, BJ Grove, P Hunt, D Kojouharova, M Kon, P Ungchusak, K Oshitani, H Pugliese, A Rizzo, C Saour, G Sunagawa, T Uzicanin, A Wachtel, C Weisfuse, I Yu, HJ Nicoll, A AF Cauchemez, Simon Van Kerkhove, Maria D. Archer, Brett N. Cetron, Martin Cowling, Benjamin J. Grove, Peter Hunt, Darren Kojouharova, Mira Kon, Predrag Ungchusak, Kumnuan Oshitani, Hitoshi Pugliese, Andrea Rizzo, Caterina Saour, Guillaume Sunagawa, Tomimase Uzicanin, Amra Wachtel, Claude Weisfuse, Isaac Yu, Hongjie Nicoll, Angus TI School closures during the 2009 influenza pandemic: national and local experiences SO BMC INFECTIOUS DISEASES LA English DT Article ID UNITED-STATES; HONG-KONG; INTERVENTIONS; EPIDEMIC; OUTBREAK; IMPACT AB Background: School closure is a non-pharmaceutical intervention that was considered in many national pandemic plans developed prior to the start of the influenza A(H1N1)pdm09 pandemic, and received considerable attention during the event. Here, we retrospectively review and compare national and local experiences with school closures in several countries during the A(H1N1) pdm09 pandemic. Our intention is not to make a systematic review of country experiences; rather, it is to present the diversity of school closure experiences and provide examples from national and local perspectives. Methods: Data were gathered during and following a meeting, organized by the European Centres for Disease Control, on school closures held in October 2010 in Stockholm, Sweden. A standard data collection form was developed and sent to all participants. The twelve participating countries and administrative regions (Bulgaria, China, France, Hong Kong Special Administrative Region (SAR), Italy, Japan, New Zealand, Serbia, South Africa, Thailand, United Kingdom, and United States) provided data. Results: Our review highlights the very diverse national and local experiences on school closures during the A (H1N1) pdm09 pandemic. The processes including who was in charge of making recommendations and who was in charge of making the decision to close, the school-based control strategies, the extent of school closures, the public health tradition of responses and expectations on school closure varied greatly between countries. Our review also discusses the many challenges associated with the implementation of this intervention and makes recommendations for further practical work in this area. Conclusions: The single most important factor to explain differences observed between countries may have been the different public health practises and public expectations concerning school closures and influenza in the selected countries. C1 [Cauchemez, Simon; Van Kerkhove, Maria D.] Univ London Imperial Coll Sci Technol & Med, Sch Publ Hlth, MRC Ctr Outbreak Anal & Modelling, Dept Infect Dis Epidemiol, London, England. [Cauchemez, Simon] Inst Pasteur, Math Modelling Infect Dis Unit, F-75724 Paris 15, France. [Archer, Brett N.] Natl Hlth Lab Serv, Natl Inst Communicable Dis, Johannesburg, South Africa. [Cetron, Martin; Uzicanin, Amra] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Dis, Atlanta, GA USA. [Cowling, Benjamin J.] Univ Hong Kong, Li Ka Shing Fac Med, Sch Publ Hlth, Hong Kong, Hong Kong, Peoples R China. [Grove, Peter] Dept Hlth, London SE1 6TE, England. [Hunt, Darren] New Zealand Minist Hlth, Off Director Publ Hlth, Wellington, New Zealand. [Kojouharova, Mira] Natl Ctr Infect & Parasit Dis, Sofia, Bulgaria. [Kon, Predrag] City Inst Publ Hlth Belgrade, Ctr Dis Control & Prevent, Belgrade, Serbia. [Ungchusak, Kumnuan] Minist Publ Hlth, Dept Dis Control, Nonthaburi, Thailand. [Oshitani, Hitoshi] Tohoku Univ, Grad Sch Med, Dept Virol, Tokyo, Japan. [Pugliese, Andrea] Univ Trento, Dipartimento Matemat, Trento, Italy. [Rizzo, Caterina] Ist Super Sanita, Natl Ctr Epidemiol Surveillance & Hlth Promot, I-00161 Rome, Italy. [Saour, Guillaume] Minist Interieur, Paris, France. [Sunagawa, Tomimase] Natl Inst Infect Dis, Infect Dis Surveillance Ctr, Sendai, Miyagi, Japan. [Wachtel, Claude] Secretariat Gen Def & Secur Natl Prime Minist Off, Paris, France. [Weisfuse, Isaac] Dept Hlth & Mental Hyg, New York, NY USA. [Yu, Hongjie] Chinese Ctr Dis Control & Prevent, Div Infect Dis Control & Prevent, Beijing, Peoples R China. [Nicoll, Angus] European Ctr Dis Prevent & Control, Stockholm, Sweden. RP Cauchemez, S (reprint author), Univ London Imperial Coll Sci Technol & Med, Sch Publ Hlth, MRC Ctr Outbreak Anal & Modelling, Dept Infect Dis Epidemiol, London, England. EM simon.cauchemez@pasteur.fr RI Pugliese, Andrea/E-1905-2011; OI Rizzo, Caterina/0000-0002-5583-7508; Pugliese, Andrea/0000-0002-3512-8560 FU Sanofi Pasteur MSD; MedImmune Inc.; Sanofi Pasteur FX SC received consulting fees from Sanofi Pasteur MSD. BJC received research funding from MedImmune Inc. and Sanofi Pasteur, and consults for Crucell NV. There are no other competing interests to declare. NR 35 TC 3 Z9 3 U1 1 U2 6 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2334 J9 BMC INFECT DIS JI BMC Infect. Dis. PD APR 16 PY 2014 VL 14 AR 207 DI 10.1186/1471-2334-14-207 PG 11 WC Infectious Diseases SC Infectious Diseases GA AG5QV UT WOS:000335474500003 PM 24739814 ER PT J AU Langa, J Sousa, C Sidat, M Kroeger, K McLellan-Lemal, E Belani, H Patel, S Shodell, D Shodell, M Benech, I Needle, R AF Langa, Judite Sousa, Cesar Sidat, Mohsin Kroeger, Karen McLellan-Lemal, Eleanor Belani, Hrishikesh Patel, Shama Shodell, Daniel Shodell, Michael Benech, Irene Needle, Richard TI HIV Risk Perception and Behavior among Sex Workers in Three Major Urban Centers of Mozambique SO PLOS ONE LA English DT Article ID RAPID ASSESSMENT; SOUTH-AFRICA; CONDOM USE; INFECTION; CITIES; DURBAN; INDIA AB HIV risk perceptions and behaviors of 236 commercial sex workers from three major Mozambican urban centers were studied using the International Rapid Assessment, Response and Evaluation (I-RARE) methodology. All were offered HIV testing and, in Maputo, syphilis testing was offered as well. Sixty-three of the 236 opted for HIV testing, with 30 (48%) testing positive for HIV. In Maputo, all 30 receiving HIV tests also had syphilis testing, with 6 (20%) found to be positive. Results include interview excerpts and qualitative results using I-RARE methodology and AnSWR-assisted analyses of the interviews and focus group sessions. C1 [Langa, Judite; Shodell, Daniel] Ctr Dis Control & Prevent, Maputo, Mozambique. [Sousa, Cesar; Sidat, Mohsin] Eduardo Mondlane Univ, Fac Med, Maputo, Mozambique. [Kroeger, Karen; McLellan-Lemal, Eleanor; Belani, Hrishikesh; Patel, Shama; Benech, Irene] Ctr Dis Control & Prevent, Atlanta, GA USA. [Shodell, Michael] Long Isl Univ, New York, NY 11201 USA. [Needle, Richard] Off Global Aids Coordinator, Washington, DE USA. RP Shodell, M (reprint author), Long Isl Univ, New York, NY 11201 USA. EM gnr8@cdc.gov FU CDC Mozambique FX This study was supported by CDC Mozambique with PEPFAR funds. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 27 TC 4 Z9 4 U1 0 U2 7 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD APR 15 PY 2014 VL 9 IS 4 AR e94838 DI 10.1371/journal.pone.0094838 PG 7 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA AI5PW UT WOS:000336922600094 PM 24736653 ER PT J AU Hales, CM Harpaz, R Bialek, SR AF Hales, Craig M. Harpaz, Rafael Bialek, Stephanie R. TI Links Between Herpes Zoster Incidence and Childhood Varicella Vaccination Response SO ANNALS OF INTERNAL MEDICINE LA English DT Letter C1 [Hales, Craig M.; Harpaz, Rafael; Bialek, Stephanie R.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Hales, CM (reprint author), Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. NR 5 TC 0 Z9 0 U1 0 U2 0 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD APR 15 PY 2014 VL 160 IS 8 BP 582 EP 583 DI 10.7326/L14-5008-6 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA AG0ZE UT WOS:000335143700017 PM 24733210 ER PT J AU Mahajan, R Xing, J Liu, SJ Ly, KN Moorman, AC Rupp, L Xu, FJ Holmberg, SD AF Mahajan, Reena Xing, Jian Liu, Stephen J. Ly, Kathleen N. Moorman, Anne C. Rupp, Loralee Xu, Fujie Holmberg, Scott D. CA Chronic Hepatitis Cohort Study CHe TI Mortality Among Persons in Care With Hepatitis C Virus Infection: The Chronic Hepatitis Cohort Study (CHeCS), 2006-2010 SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE hepatitis C virus; mortality; liver disease; cause of death. ID NON-HODGKIN-LYMPHOMA; UNITED-STATES; DIABETES-MELLITUS; VIRAL-HEPATITIS; ALL-CAUSE; RISK; LIVER; POPULATION; FIBROSIS; DISEASE AB Background. The number of deaths in hepatitis C virus (HCV)-infected persons recorded on US death certificates has been increasing, but actual rates and causes of death in these individuals have not been well elucidated. Methods. Disease-specific, liver-related, and non-liver-related mortality data for HCV-infected patients in an observational cohort study, the Chronic Hepatitis Cohort Study (CHeCS) at 4 US healthcare systems, were compared with multiple cause of death (MCOD) data in 12 million death certificates in 2006-2010. Premortem diagnoses, liver biopsies, and FIB-4 scores (a noninvasive measure of liver damage) were examined. Results. Of 2 143 369 adult patients seen at CHeCS sites in 2006-2010, 11 703 (0.5%) had diagnosed chronic HCV infection, and 1590 (14%) died. The majority of CHeCS decedents were born from 1945 to 1965 (75%), white (50%), and male (68%); mean age of death was 59 years, 15 years younger than MCOD deaths. The age-adjusted mortality rate for liver disease in CHeCS was 12 times higher than the MCOD rate. Before death, 63% of decedents had medical record evidence of chronic liver disease, 76% had elevated FIB-4 scores, and, among those biopsied, 70% had moderate or worse liver fibrosis. However, only 19% of all CHeCS decedents and only 30% of those with recorded liver disease had HCV listed on their death certificates. Conclusions. HCV infection is greatly underdocumented on death certificates. The 16 622 persons with HCV listed in 2010 may represent only one-fifth of about 80 000 HCV-infected persons dying that year, at least two-thirds of whom (53 000 patients) would have had premortem indications of chronic liver disease. C1 [Mahajan, Reena; Xing, Jian; Liu, Stephen J.; Ly, Kathleen N.; Moorman, Anne C.; Xu, Fujie; Holmberg, Scott D.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Rupp, Loralee] Henry Ford Hlth Syst, Detroit, MI USA. RP Mahajan, R (reprint author), Ctr Dis Control & Prevent, Div Viral Hepatitis, 1600 Clifton Rd,Mailstop G-37, Atlanta, GA 30333 USA. EM rmahajan1120@yahoo.com FU CDC Foundation; AbbVie; Abbott Laboratories; Genentech (a member of the Roche Group); Johnson Johnson; Vertex Pharmaceuticals; Gilead Sciences; Bristol-Myers Squibb FX CHeCS is funded by the CDC Foundation, which receives grants from AbbVie, Abbott Laboratories, Genentech (a member of the Roche Group), Janssen Pharmaceutical Companies of Johnson & Johnson, and Vertex Pharmaceuticals. Partial current and past funders include Gilead Sciences and Bristol-Myers Squibb. NR 35 TC 37 Z9 37 U1 0 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD APR 15 PY 2014 VL 58 IS 8 BP 1055 EP 1061 DI 10.1093/cid/ciu077 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA AE6OP UT WOS:000334113700008 PM 24523214 ER PT J AU Ogbuanu, IU Zeko, S Chu, SY Muroua, C Gerber, S De Wee, R Kretsinger, K Wannemuehler, K Gerndt, K Allies, M Sandhu, HS Goodson, JL AF Ogbuanu, Ikechukwu U. Zeko, Sikota Chu, Susan Y. Muroua, Clementine Gerber, Sue De Wee, Roselina Kretsinger, Katrina Wannemuehler, Kathleen Gerndt, Krysta Allies, Martina Sandhu, Hardeep S. Goodson, James L. TI Maternal, Fetal, and Neonatal Outcomes Associated With Measles During Pregnancy: Namibia, 2009-2010 SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE measles; pregnancy; maternal morbidity; neonatal outcome; fetal outcome. ID VIRUS DISEASES; AFRICA; EPIDEMIOLOGY; INFECTION; GREENLAND; MORTALITY; HEPATITIS AB Background. Previous studies of maternal, fetal, and neonatal complications of measles during pregnancy suggest the possibility of increased risk for morbidity and mortality. In 2009-2011, a nationwide laboratory-confirmed measles outbreak occurred in Namibia, with 38% of reported cases among adults. This outbreak provided an opportunity to describe clinical features of measles in pregnant women and assess the relative risk for adverse maternal, fetal, and neonatal outcomes. Methods. A cohort of pregnant women with clinical measles was identified retrospectively from 6 district hospitals and clinics over a 12-month period. Each pregnant woman with measles was matched with 3 pregnant women without measles, randomly selected from antenatal clinic registers at the same hospital during the same time interval. We reviewed hospital and clinic records and conducted in-person interviews to collect demographic and clinical information on the pregnant women and their infants. Results. Of 55 pregnant women with measles, 53 (96%) were hospitalized; measles-related complications included diarrhea (60%), pneumonia (40%), and encephalitis (5%). Among pregnant women with known human immunodeficiency virus (HIV) status, 15% of those without measles and 19% of those with measles were HIV positive. Of 42 measles-related pregnancies with known outcomes, 25 (60%) had = 1 adverse maternal, fetal, or neonatal outcome and 5 women (12%) died. Compared with 172 pregnancies without measles, after adjusting for age, pregnancies with measles carried significantly increased risks for neonatal low birth weight (adjusted relative risk [ aRR] = 3.5; 95% confidence interval [ CI], 1.5-8.2), spontaneous abortion (aRR = 5.9; 95% CI, 1.8-19.7), intrauterine fetal death (aRR = 9.0; 95% CI, 1.2-65.5), and maternal death (aRR = 9.6; 95% CI, 1.3-70.0). Conclusions. Our findings suggest that measles virus infection during pregnancy confers a high risk of adverse maternal, fetal, and neonatal outcomes, including maternal death. Maximizing measles immunity among women of childbearing age would decrease the incidence of gestational measles and the attendant maternal, fetal, and neonatal morbidity and mortality. C1 [Ogbuanu, Ikechukwu U.; Chu, Susan Y.; Kretsinger, Katrina; Wannemuehler, Kathleen; Sandhu, Hardeep S.; Goodson, James L.] Ctr Dis Control & Prevent, Global Immunizat Div, Atlanta, GA 30333 USA. [Zeko, Sikota; Muroua, Clementine; Allies, Martina] US Ctr Dis Control & Prevent Namibia, Minist Hlth & Social Serv Namibia, Windhoek, Namibia. [Gerber, Sue; Gerndt, Krysta] US Ctr Dis Control & Prevent Namibia, Div Global HIV AIDS, Windhoek, Namibia. [De Wee, Roselina] WHO, Namibia Country Off, Windhoek, Namibia. [Gerndt, Krysta] Assoc Sch & Programs Publ Hlth, Washington, DC USA. RP Ogbuanu, IU (reprint author), Ctr Dis Control & Prevent, Global Immunizat Div, 1600 Clifton Rd NE,MS A04, Atlanta, GA 30333 USA. EM ige2@cdc.gov FU President's Emergency Plan for AIDS Relief through the CDC-Namibia office; WHO; Namibia MOHSS FX This work was supported by the President's Emergency Plan for AIDS Relief through the CDC-Namibia office; WHO; and the Namibia MOHSS. NR 28 TC 11 Z9 12 U1 0 U2 8 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD APR 15 PY 2014 VL 58 IS 8 BP 1086 EP 1092 DI 10.1093/cid/ciu037 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA AE6OP UT WOS:000334113700013 PM 24457343 ER PT J AU Wang, C Yu, HJ Horby, PW Cao, B Wu, P Yang, SG Gao, HN Li, H Tsang, TK Liao, QH Gao, ZC Ip, DKM Jia, HY Jiang, H Liu, B Ni, MY Dai, XH Liu, FF Kinh, NV Liem, NT Hien, TT Li, Y Yang, J Wu, JT Zheng, YM Leung, GM Farrar, JJ Cowling, BJ Uyeki, TM Li, LJ AF Wang, Chen Yu, Hongjie Horby, Peter W. Cao, Bin Wu, Peng Yang, Shigui Gao, Hainv Li, Hui Tsang, Tim K. Liao, Qiaohong Gao, Zhancheng Ip, Dennis K. M. Jia, Hongyu Jiang, Hui Liu, Bo Ni, Michael Y. Dai, Xiahong Liu, Fengfeng Nguyen Van Kinh Nguyen Thanh Liem Tran Tinh Hien Li, Yu Yang, Juan Wu, Joseph T. Zheng, Yaming Leung, Gabriel M. Farrar, Jeremy J. Cowling, Benjamin J. Uyeki, Timothy M. Li, Lanjuan TI Comparison of Patients Hospitalized With Influenza A Subtypes H7N9, H5N1, and 2009 Pandemic H1N1 SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE influenza A(H7N9); influenza A(H5N1); clinical epidemiology. ID VIRUS-INFECTION; A(H7N9) VIRUS; CHINA; DISEASE; PREVALENCE; FERRETS; POPULATION; HUMANS; TRANSMISSION; PATHOGENESIS AB Background. Influenza A(H7N9) viruses isolated from humans show features suggesting partial adaptation to mammals. To provide insights into the pathogenesis of H7N9 virus infection, we compared risk factors, clinical presentation, and progression of patients hospitalized with H7N9, H5N1, and 2009 pandemic H1N1 (pH1N1) virus infections. Methods. We compared individual-level data from patients hospitalized with infection by H7N9 (n = 123), H5N1 (n = 119; 43 China, 76 Vietnam), and pH1N1 (n = 3486) viruses. We assessed risk factors for hospitalization after adjustment for age-and sex-specific prevalence of risk factors in the general Chinese population. Results. The median age of patients with H7N9 virus infection was older than other patient groups (63 years; P <.001) and a higher proportion was male (71%; P <.02). After adjustment for age and sex, chronic heart disease was associated with an increased risk of hospitalization with H7N9 (relative risk, 9.68; 95% confidence interval, 5.24-17.9). H7N9 patients had similar patterns of leukopenia, thrombocytopenia, and elevated alanine aminotransferase, creatinine kinase, C-reactive protein, and lactate dehydrogenase to those seen in H5N1 patients, which were all significantly different from pH1N1 patients (P <.005). H7N9 patients had a longer duration of hospitalization than either H5N1 or pH1N1 patients (P <.001), and the median time from onset to death was 18 days for H7N9 (P =.002) vs 11 days for H5N1 and 15 days for pH1N1 (P =.154). Conclusions. The identification of known risk factors for severe seasonal influenza and the more protracted clinical course compared with that of H5N1 suggests that host factors are an important contributor to H7N9 severity. C1 [Wang, Chen] Capital Med Univ, Inst Resp Med, Beijing Hosp, Natl Hlth & Family Planning Commiss, Beijing, Peoples R China. [Wang, Chen] Capital Med Univ, Dept Resp Med, Beijing, Peoples R China. [Wang, Chen] Chinese Ctr Dis Control & Prevent, Beijing Inst Resp Med, Beijing, Peoples R China. [Wang, Chen] Chinese Ctr Dis Control & Prevent, Beijing Key Lab Resp & Pulm Circulat Disorders, Beijing, Peoples R China. [Yu, Hongjie; Liao, Qiaohong; Jiang, Hui; Liu, Fengfeng; Li, Yu; Yang, Juan; Zheng, Yaming] Chinese Ctr Dis Control & Prevent, Div Infect Dis, Key Lab Surveillance & Early Warning Infect Dis, Beijing, Peoples R China. [Horby, Peter W.; Tran Tinh Hien; Farrar, Jeremy J.] Univ Oxford, Clin Res Unit, Wellcome Trust Major Overseas Programme, Hanoi, Vietnam. [Horby, Peter W.; Farrar, Jeremy J.] Univ Oxford, Nuffield Dept Clin Med, Ctr Trop Med, Oxford, England. [Horby, Peter W.; Farrar, Jeremy J.] Capital Med Univ, Singapore Infect Dis Initiat, Beijing, Peoples R China. [Cao, Bin; Li, Hui; Liu, Bo] Capital Med Univ, Beijing Inst Resp Med, Beijing Chao Yang Hosp, Beijing, Peoples R China. [Wu, Peng; Tsang, Tim K.; Ip, Dennis K. M.; Ni, Michael Y.; Wu, Joseph T.; Leung, Gabriel M.; Cowling, Benjamin J.] Univ Hong Kong, Li Ka Shing Fac Med, Sch Publ Hlth, Div Epidemiol & Biostat, Hong Kong, Hong Kong, Peoples R China. [Yang, Shigui; Gao, Hainv; Jia, Hongyu; Dai, Xiahong; Li, Lanjuan] Collaborat Innovat Ctr Diag & Treatment Infect Di, Hangzhou, Zhejiang, Peoples R China. [Yang, Shigui; Gao, Hainv; Jia, Hongyu; Dai, Xiahong; Li, Lanjuan] Zhejiang Univ, Affiliated Hosp 1, State Key Lab Diag & Treatment Infect Dis, Dept Infect Dis,Coll Med, Hangzhou 310003, Zhejiang, Peoples R China. [Gao, Zhancheng] Peking Univ, Peoples Hosp, Dept Resp & Crit Care Med, Beijing 100871, Peoples R China. [Nguyen Van Kinh] Natl Hosp Trop Dis, Hanoi, Vietnam. [Nguyen Thanh Liem] Natl Hosp Pediat, Hanoi, Vietnam. [Tran Tinh Hien] Hosp Trop Dis, Ho Chi Minh City, Vietnam. [Farrar, Jeremy J.] Univ Oxford, Churchill Hosp, Ctr Trop Med, ISARIC, Oxford, England. [Uyeki, Timothy M.] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. RP Li, LJ (reprint author), Zhejiang Univ, Affiliated Hosp 1, State Key Lab Diag & Treatment Infect Dis, Dept Infect Dis,Coll Med, Hangzhou 310003, Zhejiang, Peoples R China. EM ljli@zju.edu.cn OI Ni, Michael/0000-0002-1217-5858; Farrar, Jeremy/0000-0002-2700-623X; Wu, Peng/0000-0003-1157-9401 FU US National Institutes of Health (Comprehensive International Program for Research on AIDS) [U19 AI51915]; Ministry of Science and Technology, China [2012 ZX10004-201]; National Program for Prevention and Control of human infections by avian-origin H7N9 influenza A virus [KJYJ-2013-01]; National Natural Science Foundation of China [81070005/H0104, 81030032/H19, 81271840]; National Major S & T Research Projects for the Control and Prevention of Major Infectious Diseases in China [2012ZX10004-210, 2012ZX10004-206]; Technology Group Project for Infectious Disease Control of Zhejiang Province [2009R50041]; Fundamental Research Funds for the Central Universities; Wellcome Trust [089276/Z/09/Z, 089276/B/09/Z] FX This study was funded by the US National Institutes of Health (Comprehensive International Program for Research on AIDS, grant number U19 AI51915); the Ministry of Science and Technology, China (grant number 2012 ZX10004-201); the National Program for Prevention and Control of human infections by avian-origin H7N9 influenza A virus (grant number KJYJ-2013-01); the National Natural Science Foundation of China (grant numbers 81070005/H0104, 81030032/H19 and 81271840); the National Major S & T Research Projects for the Control and Prevention of Major Infectious Diseases in China (grant numbers 2012ZX10004-210, 2012ZX10004-206); the Technology Group Project for Infectious Disease Control of Zhejiang Province (grant number 2009R50041); and the Fundamental Research Funds for the Central Universities. P. W. H. is supported by the Wellcome Trust (grant numbers 089276/Z/09/Z and 089276/B/09/Z). NR 34 TC 40 Z9 43 U1 1 U2 21 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD APR 15 PY 2014 VL 58 IS 8 BP 1095 EP 1103 DI 10.1093/cid/ciu053 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA AE6OP UT WOS:000334113700015 PM 24488975 ER PT J AU Tseng, HF Schmid, DS Harpaz, R LaRussa, P Jensen, NJ Rivailler, P Radford, K Folster, J Jacobsen, SJ AF Tseng, Hung Fu Schmid, D. Scott Harpaz, Rafael LaRussa, Philip Jensen, Nancy J. Rivailler, Pierre Radford, Kay Folster, Jennifer Jacobsen, Steven J. TI Herpes Zoster Caused by Vaccine-Strain Varicella Zoster Virus in an Immunocompetent Recipient of Zoster Vaccine SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE herpes zoster; adult vaccination; varicella zoster; virus. ID WILD-TYPE STRAINS; SAFETY PROFILE; OLDER-ADULTS; SEQUENCES; OKA AB We report the first laboratory-documented case of herpes zoster caused by the attenuated varicella zoster virus (VZV) contained in Zostavax in a 68-year-old immunocompetent adult with strong evidence of prior wild-type VZV infection. The complete genome sequence of the isolate revealed that the strain carried 15 of 42 (36%) recognized varicella vaccine-associated single-nucleotide polymorphisms, including all 5 of the fixed vaccine markers present in nearly all of the strains in the vaccine. The case of herpes zoster was relatively mild and resolved without complications. C1 [Tseng, Hung Fu; Jacobsen, Steven J.] Kaiser Permanente So Calif, Dept Res & Evaluat, Pasadena, CA 91101 USA. [Schmid, D. Scott; Harpaz, Rafael; Jensen, Nancy J.; Rivailler, Pierre; Radford, Kay; Folster, Jennifer] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA USA. [LaRussa, Philip] Columbia Univ, Dept Pediat, Coll Phys & Surg, New York, NY 10027 USA. RP Tseng, HF (reprint author), Kaiser Permanente, Dept Res & Evaluat, So Calif Permanente Med Grp, 100 S Los Robles Ave,2nd Floor, Pasadena, CA 91101 USA. EM hung-fu.x.tseng@kp.org OI Jacobsen, Steven/0000-0002-8174-8533 FU NIAID, NIH [5R01AI089930] FX This study was supported by the NIAID, NIH (funding number 5R01AI089930). NR 17 TC 8 Z9 8 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD APR 15 PY 2014 VL 58 IS 8 BP 1125 EP 1128 DI 10.1093/cid/ciu058 PG 4 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA AE6OP UT WOS:000334113700019 PM 24470276 ER PT J AU Vellozzi, C Iqbal, S Broder, K AF Vellozzi, Claudia Iqbal, Shahed Broder, Karen TI Guillain-Barre Syndrome, Influenza, and Influenza Vaccination: The Epidemiologic Evidence SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE Guillain-Barre syndrome; influenza; influenza vaccination. ID PRACTICE RESEARCH DATABASE; SAFETY DATALINK PROJECT; 2009 MONOVALENT VACCINE; A H1N1; UNITED-STATES; CAMPYLOBACTER-JEJUNI; ASSOCIATION; RISK; SURVEILLANCE; INFECTIONS AB Guillain-Barre, syndrome (GBS) is the most common cause of acute flaccid paralysis worldwide, and is thought to be immune-mediated. It is preceded by upper respiratory or gastrointestinal infection in about two-thirds of cases and is associated with some viral infections, including influenza. GBS has also been associated with the 1976 swine-influenza vaccine. Thereafter, some studies have shown a small increased risk of GBS following receipt of seasonal and 2009 H1N1 monovalent influenza vaccines. Studies over the years have also shown an increased risk of GBS following influenza infection, and the magnitude of risk is several times greater than that following influenza vaccination. Because GBS is rare, and even rarer following vaccination, it is difficult to estimate precise risk. We try to shed light on the complex relationship of GBS and its association with influenza and influenza vaccines over the past 35 years. C1 [Vellozzi, Claudia; Iqbal, Shahed; Broder, Karen] Ctr Dis Control & Prevent, Immunizat Safety Off, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. RP Vellozzi, C (reprint author), Ctr Dis Control & Prevent, Immunizat Safety Off, 1600 Clifton Rd NE,MS D-26, Atlanta, GA 30333 USA. EM bno1@cdc.gov NR 45 TC 22 Z9 22 U1 0 U2 5 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD APR 15 PY 2014 VL 58 IS 8 BP 1149 EP 1155 DI 10.1093/cid/ciu005 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA AE6OP UT WOS:000334113700023 PM 24415636 ER PT J AU Althoff, KN Rebeiro, P Brooks, JT Buchacz, K Gebo, K Martin, J Hogg, R Thorne, JE Klein, M Gill, MJ Sterling, TR Yehia, B Silverberg, MJ Crane, H Justice, AC Gange, SJ Moore, R Kitahata, MM Horberg, MA AF Althoff, Keri N. Rebeiro, Peter Brooks, John T. Buchacz, Kate Gebo, Kelly Martin, Jeffrey Hogg, Robert Thorne, Jennifer E. Klein, Marina Gill, M. John Sterling, Timothy R. Yehia, Baligh Silverberg, Michael J. Crane, Heidi Justice, Amy C. Gange, Stephen J. Moore, Richard Kitahata, Mari M. Horberg, Michael A. CA North Amer AIDS Cohort Collaborati TI Disparities in the Quality of HIV Care When Using US Department of Health and Human Services Indicators SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE HIV; quality of care; retention in care; antiretroviral therapy; HIV RNA suppression ID METAANALYSIS; INFECTION; RETENTION AB We estimated US Department of Health and Human Services (DHHS)-approved human immunodeficiency virus (HIV) indicators. Among patients, 71% were retained in care, 82% were prescribed treatment, and 78% had HIV RNA <= 200 copies/mL; younger adults, women, blacks, and injection drug users had poorer outcomes. Interventions are needed to reduce retention-and treatment-related disparities. C1 [Althoff, Keri N.; Rebeiro, Peter; Gebo, Kelly; Thorne, Jennifer E.; Gange, Stephen J.; Moore, Richard] Johns Hopkins Univ, Baltimore, MD USA. [Brooks, John T.; Buchacz, Kate] Ctr Dis Control & Prevent, Atlanta, GA USA. [Martin, Jeffrey] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Hogg, Robert] British Columbia Ctr Excellence HIV AIDS, Vancouver, BC, Canada. [Klein, Marina] McGill Univ, Montreal, PQ, Canada. [Gill, M. John] Univ Calgary, Calgary, AB T2N 1N4, Canada. [Sterling, Timothy R.] Vanderbilt Univ, Nashville, TN 37235 USA. [Yehia, Baligh] Univ Penn, Philadelphia, PA 19104 USA. [Silverberg, Michael J.] Kaiser Permanente No Calif, Oakland, CA USA. [Crane, Heidi; Kitahata, Mari M.] Univ Washington, Seattle, WA 98195 USA. [Justice, Amy C.] Vet Adm Connecticut Healthcare Syst, West Haven, CT USA. [Justice, Amy C.] Yale Univ, West Haven, CT USA. [Horberg, Michael A.] Kaiser Permanente Midatlantic States, Rockville, MD USA. RP Althoff, KN (reprint author), 615 N Wolfe St,Rm E7142, Baltimore, MD 21205 USA. EM kalthoff@jhsph.edu RI Gill, John/G-7083-2016; OI Gill, John/0000-0002-8546-8790; Gange, Stephen/0000-0001-7842-512X; Mayor, Angel M./0000-0002-7705-837X; Rebeiro, Peter/0000-0003-1951-9104; Hogg, Robert/0000-0003-3463-5488 FU National Institutes of Health, USA [U01-AI069918, U01-AA013566, U24-AA020794, U01-AA020790, U01-AI31834, U01-AI34989, U01-AI34993, U01-AI34994, U01-AI35004, U01-AI35039, U01-AI35040, U01-AI35041, U01-AI35042, U01-AI35043, U01-AI37613, U01-AI37984, U01-AI38855, U01-AI38858, U01-AI42590, U01-AI68634, U01-AI68636]; Centers for Disease Control and Prevention, USA; [CDC200-2006-18797]; Agency for Healthcare Research and Quality, USA [90047713]; Health Resources and Services Administration, USA [90051652]; Canadian Institutes of Health Research, Canada [TGF-96118, HCP-97105]; Ontario Ministry of Health and Long Term Care; Government of Alberta, Canada; National Institutes of Health, USA. [U01-AI69432, U01-AI69434, U01-HD32632, U10-EY08057, U10-EY08052, U10-EY08067, UL1-RR024131, UL1-TR000083, U54-MD007587, F31-DA035713, G12-MD007583, K01-AI071754, K01-AI093197, K23 EY013707, K24AI065298]; The National Institutes of Health, USA [P30-AI54999, P30-AI036219, P30-MH62246, R01-CA165937, R01-AA16893, R01-DA11602, R01-DA04334, R01-DA12568, R24-AI067039, R56-AI102622, Z01-CP010214, Z01-CP010176, K24-00432, MO1-RR-00052, N02-CP55504, P30-AI027763, P30-AI094189, P30-AI27757, P30-AI27767, P30-AI50410] FX This work was supported by grants U01-AI069918, U01-AA013566, U24-AA020794, U01-AA020790, U01-AI31834, U01-AI34989, U01-AI34993, U01-AI34994, U01-AI35004, U01-AI35039, U01-AI35040, U01-AI35041, U01-AI35042, U01-AI35043, U01-AI37613, U01-AI37984, U01-AI38855, U01-AI38858, U01-AI42590, U01-AI68634, U01-AI68636, U01-AI69432, U01-AI69434, U01-HD32632, U10-EY08057, U10-EY08052, U10-EY08067, UL1-RR024131, UL1-TR000083, U54-MD007587, F31-DA035713 (P. R.), G12-MD007583, K01-AI071754 (B. R. L.), K01-AI093197 (K. N. A.), K23 EY013707, K24AI065298, K24-00432, MO1-RR-00052, N02-CP55504, P30-AI027763, P30-AI094189, P30-AI27757, P30-AI27767, P30-AI50410, P30-AI54999, P30-AI036219, P30-MH62246, R01-CA165937, R01-AA16893, R01-DA11602, R01-DA04334, R01-DA12568, R24-AI067039, R56-AI102622, Z01-CP010214, and Z01-CP010176 from the National Institutes of Health, USA; contract CDC200-2006-18797 from the Centers for Disease Control and Prevention, USA; contract 90047713 from the Agency for Healthcare Research and Quality, USA; contract 90051652 from the Health Resources and Services Administration, USA; grants TGF-96118, HCP-97105, CBR-86906, and CBR-94036 from the Canadian Institutes of Health Research, Canada; Ontario Ministry of Health and Long Term Care; and the Government of Alberta, Canada. The funding sources did not influence the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation; review; or approval of the manuscript or the decision to submit the manuscript for publication, with the exception of the Centers for Disease Control and Prevention, which did review the manuscript and provide optional feedback prior to submission. NR 13 TC 23 Z9 24 U1 0 U2 5 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD APR 15 PY 2014 VL 58 IS 8 BP 1185 EP 1189 DI 10.1093/cid/ciu044 PG 5 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA AE6OP UT WOS:000334113700028 PM 24463281 ER PT J AU Gounder, PP Bruce, MG Bruden, DJT Singleton, RJ Rudolph, K Hurlburt, DA Hennessy, TW Wenger, J AF Gounder, Prabhu P. Bruce, Michael G. Bruden, Dana J. T. Singleton, Rosalyn J. Rudolph, Karen Hurlburt, Debby A. Hennessy, Thomas W. Wenger, Jay TI Effect of the 13-Valent Pneumococcal Conjugate Vaccine on Nasopharyngeal Colonization by Streptococcus pneumoniae-Alaska, 2008-2012 SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE Streptococcus pneumoniae; conjugate vaccine; nasopharyngeal colonization; Alaska Native people; Alaska ID ANTIMICROBIAL RESISTANCE; INVASIVE DISEASE; CARRIAGE; CHILDREN; SEROTYPES; EPIDEMIOLOGY; NATIVES; TRENDS; IMPACT; FIELD AB Background. In 2010, a 13-valent pneumococcal conjugate vaccine (PCV13) replaced a 7-valent vaccine (PCV7) that contained all PCV7 serotypes plus 6 additional serotypes (PCV6+). We conducted annual surveys from 2008 to 2012 to determine the effect of PCV13 on colonization by pneumococcal serotypes. Methods. We obtained nasopharyngeal swabs for pneumococcal identification and serotyping from residents of all ages at 8 rural villages and children age < 60 months at 2 urban clinics. We conducted interviews/medical records review for all participants. Results. A total of 18 207 nasopharyngeal swabs (rural = 16 098; urban = 2109) were collected. From 2008 to 2012, 84% of rural and 90% of urban children age < 5 years were age-appropriately vaccinated with a PCV. Overall pneumococcal colonization prevalence remained stable among rural (66%) and urban (35%) children age < 5 years, and adults age >= 18 years (14%). Colonization by PCV6+ serotypes declined significantly among rural children age < 5 years, urban children age < 5, and adults age >= 18 over the course of the study (25%-5%, 22%-9%, 22%-6%, respectively). Conclusions. PCV13 was rapidly introduced into the Alaska childhood immunization schedule and reduced colonization by PCV6+ serotypes among children. Unvaccinated adults also experienced comparable reductions in vaccine serotype colonization indicating substantial indirect protection from PCV13. C1 [Gounder, Prabhu P.; Bruce, Michael G.; Bruden, Dana J. T.; Singleton, Rosalyn J.; Rudolph, Karen; Hurlburt, Debby A.; Hennessy, Thomas W.; Wenger, Jay] Ctr Dis Control & Prevent CDC, Arctic Invest Program, Div Preparedness & Emerging Infect, Natl Ctr Emerging & Zoonot Dis, Anchorage, AK 99508 USA. [Singleton, Rosalyn J.] Alaska Native Tribal Hlth Consortium, Anchorage, AK USA. RP Gounder, PP (reprint author), Ctr Dis Control & Prevent CDC, Arctic Invest Program, Div Preparedness & Emerging Infect, Natl Ctr Emerging & Zoonot Dis, 4055 Tudor Ctr Dr, Anchorage, AK 99508 USA. EM iym4@cdc.gov FU Pfizer pharmaceuticals FX This work was supported by an Investigator Originated Project grant from Pfizer pharmaceuticals and through in-kind support from CDC. The findings and conclusions in this report are those of the author(s) and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 29 TC 18 Z9 18 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD APR 15 PY 2014 VL 209 IS 8 BP 1251 EP 1258 DI 10.1093/infdis/jit642 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA AE6MO UT WOS:000334108100015 PM 24273178 ER PT J AU VanWormer, JJ Bateman, AC Irving, SA Kieke, BA Shay, DK Belongia, EA AF VanWormer, Jeffrey J. Bateman, Allen C. Irving, Stephanie A. Kieke, Burney A. Shay, David K. Belongia, Edward A. TI Influenza Vaccination Effectiveness, Unmeasured Confounding, and Immunomodulatory Treatment Reply to Fedson Reply SO JOURNAL OF INFECTIOUS DISEASES LA English DT Letter ID TEST-NEGATIVE DESIGN; SEASON; INFECTIONS; WISCONSIN; VACCINES; OUTCOMES; H1N1 C1 [VanWormer, Jeffrey J.; Kieke, Burney A.; Belongia, Edward A.] Marshfield Clin Res Fdn, Marshfield, WI 54449 USA. [Bateman, Allen C.] Ctr Infect Dis Res, Lusaka, Zambia. [Bateman, Allen C.] Univ N Carolina, Chapel Hill, NC USA. [Irving, Stephanie A.] Kaiser Permanente Ctr Hlth Res, Portland, OR USA. [Shay, David K.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. RP Belongia, EA (reprint author), Marshfield Clin Res Fdn, Epidemiol Res Ctr ML2, 1000 N Oak Ave, Marshfield, WI 54449 USA. EM belongia.edward@marshfieldclinic.org NR 11 TC 1 Z9 1 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD APR 15 PY 2014 VL 209 IS 8 BP 1301 EP 1302 DI 10.1093/infdis/jit810 PG 2 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA AE6MO UT WOS:000334108100023 PM 24342987 ER PT J AU Markowitz, LE Hariri, S Dunne, EF Steinau, M Unger, ER AF Markowitz, Lauri E. Hariri, Susan Dunne, Eileen F. Steinau, Martin Unger, Elizabeth R. TI Previous History and Cigarette Smoking as Interfering Factors for the Effect of Vaccine on Human Papillomavirus Infection SO JOURNAL OF INFECTIOUS DISEASES LA English DT Letter ID UNITED-STATES; NATIONAL-HEALTH; YOUNG-WOMEN; HPV VACCINE; PREVALENCE; IMMUNOGENICITY; FEMALES C1 [Markowitz, Lauri E.; Hariri, Susan; Dunne, Eileen F.] Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div STD Prevent, Atlanta, GA USA. [Steinau, Martin; Unger, Elizabeth R.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Div High Consequence Pathogens & Pathol, Atlanta, GA 30333 USA. RP Markowitz, LE (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd, Atlanta, GA 30333 USA. EM lem2@cdc.gov NR 9 TC 0 Z9 0 U1 1 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD APR 15 PY 2014 VL 209 IS 8 BP 1304 EP 1305 DI 10.1093/infdis/jit837 PG 2 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA AE6MO UT WOS:000334108100026 PM 24368839 ER PT J AU Gurley, ES Salje, H Homaira, N Ram, PK Haque, R Petri, WA Bresee, J Moss, WJ Luby, SP Breysse, P Azziz-Baumgartner, E AF Gurley, Emily S. Salje, Henrik Homaira, Nusrat Ram, Pavani K. Haque, Rashidul Petri, William A., Jr. Bresee, Joseph Moss, William J. Luby, Stephen P. Breysse, Patrick Azziz-Baumgartner, Eduardo TI Indoor Exposure to Particulate Matter and Age at First Acute Lower Respiratory Infection in a Low-Income Urban Community in Bangladesh SO AMERICAN JOURNAL OF EPIDEMIOLOGY LA English DT Article DE acute lower respiratory infection; Bangladesh; child health; particulate matter; survival analysis ID AIR-POLLUTION; PARTICLE MONITOR; YOUNG-CHILDREN; PNEUMONIA; MORTALITY AB The timing of a childs first acute lower respiratory infection (ALRI) is important, because the younger a child is when he or she experiences ALRI, the greater the risk of death. Indoor exposure to particulate matter less than or equal to 2.5 m in diameter (PM2.5) has been associated with increased frequency of ALRI, but little is known about how it may affect the timing of a childs first ALRI. In this study, we aimed to estimate the association between a childs age at first ALRI and indoor exposure to PM2.5 in a low-income community in Dhaka, Bangladesh. We followed 257 children from birth through age 2 years to record their age at first ALRI. Between May 2009 and April 2010, we also measured indoor concentrations of PM2.5 in childrens homes. We used generalized gamma distribution models to estimate the relative age at first ALRI associated with the mean number of hours in which PM2.5 concentrations exceeded 100 g/m(3). Each hour in which PM2.5 levels exceeded 100 g/m(3) was independently associated with a 12 decrease (95 confidence interval: 2, 21; P 0.021) in age at first ALRI. Interventions to reduce indoor exposure to PM2.5 could increase the ages at which children experience their first ALRI in this urban community. C1 [Gurley, Emily S.; Homaira, Nusrat; Haque, Rashidul; Luby, Stephen P.; Azziz-Baumgartner, Eduardo] Int Ctr Diarrhoeal Dis Res, Ctr Communicable Dis, Dhaka 1212, Bangladesh. [Gurley, Emily S.; Salje, Henrik; Petri, William A., Jr.] Johns Hopkins Univ, Dept Epidemiol, Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Breysse, Patrick] Johns Hopkins Univ, Dept Environm Hlth, Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Ram, Pavani K.] SUNY Buffalo, Dept Social & Prevent Med, Sch Publ Hlth & Hlth Profess, Buffalo, NY 14260 USA. [Petri, William A., Jr.] Univ Virginia, Sch Med, Dept Microbiol, Charlottesville, VA 22908 USA. [Petri, William A., Jr.] Univ Virginia, Sch Med, Dept Pathol, Charlottesville, VA 22908 USA. [Bresee, Joseph; Azziz-Baumgartner, Eduardo] Ctr Dis Control & Prevent, Influenza Div, US Dept HHS, Atlanta, GA USA. [Luby, Stephen P.] Ctr Dis Control & Prevent, Global Dis Detect Branch, US Dept HHS, Atlanta, GA USA. RP Gurley, ES (reprint author), Int Ctr Diarrhoeal Dis Res, Ctr Communicable Dis, 68 Shaheed Tajuddin Ahmed Sarani, Dhaka 1212, Bangladesh. EM egurley@icddrb.org RI Gurley, Emily/B-7903-2010; OI Gurley, Emily/0000-0002-8648-9403; Luby, Stephen/0000-0001-5385-899X; Salje, Henrik/0000-0003-3626-4254 FU US Centers for Disease Control and Prevention [U01/CI000628-02]; US National Institutes of Health [5R01 AI043596] FX This study was funded by the US Centers for Disease Control and Prevention (grant U01/CI000628-02) and the US National Institutes of Health (grant 5R01 AI043596). NR 31 TC 5 Z9 5 U1 0 U2 10 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9262 EI 1476-6256 J9 AM J EPIDEMIOL JI Am. J. Epidemiol. PD APR 15 PY 2014 VL 179 IS 8 BP 967 EP 973 DI 10.1093/aje/kwu002 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AE6CI UT WOS:000334075700005 PM 24607596 ER PT J AU Zhang, XY Holt, JB Lu, H Wheaton, AG Ford, ES Greenlund, KJ Croft, JB AF Zhang, Xingyou Holt, James B. Lu, Hua Wheaton, Anne G. Ford, Earl S. Greenlund, Kurt J. Croft, Janet B. TI Multilevel Regression and Poststratification for Small-Area Estimation of Population Health Outcomes: A Case Study of Chronic Obstructive Pulmonary Disease Prevalence Using the Behavioral Risk Factor Surveillance System SO AMERICAN JOURNAL OF EPIDEMIOLOGY LA English DT Article DE Behavioral Risk Factor Surveillance System; chronic obstructive pulmonary disease; multilevel regression and poststratification; population health outcomes; small-area estimation ID UNITED-STATES; PRIORITIZING COMMUNITIES; PUBLIC-OPINION; MODEL; MASSACHUSETTS; DISPARITIES; MORTALITY; OBESITY; US AB A variety of small-area statistical models have been developed for health surveys, but none are sufficiently flexible to generate small-area estimates (SAEs) to meet data needs at different geographic levels. We developed a multilevel logistic model with both state- and nested county-level random effects for chronic obstructive pulmonary disease (COPD) using 2011 data from the Behavioral Risk Factor Surveillance System. We applied poststratification with the (decennial) US Census 2010 counts of census-block population to generate census-block-level SAEs of COPD prevalence which could be conveniently aggregated to all other census geographic units, such as census tracts, counties, and congressional districts. The model-based SAEs and direct survey estimates of COPD prevalence were quite consistent at both the county and state levels. The Pearson correlation coefficient was 0.99 at the state level and ranged from 0.88 to 0.95 at the county level. Our extended multilevel regression modeling and poststratification approach could be adapted for other geocoded national health surveys to generate reliable SAEs for population health outcomes at all administrative and legislative geographic levels of interest in a scalable framework. C1 [Zhang, Xingyou; Holt, James B.; Lu, Hua; Wheaton, Anne G.; Ford, Earl S.; Greenlund, Kurt J.; Croft, Janet B.] Ctr Dis Control & Prevent, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. RP Zhang, XY (reprint author), Ctr Dis Control & Prevent, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway,Mailstop F78, Atlanta, GA 30341 USA. EM gyx8@cdc.gov NR 33 TC 18 Z9 18 U1 1 U2 9 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9262 EI 1476-6256 J9 AM J EPIDEMIOL JI Am. J. Epidemiol. PD APR 15 PY 2014 VL 179 IS 8 BP 1025 EP 1033 DI 10.1093/aje/kwu018 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AE6CI UT WOS:000334075700011 PM 24598867 ER PT J AU Briggs, MA Kalolella, A Bruxvoort, K Wiegand, R Lopez, G Festo, C Lyaruu, P Kenani, M Abdulla, S Goodman, C Kachur, SP AF Briggs, Melissa A. Kalolella, Admirabilis Bruxvoort, Katia Wiegand, Ryan Lopez, Gerard Festo, Charles Lyaruu, Pierre Kenani, Mitya Abdulla, Salim Goodman, Catherine Kachur, S. Patrick TI Prevalence of Malaria Parasitemia and Purchase of Artemisinin-Based Combination Therapies (ACTs) among Drug Shop Clients in Two Regions in Tanzania with ACT Subsidies SO PLOS ONE LA English DT Article ID RAPID DIAGNOSTIC-TESTS; AFFORDABLE MEDICINES FACILITY; SUB-SAHARAN AFRICA; RURAL TANZANIA; ANTIMALARIALS; SERVICES; QUALITY; IMPACT; UGANDA; MODEL AB Background: Throughout Africa, many people seek care for malaria in private-sector drug shops where diagnostic testing is often unavailable. Recently, subsidized artemisinin-based combination therapies (ACTs), a first-line medication for uncomplicated malaria, were made available in these drug shops in Tanzania. This study assessed the prevalence of malaria among and purchase of ACTs by drug shop clients in the setting of a national ACT subsidy program and sub-national drug shop accreditation program. Method and Findings: A cross-sectional survey of drug shop clients was performed in two regions in Tanzania, one with a government drug shop accreditation program and one without, from March-May, 2012. Drug shops were randomly sampled from non-urban districts. Shop attendants were interviewed about their education, training, and accreditation status. Clients were interviewed about their symptoms and medication purchases, then underwent a limited physical examination and laboratory testing for malaria. Malaria prevalence and predictors of ACT purchase were assessed using univariate analysis and multiple logistic regression. Amongst 777 clients from 73 drug shops, the prevalence of laboratory-confirmed malaria was 12% (95% CI: 6-18%). Less than a third of clients with malaria had purchased ACTs, and less than a quarter of clients who purchased ACTs tested positive for malaria. Clients were more likely to have purchased ACTs if the participant was>5 years old (aOR: 6.6; 95% CI: 3.9-11.0) or the shop attendant had>5 years, experience (aOR: 2.8; 95% CI: 1.2-6.3). Having malaria was only a predictor of ACT purchase in the region with a drug shop accreditation program (aOR: 3.4; 95% CI: 1.5-7.4). Conclusion: Malaria is common amongst persons presenting to drug shops with a complaint of fever. The low proportion of persons with malaria purchasing ACTs, and the high proportion of ACTs going to persons without malaria demonstrates a need to better target who receives ACTs in these drug shops. C1 [Briggs, Melissa A.; Wiegand, Ryan; Lopez, Gerard; Kachur, S. Patrick] Ctr Dis Control & Prevent, Malaria Branch, Atlanta, GA 30333 USA. [Kalolella, Admirabilis; Festo, Charles; Lyaruu, Pierre; Kenani, Mitya; Abdulla, Salim] Ifakara Hlth Inst, Dar Es Salaam, Tanzania. [Bruxvoort, Katia; Goodman, Catherine] London Sch Hyg & Trop Med, London WC1, England. RP Briggs, MA (reprint author), Ctr Dis Control & Prevent, Malaria Branch, 4770 Buford Highway,Mail Stop F-12, Atlanta, GA 30333 USA. EM MBriggs1@cdc.gov FU ACT Consortium; Bill & Melinda Gates Foundation FX This research was completed under a cooperative agreement between the US Centers for Disease Control and Prevention (CDC) and Ifakara Health Institute (IHI). Additional support was provided by the ACT Consortium, which is funded through a grant from the Bill & Melinda Gates Foundation to the London School of Hygiene & Tropical Medicine (LSHTM). Investigators from the CDC, IHI, and LSHTM were involved in protocol development, data collection, data analysis, and preparation of this manuscript for publication. NR 43 TC 8 Z9 8 U1 0 U2 4 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD APR 14 PY 2014 VL 9 IS 4 AR e94074 DI 10.1371/journal.pone.0094074 PG 11 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA AI6GP UT WOS:000336970400018 PM 24732258 ER PT J AU Minniear, TD Girde, S Angira, F Mills, LA Zeh, C Peters, PJ Masaba, R Lando, R Thomas, TK Taylor, AW AF Minniear, Timothy D. Girde, Sonali Angira, Frank Mills, Lisa A. Zeh, Clement Peters, Philip J. Masaba, Rose Lando, Richard Thomas, Timothy K. Taylor, Allan W. CA Kisumu Breastfeeding Study Team TI Outcomes in a Cohort of Women Who Discontinued Maternal Triple-Antiretroviral Regimens Initially Used to Prevent Mother-to-Child Transmission during Pregnancy and Breastfeeding-Kenya, 2003-2009 SO PLOS ONE LA English DT Article ID CONTROLLED-TRIAL; HIV-1 INFECTION; THERAPY; SURVIVAL AB Background: In 2012, the World Health Organization (WHO) amended their 2010 guidelines for women receiving limited duration, triple-antiretroviral drug regimens during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV (tARV-PMTCT) (Option B) to include the option to continue lifelong combination antiretroviral therapy (cART) (Option B+). We evaluated clinical and CD4 outcomes in women who had received antiretrovirals for prevention of mother-to-child transmission and then discontinued antiretrovirals 6-months postpartum. Methods and Findings: The Kisumu Breastfeeding Study, 2003-2009, was a prospective, non-randomized, open-label clinical trial of tARV-PMTCT in ARV-naive, Kenyan women. Women received tARV-PMTCT from 34 weeks' gestation until 6-months postpartum when women were instructed to discontinue breastfeeding. Women with CD4 count (CD4) <250cells/mm3 or WHO stage III/IV prior to 6-months postpartum continued cART indefinitely. We estimated the change in CD4 after discontinuing tARV-PMTCT and the adjusted relative risk [aRR] for factors associated with declines in maternal CD4. We compared maternal and infant outcomes following weaning-when tARV-PMTCT discontinued-by maternal ARV status through 24-months postpartum. Compared with women who continued cART, discontinuing antiretrovirals was associated with infant HIV transmission and death (10.1% vs. 2.4%; P = 0.03). Among women who discontinued antiretrovirals, CD4,500 cells/mm3 at either initiation (21.8% vs. 1.5%; P = 0.002; aRR: 9.8; 95%-confidence interval [CI]: 2.4-40.6) or discontinuation (36.9% vs. 8.3%; P<0.0001; aRR: 4.4; 95%-CI: 1.9-5.0) were each associated with increased risk of women requiring cART for their own health within 6 months after discontinuing. Conclusions: Considering the serious health risks to the woman's infant and the brief reprieve from cART gained by stopping, every country should evaluate the need for and feasibility to implement WHO Option B+ for PMTCT. Evaluating CD4 at antiretroviral initiation or 6-months postpartum can identify pregnant women who would most benefit from continuing cART in settings unable to implement WHO Option B+. C1 [Minniear, Timothy D.] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Minniear, Timothy D.; Mills, Lisa A.; Zeh, Clement; Peters, Philip J.; Thomas, Timothy K.; Taylor, Allan W.] CDC, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. [Minniear, Timothy D.] St Jude Childrens Res Hosp, Dept Infect Dis, Memphis, TN 38105 USA. [Girde, Sonali] ICF Int, CDC Informat Management Serv, Atlanta, GA USA. [Angira, Frank; Mills, Lisa A.; Zeh, Clement; Masaba, Rose; Lando, Richard] CDC Res & Publ Hlth Collaborat, Kenya Med Res Inst, Kisumu, Kenya. RP Taylor, AW (reprint author), CDC, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. EM avt0@cdc.gov FU Kenya Medical Research Institute (KEMRI) through US Centers for Disease Control and Prevention (CDC) FX Funding for the study was provided by the Kenya Medical Research Institute (KEMRI) through a cooperative agreement with the US Centers for Disease Control and Prevention (CDC). The study design, data collection instruments, data collection, data analysis, decision to publish, and preparation of the manuscript were led by CDC and KEMRI staff based in Atlanta and at the KEMRI/CDC Research and Public Health Collaboration in Kisumu, Kenya. This publication has been approved by the Director of the Kenya Medical Research Institute. NR 13 TC 2 Z9 2 U1 0 U2 2 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD APR 14 PY 2014 VL 9 IS 4 AR e93556 DI 10.1371/journal.pone.0093556 PG 5 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA AI6GP UT WOS:000336970400008 PM 24733021 ER PT J AU Amer, S Abd El Wahab, T Metwaly, A Ye, JB Roellig, D Feng, YY Xiao, LH AF Amer, Said Abd El Wahab, Taher Metwaly, Abd El Naby Ye, Jianbin Roellig, Dawn Feng, Yaoyu Xiao, Lihua TI Preliminary Molecular Characterizations of Sarcoptes scaibiei (Acari: Sarcoptidae) from Farm Animals in Egypt SO PLOS ONE LA English DT Article ID NORTHERN AUSTRALIA; SCABIES; MITES; MANGE; DISEASE; BIOLOGY; SHEEP; EPIDEMIOLOGY; POPULATIONS; PREVALENCE AB Little is known about the genetic diversity of Sarcoptes scabiei mites in farm animals in Egypt. In this study, we characterized S. scabiei in 25 skin scrapes from water buffalo, cattle, sheep, and rabbits at the nuclear marker ITS2 and mitochondrial markers COX1 and 16S rRNA. Sequences of the ITS2 showed no host segregation or geographical isolation, whereas those of the mitochondrial COX1 and 16S rRNA genes indicated the presence of both host-adapted and geographically segregated populations of S. scabiei. Host adaptation may limit inter-species transmission of. S. scabiei, thus restrict gene flow among S. scabiei from different hosts. This is the first report on the molecular characterization of sarcoptic mites in Egypt. Further genetic studies involving larger numbers of specimens, especially those from humans and companion animals, are needed to understand the molecular epidemiology of sarcoptic mange in Egypt. C1 [Amer, Said; Ye, Jianbin; Roellig, Dawn; Xiao, Lihua] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30333 USA. [Amer, Said] Kafr El Sheikh Univ, Dept Zool, Kafr Al Sheikh, Egypt. [Abd El Wahab, Taher; Metwaly, Abd El Naby] Anim Hlth Res Inst, Kafr El Sheikh Prov Lab, Kafr Al Sheikh, Egypt. [Ye, Jianbin; Feng, Yaoyu] E China Univ Sci & Technol, State Environm Protect Key Lab Environm Risk Asse, Shanghai 200237, Peoples R China. RP Feng, YY (reprint author), Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30333 USA. EM yyfeng@ecust.edu.cn; lxiao@cdc.gov RI Xiao, Lihua/B-1704-2013; Metwaly, Mohamed/H-9450-2012; Feng, Yaoyu/B-3076-2014 OI Xiao, Lihua/0000-0001-8532-2727; Metwaly, Mohamed/0000-0001-8770-0306; FU Arab Fund for Economic and Social Development (Zamalat Program); National Natural Science Foundation of China [31110103901]; Centers for Disease Control and Prevention FX This research was supported by the Arab Fund for Economic and Social Development (Zamalat Program), National Natural Science Foundation of China (Project No. 31110103901), and Centers for Disease Control and Prevention. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 46 TC 7 Z9 7 U1 2 U2 12 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD APR 11 PY 2014 VL 9 IS 4 AR e94705 DI 10.1371/journal.pone.0094705 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA AI3CI UT WOS:000336736200116 PM 24728386 ER PT J AU Ko, SC Schillie, SF Walker, T Veselsky, SL Nelson, NP Lazaroff, J Crowley, S Dusek, C Loggins, K Onye, K Fenlon, N Murphy, TV AF Ko, Stephen C. Schillie, Sarah F. Walker, Tanja Veselsky, Steven L. Nelson, Noele P. Lazaroff, Julie Crowley, Susan Dusek, Cristina Loggins, Khalilah Onye, Kenneth Fenlon, Nancy Murphy, Trudy V. TI Hepatitis B vaccine response among infants born to hepatitis B surface antigen-positive women SO VACCINE LA English DT Article DE Hepatitis B; Antibody response; Perinatal; Vaccine; Immunization ID TERM FOLLOW-UP; CARRIER MOTHERS; PRETERM INFANTS; HEPATOCELLULAR-CARCINOMA; PERINATAL TRANSMISSION; PROTECTIVE EFFICACY; NEWBORN-INFANTS; IMMUNOGENICITY; VIRUS; RISK AB Purpose: Annually, an estimated 25,000 infants are born to hepatitis B surface antigen (HBsAg)-positive women in the United States. Hepatitis B (HepB) vaccine and hepatitis B immune globulin (HBIG) are recommended at birth, followed by completion of vaccine series and post-vaccination serologic testing (PVST). In a large cohort of infants born to HBsAg-positive women, factors influencing vaccine response were evaluated. Methods: Data were from HBsAg-negative infants born to HBsAg-positive women in the Enhanced Perinatal Hepatitis B Prevention Program (EPHBPP) from 2008 to 2013. Vaccine non-responders were defined as infants with antibody to hepatitis B surface antigen (anti-HBs) <10 mIU/mL at PVST after receiving >= 3 vaccine doses. Multivariable analyses modeled statistically significant predictor variables associated with non-response. Results: A total of 17,951 maternal-infant pairs were enrolled; 8654 HBsAg-negative infants born to HBsAg-positive mothers received >= 3 doses of vaccine with anti-HBs results. 8199 (94.7%) infants responded to a primary HepB series; 199 (94.8%) to a second series. Factors associated with anti-HBs <10 mIU/mL included gestational age <37 weeks, vaccine birth dose >12 h afterbirth, timing of final vaccine dose <6 months after birth, receipt of 3 vs. 4 vaccine doses, and PVST interval >6 months from final vaccine dose in bivariate analysis. PVST interval >6 months from final vaccine dose (OR = 2.7, CI = 2.0, 3.6) was significantly associated with anti-HBs <10 mIU/mL; the proportion increased from 2% at 1-2 months to 21.6% at 15-16 months after the final dose. Receipt of a 4th dose improved the response rate (OR = 0.5, CI = 0.3, 0.8). Conclusions: Ninety-five percent of a large cohort of uninfected infants born to HBsAg-positive mothers in the United States responded to primary HepB vaccine series. The proportion of infants with anti-HBs <10 mIU/mL increased with longer interval between the final vaccine dose and PVST. Optimal timing of PVST is within 1-2 months of final vaccine dose to avoid unnecessary revaccination. Published by Elsevier Ltd. C1 [Ko, Stephen C.; Schillie, Sarah F.; Walker, Tanja; Veselsky, Steven L.; Nelson, Noele P.; Murphy, Trudy V.] Ctr Dis Control & Prevent, Div Viral Hepatitis, Natl Ctr HIVAIDS Viral Hepatitis STD & TB Prevent, Atlanta, GA 30333 USA. [Lazaroff, Julie] New York City Dept Hlth & Mental Hyg, New York, NY USA. [Crowley, Susan] Minnesota Dept Hlth, St Paul, MN USA. [Dusek, Cristina] Florida Dept Hlth, Tallahassee, FL USA. [Loggins, Khalilah] Texas Dept State Hlth Serv, Austin, TX USA. [Onye, Kenneth] Michigan Dept Community Hlth, Lansing, MI USA. [Fenlon, Nancy] Ctr Dis Control & Prevent, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Ko, SC (reprint author), Ctr Dis Control & Prevent, Div Viral Hepatitis, Natl Ctr HIVAIDS Viral Hepatitis STD & TB Prevent, Atlanta, GA 30333 USA. EM shk3@cdc.gov FU US Department of Energy; Centers for Disease Control and Prevention FX This research was supported in part by an appointment to the Research Participation Program at the Centers for Disease Control and Prevention administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the US Department of Energy and the Centers for Disease Control and Prevention. NR 41 TC 9 Z9 9 U1 0 U2 10 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD APR 11 PY 2014 VL 32 IS 18 BP 2127 EP 2133 DI 10.1016/j.vaccine.2014.01.099 PG 7 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA AF8QN UT WOS:000334980800017 PM 24560676 ER PT J AU Cox, S Pazol, K Warner, L Romero, L Spitz, A Gavin, L Barfield, W AF Cox, Shanna Pazol, Karen Warner, Lee Romero, Lisa Spitz, Alison Gavin, Lorrie Barfield, Wanda TI Vital Signs: Births to Teens Aged 15-17 Years - United States, 1991-2012 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID ACTING REVERSIBLE CONTRACEPTION; ADOLESCENT PREGNANCY AB Background: Teens who give birth at age 15-17 years are at increased risk for adverse medical and social outcomes of teen pregnancy. Methods: To examine trends in the rate and proportion of births to teens aged 15-19 years that were to teens aged 15-17 years, CDC analyzed 1991-2012 National Vital Statistics System data. National Survey of Family Growth (NSFG) data from 2006-2010 were used to examine sexual experience, contraceptive use, and receipt of prevention opportunities among female teens aged 15-17 years. Results: During 1991-2012, the rate of births per 1,000 teens declined from 17.9 to 5.4 for teens aged 15 years, 36.9 to 12.9 for those aged 16 years, and 60.6 to 23.7 for those aged 17 years. In 2012, the birth rate per 1,000 teens aged 15-17 years was higher for Hispanics (25.5), non-Hispanic blacks (21.9), and American Indians/Alaska Natives (17.0) compared with non-Hispanic whites (8.4) and Asians/Pacific Islanders (4.1). The rate also varied by state, ranging from 6.2 per 1,000 teens aged 15-17 years in New Hampshire to 29.0 in the District of Columbia. In 2012, there were 86,423 births to teens aged 15-17 years, accounting for 28% of all births to teens aged 15-19 years. This percentage declined from 36% in 1991 to 28% in 2012 (p<0.001). NSFG data for 2006-2010 indicate that although 91% of female teens aged 15-17 years received formal sex education on birth control or how to say no to sex, 24% had not spoken with parents about either topic; among sexually experienced female teens, 83% reported no formal sex education before first sex. Among currently sexually active female teens (those who had sex within 3 months of the survey) aged 15-17 years, 58% used clinical birth control services in the past 12 months, and 92% used contraception at last sex; however, only 1% used the most effective reversible contraceptive methods. Conclusions: Births to teens aged 15-17 years have declined but still account for approximately one quarter of births to teens aged 15-19 years. Implications for public health practice: These data highlight opportunities to increase younger teens exposure to interventions that delay initiation of sex and provide contraceptive services for those who are sexually active; these strategies include support for evidence-based programs that reach youths before they initiate sex, resources for parents in talking to teens about sex and contraception, and access to reproductive health-care services. C1 [Cox, Shanna; Pazol, Karen; Warner, Lee; Romero, Lisa; Spitz, Alison; Gavin, Lorrie; Barfield, Wanda] CDC, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP Cox, S (reprint author), CDC, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM cio8@cdc.gov NR 19 TC 0 Z9 0 U1 2 U2 7 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD APR 11 PY 2014 VL 63 IS 14 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AE9TC UT WOS:000334351900004 ER PT J AU Nyangoma, EN Olson, CK Benoit, SR Bos, J DeBolt, C Kay, M Rietberg, K Tasslimi, A Baker, D Feng, XW Lippold, S Blumensaadt, S Schembri, C Vang, A Burke, H Wallace, G Zhou, WG AF Nyangoma, Edith N. Olson, Christine K. Benoit, Stephen R. Bos, John DeBolt, Chas Kay, Meagan Rietberg, Krista Tasslimi, Azadeh Baker, Douglas Feng, Xinwen Lippold, Susan Blumensaadt, Sena Schembri, Christopher Vang, Arnold Burke, Heather Wallace, Gregory Zhou, Weigong TI Measles Outbreak Associated with Adopted Children from China - Missouri, Minnesota, and Washington, July 2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Nyangoma, Edith N.] CDC, Atlanta, GA 30333 USA. [Olson, Christine K.; Benoit, Stephen R.; Lippold, Susan; Blumensaadt, Sena; Schembri, Christopher; Vang, Arnold; Burke, Heather; Zhou, Weigong] CDC, Div Global Migrat & Quarantine, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Bos, John; Baker, Douglas] Missouri Dept Hlth & Senior Serv, Jefferson City, MO USA. [Kay, Meagan; Rietberg, Krista] Publ Hlth Seattle & King Cty, Washington, DC USA. CDC, Div Viral Resp Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Nyangoma, EN (reprint author), CDC, Atlanta, GA 30333 USA. EM xdf9@cdc.gov NR 8 TC 0 Z9 0 U1 0 U2 2 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD APR 11 PY 2014 VL 63 IS 14 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AE9TC UT WOS:000334351900001 ER PT J AU Selik, RM Mokotoff, ED Branson, B Owen, SM Whitmore, S Hall, HI AF Selik, Richard M. Mokotoff, Eve D. Branson, Bernard Owen, S. Michele Whitmore, Suzanne Hall, H. Irene TI Revised Surveillance Case Definition for HIV Infection - United States, 2014 SO MMWR RECOMMENDATIONS AND REPORTS LA English DT Article ID ANTIRETROVIRAL THERAPY; PERCENTAGE AB Following extensive consultation and peer review, CDC and the Council of State and Territorial Epidemiologists have revised and combined the surveillance case definitions for human immunodeficiency virus (HIV) infection into a single case definition for persons of all ages (i. e., adults and adolescents aged >= 13 years and children aged < 13 years). The revisions were made to address multiple issues, the most important of which was the need to adapt to recent changes in diagnostic criteria. Laboratory criteria for defining a confirmed case now accommodate new multitest algorithms, including criteria for differentiating between HIV-1 and HIV-2 infection and for recognizing early HIV infection. A confirmed case can be classified in one of five HIV infection stages ( 0, 1, 2, 3, or unknown); early infection, recognized by a negative HIV test within 6 months of HIV diagnosis, is classified as stage 0, and acquired immunodeficiency syndrome ( AIDS) is classified as stage 3. Criteria for stage 3 have been simplified by eliminating the need to differentiate between definitive and presumptive diagnoses of opportunistic illnesses. Clinical (nonlaboratory) criteria for defining a case for surveillance purposes have been made more practical by eliminating the requirement for information about laboratory tests. The surveillance case definition is intended primarily for monitoring the HIV infection burden and planning for prevention and care on a population level, not as a basis for clinical decisions for individual patients. CDC and the Council of State and Territorial Epidemiologists recommend that all states and territories conduct case surveillance of HIV infection using this revised surveillance case definition. C1 [Selik, Richard M.; Branson, Bernard; Owen, S. Michele; Whitmore, Suzanne; Hall, H. Irene] CDC, Div HIV AIDS Prevent, Natl Ctr HIV AIDS, Viral Hepatitis STD & TB Prevent, Atlanta, GA 30333 USA. [Mokotoff, Eve D.] Michigan Dept Community Hlth, HIV STD VH TB Epidemiol Sect, Flint, MI USA. RP Selik, RM (reprint author), CDC, Div HIV AIDS Prevent, Natl Ctr HIV AIDS, Viral Hepatitis STD & TB Prevent, Atlanta, GA 30333 USA. EM rms1@cdc.gov NR 20 TC 6 Z9 6 U1 1 U2 3 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 1057-5987 EI 1545-8601 J9 MMWR RECOMM REP JI MMWR Recomm. Rep. PD APR 11 PY 2014 VL 63 IS 3 PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AE9TG UT WOS:000334352300001 ER PT J AU Blaya, JA Shin, SS Yagui, M Contreras, C Cegielski, P Yale, G Suarez, C Asencios, L Bayona, J Kim, J Fraser, HSF AF Blaya, Joaquin A. Shin, Sonya S. Yagui, Martin Contreras, Carmen Cegielski, Peter Yale, Gloria Suarez, Carmen Asencios, Luis Bayona, Jaime Kim, Jihoon Fraser, Hamish S. F. TI Reducing Communication Delays and Improving Quality of Care with a Tuberculosis Laboratory Information System in Resource Poor Environments: A Cluster Randomized Controlled Trial SO PLOS ONE LA English DT Article ID MULTIDRUG-RESISTANT TUBERCULOSIS; HIV-INFECTION; MDR-TB; PERU; IMPLEMENTATION; DIAGNOSIS AB Background: Lost, delayed or incorrect laboratory results are associated with delays in initiating treatment. Delays in treatment for Multi-Drug Resistant Tuberculosis (MDR-TB) can worsen patient outcomes and increase transmission. The objective of this study was to evaluate the impact of a laboratory information system in reducing delays and the time for MDR-TB patients to culture convert (stop transmitting). Methods: Setting: 78 primary Health Centers (HCs) in Lima, Peru. Participants lived within the catchment area of participating HCs and had at least one MDR-TB risk factor. The study design was a cluster randomized controlled trial with baseline data. The intervention was the e-Chasqui web-based laboratory information system. Main outcome measures were: times to communicate a result; to start or change a patient's treatment; and for that patient to culture convert. Results: 1671 patients were enrolled. Intervention HCs took significantly less time to receive drug susceptibility test (DST) (median 11 vs. 17 days, Hazard Ratio 0.67 [0.62-0.72]) and culture (5 vs. 8 days, 0.68 [0.65-0.72]) results. The time to treatment was not significantly different, but patients in intervention HCs took 16 days (20%) less time to culture convert (p = 0.047). Conclusions: The eChasqui system reduced the time to communicate results between laboratories and HCs and time to culture conversion. It is now used in over 259 HCs covering 4.1 million people. This is the first randomized controlled trial of a laboratory information system in a developing country for any disease and the only study worldwide to show clinical impact of such a system. C1 [Blaya, Joaquin A.; Shin, Sonya S.; Fraser, Hamish S. F.] Brigham & Womens Hosp, Div Global Hlth Equ, Boston, MA 02115 USA. [Blaya, Joaquin A.] EHlth Syst, Santiago, Chile. [Yagui, Martin; Asencios, Luis] Inst Nacl Salud, Lima, Peru. [Contreras, Carmen; Bayona, Jaime] Socios Salud Sucursal Peru, Lima, Peru. [Cegielski, Peter] Ctr Dis Control & Prevent, Atlanta, GA USA. [Yale, Gloria] DISA V Lima Ciudad, Lima, Peru. [Suarez, Carmen] DISA IV Lima Este, Lima, Peru. [Kim, Jihoon] Univ Calif San Diego, Div Biomed Informat, La Jolla, CA 92093 USA. [Fraser, Hamish S. F.] Partners Hlth, Boston, MA USA. [Fraser, Hamish S. F.] Univ Leeds, Leeds, W Yorkshire, England. RP Fraser, HSF (reprint author), Brigham & Womens Hosp, Div Global Hlth Equ, 75 Francis St, Boston, MA 02115 USA. EM h.fraser@leeds.ac.uk RI Fraser, Hamish/E-3773-2013 FU Harvard Global Infectious Diseases Program; David Rockefeller Center for Latin American Studies; MIT Public Services Center; MIT Hugh Y. Hampton Fellowship; NIH FX This research was supported by grants from the Harvard Global Infectious Diseases Program and David Rockefeller Center for Latin American Studies. JAB received a MIT Public Services Center grant, the MIT Hugh Y. Hampton Fellowship, and a National Research Service Award from the NIH. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 32 TC 3 Z9 3 U1 2 U2 9 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD APR 10 PY 2014 VL 9 IS 4 AR e90110 DI 10.1371/journal.pone.0090110 PG 7 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA AI5LS UT WOS:000336909100004 PM 24721980 ER PT J AU Loveday, M Padayatchi, N Wallengren, K Roberts, J Brust, JCM Ngozo, J Master, I Voce, A AF Loveday, Marian Padayatchi, Nesri Wallengren, Kristina Roberts, Jacquelin Brust, James C. M. Ngozo, Jacqueline Master, Iqbal Voce, Anna TI Association between Health Systems Performance and Treatment Outcomes in Patients Co-Infected with MDR-TB and HIV in KwaZulu-Natal, South Africa: Implications for TB Programmes SO PLOS ONE LA English DT Article ID MULTIDRUG-RESISTANT TUBERCULOSIS; PRIMARY-CARE; SCALE-UP; IMPLEMENTATION; INTEGRATION; HIV/AIDS; INTERVENTIONS; MANAGEMENT; SETTINGS; OUTREACH AB Objective: To improve the treatment of MDR-TB and HIV co-infected patients, we investigated the relationship between health system performance and patient treatment outcomes at 4 decentralised MDR-TB sites. Methods: In this mixed methods case study which included prospective comparative data, we measured health system performance using a framework of domains comprising key health service components. Using Pearson Product Moment Correlation coefficients we quantified the direction and magnitude of the association between health system performance and MDR-TB treatment outcomes. Qualitative data from participant observation and interviews analysed using systematic text condensation (STC) complemented our quantitative findings. Findings: We found significant differences in treatment outcomes across the sites with successful outcomes varying from 72% at Site 1 to 52% at Site 4 (p<0.01). Health systems performance scores also varied considerably across the sites. Our findings suggest there is a correlation between treatment outcomes and overall health system performance which is significant (r = 0.99, p<0.01), with Site 1 having the highest number of successful treatment outcomes and the highest health system performance. Although the 'integration' domain, which measured integration of MDR-TB services into existing services appeared to have the strongest association with successful treatment outcomes (r = 0.99, p<0.01), qualitative data indicated that the 'context' domain influenced the other domains. Conclusion: We suggest that there is an association between treatment outcomes and health system performance. The chance of treatment success is greater if decentralised MDR-TB services are integrated into existing services. To optimise successful treatment outcomes, regular monitoring and support are needed at a district, facility and individual level to ensure the local context is supportive of new programmes and implementation is according to guidelines. C1 [Loveday, Marian] South African Med Res Council, Hlth Syst Res Unit, Cape Town, South Africa. [Padayatchi, Nesri] Univ KwaZulu Natal, Ctr AIDS Programme Res South Africa CAPRISA, Durban, South Africa. [Wallengren, Kristina] TB & HIV Invest Network KwaZulu Natal THINK, Durban, South Africa. [Roberts, Jacquelin] Ctr Dis Control & Prevent, Atlanta, GA USA. [Brust, James C. M.] Montefiore Med Ctr, Dept Med, Bronx, NY 10467 USA. [Brust, James C. M.] Albert Einstein Coll Med, Bronx, NY 10467 USA. [Ngozo, Jacqueline] KwaZulu Natal Dept Hlth, Pietermaritzburg, South Africa. [Master, Iqbal] KwaZulu Natal Dept Hlth, King Dinuzulu Hosp Complex, Durban, South Africa. [Voce, Anna] Univ KwaZulu Natal, Discipline Publ Hlth Med, Durban, South Africa. RP Loveday, M (reprint author), South African Med Res Council, Hlth Syst Res Unit, Cape Town, South Africa. EM marian.loveday@mrc.ac.za FU Izumi Foundation; Medical Research Council of South Africa; Eli-Lilly Foundation; National Institute of Allergy and Infectious Diseases [K23AI083088] FX This work was supported by the Izumi Foundation (http://izumi.org), the Medical Research Council of South Africa (www.mrc.ac.za), and the Eli-Lilly Foundation (www.lilly.com/about/lilly-foundation). James Brust is supported by the National Institute of Allergy and Infectious Diseases (K23AI083088). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 41 TC 6 Z9 6 U1 0 U2 6 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD APR 9 PY 2014 VL 9 IS 4 AR e94016 DI 10.1371/journal.pone.0094016 PG 10 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA AE9PC UT WOS:000334339000065 PM 24718306 ER PT J AU Tabernero, P Fernandez, FM Green, M Guerin, PJ Newton, PN AF Tabernero, Patricia Fernandez, Facundo M. Green, Michael Guerin, Philippe J. Newton, Paul N. TI Mind the gaps - the epidemiology of poor-quality anti-malarials in the malarious world - analysis of the WorldWide Antimalarial Resistance Network database SO MALARIA JOURNAL LA English DT Article ID PLASMODIUM-FALCIPARUM MALARIA; IONIZATION MASS-SPECTROMETRY; RAMAN-SPECTROSCOPY; DRUG-RESISTANCE; SOUTHEAST-ASIA; COUNTERFEIT; TABLETS; IDENTIFICATION; MEDICINES; PAKISTAN AB Background: Poor quality medicines threaten the lives of millions of patients and are alarmingly common in many parts of the world. Nevertheless, the global extent of the problem remains unknown. Accurate estimates of the epidemiology of poor quality medicines are sparse and are influenced by sampling methodology and diverse chemical analysis techniques. In order to understand the existing data, the Antimalarial Quality Scientific Group at WWARN built a comprehensive, open-access, global database and linked Antimalarial Quality Surveyor, an online visualization tool. Analysis of the database is described here, the limitations of the studies and data reported, and their public health implications discussed. Methods: The database collates customized summaries of 251 published anti-malarial quality reports in English, French and Spanish by time and location since 1946. It also includes information on assays to determine quality, sampling and medicine regulation. Results: No publicly available reports for 60.6% (63) of the 104 malaria-endemic countries were found. Out of 9,348 anti-malarials sampled, 30.1% (2,813) failed chemical/packaging quality tests with 39.3% classified as falsified, 2.3% as substandard and 58.3% as poor quality without evidence available to categorize them as either substandard or falsified. Only 32.3% of the reports explicitly described their definitions of medicine quality and just 9.1% (855) of the samples collected in 4.6% (six) surveys were conducted using random sampling techniques. Packaging analysis was only described in 21.5% of publications and up to twenty wrong active ingredients were found in falsified anti-malarials. Conclusions: There are severe neglected problems with anti-malarial quality but there are important caveats to accurately estimate the prevalence and distribution of poor quality anti-malarials. The lack of reports in many malaria-endemic areas, inadequate sampling techniques and inadequate chemical analytical methods and instrumental procedures emphasizes the need to interpret medicine quality results with caution. The available evidence demonstrates the need for more investment to improve both sampling and analytical methodology and to achieve consensus in defining different types of poor quality medicines. C1 [Tabernero, Patricia; Guerin, Philippe J.; Newton, Paul N.] Univ Oxford, Churchill Hosp, Worldwide Antimalarial Resistance Network WWARN, Oxford, England. [Tabernero, Patricia; Guerin, Philippe J.; Newton, Paul N.] Univ Oxford, Churchill Hosp, Nuffield Dept Clin Med, Ctr Trop Med, Oxford, England. [Tabernero, Patricia; Newton, Paul N.] Lao Oxford Mahosot Hosp Wellcome Trust Res Unit L, Mahosot Hosp, Microbiol Lab, Viangchan, Laos. [Fernandez, Facundo M.] Georgia Inst Technol, Sch Chem & Biochem, Atlanta, GA 30332 USA. [Green, Michael] US Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA USA. [Newton, Paul N.] London Sch Hyg & Trop Med, London WC1, England. RP Tabernero, P (reprint author), Univ Oxford, Churchill Hosp, Worldwide Antimalarial Resistance Network WWARN, Oxford, England. EM patricia.tabernero@wwarn.org; paul@tropmedres.ac OI Guerin, Philippe/0000-0002-6008-2963 FU French Ministry of Foreign and European Affairs (FSP Mekong Project); Bill and Melinda Gates Foundation; Wellcome Trust of Great Britain FX We thank the French Ministry of Foreign and European Affairs (FSP Mekong Project), the Bill and Melinda Gates Foundation and the Wellcome Trust of Great Britain for financial support. NR 70 TC 27 Z9 28 U1 1 U2 17 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1475-2875 J9 MALARIA J JI Malar. J. PD APR 8 PY 2014 VL 13 AR 139 DI 10.1186/1475-2875-13-139 PG 14 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA AF6FQ UT WOS:000334810200001 PM 24712972 ER PT J AU Kim, SY Russell, LB Park, J Verani, JR Madhi, SA Cutland, CL Schrag, SJ Sinha, A AF Kim, Sun-Young Russell, Louise B. Park, Jeehyun Verani, Jennifer R. Madhi, Shabir A. Cutland, Clare L. Schrag, Stephanie J. Sinha, Anushua TI Cost-effectiveness of a potential group B streptococcal vaccine program for pregnant women in South Africa SO VACCINE LA English DT Article DE Group B streptococcal (GBS); Neonatal sepsis; GBS vaccine; Intrapartum antibiotic prophylaxis (IAP); Cost-effectiveness; South Africa ID PRETERM BIRTH; DISEASE; PREVENTION; INFANTS; INFECTION; BURDEN; LEVEL; CHEMOPROPHYLAXIS; EPIDEMIOLOGY; PROPHYLAXIS AB Background: In low- and middle-income countries neonatal infections are important causes of infant mortality. Group B streptococcus (CBS) is a major pathogen. A GBS polysaccharide-protein conjugate vaccine, the only option that has the potential to prevent both early- and late-onset CBS disease, has completed Phase II trials. Screening-based intrapartum antibiotic prophylaxis (LAP) for pregnant women, an effective strategy in high-income countries, is often not practical in these settings. Risk factor-based IAP (RFB-IAP) for women with risk factors at delivery has had limited success in preventing neonatal infection. We evaluated the cost and health impacts of maternal CBS vaccination in South Africa. Methods and findings: We developed a decision-analytic model for an annual cohort of pregnant women that simulates the natural history of GBS disease in their infants. We compared four strategies: doing nothing, maternal GBS vaccination, RFB-LAP, and vaccination plus RFB-IAP. Assuming vaccine efficacy varies from 50% to 90% against covered serotypes and 75% of pregnant women are vaccinated, CBS vaccination alone prevents 30-54% of infant CBS cases compared to doing nothing. For vaccine prices between $10 and $30, and mid-range efficacy, its cost ranges from $676 to $2390 per disability-adjusted life-year (DALY) averted ($US 2010), compared to doing nothing. RFB-IAP alone, compared to doing nothing, prevents 10% of infant CBS cases at a cost of $240/DALY. Vaccine plus RFB-LAP prevents 48% of cases at a cost of $664-2128/DALY. Conclusions: Vaccination would substantially reduce the burden of infant CBS disease in South Africa and would be very cost-effective by WHO guidelines. RFB-IAP is also very cost-effective, but prevents only 10% of cases. Vaccination plus RFB-IAP is more effective and more costly than vaccination alone, and consistently very cost-effective. (C) 2014 Elsevier Ltd. All rights reserved. C1 [Kim, Sun-Young; Sinha, Anushua] Univ Texas San Antonio, Sch Publ Hlth, Div Management Policy & Community Hlth, San Antonio, TX 78229 USA. [Russell, Louise B.; Park, Jeehyun] Rutgers State Univ, Inst Hlth Hlth Care Policy & Aging Res, New Brunswick, NJ 08903 USA. [Russell, Louise B.; Park, Jeehyun] Rutgers State Univ, Dept Econ, New Brunswick, NJ 08903 USA. [Verani, Jennifer R.; Schrag, Stephanie J.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Madhi, Shabir A.; Cutland, Clare L.] Univ Witwatersrand, Natl Res Fdn Vaccine Preventable Dis, Med Res Council, Resp & Meningeal Pathogens Res Unit, Johannesburg, South Africa. [Madhi, Shabir A.; Cutland, Clare L.] Univ Witwatersrand, Natl Res Fdn Vaccine Preventable Dis, Dept Sci & Technol, Johannesburg, South Africa. [Sinha, Anushua] Rutgers State Univ, New Jersey Med Sch, Dept Prevent Med & Community Hlth, Newark, NJ USA. RP Kim, SY (reprint author), Univ Texas San Antonio, Sch Publ Hlth, 7411 John Smith Dr, San Antonio, TX 78229 USA. EM Sun-Young.Kim@uth.tmc.edu FU U.S. Centers for Disease Control and Prevention (Atlanta, GA, USA); PATH (Seattle, WA, USA) FX This study was supported by grants from the U.S. Centers for Disease Control and Prevention (Atlanta, GA, USA) and PATH (Seattle, WA, USA). Two (Jennifer R. Verani and Stephanie J. Schrag) of the coauthors are employees of the U.S. CDC, and one (Debbie Atherly) of the contributors in the Acknowledgements is an employee of PATH. NR 42 TC 14 Z9 16 U1 1 U2 5 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD APR 7 PY 2014 VL 32 IS 17 BP 1954 EP 1963 DI 10.1016/j.vaccine.2014.01.062 PG 10 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA AH3IK UT WOS:000336016700007 PM 24530145 ER PT J AU Nyaga, MM Esona, MD Jere, KC Peenze, I Seheri, ML Mphahlele, MJ AF Nyaga, Martin M. Esona, Mathew D. Jere, Khuzwayo C. Peenze, Ina Seheri, Mapaseka L. Mphahlele, M. Jeffrey TI Genetic diversity of rotavirus genome segment 6 (encoding VP6) in Pretoria, South Africa SO SPRINGERPLUS LA English DT Article DE Rotaviruses; Viral protein 6; Genetic diversity; South Africa; Pretoria ID POLYMERASE-CHAIN-REACTION; GROUP-A ROTAVIRUSES; STRAINS; AMPLIFICATION; G9 AB Background: Rotavirus viral protein 6 (VP6), encoded by genome segment (GS) 6, is the primary target for rotavirus diagnosis by serological and some molecular techniques. Selected full length nucleotide sequences of GS 6 of rotavirus strains from South Africa were sequenced and analysed to determine genetic diversity and variations within the circulating rotaviruses. Findings: The VP6 amplicons were sequenced using the Sanger ABI 3130xl. Phylogenetic and pairwise analysis revealed that the VP6 genes of the study strains belonged to two different VP6 [ I] genotypes. Five sequences were assigned genotype I1 and seven as genotype I2. Comparison of the group specific antigenic regions of the South African strains to the reference strains, shows that the South African VP6 sequences belonging to the VP6 genotype I2 were highly conserved, with only two amino acids changes at positions 239 (T>N) and 261(I>V). On the other hand, South African VP6 sequences belonging to I1 genotypes revealed several amino acid variations mostly within the antigenic region III. Conclusions: Rotavirus strains with I1 and I2 genotype are predominantly circulating within the South African communities of which the later seems to be more conserved within the antigenic regions. The observed genetic variations observed within GS 6 of rotaviruses analysed in the current study are unlikely to impact negatively on the performance of the current VP6-based detection methods. Nevertheless, investigators should continually consider this diversity and adapt the primer design for the detection and characterization of the VP6 gene accordingly. C1 [Nyaga, Martin M.; Esona, Mathew D.; Jere, Khuzwayo C.; Peenze, Ina; Seheri, Mapaseka L.; Mphahlele, M. Jeffrey] Univ Limpopo, MRC, Diarrhoeal Pathogens Res Unit, Dept Virol,NHLS Dr George Mukhari Tertiary Lab, Pretoria, South Africa. [Esona, Mathew D.] CDC, NCIRD, Gastroenteritis & Resp Viruses Lab Branch, Div Viral Dis, Atlanta, GA 30333 USA. [Jere, Khuzwayo C.] Univ Liverpool, Inst Infect & Global Hlth, Dept Clin Infect Microbiol & Immunol, Liverpool L69 3BX, Merseyside, England. RP Nyaga, MM (reprint author), Univ Limpopo, MRC, Diarrhoeal Pathogens Res Unit, Dept Virol,NHLS Dr George Mukhari Tertiary Lab, Medunsa Campus, Pretoria, South Africa. EM wamodylan@gmail.com OI Jere, Khuzwayo/0000-0003-3376-8529 FU Medical Research Council of South Africa; Poliomyelitis Research Foundation [09/43, 13/62] FX We thank the Medical Research Council of South Africa and Poliomyelitis Research Foundation for financial support (Grant no: 09/43; 13/62 [PhD]), Lancet laboratories for providing the samples and all staff of the MRC/DPRU for their support. NR 27 TC 1 Z9 2 U1 0 U2 0 PU SPRINGER INTERNATIONAL PUBLISHING AG PI CHAM PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND SN 2193-1801 J9 SPRINGERPLUS JI SpringerPlus PD APR 5 PY 2014 VL 3 AR 179 DI 10.1186/2193-1801-3-179 PG 5 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CO2DG UT WOS:000358964900004 PM 24790824 ER PT J AU Asma, S Song, Y Cohen, J Eriksen, M Pechacek, T Cohen, N Iskander, J AF Asma, Samira Song, Yang Cohen, Joanna Eriksen, Michael Pechacek, Terry Cohen, Nicole Iskander, John TI CDC Grand Rounds: Global Tobacco Control SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Asma, Samira; Song, Yang] CDC, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Cohen, Joanna] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Eriksen, Michael; Pechacek, Terry] Georgia State Univ, Sch Publ Hlth, Atlanta, GA 30303 USA. [Cohen, Nicole; Iskander, John] CDC, Off Director, Atlanta, GA 30333 USA. RP Iskander, J (reprint author), CDC, Off Director, Atlanta, GA 30333 USA. EM jiskander@cdc.gov NR 20 TC 9 Z9 9 U1 0 U2 4 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD APR 4 PY 2014 VL 63 IS 13 BP 277 EP 280 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AE1TD UT WOS:000333752000001 PM 24699763 ER PT J AU Masresha, BG Kaiser, R Eshetu, M Katsande, R Luce, R Fall, A Dosseh, ARGA Naouri, B Byabamazima, CR Perry, R Dabbagh, AJ Strebel, P Kretsinger, K Goodson, JL Nshimirimana, D AF Masresha, Balcha G. Kaiser, Reinhard Eshetu, Messeret Katsande, Reggis Luce, Richard Fall, Amadou Dosseh, Annick R. G. A. Naouri, Boubker Byabamazima, Charles R. Perry, Robert Dabbagh, Alya J. Strebel, Peter Kretsinger, Katrina Goodson, James L. Nshimirimana, Deo TI Progress Toward Measles Preelimination - African Region, 2011-2012 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Masresha, Balcha G.; Katsande, Reggis; Nshimirimana, Deo] World Hlth Org WHO Reg Off Africa, Immunizat & Vaccine Dev Program, Brazzaville, Congo. [Kaiser, Reinhard; Eshetu, Messeret; Byabamazima, Charles R.] WHO Reg Off Africa, Expanded Program Immunizat, Intercountry Support Team, Harare, Zimbabwe. [Luce, Richard] WHO Reg Off Africa, Expanded Program Immunizat, Intercountry Support Team, Libreville, Gabon. [Fall, Amadou; Dosseh, Annick R. G. A.] WHO Reg Off Africa, Expanded Program Immunizat, Intercountry Support Team, Ouagadougou, Burkina Faso. [Naouri, Boubker; Kretsinger, Katrina; Goodson, James L.] CDC, Global Immunizat Div, Ctr Global Hlth, Atlanta, GA 30333 USA. [Perry, Robert; Dabbagh, Alya J.; Strebel, Peter] WHO, Dept Immunizat Vaccines & Biol, CH-1211 Geneva, Switzerland. RP Kaiser, R (reprint author), WHO Reg Off Africa, Expanded Program Immunizat, Intercountry Support Team, Harare, Zimbabwe. EM kaisere@who.int NR 10 TC 5 Z9 5 U1 0 U2 1 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD APR 4 PY 2014 VL 63 IS 13 BP 285 EP 291 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AE1TD UT WOS:000333752000003 PM 24699765 ER PT J AU Chatham-Stephens, K Law, R Taylor, E Melstrom, P Bunnell, R Wang, BG Apelberg, B Schier, JG AF Chatham-Stephens, Kevin Law, Royal Taylor, Ethel Melstrom, Paul Bunnell, Rebecca Wang, Baoguang Apelberg, Benjamin Schier, Joshua G. TI Calls to Poison Centers for Exposures to Electronic Cigarettes - United States, September 2010-February 2014 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Chatham-Stephens, Kevin] CDC, Atlanta, GA 30333 USA. [Law, Royal; Taylor, Ethel; Schier, Joshua G.] CDC, Div Environm Hazards & Hlth Effects, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. [Melstrom, Paul; Bunnell, Rebecca] CDC, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Wang, Baoguang; Apelberg, Benjamin] US FDA, Ctr Tobacco Prod, Rockville, MD 20857 USA. RP Chatham-Stephens, K (reprint author), CDC, Atlanta, GA 30333 USA. EM xdc4@cdc.gov FU NIH HHS [T35 OD010991] NR 5 TC 69 Z9 70 U1 0 U2 10 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD APR 4 PY 2014 VL 63 IS 13 BP 292 EP 293 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AE1TD UT WOS:000333752000004 PM 24699766 ER PT J AU Choi, MJ Jackson, KA Medus, C Beal, J Rigdon, CE Cloyd, TC Forstner, MJ Ball, J Bosch, S Bottichio, L Cantu, V Melka, DC Ishow, W Slette, S Irvin, K Wise, M Tarr, C Mahon, B Smith, KE Silk, BJ AF Choi, Mary J. Jackson, Kelly A. Medus, Carlota Beal, Jennifer Rigdon, Carrie E. Cloyd, Tami C. Forstner, Matthew J. Ball, Jill Bosch, Stacy Bottichio, Lyndsay Cantu, Venessa Melka, David C. Ishow, Wilete Slette, Sarah Irvin, Kari Wise, Matthew Tarr, Cheryl Mahon, Barbara Smith, Kirk E. Silk, Benjamin J. TI Multistate Outbreak of Listeriosis Linked to Soft-Ripened Cheese - United States, 2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Choi, Mary J.; Medus, Carlota; Smith, Kirk E.] Minnesota Dept Hlth, Minneapolis, MN 55414 USA. [Jackson, Kelly A.; Bosch, Stacy; Wise, Matthew; Tarr, Cheryl; Mahon, Barbara; Silk, Benjamin J.] CDC, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Beal, Jennifer; Cloyd, Tami C.; Irvin, Kari] US FDA, Coordinated Outbreak Response & Evaluat Network, Rockville, MD 20857 USA. [Rigdon, Carrie E.; Forstner, Matthew J.] Minnesota Dept Agr, St Paul, MN USA. [Ball, Jill] Wisconsin Dept Agr Trade & Consumer Protect, Madison, WI USA. [Bottichio, Lyndsay] Ohio Dept Hlth, Columbus, OH 43266 USA. [Cantu, Venessa] Texas Dept State Hlth Serv, Austin, TX USA. [Melka, David C.] US FDA, Ctr Food Safety & Appl Nutr, Rockville, MD 20857 USA. [Ishow, Wilete] Chicago Dept Publ Hlth, Chicago, IL USA. [Slette, Sarah] Indiana State Dept Hlth, Indianapolis, IN 46202 USA. RP Choi, MJ (reprint author), Minnesota Dept Hlth, Minneapolis, MN 55414 USA. EM mjchoi@cdc.gov NR 4 TC 7 Z9 8 U1 0 U2 8 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD APR 4 PY 2014 VL 63 IS 13 BP 294 EP 295 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AE1TD UT WOS:000333752000005 PM 24699767 ER PT J AU Bergen, G Yao, J Shults, RA Romano, E Lacey, JH AF Bergen, Gwen Yao, Jie Shults, Ruth A. Romano, Eduardo Lacey, John H. TI Characteristics of Designated Drivers and Their Passengers From the 2007 National Roadside Survey in the United States SO TRAFFIC INJURY PREVENTION LA English DT Article DE impaired; DUI; designated drivers; interventions ID ALCOHOL; PROGRAMS; ADULTS; RISK; BEHAVIORS AB Objective: The objectives of this study were to estimate the prevalence of designated driving in the United States, compare these results with those from the 1996 National Roadside Survey, and explore the demographic, drinking, and trip characteristics of both designated drivers and their passengers. Methods: The data used were from the 2007 National Roadside Survey, which randomly stopped drivers, administered breath tests for alcohol, and administered a questionnaire to drivers and front seat passengers. Results: Almost a third (30%) of nighttime drivers reported being designated drivers, with 84 percent of them having a blood alcohol concentration of zero. Drivers who were more likely to be designated drivers were those with a blood alcohol concentration that was over zero but still legal; who were under 35years of age; who were African American, Hispanic, or Asian; and whose driving trip originated at a bar, tavern, or club. Over a third of passengers of designated drivers reported consuming an alcoholic drink the day of the survey compared to a fifth of passengers of nondesignated drivers. One fifth of passengers of designated drivers who reported drinking consumed 5 or more drinks that day. Conclusions: Designated driving is widely used in the United States, with the majority of designated drivers abstaining from drinking alcohol. However, because designated driving separates drinking from driving for passengers in a group traveling together, this may encourage passengers to binge drink, which is associated with many adverse health consequences in addition to those arising from alcohol-impaired driving. Designated driving programs and campaigns, although not proven to be effective when used alone, can complement proven effective interventions to help reduce excessive drinking and alcohol-impaired driving. C1 [Bergen, Gwen; Shults, Ruth A.] Ctr Dis Control & Prevent, Div Unintent Injury Prevent, Atlanta, GA 30341 USA. [Yao, Jie; Romano, Eduardo; Lacey, John H.] Pacific Inst Res & Evaluat, Calverton, MD USA. RP Bergen, G (reprint author), Ctr Dis Control & Prevent, Div Unintent Injury Prevent, 4770 Buford Highway NE,MS F62, Atlanta, GA 30341 USA. EM GBergen@cdc.gov FU Intramural CDC HHS [CC999999] NR 21 TC 0 Z9 0 U1 1 U2 10 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1538-9588 EI 1538-957X J9 TRAFFIC INJ PREV JI Traffic Inj. Prev. PD APR 3 PY 2014 VL 15 IS 3 BP 273 EP 277 DI 10.1080/15389588.2013.810334 PG 5 WC Public, Environmental & Occupational Health; Transportation SC Public, Environmental & Occupational Health; Transportation GA 279AM UT WOS:000328931000008 PM 24372499 ER PT J AU Hanson, C Waiswa, P Marchant, T Marx, M Manzi, F Mbaruku, G Rowe, A Tomson, G Schellenberg, J Peterson, S AF Hanson, Claudia Waiswa, Peter Marchant, Tanya Marx, Michael Manzi, Fatuma Mbaruku, Godfrey Rowe, Alex Tomson, Goran Schellenberg, Joanna Peterson, Stefan CA EQUIP Study Team TI Expanded Quality Management Using Information Power (EQUIP): protocol for a quasi-experimental study to improve maternal and newborn health in Tanzania and Uganda SO IMPLEMENTATION SCIENCE LA English DT Article DE Quality management; Quality improvement; Maternal and child health; Health system strengthening; Community empowerment; Tanzania; Uganda ID DEVELOPING-COUNTRIES; SYSTEMATIC ANALYSIS; CHILD SURVIVAL; SCALE-UP; OF-CARE; SUPPORT; IMPACT; ATTENDANCE; TRENDS AB Background: Maternal and newborn mortality remain unacceptably high in sub-Saharan Africa. Tanzania and Uganda are committed to reduce maternal and newborn mortality, but progress has been limited and many essential interventions are unavailable in primary and referral facilities. Quality management has the potential to overcome low implementation levels by assisting teams of health workers and others finding local solutions to problems in delivering quality care and the underutilization of health services by the community. Existing evidence of the effect of quality management on health worker performance in these contexts has important limitations, and the feasibility of expanding quality management to the community level is unknown. We aim to assess quality management at the district, facility, and community levels, supported by information from high-quality, continuous surveys, and report effects of the quality management intervention on the utilization and quality of services in Tanzania and Uganda. Methods: In Uganda and Tanzania, the Expanded Quality Management Using Information Power (EQUIP) intervention is implemented in one intervention district and evaluated using a plausibility design with one non-randomly selected comparison district. The quality management approach is based on the collaborative model for improvement, in which groups of quality improvement teams test new implementation strategies (change ideas) and periodically meet to share results and identify the best strategies. The teams use locally-generated community and health facility data to monitor improvements. In addition, data from continuous health facility and household surveys are used to guide prioritization and decision making by quality improvement teams as well as for evaluation of the intervention. These data include input, process, output, coverage, implementation practice, and client satisfaction indicators in both intervention and comparison districts. Thus, intervention districts receive quality management and continuous surveys, and comparison districts-only continuous surveys. Discussion: EQUIP is a district-scale, proof-of-concept study that evaluates a quality management approach for maternal and newborn health including communities, health facilities, and district health managers, supported by high-quality data from independent continuous household and health facility surveys. The study will generate robust evidence about the effectiveness of quality management and will inform future nationwide implementation approaches for health system strengthening in low-resource settings. C1 [Hanson, Claudia; Waiswa, Peter; Tomson, Goran; Peterson, Stefan] Karolinska Inst, Dept Publ Hlth Sci, Stockholm, Sweden. [Hanson, Claudia; Marchant, Tanya; Schellenberg, Joanna] Univ London London Sch Hyg & Trop Med, Dept Dis Control, London WC1E 7HT, England. [Waiswa, Peter; Peterson, Stefan] Makerere Univ, Coll Hlth Sci, Sch Publ Hlth, Kampala, Uganda. [Marx, Michael] Heidelberg Univ, Evaplan GmbH, Heidelberg, Germany. [Hanson, Claudia; Manzi, Fatuma; Mbaruku, Godfrey] Ifakara Hlth Inst, Dar Es Salaam, Tanzania. [Rowe, Alex] Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, Atlanta, GA USA. [Tomson, Goran] Karolinska Inst, Dept Learning, Stockholm, Sweden. [Peterson, Stefan] Uppsala Univ, Int Maternal & Child Hlth Unit, Dept Womens & Childrens Hlth, Uppsala, Sweden. RP Hanson, C (reprint author), Karolinska Inst, Dept Publ Hlth Sci, Stockholm, Sweden. EM claudia.hanson@ki.se OI Tomson, Goran/0000-0001-9222-3604; Manzi, Fatuma/0000-0001-9110-0776 FU European Union [265827] FX European Union (under FP-7 grant agreement no 265827). NR 39 TC 9 Z9 9 U1 1 U2 15 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1748-5908 J9 IMPLEMENT SCI JI Implement. Sci. PD APR 2 PY 2014 VL 9 AR 41 DI 10.1186/1748-5908-9-41 PG 10 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA AF7KF UT WOS:000334893000001 PM 24690284 ER PT J AU Inzaule, S Otieno, J Kalyango, J Nafisa, L Kabugo, C Nalusiba, J Kwaro, D Zeh, C Karamagi, C AF Inzaule, Seth Otieno, Juliana Kalyango, Joan Nafisa, Lillian Kabugo, Charles Nalusiba, Josephine Kwaro, Daniel Zeh, Clement Karamagi, Charles TI Incidence and Predictors of First Line Antiretroviral Regimen Modification in Western Kenya SO PLOS ONE LA English DT Article ID RESOURCE-LIMITED SETTINGS; HIV-INFECTION; SOUTH-AFRICA; THERAPY; STAVUDINE; COHORT; PREVALENCE; TOXICITY; ADULTS; DISCONTINUATION AB Background: Limited antiretroviral treatment regimens in resource-limited settings require long-term sustainability of patients on the few available options. We evaluated the incidence and predictors of combined antiretroviral treatment (cART) modifications, in an outpatient cohort of 955 patients who initiated cART between January 2009 and January 2011 in western Kenya. Methods: cART modification was defined as either first time single drug substitution or switch. Incidence rates were determined by Poisson regression and risk factor analysis assessed using multivariate Cox regression modeling. Results: Over a median follow-up period of 10.7 months, 178 (18.7%) patients modified regimens (incidence rate (IR); 18.6 per 100 person years [95% CI: 16.2-21.8]). Toxicity was the most common cited reason (66.3%). In adjusted multivariate Cox piecewise regression model, WHO disease stage III/IV (aHR; 1.82, 95% CI: 1.25-2.66), stavudine (d4T) use (aHR; 2.21 95% CI: 1.49-3.30) and increase in age (aHR; 1.02, 95% CI: 1.0-1.04) were associated with increased risk of treatment modification within the first year post-cART. Zidovudine (AZT) and tenofovir (TDF) use had a reduced risk for modification (aHR; 0.60 95% CI: 0.38-0.96 and aHR; 0.51 95% CI: 0.29-0.91 respectively). Beyond one year of treatment, d4T use (aHR; 2.75, 95% CI: 1.25-6.05), baseline CD4 counts <= 350 cells/mm(3) (aHR; 2.45, 95% CI: 1.14-5.26), increase in age (aHR; 1.05 95% CI: 1.02-1.07) and high baseline weight >60kg aHR; 2.69 95% CI: 1.58-4.59) were associated with risk of cART modification. Conclusions: Early treatment initiation at higher CD4 counts and avoiding d4T use may reduce treatment modification and subsequently improve sustainability of patients on the available limited options. C1 [Inzaule, Seth; Nafisa, Lillian; Kwaro, Daniel] Kenya Govt Med Res Ctr, Kisumu, Kenya. [Otieno, Juliana] Jaramogi Oginga Odinga Teaching & Referral Hosp, Kisumu, Kenya. [Inzaule, Seth; Kalyango, Joan; Kabugo, Charles; Nalusiba, Josephine; Karamagi, Charles] Makerere Univ, Sch Med, Clin Epidemiol Unit, Kampala, Uganda. [Kwaro, Daniel; Zeh, Clement] US Ctr Dis Control & Prevent, HIV Res Branch, Kisumu, Kenya. [Zeh, Clement] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. RP Inzaule, S (reprint author), Kenya Govt Med Res Ctr, Kisumu, Kenya. EM maserya@gmail.com FU European and Developing Countries Clinical Trial Partnership (EDCTP); Training Health Researchers into Vocational Excellence in East Africa, (THRIVE) initiative; Wellcome Trust [087540] FX This work was supported by European and Developing Countries Clinical Trial Partnership (EDCTP, http://www.edctp.org/), and Training Health Researchers into Vocational Excellence in East Africa, (THRIVE) initiative(grant number 087540 funded by the Wellcome Trust (http://thrive.or.ug/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 45 TC 4 Z9 4 U1 0 U2 2 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD APR 2 PY 2014 VL 9 IS 4 AR e93106 DI 10.1371/journal.pone.0093106 PG 8 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA AE6LC UT WOS:000334103000041 PM 24695108 ER PT J AU Napolitano, LM Angus, DC Uyeki, TM AF Napolitano, Lena M. Angus, Derek C. Uyeki, Timothy M. TI Critically Ill Patients With Influenza A(H1N1)pdm09 Virus Infection in 2014 SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Editorial Material ID UNITED-STATES C1 [Napolitano, Lena M.] Univ Michigan Hosp, Univ Michigan Hlth Syst, Dept Surg Surg Crit Care & Trauma, Ann Arbor, MI 48109 USA. [Angus, Derek C.] Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA USA. [Angus, Derek C.] UPMC Hlth Syst, CRISMA Ctr, Dept Crit Care Med, Pittsburgh, PA USA. [Uyeki, Timothy M.] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. RP Napolitano, LM (reprint author), Univ Michigan, Dept Surg, 1500 E Med Ctr Dr,1C340A UH, Ann Arbor, MI 48109 USA. EM lenan@umich.edu NR 10 TC 8 Z9 8 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD APR 2 PY 2014 VL 311 IS 13 BP 1289 EP 1290 DI 10.1001/jama.2014.2116 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA AE0HU UT WOS:000333645400008 PM 24566924 ER PT J AU Gunnala, R Perrine, C Subedi, GR Mebrahtu, S Dahal, P Jefferds, M AF Gunnala, Rajni Perrine, Cria Subedi, Giri Raj Mebrahtu, Saba Dahal, Pradiumna Jefferds, Maria TI Who is willing to pay for micronutrient powders for children 2-5 years of age in Nepal? SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology Meeting CY APR 26-30, 2014 CL San Diego, CA SP Cenveo, LI COR, Wiley, Mead Johnson Pediat Nutr Inst, IPRECIO, F1000 Res, Amer Assoc Anatomists, Amer Physiol Soc, Amer Soc Biochem & Mol Biol, Amer Soc Investigat Pathol, Amer Soc Nutr, Amer Soc Pharmacol & Expt Therapeut C1 [Gunnala, Rajni; Perrine, Cria; Jefferds, Maria] CDC, Atlanta, GA 30333 USA. [Subedi, Giri Raj] Minist Hlth & Populat, Nutr Sect, Kathmandu, Nepal. [Mebrahtu, Saba; Dahal, Pradiumna] UNICEF, Nutr Sect, Kathmandu, Nepal. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 EI 1530-6860 J9 FASEB J JI Faseb J. PD APR PY 2014 VL 28 IS 1 SU S MA 250.2 PG 2 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA AX0MP UT WOS:000346646700297 ER PT J AU Gusev, P Andrews, K Palachuvattil, J Dang, P Roseland, J Holden, J Savarala, S Pehrsson, P Dwyer, J Betz, J Saldanha, L Bailey, R Costello, R Gahche, J Hardy, C Emenaker, N Douglass, L AF Gusev, P. Andrews, K. Palachuvattil, J. Dang, P. Roseland, J. Holden, J. Savarala, S. Pehrsson, P. Dwyer, J. Betz, J. Saldanha, L. Bailey, R. Costello, R. Gahche, J. Hardy, C. Emenaker, N. Douglass, L. TI Over-the-counter prenatal multivitamin/mineral products: chemical analysis for the Dietary Supplement Ingredient Database SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology Meeting CY APR 26-30, 2014 CL San Diego, CA SP Cenveo, LI COR, Wiley, Mead Johnson Pediat Nutr Inst, IPRECIO, F1000 Res, Amer Assoc Anatomists, Amer Physiol Soc, Amer Soc Biochem & Mol Biol, Amer Soc Investigat Pathol, Amer Soc Nutr, Amer Soc Pharmacol & Expt Therapeut C1 [Gahche, J.] CDC, NHANES, NCHS, Hyattsville, MD USA. [Douglass, L.] Consulting Statistician, Longmont, CO USA. [Hardy, C.] FDA, CFSAN, College Pk, MD USA. [Emenaker, N.] NCI, NIH, Bethesda, MD 20892 USA. [Dwyer, J.; Betz, J.; Saldanha, L.; Bailey, R.; Costello, R.] NIH, ODS, Bethesda, MD 20892 USA. [Gusev, P.; Andrews, K.; Palachuvattil, J.; Dang, P.; Roseland, J.; Holden, J.; Savarala, S.; Pehrsson, P.] ARS, BHNRC, NDL, USDA, Beltsville, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 EI 1530-6860 J9 FASEB J JI Faseb J. PD APR PY 2014 VL 28 IS 1 SU S MA 809.3 PG 2 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA AX0MP UT WOS:000346646704408 ER PT J AU Marchetta, C Hamner, H AF Marchetta, Claire Hamner, Heather TI Blood folate concentrations among women of childbearing age by race/ethnicity and acculturation, NHANES 2001-2010 SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology Meeting CY APR 26-30, 2014 CL San Diego, CA SP Cenveo, LI COR, Wiley, Mead Johnson Pediat Nutr Inst, IPRECIO, F1000 Res, Amer Assoc Anatomists, Amer Physiol Soc, Amer Soc Biochem & Mol Biol, Amer Soc Investigat Pathol, Amer Soc Nutr, Amer Soc Pharmacol & Expt Therapeut C1 [Marchetta, Claire; Hamner, Heather] Ctr Dis Control, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Marchetta, Claire] Oak Ridge Inst Sci & Educ, Oak Ridge, TN USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 EI 1530-6860 J9 FASEB J JI Faseb J. PD APR PY 2014 VL 28 IS 1 SU S MA 130.5 PG 2 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA AX0MP UT WOS:000346646700071 ER PT J AU Nielsen, SJ Kit, B Aoki, Y Ogden, C AF Nielsen, Samara Joy Kit, Brian Aoki, Yutaka Ogden, Cynthia TI Seafood consumption and blood mercury concentrations in youth ages 1-19 years, 2007-2010 SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology Meeting CY APR 26-30, 2014 CL San Diego, CA SP Cenveo, LI COR, Wiley, Mead Johnson Pediat Nutr Inst, IPRECIO, F1000 Res, Amer Assoc Anatomists, Amer Physiol Soc, Amer Soc Biochem & Mol Biol, Amer Soc Investigat Pathol, Amer Soc Nutr, Amer Soc Pharmacol & Expt Therapeut C1 [Nielsen, Samara Joy; Kit, Brian; Aoki, Yutaka; Ogden, Cynthia] CDC, DHANES, NCHS, Hyattsville, MD USA. RI Quinn, Nigel/G-2407-2015 OI Quinn, Nigel/0000-0003-3333-4763 NR 0 TC 0 Z9 0 U1 0 U2 1 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 EI 1530-6860 J9 FASEB J JI Faseb J. PD APR PY 2014 VL 28 IS 1 SU S MA 369.4 PG 2 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA AX0MP UT WOS:000346646700488 ER PT J AU Perrine, C Chen, J Scanlon, K AF Perrine, Cria Chen, Jian Scanlon, Kelley TI Early formula supplementation and breastfeeding duration SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology Meeting CY APR 26-30, 2014 CL San Diego, CA SP Cenveo, LI COR, Wiley, Mead Johnson Pediat Nutr Inst, IPRECIO, F1000 Res, Amer Assoc Anatomists, Amer Physiol Soc, Amer Soc Biochem & Mol Biol, Amer Soc Investigat Pathol, Amer Soc Nutr, Amer Soc Pharmacol & Expt Therapeut C1 [Perrine, Cria; Chen, Jian; Scanlon, Kelley] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 EI 1530-6860 J9 FASEB J JI Faseb J. PD APR PY 2014 VL 28 IS 1 SU S MA 131.4 PG 2 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA AX0MP UT WOS:000346646700077 ER PT J AU Rybak, M Pao, CI Sternberg, M Pfeiffer, C AF Rybak, Michael Pao, Ching-I Sternberg, Maya Pfeiffer, Christine TI Urine caffeine and caffeine metabolites as indicators of dietary caffeine exposure and metabolism phenotypes in population studies SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology Meeting CY APR 26-30, 2014 CL San Diego, CA SP Cenveo, LI COR, Wiley, Mead Johnson Pediat Nutr Inst, IPRECIO, F1000 Res, Amer Assoc Anatomists, Amer Physiol Soc, Amer Soc Biochem & Mol Biol, Amer Soc Investigat Pathol, Amer Soc Nutr, Amer Soc Pharmacol & Expt Therapeut C1 [Rybak, Michael; Pao, Ching-I; Sternberg, Maya; Pfeiffer, Christine] US Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 EI 1530-6860 J9 FASEB J JI Faseb J. PD APR PY 2014 VL 28 IS 1 SU S MA 245.1 PG 2 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA AX0MP UT WOS:000346646700268 ER PT J AU Saldanha, L Dwyer, J Bailen, R Andrews, K Bailey, R Betz, J Burt, V Chang, F Costello, R Emenaker, N Gahche, J Harnly, J Hardy, C Pehrsson, P AF Saldanha, L. Dwyer, J. Bailen, R. Andrews, K. Bailey, R. Betz, J. Burt, V. Chang, F. Costello, R. Emenaker, N. Gahche, J. Harnly, J. Hardy, C. Pehrsson, P. TI When a dietary supplement product name says "energy", what's in the bottle? SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology Meeting CY APR 26-30, 2014 CL San Diego, CA SP Cenveo, LI COR, Wiley, Mead Johnson Pediat Nutr Inst, IPRECIO, F1000 Res, Amer Assoc Anatomists, Amer Physiol Soc, Amer Soc Biochem & Mol Biol, Amer Soc Investigat Pathol, Amer Soc Nutr, Amer Soc Pharmacol & Expt Therapeut C1 [Andrews, K.; Harnly, J.; Pehrsson, P.] USDA ARS, Beltsville, MD USA. [Hardy, C.] US FDA, CFSAN, College Pk, MD USA. [Emenaker, N.] NCI, NIH, Rockville, MD USA. [Burt, V.; Gahche, J.] CDC, NHANES, Hyattsville, MD USA. [Chang, F.] Natl Lib Med, NIH, Bethesda, MD USA. [Saldanha, L.; Dwyer, J.; Bailen, R.; Bailey, R.; Betz, J.; Costello, R.] NIH, ODS, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 EI 1530-6860 J9 FASEB J JI Faseb J. PD APR PY 2014 VL 28 IS 1 SU S MA 634.1 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA AX0MP UT WOS:000346646702298 ER PT J AU Schap, T Thompson, F Dodd, K Potischman, N George, S Coleman, L Gahche, J Alexander, G Groesbeck, M Kahle, L Kushi, L Clancy, H Sundaram, M Kirkpatrick, S Dixit-Joshi, S Zimmerman, T Douglass, D Mittl, B Bailey, R Subar, A AF Schap, TusaRebecca Thompson, Frances Dodd, Kevin Potischman, Nancy George, Stephanie Coleman, Laura Gahche, Jaime Alexander, Gwen Groesbeck, Michelle Kahle, Lisa Kushi, Lawrence Clancy, Heather Sundaram, Maria Kirkpatrick, Sharon Dixit-Joshi, Sujata Zimmerman, Thea Douglass, Deirdre Mittl, Beth Bailey, Regan Subar, Amy TI Comparison of dietary supplement intake reporting between the Automated Self-Administered 24-Hour Recall (ASA24) and Automated Multiple Pass Method (AMPM) recalls SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology Meeting CY APR 26-30, 2014 CL San Diego, CA SP Cenveo, LI COR, Wiley, Mead Johnson Pediat Nutr Inst, IPRECIO, F1000 Res, Amer Assoc Anatomists, Amer Physiol Soc, Amer Soc Biochem & Mol Biol, Amer Soc Investigat Pathol, Amer Soc Nutr, Amer Soc Pharmacol & Expt Therapeut C1 [Coleman, Laura] Abbott Nutr, Columbus, OH USA. [Gahche, Jaime] Ctr Dis Control & Prevent, Hyattsville, MD USA. [Alexander, Gwen; Groesbeck, Michelle] Henry Ford Hlth Syst, Detroit, MI USA. [Kahle, Lisa] InformationManagement Syst, Silver Spring, MD USA. [Kushi, Lawrence; Clancy, Heather] Kaiser Permanente No Calif, Oakland, CA USA. [Sundaram, Maria] Marshfield Clin Res Fdn, Marshfield, WI USA. [Schap, TusaRebecca; Thompson, Frances; Dodd, Kevin; Potischman, Nancy; George, Stephanie; Subar, Amy] NCI, Rockville, MD USA. [Bailey, Regan] Off Dietary Supplements, Rockville, MD USA. [Kirkpatrick, Sharon] Univ Waterloo, Waterloo, ON N2L 3G1, Canada. [Dixit-Joshi, Sujata; Zimmerman, Thea; Douglass, Deirdre; Mittl, Beth] WESTAT Corp, Rockville, MD 20850 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 EI 1530-6860 J9 FASEB J JI Faseb J. PD APR PY 2014 VL 28 IS 1 SU S MA 245.2 PG 2 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA AX0MP UT WOS:000346646700269 ER PT J AU Wang, CY Carriquiry, A Chen, TC Loria, C Pfeiffer, C Liu, K Sempos, C Perrine, C Swanson, C Cogswell, M AF Wang, Chia-Yih Carriquiry, Alicia Chen, Te-Ching Loria, Catherine Pfeiffer, Christine Liu, Kiang Sempos, Christopher Perrine, Cria Swanson, Christine Cogswell, Mary TI Estimating distributions of usual 24-hour sodium excretion from timed-spot urines in adults 18-39 years SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology Meeting CY APR 26-30, 2014 CL San Diego, CA SP Cenveo, LI COR, Wiley, Mead Johnson Pediat Nutr Inst, IPRECIO, F1000 Res, Amer Assoc Anatomists, Amer Physiol Soc, Amer Soc Biochem & Mol Biol, Amer Soc Investigat Pathol, Amer Soc Nutr, Amer Soc Pharmacol & Expt Therapeut C1 [Pfeiffer, Christine; Perrine, Cria; Cogswell, Mary] CDC, Atlanta, GA 30333 USA. [Wang, Chia-Yih; Chen, Te-Ching] CDC, Hyattsville, MD USA. [Carriquiry, Alicia] Iowa State Univ, Ames, IA USA. [Loria, Catherine; Sempos, Christopher; Swanson, Christine] NIH, Bethesda, MD 20892 USA. [Liu, Kiang] Northwestern Univ, Chicago, IL 60611 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 EI 1530-6860 J9 FASEB J JI Faseb J. PD APR PY 2014 VL 28 IS 1 SU S MA 632.11 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA AX0MP UT WOS:000346646702284 ER PT J AU Ahuja, J Pehrsson, P Haytowitz, D Showell, B Nickle, M Wasswa-Kintu, S Cogswell, M AF Ahuja, Jaspreet Pehrsson, Pamela Haytowitz, David Showell, Bethany Nickle, Melissa Wasswa-Kintu, Shirley Cogswell, Mary TI Comparison of corresponding commercially processed foods from store and restaurant for sodium, fat, sugar and potassium content in a nationwide sample SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Cogswell, Mary] Ctr Dis Control & Prevent, Atlanta, GA USA. [Ahuja, Jaspreet; Pehrsson, Pamela; Haytowitz, David; Showell, Bethany; Nickle, Melissa; Wasswa-Kintu, Shirley] ARS, USDA, Beltsville Human Nutr Res Ctr, Beltsville, MD USA. NR 0 TC 0 Z9 0 U1 1 U2 3 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 EI 1530-6860 J9 FASEB J JI Faseb J. PD APR PY 2014 VL 28 IS 1 SU S MA 1019.11 PG 2 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA AX0OG UT WOS:000346651000121 ER PT J AU Gahche, J Fakhouri, T Fulton, J Carroll, D Wang, CY Burt, V AF Gahche, Jaime Fakhouri, Tala Fulton, Janet Carroll, Dianna Wang, Chia-Yih Burt, Vicki TI Cardiorespiratory fitness levels among US adolescents SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Carroll, Dianna] CDC, Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Fulton, Janet] CDC, Nat Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Gahche, Jaime; Fakhouri, Tala; Wang, Chia-Yih; Burt, Vicki] CDC, Natl Ctr Hlth Stat, Hyattsville, MD USA. NR 0 TC 1 Z9 1 U1 0 U2 2 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 EI 1530-6860 J9 FASEB J JI Faseb J. PD APR PY 2014 VL 28 IS 1 SU S MA 1028.4 PG 2 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA AX0OG UT WOS:000346651000192 ER PT J AU Park, S Blanck, H Dooyema, C Ayala, G AF Park, Sohyun Blanck, Heidi Dooyema, Carrie Ayala, Guadalupe TI Association between sugar-sweetened beverage intake and proxies of acculturation among Hispanic and non-Hispanic white adults SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Park, Sohyun; Blanck, Heidi; Dooyema, Carrie] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Atlanta, GA USA. [Ayala, Guadalupe] San Diego State Univ, Div Hlth Promot & Behav Sci, San Diego, CA 92182 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 EI 1530-6860 J9 FASEB J JI Faseb J. PD APR PY 2014 VL 28 IS 1 SU S MA LB373 PG 2 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA AX0OG UT WOS:000346651004367 ER PT J AU Tsang, B Cordero, A Marchetta, C Mulinare, J Mersereau, P Guo, J Qi, YP Berry, R Rosenthal, J Crider, K Hamner, H AF Tsang, Becky Cordero, Amy Marchetta, Claire Mulinare, Joseph Mersereau, Patricia Guo, Jing Qi, Yan Ping Berry, Robert Rosenthal, Jorge Crider, Krista Hamner, Heather TI Assessing the association between the methylenetetrahydrofolate reductase (MTHFR) 677C -> T polymorphism on blood folate concentrations: a systematic review and meta-analysis of trials and observational studies SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Guo, Jing] Acentia, Falls Church, VA USA. [Mulinare, Joseph; Mersereau, Patricia; Qi, Yan Ping] Carter Consulting, Atlanta, GA USA. [Mulinare, Joseph] Ctr Dis Control & Prevent, Atlanta, GA USA. [Cordero, Amy; Marchetta, Claire; Mersereau, Patricia; Guo, Jing; Qi, Yan Ping; Berry, Robert; Rosenthal, Jorge; Crider, Krista; Hamner, Heather] Ctr Dis Control & Prevent, Div Birth Defects & Dev Disabil, Atlanta, GA USA. [Tsang, Becky; Marchetta, Claire; Qi, Yan Ping] Oak Ridge Inst Sci & Educ, Oak Ridge, TN USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 EI 1530-6860 J9 FASEB J JI Faseb J. PD APR PY 2014 VL 28 IS 1 SU S MA LB311 PG 2 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA AX0OG UT WOS:000346651004340 ER PT J AU Merlo, CL Olsen, EO Galic, M Brener, ND AF Merlo, Caitlin L. Olsen, Emily O'Malley Galic, Mara Brener, Nancy D. TI The Relationship Between State Policies for Competitive Foods and School Nutrition Practices in the United States SO PREVENTING CHRONIC DISEASE LA English DT Article ID US PUBLIC-SCHOOLS; SWEETENED BEVERAGES; DIETARY BEHAVIORS; HEALTH POLICIES; MIDDLE SCHOOL; BAR FOODS; CONSUMPTION; VEGETABLES; PROGRAMS; FRUITS AB Introduction Most students in grades kindergarten through 12 have access to foods and beverages during the school day outside the federal school meal programs, which are called competitive foods. At the time of this study, competitive foods were subject to minimal federal nutrition standards, but states could implement additional standards. Our analysis examined the association between school nutrition practices and alignment of state policies with Institute of Medicine recommendations (IOM Standards). Methods For this analysis we used data from the Centers for Disease Control and Prevention's (CDC's) report, Competitive Foods and Beverages in US Schools: A State Policy Analysis and CDC's 2010 School Health Profiles (Profiles) survey to examine descriptive associations between state policies for competitive foods and school nutrition practices. Results Access to chocolate candy, soda pop, sports drinks, and caffeinated foods or beverages was lower in schools in states with policies more closely aligned with IOM Standards. No association was found for access to fruits or nonfried vegetables. Conclusion Schools in states with policies more closely aligned with the IOM Standards reported reduced access to less healthful competitive foods. Encouraging more schools to follow these standards will help create healthier school environments and may help promote healthy eating among US children. C1 [Merlo, Caitlin L.; Olsen, Emily O'Malley; Brener, Nancy D.] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. [Galic, Mara] Danya Consultants, Atlanta, GA USA. RP Merlo, CL (reprint author), Ctr Dis Control & Prevent, 4770 Buford Highway NE,Mailstop F-78, Atlanta, GA 30341 USA. EM cmerlo@cdc.gov NR 24 TC 0 Z9 0 U1 2 U2 5 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD APR PY 2014 VL 11 AR 130216 DI 10.5888/pcd11.130216 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AR3XG UT WOS:000343521900006 ER PT J AU Onufrak, SJ Park, S Wilking, C AF Onufrak, Stephen J. Park, Sohyun Wilking, Cara TI Student-Reported School Drinking Fountain Availability by Youth Characteristics and State Plumbing Codes SO PREVENTING CHRONIC DISEASE LA English DT Article ID WATER; CONSUMPTION; CHILDREN AB Introduction Caloric intake among children could be reduced if sugar-sweetened beverages were replaced by plain water. School drinking water infrastructure is dictated in part by state plumbing codes, which generally require a minimum ratio of drinking fountains to students. Actual availability of drinking fountains in schools and how availability differs according to plumbing codes is unknown. Methods We abstracted state plumbing code data and used the 2010 YouthStyles survey data from 1,196 youth aged 9 through 18 years from 47 states. We assessed youth-reported school drinking fountain or dispenser availability and differences in availability according to state plumbing codes, sociodemographic characteristics, and area-level characteristics. Results Overall, 57.3% of youth reported that drinking fountains or dispensers in their schools were widely available, 40.1% reported there were only a few, and 2.6% reported that there were no working fountains. Reported fountain availability differed significantly (P <.01) by race/ethnicity, census region, the fountain to student ratio specified in plumbing codes, and whether plumbing codes allowed substitution of nonplumbed water sources for plumbed fountains. "Widely available" fountain access ranged from 45.7% in the West to 65.4% in the Midwest and was less common where state plumbing codes required 1 fountain per more than 100 students (45.4%) compared with 1 fountain per 100 students (60.1%) or 1 fountain per fewer than 100 students (57.6%). Conclusion Interventions designed to increase consumption of water may want to consider the role of plumbing codes in availability of school drinking fountains. C1 [Onufrak, Stephen J.] Ctr Dis Control & Prevent, DIv Nutr Phys Act & Obes, Obes Prevent & Control Branch, Atlanta, GA 30341 USA. [Park, Sohyun] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. [Wilking, Cara] Northeastern Univ, Sch Law, Boston, MA 02115 USA. RP Onufrak, SJ (reprint author), Ctr Dis Control & Prevent, DIv Nutr Phys Act & Obes, Obes Prevent & Control Branch, 4770 Buford Hwy NE,MS K-77, Atlanta, GA 30341 USA. EM seo5@cdc.gov FU CDC (Nutrition and Obesity Policy Research and Evaluation Network) [U48DP001946] FX Additional support for this project was provided in part by cooperative agreements with CDC (no. U48DP001946, including the Nutrition and Obesity Policy Research and Evaluation Network). NR 23 TC 1 Z9 1 U1 1 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD APR PY 2014 VL 11 AR 130314 DI 10.5888/pcd11.130314 PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AR3XG UT WOS:000343521900017 ER PT J AU Park, S Pan, LP Sherry, B Blanck, HM AF Park, Sohyun Pan, Liping Sherry, Bettylou Blanck, Heidi M. TI Consumption of Sugar-Sweetened Beverages Among US Adults in 6 States: Behavioral Risk Factor Surveillance System, 2011 SO PREVENTING CHRONIC DISEASE LA English DT Article ID UNITED-STATES; FRUCTOSE CONSUMPTION; YOUNG-ADULTS; MEN; DISEASE; QUESTIONNAIRE; VALIDITY; OBESITY; WEIGHT AB Introduction Sugar-sweetened beverage (SSB) intake is linked to weight gain. Our objective was to examine state-specific SSB intake and behavioral characteristics associated with SSB intake. Methods We used data from the 2011 Behavioral Risk Factor Surveillance System for 38,978 adults aged 18 years or older from 6 states: Delaware, Hawaii, Iowa, Minnesota, New Jersey, and Wisconsin. Multivariate logistic regression was used to estimate adjusted odds ratios for characteristics associated with SSB intake from regular soda and fruit drinks. Results Overall, 23.9% of adults drank SSBs at least once a day. Odds of drinking SSBs 1 or more times per day were significantly greater among younger adults; males; non-Hispanic blacks; adults with lower education; low-income adults or adults with missing income data; adults living in Delaware, Iowa, and Wisconsin versus those living in Minnesota; adults with fruit intake of less than 1 time a day versus 1 or more times a day; adults who were physically inactive versus highly active adults; and current smokers versus nonsmokers. Odds for drinking SSBs 1 or more times per day were significantly lower among adults with 100% fruit juice intake of less than 1 time per day versus 1 or more times per day and among adults who drank alcohol versus those who did not drink alcohol. Conclusions SSB intake varied by states and certain sociodemographic and behavioral characteristics. States can use findings from this study to tailor efforts to decrease SSB intake and to encourage consumption of more healthful beverages (eg, water) among their high-risk populations. C1 [Park, Sohyun] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Pan, Liping; Sherry, Bettylou; Blanck, Heidi M.] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. RP Park, S (reprint author), Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway NE, Atlanta, GA 30341 USA. EM spark3@cdc.gov NR 30 TC 3 Z9 3 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD APR PY 2014 VL 11 AR 130304 DI 10.5888/pcd11.130304 PG 12 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AR3XG UT WOS:000343521900016 ER PT J AU Redwood, D Provost, E Asay, E Roberts, D Haverkamp, D Perdue, D Bruce, MG Sacco, F Espey, D AF Redwood, Diana Provost, Ellen Asay, Elvin Roberts, Diana Haverkamp, Donald Perdue, David Bruce, Michael G. Sacco, Frank Espey, David TI Comparison of Fecal Occult Blood Tests for Colorectal Cancer Screening in an Alaska Native Population With High Prevalence of Helicobacter pylori Infection, 2008-2012 SO PREVENTING CHRONIC DISEASE LA English DT Article ID PROSPECTIVE MULTICENTER; IMMUNOCHEMICAL TEST; ADENOMATOUS POLYPS; UNITED-STATES; COLONOSCOPY; NEOPLASIA; ADULTS; COMMUNITIES; DISPARITIES; HEMOGLOBIN AB Introduction Alaska Native colorectal cancer (CRC) incidence and mortality rates are the highest of any ethnic/racial group in the United States. CRC screening using guaiac-based fecal occult blood tests (gFOBT) are not recommended for Alaska Native people because of false-positive results associated with a high prevalence of Helicobacter pylori-associated hemorrhagic gastritis. This study evaluated whether the newer immunochemical FOBT (iFOBT) resulted in a lower false-positive rate and higher specificity for detecting advanced colorectal neoplasia than gFOBT in a population with elevated prevalence of H. pylori infection. Methods We used a population-based sample of 304 asymptomatic Alaska Native adults aged 40 years or older undergoing screening or surveillance colonoscopy (April 2008 January 2012). Results Specificity differed significantly (P <.001) between gFOBT (76%; 95% CI, 71%-81%) and iFOBT (92%; 95% CI, 89% 96%). Among H. pylori-positive participants (54%), specificity of iFOBT was even higher (93% vs 69%). Overall, sensitivity did not differ significantly (P =.73) between gFOBT (29%) and iFOBT (36%). Positive predictive value was 11% for gFOBT and 32% for iFOBT. Conclusion The iFOBT had a significantly higher specificity than gFOBT, especially in participants with current H. pylori infection. The iFOBT represents a potential strategy for expanding CRC screening among Alaska Native and other populations with elevated prevalence of H. pylori, especially where access to screening endoscopy is limited. C1 [Redwood, Diana] C DCHS, Anchorage, AK 99508 USA. [Provost, Ellen; Asay, Elvin; Sacco, Frank] Alaska Native Tribal Hlth Consortium, Anchorage, AK USA. [Roberts, Diana; Haverkamp, Donald; Espey, David] Ctr Dis Control & Prevent, Albuquerque, NM USA. [Perdue, David] Amer Indian Canc Fdn, Minneapolis, MN USA. [Perdue, David] Minnesota Gastroenterol PA, Minneapolis, MN USA. [Bruce, Michael G.] Ctr Dis Control & Prevent, Anchorage, AK USA. RP Redwood, D (reprint author), C DCHS, 4000 Ambassador Dr, Anchorage, AK 99508 USA. EM dredwood@anthc.org FU CDC Division of Cancer Prevention and Control; Indian Health Service; Alaska Native Tribal Health Consortium Board of Directors; CDC Arctic Investigations Program for H. pylori urea breath test kits and analysis FX Funding for this study was provided by the CDC Division of Cancer Prevention and Control. We acknowledge the contributions and support of the Indian Health Service; the Alaska Native Tribal Health Consortium Board of Directors; the CDC Arctic Investigations Program for H. pylori urea breath test kits and analysis; Quest Diagnostics, Inc, who provided the InSure FIT fecal immunochemical test kits and analysis to the study at no cost, and study staff, including Margaret Cobey, Pam Sacco, Donna Gerwin, Jill Evon Otto, and Julie Morris. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of CDC. NR 31 TC 0 Z9 0 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD APR PY 2014 VL 11 AR 130281 DI 10.5888/pcd11.130281 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AR3XG UT WOS:000343521900015 ER PT J AU Ward, BW Schiller, JS Goodman, RA AF Ward, Brian W. Schiller, Jeannine S. Goodman, Richard A. TI Multiple Chronic Conditions Among US Adults: A 2012 Update SO PREVENTING CHRONIC DISEASE LA English DT Article AB The objective of this research was to update earlier estimates of prevalence rates of single chronic conditions and multiple (>2) chronic conditions (MCC) among the noninstitutionalized, civilian US adult population. Data from the 2012 National Health Interview Survey (NHIS) were used to generate estimates of MCC for US adults and by select demographic characteristics. Approximately half (117 million) of US adults have at least one of the 10 chronic conditions examined (ie, hypertension, coronary heart disease, stroke, diabetes, cancer, arthritis, hepatitis, weak or failing kidneys, current asthma, or chronic obstructive pulmonary disease [COPD]). Furthermore, 1 in 4 adults has MCC. C1 [Ward, Brian W.] Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. [Schiller, Jeannine S.] Ctr Dis Control & Prevent, Hyattsville, MD USA. [Goodman, Richard A.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Goodman, Richard A.] Emory Univ, Div Gen Med & Geriatr, Atlanta, GA 30322 USA. RP Ward, BW (reprint author), Natl Ctr Hlth Stat, 3311 Toledo Rd,Rm 2330, Hyattsville, MD 20782 USA. EM bwward@cdc.gov NR 8 TC 75 Z9 75 U1 2 U2 12 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD APR PY 2014 VL 11 AR 130389 DI 10.5888/pcd11.130389 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AR3XG UT WOS:000343521900018 PM 24742395 ER PT J AU Vellozzi, C Iqbal, S Stewart, B Tokars, J DeStefano, F AF Vellozzi, Claudia Iqbal, Shahed Stewart, Brock Tokars, Jerome DeStefano, Frank TI Cumulative Risk of Guillain-Barre Syndrome Among Vaccinated and Unvaccinated Populations During the 2009 H1N1 Influenza Pandemic SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID UNITED-STATES; A H1N1; MONOVALENT VACCINE; SAFETY; PROGRAM; CAMPYLOBACTER; SURVEILLANCE; INFECTION; RECEIPT; ENGLAND AB Objectives. We sought to assess risk of Guillain-Barre syndrome (GBS) among influenza A (H1N1) 2009 monovalent (pH1N1) vaccinated and unvaccinated populations at the end of the 2009 pandemic. Methods. We applied GBS surveillance data from a US population catchment area of 45 million from October 15, 2009, through May 31, 2010. GBS cases meeting Brighton Collaboration criteria were included. We calculated the incidence density ratio (IDR) among pH1N1 vaccinated and unvaccinated populations. We also estimated cumulative GBS risk using life table analysis. Additionally, we used vaccine coverage data and census population estimates to calculate denominators. Results. There were 392 GBS cases; 64 (16%) occurred after pH1N1 vaccination. The vaccinated population had lower average risk (IDR = 0.83, 95% confidence interval = 0.63, 1.08) and lower cumulative risk (6.6 vs 9.2 cases per million persons, P = .012) of GBS. Conclusions. Our findings suggest that at the end of the influenza season cumulative GBS risk was less among the pH1N1 vaccinated than the unvaccinated population, suggesting the benefit of vaccination as it relates to GBS. The observed potential protective effect on GBS attributed to vaccination warrants further study. C1 [Vellozzi, Claudia; Iqbal, Shahed; Stewart, Brock; DeStefano, Frank] Ctr Dis Control & Prevent, Immunizat Safety Off, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Tokars, Jerome] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Vellozzi, C (reprint author), Ctr Dis Control & Prevent, Immunizat Safety Off, 1600 Clifton Rd NE,MS d-26, Atlanta, GA 30333 USA. EM Bno1@cdc.gov NR 35 TC 11 Z9 12 U1 0 U2 2 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD APR PY 2014 VL 104 IS 4 BP 696 EP 701 DI 10.2105/AJPH.2013.301651 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AP0XI UT WOS:000341789200040 PM 24524517 ER PT J AU Ellingson, K McCormick, K Sinkowitz-Cochran, R Woodard, T Jernigan, J Srinivasan, A Rask, K AF Ellingson, Katherine McCormick, Kelly Sinkowitz-Cochran, Ronda Woodard, Tiffanee Jernigan, John Srinivasan, Arjun Rask, Kimberly CA State-Based Healthcare-Associated TI Enhancement of Health Department Capacity for Health Care-Associated Infection Prevention Through Recovery Act-Funded Programs SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID BLOOD-STREAM INFECTIONS; STATEWIDE; ICU AB Objectives. We evaluated capacity built and outcomes achieved from September 1, 2009, to December 31, 2011, by 51 health departments (HDs) funded through the American Recovery and Reinvestment Act (ARRA) for health care-associated infection (HAI) program development. Methods. We defined capacity for HAI prevention at HDs by 25 indicators of activity in 6 categories: staffing, partnerships, training, technical assistance, surveillance, and prevention. We assessed state-level infection outcomes by modeling quarterly standardized infection ratios (SIRs) for device- and procedure-associated infections with longitudinal regression models. Results. With ARRA funds, HDs created 188 HAI-related positions and supported 1042 training programs, 53 surveillance data validation projects, and 60 prevention collaboratives. All states demonstrated significant declines in central line-associated bloodstream and surgical site infections. States that implemented ARRA-funded catheter-associated urinary tract infection prevention collaboratives showed significantly greater SIR reductions over time than states that did not (P =.02). Conclusions. ARRA-HAI funding substantially improved HD capacity to reduce HAIs not targeted by other national efforts, suggesting that HDs can play a critical role in addressing emerging or neglected HAIs. C1 [Ellingson, Katherine; McCormick, Kelly; Sinkowitz-Cochran, Ronda; Woodard, Tiffanee; Jernigan, John; Srinivasan, Arjun] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA USA. [Rask, Kimberly] Emory Univ, Rollins Sch Publ Hlth, Dept Hlth Policy & Management, Atlanta, GA 30322 USA. RP Ellingson, K (reprint author), 1600 Clifton Rd NE,MS-A31, Atlanta, GA 30329 USA. EM kdellingson@gmail.com RI rask, kimberly/M-8001-2016 NR 17 TC 3 Z9 3 U1 0 U2 2 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD APR PY 2014 VL 104 IS 4 BP E27 EP E33 DI 10.2105/AJPH.2013.301809 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AP0XI UT WOS:000341789200011 PM 24524522 ER PT J AU Guy, GP Berkowitz, Z Jones, SE Olsen, EO Miyamoto, JN Michael, SL Saraiya, M AF Guy, Gery P., Jr. Berkowitz, Zahava Jones, Sherry Everett Olsen, Emily O'Malley Miyamoto, Justin N. Michael, Shannon L. Saraiya, Mona TI State Indoor Tanning Laws and Adolescent Indoor Tanning SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID RISK BEHAVIOR SURVEILLANCE; NONMELANOMA SKIN-CANCER; UNITED-STATES; YOUTH ACCESS; REGULATIONS; US; MASSACHUSETTS; METAANALYSIS; LEGISLATION; PREVALENCE AB Objectives. Recently, several state indoor tanning laws, including age restrictions, were promulgated to reduce indoor tanning among minors. We examined the effects of these laws on adolescent indoor tanning. Methods. We used nationally representative data from the 2009 and 2011 national Youth Risk Behavior Surveys (n = 31 835). Using multivariable logistic regression, we examined the association between state indoor tanning laws and indoor tanning among US high school students. Results. Female students in states with indoor tanning laws were less likely to engage in indoor tanning than those in states without any laws. We observed a stronger association among female students in states with systems access, parental permission, and age restriction laws than among those in states without any laws. We found no significant association among female students in states with only systems access and parental permission laws or among male students. Conclusions. Indoor tanning laws, particularly those including age restrictions, may be effective in reducing indoor tanning among female high school students, for whom rates are the highest. Such reductions have the potential to reduce the health and economic burden of skin cancer. C1 [Guy, Gery P., Jr.; Berkowitz, Zahava; Saraiya, Mona] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Jones, Sherry Everett; Olsen, Emily O'Malley; Michael, Shannon L.] Ctr Dis Control & Prevent, Div Adolescent, Atlanta, GA 30341 USA. [Jones, Sherry Everett; Olsen, Emily O'Malley; Michael, Shannon L.] Ctr Dis Control & Prevent, Sch Hlth, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30341 USA. [Miyamoto, Justin N.] Seattle Childrens Hosp, Dept Pediat, Seattle, WA USA. RP Guy, GP (reprint author), Ctr Dis Control & Prevent, Div Canc Prevent & Control, 4770 Buford Highway,NE,MS F-76, Atlanta, GA 30341 USA. EM irm2@cdc.gov NR 39 TC 22 Z9 22 U1 0 U2 4 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD APR PY 2014 VL 104 IS 4 BP E69 EP E74 DI 10.2105/AJPH.2013.301850 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AP0XI UT WOS:000341789200017 PM 24524515 ER PT J AU Baumblatt, JAG Dunn, JR Schaffner, W Moncayo, AC Stull-Lane, A Jones, TF AF Baumblatt, Jane A. Gwira Dunn, John R. Schaffner, William Moncayo, Abelardo C. Stull-Lane, Annica Jones, Timothy F. TI An Outbreak of Bed Bug Infestation in an Office Building SO JOURNAL OF ENVIRONMENTAL HEALTH LA English DT Article ID BITES AB Since 2000, resurgence in bed bugs has occurred in the U.S. Reports of infestations of homes, hospitals, hotels, and offices have been described. On September 1, 2011, complaints of itching and bites among workers in an office were reported to the Tennessee Department of Health. A retrospective cohort study and environmental assessments were performed in response to the complaints. Canines certified to detect live bed bugs were used to inspect the office and arthropod samples were collected. Of 76 office workers, 61 (80%) were interviewed; 39 (64%) met the case definition. Pruritic maculopapular lesions were consistent with arthropod bites. One collected arthropod sample was identified as a bed bug by three entomologists. Exposures associated with symptoms included working in a cubicle in which a canine identified bed bugs (risk ratio [RR]: 1.8; 95% confidence interval [CI]: 1.3-3.6), and self-reported seasonal allergies (RR: 1.6, 95% CI: 1.0-2.4). Bed bugs represent a reemerging and challenging environmental problem with clinical, psychological, and financial impacts. C1 [Baumblatt, Jane A. Gwira] Ctr Dis Control & Prevent, Tennessee Dept Hlth, Hyattsville, MD USA. [Dunn, John R.; Schaffner, William; Jones, Timothy F.] Vanderbilt Univ, Sch Med, Tennessee Dept Hlth, Nashville, TN USA. [Moncayo, Abelardo C.; Stull-Lane, Annica] Tennessee Dept Hlth, Nashville, TN USA. RP Baumblatt, JAG (reprint author), Agcy Healthcare Res & Qual, 540 Gaither Rd, Rockville, MD 20850 USA. EM Jane.Baumblatt@ahrq.hhs.gov NR 9 TC 2 Z9 2 U1 0 U2 9 PU NATL ENVIRON HEALTH ASSOC PI DENVER PA 720 S COLORADO BLVD SUITE 970, SOUTH TOWER, DENVER, CO 80246 USA SN 0022-0892 J9 J ENVIRON HEALTH JI J. Environ. Health PD APR PY 2014 VL 76 IS 8 BP 16 EP 18 PG 3 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA AO7NS UT WOS:000341540500003 PM 24749221 ER PT J AU Murray, HE Thayer, KA AF Murray, H. Edward Thayer, Kristina A. TI Implementing Systematic Review in Toxicological Profiles: ATSDR and NIEHS/NTP Collaboration SO JOURNAL OF ENVIRONMENTAL HEALTH LA English DT Article AB As part of our continuing effort to highlight innovative approaches to improving the health and environment of communities, the Journal is pleased to publish a bimonthly column from the U.S. Agency for Toxic Substances and Disease Registry (ATSDR). ATSDR is a federal public health agency of the U.S. Department of Health and Human Services and shares a common office of the Director with the National Center for Environmental Health at the Centers for Disease Control and Prevention (CDC). ATSDR serves the public by using the best science, taking responsive public health actions, and providing trusted health information to prevent harmful exposures and diseases related to toxic substances. The purpose of this column is to inform readers of ATSDR's activities and initiatives to better understand the relationship between exposure to hazardous substances in the environment and their impact on human health and how to protect public health. We believe that the column will provide a valuable resource to our readership by helping to make known the considerable resources and expertise that ATSDR has available to assist communities, states, and others to assure good environmental health practice for all is served. Dr. Ed Murray is the acting director of the Division of Toxicology and Human Health Science at ATSDR. He has published extensively on chemical pollutants in the environment. Dr. Kristina Thayer is director of the National Toxicology Program's (NTP's) Office of Health Assessment and Translation located on the campus of the National Institute for Environmental Health Sciences (NIEHS). Prior to joining NTP/NIEHS, she was a senior scientist at the World Wildlife Fund and at the Environmental Working Group. C1 ATSDR, Div Toxicol & Human Hlth Sci, Atlanta, GA 30341 USA. RP Murray, HE (reprint author), ATSDR, Div Toxicol & Human Hlth Sci, Chamblee Bldg 106,3rd Floor,Room 3031, Atlanta, GA 30341 USA. EM HEM0@cdc.gov NR 10 TC 1 Z9 1 U1 0 U2 1 PU NATL ENVIRON HEALTH ASSOC PI DENVER PA 720 S COLORADO BLVD SUITE 970, SOUTH TOWER, DENVER, CO 80246 USA SN 0022-0892 J9 J ENVIRON HEALTH JI J. Environ. Health PD APR PY 2014 VL 76 IS 8 BP 34 EP 35 PG 2 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA AO7NS UT WOS:000341540500006 PM 24749224 ER PT J AU Cooper, RH Smalligan, RD Stoughton, C Richardson, JM Duke, D Geissler, AL Rao, AK Bennett, SD Harvey, R Syeda, S Nixon-Lewis, B AF Cooper, Robert H. Smalligan, Roger D. Stoughton, Casie Richardson, J. M. Duke, Deree Geissler, Aimee L. Rao, Agam K. Bennett, Sarah D. Harvey, Reid Syeda, Sara Nixon-Lewis, Beverly TI WHEN EYES DROOP AND THINGS GET BLURRY - THINK BOTULISM SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 37th Annual Meeting of the Society-General-Internal-Medicine CY APR 23-26, 2014 CL San Diego, CA SP Soc Gen Internal Med C1 [Cooper, Robert H.; Smalligan, Roger D.; Syeda, Sara; Nixon-Lewis, Beverly] Texas Tech Univ HSC, Amarillo, TX USA. [Geissler, Aimee L.; Rao, Agam K.; Bennett, Sarah D.; Harvey, Reid] Ctr Dis Control & Prevent, Atlanta, GA USA. [Stoughton, Casie; Richardson, J. M.; Duke, Deree] Potter Randall BiCty, Amarillo, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2014 VL 29 SU 1 BP S468 EP S468 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AO0JZ UT WOS:000340996202442 ER PT J AU Hurley, L Lindley, MC Allison, M Crane, LA Brtnikova, M Beaty, B Snow, M Bridges, C Kempe, A AF Hurley, Laura Lindley, Megan C. Allison, Mandy Crane, Lori A. Brtnikova, Michaela Beaty, Brenda Snow, Megan Bridges, Carolyn Kempe, Allison TI PHYSICIAN REPORTED USE OF STRATEGIES TO IMPROVE ADULT IMMUNIZATION SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 37th Annual Meeting of the Society-General-Internal-Medicine CY APR 23-26, 2014 CL San Diego, CA SP Soc Gen Internal Med C1 [Hurley, Laura; Allison, Mandy; Crane, Lori A.; Brtnikova, Michaela; Beaty, Brenda; Snow, Megan; Kempe, Allison] Childrens Hosp Colorado, Aurora, CO USA. [Hurley, Laura] Denver Hlth, Denver, CO USA. [Allison, Mandy; Beaty, Brenda; Kempe, Allison] Univ Colorado, Aurora, CO USA. [Lindley, Megan C.; Bridges, Carolyn] Ctr Dis Control & Prevent, Atlanta, GA USA. [Crane, Lori A.] Univ Colorado, Colorado Sch Publ Hlth, Denver, CO 80202 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2014 VL 29 SU 1 BP S173 EP S174 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AO0JZ UT WOS:000340996201048 ER PT J AU Hurley, L Lindley, MC Allison, M Crane, LA Brtnikova, M Beaty, B Snow, M Bridges, C Kempe, A AF Hurley, Laura Lindley, Megan C. Allison, Mandy Crane, Lori A. Brtnikova, Michaela Beaty, Brenda Snow, Megan Bridges, Carolyn Kempe, Allison TI FINANCIAL ISSUES AND ADULT IMMUNIZATION: MEDICARE COVERAGE AND THE AFFORDABLE CARE ACT SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 37th Annual Meeting of the Society-General-Internal-Medicine CY APR 23-26, 2014 CL San Diego, CA SP Soc Gen Internal Med C1 [Hurley, Laura; Allison, Mandy; Crane, Lori A.; Brtnikova, Michaela; Beaty, Brenda; Snow, Megan; Kempe, Allison] Childrens Hosp Colorado, Aurora, CO USA. [Hurley, Laura] Denver Hlth, Denver, CO USA. [Allison, Mandy; Beaty, Brenda; Kempe, Allison] Univ Colorado, Aurora, CO USA. [Lindley, Megan C.; Bridges, Carolyn] Ctr Dis Control & Prevent, Atlanta, GA USA. [Crane, Lori A.] Univ Colorado, Colorado Sch Publ Hlth, Denver, CO 80202 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2014 VL 29 SU 1 BP S98 EP S99 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AO0JZ UT WOS:000340996200235 ER PT J AU Krauskopf, K Kil, N Sofianou, A Toribio, W Lyons, J Singer, M Kannry, J Smiith, B Rein, DB Federman, A AF Krauskopf, Katherine Kil, Natalie Sofianou, Anastasia Toribio, Wilma Lyons, Joanne Singer, Mark Kannry, Joseph Smiith, Bryce Rein, David B. Federman, Alex TI EVALUATION OF AN ELECTRONIC HEALTH RECORD PROMPT FOR HEPATITIS C ANTIBODY SCREENING OF BABY BOOMERS EN PRIMARY CARE - A CLUSTER RANDOMIZED CONTROL TRIAL SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 37th Annual Meeting of the Society-General-Internal-Medicine CY APR 23-26, 2014 CL San Diego, CA SP Soc Gen Internal Med C1 [Krauskopf, Katherine; Kil, Natalie; Sofianou, Anastasia; Toribio, Wilma; Kannry, Joseph; Federman, Alex] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. [Lyons, Joanne; Singer, Mark] Mt Sinai Hlth Syst, Huntington, NY USA. [Rein, David B.] Univ Chicago, NORC, Atlanta, GA USA. [Smiith, Bryce] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2014 VL 29 SU 1 BP S88 EP S89 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AO0JZ UT WOS:000340996200214 ER PT J AU Cegielski, JP Griffith, DE McGaha, PK Wolfgang, M Robinson, CB Clark, PA Hassell, WL Robison, VA Walker, KP Wallace, C AF Cegielski, J. Peter Griffith, David E. McGaha, Paul K. Wolfgang, Melanie Robinson, Celia B. Clark, Patricia A. Hassell, Willis L. Robison, Valerie A. Walker, Kerfoot P., Jr. Wallace, Charles TI Eliminating Tuberculosis One Neighborhood at a Time SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID UNITED-STATES; INFECTION; HOSPITALIZATION; HEALTH AB Objectives. We evaluated a strategy for preventing tuberculosis (TB) in communities most affected by it. Methods. In 1996, we mapped reported TB cases (1985-1995) and positive tuberculin skin test (TST) reactors (1993-1995) in Smith County, Texas. We delineated the 2 largest, densest clusters, identifying 2 highest-incidence neighborhoods (180 square blocks, 3153 residents). After extensive community preparation, trained health care workers went door-to-door offering TST to all residents unless contraindicated. TST-positive individuals were escorted to a mobile clinic for radiography, clinical evaluation, and isoniazid preventive treatment (IPT) as indicated. To assess long-term impact, we mapped all TB cases in Smith County during the equivalent time period after the project. Results. Of 2258 eligible individuals, 1291 (57.1%) were tested, 229 (17.7%) were TST positive, and 147 were treated. From 1996 to 2006, there were no TB cases in either project neighborhood, in contrast with the preintervention decade and the continued occurrence of TB in the rest of Smith County. Conclusions. Targeting high-incidence neighborhoods for active, community-based screening and IPT may hasten TB elimination in the United States. C1 [Cegielski, J. Peter; Wolfgang, Melanie; Robison, Valerie A.] Ctr Dis Control & Prevent CDC, Atlanta, GA USA. [Griffith, David E.; Clark, Patricia A.; Hassell, Willis L.] Univ Texas Hlth Sci Ctr, Tyler, TX USA. [McGaha, Paul K.; Robinson, Celia B.] Texas Dept State Hlth Serv, Tyler, TX USA. [Walker, Kerfoot P., Jr.] Smith Cty Publ Hlth Dist, Tyler, TX USA. [Wallace, Charles] Texas Dept State Hlth Serv, Austin, TX USA. RP Cegielski, JP (reprint author), CDC, Mailstop E-10,1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM pcegielski@cdc.gov FU Tuberculosis Innovative Demonstration Project Grant from the Texas Department of State Health Services, Austin FX This project was supported by a Tuberculosis Innovative Demonstration Project Grant from the Texas Department of State Health Services, Austin. NR 18 TC 0 Z9 0 U1 0 U2 0 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD APR PY 2014 VL 104 SU 2 BP S225 EP S233 DI 10.2105/AJPH.2012.300781 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AO5DH UT WOS:000341361900007 ER PT J AU Runyan, C Garrettson, M Yee, SL AF Runyan, Carol Garrettson, Mariana Yee, Sue Lin TI Development of a Set of Indicators to Evaluate Injury Control Research Centers SO EVALUATION REVIEW LA English DT Article DE methodological development; measurement; methodology; academic research; injury ID TRANSDISCIPLINARY RESEARCH; TEAM SCIENCE; COLLABORATION; HEALTH AB Background: Few methods have been defined for evaluating the individual and collective impacts of academic research centers. In this project, with input from injury center directors, we systematically defined indicators to assess the progress and contributions of individual Injury Control Research Centers (ICRCs) and, ultimately, to monitor progress of the overall injury center program. Method: We used several methods of deriving a list of recommended priority and supplemental indicators. This included published literature review, telephone interviews with selected federal agency staff, an e-mail survey of injury center directors, an e-mail survey of staff at the Centers for Disease Control and Prevention, a two-stage Delphi process (e-mailed), and an in-person focus group with injury center directors. We derived the final indicators from an analysis of ratings of potential indicators by center directors and CDC staff. We also examined qualitative responses to open-ended items that address conceptual and implementation issues. Results: All currently funded ICRCs participated in at least one part of the process, resulting in a list of 27 primary indicators (some with subcomponents), 31 supplemental indicators, and multiple suggestions for using the indicators. Conclusion: Our results support an approach that combines standardized definitions and quantifiable indicators with qualitative reporting, which allows consideration of center distinctions and priorities. The center directors urged caution in using the indicators, given funding constraints and recognition of unique institutional environments. While focused on injury research centers, we suggest these indicators also may be useful to academic research centers of other types. C1 [Runyan, Carol; Garrettson, Mariana] SAVIR, Birmingham, AL USA. [Runyan, Carol] Colorado Sch Publ Hlth, Dept Epidemiol, Aurora, CO 80045 USA. [Runyan, Carol] Univ Colorado, Pediat Injury Prevent Educ & Res PIPER Program, Denver, CO 80202 USA. [Garrettson, Mariana] Univ N Carolina, Injury Prevent Res Ctr, Chapel Hill, NC USA. [Yee, Sue Lin] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA. RP Runyan, C (reprint author), Colorado Sch Publ Hlth, 13001 East 17th Pl,Mailstop B119, Aurora, CO 80045 USA. EM carol.runyan@ucdenver.edu NR 15 TC 0 Z9 0 U1 0 U2 1 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0193-841X EI 1552-3926 J9 EVALUATION REV JI Eval. Rev. PD APR PY 2014 VL 38 IS 2 BP 133 EP 159 DI 10.1177/0193841X14529287 PG 27 WC Social Sciences, Interdisciplinary SC Social Sciences - Other Topics GA AN9SC UT WOS:000340947600002 PM 24743645 ER PT J AU Li, RX McNeil, MM Pickering, S Pemberton, MR Duran, LL Collins, LC Nelson, MR Engler, RJM AF Li, Rongxia McNeil, Michael M. Pickering, Susanne Pemberton, Michael R. Duran, Laurie L. Collins, Limone C. Nelson, Michael R. Engler, Renata J. M. TI Military Healthcare Providers Reporting of Adverse Events Following Immunizations to the Vaccine Adverse Event Reporting System SO MILITARY MEDICINE LA English DT Article ID SAFETY AB Objectives: We studied military health care provider (HCP) practices regarding reporting of adverse events following immunization (AEFI). Methods: A convenience sample of HCP was surveyed to assess familiarity with Vaccine Adverse Event Reporting System (VAERS), AEFI they were likely to report, methods used and preferred for reporting, and perceived barriers to reporting. We analyzed factors associated with HCP reporting AEFI to VAERS. Results: A total of 547 surveys were distributed with 487 completed and returned for an 89% response rate. The percentage of HCP aware of VAERS (54%) varied by occupation. 47% of respondents identified knowledge of at least one AEFI with only 34% of these indicating that they had ever reported to VAERS. More serious events were more likely to be reported. Factors associated with HCP reporting AEFIs in bivariate analysis included HCP familiarity with filing a paper VAERS report, HCP familiarity with filing an electronic VAERS report, HCP familiarity with VAERS, and time spent on immunization tasks. In a multivariable analysis, only HCP familiarity with filing a paper VAERS report was statistically significant (Odds ratio = 115.3; p < 0.001). Conclusions: Specific educational interventions targeted to military HCP likely to see AEFIs but not currently filing VAERS reports may improve vaccine safety reporting practices. C1 [Li, Rongxia; McNeil, Michael M.; Pickering, Susanne] Ctr Dis Control & Prevent, Immunizat Safety Off, Atlanta, GA 30333 USA. [Pemberton, Michael R.] RTI Int, Res Triangle Pk, NC 27709 USA. [Duran, Laurie L.; Collins, Limone C.; Nelson, Michael R.; Engler, Renata J. M.] US Army Publ Hlth Command, Walter Reed Natl Mil Med Ctr, Healthcare Ctr Network, Mil Vaccine Agcy, Gaithersburg, MD 20899 USA. RP Li, RX (reprint author), Ctr Dis Control & Prevent, Immunizat Safety Off, MS D-26,1600 Clifton Rd NE, Atlanta, GA 30333 USA. FU Centers for Disease Control and Prevention FX The authors thank the following individuals for their invaluable assistance with this study: Sandra L. Schneider, DrPH; Patricia A. Hutchinson, MD; John Grabenstein, PharmD, PhD; Mary C. Minor, FNP; Jeannette F. Williams, FNP; Sheila L. Hill, RN; Bryan L. Martin, DO; Christina Spooner, MS; Elaine Colen; and the supporting staff of the Vaccine Healthcare Centers Network (Walter Reed National Military Medical Center, Bethesda, MD; Womack Army Medical Center, Fort Bragg, NC; Wilford Hall Medical Center, San Antonio, TX; and Naval Medical Center Portsmouth, VA). The authors also thank RTI personnel for their assistance with the study and Frank DeStefano, MD MPH for critical review of the manuscript. The funding for this study was provided solely by the Centers for Disease Control and Prevention. NR 13 TC 1 Z9 1 U1 0 U2 1 PU ASSOC MILITARY SURG US PI BETHESDA PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA SN 0026-4075 EI 1930-613X J9 MIL MED JI Milit. Med. PD APR PY 2014 VL 179 IS 4 BP 435 EP 441 DI 10.7205/MILMED-D-13-00391 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA AN7UK UT WOS:000340806300013 PM 24690969 ER PT J AU Maddox, RA Person, MK Minino, AM Blevins, JE Schonberger, LB Belay, ED AF Maddox, Ryan A. Person, Marissa K. Minino, Arialdi M. Blevins, Janis E. Schonberger, Lawrence B. Belay, Ermias D. TI Creutzfeldt-Jakob disease in the aging United States population SO PRION LA English DT Meeting Abstract C1 [Maddox, Ryan A.; Person, Marissa K.; Schonberger, Lawrence B.; Belay, Ermias D.] Ctr Dis Control & Prevent CDC, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Minino, Arialdi M.] CDC, Natl Ctr Hlth Stat, Hyattsville, MD USA. [Blevins, Janis E.] Case Western Reserve Univ, Natl Prion Dis Pathol Surveillance Ctr NPDPSC, Cleveland, OH 44106 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LANDES BIOSCIENCE PI AUSTIN PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA SN 1933-6896 EI 1933-690X J9 PRION JI Prion PD APR-JUN PY 2014 VL 8 SU S MA P.204 BP 122 EP 122 PG 1 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA AN5FD UT WOS:000340614900259 ER PT J AU Broz, D Pham, H Spiller, M Wejnert, C Le, B Neaigus, A Paz-Bailey, G AF Broz, Dita Pham, Huong Spiller, Michael Wejnert, Cyprian Le, Binh Neaigus, Alan Paz-Bailey, Gabriela TI Prevalence of HIV Infection and Risk Behaviors Among Younger and Older Injecting Drug Users in the United States, 2009 SO AIDS AND BEHAVIOR LA English DT Article DE Injecting drug users; Young; Risk behaviors; HIV; United States ID HEPATITIS-C-VIRUS; NEW-YORK-CITY; HUMAN-IMMUNODEFICIENCY; SURVEILLANCE SYSTEM; SAN-FRANCISCO; RACIAL/ETHNIC-DISPARITIES; SEXUAL TRANSMISSION; SYNTHESIS PROJECT; TEMPORAL TRENDS; NEEDLE EXCHANGE AB This study compared HIV sero-prevalence and risk behaviors between younger and older injecting drug users (IDUs). IDUs aged >= 18 years were interviewed for the 2009 National HIV Behavioral Surveillance System. Using GEE regression, we assessed characteristics of younger (18-29 years) and older (>= 30 years) IDUs, and factors associated with past 12-month receptive syringe sharing and unprotected sex (vaginal/anal). Of 10,090 participants, 10 % were younger. HIV sero-prevalence was lower among younger than older IDUs (4 vs. 10 %, p = 0.001). Younger IDUs were more likely (p <= 0.002) to be non-black race/ethnicity, report higher household income, homelessness, being arrested and to engage in receptive syringe sharing and unprotected sex. In multivariable models, age remained associated (p < 0.001) with receptive syringe sharing (aPR = 1.14, 95 % CI1.07-1.22) and unprotected sex (aPR = 1.10, 95 % CI1.06-1.14). Although younger IDUs had lower HIV prevalence, their behaviors place them at increased risk of HIV infection and could lead to a rapid spread in this susceptible population. C1 [Broz, Dita; Spiller, Michael; Wejnert, Cyprian; Le, Binh; Paz-Bailey, Gabriela] Ctr Dis Control & Prevent, Behav & Clin Surveillance Branch, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Pham, Huong] ICF Int, Atlanta, GA USA. [Neaigus, Alan] New York City Dept Hlth & Mental Hyg, HIV Epidemiol & Field Serv Program, New York, NY USA. RP Broz, D (reprint author), Ctr Dis Control & Prevent, Behav & Clin Surveillance Branch, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, 1600 Clifton Rd NE,MS-E46, Atlanta, GA 30333 USA. EM dbroz@cdc.gov OI Spiller, Michael/0000-0002-7950-6199 FU Intramural CDC HHS [CC999999] NR 101 TC 8 Z9 8 U1 1 U2 2 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1090-7165 EI 1573-3254 J9 AIDS BEHAV JI AIDS Behav. PD APR PY 2014 VL 18 SU 3 BP S284 EP S296 DI 10.1007/s10461-013-0660-4 PG 13 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA AM4CG UT WOS:000339799000007 PM 24242754 ER PT J AU Burt, RD Oster, AM Golden, MR Thiede, H AF Burt, Richard D. Oster, Alexandra M. Golden, Mathew R. Thiede, Hanne TI Comparing Study Populations of Men Who Have Sex with Men: Evaluating Consistency Within Repeat Studies and Across Studies in the Seattle Area Using Different Recruitment Methodologies SO AIDS AND BEHAVIOR LA English DT Article DE MSM; Recruitment methods; VDTS; HIV prevention; RDD ID HIV BEHAVIORAL SURVEILLANCE; INJECTION-DRUG USERS; UNITED-STATES; PROBABILITY SAMPLE; RISK; PREVENTION; PREVALENCE AB There is no gold standard for recruiting unbiased samples of men who have sex with men (MSM). To assess differing recruitment methods, we compared Seattle-area MSM samples from: venue-day-time sampling-based National HIV Behavioral Surveillance (NHBS) surveys in 2008 and 2011, random-digit-dialed (RDD) surveys in 2003 and 2006, and STD clinic patient data 2001-2011. We compared sociodemographics, sexual and drug-associated behavior, and HIV status and testing. There was generally good consistency between the two NHBS surveys and within STD clinic data across time. NHBS participants reported higher levels of drug-associated and lower levels of sexual risk than STD clinic patients. RDD participants differed from the other study populations in sociodemographics and some risk behaviors. While neither NHBS nor the STD clinic study populations may be representative of all MSM, both appear to provide consistent samples of MSM subpopulations across time that can provide useful information to guide HIV prevention. C1 [Burt, Richard D.; Golden, Mathew R.; Thiede, Hanne] Publ Hlth Seattle & King Cty, HIV STD Program, Seattle, WA 98104 USA. [Oster, Alexandra M.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. [Golden, Mathew R.] Univ Washington, Ctr AIDS & STD, Seattle, WA 98195 USA. RP Burt, RD (reprint author), Publ Hlth Seattle & King Cty, HIV STD Program, 401 Fifth Ave,Suite 1152, Seattle, WA 98104 USA. EM richard.burt@kingcounty.gov FU NCHHSTP CDC HHS [5U62PS000969, U1B PS003250, U62 PS000969]; NIAID NIH HHS [P30 AI027757, P30AI027757]; NIDA NIH HHS [1 R03 DA031072-01A1, R03 DA031072]; PHS HHS [1U1BPS003250] NR 23 TC 3 Z9 3 U1 0 U2 1 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1090-7165 EI 1573-3254 J9 AIDS BEHAV JI AIDS Behav. PD APR PY 2014 VL 18 SU 3 BP S370 EP S381 DI 10.1007/s10461-013-0568-z PG 12 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA AM4CG UT WOS:000339799000016 PM 23900958 ER PT J AU Ivy, W Miles, I Le, B Paz-Bailey, G AF Ivy, Wade, III Miles, Isa Le, Binh Paz-Bailey, Gabriela TI Correlates of HIV Infection Among African American Women from 20 Cities in the United States SO AIDS AND BEHAVIOR LA English DT Article DE HIV; Women; African American; Unaware; NHBS ID SEXUALLY-TRANSMITTED-DISEASES; LOS-ANGELES-COUNTY; CONCURRENT PARTNERSHIPS; RACIAL DISPARITIES; HETEROSEXUAL HIV; RISK BEHAVIOR; BLACK-WOMEN; DRUG-USERS; NETWORKS; PREVENTION AB Little research has been conducted to investigate multiple levels of HIV risk-individual risk factors, sex partner characteristics, and socioeconomic factors-among African American women, who, in 2010, comprised 64 % of the estimated 9,500 new infections in women. Respondent-driven sampling was used to recruit and interview women in 20 cities with high AIDS prevalence in the United States through the National HIV Behavioral Surveillance System. We assessed individual risk factors, sex partner characteristics, and socioeconomic characteristics associated with being HIV-positive but unaware of the infection among African American women. Among 3,868 women with no previous diagnosis of HIV, 68 % had high school education or more and 84 % lived at or below the poverty line. In multivariable analysis, women who were 35 years or older, homeless, received Medicaid, whose last sex partner ever used crack cocaine or was an exchange sex partner were more likely to be HIV-positive-unaware. Developing and implementing strategies that address socioeconomic factors, such as homelessness and living in poverty, as well as individual risk factors, can help to maximize the effectiveness of the public health response to the HIV epidemic. C1 [Ivy, Wade, III; Miles, Isa; Le, Binh; Paz-Bailey, Gabriela] Ctr Dis Control & Prevent, Behav & Clin Surveillance Branch, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. RP Ivy, W (reprint author), Ctr Dis Control & Prevent, Behav & Clin Surveillance Branch, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, 1600 Clifton Rd NE,MS-E46, Atlanta, GA 30333 USA. EM ibw4@cdc.gov FU Intramural CDC HHS [CC999999] NR 63 TC 4 Z9 4 U1 3 U2 5 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1090-7165 EI 1573-3254 J9 AIDS BEHAV JI AIDS Behav. PD APR PY 2014 VL 18 SU 3 BP S266 EP S275 DI 10.1007/s10461-013-0614-x PG 10 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA AM4CG UT WOS:000339799000005 PM 24077972 ER PT J AU Oster, AM Johnson, CH Le, BC Balaji, AB Finlayson, TJ Lansky, A Mermin, J Valleroy, L MacKellar, D Behel, S Paz-Bailey, G AF Oster, Alexandra M. Johnson, Christopher H. Le, Binh C. Balaji, Alexandra B. Finlayson, Teresa J. Lansky, Amy Mermin, Jonathan Valleroy, Linda MacKellar, Duncan Behel, Stephanie Paz-Bailey, Gabriela TI Trends in HIV Prevalence and HIV Testing Among Young MSM: Five United States Cities, 1994-2011 SO AIDS AND BEHAVIOR LA English DT Article DE Young men who have sex with men; HIV prevalence; HIV incidence; HIV testing; Temporal trends ID BEHAVIORAL SURVEILLANCE SYSTEM; SAN-FRANCISCO; RISK BEHAVIORS; BISEXUAL MEN; GAY MEN; SEX; INFECTION; PREVENTION; HEALTH; SEROPREVALENCE AB We examined trends in cross-sectional HIV prevalence (a surrogate for incidence) and past 12 month testing behavior among young men who have sex with men (MSM). The Young Men's Survey and the National HIV Behavioral Surveillance System conducted interviews and HIV testing among MSM recruited by venue-based sampling during 1994-2011. Using data from five cities, we determined whether interview year was associated with HIV prevalence and recent testing for MSM ages 18-22 and 23-29 years, after adjusting for city, race/ethnicity, and education. Multivariable analysis demonstrated an overall increase in prevalence among MSM ages 23-29 years, driven by an increase in Baltimore. There was no change in HIV prevalence among MSM ages 18-22 years overall, although prevalence increased in Baltimore. HIV testing increased significantly for both age groups. Gains in HIV testing are encouraging, but increasing prevalence among young MSM in Baltimore suggests increasing incidence and the need for additional efforts for this population. C1 [Oster, Alexandra M.; Johnson, Christopher H.; Le, Binh C.; Balaji, Alexandra B.; Finlayson, Teresa J.; Lansky, Amy; Mermin, Jonathan; Valleroy, Linda; MacKellar, Duncan; Behel, Stephanie; Paz-Bailey, Gabriela] Ctr Dis Control & Prevent CDC, Div HIV AIDS Prevent, NCHHSTP, Atlanta, GA 30333 USA. RP Oster, AM (reprint author), Ctr Dis Control & Prevent CDC, Div HIV AIDS Prevent, NCHHSTP, 1600 Clifton Rd,MS E-47, Atlanta, GA 30333 USA. EM aoster@cdc.gov NR 32 TC 14 Z9 14 U1 0 U2 5 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1090-7165 EI 1573-3254 J9 AIDS BEHAV JI AIDS Behav. PD APR PY 2014 VL 18 SU 3 BP S237 EP S247 DI 10.1007/s10461-013-0566-1 PG 11 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA AM4CG UT WOS:000339799000002 PM 23955658 ER PT J AU Paz-Bailey, G Raymond, HF Lansky, A Mermin, J AF Paz-Bailey, Gabriela Raymond, H. Fisher Lansky, Amy Mermin, Jonathan TI Using the National HIV Behavioral Surveillance System to Inform HIV Prevention Efforts in the United States SO AIDS AND BEHAVIOR LA English DT Article DE HIV; Behavioral surveillance; MSM; Heterosexuals; IDU ID INJECTION-DRUG USERS; MEN-21 CITIES; INFECTION; SEX; RISK; US AB The National HIV Behavioral Surveillance system (NHBS) was designed to monitor HIV prevalence and risk factors for infection among higher-risk individuals, i.e., sexually active men who have sex with men who attend venues, injection drug users who injected in the past 12 months, and heterosexuals living in low socioeconomic urban areas. These groups were selected as priorities for behavioral surveillance since they represent the major HIV transmission routes and the populations with the highest HIV burden. NHBS contributes to the nation's program of HIV surveillance by being the only multi-site population-based system that provides estimates on key HIV prevention measures among high-risk HIV-negative individuals, HIV-positive individuals unaware of their infection, and HIV-positive individuals aware of their infection who are in and out of care. Accurate and precise data on the behaviors in these populations are critical for tracking the epidemic, planning effective responses, and monitoring and evaluating those responses. Reports in this supplement illustrate the uses of NHBS data at the national and local level and reflect ongoing efforts to improve the system and methods. As we look to the future, behavioral surveillance remains essential for characterizing and monitoring the burden of HIV infection and sexual and behavioral risks. C1 [Paz-Bailey, Gabriela; Lansky, Amy; Mermin, Jonathan] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Raymond, H. Fisher] San Francisco Dept Publ Hlth, San Francisco, CA USA. [Raymond, H. Fisher] Univ Calif San Francisco, San Francisco, CA 94143 USA. RP Paz-Bailey, G (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS E-46, Atlanta, GA 30333 USA. EM gmb5@cdc.gov NR 37 TC 0 Z9 0 U1 1 U2 3 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1090-7165 EI 1573-3254 J9 AIDS BEHAV JI AIDS Behav. PD APR PY 2014 VL 18 SU 3 BP S233 EP S236 DI 10.1007/s10461-014-0738-7 PG 4 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA AM4CG UT WOS:000339799000001 PM 24659359 ER PT J AU Paz-Bailey, G Pham, H Oster, AM Lansky, A Bingham, T Wiegand, RE DiNenno, E Skarbinski, J Heffelfinger, JD AF Paz-Bailey, Gabriela Pham, Huong Oster, Alexandra M. Lansky, Amy Bingham, Trista Wiegand, Ryan E. DiNenno, Elizabeth Skarbinski, Jacek Heffelfinger, James D. TI Engagement in HIV Care Among HIV-Positive Men Who Have Sex with Men From 21 Cities in the United States SO AIDS AND BEHAVIOR LA English DT Article DE Men who have sex with men (MSM); Linkage to care; Antiretroviral therapy (ART); HIV/AIDS; United States ID BEHAVIORAL SURVEILLANCE SYSTEM; ACTIVE ANTIRETROVIRAL THERAPY; SOCIETY-USA PANEL; MEASURING RETENTION; TESTING BEHAVIORS; DELAYED ENTRY; MEDICAL-CARE; PREVENTION; INFECTION; RISK AB We assessed factors associated with HIV care among HIV-infected men who have sex with men (MSM). We used 2008 data on MSM from the National HIV Behavioral Surveillance System (NHBS). Venue-based, time-space sampling was used to recruit and interview men in 21 U.S. cities with high AIDS prevalence. Among self-reported HIV-positive MSM, we used generalized estimating equations (clustered on city of interview) to evaluate factors associated with delayed linkage to care (care entry >3 months after diagnosis), not currently receiving care (no visit for HIV care during the 6 months before the study interview), and not being on antiretroviral therapy (ART). Among 8,153 MSM, 882 (11 %) were self-reported HIV-positive. 25 % had delayed linkage, 12 % were not currently receiving care and among those with at least one heath care visit 30 % were not on ART. In multivariate analysis, lower income and testing positive at their first HIV test were associated with delayed linkage. Age 18-29 years, and not having health insurance were associated with not currently receiving care. Among those with at least one health care visit, being age 18-39 years, having private or no health insurance, and stimulant use were associated with not being on ART. These findings can inform efforts to improve engagement in care. C1 [Paz-Bailey, Gabriela; Oster, Alexandra M.; Lansky, Amy; Wiegand, Ryan E.; DiNenno, Elizabeth; Skarbinski, Jacek; Heffelfinger, James D.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Pham, Huong] ICF Int, Atlanta, GA USA. [Bingham, Trista] Dept Publ Hlth, Los Angeles, CA USA. RP Paz-Bailey, G (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS E-46, Atlanta, GA 30333 USA. EM gmb5@cdc.gov NR 39 TC 11 Z9 11 U1 0 U2 6 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1090-7165 EI 1573-3254 J9 AIDS BEHAV JI AIDS Behav. PD APR PY 2014 VL 18 SU 3 BP S348 EP S358 DI 10.1007/s10461-013-0605-y PG 11 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA AM4CG UT WOS:000339799000014 PM 24026502 ER PT J AU Pitasi, MA Bingham, TA Sey, EK Smith, AJ Teshale, EH AF Pitasi, Marc A. Bingham, Trista A. Sey, Ekow Kwa Smith, Amanda J. Teshale, Eyasu H. TI Hepatitis B Virus (HBV) Infection, Immunity and Susceptibility Among Men Who Have Sex with Men (MSM), Los Angeles County, USA SO AIDS AND BEHAVIOR LA English DT Article DE Hepatitis B virus (HBV); Men who have sex with men (MSM); Gay men; Immunization; Susceptibility ID UNITED-STATES; YOUNG MEN; VACCINATION; RISK; IMMUNIZATION; PREVENTION; SURVEILLANCE; EFFICACY; TRIAL AB Men who have sex with men (MSM) bear a disproportionate burden of hepatitis B virus (HBV) infections. We used serologic data from the National HIV Behavioral Surveillance (NHBS) system to determine the prevalence and correlates of HBV infection, immunization, and susceptibility in a sample of Los Angeles County MSM. Approximately 19 % (95 % CI 15-24 %) had serologic evidence of current or past infection, while 35 % (95 % CI 30-40 %) were susceptible. Compared with the youngest age group, MSM ages 40-49 years had a lower prevalence of immunization (aPR 0.28, 95 % CI 0.17-0.45) and a higher prevalence of infection (aPR 8.53, 95 % CI 3.95-18.4) and susceptibility (aPR 2.02, 95 % CI 1.13-3.63). We also observed poor concordance between self-reported and serologic measures of vaccination. Our results indicate the possibility of missed opportunities to vaccinate MSM. Gaps in implementing existing vaccination strategies must be addressed to increase hepatitis B vaccination coverage for MSM, especially in older age groups. C1 [Pitasi, Marc A.] Emory Univ, Dept Epidemiol, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Bingham, Trista A.; Sey, Ekow Kwa] Los Angeles Cty Dept Publ Hlth, Div HIV & STD Programs, Los Angeles, CA 90005 USA. [Smith, Amanda J.] CDC, Div HIV AIDS Prevent, NCHHSTP, Atlanta, GA 30333 USA. [Teshale, Eyasu H.] CDC, Div Viral Hepatitis, NCHHSTP, Atlanta, GA 30333 USA. RP Bingham, TA (reprint author), Los Angeles Cty Dept Publ Hlth, Div HIV & STD Programs, 600 S Commonwealth Ave,Suite 1920, Los Angeles, CA 90005 USA. EM tub9@cdc.gov FU NCHHSTP CDC HHS [1U62/PS000975-01] NR 28 TC 4 Z9 4 U1 0 U2 2 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1090-7165 EI 1573-3254 J9 AIDS BEHAV JI AIDS Behav. PD APR PY 2014 VL 18 SU 3 BP S248 EP S255 DI 10.1007/s10461-013-0670-2 PG 8 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA AM4CG UT WOS:000339799000003 PM 24276792 ER PT J AU Issack, MI Hendriksen, RS Hyytiae-Trees, E Svendsen, CA Mikoleit, M AF Issack, Mohammad I. Hendriksen, Rene S. Hyytiae-Trees, Eija Svendsen, Christina A. Mikoleit, Matthew TI Emergence and clonal dissemination of Salmonella enterica serovar Enteritidis causing salmonellosis in Mauritius SO JOURNAL OF INFECTION IN DEVELOPING COUNTRIES LA English DT Article DE Salmonella Enteritidis; antimicrobial resistance; human infections; MLVA; Mauritius ID SURVEILLANCE; SEROTYPE AB Introduction: For decades, Salmonella enterica serovar Enteritidis has been among the most prevalent serovars reported worldwide. However, it was rarely encountered in Mauritius until 2007; since then the number of non-typhoidal Salmonella serogroup O:9 (including serovar Enteritidis) increased. A study was conducted to investigate the genetic relatedness between S. Enteritidis isolates recovered in Mauritius from food and clinical specimens (stool, blood, and exudate). Methodology: Forty-seven isolates of S. Enteritidis obtained in 2009 from human stools, blood cultures and exudates, and from food specimens were characterized by antimicrobial susceptibility testing and Multiple-Locus Variable-number tandem repeat Analysis (MLVA). Results: With the exception of a single isolate which demonstrated intermediate susceptibility to streptomycin, all isolates were pansusceptible to the 14 antimicrobials tested. Thirty seven out of the 47 isolates (78.7%) exhibited an indistinguishable MLVA profile which included isolates from ready-to-eat food products, chicken, and human clinical isolates from stool, blood and exudate. Conclusions: The presence of highly related strains in both humans and raw chicken, and the failure to isolate the serovar from other foods, suggests that poultry is the main reservoir of S. Enteritidis in Mauritius and that the majority of human cases are associated with chicken consumption which originated from one major producer. Stool isolates were indistinguishable or closely related to blood and exudate isolates, indicating that, besides gastroenteritis, the same strain caused invasive infections. Control of S. Enteritidis by poultry breeders would lower the financial burden associated with morbidity in humans caused by this organism in Mauritius. C1 [Issack, Mohammad I.] Victoria Hosp, Cent Hlth Lab, Candos, Mauritius. [Hendriksen, Rene S.; Svendsen, Christina A.] Tech Univ Denmark, WHO Collaborating Ctr Antimicrobial Resistance Fo, Lyngby, Denmark. [Hendriksen, Rene S.; Svendsen, Christina A.] Tech Univ Denmark, Natl Food Inst, European Union Reference Lab Antimicrobial Resist, Lyngby, Denmark. [Hyytiae-Trees, Eija; Mikoleit, Matthew] Natl Ctr Emerging & Zoonot Infect Dis, Ctr Dis Control & Prevent, Enter Dis Lab Branch, Div Foodborne Waterborne & Environm Dis, Atlanta, GA USA. RP Issack, MI (reprint author), Victoria Hosp, Cent Hlth Lab, Candos, Mauritius. EM moissack@yahoo.com FU World Health Organization Global Foodborne Infections Network (WHO GFN) FX This work was supported by the World Health Organization Global Foodborne Infections Network (WHO GFN) (www.who.int/gfn). We would also like to thank Mrs. P Lan Keng Lun, Mr RK Lutchun, Miss N Kanaksabee, and all the technical staff of the bacteriology section of the CHL for their technical assistance. Additionally, we would like to thank Ms. Ashley Sabol from CDC for performing MLVA. NR 20 TC 2 Z9 2 U1 0 U2 4 PU J INFECTION DEVELOPING COUNTRIES PI TRAMANIGLIO PA JIDC CENT OFF PORTO CONTE RICERCHE RES CTR, S P 55, PORTO CONTE CAPO CACCIA KM 8.400 LOC, TRAMANIGLIO, 07041, ITALY SN 1972-2680 J9 J INFECT DEV COUNTR JI J. Infect. Dev. Ctries. PD APR PY 2014 VL 8 IS 4 BP 454 EP 460 DI 10.3855/jidc.3695 PG 7 WC Infectious Diseases SC Infectious Diseases GA AM5VA UT WOS:000339927900009 PM 24727511 ER PT J AU Vijayadeva, V Spradling, PR Moorman, AC Rupp, LB Lu, M Gordon, SC Henkle, E Boscarino, JA Teshale, EH Nakasato, C AF Vijayadeva, Vinutha Spradling, Philip R. Moorman, Anne C. Rupp, Loralee B. Lu, Mei Gordon, Stuart C. Henkle, Emily Boscarino, Joseph A. Teshale, Eyasu H. Nakasato, Cynthia TI Hepatitis B Virus Infection Testing and Prevalence Among Asian and Pacific Islanders SO AMERICAN JOURNAL OF MANAGED CARE LA English DT Article ID UNITED-STATES; HEPATOCELLULAR-CARCINOMA; CALIFORNIA; ADULTS; BORN AB Objectives: Asian and Pacific Islanders (APIs) constitute less than 6% of the US population, but account for more than half of Americans with chronic hepatitis B virus (HBV) infection. We sought to examine the effect of country of origin on HBV testing and chronic HBV infection prevalence among APIs. Methods: We analyzed demographic and clinical data collected for adults from Kaiser Permanente Hawaii with 1 or more healthcare encounters during 2006 to 2008, 12 months or more of follow-up before 2009, and no HBV-related diagnosis within 6 months of enrollment. Persons who received a test and a positive test result for HBV surface antigen or HBV DNA were classified "tested" and with "chronic HBV infection," respectively. Results: Of 92,687 eligible APIs, 53,573 (58%) had country-of-origin data available. Among those, 41,263 were US born; 28.3% were tested; and 1.8% of those tested had chronic HBV infection. Of 12,310 foreign-born APIs, 30.5% were tested and 7.4% of those tested had chronic HBV infection. Foreign-born APIs had higher odds of being tested (odds ratio [OR] = 1.15) and testing positive (OR = 4.18) compared with US-born APIs. Persons with 2 or more abnormal tests for alanine aminotransferase (ALT) levels had higher odds of getting tested (OR = 6.12) and of testing positive (OR = 1.86) compared with persons with other ALT levels. Conclusions: Less than one-third of this managed care API population (29% of 53,5731 was tested, yet the prevalence of chronic HBV infection (3.2%) was 12 times higher than that of the general US population. These findings underscore the importance of adherence to HBV testing guidelines to identify persons with infection so they may be linked to care. C1 [Vijayadeva, Vinutha; Nakasato, Cynthia] Kaiser Permanence Ctr Hlth Res Hawaii, Honolulu, HI 96817 USA. [Spradling, Philip R.; Moorman, Anne C.; Teshale, Eyasu H.] Ctr Dis Control & Prevent CDC, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. [Lu, Mei; Gordon, Stuart C.] Henry Ford Hlth Syst, Detroit, MI USA. [Henkle, Emily] Kaiser Permanente Ctr Hlth Res Northwest, Portland, OR USA. [Boscarino, Joseph A.] Geisinger Hlth Syst, Danville, PA USA. RP Vijayadeva, V (reprint author), Kaiser Permanence Ctr Hlth Res Hawaii, 501 Alakawa St,Ste 201, Honolulu, HI 96817 USA. EM vinutha.x.vijayadeva@kp.org FU CDC Foundation; Abbott Laboratories; Genentech, a member of the Roche Group; Janssen Pharmaceutical Companies of Johnson Johnson; Vertex Pharmaceuticals FX CHeCS was funded by the CDC Foundation, which received grants from Abbott Laboratories; Genentech, a member of the Roche Group; Janssen Pharmaceutical Companies of Johnson & Johnson; and Vertex Pharmaceuticals. NR 19 TC 2 Z9 2 U1 1 U2 4 PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC PI PLAINSBORO PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA SN 1088-0224 J9 AM J MANAG CARE JI Am. J. Manag. Care PD APR PY 2014 VL 20 IS 4 BP E98 EP E103 PG 6 WC Health Care Sciences & Services; Health Policy & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AL5AS UT WOS:000339146500002 PM 24884958 ER PT J AU Skinner, MW Soucie, JM McLaughlin, K AF Skinner, Mark W. Soucie, J. Michael McLaughlin, Kathryn TI The National Haemophilia Program Standards, Evaluation and Oversight Systems in the United States of America SO BLOOD TRANSFUSION LA English DT Review DE Haemophilia Treatment Center; Program evaluation; Child Health Bureau (MCHB); Centers for Disease Control and Prevention (CDC); National Hemophilia Foundation (NHF) ID HEALTH-CARE EXPENDITURES; BLEEDING DISORDERS; MALES; SURVEILLANCE C1 [Skinner, Mark W.] Natl Hemophilia Fdn, Washington, DC 20037 USA. [Soucie, J. Michael] Ctr Dis Control & Prevent, Div Blood Disorders, Natl Ctr Birth Defects & Dev Disabil, US Dept HHS, Atlanta, GA USA. [McLaughlin, Kathryn] US Dept HHS, Genet Serv Branch, Div Children Special Hlth Care Needs, Maternal & Child Hlth Bur,Hlth Resources & Serv A, Washington, DC 20201 USA. RP Skinner, MW (reprint author), Natl Hemophilia Fdn, 1155 23rd St NW 3A, Washington, DC 20037 USA. EM mskinnerdc@gmail.com NR 20 TC 2 Z9 2 U1 0 U2 1 PU SIMITI SERVIZI SRL PI MILAN PA VIA DESIDERIO 21, MILAN, 20131, ITALY SN 1723-2007 J9 BLOOD TRANSFUS-ITALY JI Blood Transf. PD APR PY 2014 VL 12 SU 3 BP S542 EP S548 DI 10.2450/2014.0019-14s PG 7 WC Hematology SC Hematology GA AK5SX UT WOS:000338487800011 ER PT J AU Kardous, CA Shaw, PB AF Kardous, Chucri A. Shaw, Peter B. TI Evaluation of smartphone sound measurement applications SO JOURNAL OF THE ACOUSTICAL SOCIETY OF AMERICA LA English DT Article AB This study reports on the accuracy of smartphone sound measurement applications (apps) and whether they can be appropriately employed for occupational noise measurements. A representative sample of smartphones and tablets on various platforms were acquired, more than 130 iOS apps were evaluated but only 10 apps met our selection criteria. Only 4 out of 62 Android apps were tested. The results showed two apps with mean differences of 0.07 dB (unweighted) and -0.52 dB (A-weighted) from the reference values. Two other apps had mean differences within +/- 2 dB. The study suggests that certain apps may be appropriate for use in occupational noise measurements. C1 [Kardous, Chucri A.; Shaw, Peter B.] NIOSH, Cincinnati, OH 45226 USA. RP Kardous, CA (reprint author), NIOSH, 4676 Columbia Pkwy, Cincinnati, OH 45226 USA. EM ckardous@cdc.gov; pbs3@cdc.gov FU Intramural CDC HHS [CC999999] NR 7 TC 29 Z9 29 U1 2 U2 9 PU ACOUSTICAL SOC AMER AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0001-4966 EI 1520-8524 J9 J ACOUST SOC AM JI J. Acoust. Soc. Am. PD APR PY 2014 VL 135 IS 4 BP EL186 EP EL192 DI 10.1121/1.4865269 PG 7 WC Acoustics; Audiology & Speech-Language Pathology SC Acoustics; Audiology & Speech-Language Pathology GA AK3EX UT WOS:000338307200002 PM 25236152 ER PT J AU Hanson, D Allegrante, JP Sleet, DA Finch, CF AF Hanson, Dale Allegrante, John P. Sleet, David A. Finch, Caroline F. TI Research alone is not sufficient to prevent sports injury SO BRITISH JOURNAL OF SPORTS MEDICINE LA English DT Editorial Material ID HEALTH-PROMOTION RESEARCH; IMPLEMENTATION; TRANSLATION; INTERVENTIONS; FRAMEWORK; SCIENCE C1 [Hanson, Dale] James Cook Univ, Sch Publ Hlth Trop Med & Rehabil Sci, Mackay, Qld, Australia. [Allegrante, John P.] Columbia Univ, Teachers Coll, Dept Hlth & Behav Studies, New York, NY 10027 USA. [Allegrante, John P.] Columbia Univ, Mailman Sch Publ Hlth, Dept Sociomed Sci, New York, NY USA. [Sleet, David A.] Ctr Dis Control & Prevent, Div Unintent Injury Prevent, Atlanta, GA USA. [Finch, Caroline F.] Monash Univ, Australian Ctr Res Injury Sport & Its Prevent, Monash Injury Res Inst, Clayton, Vic, Australia. RP Hanson, D (reprint author), Queensland Hlth, Clin Training, Mackay Hlth Serv Dist, Brisbane, Qld, Australia. EM dale.hanson@jcu.edu.au NR 21 TC 9 Z9 9 U1 0 U2 4 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0306-3674 EI 1473-0480 J9 BRIT J SPORT MED JI Br. J. Sports Med. PD APR PY 2014 VL 48 IS 8 BP 682 EP 684 DI 10.1136/bjsports-2012-091434 PG 3 WC Sport Sciences SC Sport Sciences GA AJ0OE UT WOS:000337353600005 PM 22821718 ER PT J AU Rebolledo, J Garvey, P Ryan, A O'Donnell, J Cormican, M Jackson, S Cloak, F Cullen, L Swaan, CM Schimmer, B Appels, RW Nygard, K Finley, R Sreenivasan, N Lenglet, A Gossner, C Mckeown, P AF Rebolledo, J. Garvey, P. Ryan, A. O'Donnell, J. Cormican, M. Jackson, S. Cloak, F. Cullen, L. Swaan, C. M. Schimmer, B. Appels, R. W. Nygard, K. Finley, R. Sreenivasan, N. Lenglet, A. Gossner, C. Mckeown, P. TI International outbreak investigation of Salmonella Heidelberg associated with in-flight catering SO EPIDEMIOLOGY AND INFECTION LA English DT Article DE Aircraft; food poisoning; in-flight catering; international travel; Salmonella ID FOODBORNE OUTBREAK; AIR-TRAVEL; INFECTIOUS-DISEASES; AIRLINE PASSENGERS; AIRCRAFT; ILLNESS; SPREAD; MEALS AB Rapid and wide dispersal of passengers after flights makes investigation of flight-related outbreaks challenging. An outbreak of Salmonella Heidelberg was identified in a group of Irish travellers returning from Tanzania. Additional international cases sharing the same flight were identified. Our aim was to determine the source and potential vehicles of infection. Case-finding utilized information exchange using experts' communication networks and national surveillance systems. Demographic, clinical and food history information was collected. Twenty-five additional cases were identified from Ireland, The Netherlands, Norway, USA and Canada. We conducted a case-control study which indicated a significant association between illness and consumption of milk tart (OR 10.2) and an egg dish (OR 6) served on-board the flight. No food consumed before the flight was associated with illness. Cases from countries other than Ireland provided supplementary information that facilitated the identification of likely vehicles of infection. Timely, committed international collaboration is vital in such investigations. C1 [Rebolledo, J.] European Ctr Dis Prevent & Control ECDC, European Programme Intervent Epidemiol Training, Stockholm, Sweden. [Rebolledo, J.; Garvey, P.; O'Donnell, J.; Jackson, S.; Cloak, F.; Mckeown, P.] Hlth Protect Surveillance Ctr, Dublin, Ireland. [Ryan, A.; Cullen, L.] HSE West Northwest, Dept Publ Hlth Med, Dublin, Ireland. [Cormican, M.] Natl Salmonella Shigella & Listeria Reference Lab, Galway, Ireland. [Swaan, C. M.; Schimmer, B.] Natl Inst Publ Hlth & Environm, Ctr Infect Dis Control, NL-3720 BA Bilthoven, Netherlands. [Appels, R. W.] Publ Hlth Serv Kennemerland, Schippol, Netherlands. [Nygard, K.] Norwegian Inst Publ Hlth, Oslo, Norway. [Finley, R.] Publ Hlth Agcy Canada, Ctr Food Borne Environm & Zoonot Infect Dis, Guelph, ON, Canada. [Sreenivasan, N.] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Lenglet, A.; Gossner, C.] European Ctr Dis Prevent & Control, Surveillance & Response Support Unit, Stockholm, Sweden. RP Rebolledo, J (reprint author), Hlth Protect Surveillance Ctr VPD, 25-27 Middle Gardiner St, Dublin 1, Ireland. EM javierarebolledo@gmail.com NR 31 TC 6 Z9 6 U1 2 U2 15 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0950-2688 EI 1469-4409 J9 EPIDEMIOL INFECT JI Epidemiol. Infect. PD APR PY 2014 VL 142 IS 4 BP 833 EP 842 DI 10.1017/S0950268813001714 PG 10 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA AJ5FY UT WOS:000337709300020 PM 23890227 ER PT J AU Menon, MP Yu, PA Iwamoto, M Painter, J AF Menon, M. P. Yu, P. A. Iwamoto, M. Painter, J. TI Pre-existing medical conditions associated with Vibrio vulnificus septicaemia SO EPIDEMIOLOGY AND INFECTION LA English DT Article DE Pre-existing condition; septicaemia; Vibrio vulnificus ID UNITED-STATES; EPIDEMIOLOGY; INFECTIONS; ILLNESS; DISEASE AB Vibrio vulnificus (Vv) can result in severe disease. Although pre-existing liver disease is a recognized risk factor for serious infection, the relative importance of other comorbidities has not been fully assessed. We analysed reports of Vv infections submitted to CDC from January 1988 to September 2006 in order to assess the role of pre-existing conditions contributing to severe outcomes. A total of 1212 patients with Vv infection were reported. Only patients with liver disease [adjusted odds ratio (aOR) 5.1)] were more likely to become septic when exposure was due to contaminated food. Patients with liver disease (aOR 4.1), a haematological disease (aOR 3.2), or malignancy (aOR 3.2) were more likely to become septic when infection was acquired via a non-foodborne exposure. As such, patients with these pre-existing medical conditions should be advised of the risk of life-threatening illness after eating undercooked contaminated seafood or exposing broken skin to warm seawater. C1 [Menon, M. P.; Yu, P. A.; Iwamoto, M.; Painter, J.] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA USA. RP Menon, MP (reprint author), 1600 Clifton Rd,MS A06, Atlanta, GA 30329 USA. EM manoj@u.washington.edu FU Intramural CDC HHS [CC999999] NR 12 TC 6 Z9 6 U1 3 U2 4 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0950-2688 EI 1469-4409 J9 EPIDEMIOL INFECT JI Epidemiol. Infect. PD APR PY 2014 VL 142 IS 4 BP 878 EP 881 DI 10.1017/S0950268813001593 PG 4 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA AJ5FY UT WOS:000337709300026 PM 23842472 ER PT J AU Yang, QH Zhang, ZF Gregg, EW Flanders, D Merritt, R Hu, FB AF Yang, Quanhe Zhang, Zefeng Gregg, Edward W. Flanders, Dana Merritt, Robert Hu, Frank B. TI Added Sugar Intake and Cardiovascular Diseases Mortality Among US Adults SO JAMA INTERNAL MEDICINE LA English DT Article ID SWEETENED BEVERAGE CONSUMPTION; EPISODICALLY CONSUMED FOODS; CORONARY-HEART-DISEASE; MEASUREMENT ERROR; WEIGHT-GAIN; BODY-WEIGHT; RISK; HEALTH; MEN; INFLAMMATION AB IMPORTANCE Epidemiologic studies have suggested that higher intake of added sugar is associated with cardiovascular disease (CVD) risk factors. Few prospective studies have examined the association of added sugar intake with CVD mortality. OBJECTIVE To examine time trends of added sugar consumption as percentage of daily calories in the United States and investigate the association of this consumption with CVD mortality. DESIGN, SETTING, AND PARTICIPANTS National Health and Nutrition Examination Survey (NHANES, 1988-1994 [III], 1999-2004, and 2005-2010 [n = 31 147]) for the time trend analysis and NHANES III Linked Mortality cohort (1988-2006 [n = 11 733]), a prospective cohort of a nationally representative sample of US adults for the association study. MAIN OUTCOMES AND MEASURES Cardiovascular disease mortality. RESULTS Among US adults, the adjusted mean percentage of daily calories from added sugar increased from 15.7%(95% CI, 15.0%-16.4%) in 1988-1994 to 16.8%(16.0%-17.7%; P =.02) in 1999-2004 and decreased to 14.9%(14.2%-15.5%; P <.001) in 2005-2010. Most adults consumed 10% or more of calories from added sugar (71.4%) and approximately 10% consumed 25% or more in 2005-2010. During a median follow-up period of 14.6 years, we documented 831 CVD deaths during 163 039 person-years. Age-, sex-, and race/ethnicity-adjusted hazard ratios (HRs) of CVD mortality across quintiles of the percentage of daily calories consumed from added sugar were 1.00 (reference), 1.09 (95% CI, 1.05-1.13), 1.23 (1.12-1.34), 1.49 (1.24-1.78), and 2.43 (1.63-3.62; P <.001), respectively. After additional adjustment for sociodemographic, behavioral, and clinical characteristics, HRs were 1.00 (reference), 1.07 (1.02-1.12), 1.18 (1.06-1.31), 1.38 (1.11-1.70), and 2.03 (1.26-3.27; P =.004), respectively. Adjusted HRs were 1.30 (95% CI, 1.09-1.55) and 2.75 (1.40-5.42; P =.004), respectively, comparing participants who consumed 10.0% to 24.9% or 25.0% or more calories from added sugar with those who consumed less than 10.0% of calories from added sugar. These findings were largely consistent across age group, sex, race/ethnicity (except among non-Hispanic blacks), educational attainment, physical activity, health eating index, and body mass index. CONCLUSIONS AND RELEVANCE Most US adults consume more added sugar than is recommended for a healthy diet. We observed a significant relationship between added sugar consumption and increased risk for CVD mortality. C1 [Yang, Quanhe; Zhang, Zefeng; Merritt, Robert] Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Atlanta, GA 30341 USA. [Gregg, Edward W.] Ctr Dis Control & Prevent, Div Diabet Control, Atlanta, GA 30341 USA. [Flanders, Dana] Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA 30322 USA. [Hu, Frank B.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA. [Hu, Frank B.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. RP Yang, QH (reprint author), Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, 4770 Buford Hwy,Mail Stop F-72, Atlanta, GA 30341 USA. EM qay0@cdc.gov NR 57 TC 122 Z9 122 U1 11 U2 62 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD APR PY 2014 VL 174 IS 4 BP 516 EP 524 DI 10.1001/jamainternmed.2013.13563 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA AI4NK UT WOS:000336841900008 PM 24493081 ER PT J AU Peterson, C Ailes, E Riehle-Colarusso, T Oster, ME Olney, RS Cassell, CH Fixler, DE Carmichael, SL Shaw, GM Gilboa, SM AF Peterson, Cora Ailes, Elizabeth Riehle-Colarusso, Tiffany Oster, Matthew E. Olney, Richard S. Cassell, Cynthia H. Fixler, David E. Carmichael, Suzan L. Shaw, Gary M. Gilboa, Suzanne M. TI Late Detection of Critical Congenital Heart Disease Among US Infants Estimation of the Potential Impact of Proposed Universal Screening Using Pulse Oximetry SO JAMA PEDIATRICS LA English DT Article ID BIRTH-DEFECTS PREVENTION; NEWBORN-INFANTS; CARDIOVASCULAR MALFORMATIONS; ASYMPTOMATIC NEWBORNS; DELAYED DIAGNOSIS; NEW-JERSEY; MORTALITY; FEASIBILITY; ACCURACY; FAILURE AB IMPORTANCE Critical congenital heart disease (CCHD) was added to the Recommended Uniform Screening Panel for Newborns in the United States in 2011. Many states have recently adopted or are considering requirements for universal CCHD screening through pulse oximetry in birth hospitals. Limited previous research is directly applicable to the question of how many US infants with CCHD might be identified through screening. OBJECTIVES To estimate the proportion of US infants with late detection of CCHD (>3 days after birth) based on existing clinical practice and to investigate factors associated with late detection. DESIGN, SETTING, AND PARTICIPANTS Descriptive and multivariable analysis. Data were obtained from a multisite population-based study of birth defects in the United States, the National Birth Defects Prevention Study (NBDPS). We included all live-born infants with estimated dates of delivery from January 1, 1998, through December 31, 2007, and nonsyndromic, clinically verified CCHD conditions potentially detectable through screening via pulse oximetry. MAIN OUTCOMES AND MEASURES The main outcome measure was the proportion of infants with late detection of CCHD through echocardiography or at autopsy under the assumption that universal screening at birth hospitals might reduce the number of such late diagnoses. Secondary outcome measures included prevalence ratios for associations between selected demographic and clinical factors and late detection of CCHD. RESULTS Of 3746 live-born infants with nonsyndromic CCHD, late detection occurred in 1106 (29.5%[95% CI, 28.1%-31.0%]), including 6 (0.2%) (0.1%-0.4%) first receiving a diagnosis at autopsy more than 3 days after birth. Late detection varied by CCHD type from 9 of 120 infants (7.5%[95% CI, 3.5%-13.8%]) with pulmonary atresia to 497 of 801 (62.0% [58.7%-65.4%]) with coarctation of the aorta. In multivariable analysis, late detection varied significantly by CCHD type and study site, and infants with extracardiac defects were significantly less likely to have late detection of CCHD (adjusted prevalence ratio, 0.58 [95% CI, 0.49-0.69]). CONCLUSIONS AND RELEVANCE We estimate that 29.5% of live-born infants with nonsyndromic CCHD in the NBDPS received a diagnosis more than 3 days after birth and therefore might have benefited from routine CCHD screening at birth hospitals. The number of infants in whom CCHD was detected through screening likely varies by several factors, including CCHD type. Additional population-based studies of screening in practice are needed. Copyright 2014 American Medical Association. All rights reserved. C1 [Peterson, Cora; Ailes, Elizabeth; Riehle-Colarusso, Tiffany; Oster, Matthew E.; Olney, Richard S.; Cassell, Cynthia H.; Gilboa, Suzanne M.] Ctr Dis Control & Prevent, Div Birth Defects & Dev Disabil, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30341 USA. [Ailes, Elizabeth] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Sci Educ & Profess Dev Program Off, Atlanta, GA 30341 USA. [Oster, Matthew E.] Emory Univ, Childrens Healthcare Atlanta, Sibley Heart Ctr, Atlanta, GA 30322 USA. [Fixler, David E.] Univ Texas SW Med Ctr Dallas, Dept Pediat, Dallas, TX 75390 USA. [Carmichael, Suzan L.; Shaw, Gary M.] Stanford Univ, Sch Med, Dept Pediat, Div Neonatal & Dev Med, Palo Alto, CA 94304 USA. RP Peterson, C (reprint author), Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Mailstop F-62,4770 Buford Hwy, Atlanta, GA 30341 USA. EM cora.peterson@cdc.hhs.gov OI Peterson, Cora/0000-0001-7955-0977 FU Centers for Disease Control and Prevention (CDC) [PA 96043, PA 02081, FOA DD09-001] FX This study was supported by cooperative agreements under PA 96043, PA 02081 and FOA DD09-001 from the Centers for Disease Control and Prevention (CDC). NR 51 TC 27 Z9 28 U1 0 U2 5 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6203 EI 2168-6211 J9 JAMA PEDIATR JI JAMA Pediatr. PD APR PY 2014 VL 168 IS 4 BP 361 EP 370 DI 10.1001/jamapediatrics.2013.4779 PG 10 WC Pediatrics SC Pediatrics GA AI4MJ UT WOS:000336839200013 PM 24493342 ER PT J AU Kim, SY Sharma, AJ Sappenfield, W Wilson, HG Salihu, HM AF Kim, Shin Y. Sharma, Andrea J. Sappenfield, William Wilson, Hoyt G. Salihu, Hamisu M. TI Association of Maternal Body Mass Index, Excessive Weight Gain, and Gestational Diabetes Mellitus With Large-for-Gestational-Age Births SO OBSTETRICS AND GYNECOLOGY LA English DT Article ID UNITED-STATES; OBESITY; OVERWEIGHT; TRENDS; RISK AB OBJECTIVE: To estimate the percentage of large-for-gestational age (LGA) neonates associated with maternal overweight and obesity, excessive gestational weight gain, and gestational diabetes mellitus (GDM)-both individually and in combination-by race or ethnicity. METHODS: We analyzed 2004-2008 linked birth certificate and maternal hospital discharge data of live, singleton deliveries in Florida. We used multivariable logistic regression to assess the independent contributions of mother's prepregnancy body mass index (BMI), gestational weight gain, and GDM status on LGA (birth weight-for-gestational age 90th percentile or greater) risk by race and ethnicity while controlling for maternal age, nativity, and parity. We then calculated the adjusted population-attributable fraction of LGA neonates to each of these exposures. RESULTS: Large-for-gestational age prevalence was 5.7% among normal-weight women with adequate gestational weight gain and no GDM and 12.6%, 13.5% and 17.3% among women with BMIs of 25 or higher, excess gestational weight gain, and GDM, respectively. A reduction ranging between 46.8% in Asian and Pacific Islanders and 61.0% in non-Hispanic black women in LGA prevalence might result if women had none of the three exposures. For all race or ethnic groups, GDM contributed the least (2.0-8.0%), whereas excessive gestational weight gain contributed the most (33.3-37.7%) to LGA. CONCLUSION: Overweight and obesity, excessive gestational weight gain, and GDM all are associated with LGA; however, preventing excessive gestational weight gain has the greatest potential to reduce LGA risk. C1 Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. US Publ Hlth Serv Commissioned Corps, Atlanta, GA USA. Univ S Florida, Coll Publ Hlth, Tampa, FL USA. Univ S Florida, Dept Biostat & Epidemiol, Tampa, FL USA. DB Consulting Grp Inc, Silver Spring, MD USA. RP Kim, SY (reprint author), 4770 Buford Highway,NE MS K-23, Atlanta, GA 30341 USA. EM skim1@cdc.gov OI Sharma, Andrea/0000-0003-0385-0011 FU Intramural CDC HHS [CC999999] NR 18 TC 46 Z9 47 U1 1 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0029-7844 EI 1873-233X J9 OBSTET GYNECOL JI Obstet. Gynecol. PD APR PY 2014 VL 123 IS 4 BP 737 EP 744 DI 10.1097/AOG.0000000000000177 PG 8 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA AI4BC UT WOS:000336809300003 PM 24785599 ER PT J AU Whiteman, MK Tepper, NK Kottke, M Curtis, KM Goedken, P Mandel, MG Marchbanks, PA AF Whiteman, Maura K. Tepper, Naomi K. Kottke, Melissa Curtis, Kathryn M. Goedken, Peggy Mandel, Michele G. Marchbanks, Polly A. TI Using a Checklist to Assess Pregnancy in Teenagers and Young Women SO OBSTETRICS AND GYNECOLOGY LA English DT Article ID FAMILY-PLANNING CLIENTS; STEROID-CONTRACEPTIVES; INUTERO EXPOSURE; JOB AID; RULE AB OBJECTIVE: Health care providers should assess pregnancy in women seeking contraceptive services. Although urine pregnancy tests are available in most U. S. settings, their accuracy varies based on timing relative to missed menses, recent intercourse, or recent pregnancy. We examined the performance of a checklist based on criteria recommended in family planning guidance documents to assist health care providers in assessing pregnancy in a sample of U. S. teenagers and young women. METHODS: Study participants were a convenience sample of sexually active black females aged 14-19 years seeking care in an urban family planning clinic. Each participant provided a urine sample for pregnancy testing and was then administered the checklist in two formats, audio computer-assisted self-interview and in-person interview. We estimated measures of the checklist performance compared with urine pregnancy test as the reference standard, including negative predictive value, sensitivity, specificity, and positive predictive value. RESULTS: Of 350 participants, 31 (8.9%) had a positive urine pregnancy test. The audio computer-assisted self-interview checklist indicated pregnancy was unlikely for 250 participants, of whom 241 had a negative urine pregnancy test (negative predictive value596.4%). The sensitivity of the audio computer-assisted self-interview checklist was 71%, the specificity was 75.6%, and the positive predictive value was 22%. The in-person checklist yielded similar results. CONCLUSION: The checklist may be a valuable tool to assist in assessing pregnancy in teenagers and young women. Appropriate use of the checklist by family planning providers in combination with discussion and clinically indicated use of urine pregnancy tests may reduce unnecessary barriers to contraception in this population. C1 Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. Emory Univ, Sch Med, Dept Gynecol & Obstet, Atlanta, GA USA. RP Whiteman, MK (reprint author), Ctr Dis Control & Prevent, 4770 Buford Highway NE,Mailstop F-74, Atlanta, GA 30341 USA. EM acq5@cdc.gov FU Centers for Disease Control and Prevention [U48DP001909-01] FX Supported by Cooperative Agreement Number U48DP001909-01 from the Centers for Disease Control and Prevention. NR 18 TC 0 Z9 0 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0029-7844 EI 1873-233X J9 OBSTET GYNECOL JI Obstet. Gynecol. PD APR PY 2014 VL 123 IS 4 BP 777 EP 784 DI 10.1097/AOG.0000000000000179 PG 8 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA AI4BC UT WOS:000336809300008 PM 24785604 ER PT J AU Sinno, AK Saraiya, M Thompson, TD Hernandez, BY Goodman, MT Steinau, M Lynch, CF Cozen, W Saber, MS Peters, ES Wilkinson, EJ Copeland, G Hopenhayn, C Watson, M Lyu, C Unger, ER AF Sinno, Abdulrahman K. Saraiya, Mona Thompson, Trevor D. Hernandez, Brenda Y. Goodman, Marc T. Steinau, Martin Lynch, Charles F. Cozen, Wendy Saber, Maria Sibug Peters, Edward S. Wilkinson, Edward J. Copeland, Glenn Hopenhayn, Claudia Watson, Meg Lyu, Christopher Unger, Elizabeth R. TI Human Papillomavirus Genotype Prevalence in Invasive Vaginal Cancer From a Registry-Based Population SO OBSTETRICS AND GYNECOLOGY LA English DT Article ID UNITED-STATES; PARTICLE VACCINE; CARCINOMA; DNA; HPV; WOMEN; INFECTION AB OBJECTIVE: To describe the human papillomavirus (HPV) genotype distribution in invasive vaginal cancers diagnosed before the introduction of the HPV vaccine and evaluate if survival differed by HPV status. METHODS: Four population-based registries and three residual tissue repositories provided formalin-fixed, paraffin-embedded tissue from microscopically confirmed primary vaginal cancer cases diagnosed between 1994 and 2005 that were tested by L1 consensus polymerase chain reaction with type-specific hybridization in a central laboratory. Clinical, demographic, and all-cause survival data were assessed by HPV status. RESULTS: Sixty cases of invasive vaginal cancer were included. Human papillomavirus was detected in 75% (45) and 25% (15) were HPV-negative. HPV 16 was most frequently detected (55% [33/60]) followed by HPV 33 (18.3% [11/60]). Only one case was positive for HPV 18 (1.7%) Multiple types were detected in 15% of the cases. Vaginal cancers in women younger than 60 years were more likely to be HPV 16- or HPV 18-positive (HPV 16 and 18) than older women, 77.3% compared with 44.7% (P=.038). The median age at diagnosis was younger in the HPV 16 and 18 (59 years) group compared with other HPV-positive (68 years) and no HPV (77 years) (P=.003). The HPV distribution did not significantly vary by race or ethnicity or place of residence. The 5-year unadjusted all-cause survival was 57.4% for women with HPV-positive vaginal cancers compared with 35.7% among those with HPV-negative tumors (P=.243). CONCLUSION: Three fourths of all vaginal cancers in the United States had HPV detected, much higher than previously found, and 57% could be prevented by current HPV vaccines. C1 Johns Hopkins Univ, Dept Gynecol & Obstet, Kelly Gynecol Oncol Serv, Baltimore, MD USA. Emory Univ, Div Gynecol Oncol, Dept Gynecol & Obstet, Atlanta, GA 30322 USA. Ctr Dis Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Canc Prevent & Control, Atlanta, GA 30333 USA. Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. Univ Hawaii, Ctr Canc, Honolulu, HI 96822 USA. Univ Iowa, Coll Publ Hlth, Dept Epidemiol, Iowa City, IA USA. Univ So Calif, Keck Sch Med, Norris Comprehens Canc Ctr, Los Angeles, CA 90033 USA. Univ So Calif, Dept Pathol, Keck Sch Med, Los Angeles, CA 90089 USA. Louisiana State Univ, Hlth Sci Ctr, Sch Publ Hlth, Dept Epidemiol, New Orleans, LA USA. Univ Florida, Coll Med, Dept Pathol Immunol & Lab Med, Gainesville, FL USA. Florida Dept Hlth, Tallahassee, FL USA. Michigan Dept Community Hlth, Lansing, MI USA. Univ Kentucky, Coll Publ Hlth, Dept Epidemiol, Lexington, KY USA. Battelle Mem Inst, Durham, NC USA. RP Saraiya, M (reprint author), 4770 Buford Highway,Mailstop K76, Atlanta, GA 30341 USA. EM msaraiya@cdc.gov OI /0000-0003-4928-6532; Sinno, Abdulrahman/0000-0002-4630-3408 FU Merck and Co, Inc. FX Dr. Hernandez has received consultation and speaker fees from Merck and Co, Inc. The other authors did not report any potential conflicts of interest. NR 21 TC 10 Z9 10 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0029-7844 EI 1873-233X J9 OBSTET GYNECOL JI Obstet. Gynecol. PD APR PY 2014 VL 123 IS 4 BP 817 EP 821 DI 10.1097/AOG.0000000000000171 PG 5 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA AI4BC UT WOS:000336809300014 PM 24785610 ER PT J AU Verani, JR Spina, NL Lynfield, R Schaffner, W Harrison, LH Holst, A Thomas, S Garcia, JM Scherzinger, K Aragon, D Petit, S Thompson, J Pasutti, L Carey, R McGee, L Weston, E Schrag, SJ AF Verani, Jennifer R. Spina, Nancy L. Lynfield, Ruth Schaffner, William Harrison, Lee H. Holst, Amy Thomas, Stepy Garcia, Jessica M. Scherzinger, Karen Aragon, Deborah Petit, Susan Thompson, Jamie Pasutti, Lauren Carey, Roberta McGee, Lesley Weston, Emily Schrag, Stephanie J. TI Early-Onset Group B Streptococcal Disease in the United States Potential for Further Reduction SO OBSTETRICS AND GYNECOLOGY LA English DT Article ID INTRAPARTUM ANTIBIOTIC-PROPHYLAXIS; CONJUGATE VACCINE; PREVENTION; TIME; COLONIZATION; EPIDEMIOLOGY; ACCURACY; TESTS; WOMEN; ASSAY AB OBJECTIVE: To describe lapses in adherence to group B streptococcus (GBS) prevention guidelines among cases of early-onset GBS disease in term and preterm neonates and to estimate the potential for further reduction in disease burden under current prevention strategies. METHODS: We reviewed labor and delivery and prenatal records of mothers of neonates with early-onset GBS disease (aged younger than 7 days with GBS isolated from a normally sterile site) identified at population-based surveillance sites in 2008-2009. We interviewed prenatal care providers about GBS screening practices and obtained relevant laboratory records. We evaluated the data for errors in prenatal screening, laboratory methods, communication of results, and intrapartum antibiotic prophylaxis. Using published data on screening sensitivity and intrapartum prophylaxis effectiveness, we estimated the potential reduction in cases under optimal prevention implementation. RESULTS: Among 309 cases, 179 (57.9%) had one or more implementation errors. The most common error type in term and preterm case-patients was prenatal screening (80 of 222 [ 36.0%]) and intrapartum prophylaxis (46 of 85 [ 54.1%]), respectively. We estimated that under optimal implementation, cases of early-onset GBS disease could be reduced by 26-59% with the largest benefit from a single intervention coming from improved use of intrapartum prophylaxis (16% decrease). CONCLUSION: Further reduction of early-onset GBS disease burden is possible under current prevention strategies, particularly with improved implementation of antibiotic prophylaxis. However, even with perfect adherence to recommended practices, the decline in cases may be modest. Therefore, novel prevention approaches such as improved intrapartum assays and vaccines are also needed. C1 Ctr Dis Control & Prevent, Georgia Emerging Infect Program, Atlanta VA Med Ctr, Atlanta, GA USA. Georgia Dept Community Hlth, Atlanta, GA USA. New York State Dept Hlth, Emerging Infect Program, Albany, NY USA. Minnesota Dept Hlth, St Paul, MN USA. Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA. Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA. Univ New Mexico, Albuquerque, NM 87131 USA. Colorado Dept Publ Hlth & Environm, Denver, CO USA. Connecticut Dept Publ Hlth, Hartford, CT USA. Oregon Publ Hlth Div, Portland, OR USA. Calif Emerging Infect Program, Oakland, CA USA. RP Verani, JR (reprint author), 1600 Clifton Rd,MS-C25, Atlanta, GA 30307 USA. EM jverani@cdc.gov NR 19 TC 15 Z9 15 U1 3 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0029-7844 EI 1873-233X J9 OBSTET GYNECOL JI Obstet. Gynecol. PD APR PY 2014 VL 123 IS 4 BP 828 EP 837 DI 10.1097/AOG.0000000000000163 PG 10 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA AI4BC UT WOS:000336809300016 PM 24785612 ER PT J AU Li, TG Miller, CH Driggers, J Payne, AB Ellingsen, D Hooper, WC AF Li, Tengguo Miller, Connie H. Driggers, Jennifer Payne, Amanda B. Ellingsen, Dorothy Hooper, W. Craig TI Mutation analysis of a cohort of US patients with hemophilia B SO AMERICAN JOURNAL OF HEMATOLOGY LA English DT Article ID FACTOR-IX-GENE; F9 MUTATIONS; INHIBITOR; POPULATION; PREVALENCE; DELETIONS; INSIGHTS; DATABASE; THERAPY; SERIES AB Hemophilia B (HB) is a disorder resulting from genetic mutations in the Factor 9 gene (F9). Genotyping of HB patients is important for genetic counseling and patient management. Here we report a study of mutations identified in a large sample of HB patients in the US. Patients were enrolled through an inhibitor surveillance study at 17 hemophilia treatment centers. A total of 87 unique mutations were identified from 225 of the 226 patients, including deletions, insertions, and point mutations. Point mutations were distributed throughout the F9 gene and were found in 86% of the patients. Of these mutations, 24 were recurrent in the population, and 3 of them (c.316G>A, c.1025C>T, and c.1328T>A) accounted for 84 patients (37.1%). Haplotype analysis revealed that the high recurrence arose from a founder effect. The severity of HB was found to correlate with the type of mutation. Inhibitors developed only in severe cases with large deletions and nonsense mutations. None of the mild or moderate patients developed inhibitors. Our results provide a resource describing F9 mutations in US HB patients and confirm previous findings that patients bearing large deletions and nonsense mutations are at high risk of developing inhibitors. Am. J. Hematol. 89:375-379, 2014. Published 2013. C1 [Li, Tengguo; Miller, Connie H.; Driggers, Jennifer; Payne, Amanda B.; Ellingsen, Dorothy; Hooper, W. Craig] Ctr Dis Control & Prevent, Div Blood Disorders, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. RP Li, TG (reprint author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, 1600 Clifton Rd,MS D02, Atlanta, GA 30333 USA. EM uyy7@cdc.gov OI Miller, Connie H/0000-0002-3989-7973 FU CDC Foundation (through Pfizer Inc.); CDC Foundation (through Baxter Healthcare) FX Contract grant sponsor: CDC Foundation (through Pfizer Inc. and Baxter Healthcare). NR 28 TC 4 Z9 4 U1 3 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0361-8609 EI 1096-8652 J9 AM J HEMATOL JI Am. J. Hematol. PD APR PY 2014 VL 89 IS 4 BP 375 EP 379 DI 10.1002/ajh.23645 PG 5 WC Hematology SC Hematology GA AF3XL UT WOS:000334645900005 PM 24375831 ER PT J AU Mhyre, JM Tsen, LC Einav, S Kuklina, EV Leffert, LR Bateman, BT AF Mhyre, Jill M. Tsen, Lawrence C. Einav, Sharon Kuklina, Elena V. Leffert, Lisa R. Bateman, Brian T. TI Cardiac Arrest during Hospitalization for Delivery in the United States, 1998-2011 SO ANESTHESIOLOGY LA English DT Article ID CHRONIC HEART-DISEASE; MATERNAL MORBIDITY; CARDIOPULMONARY-RESUSCITATION; PREGNANCY; MORTALITY; SURVIVAL; WOMEN; RISK AB Background: The objective of this analysis was to evaluate the frequency, distribution of potential etiologies, and survival rates of maternal cardiopulmonary arrest during the hospitalization for delivery in the United States. Methods: By using data from the Nationwide Inpatient Sample during the years 1998 through 2011, the authors obtained weighted estimates of the number of U.S. hospitalizations for delivery complicated by maternal cardiac arrest. Clinical and demographic risk factors, potential etiologies, and outcomes were identified and compared in women with and without cardiac arrest. The authors tested for temporal trends in the occurrence and survival associated with maternal arrest. Results: Cardiac arrest complicated 1 in 12,000 or 8.5 per 100,000 hospitalizations for delivery (99% CI, 7.7 to 9.3 per 100,000). The most common potential etiologies of arrest included hemorrhage, heart failure, amniotic fluid embolism, and sepsis. Among patients with cardiac arrest, 58.9% of patients (99% CI, 54.8 to 63.0%) survived to hospital discharge. Conclusions: Approximately 1 in 12,000 hospitalizations for delivery is complicated by cardiac arrest, most frequently due to hemorrhage, heart failure, amniotic fluid embolism, or sepsis. Survival depends on the underlying etiology of arrest. C1 [Mhyre, Jill M.] Univ Michigan Hlth Syst, Dept Anesthesiol, Ann Arbor, MI USA. [Tsen, Lawrence C.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Anesthesiol Perioperat & Pain Med, Boston, MA 02115 USA. [Einav, Sharon] Shaare Zedek Med Ctr, Intens Care Unit, Jerusalem, Israel. [Einav, Sharon] Hebrew Univ Jerusalem, Sch Med, IL-91010 Jerusalem, Israel. [Kuklina, Elena V.] US Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Atlanta, GA USA. [Leffert, Lisa R.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesiol Crit Care & Pain Med, Boston, MA USA. [Bateman, Brian T.] Massachusetts Gen Hosp, Dept Anesthesiol Crit Care & Pain Med, Boston, MA 02114 USA. [Bateman, Brian T.] Harvard Univ, Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, Dept Med,Med Sch, Boston, MA 02115 USA. RP Mhyre, JM (reprint author), Univ Arkansas Med Sci, Dept Anesthesiol, 4301 West Markham St,Slot 515, Little Rock, AR 72205 USA. EM jmmhyre@uams.edu OI Tsen, Lawrence/0000-0002-1964-723X FU Intramural CDC HHS [CC999999] NR 32 TC 33 Z9 36 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0003-3022 EI 1528-1175 J9 ANESTHESIOLOGY JI Anesthesiology PD APR PY 2014 VL 120 IS 4 BP 810 EP 818 DI 10.1097/ALN.0000000000000159 PG 9 WC Anesthesiology SC Anesthesiology GA AG4HT UT WOS:000335381000009 PM 24694844 ER PT J AU Salje, H Gurley, ES Homaira, N Ram, PK Haque, R Petri, W Moss, WJ Luby, SP Breysse, P Azziz-Baumgartner, E AF Salje, H. Gurley, E. S. Homaira, N. Ram, P. K. Haque, R. Petri, W. Moss, W. J. Luby, S. P. Breysse, P. Azziz-Baumgartner, E. TI Impact of neighborhood biomass cooking patterns on episodic high indoor particulate matter concentrations in clean fuel homes in Dhaka, Bangladesh SO INDOOR AIR LA English DT Article DE Biomass; Air pollution; Particulate matter; Cookstove; Bangladesh ID GENERALIZED ADDITIVE-MODELS; AIR-POLLUTION; RESPIRATORY-INFECTIONS; DEVELOPING-COUNTRIES; SUBCHRONIC EXPOSURE; WOOD SMOKE; AREAS; URBAN; RATS AB Exposure to particulate matter (PM2.5) from the burning of biomass is associated with increased risk of respiratory disease. In Dhaka, Bangladesh, households that do not burn biomass often still experience high concentrations of PM2.5, but the sources remain unexplained. We characterized the diurnal variation in the concentrations of PM2.5 in 257 households and compared the risk of experiencing high PM2.5 concentrations in biomass and non-biomass users. Indoor PM2.5 concentrations were estimated every minute over 24h once a month from April 2009 through April 2010. We found that households that used gas or electricity experienced PM2.5 concentrations exceeding 1000 mu g/m(3) for a mean of 35min within a 24-h period compared with 66min in biomass-burning households. In both households that used biomass and those that had no obvious source of particulate matter, the probability of PM2.5 exceeding 1000 mu g/m(3) were highest during distinct morning, afternoon, and evening periods. In such densely populated settings, indoor pollution in clean fuel households may be determined by biomass used by neighbors, with the highest risk of exposure occurring during cooking periods. Community interventions to reduce biomass use may reduce exposure to high concentrations of PM2.5 in both biomass and non-biomass using households. C1 [Salje, H.; Gurley, E. S.; Moss, W. J.; Breysse, P.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Gurley, E. S.; Homaira, N.; Haque, R.; Luby, S. P.; Azziz-Baumgartner, E.] Int Ctr Diarrheal Dis Res Bangladesh, Dhaka, Bangladesh. [Ram, P. K.] SUNY Buffalo, Sch Publ Hlth & Hlth Profess, Buffalo, NY 14260 USA. [Petri, W.] Univ Virginia, Charlottesville, VA USA. [Luby, S. P.; Azziz-Baumgartner, E.] Ctr Dis Control & Prevent CDC, Global Dis Detect Program, Atlanta, GA USA. RP Salje, H (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth JHSPH, E6003,615 N Wolfe St, Baltimore, MD 21205 USA. EM hsalje@jhsph.edu RI Gurley, Emily/B-7903-2010; OI Gurley, Emily/0000-0002-8648-9403; Luby, Stephen/0000-0001-5385-899X; Salje, Henrik/0000-0003-3626-4254 FU United States Centers for Disease Control and Prevention (CDC) [U01/CI000628-02]; National Institutes of Health, USA (NIH) [5R01 AI043596] FX This study was funded by the United States Centers for Disease Control and Prevention (CDC), Grant number U01/CI000628-02 and the National Institutes of Health, USA (NIH), Grant number 5R01 AI043596. ICDDR, B acknowledges with gratitude the commitment of CDC and NIH to its research efforts. The authors would like to thank Dr. Justin Lessler for his advice on statistical approaches. The authors also wish to thank the children and their families for their participation in this cohort. NR 29 TC 5 Z9 5 U1 3 U2 12 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0905-6947 EI 1600-0668 J9 INDOOR AIR JI Indoor Air PD APR PY 2014 VL 24 IS 2 BP 213 EP 220 DI 10.1111/ina.12065 PG 8 WC Construction & Building Technology; Engineering, Environmental; Public, Environmental & Occupational Health SC Construction & Building Technology; Engineering; Public, Environmental & Occupational Health GA AC8HC UT WOS:000332773100011 PM 24033488 ER PT J AU Lyles, RD Moore, NM Weiner, SB Sikka, M Lin, MY Weinstein, RA Hayden, MK Sinkowitz-Cochran, RL AF Lyles, Rosie D. Moore, Nicholas M. Weiner, Shayna B. Sikka, Monica Lin, Michael Y. Weinstein, Robert A. Hayden, Mary K. Sinkowitz-Cochran, Ronda L. CA CDC Prevention Epictr Program TI Understanding Staff Perceptions about Klebsiella pneumoniae Carbapenemase-Producing Enterobacteriaceae Control Efforts in Chicago Long-Term Acute Care Hospitals SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID RESISTANT STAPHYLOCOCCUS-AUREUS; NEW-YORK-CITY; QUALITY IMPROVEMENT; ORGANIZATIONAL CULTURE; HEALTH-CARE; INFECTION; EMERGENCE; OUTBREAK; IMPACT; SPREAD AB Objective.To identify differences in organizational culture and better understand motivators to implementation of a bundle intervention to control Klebsiella pneumoniae carbapenemase--producing Enterobacteriaceae (KPC).Design.Mixed-methods study.Setting.Four long-term acute care hospitals (LTACHs) in Chicago.Participants.LTACH staff across 3 strata of employees (administration, midlevel management, and frontline clinical workers).Methods.Qualitative interviews or focus groups and completion of a quantitative questionnaire.Results.Eighty employees (frontline, 72.5%; midlevel, 17.5%; administration, 10%) completed surveys and participated in qualitative discussions in August 2012. Although 82.3% of respondents felt that quality improvement was a priority at their LTACH, there were statistically significant differences in organizational culture between staff strata, with administrative-level having higher organizational culture scores (ie, more favorable responses) than midlevel or frontline staff. When asked to rank the success of the KPC control program, mean response was 8.0 (95% confidence interval, 7.6--8.5), indicating a high level of agreement with the perception that the program was a success. Patient safety and personal safety were reported most often as personal motivators for intervention adherence. The most convergent theme related to prevention across groups was that proper hand hygiene is vital to prevention of KPC transmission.Conclusions.Despite differences in organizational culture across 3 strata of LTACH employees, the high degree of convergence in motivation, understanding, and beliefs related to implementation of a KPC control bundle suggests that all levels of staff may be able to align perspectives when faced with a key infection control problem and quality improvement initiative. C1 [Lyles, Rosie D.; Weinstein, Robert A.] John H Stroger Hosp Cook Cty, Div Infect Dis, Chicago, IL USA. [Moore, Nicholas M.] Rush Univ, Med Ctr, Dept Med Lab Sci, Chicago, IL 60612 USA. [Weiner, Shayna B.; Lin, Michael Y.; Weinstein, Robert A.; Hayden, Mary K.] Rush Univ, Med Ctr, Infect Dis Sect, Chicago, IL 60612 USA. [Sikka, Monica] Univ Illinois, Infect Dis Sect, Chicago, IL USA. [Hayden, Mary K.] Rush Univ, Dept Pathol, Med Ctr, Chicago, IL 60612 USA. [Sinkowitz-Cochran, Ronda L.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA USA. RP Lyles, RD (reprint author), 1900 West Polk St,Suite 1256, Chicago, IL 60612 USA. EM rlyles@cookcountyhhs.org FU Centers for Disease Control and Prevention (CDC) Prevention Epicenters Program [1U54CK000161] FX Financial support. This study was supported in part by the Centers for Disease Control and Prevention (CDC) Prevention Epicenters Program (R.A.W., principal investigator; 1U54CK000161). NR 27 TC 0 Z9 0 U1 1 U2 3 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X EI 1559-6834 J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD APR 1 PY 2014 VL 35 IS 4 SI SI BP 367 EP 374 DI 10.1086/675596 PG 8 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA AC2DP UT WOS:000332308400007 PM 24602941 ER PT J AU Epson, EE Pisney, LM Wendt, JM MacCannell, DR Janelle, SJ Kitchel, B Rasheed, JK Limbago, BM Gould, CV Kallen, AJ Barron, MA Bamberg, WM AF Epson, Erin E. Pisney, Larissa M. Wendt, Joyanna M. MacCannell, Duncan R. Janelle, Sarah J. Kitchel, Brandon Rasheed, J. Kamile Limbago, Brandi M. Gould, Carolyn V. Kallen, Alexander J. Barron, Michelle A. Bamberg, Wendy M. TI Carbapenem-Resistant Klebsiella pneumoniae Producing New Delhi Metallo-beta-Lactamase at an Acute Care Hospital, Colorado, 2012 SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID GLOBAL SPREAD; ENTEROBACTERIACEAE; OUTBREAK; EPIDEMIOLOGY; CANADA AB Objective.To investigate an outbreak of New Delhi metallo--lactamase (NDM)--producing carbapenem-resistant Enterobacteriaceae (CRE) and determine interventions to interrupt transmission.Design, Setting, and Patients.Epidemiologic investigation of an outbreak of NDM-producing CRE among patients at a Colorado acute care hospital.Methods.Case patients had NDM-producing CRE isolated from clinical or rectal surveillance cultures (SCs) collected during the period January 1, 2012, through October 20, 2012. Case patients were identified through microbiology records and 6 rounds of SCs in hospital units where they had resided. CRE isolates were tested by real-time polymerase chain reaction for bla(NDM). Medical records were reviewed for epidemiologic links; relatedness of isolates was evaluated by pulsed-field gel electrophoresis (PFGE) and whole genome sequencing (WGS). Infection control (IC) was assessed through staff interviews and direct observations.Results.Two patients were initially identified with NDM-producing CRE during July--August 2012. A third case patient, admitted in May, was identified through microbiology records review. SC identified 5 additional case patients. Patients had resided in 11 different units before identification. All isolates were highly related by PFGE. WGS suggested 3 clusters of CRE. Combining WGS with epidemiology identified 4 units as likely transmission sites. NDM-producing CRE positivity in certain patients was not explained by direct epidemiologic overlap, which suggests that undetected colonized patients were involved in transmission.Conclusions.A 4-month outbreak of NDM-producing CRE occurred at a single hospital, highlighting the risk for spread of these organisms. Combined WGS and epidemiologic data suggested transmission primarily occurred on 4 units. Timely SC, combined with targeted IC measures, were likely responsible for controlling transmission. C1 [Epson, Erin E.; Wendt, Joyanna M.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. [Epson, Erin E.; Janelle, Sarah J.; Bamberg, Wendy M.] Colorado Dept Publ Hlth & Environm, Denver, CO 80246 USA. [Pisney, Larissa M.; Barron, Michelle A.] Univ Colorado, Div Infect Dis, Aurora, CO USA. [Wendt, Joyanna M.; Kitchel, Brandon; Rasheed, J. Kamile; Limbago, Brandi M.; Gould, Carolyn V.; Kallen, Alexander J.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA USA. [MacCannell, Duncan R.] Ctr Dis Control & Prevent, Antimicrobial Resistance & Characterizat Lab, Atlanta, GA USA. RP Epson, EE (reprint author), Colorado Dept Publ Hlth & Environm, 4300 Cherry Creek Dr South, Denver, CO 80246 USA. EM erin.epson@state.co.us FU Centers for Disease Control and Prevention Emerging Infections Program grant FX Financial support. W.M.B. and S.J.J. report grant support through the Centers for Disease Control and Prevention Emerging Infections Program grant. NR 30 TC 20 Z9 20 U1 0 U2 1 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X EI 1559-6834 J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD APR 1 PY 2014 VL 35 IS 4 SI SI BP 390 EP 397 DI 10.1086/675607 PG 8 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA AC2DP UT WOS:000332308400010 PM 24602944 ER PT J AU Mortensen, E Trivedi, KK Rosenberg, J Cody, SH Long, J Jensen, BJ Vugia, DJ AF Mortensen, Eva Trivedi, Kavita K. Rosenberg, Jon Cody, Sara H. Long, Janet Jensen, Bette J. Vugia, Duc J. TI Multidrug-Resistant Acinetobacter baumannii Infection, Colonization, and Transmission Related to a Long-Term Care Facility Providing Subacute Care SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID CARBAPENEMASE-PRODUCING ENTEROBACTERIACEAE; KLEBSIELLA-PNEUMONIAE; HOSPITALS; EPIDEMIOLOGY; CARRIAGE; OUTBREAK; FEATURES AB Objective.To investigate Acinetobacter baumannii infection, colonization, and transmission related to a long-term care facility (LTCF) providing subacute care (facility A).Methods.We reviewed facility A and affiliated local hospital records for facility A residents with A. baumannii isolated during the period January 2009 through February 2010 and compared A. baumannii antimicrobial resistance patterns of residents with those of hospital patients. During March 2010, we implemented a colonization survey of facility A residents who received respiratory support or who could provide sputum samples and looked for A. baumannii colonization risks. Available clinical and survey isolates underwent pulsed-field gel electrophoresis (PFGE); PFGE strains were linked with overlapping stays to identify possible transmission.Results.During the period January 2009 through February 2010, 33 facility A residents had A. baumannii isolates; all strains were multidrug resistant (MDR), which was a significantly higher prevalence of MDR strains than that found among isolates from hospital patients (81 [66%%] of 122 hospital patient isolates were MDR; P < .001). The sputum survey found that 14 (20%%) of 70 residents had A. baumannii colonization, which was associated with ventilator use (adjusted odds ratio, 4.24 [95%% confidence interval, 1.06--16.93]); 12 (86%%) of 14 isolates were MDR. Four facility A resident groups clustered with 3 PFGE strains and overlapping stays. One of these facility A residents also clustered with 3 patients at an affiliated hospital.Conclusions.We documented substantial MDR A. baumannii infections and colonization with probable intra- and interfacility spread associated with a single LTCF providing subacute care. Given the limited infection prevention and antimicrobial stewardship resources in such settings, regional collaborations among facilities across the spectrum of health care are needed to address this MDR threat. C1 [Mortensen, Eva; Vugia, Duc J.] Calif Dept Publ Hlth, Ctr Infect Dis, Div Communicable Dis Control, Richmond, CA USA. [Mortensen, Eva] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Sci Educ & Profess Dev Program Off, Atlanta, GA USA. [Trivedi, Kavita K.; Rosenberg, Jon] Calif Dept Publ Hlth, Ctr Hlth Care Qual, Healthcare Associated Infect Program, Richmond, CA USA. [Cody, Sara H.] Santa Clara Cty Publ Hlth Dept, San Jose, CA USA. [Long, Janet] John Muir Hlth, Concord, CA USA. [Jensen, Bette J.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. RP Vugia, DJ (reprint author), Infect Dis Branch, 850 Marina Bay Pkwy,Bldg P,2nd Floor, Richmond, CA 94804 USA. EM duc.vugia@cdph.ca.gov NR 29 TC 9 Z9 10 U1 0 U2 8 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X EI 1559-6834 J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD APR 1 PY 2014 VL 35 IS 4 SI SI BP 406 EP 411 DI 10.1086/675612 PG 6 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA AC2DP UT WOS:000332308400012 PM 24602946 ER PT J AU Pereira, EC Shaw, KM Vagnone, PMS Harper, JE Kallen, AJ Limbago, BM Lynfield, R AF Pereira, Edwin C. Shaw, Kristin M. Vagnone, Paula M. Snippes Harper, Jane E. Kallen, Alexander J. Limbago, Brandi M. Lynfield, Ruth TI Thirty-Day Laboratory-Based Surveillance for Carbapenem-Resistant Enterobacteriaceae in the Minneapolis-St. Paul Metropolitan Area SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article AB Carbapenem-resistant Enterobacteriaceae (CRE) are a growing problem in the United States. We explored the feasibility of active laboratory-based surveillance of CRE in a metropolitan area not previously considered to be an area of CRE endemicity. We provide a framework to address CRE surveillance and to monitor changes in the incidence of CRE infection over time. C1 [Pereira, Edwin C.] Univ Minnesota, Div Infect Dis & Int Med, Minneapolis, MN USA. [Shaw, Kristin M.; Vagnone, Paula M. Snippes; Harper, Jane E.; Lynfield, Ruth] Minnesota Dept Hlth, St Paul, MN USA. [Kallen, Alexander J.; Limbago, Brandi M.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA USA. RP Pereira, EC (reprint author), 420 Delaware St SE,MMC 250, Minneapolis, MN 55455 USA. EM pere0051@umn.edu FU CDC [3U01CI000313]; Applied Epidemiology Fellowship Program; Council of State and Territorial Epidemiologists [5U38HM000414] FX Financial support. This report was funded by CDC cooperative agreement 3U01CI000313 and supported in part by an appointment to the Applied Epidemiology Fellowship Program administered by the Council of State and Territorial Epidemiologists under cooperative agreement 5U38HM000414. NR 3 TC 2 Z9 2 U1 0 U2 0 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X EI 1559-6834 J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD APR 1 PY 2014 VL 35 IS 4 SI SI BP 423 EP 425 DI 10.1086/675602 PG 3 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA AC2DP UT WOS:000332308400015 PM 24602949 ER PT J AU Florence, C Shepherd, J Brennan, I Simon, TR AF Florence, Curtis Shepherd, Jonathan Brennan, Iain Simon, Thomas R. TI An economic evaluation of anonymised information sharing in a partnership between health services, police and local government for preventing violence-related injury SO INJURY PREVENTION LA English DT Article ID PART 2; CRIME AB Objective To assess the costs and benefits of a partnership between health services, police and local government shown to reduce violence-related injury. Methods Benefit-cost analysis. Results Anonymised information sharing and use led to a reduction in wounding recorded by the police that reduced the economic and social costs of violence by 6.9 million in 2007 compared with the costs the intervention city, Cardiff UK, would have experienced in the absence of the programme. This includes a gross cost reduction of 1.25 pound million to the health service and 1.62 pound million to the criminal justice system in 2007. By contrast, the costs associated with the programme were modest: setup costs of software modifications and prevention strategies were 107769 pound, while the annual operating costs of the system were estimated as 210433 pound (2003 UK pound). The cumulative social benefit-cost ratio of the programme from 2003 to 2007 was 82 pound in benefits for each pound spent on the programme, including a benefit-cost ratio of 14.80 for the health service and 19.1 for the criminal justice system. Each of these benefit-cost ratios is above 1 across a wide range of sensitivity analyses. Conclusions An effective information-sharing partnership between health services, police and local government in Cardiff, UK, led to substantial cost savings for the health service and the criminal justice system compared with 14 other cities in England and Wales designated as similar by the UK government where this intervention was not implemented. C1 [Florence, Curtis] Ctr Dis Control & Prevent, Div Anal Res & Practice Integrat, Atlanta, GA USA. [Shepherd, Jonathan] Cardiff Univ, Violence & Soc Res Grp, Sch Dent, Cardiff CF14 4XY, S Glam, Wales. [Brennan, Iain] Univ Hull, Dept Social Sci, Kingston Upon Hull HU6 7RX, N Humberside, England. [Simon, Thomas R.] Ctr Dis Control & Prevent, Div Violence Prevent, Atlanta, GA USA. RP Shepherd, J (reprint author), Cardiff Univ, Violence & Soc Res Grp, Sch Dent, Cardiff CF14 4XY, S Glam, Wales. EM shepherdjp@cardiff.ac.uk FU Home Office targeted policing fund; Wales Office for Research and Development in Health and Social Care (WORD) [R/98/037] FX The development of the prototype partnership was funded, in part, by a grant from the Home Office targeted policing fund. The effectiveness study (not the benefit-cost analysis) was funded in part by the Wales Office for Research and Development in Health and Social Care (WORD), grant No R/98/037. NR 16 TC 5 Z9 5 U1 10 U2 21 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1353-8047 EI 1475-5785 J9 INJURY PREV JI Inj. Prev. PD APR PY 2014 VL 20 IS 2 BP 108 EP 114 DI 10.1136/injuryprev-2012-040622 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AD2AJ UT WOS:000333034500007 PM 24048916 ER PT J AU Hopenhayn, C Christian, A Christian, WJ Watson, M Unger, ER Lynch, CF Peters, ES Wilkinson, EJ Huang, Y Copeland, G Cozen, W Saber, MS Goodman, MT Hernandez, BY Steinau, M Lyu, C Tucker, TT Saraiya, M AF Hopenhayn, Claudia Christian, Amy Christian, Warren Jay Watson, Meg Unger, Elizabeth R. Lynch, Charles F. Peters, Edward S. Wilkinson, Edward J. Huang, Youjie Copeland, Glenn Cozen, Wendy Saber, Maria Sibug Goodman, Marc T. Hernandez, Brenda Y. Steinau, Martin Lyu, Christopher Tucker, Thomas T. Saraiya, Mona TI Prevalence of Human Papillomavirus Types in Invasive Cervical Cancers From 7 US Cancer Registries Before Vaccine SO JOURNAL OF LOWER GENITAL TRACT DISEASE LA English DT Article DE human papillomavirus; HPV typing; HPV prevalence; invasive cervical cancer ID UNITED-STATES; WORLDWIDE; METAANALYSIS; ATTRIBUTION; PROGNOSIS; BURDEN; ASSAY; DNA AB Objective We conducted a baseline study of human papillomavirus (HPV) type prevalence in invasive cervical cancers (ICCs) using data from 7 cancer registries (CRs) in the United States. Cases were diagnosed between 1994 and 2005 before the implementation of the HPV vaccines. Materials and Methods Cancer registries from Florida, Kentucky, Louisiana, Michigan, Hawaii, Iowa, and Los Angeles, California identified eligible ICC cases and obtained sections from representative blocks of archived tumor specimens for DNA extraction. All extracts were assayed by linear array and, if inadequate or HPV negative, retested with INNO-LiPA Genotype test. Clinical and demographic factors were obtained from the CRs and merged with the HPV typing data to analyze factors associated with different types and with HPV negativity. Results A total of 777 ICCs were included in this analysis, with broad geographic, age, and race distribution. Overall, HPV was detected in 91% of cases, including 51% HPV-16, 16% HPV-18 (HPV-16-negative), and 24% other oncogenic and rare types. After HPV-16 and -18, the most common types were 45, 33, 31, 35, and 52. Older age and nonsquamous histology were associated with HPV-negative typing. Conclusions This study provides baseline prevaccine HPV types for postvaccine ICC surveillance in the future. HPV-16 and/or -18 were found in 67% of ICCs, indicating the potential for vaccines to prevent a significant number of cervical cancers. C1 [Hopenhayn, Claudia; Christian, Amy; Christian, Warren Jay; Tucker, Thomas T.] Univ Kentucky, Coll Publ Hlth, Dept Epidemiol, Lexington, KY 40536 USA. [Watson, Meg; Saraiya, Mona] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Unger, Elizabeth R.; Steinau, Martin] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Lynch, Charles F.] Univ Iowa, Dept Epidemiol, Coll Publ Hlth, Iowa City, IA USA. [Peters, Edward S.] Louisiana State Univ, Hlth Sci Ctr, Sch Publ Hlth, Dept Epidemiol, New Orleans, LA USA. [Wilkinson, Edward J.] Univ Florida, Coll Med, Dept Pathol Immunol & Lab Med, Gainesville, FL USA. [Huang, Youjie] Florida Dept Hlth, Tallahassee, FL USA. [Copeland, Glenn] Michigan Dept Community Hlth, Lansing, MI USA. [Cozen, Wendy; Saber, Maria Sibug] Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90033 USA. [Cozen, Wendy; Saber, Maria Sibug] Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90033 USA. [Goodman, Marc T.; Hernandez, Brenda Y.] Univ Hawaii, Ctr Canc, Honolulu, HI 96822 USA. [Lyu, Christopher] Battelle Mem Inst, Durham, NC USA. [Tucker, Thomas T.] Univ Kentucky, Markey Canc Control Program, Lexington, KY 40536 USA. RP Hopenhayn, C (reprint author), Univ Kentucky, 111 Washington Ave, Lexington, KY 40536 USA. EM claudia.hopenhayn@uky.edu FU Centers for Disease Control and Prevention (CDC) (Kentucky) [5U58DP000810-5]; Centers for Disease Control and Prevention (CDC) (Florida) [5U58DP000844-5]; Centers for Disease Control and Prevention (CDC) (Michigan) [5U58DP000812-5]; Centers for Disease Control and Prevention (CDC) (Louisiana) [5U58DP000769-5]; SEER Program, National Institutes of Health, Department of Health and Human Services (Los Angeles) [N01-PC-35139]; SEER Program, National Institutes of Health, Department of Health and Human Services (Iowa) [N01-PC-35143]; SEER Program, National Institutes of Health, Department of Health and Human Services (Hawaii) [N01-PC-35137]; CDC intramural funds; Vaccine for Children Funds; California Department of Health Services [103885]; National Cancer Institute, National Institutes of Health, Department of Health and Human Services [N01-PC-2010-00035]; CDC [1U58DP000807-3] FX This project was supported in part by the Centers for Disease Control and Prevention (CDC) grant nos. 5U58DP000810-5 (Kentucky), 5U58DP000844-5 (Florida), 5U58DP000812-5 (Michigan), and 5U58DP000769-5 (Louisiana) and from the SEER Program, National Institutes of Health, Department of Health and Human Services, under Contracts N01-PC-35139 (Los Angeles), N01-PC-35143 (Iowa), and N01-PC-35137 (Hawaii). Support for collection of specimens from Kentucky, Florida, Michigan, and Louisiana; coordination of genotyping data from both SEER registry and National Program of Cancer Registries; and genotyping was largely supported by CDC intramural funds and Vaccine for Children Funds.; Data collection from California was largely supported by the California Department of Health Services as part of the statewide cancer reporting program mandated by California Health and Safety Code Section 103885; by the National Cancer Institute, National Institutes of Health, Department of Health and Human Services under Contract N01-PC-2010-00035; and grant number 1U58DP000807-3 from the CDC. NR 27 TC 19 Z9 20 U1 1 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1089-2591 EI 1526-0976 J9 J LOW GENIT TRACT DI JI J. Low. Genit. Tract. Dis. PD APR PY 2014 VL 18 IS 2 BP 182 EP 189 DI 10.1097/LGT.0b013e3182a577c7 PG 8 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA AD7PK UT WOS:000333455900024 PM 24477171 ER PT J AU Yucesoy, B Johnson, VJ Lummus, ZL Kashon, ML Rao, M Bannerman-Thompson, H Frye, B Wang, W Gautrin, D Cartier, A Boulet, LP Sastre, J Quirce, S Tarlo, SM Germolec, DR Luster, MI Bernstein, DI AF Yucesoy, Berran Johnson, Victor J. Lummus, Zana L. Kashon, Michael L. Rao, Marepalli Bannerman-Thompson, Hansen Frye, Bonnie Wang, Wei Gautrin, Denyse Cartier, Andre Boulet, Louis-Philippe Sastre, Joaquin Quirce, Santiago Tarlo, Susan M. Germolec, Dori R. Luster, Michael I. Bernstein, David I. TI Genetic Variants in the Major Histocompatibility Complex Class I and Class II Genes Are Associated With Diisocyanate-Induced Asthma SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE LA English DT Article ID HLA CLASS-II; ISOCYANATE-INDUCED ASTHMA; INDUCED OCCUPATIONAL ASTHMA; EXPOSED WORKERS; POPULATION; ANTIBODIES; SENSITIZATION; ANNOTATION; CONJUGATE; HAPLOTYPE AB Objective: To investigate the association between single nucleotide polymorphisms (SNPs) located across the major histocompatibility complex and susceptibility to diisocyanate-induced asthma (DA). Methods: The study population consisted of 140 diisocyanate-exposed workers. Genotyping was performed using the Illumina GoldenGate major histocompatibility complex panels. Results: The HLA-E rs1573294 and HLA-DPB1 rs928976 SNPs were associated with an increased risk of DA under dominant (odds ratio [OR], 6.27; 95% confidence interval [CI], 2.37 to 16.6; OR, 2.79, 95% CI, 0.99 to 7.81, respectively) and recessive genetic models (OR, 6.27, 95% CI, 1.63 to 24.13; OR, 10.10, 95% CI, 3.16 to 32.33, respectively). The HLA-B rs1811197, HLA-DOA rs3128935, and HLA-DQA2 rs7773955 SNPs conferred an increased risk of DA in a dominant model (OR, 7.64, 95% CI, 2.25 to 26.00; OR, 19.69, 95% CI, 2.89 to 135.25; OR, 8.43, 95% CI, 3.03 to 23.48, respectively). Conclusion: These results suggest that genetic variations within HLA genes play a role in DA risk. C1 [Yucesoy, Berran; Kashon, Michael L.; Frye, Bonnie; Wang, Wei] NIOSH, Hlth Effects Lab Div, CDC, Morgantown, WV USA. [Johnson, Victor J.] BRT, Morrisville, NC USA. [Yucesoy, Berran; Lummus, Zana L.; Bernstein, David I.] Univ Cincinnati, Div Immunol Allergy & Rheumatol, Dept Med, Cincinnati, OH 45267 USA. [Rao, Marepalli; Bannerman-Thompson, Hansen] Univ Cincinnati, Dept Environm Hlth, Cincinnati, OH 45267 USA. [Gautrin, Denyse; Cartier, Andre] Univ Montreal, Hop Sacre Coeur Montreal, Ste Foy, PQ, Canada. [Boulet, Louis-Philippe] Univ Laval, Hop Laval, Ste Foy, PQ G1K 7P4, Canada. [Sastre, Joaquin] Fdn Jimenez Diaz, Dept Allergy, E-28040 Madrid, Spain. CIBER Enfermedades Resp CIBERES, Madrid, Spain. [Quirce, Santiago] Hosp La Paz IdiPAZ, Dept Allergy, Madrid, Spain. [Tarlo, Susan M.] Univ Toronto, Dept Med, Toronto, ON M5S 1A1, Canada. [Germolec, Dori R.] NIEHS, Toxicol Branch, DNTP, Res Triangle Pk, NC 27709 USA. [Luster, Michael I.] W Virginia Univ, Sch Publ Hlth, Morgantown, WV 26506 USA. RP Yucesoy, B (reprint author), Univ Cincinnati, Coll Med, Div Immunol Allergy & Rheumatol, Cincinnati, OH 45267 USA. EM yucesobn@ucmail.uc.edu FU National Institute of Environmental Health Sciences [Y1-ES0001]; National Institute for Occupational Safety and Health [Y1-ES0001]; NIOSH/CDC [R01 OH 008795]; CDC Seed Funding for Public Health Genomics Research Program FX This work was supported in part by an interagency agreement between National Institute of Environmental Health Sciences and National Institute for Occupational Safety and Health (Agreement No. Y1-ES0001), NIOSH/CDC R01 OH 008795 and CDC Seed Funding for Public Health Genomics Research Program. The authors declare no conflict of interest. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the National Institute for Occupational Safety and Health. This article may be the work product of an employee or a group of employees of the National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health (NIH); however, the statements, opinions, or conclusions contained therein do not necessarily represent the statements, opinions, or conclusions of NIEHS, NIH, or the US government. NR 42 TC 7 Z9 7 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1076-2752 EI 1536-5948 J9 J OCCUP ENVIRON MED JI J. Occup. Environ. Med. PD APR PY 2014 VL 56 IS 4 BP 382 EP 387 DI 10.1097/JOM.0000000000000138 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AG6ZJ UT WOS:000335567400013 PM 24709764 ER PT J AU Graves, MA Harris, JR Hannon, PA Hammerback, K Ahmed, F Zhou, C AF Graves, Meredith A. Harris, Jeffrey R. Hannon, Peggy A. Hammerback, Kristen Ahmed, Faruque Zhou, Chuan TI Workplace-Based Influenza Vaccination Promotion Practices Among Large Employers in the United States SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE LA English DT Article ID HEALTH-CARE WORKERS; SEASONAL INFLUENZA; INSTITUTIONAL REQUIREMENTS; INTERVENTIONS; HOSPITALS; COVERAGE; ADULTS; IMPACT; RATES; US AB Objective: Influenza vaccination levels in the working-age population are low. Workplace promotion practices can increase employee vaccination levels, but the extent of employers' use of these practices is unknown. We aimed to estimate the prevalence of employers' use of evidence-based practices for promoting influenza vaccination in the workplace. Methods: We conducted a telephone survey of large employers across the United States regarding their use of evidence-based practices to promote vaccination. Results: Eighty-four percent of 583 employers surveyed offered on-site vaccination. Use of four promotion practices was high (75% or more), but the remaining four practices were used by only a minority of employers. There is particular room for improvement in the use of practices that increase physical access to vaccination. Conclusions: Employers are highly engaged in basic influenza vaccination promotion practices, but there is potential to increase levels of use. C1 [Graves, Meredith A.; Harris, Jeffrey R.; Hannon, Peggy A.; Hammerback, Kristen] Univ Washington, Hlth Promot Res Ctr, Dept Hlth Serv, Sch Publ Hlth, Seattle, WA 98105 USA. [Ahmed, Faruque] Ctr Dis Control & Prevent, Immunizat Serv Div, Atlanta, GA USA. [Zhou, Chuan] Seattle Childrens Res Inst, Seattle, WA USA. RP Graves, MA (reprint author), Univ Washington, Hlth Promot Res Ctr, Dept Hlth Serv, Sch Publ Hlth, 1107 NE 45th St,Suite 200, Seattle, WA 98105 USA. EM cookm3@uw.edu OI Harris, Jeffrey/0000-0001-8728-7195 FU Centers for Disease Control and Prevention, Prevention Research Centers Program, through the University of Washington Health Promotion Research Centers [U48DP001911] FX The Health Promotion Research Center is funded in part by the Centers for Disease Control and Prevention, Prevention Research Centers Program, through the University of Washington Health Promotion Research Centers Cooperative Agreement U48DP001911. NR 27 TC 0 Z9 0 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1076-2752 EI 1536-5948 J9 J OCCUP ENVIRON MED JI J. Occup. Environ. Med. PD APR PY 2014 VL 56 IS 4 BP 397 EP 402 DI 10.1097/JOM.0000000000000115 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AG6ZJ UT WOS:000335567400015 PM 24492538 ER PT J AU Barraza-Villarreal, A Escamilla-Nunez, MC Schilmann, A Hernandez-Cadena, L Li, Z Romanoff, L Sjodin, A Del Rio-Navarro, BE Diaz-Sanchez, D Diaz-Barriga, F Sly, P Romieu, I AF Barraza-Villarreal, Albino Consuelo Escamilla-Nunez, Maria Schilmann, Astrid Hernandez-Cadena, Leticia Li, Zheng Romanoff, Lovisa Sjoedin, Andreas Estela Del Rio-Navarro, Blanca Diaz-Sanchez, David Diaz-Barriga, Fernando Sly, Peter Romieu, Isabelle TI Lung Function, Airway Inflammation, and Polycyclic Aromatic Hydrocarbons Exposure in Mexican Schoolchildren A Pilot Study SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE LA English DT Article ID CITY; CHILDREN; COHORT; POLLUTANTS; POLLUTION; GROWTH; CANCER AB Objective: To determine the association of exposure to polycyclic aromatic hydrocarbons (PAHs) with lung function and pH of exhaled breath condensate (EBC) in Mexican schoolchildren. Methods: A pilot study was performed in a subsample of 64 schoolchildren from Mexico City. Lung function and pH of EBC were measured and metabolites of PAHs in urine samples were determined. The association was analyzed using robust regression models. Results: A 10% increase in the concentrations of 2-hydroxyfluorene was significantly negatively associated with forced expiratory volume in 1 second (-11.2 mL, 95% CI: -22.2 to -0.02), forced vital capacity (-11.6 mL, 95% CI: -22.9 to -0.2), and pH of EBC (-0.035, 95% CI: -0.066 to -0.005). Conclusion: Biomarkers of PAHs exposure were inversely associated with lung function and decrease of ph of EBC as a marker of airway inflammation in Mexican schoolchildren. C1 [Barraza-Villarreal, Albino; Consuelo Escamilla-Nunez, Maria; Schilmann, Astrid; Hernandez-Cadena, Leticia; Romieu, Isabelle] Natl Inst Publ Hlth, Cuernavaca, Morelos, Mexico. [Li, Zheng; Romanoff, Lovisa; Sjoedin, Andreas] Ctr Dis Control & Prevent, Atlanta, GA USA. [Estela Del Rio-Navarro, Blanca] Hosp Infantil Mexico Dr Federico Gomez, Mexico City, DF, Mexico. [Diaz-Sanchez, David] US EPA, Res Triangle Pk, NC 27711 USA. [Diaz-Barriga, Fernando] Univ Autonoma San Luis Potosi, San Luis Potosi, Mexico. [Sly, Peter] Univ Western Australia, Div Clin Sci, Telethon Inst Child Hlth Res, Perth, WA 6009, Australia. Univ Western Australia, Ctr Child Hlth Res, Perth, WA 6009, Australia. [Romieu, Isabelle] Int Agcy Res Canc, F-69372 Lyon 08, France. RP Romieu, I (reprint author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France. EM romieui@iarc.fr RI Sjodin, Andreas/F-2464-2010; Sly, Peter/F-1486-2010 OI Sly, Peter/0000-0001-6305-2201 FU Mexican Sciences and Technology Council (CONACYT) [38911-M, 2002-C01-7624] FX The study was supported by the Mexican Sciences and Technology Council (CONACYT) grant 38911-M and 2002-C01-7624. NR 22 TC 6 Z9 6 U1 0 U2 17 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1076-2752 EI 1536-5948 J9 J OCCUP ENVIRON MED JI J. Occup. Environ. Med. PD APR PY 2014 VL 56 IS 4 BP 415 EP 419 DI 10.1097/JOM.0000000000000111 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AG6ZJ UT WOS:000335567400018 PM 24500378 ER PT J AU Masterson, EA Sweeney, MH Deddens, JA Themann, CL Wall, DK AF Masterson, Elizabeth A. Sweeney, Marie Haring Deddens, James A. Themann, Christa L. Wall, David K. TI Prevalence of Workers With Shifts in Hearing by Industry A Comparison of OSHA and NIOSH Hearing Shift Criteria SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE LA English DT Article ID OCCUPATIONAL NOISE; THRESHOLD SHIFT; PRIMARY-CARE; MANAGEMENT; RISK AB Objective: The purpose of this study was to compare the prevalence of workers with National Institute for Occupational Safety and Health significant threshold shifts (NSTS), Occupational Safety and Health Administration standard threshold shifts (OSTS), and with OSTS with age correction (OSTS-A), by industry using North American Industry Classification System codes. Methods: From 2001 to 2010, worker audiograms were examined. Prevalence and adjusted prevalence ratios for NSTS were estimated by industry. NSTS, OSTS, and OSTS-A prevalences were compared by industry. Results: Twenty percent of workers had an NSTS, 14% had an OSTS, and 6% had an OSTS-A. For most industries, the OSTS and OSTS-A criteria identified 28% to 36% and 66% to 74% fewer workers than the NSTS criteria, respectively. Conclusions: Use of NSTS criteria allowing for earlier detection of shifts in hearing is recommended for improved prevention of occupational hearing loss. C1 [Masterson, Elizabeth A.; Sweeney, Marie Haring; Deddens, James A.; Themann, Christa L.; Wall, David K.] NIOSH, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. RP Masterson, EA (reprint author), NIOSH, Div Surveillance Hazard Evaluat & Field Studies, 4676 Columbia Pkwy,MS-R17, Cincinnati, OH 45226 USA. EM EMasterson@cdc.gov FU Intramural CDC HHS [CC999999] NR 40 TC 3 Z9 3 U1 1 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1076-2752 EI 1536-5948 J9 J OCCUP ENVIRON MED JI J. Occup. Environ. Med. PD APR PY 2014 VL 56 IS 4 BP 446 EP 455 DI 10.1097/JOM.0000000000000124 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AG6ZJ UT WOS:000335567400024 PM 24662953 ER PT J AU Pukuta, ES Esona, MD Nkongolo, A Seheri, M Makasi, M Nyembwe, M Mondonge, V Dahl, BA Mphahlele, MJ Cavallaro, K Gentsch, J Bowen, MD Waku-Kouomou, D Muyembe, JJ AF Pukuta, Elizabeth S. Esona, Mathew D. Nkongolo, Adolphe Seheri, Mapaseka Makasi, Mingiele Nyembwe, Michel Mondonge, Vital Dahl, Benjamin A. Mphahlele, M. Jeffrey Cavallaro, Kathleen Gentsch, Jon Bowen, Michael D. Waku-Kouomou, Diane Muyembe, Jean-Jacques CA SURVAC Working Grp TI Molecular Surveillance of Rotavirus Infection in the Democratic Republic of the Congo August 2009 to June 2012 SO PEDIATRIC INFECTIOUS DISEASE JOURNAL LA English DT Article DE pediatric; Democratic Republic of the Congo; surveillance; rotavirus ID VACCINATION PROGRAMS; CHILDREN; NEUTRALIZATION; EPIDEMIOLOGY; DIVERSITY; DIARRHEA; DISEASE; IMPACT AB Background: Rotavirus is a major cause of severe diarrhea worldwide. It causes 453,000 deaths in children annually. In the Democratic Republic of the Congo, sentinel site surveillance of rotavirus gastroenteritis started in 2009 and aimed to document burden of rotavirus diarrhea and identify circulating rotavirus genotypes. Methods: Between August 2009 to June 2012, stool samples were collected in Kinshasa and Lubumbashi, from children < 5 years of age who met the WHO case definition for rotavirus gastroenteritis. Rotavirus antigen detection was performed using an enzyme immunoassay technique and rotavirus strains were characterized using a multiplex reverse transcription polymerase chain reaction assay. Results: During the study period, 1614 stool samples were screened for rotavirus by enzyme immunoassay and 990 (61%) were positive. Of these, the genotype was determined in 330 (33%) samples. The most common genotypes found in the samples analyzed were G1P[8] in 2009 (28%) and 2012 (33%), G2P[4] (33%) in 2010 and G2P[6] (28%) in 2011. Uncommon strains like G8P[6] (5%), G6P[6] (5%), G12P[6] (3%), G12P[8] (3%) and G8P[8] (2%) were also detected. Conclusions: In Democratic Republic of the Congo, 61% of the diarrhea in children in < 5 years of age was caused by rotavirus infection and a variety of rotavirus genotypes were detected. Implementation of rotavirus genotyping at the national level has improved the timely identification of rotavirus strains. These results will help decision makers in Democratic Republic of the Congo plan the implementation of a rotavirus vaccination program. C1 [Pukuta, Elizabeth S.; Muyembe, Jean-Jacques] Inst Natl Rech Biomed, Kinshasa, Congo. [Esona, Mathew D.; Gentsch, Jon; Bowen, Michael D.; Waku-Kouomou, Diane] US Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Nkongolo, Adolphe; Mondonge, Vital] World Hlth Org Country, Off DRC, Kinshasa, Congo. [Seheri, Mapaseka; Mphahlele, M. Jeffrey] Univ Limpopo, MRC, Diarrhoeal Pathogens Res Unit, Mankweng E, South Africa. [Makasi, Mingiele] Ctr Hosp Pediat Kalembelembe, Kinshasa, Congo. [Nyembwe, Michel] Minist Heath, Direct Immunizat Program, Kinshasa, Congo. [Dahl, Benjamin A.; Cavallaro, Kathleen] US Ctr Dis Control & Prevent, Ctr Global Hlth, Global Immunizat Div, Atlanta, GA USA. RP Waku-Kouomou, D (reprint author), US Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd NE,MS C-22, Atlanta, GA 30333 USA. EM irf6@cdc.gov FU Bill and Melinda Gates Foundation [51214]; World Health Organization; U.S. Centers for Diseases Control and Prevention; CDC Foundation; Ministry of Health of the Democratic Republic of the Congo FX Funding for this work was provided by the Bill and Melinda Gates Foundation through the SURVAC Project (Grant number 51214), the World Health Organization, the U.S. Centers for Diseases Control and Prevention, the CDC Foundation and the Ministry of Health of the Democratic Republic of the Congo. The authors have no other funding or conflicts of interest to disclose. NR 18 TC 10 Z9 10 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0891-3668 EI 1532-0987 J9 PEDIATR INFECT DIS J JI Pediatr. Infect. Dis. J. PD APR PY 2014 VL 33 IS 4 BP 355 EP 359 DI 10.1097/INF.0000000000000212 PG 5 WC Immunology; Infectious Diseases; Pediatrics SC Immunology; Infectious Diseases; Pediatrics GA AD4SM UT WOS:000333240800010 PM 24637513 ER PT J AU Daskalaki, I Thermitus, R Perella, D Viner, K Spells, N Mohanty, S Lopez, A Johnson, C AF Daskalaki, Irini Thermitus, Rodrerica Perella, Dana Viner, Kendra Spells, Niya Mohanty, Salini Lopez, Adriana Johnson, Caroline TI Varicella Outbreak in a Daycare Challenges and Opportunities for Preventing Varicella Outbreaks in this Setting SO PEDIATRIC INFECTIOUS DISEASE JOURNAL LA English DT Article DE varicella vaccine; outbreak; varicella; childcare ID EPIDEMIOLOGY; VACCINATION; PARENTS AB As a result of single-dose varicella vaccination, daycare outbreaks have become rare. We investigated a daycare outbreak resulting from a misdiagnosed varicella case in an unvaccinated attendee. Of 25 attendees aged 12-32 months without evidence of immunity, 7 (28%) were unvaccinated due to religious/philosophical opposition or recent 1st birthday. Single-dose vaccination reduced disease by 92% compared with no vaccination. C1 [Daskalaki, Irini; Thermitus, Rodrerica; Perella, Dana; Viner, Kendra; Spells, Niya; Mohanty, Salini; Johnson, Caroline] Philadelphia Dept Publ Hlth, Div Dis Control, Philadelphia, PA USA. [Daskalaki, Irini] Drexel Univ, Coll Med, Dept Pediat, Philadelphia, PA 19104 USA. [Daskalaki, Irini] St Christophers Hosp Children, Dept Pediat, Philadelphia, PA 19134 USA. [Lopez, Adriana] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Daskalaki, I (reprint author), St Christophers Hosp Children, Erie Ave & Front St, Philadelphia, PA 19134 USA. EM daskalaki.i@gmail.com FU Centers for Disease Control and Prevention [3U01IP000019]; Philadelphia Department of Public Health FX The Centers for Disease Control and Prevention funded this study through cooperative agreement 3U01IP000019 with the Philadelphia Department of Public Health for active varicella surveillance and epidemiologic studies. The authors have no other funding or conflicts of interest to disclose. NR 10 TC 3 Z9 3 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0891-3668 EI 1532-0987 J9 PEDIATR INFECT DIS J JI Pediatr. Infect. Dis. J. PD APR PY 2014 VL 33 IS 4 BP 420 EP 422 DI 10.1097/INF.0000000000000127 PG 3 WC Immunology; Infectious Diseases; Pediatrics SC Immunology; Infectious Diseases; Pediatrics GA AD4SM UT WOS:000333240800028 PM 24136372 ER PT J AU Han, GS Stromdahl, EY Wong, D Weltman, AC AF Han, George S. Stromdahl, Ellen Y. Wong, David Weltman, Andre C. TI Exposure to Borrelia burgdorferi and Other Tick-Borne Pathogens in Gettysburg National Military Park, South-Central Pennsylvania, 2009 SO VECTOR-BORNE AND ZOONOTIC DISEASES LA English DT Article DE Ixodes scapularis; Borrelia burgdorferi; Lyme disease; Gettysburg National Military Park; Tick-borne pathogens ID LYME-DISEASE; UNITED-STATES; AMBLYOMMA-AMERICANUM; HUMAN RISK; IXODIDAE; ACARI; INFECTION; VECTOR; HEALTH; AGENT AB Since 1998, Lyme disease cases have increased in south-central Pennsylvania, which includes Gettysburg National Military Park (NMP). Limited information is available about tick populations or pathogens in this area, and no data regarding frequency of tick bites or prevention measures among Gettysburg NMP employees are available. To address these gaps, ticks were collected, classified, and replaced (to minimize disruptions to tick populations) at two sites within Gettysburg NMP during April-September, 2009, among eight nonremoval samplings. On two additional occasions during May and June, 2009, ticks were collected and removed from the two original sites plus 10 additional sites and tested for tick-borne pathogens by using PCR. A self-administered anonymous survey of Gettysburg NMP employees was conducted to determine knowledge, attitudes, and practices regarding tick-borne diseases. Peak Ixodes scapularis nymph populations were observed during May-July. Of 115 I. scapularis ticks tested, 21% were infected with Borrelia burgdorferi, including 18% of 74 nymphs and 27% of 41 adults; no other pathogen was identified. The entomologic risk index was calculated at 1.3 infected nymphs/hour. An adult and nymph Amblyomma americanum were also found, representing the first confirmed field collection of this tick in Pennsylvania, but no pathogens were detected. The survey revealed that most park employees believed Lyme disease was a problem at Gettysburg NMP and that they frequently found ticks on their skin and clothing. However, use of personal preventive measures was inconsistent, and 6% of respondents reported contracting Lyme disease while employed at Gettysburg NMP. These findings indicate a need to improve surveillance for tick bites among employees and enhance prevention programs for park staff and visitors. C1 [Han, George S.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. [Han, George S.; Weltman, Andre C.] Penn Dept Hlth, Harrisburg, PA 17108 USA. [Stromdahl, Ellen Y.] US Army Publ Hlth Command, Aberdeen Proving Ground, MD 21084 USA. [Wong, David] Natl Pk Serv Off Publ Hlth, Albuquerque, NM USA. RP Stromdahl, EY (reprint author), US Army Publ Hlth Command, 5158 Blackhawk Rd,BLDG E-5800, Aberdeen Proving Ground, MD 21084 USA. EM ellen.y.stromdahl.civ@mail.mil FU National Park Service Office of Public Health FX The authors thank the numerous persons from the Pennsylvania Department of Health, the U. S. Army Public Health Command, and the U. S. Army 1st and 9th Area Medical Laboratories who assisted in tick sampling efforts. We also thank Mary Vince and the Tick-Borne Disease Laboratory for their contribution to the laboratory identification of tick pathogens and the National Park Service Office of Public Health for providing funding for tick pathogen testing. We thank Zach Bolitho and the administrators and employees of Gettysburg National Military Park and Eisenhower National Historic Site for their participation in the survey and assistance with selecting tick-sampling sites, as well as Gettysburg College professor Steven James for local background information. Finally, we acknowledge the contributions of Rebecca Eisen, Heidi Brown, Paul Mead, Kevin Griffith, and Joseph Piesman of the Division of Vector-Borne Diseases, National Center for Emerging and Zoonotic Infectious Diseases, CDC for providing invaluable feedback regarding the study design, tick sampling protocols, and the employee survey. NR 24 TC 4 Z9 4 U1 0 U2 14 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1530-3667 EI 1557-7759 J9 VECTOR-BORNE ZOONOT JI Vector-Borne Zoonotic Dis. PD APR PY 2014 VL 14 IS 4 BP 227 EP 233 DI 10.1089/vbz.2013.1363 PG 7 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA AH8FX UT WOS:000336372200001 PM 24689815 ER PT J AU Prusinski, MA White, JL Wong, SJ Conlon, MA Egan, C Kelly-Cirino, CD Laniewicz, BR Backenson, PB Nicholson, WL Eremeeva, ME Karpathy, SE Dasch, GA White, DJ AF Prusinski, Melissa A. White, Jennifer L. Wong, Susan J. Conlon, Maureen A. Egan, Christina Kelly-Cirino, Cassandra D. Laniewicz, Brian R. Backenson, P. Bryon Nicholson, William L. Eremeeva, Marina E. Karpathy, Sandor E. Dasch, Gregory A. White, Dennis J. TI Sylvatic Typhus Associated with Flying Squirrels (Glaucomys volans) in New York State, United States SO VECTOR-BORNE AND ZOONOTIC DISEASES LA English DT Article DE Rickettsia prowazekii; Typhus; Flying squirrels; Lice; Fleas; Diagnostic; Investigation ID EPIDEMIC TYPHUS; RICKETTSIA-PROWAZEKII; INFECTION AB Sylvatic typhus is an infrequent, potentially life-threatening emerging zoonotic disease. In January of 2009, the New York State Department of Health was notified of a familial cluster of two suspected cases. Due to the paucity of typhus cases in New York, epidemiologic and environmental investigations were conducted to establish rickettsial etiology and determine potential sources of infection. Patients presented with symptoms consistent with typhus, and serologic testing of each patient confirmed infection with typhus group rickettsiae. Serologic analysis of blood obtained from southern flying squirrels (Glaucomys volans) captured from the attic crawlspace above an enclosed front porch of the cases' residence indicated evidence of infection with Rickettsia prowazekii, with 100% seroprevalence (n = 11). Both patients reported spending significant time on the porch and hearing animal activity above the ceiling prior to onset of illness, implicating these flying squirrels as the likely source of infection. C1 [Prusinski, Melissa A.; White, Jennifer L.; Laniewicz, Brian R.; Backenson, P. Bryon; White, Dennis J.] Bur Communicable Dis Control, New York State Dept Hlth, Albany, NY 12237 USA. [Wong, Susan J.] New York State Dept Hlth, Wadsworth Ctr Diagnost Immunol Lab, Albany, NY USA. [Conlon, Maureen A.; Egan, Christina; Kelly-Cirino, Cassandra D.] New York State Dept Hlth, Wadsworth Ctr Biodef Lab, Albany, NY USA. [Nicholson, William L.; Eremeeva, Marina E.; Karpathy, Sandor E.; Dasch, Gregory A.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Rickettsial Zoonoses Branch, Atlanta, GA USA. RP Prusinski, MA (reprint author), Bur Communicable Dis Control, New York State Dept Hlth, Vector Ecol Lab, Wadsworth Ctr Biggs Labs C-461,Empire State Plaza, Albany, NY 12237 USA. EM map11@health.state.ny.us OI Kelly-Cirino, Cassandra/0000-0002-4526-8487 FU NYSDOH; CDC FX This study was a joint investigation by the NYSDOH and CDC using state and federally appropriated funds. The authors express our gratitude to Robert Massung, Jennifer McQuiston, and John Krebs, at the CDC, for guidance. The authors thank Debra Simmerly, NYSDOH Capital District Regional Office, and Gayle Zimmerman, Saratoga County Public Health Nursing Service, Kathleen Downey, and David Rockwell, for their involvement with human case investigation. We also thank Catherine Turcotte, New York State Department of Health, and John Berghammer, Ace Pest Control, for assistance with mammal trapping and/or processing. The authors had full access to all study data and take responsibility for the integrity of the data and accuracy of analysis. The findings and conclusions of this study are those of the authors and do not necessarily reflect the views of the NYSDOH or U.S. Department of Health and Human Services. NR 16 TC 1 Z9 1 U1 0 U2 7 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1530-3667 EI 1557-7759 J9 VECTOR-BORNE ZOONOT JI Vector-Borne Zoonotic Dis. PD APR PY 2014 VL 14 IS 4 BP 240 EP 244 DI 10.1089/vbz.2013.1392 PG 5 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA AH8FX UT WOS:000336372200003 PM 24689928 ER PT J AU Harris-Adamson, C Eisen, EC Dale, AM Evanoff, B Hegmann, KT Thiese, MS Kapellusch, J Garg, A Burt, S Silverstein, B Bao, S Merlino, L Gerr, F Rempel, D AF Harris-Adamson, Carisa Eisen, Ellen Christoph Dale, Ann Marie Evanoff, Bradley Hegmann, Kurt T. Thiese, Matthew S. Kapellusch, Jay Garg, Arun Burt, Susan Silverstein, Barbara Bao, Stephen Merlino, Linda Gerr, Fred Rempel, David TI Personal and workplace psychosocial risk factors for carpal tunnel syndrome: a pooled study cohort: author response SO OCCUPATIONAL AND ENVIRONMENTAL MEDICINE LA English DT Letter C1 [Harris-Adamson, Carisa] Samuel Merritt Univ, Dept Phys Therapy, Oakland, CA 94609 USA. [Harris-Adamson, Carisa; Eisen, Ellen Christoph] Univ Calif Berkeley, Dept Environm Hlth Sci, Berkeley, CA 94720 USA. [Dale, Ann Marie; Evanoff, Bradley] Washington Univ, Sch Med, Div Gen Med Sci, St Louis, MO USA. [Hegmann, Kurt T.; Thiese, Matthew S.] Univ Utah, RMCOEH, Salt Lake City, UT USA. [Kapellusch, Jay; Garg, Arun] Univ Wisconsin, Ctr Ergon, Milwaukee, WI 53201 USA. [Burt, Susan] NIOSH, Cincinnati, OH 45226 USA. [Silverstein, Barbara; Bao, Stephen] Washington State Dept Labor & Ind, Safety & Hlth Assessment & Res Prevent SHARP Prog, Olympia, WA 98504 USA. [Merlino, Linda] Univ Iowa, Coll Publ Hlth, Dept Occupat & Environm Hlth, Iowa City, IA USA. [Gerr, Fred; Rempel, David] Univ Calif San Francisco, Div Occupat & Environm Med, San Francisco, CA 94143 USA. [Rempel, David] Univ Calif Berkeley, Dept Bioengn, Berkeley, CA 94720 USA. RP Harris-Adamson, C (reprint author), Samuel Merritt Univ, Dept Phys Therapy, Oakland, CA 94609 USA. EM charrisadamson@samuelmerritt.edu RI Dale, Ann Marie/P-1382-2014 OI Dale, Ann Marie/0000-0002-5624-8967 NR 3 TC 0 Z9 0 U1 0 U2 5 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1351-0711 EI 1470-7926 J9 OCCUP ENVIRON MED JI Occup. Environ. Med. PD APR PY 2014 VL 71 IS 4 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AC1PL UT WOS:000332268400016 ER PT J AU Kamm, KB Feikin, DR Bigogo, GM Aol, G Audi, A Cohen, AL Shah, MM Yu, J Breiman, RF Ram, PK AF Kamm, K. B. Feikin, D. R. Bigogo, G. M. Aol, G. Audi, A. Cohen, A. L. Shah, M. M. Yu, J. Breiman, R. F. Ram, P. K. TI Associations between presence of handwashing stations and soap in the home and diarrhoea and respiratory illness, in children less than five years old in rural western Kenya SO TROPICAL MEDICINE & INTERNATIONAL HEALTH LA English DT Article DE handwashing; diarrhoea; acute respiratory infection; Kenya ID RANDOMIZED CONTROLLED-TRIAL; HYGIENE PRACTICES; SYSTEMATIC ANALYSIS; CHILDHOOD DIARRHEA; URBAN BANGLADESH; BURKINA-FASO; RISK-FACTORS; DISEASE; HEALTH; PROMOTION AB ObjectiveWe tested whether soap presence in the home or a designated handwashing station was associated with diarrhoea and respiratory illness in Kenya. MethodsIn April 2009, we observed presence of a handwashing station and soap in households participating in a longitudinal health surveillance system in rural Kenya. Diarrhoea and acute respiratory illness (ARI) in children <5years old were identified using parent-reported syndromic surveillance collected January-April 2009. We used multivariate generalised linear regression to estimate differences in prevalence of illness between households with and without the presence of soap in the home and a handwashing station. ResultsAmong 2547 children, prevalence of diarrhoea and ARI was 2.3 and 11.4days per 100 child-days, respectively. Soap was observed in 97% of households. Children in households with soap had 1.3 fewer days of diarrhoea/100 child-days (95% CI -2.6, -0.1) than children in households without soap. ARI prevalence was not associated with presence of soap. A handwashing station was identified in 1.4% of households and was not associated with a difference in diarrhoea or ARI prevalence. ConclusionsSoap presence in the home was significantly associated with reduced diarrhoea, but not ARI, in children in rural western Kenya. Whereas most households had soap in the home, almost none had a designated handwashing station, which may prevent handwashing at key times of hand contamination. ObjectifNous avons teste si la presence de savon dans la maison ou dans un endroit designe de lavage des mains etait associee a la diarrhee et aux maladies respiratoires au Kenya. MethodesEn avril 2009, nous avons observe la presence d'un endroit de lavage des mains et du savon dans les menages participant a un systeme de surveillance longitudinale sur la sante en zone rurale au Kenya. La diarrhee et les infections respiratoires aigues (IRA) chez les enfants de <5 ans ont ete identifiees en utilisant la surveillance syndromique rapportee par les parents, recueillies entre janvier et avril 2009. Nous avons utilise la regression lineaire multivariee generalisee pour estimer les differences dans la prevalence de la maladie entre les menages avec et sans la presence de savon dans la maison et dans un endroit de lavage des mains. ResultatsChez 2547 enfants, la prevalence de la diarrhee et des IRA etaient de 2,3 et 11,4 jours pour 100 enfant-jours, respectivement. Le savon a ete observe dans 97% des menages. Les enfants dans les menages avec du savon avaient 1.3 jours de moins de diarrhee/100 enfant-jours (IC95% -2.6 a -0.1) que dans les menages sans savon. La prevalence des IRA n'a pas ete associee a la presence de savon. Un endroit de lavage des mains a ete identifie chez 1.4% des menages et n'etait pas associe a une difference dans la prevalence de la diarrhee ou des ARI. ConclusionsLa presence de savon dans la maison etait significativement associee a une reduction de la diarrhee, mais pas des IRA, chez les enfants dans les regions rurales de l'ouest du Kenya. Alors que la plupart des menages avaient du savon a la maison, presqu'aucun n'avait un endroit designe pour le lavage des mains, ce qui peut empecher le lavage des mains a des moments cles de la contamination des mains. ObjetivoHemos evaluado si existia asociacion entre la presencia de jabon o de una estacion de lavado de manos en los hogares y las enfermedades diarreicas y respiratorias en Kenia. MetodosEn Abril del 2009, observamos la presencia de una estacion de lavado de manos y de jabon en los hogares que participaban dentro del sistema de vigilancia sanitaria longitudinal en zonas rurales de Kenia. Se identifico la presencia de diarreas y enfermedades respiratorias agudas (ERAs) en ninos <5 anos utilizando datos de un estudio de vigilancia de sindromes mediante informes paternos recogidos entre Enero-Abril 2009. Mediante una regresion linear multivariada se calcularon las diferencias en la prevalencia de enfermedad entre los hogares con y sin presencia de jabon en el hogar y una estacion de lavado de manos. ResultadosEntre 2547 ninos, la prevalencia de diarrea y ERAs eran de 2.3 y 11.4 dias por 100 nino-dias, respectivamente. La presencia de jabon se observo en un 97% de los hogares. Los ninos en hogares con presencia de jabon tenian 1.3 dias menos de diarrea/100 nino-dias (IC 95% -2.6, -0.1) que los ninos en hogares sin jabon. La prevalencia de ERAs no estaba asociada con la presencia de jabon. Se identificaron estaciones de lavado de manos en un 1.4% de los hogares y no se observo que su presencia estuviese asociada con una diferencia en la prevalencia de diarreas o ERAs. ConclusionesLa presencia de jabon en el hogar estaba significativamente asociada con una reduccion en los episodios de diarrea, pero no de ERAs, en ninos de la zona rural de Kenia occidental. Si bien la mayoria de los hogares tenian jabon, casi ninguno tenia una estacion de lavado de manos, lo cual puede prevenir el lavado de manos en momentos clave para la contaminacion de las manos. C1 [Kamm, K. B.; Yu, J.; Ram, P. K.] SUNY Buffalo, Buffalo, NY 14260 USA. [Feikin, D. R.; Bigogo, G. M.; Aol, G.; Audi, A.; Breiman, R. F.] Ctr Dis Control & Prevent, Global Dis Detect Program, Int Emerging Infect Program, Nairobi, Kenya. [Feikin, D. R.; Bigogo, G. M.; Aol, G.; Audi, A.; Breiman, R. F.] Ctr Dis Control & Prevent, Kenya Med Res Inst, Publ Hlth & Res Collaborat, Kisumu, Kenya. [Feikin, D. R.] Ctr Dis Control & Prevent, Global Dis Detect Branch, Div Global Hlth Protect, Atlanta, GA USA. [Cohen, A. L.] Ctr Dis Control & Prevent, Resp Dis Branch, Div Bacterial Dis, Atlanta, GA USA. [Shah, M. M.] Emory Univ, Sch Med, Atlanta, GA USA. [Breiman, R. F.] Ctr Dis Control & Prevent, Ctr Global Hlth, Atlanta, GA USA. [Breiman, R. F.] Emory Univ, Global Hlth Inst, Atlanta, GA 30322 USA. RP Kamm, KB (reprint author), SUNY Buffalo, Buffalo, NY 14260 USA. EM kbkamm@buffalo.edu FU Intramural CDC HHS [CC999999] NR 37 TC 1 Z9 1 U1 1 U2 9 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1360-2276 EI 1365-3156 J9 TROP MED INT HEALTH JI Trop. Med. Int. Health PD APR PY 2014 VL 19 IS 4 BP 398 EP 406 DI 10.1111/tmi.12263 PG 9 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA AF0IR UT WOS:000334398000003 PM 24405627 ER PT J AU Alemnji, GA Zeh, C Yao, K Fonjungo, PN AF Alemnji, G. A. Zeh, C. Yao, K. Fonjungo, P. N. TI Strengthening national health laboratories in sub-Saharan Africa: a decade of remarkable progress SO TROPICAL MEDICINE & INTERNATIONAL HEALTH LA English DT Article DE collaboration with partners; remarkable progress; Strengthening national laboratories; sub-Saharan Africa ID DEVELOPING-COUNTRIES; DIAGNOSTIC CAPACITY; SYSTEMS; MALARIA; QUALITY; ACCREDITATION; SETTINGS; MEDICINE; REGION; GHANA AB ObjectivesEfforts to combat the HIV/AIDS pandemic have underscored the fragile and neglected nature of some national health laboratories in Africa. In response, national and international partners and various governments have worked collaboratively over the last several years to build sustainable laboratory capacities within the continent. Key accomplishments reflecting this successful partnership include the establishment of the African-based World Health Organization Regional Office for Africa (WHO-AFRO) Stepwise Laboratory Quality Improvement Process Towards Accreditation (SLIPTA); development of the Strengthening Laboratory Management Toward Accreditation (SLMTA) training programme; and launching of a Pan African-based institution, the African Society for Laboratory Medicine (ASLM). These platforms continue to serve as the foundations for national health laboratory infrastructure enhancement, capacity development and overall quality system improvement. Further targeted interventions should encourage countries to aim at integrated tiered referral networks, promote quality system improvement and accreditation, develop laboratory policies and strategic plans, enhance training and laboratory workforce development and a retention strategy, create career paths for laboratory professionals and establish public-private partnerships. Maintaining the gains and ensuring sustainability will require concerted action by all stakeholders with strong leadership and funding from African governments and from the African Union. Les efforts visant a lutter contre la pandemie du VIH/SIDA ont souligne le caractere fragile et neglige de certains laboratoires nationaux de la sante en Afrique. En reponse, les partenaires nationaux et internationaux et divers gouvernements ont collabore au cours des dernieres annees a developper des capacites de laboratoire durables sur le continent. Les principales realisations refletant ce partenariat fructueux comprennent la mise en place du Processus d'Amelioration par Etape de la Qualite de Laboratoire vers l'Accreditation (SLIPTA) de l'Office Regional de l'Organisation Mondiale de la Sante pour l'Afrique base en Afrique (OMS-AFRO), le developpement du programme de formation pour le Renforcement de la Gestion de Laboratoire vers l'accreditation (SLMTA) et le lancement d'une institution panafricaine, la Societe Africaine de Laboratoire de Medecine (ASLM). Ces plates-formes continuent a servir de base pour l'amelioration de l'infrastructure nationale de laboratoires de sante, le developpement des capacites et l'amelioration globale des systemes de qualite. Des interventions supplementaires plus ciblees devraient encourager les pays a viser des reseaux integres d'aiguillage a plusieurs niveaux, promouvoir l'amelioration des systemes de qualite et l'accreditation, elaborer des politiques de laboratoire et des plans strategiques, ameliorer la formation et le developpement de la main-d'OEuvre de laboratoire et une strategie de retention, creer des voies de carriere pour les professionnels de laboratoire et etablir des partenariats public-prives. Le maintenir des acquis et l'assurance de la durabilite necessiteront une action concertee de toutes les parties prenantes avec un leadership fort et un financement des gouvernements africains et de l'Union Africaine. Los esfuerzos para combatir la pandemia de VIH/SIDA han puesto de manifiesto la naturaleza fragil y olvidada de algunos laboratorios nacionales de salud en africa. Como respuesta, los socios nacionales e internacionales, asi como varios gobiernos, han trabajado de forma colaborativa durante los ultimos anos para construir en el continente unas instalaciones de laboratorios sostenibles. Algunos logros pivotales, reflejo de esta colaboracion exitosa, incluyen el establecimiento de una oficina regional de la OMS en africa y para africa (OMS-AFRO), el proceso de acreditacion de calidad en el laboratorio SLIPTA (Stepwise Laboratory Quality Improvement Process Towards Accreditation); el desarrollo del programa de entrenamiento SLMTA (Strengthening Laboratory Management Toward Accreditation); y el lanzamiento de una institucion Panafricana - la Sociedad Africana de Patologia Clinica (ASLM). Estas plataformas continuan sirviendo como base para la mejora de las infraestructuras nacionales de laboratorios sanitarios, el desarrollo de capacidades y una mejora general de los sistemas de calidad. Unas intervenciones mas dirigidas deberian animar a los paises a buscar integrarse en redes de referencia, promover la mejora de los sistemas de calidad y de acreditacion, desarrollar politicas de laboratorio y planes estrategicos; mejorar el entrenamiento y el desarrollo del personal de laboratorio y definir una estrategia de retencion, establecer carreras profesionales para el personal de laboratorio y alianzas publico-privadas. Mantener las ganancias y asegurar la sostenibilidad requiere de una accion concertada por parte de todas las partes interesadas con un liderazgo fuerte y financiacion por parte de los gobiernos Africanos y la Union Africana. C1 [Alemnji, G. A.] Ctr Dis Control & Prevent, Div Global HIV AIDS, Caribbean Reg Off, Bridgetown, Barbados. [Zeh, C.] Ctr Dis Control & Prevent, Kisumu Off, Kisumu, Kenya. [Yao, K.; Fonjungo, P. N.] Ctr Dis Control & Prevent, Div Global HIV AIDS, Int Lab Branch, Atlanta, GA USA. RP Alemnji, GA (reprint author), Ctr Dis Control & Prevent CDC, Div Global HIV AIDS, Caribbean Reg Off, Bridgetown, Barbados. EM ikv3@cdc.gov FU U.S. Centers for Disease Control and Prevention (CDC) FX This research was supported by the President's Emergency Plan for AIDS Relief (PEPFAR) through the U.S. Centers for Disease Control and Prevention (CDC). The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the U.S. Centers for Disease Control and Prevention/the Agency for Toxic Substances and Disease Registry. NR 43 TC 10 Z9 10 U1 4 U2 63 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1360-2276 EI 1365-3156 J9 TROP MED INT HEALTH JI Trop. Med. Int. Health PD APR PY 2014 VL 19 IS 4 BP 450 EP 458 DI 10.1111/tmi.12269 PG 9 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA AF0IR UT WOS:000334398000010 PM 24506521 ER PT J AU Camargo, MC Garcia, A Riquelme, A Otero, W Camargo, CA Hernandez-Garcia, T Candia, R Bruce, MG Rabkin, CS AF Camargo, M. Constanza Garcia, Apolinaria Riquelme, Arnoldo Otero, William Camargo, Claudia A. Hernandez-Garcia, Tomas Candia, Roberto Bruce, Michael G. Rabkin, Charles S. TI The Problem of Helicobacter pylori Resistance to Antibiotics: A Systematic Review in Latin America SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Review ID AGAR DILUTION; INFECTION; METAANALYSIS; ERADICATION; MANAGEMENT; AGENTS; EVOLUTION; STRAINS; BIAS AB OBJECTIVES: Latin America has a high prevalence of Helicobacter pylori infection and associated diseases, including gastric cancer. Antibiotic therapy can eradicate the bacterial infection and decrease associated morbidity and mortality. To tailor recommendations for optimal treatments, we summarized published literature and calculated region-and country-specific prevalences of antibiotic resistance. METHODS: Searches of PubMed and regional databases for observational studies evaluating H. pylori antibiotic resistance yielded a total of 59 independent studies (56 in adults, 2 in children, and 1 in both groups) published up to October 2013 regarding H. pylori isolates collected between 1988 and 2011. Study-specifi c prevalences of primary resistance to commonly prescribed antibiotics were summarized using random-effects models. Between-study heterogeneity was assessed by meta-regression. As a sensitivity analysis, we extended our research to studies of patients with prior H. pylori-eradication therapy. RESULTS: Summary prevalences of antimicrobial primary resistance among adults varied by antibiotic, including 12% for clarithromycin (n=35 studies), 53% for metronidazole (n=34), 4% for amoxicillin (n=28), 6% for tetracycline (n=20), 3% for furazolidone (n=6), 15% for fluoroquinolones (n=5), and 8% for dual clarithromycin and metronidazole (n=10). Resistance prevalence varied significantly by country, but not by year of sample collection. Analyses including studies of patients with prior therapy yielded similar estimates. Pediatric reports were too few to be summarized by meta-analysis. CONCLUSIONS: Resistance to first-line anti-H. pylori antibiotics is high in Latin American populations. In some countries, the empirical use of clarithromycin without susceptibility testing may not be appropriate. These findings stress the need for appropriate surveillance programs, improved antimicrobial regulations, and increased public awareness. C1 [Camargo, M. Constanza; Rabkin, Charles S.] NCI, Div Canc Epidemiol & Genet, Rockville, MD 20850 USA. [Garcia, Apolinaria; Hernandez-Garcia, Tomas] Univ Concepcion, Dept Microbiol, Concepcion, Chile. [Riquelme, Arnoldo; Candia, Roberto] Pontificia Univ Catolica, Sch Med, Dept Gastroenterol, Santiago, Chile. [Otero, William] Univ Nacl Colombia, Sch Med, Dept Gastroenterol, Bogota, Colombia. [Otero, William] Clin Fundadores, Bogota, Colombia. [Camargo, Claudia A.] Secretaria Salud Mexico, Mexico City, DF, Mexico. [Bruce, Michael G.] Ctr Dis Control & Prevent, Div Preparedness & Emerging Infect, Art Investigat Program, Anchorage, AK USA. RP Camargo, MC (reprint author), NCI, Infect & Immunoepidemiol Branch, Div Canc Epidemiol & Genet, NIH, 9609 Med Ctr Dr,BG 9609-6E206, Rockville, MD 20850 USA. EM camargomc@mail.nih.gov RI Camargo, M. Constanza/R-9891-2016; OI Candia, Roberto/0000-0003-1856-7737 FU Intramural Research Program of the United States National Institutes of Health; National Cancer Institute FX This work was supported by the Intramural Research Program of the United States National Institutes of Health, National Cancer Institute. NR 44 TC 30 Z9 36 U1 0 U2 12 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD APR PY 2014 VL 109 IS 4 BP 485 EP 495 DI 10.1038/ajg.2014.24 PG 11 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AG5HO UT WOS:000335450300004 PM 24589670 ER PT J AU Altekruse, SF Henley, SJ Cucinelli, JE McGlynn, KA AF Altekruse, Sean F. Henley, S. Jane Cucinelli, James E. McGlynn, Katherine A. TI Changing Hepatocellular Carcinoma Incidence and Liver Cancer Mortality Rates in the United States SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Article ID C VIRUS-INFECTION; US ADULTS; TRENDS; EPIDEMIOLOGY; PREVALENCE; HEPATITIS; OBESITY; JAPAN; DISEASE; FUTURE AB OBJECTIVES: The objectives were to describe Surveillance, Epidemiology and End Results (SEER) hepatocellular carcinoma (HCC) incidence trends and the US liver cancer mortality trends by geography, age, race /ethnicity, and gender. METHODS: HCC incidence data from SEER 18 registries and liver cancer mortality data from the National Center for Health Statistics were analyzed. Rates and joinpoint trends were calculated by demographic subgroup. State-level liver cancer mortality rates and trends were mapped. RESULTS: HCC incidence rates in SEER registries did not signifi cantly increase during 2007-2010; however, the US liver cancer mortality rates did increase. HCC incidence and liver cancer mortality rates increased among black, Hispanic, and white men aged 50 + years and decreased among 35-49-year-old men in all racial /ethnic groups including Asians /Pacifi c Islanders. Signifi cantly increasing incidence and mortality rates among women were restricted to blacks, Hispanics, and whites aged 50 + years. Asian /Pacifi c Islander liver cancer mortality rates decreased during 2000 -2010 with decreasing rates among women aged 50-64 years and men aged 35-49 years and stable rates in other groups. During 2006 -2010, among individuals 50-64 years of age, blacks and Hispanics had higher incidence and mortality rates than Asians /Pacifi c Islanders. Liver cancer mortality rates were highest in Louisiana, Mississippi, Texas, and Washington, DC. CONCLUSIONS: Decreasing HCC incidence and liver cancer mortality rates among Asians /Pacifi c Islanders, men aged 35-49 years, and the nonsignifi cant increase in overall HCC incidence rates suggest that the peak of the epidemic may be near or have passed. Findings of geographic variation in mortality rates can inform control efforts. C1 [Altekruse, Sean F.] NCI, Div Canc Control & Populat Sci, Rockville, MD 20852 USA. [Henley, S. Jane] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA USA. [Cucinelli, James E.] Informat Management Serv Inc, Silver Spring, MD USA. [McGlynn, Katherine A.] NCI, Div Canc Epidemiol & Genet, Rockville, MD 20852 USA. RP Altekruse, SF (reprint author), NCI, Div Canc Control & Populat Sci, 6116 Execut Blvd,Suite 504, Rockville, MD 20852 USA. EM altekrusesf@mail.nih.gov OI Henley, S Jane/0000-0002-2420-306X FU Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health; Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention FX This study was supported by Division of Cancer Control and Population Sciences; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health; and Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention. NR 35 TC 76 Z9 76 U1 0 U2 10 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD APR PY 2014 VL 109 IS 4 BP 542 EP 553 DI 10.1038/ajg.2014.11 PG 12 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AG5HO UT WOS:000335450300011 PM 24513805 ER PT J AU Kancherla, V Romitti, PA Sun, L Carey, JC Burns, TL Siega-Riz, AM Druschel, CM Lin, AE Olney, RS AF Kancherla, Vijaya Romitti, Paul A. Sun, Lixian Carey, John C. Burns, Trudy L. Siega-Riz, Anna Maria Druschel, Charlotte M. Lin, Angela E. Olney, Richard S. CA Natl Birth Defects Prevention Stud TI Descriptive and risk factor analysis for choanal atresia: The National Birth Defects Prevention Study, 1997-2007 SO EUROPEAN JOURNAL OF MEDICAL GENETICS LA English DT Article DE Alcohol drinking; Caffeine; Choanal atresia; Cigarette smoking; Diet ID PLASMA ZINC CONCENTRATIONS; MONITORING-SYSTEM PRAMS; NEURAL CREST CELLS; ORAL CLEFTS; CHARGE-SYNDROME; UNITED-STATES; CONGENITAL MALFORMATIONS; PHENOTYPIC SPECTRUM; OROFACIAL CLEFTS; CAFFEINE INTAKE AB Choanal atresia causes serious posterior nasal obstruction. This defect is the leading cause of nasal surgery in newborns, although its etiology is largely unknown. Data from the National Birth Defects Prevention Study, a population-based case-control study, were used to examine associations between maternal self-reports of exposures and occurrence of choanal atresia in their offspring. Overall, 117 case and 8350 control mothers with deliveries from 1997 through 2007 provided telephone interview reports of pre-pregnancy (one year before conception) and periconceptional (one month before through three months after conception) exposures. The exposures analyzed were pre-pregnancy dietary intake, pre-pregnancy and periconceptional caffeine consumption, and periconceptional cigarette smoking, alcohol drinking, and medication use. Independent associations between each exposure and all choanal atresia cases combined (n = 117) and isolated choanal atresia cases (those without additional unrelated major defects; n = 61) were examined. Odds ratios (ORs), both unadjusted (uORs) and adjusted (aORs) for potential confounders, and 95% confidence intervals (CIs) were estimated using unconditional logistic regression analysis. For all choanal atresia cases combined, positive associations were observed with maternal pre-pregnancy intake in the highest quartile for vitamin B-12 (aOR = 1.9; CI = 1.1,3.1), zinc (aOR = 1.7; CI = 1.0,3.1), and niacin (aOR = 1.8; CI = 1.0,3.1), and intake in the lowest quartile for methionine (aOR = 1.6; CI = 1.0,2.6) and vitamin D (aOR = 1.6; CI = 1.0,2.4) compared to intake in the two intermediate quartiles combined. Further, a positive association was observed with periconceptional use of thyroid medications (uOR = 2.6; CI = 1.0,6.3) compared to no use of such medications. Among isolated choanal atresia cases, negative associations were observed for pantothenic acid (aOR = 0.4; CI = 0.2,0.9) and fat (aOR = 0.5; 95% CI = 0.2,1.0) intake in the lowest quartile compared to that in the intermediate quartiles, and positive associations were observed for periconceptional cigarette smoking (aOR = 2.3; CI = 1.1,4.7) compared to no smoking and pre-pregnancy daily coffee intake of 3 or more cups (aOR = 2.5; CI = 1.1,5.6) compared to intake of less than 1 cup per day. The positive association for periconceptional exposure to thyroid medications also persisted for isolated choanal atresia cases (uOR = 4.0; CI = 1.1,11.2). Because of the large number of associations tested, these findings may be due to chance. Alternatively, they may contribute new hypotheses regarding the etiology of choanal atresia; thus, requiring replication in additional studies. (C) 2014 Elsevier Masson SAS. All rights reserved. C1 [Kancherla, Vijaya; Romitti, Paul A.; Sun, Lixian; Burns, Trudy L.] Univ Iowa, Dept Epidemiol, Iowa City, IA 52242 USA. [Carey, John C.] Univ Utah, Dept Pediat, Salt Lake City, UT USA. [Siega-Riz, Anna Maria] Univ N Carolina, Dept Epidemiol & Nutr, Chapel Hill, NC USA. [Druschel, Charlotte M.] New York State Dept Hlth, Albany, NY USA. [Lin, Angela E.] MassGen Hosp Children, Boston, MA USA. [Olney, Richard S.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. RP Romitti, PA (reprint author), Univ Iowa, Coll Publ Hlth, Dept Epidemiol, S416 CPHB,145 N Riverside Dr, Iowa City, IA 52242 USA. EM paul-romitti@uiowa.edu FU Centers for Disease Control and Prevention (CDC) [5U01DD000492, 1U01DD001035]; Nutrition Epidemiology Core of the University of North Carolina Clinical Nutrition Research Center [DK56350] FX The authors thank the many study participants and study staff at each site who have contributed to the NBDPS. We also are grateful for the expert administrative assistance provided by Ms. Julee Bormet in the preparation of this manuscript. This work was funded by grants (5U01DD000492 and 1U01DD001035) from the Centers for Disease Control and Prevention (CDC). The CDC was a participating site in the NBDPS and contributed to: study design; data collection, analysis, and interpretation; co-authoring the article, and in the decision to submit the article for publication. Coding of drug information in the National Birth Defects Prevention Study used the Slone Drug Dictionary under license from the Slone Epidemiology Center of Boston University. Nutritional analysis was supported by grant no. DK56350 from the Nutrition Epidemiology Core of the University of North Carolina Clinical Nutrition Research Center. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 69 TC 0 Z9 0 U1 2 U2 5 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1769-7212 EI 1878-0849 J9 EUR J MED GENET JI Eur. J. Med. Genet. PD APR PY 2014 VL 57 IS 5 BP 220 EP 229 DI 10.1016/j.ejmg.2014.02.010 PG 10 WC Genetics & Heredity SC Genetics & Heredity GA AG5GJ UT WOS:000335447200007 PM 24576610 ER PT J AU Zhou, FJ Shefer, A Wenger, J Messonnier, M Wang, LY Lopez, A Moore, M Murphy, TV Cortese, M Rodewald, L AF Zhou, Fangjun Shefer, Abigail Wenger, Jay Messonnier, Mark Wang, Li Yan Lopez, Adriana Moore, Matthew Murphy, Trudy V. Cortese, Margaret Rodewald, Lance TI Economic Evaluation of the Routine Childhood Immunization Program in the United States, 2009 SO PEDIATRICS LA English DT Article DE diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP); tetanus and diphtheria toxoids vaccine (Td); Haemophilus influenzae type b conjugate vaccine (Hib); inactivated poliovirus vaccine (IPV); measles/mumps/rubella vaccine (MMR); hepatitis B vaccine (HepB); varicella vaccine (VAR); 7-valent pneumococcal conjugate vaccine (PCV7); hepatitis A vaccine (HepA); rotavirus vaccine (Rota); net savings; benefit-cost analysis ID PNEUMOCOCCAL CONJUGATE VACCINE; PENTAVALENT ROTAVIRUS VACCINE; AGED 19-35 MONTHS; COST-EFFECTIVENESS; HEPATITIS-A; YOUNG-CHILDREN; COVERAGE; IMPACT; INFANTS; MEASLES AB OBJECTIVES: To evaluate the economic impact of the 2009 routine US childhood immunization schedule, including diphtheria and tetanus toxoids and acellular pertussis, Haemophilus influenzae type b conjugate, inactivated poliovirus, measles/mumps/rubella, hepatitis B, varicella, 7-valent pneumococcal conjugate, hepatitis A, and rotavirus vaccines; influenza vaccine was not included. METHODS: Decision analysis was conducted using population-based vaccination coverage, published vaccine efficacies, historical data on disease incidence before vaccination, and disease incidence reported during 2005 to 2009. Costs were estimated using the direct cost and societal (direct and indirect costs) perspectives. Program costs included vaccine, administration, vaccine-associated adverse events, and parent travel and work time lost. All costs were inflated to 2009 dollars, and all costs and benefits in the future were discounted at a 3% annual rate. A hypothetical 2009 US birth cohort of 4261494 infants over their lifetime was followed up from birth through death. Net present value (net savings) and benefit-cost ratios of routine childhood immunization were calculated. RESULTS: Analyses showed that routine childhood immunization among members of the 2009 US birth cohort will prevent similar to 42000 early deaths and 20 million cases of disease, with net savings of $13.5 billion in direct costs and $68.8 billion in total societal costs, respectively. The direct and societal benefit-cost ratios for routine childhood vaccination with these 9 vaccines were 3.0 and 10.1. CONCLUSIONS: From both direct cost and societal perspectives, vaccinating children as recommended with these vaccines results in substantial cost savings. C1 [Zhou, Fangjun; Shefer, Abigail; Wenger, Jay; Messonnier, Mark; Lopez, Adriana; Moore, Matthew; Cortese, Margaret; Rodewald, Lance] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Wang, Li Yan; Murphy, Trudy V.] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. RP Zhou, FJ (reprint author), Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd NE,Mail Stop A19, Atlanta, GA 30333 USA. EM faz1@cdc.gov OI Rodewald, Lance/0000-0003-2593-542X NR 73 TC 39 Z9 39 U1 0 U2 22 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD APR PY 2014 VL 133 IS 4 BP 577 EP 585 DI 10.1542/peds.2013-0698 PG 9 WC Pediatrics SC Pediatrics GA AG3TU UT WOS:000335343500003 PM 24590750 ER PT J AU Wendt, JM Cohen, JA Mu, Y Dumyati, GK Dunn, JR Holzbauer, SM Winston, LG Johnston, HL Meek, JI Farley, MM Wilson, LE Phipps, EC Beldavs, ZG Gerding, DN McDonald, LC Gould, CV Lessa, FC AF Wendt, Joyanna M. Cohen, Jessica A. Mu, Yi Dumyati, Ghinwa K. Dunn, John R. Holzbauer, Stacy M. Winston, Lisa G. Johnston, Helen L. Meek, James I. Farley, Monica M. Wilson, Lucy E. Phipps, Erin C. Beldavs, Zintars G. Gerding, Dale N. McDonald, L. Clifford Gould, Carolyn V. Lessa, Fernanda C. TI Clostridium difficile Infection Among Children Across Diverse US Geographic Locations SO PEDIATRICS LA English DT Article DE Clostridium difficile; pediatric; community-associated; antimicrobial stewardship ID PROTON PUMP INHIBITORS; RETAIL MEAT; INFANTS; RISK; DISEASE; COLONIZATION; EPIDEMIOLOGY; COMMUNITY; INPATIENTS; DIARRHEA AB OBJECTIVE: Little is known about the epidemiology of Clostridium difficile infection (CDI) among children, particularly children <= 3 years of age in whom colonization is common but pathogenicity uncertain. We sought to describe pediatric CDI incidence, clinical presentation, and outcomes across age groups. METHODS: Data from an active population-and laboratory-based CDI surveillance in 10 US geographic areas during 2010-2011 were used to identify cases (ie, residents with C difficile-positive stool without a positive test in the previous 8 weeks). Community-associated (CA) cases had stool collected as outpatients or <= 3 days after hospital admission and no overnight health care facility stay in the previous 12 weeks. A convenience sample of CA cases were interviewed. Demographic, exposure, and clinical data for cases aged 1 to 17 years were compared across 4 age groups: 1 year, 2 to 3 years, 4 to 9 years, and 10 to 17 years. RESULTS: Of 944 pediatric CDI cases identified, 71% were CA. CDI incidence per 100 000 children was highest among 1-year-old (66.3) and white (23.9) cases. The proportion of cases with documented diarrhea (72%) or severe disease (8%) was similar across age groups; no cases died. Among the 84 cases interviewed who reported diarrhea on the day of stool collection, 73% received antibiotics during the previous 12 weeks. CONCLUSIONS: Similar disease severity across age groups suggests an etiologic role for C difficile in the high rates of CDI observed in younger children. Prevention efforts to reduce unnecessary antimicrobial use among young children in outpatient settings should be prioritized. C1 [Wendt, Joyanna M.; Cohen, Jessica A.; Mu, Yi; McDonald, L. Clifford; Gould, Carolyn V.; Lessa, Fernanda C.] CDC, Div Healthcare Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Wendt, Joyanna M.] CDC, Epidem Intelligence Serv, Off Surveillance Epidemiol & Lab Serv, Atlanta, GA 30333 USA. [Holzbauer, Stacy M.] CDC, Off Publ Hlth Preparedness & Response, Career Epidemiol Field Off Program, Atlanta, GA 30333 USA. [Cohen, Jessica A.] Atlanta Res & Educ Fdn, Atlanta, GA USA. [Dumyati, Ghinwa K.] Univ Rochester, Med Ctr, Dept Med, Rochester, NY 14642 USA. [Dunn, John R.] Tennessee Dept Hlth, Nashville, TN USA. [Holzbauer, Stacy M.] Minnesota Dept Hlth, Dept Med, St Paul, MN USA. [Winston, Lisa G.] Univ Calif San Francisco, Sch Med, San Francisco, CA USA. [Johnston, Helen L.] Colorado Dept Publ Hlth & Environm, Denver, CO USA. [Meek, James I.] Yale Univ, Sch Publ Hlth, Connecticut Emerging Infect Program, New Haven, CT USA. [Farley, Monica M.] Emory Univ, Sch Med, Dept Med, Atlanta, GA USA. [Farley, Monica M.] Atlanta Vet Affairs Med Ctr, Atlanta, GA USA. [Wilson, Lucy E.] Maryland Dept Hlth & Mental Hyg, Baltimore, MD USA. [Phipps, Erin C.] Univ New Mexico, Emerging Infect Program, Albuquerque, NM 87131 USA. [Beldavs, Zintars G.] Oregon Hlth Author, Publ Hlth Div, Portland, OR USA. [Gerding, Dale N.] Loyola Univ Chicago, Stritch Sch Med, Dept Med, Maywood, IL USA. [Gerding, Dale N.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA. RP Lessa, FC (reprint author), 1600 Clifton Rd,MS A-24, Atlanta, GA 30333 USA. EM flessa@cdc.gov FU Centers for Disease Control and Prevention FX This work was funded by the Centers for Disease Control and Prevention. No external funding was used for this study. NR 33 TC 29 Z9 31 U1 0 U2 2 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD APR PY 2014 VL 133 IS 4 BP 651 EP 658 DI 10.1542/peds.2013-3049 PG 8 WC Pediatrics SC Pediatrics GA AG3TU UT WOS:000335343500012 PM 24590748 ER PT J AU Dabelea, D Rewers, A Stafford, JM Standiford, DA Lawrence, JM Saydah, S Imperatore, G D'Agostino, RB Mayer-Davis, EJ Pihoker, C AF Dabelea, Dana Rewers, Arleta Stafford, Jeanette M. Standiford, Debra A. Lawrence, Jean M. Saydah, Sharon Imperatore, Giuseppina D'Agostino, Ralph B., Jr. Mayer-Davis, Elizabeth J. Pihoker, Catherine CA SEARCH Diabet Youth Study Grp TI Trends in the Prevalence of Ketoacidosis at Diabetes Diagnosis: The SEARCH for Diabetes in Youth Study SO PEDIATRICS LA English DT Article DE diabetic ketoacidosis; youth; diabetes type ID CLINICAL CHARACTERISTICS; CHILDREN; TYPE-1; ADOLESCENTS; MELLITUS; ONSET; MULTICENTER AB OBJECTIVE: To estimate temporal changes in the prevalence of diabetic ketoacidosis (DKA) at diagnosis of type 1 or type 2 diabetes in youth and to explore factors associated with its occurrence. METHODS: Five centers identified incident cases of diabetes among youth aged 0 to 19 years starting in 2002. DKA presence was defined as a bicarbonate level < 15 mmol/L and/or a pH < 7.25 (venous) or < 7.30 (arterial or capillary) or mention of DKA in the medical records. We assessed trends in the prevalence of DKA over 3 time periods (2002-2003, 2004-2005, and 2008-2010). Logistic regression was used to determine factors associated with DKA. RESULTS: In youth with type 1 diabetes (n = 5615), the prevalence of DKA was high and stable over time (30.2% in 2002-2003, 29.1% in 2004-2005, and 31.1% in 2008-2010; P for trend = .42). Higher prevalence was associated with younger age at diagnosis (P < .0001), minority race/ethnicity (P = .019), income (P = .019), and lack of private health insurance (P = 008). Among youth with type 2 diabetes (n = 1425), DKA prevalence decreased from 11.7% in 2002-2003 to 5.7% in 2008-2010 (P for trend = .005). Higher prevalence was associated with younger age at diagnosis (P = .001), minority race/ethnicity (P = .013), and male gender (P = .001). CONCLUSIONS: The frequency of DKA in youth with type 1 diabetes, although stable, remains high, indicating a persistent need for increased awareness of signs and symptoms of diabetes and better access to health care. In youth with type 2 diabetes, DKA at onset is less common and is decreasing over time. C1 [Dabelea, Dana] Colorado Sch Publ Hlth, Dept Epidemiol, Aurora, CO 80045 USA. [Rewers, Arleta] Univ Colorado, Sch Med, Dept Pediat, Aurora, CO USA. [Stafford, Jeanette M.; D'Agostino, Ralph B., Jr.] Wake Forest Sch Med, Dept Biostat Sci, Winston Salem, NC USA. [Standiford, Debra A.] Cincinnati Childrens Hosp Med Ctr, Dept Endocrinol, Cincinnati, OH 45229 USA. [Lawrence, Jean M.] Kaiser Permanente So Calif, Dept Res & Evaluat, Pasadena, CA 91101 USA. [Saydah, Sharon; Imperatore, Giuseppina] Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA USA. [Mayer-Davis, Elizabeth J.] Univ N Carolina, Dept Nutr, Chapel Hill, NC USA. [Pihoker, Catherine] Univ Washington, Dept Pediat, Seattle, WA 98195 USA. RP Dabelea, D (reprint author), Colorado Sch Publ Hlth, Dept Epidemiol, 13001 East 17th Pl,B-119, Aurora, CO 80045 USA. EM dana.dabelea@ucdenver.edu RI Dagostino Jr, Ralph/C-4060-2017 OI Dagostino Jr, Ralph/0000-0002-3550-8395 FU NCATS NIH HHS [UL1 TR001082]; NCCDPHP CDC HHS [U01DP000248, DP-05-069, U01 DP000244, U01 DP000246, U01 DP000247, U01 DP000248, U01 DP000250, U01 DP000254]; NCRR NIH HHS [M01 RR000037, M01 RR000069, M01 RR001070, M01 RR001271, M01 RR008084, M01 RR01070, M01 RR08084, M01RR00037, M01RR00069, M01RR001271]; PHS HHS [00097] NR 30 TC 41 Z9 41 U1 0 U2 5 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD APR PY 2014 VL 133 IS 4 BP E938 EP E945 DI 10.1542/peds.2013-2795 PG 8 WC Pediatrics SC Pediatrics GA AG3TU UT WOS:000335343500043 PM 24685959 ER PT J AU Garbers, S Scheinmann, R Friedman, A Bermudez, D Chiasson, MA AF Garbers, Samantha Scheinmann, Roberta Friedman, Allison Bermudez, Dayana Chiasson, Mary Ann TI KNOWLEDGE AND STD TESTING BEHAVIOR AMONG SEXUAL MINORITY YOUTH SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Garbers, Samantha; Scheinmann, Roberta; Bermudez, Dayana; Chiasson, Mary Ann] Publ Hlth Solut, New York, NY 10013 USA. [Friedman, Allison] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. EM sgarbers@healthsolutions.org NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 EI 1532-4796 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2014 VL 47 SU 1 BP S43 EP S43 PG 1 WC Psychology, Multidisciplinary SC Psychology GA AF0MI UT WOS:000334408300169 ER PT J AU Oakley, L Philyaw, M Lin, JMS AF Oakley, Lisa Philyaw, Meredith Lin, Jin-Mann S. TI SOCIAL DETERMINANTS OF BARRIERS TO HEALTHCARE UTILIZATION IN CHRONIC FATIGUE SYNDROME (CFS) SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Oakley, Lisa; Philyaw, Meredith; Lin, Jin-Mann S.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Oakley, Lisa; Philyaw, Meredith] Emory Univ, Atlanta, GA 30322 USA. EM lisa.p.oakley@gmail.com NR 0 TC 0 Z9 0 U1 3 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 EI 1532-4796 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2014 VL 47 SU 1 BP S122 EP S122 PG 1 WC Psychology, Multidisciplinary SC Psychology GA AF0MI UT WOS:000334408300466 ER PT J AU Schauer, G Wheaton, AG Malarcher, AM Croft, JB AF Schauer, Gillian Wheaton, Anne G. Malarcher, Ann M. Croft, Janet B. TI SMOKING CESSATION BEHAVIORS AMONG US ADULTS WITH AND WITHOUT COPD: FINDINGS FROM THE 2011 BEHAVIORAL RISK FACTOR SURVEILLANCE SYSTEM SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Schauer, Gillian] Emory Univ, Atlanta, GA 30322 USA. [Schauer, Gillian; Malarcher, Ann M.] Ctr Dis Control & Prevent, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Wheaton, Anne G.; Croft, Janet B.] Ctr Dis Control & Prevent, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. EM gillian.schauer@emory.edu NR 0 TC 0 Z9 0 U1 0 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 EI 1532-4796 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2014 VL 47 SU 1 BP S225 EP S225 PG 1 WC Psychology, Multidisciplinary SC Psychology GA AF0MI UT WOS:000334408301115 ER PT J AU Tinney-Zara, CA Charles, LE Fekedulegn, D Adjeroh, LC Andrew, ME Miller, DB Wactawski-Wende, J Violanti, JM Burchfiel, CM AF Tinney-Zara, Cathy A. Charles, Luenda E. Fekedulegn, Desta Adjeroh, Leonie C. Andrew, Michael E. Miller, Diane B. Wactawski-Wende, Jean Violanti, John M. Burchfiel, Cecil M. TI SHIFT WORK AND BONE MINERAL DENSITY IN BUFFALO POLICE OFFICERS SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Tinney-Zara, Cathy A.; Charles, Luenda E.; Fekedulegn, Desta; Adjeroh, Leonie C.; Andrew, Michael E.; Miller, Diane B.; Burchfiel, Cecil M.] NIOSH, Hlth Effects Lab Div, CDC, Morgantown, WV USA. [Wactawski-Wende, Jean; Violanti, John M.] SUNY Buffalo, Buffalo, NY 14260 USA. EM cat6@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 EI 1532-4796 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2014 VL 47 SU 1 BP S121 EP S121 PG 1 WC Psychology, Multidisciplinary SC Psychology GA AF0MI UT WOS:000334408300462 ER PT J AU Violanti, JM Fekedulegn, D Hartley, TA Andrew, ME Charles, LE Burchfiel, CM AF Violanti, John M. Fekedulegn, Desta Hartley, Tara A. Andrew, Michael E. Charles, Luenda E. Burchfiel, Cecil M. TI POLICE WORK ABSENCE: AN ANALYSIS OF POLICE-SPECIFIC STRESS SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Violanti, John M.] SUNY Buffalo, Buffalo, NY 14214 USA. [Fekedulegn, Desta; Hartley, Tara A.; Andrew, Michael E.; Charles, Luenda E.; Burchfiel, Cecil M.] NIOSH, Biostat & Epidemiol Branch, Hlth Effects Lab Div, CDC, Morgantown, WV USA. EM violanti@buffalo.edu NR 0 TC 0 Z9 0 U1 3 U2 6 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 EI 1532-4796 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2014 VL 47 SU 1 BP S47 EP S47 PG 1 WC Psychology, Multidisciplinary SC Psychology GA AF0MI UT WOS:000334408300184 ER PT J AU Zarrett, N Czajkowski, SM Blanck, HM Yaroch, AL AF Zarrett, Nicole Czajkowski, Susan M. Blanck, Heidi Michels Yaroch, Amy Lazarus TI FUNDING OPPORTUNITIES AND STRATEGIES FOR DIET, PHYSICAL ACTIVITY, AND OBESITY PREVENTION SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Zarrett, Nicole] Univ S Carolina, Columbia, SC 29208 USA. [Czajkowski, Susan M.] NIH, Div Cardiovasc Sci, Clin Applicat & Prevent Branch, Bethesda, MD 20892 USA. [Blanck, Heidi Michels] CDC, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Yaroch, Amy Lazarus] Gretchen Swanson Ctr Nutr, Omaha, NE USA. EM zarrettn@mailbox.sc.edu NR 0 TC 0 Z9 0 U1 0 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 EI 1532-4796 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2014 VL 47 SU 1 BP S63 EP S63 PG 1 WC Psychology, Multidisciplinary SC Psychology GA AF0MI UT WOS:000334408300242 ER PT J AU Agoti, CN Mayieka, LM Otieno, JR Ahmed, JA Fields, BS Waiboci, LW Nyoka, R Eidex, RB Marano, N Burton, W Montgomery, JM Breiman, RF Nokes, DJ AF Agoti, Charles N. Mayieka, Lillian M. Otieno, James R. Ahmed, Jamal A. Fields, Barry S. Waiboci, Lilian W. Nyoka, Raymond Eidex, Rachel B. Marano, Nina Burton, Wagacha Montgomery, Joel M. Breiman, Robert F. Nokes, D. James TI Examining strain diversity and phylogeography in relation to an unusual epidemic pattern of respiratory syncytial virus (RSV) in a long-term refugee camp in Kenya SO BMC INFECTIOUS DISEASES LA English DT Article DE Attachment (G) protein; Displaced population; Epidemics; Genetic diversity; Genotype; Refugee; RSV ID GROUP-B GENOTYPE; GROUP-A; 60-NUCLEOTIDE DUPLICATION; CIRCULATION PATTERNS; GENETIC-VARIABILITY; ATTACHMENT PROTEIN; VIRAL-INFECTIONS; BIENNIAL CYCLE; PUBLIC-HEALTH; SUBGROUP AB Background: A recent longitudinal study in the Dadaab refugee camp near the Kenya-Somalia border identified unusual biannual respiratory syncytial virus (RSV) epidemics. We characterized the genetic variability of the associated RSV strains to determine if viral diversity contributed to this unusual epidemic pattern. Methods: For 336 RSV positive specimens identified from 2007 through 2011 through facility-based surveillance of respiratory illnesses in the camp, 324 (96.4%) were sub-typed by PCR methods, into 201 (62.0%) group A, 118 (36.4%) group B and 5 (1.5%) group A-B co-infections. Partial sequencing of the G gene (coding for the attachment protein) was completed for 290 (89.5%) specimens. These specimens were phylogenetically analyzed together with 1154 contemporaneous strains from 22 countries. Results: Of the 6 epidemic peaks recorded in the camp over the period, the first and last were predominantly made up of group B strains, while the 4 in between were largely composed of group A strains in a consecutive series of minor followed by major epidemics. The Dadaab group A strains belonged to either genotype GA2 (180, 98.9%) or GA5 (2, < 1%) while all group B strains (108, 100%) belonged to BA genotype. In sequential epidemics, strains within these genotypes appeared to be of two types: those continuing from the preceding epidemics and those newly introduced. Genotype diversity was similar in minor and major epidemics. Conclusion: RSV strain diversity in Dadaab was similar to contemporaneous diversity worldwide, suggested both between-epidemic persistence and new introductions, and was unrelated to the unusual epidemic pattern. C1 [Agoti, Charles N.; Otieno, James R.; Nokes, D. James] Kenya Med Res Inst KEMRI, Wellcome Trust Res Programme, Kilifi, Kenya. [Mayieka, Lillian M.; Ahmed, Jamal A.; Fields, Barry S.; Waiboci, Lilian W.; Nyoka, Raymond; Eidex, Rachel B.; Marano, Nina; Burton, Wagacha; Montgomery, Joel M.] US Centers Dis Control & Prevent, Nairobi, Kenya. [Breiman, Robert F.] Emory Univ, Atlanta, GA 30322 USA. [Burton, Wagacha; Montgomery, Joel M.; Breiman, Robert F.] Ctr Dis Control & Prevent, Ctr Global Hlth, Div Global Hlth Protect, Atlanta, GA USA. [Nokes, D. James] Univ Warwick, Sch Life Sci, Coventry CV4 7AL, W Midlands, England. [Nokes, D. James] Univ Warwick, WIDER, Coventry CV4 7AL, W Midlands, England. RP Agoti, CN (reprint author), Kenya Med Res Inst KEMRI, Wellcome Trust Res Programme, Kilifi, Kenya. EM cnyaigoti@kemri-wellcome.org OI Otieno, James/0000-0001-9790-2307 FU KEMRI; CDC; International Rescue Committee; Wellcome Trust, UK [084633] FX We thank the study participants who provided the samples analyzed here, the surveillance team in Dadaab who collected the specimens, and the laboratory teams from CDC for performing initial specimen processing including RSV screening and the Viral Epidemiology and Control group from Kilifi for the RSV sub-typing, and sequencing assays. We also thank the United Nations High Commissioner for Refugees and the Kenya Ministry of Public Health and Sanitation for their continued support. The primary surveillance project is supported by a cooperative agreement between KEMRI, CDC, and the International Rescue Committee. The work presented here was supported by a Wellcome Trust, UK, Programme Grant to DJN (Ref no. 084633) and CDC. The study is published with the permission of the Director of KEMRI. The findings and conclusion of this manuscript are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or other affiliated institutions. NR 40 TC 3 Z9 4 U1 0 U2 4 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2334 J9 BMC INFECT DIS JI BMC Infect. Dis. PD APR 1 PY 2014 VL 14 AR 178 DI 10.1186/1471-2334-14-178 PG 14 WC Infectious Diseases SC Infectious Diseases GA AG5PH UT WOS:000335470400001 PM 24690157 ER PT J AU Nelson, DE Faupel-Badger, J Phillips, S Belcher, B Chang, S Abrams, DB Kramer, BS White, MC O'Malley, M Varanasi, AP Fabian, CJ Wiest, JS Colditz, GA Hall, K Shields, PG Weitzel, JN AF Nelson, David E. Faupel-Badger, Jessica Phillips, Siobhan Belcher, Britni Chang, Shine Abrams, David B. Kramer, Barnett S. White, Mary C. O'Malley, Michael Varanasi, Arti P. Fabian, Carol J. Wiest, Jonathan S. Colditz, Graham A. Hall, Kara Shields, Peter G. Weitzel, Jeffrey N. TI Future Directions for Postdoctoral Training in Cancer Prevention: Insights from a Panel of Experts SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION LA English DT Review ID SYSTEMS SCIENCE; TEAM SCIENCE; HEALTH AB Cancer prevention postdoctoral fellowships have existed since the 1970s. The National Cancer Institute facilitated a meeting by a panel of experts in April 2013 to consider four important topics for future directions for cancer prevention postdoctoral training programs: (i) future research needs; (ii) underrepresented disciplines; (iii) curriculum; and (iv) career preparation. Panelists proffered several areas needing more research or emphasis, ranging from computational science to culture. Health care providers, along with persons from nontraditional disciplines in scientific training programs such as engineers and lawyers, were among those recognized as being underrepresented in training programs. Curriculum suggestions were that fellows receive training in topics such as leadership and human relations, in addition to learning the principles of epidemiology, cancer biologic mechanisms, and behavioral science. For career preparation, there was a clear recognition of the diversity of employment options available besides academic positions, and that programleaders should do more to help fellows identify and prepare for different career paths. The major topics and strategies covered at this meeting can help form the basis for cancer prevention training programleaders to consider modifications or new directions, and keep them updated with the changing scientific and employment climate for doctoral degree recipients and postdoctoral fellows. C1 [Nelson, David E.; Faupel-Badger, Jessica; Phillips, Siobhan; Belcher, Britni; Kramer, Barnett S.; Wiest, Jonathan S.; Hall, Kara] NCI, Bethesda, MD 20892 USA. [Varanasi, Arti P.] Advancing Synergy LLC, Baltimore, MD USA. [Chang, Shine] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Abrams, David B.] Legacy, Schroeder Inst Tobacco Res & Policy Studies, Washington, DC USA. [White, Mary C.] Ctr Dis Control & Prevent, Atlanta, GA USA. [O'Malley, Michael] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA. [Fabian, Carol J.] Univ Kansas, Med Ctr, Kansas City, KS 66103 USA. [Colditz, Graham A.] Washington Univ, Sch Med, St Louis, MO USA. [Shields, Peter G.] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA. [Weitzel, Jeffrey N.] City Hope Natl Med Ctr, Duarte, CA USA. RP Nelson, DE (reprint author), NCI, 9609 Med Ctr Dr,Suite 2W-138,MSC 9712, Bethesda, MD 20892 USA. EM nelsonde@mail.nih.gov RI White, Mary /C-9242-2012; Colditz, Graham/A-3963-2009 OI White, Mary /0000-0002-9826-3962; Colditz, Graham/0000-0002-7307-0291 FU Intramural NIH HHS [Z99 CA999999]; NCI NIH HHS [R25 CA057726] NR 23 TC 2 Z9 2 U1 0 U2 6 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1055-9965 EI 1538-7755 J9 CANCER EPIDEM BIOMAR JI Cancer Epidemiol. Biomarkers Prev. PD APR PY 2014 VL 23 IS 4 BP 679 EP 683 DI 10.1158/1055-9965.EPI-13-1209 PG 5 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA AG0ZR UT WOS:000335145000016 PM 24604827 ER PT J AU Sandora, TJ Gerner-Smidt, P McAdam, AJ AF Sandora, Thomas J. Gerner-Smidt, Peter McAdam, Alexander J. TI What's Your Subtype? The Epidemiologic Utility of Bacterial Whole-Genome Sequencing SO CLINICAL CHEMISTRY LA English DT Editorial Material ID DIFFICILE INFECTION; GUIDELINES C1 [Sandora, Thomas J.] Boston Childrens Hosp, Div Infect Dis, Dept Med, Boston, MA 02115 USA. [Sandora, Thomas J.; McAdam, Alexander J.] Boston Childrens Hosp, Dept Lab Med, Boston, MA 02115 USA. [Gerner-Smidt, Peter] CDC, Enter Dis Lab Branch, Atlanta, GA 30333 USA. RP McAdam, AJ (reprint author), Boston Childrens Hosp, 300 Longwood Ave, Boston, MA 02115 USA. EM alexander.mcadam@childrens.harvard.edu NR 5 TC 1 Z9 1 U1 1 U2 3 PU AMER ASSOC CLINICAL CHEMISTRY PI WASHINGTON PA 2101 L STREET NW, SUITE 202, WASHINGTON, DC 20037-1526 USA SN 0009-9147 EI 1530-8561 J9 CLIN CHEM JI Clin. Chem. PD APR PY 2014 VL 60 IS 4 BP 586 EP 588 DI 10.1373/clinchem.2013.217141 PG 3 WC Medical Laboratory Technology SC Medical Laboratory Technology GA AG1AO UT WOS:000335147400006 PM 24398073 ER PT J AU Fairley, T Buchanan, N Johnson-Turbes, A Moore, A AF Fairley, Temeika Buchanan, Natasha Johnson-Turbes, Ashani Moore, Angela TI A Culturally Responsive Evaluation of the Young Sisters Initiative: A Guide to A Better You! Program SO JOURNAL OF WOMENS HEALTH LA English DT Meeting Abstract C1 [Fairley, Temeika; Buchanan, Natasha; Moore, Angela] Ctr Dis Control & Prevent, Atlanta, GA USA. [Johnson-Turbes, Ashani] ICF Int, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 EI 1931-843X J9 J WOMENS HEALTH JI J. Womens Health PD APR 1 PY 2014 VL 23 IS 4 MA P71 BP 25 EP 25 PG 1 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA AE4EO UT WOS:000333934900072 ER PT J AU Vaid, I Ahmed, K May, D Manheim, D AF Vaid, Isam Ahmed, Kaha May, Dianne Manheim, Diane TI The WISEWOMAN Program: Smoking Prevalence and Key Approaches to Smoking Cessation Among Participants, July 2008-June 2013 SO JOURNAL OF WOMENS HEALTH LA English DT Article ID POSTMENOPAUSAL HORMONE-THERAPY; RANDOMIZED CONTROLLED-TRIAL; BREAST-CANCER INCIDENCE; ESTROGEN THERAPY; CARDIOVASCULAR-DISEASE; HEALTH; WOMEN; RISK; MENOPAUSE; BENEFITS AB Background: Tobacco use is a major risk factor for cardiovascular disease (CVD) and is the leading preventable cause of death, disease, and disability in the United States. The CDC's Well-Integrated Screening and Evaluation for Women Across the Nation (WISEWOMAN) program addresses the heart health of low-income under- or uninsured women between the ages of 40 and 64 years. This article discusses WISEWOMAN's key approaches to smoking cessation and their impact on WISEWOMAN participants' cardiovascular health. Methods: A longitudinal retrospective analysis was conducted using data from 21 funded CDC programs from July 2008 to June 2013. Data were collected on 149,767 women to assess CVD risk, smoking status, and utilization of programs related to tobacco cessation. Results: The overall prevalence of smoking among the WISEWOMAN population during this period was 28%. Increases in referrals to tobacco quitlines, tobacco-cessation counseling, lifestyle interventions, and other community-based tobacco-cessation programs contributed to a 15% smoking-cessation rate among smokers who returned for a rescreening assessment over the 5-year program period. Conclusion: The WISEWOMAN program has observed a smoking-cessation rate of 15% over the 5-year program period. WISEWOMAN's key approaches include continuous technical assistance that highlights quitline referrals, motivational interviewing done by program staff, and professional-development strategies for WISEWOMAN healthcare providers. WISEWOMAN will continue its programmatic emphasis on smoking cessation by partnering with state tobacco-cessation programs to work toward a lower smoking-prevalence rate among program participants. C1 [Vaid, Isam; Ahmed, Kaha; May, Dianne; Manheim, Diane] Ctr Dis Control & Prevent, WISEWOMAN Program, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. RP Vaid, I (reprint author), Ctr Dis Control & Prevent, DHDSP PDSB WW, 4770 Buford Highway NE,Bldg 102,Mailstop F72, Atlanta, GA 30341 USA. EM Isam.Vaid@cdc.hhs.gov FU Intramural CDC HHS [CC999999] NR 50 TC 1 Z9 1 U1 3 U2 5 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 EI 1931-843X J9 J WOMENS HEALTH JI J. Womens Health PD APR 1 PY 2014 VL 23 IS 4 BP 288 EP 295 DI 10.1089/jwh.2013.4712 PG 8 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA AE4EO UT WOS:000333934900130 PM 24552434 ER PT J AU White, A Richardson, LC Krontiras, H Pisu, M AF White, Arica Richardson, Lisa C. Krontiras, Helen Pisu, Maria TI Socioeconomic Disparities in Breast Cancer Treatment Among Older Women SO JOURNAL OF WOMENS HEALTH LA English DT Article ID FACTOR-V-LEIDEN; ORAL-CONTRACEPTIVE USE; DEEP-VEIN THROMBOSIS; FACTOR-VIII LEVELS; PROGESTOGEN-ONLY CONTRACEPTION; SYSTEMIC-LUPUS-ERYTHEMATOSUS; RETROSPECTIVE FAMILY COHORT; HORMONE REPLACEMENT THERAPY; VENOUS THROMBOEMBOLISM; ANTIPHOSPHOLIPID SYNDROME AB Background: Racial disparities in breast cancer treatment among Medicare beneficiaries have been documented. This study aimed to determine whether racial disparities exist among white and black female Medicare beneficiaries in Alabama, an economically disadvantaged U.S. state. Methods: From a linked dataset of breast cancer cases from the Alabama Statewide Cancer Registry and feefor-service claims from Medicare, we identified 2,097 white and black females, aged 66 years and older, who were diagnosed with stages 1-3 breast cancer from January 1, 2000, to December 31, 2002. Generalized estimating equation (GEE) models were used to determine whether there were racial differences in initiating and completing National Comprehensive Cancer Network Clinical Practice guideline-specific treatment. Results: Sixty-two percent of whites and 64.7% of blacks had mastectomy ( p = 0.27); 34.6% of whites and 30.2% of blacks had breast conserving surgery (BCS) ( p = 0.12). Among those who had BCS, 76.8% of whites and 83.3% of blacks started adjuvant radiation therapy ( p = 0.33) and they equally completed adjuvant radiation therapy ( p = 0.29). For women with tumors over 1 centimeter, whites and blacks were equally likely to start (16.1% of whites and 18.3% of black; p = 0.34) and complete (50.6% of whites and 46.3% of black; p = 0.87) adjuvant chemotherapy. There were still no differences after adjusting for confounders using GEE. However, differences were observed by area-level socioeconomic status (SES), with lower SES residents more likely to receive a mastectomy (odds ratio [OR] = 1.26; 95% confidence interval [CI]: 1.01-1.57) and initiate radiation after BCS (OR = 2.24; 95% CI: 1.28-3.93). Conclusions: No racial differences were found in guideline-specific breast cancer treatment or treatment completion, but there were differences by SES. Future studies should explore reasons for SES differences and whether similar results hold in other economically disadvantaged U.S. states. C1 [White, Arica; Richardson, Lisa C.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis & Hlth Promot, Atlanta, GA 30341 USA. [Krontiras, Helen] Univ Alabama Birmingham, Sch Med, Birmingham, AL USA. [Pisu, Maria] Univ Alabama Birmingham, Div Prevent Med, Birmingham, AL USA. RP White, A (reprint author), Ctr Dis Control & Prevent, Div Canc Prevent & Control, 4770 Buford Highway Northeast,Mailstop F76, Atlanta, GA 30341 USA. EM awhite5@cdc.gov FU Centers for Disease Control and Prevention's Prevention Research Centers Program [U48 DP000225-01] FX This study was supported by Cooperative Agreement U48 DP000225-01 from the Centers for Disease Control and Prevention's Prevention Research Centers Program. NR 84 TC 7 Z9 7 U1 0 U2 5 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 EI 1931-843X J9 J WOMENS HEALTH JI J. Womens Health PD APR 1 PY 2014 VL 23 IS 4 BP 335 EP 341 DI 10.1089/jwh.2013.4460 PG 7 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA AE4EO UT WOS:000333934900136 PM 24350590 ER PT J AU Kawwass, JF Monsour, M Crawford, S Kissin, DM Session, DR Kulkarni, AD Jamieson, DJ AF Kawwass, Jennifer F. Monsour, Michael Crawford, Sara Kissin, Dmitry M. Session, Donna R. Kulkarni, Aniket D. Jamieson, Denise J. CA Natl ART Surveillance Syst NASS TI Trends and Outcomes for Donor Oocyte Cycles in the United States, 2000-2010 SO OBSTETRICAL & GYNECOLOGICAL SURVEY LA English DT Meeting Abstract C1 [Kawwass, Jennifer F.; Kissin, Dmitry M.; Session, Donna R.; Jamieson, Denise J.] Emory Univ, Sch Med, Dept Gynecol & Obstet, Div Reprod Endocrinol & Infertil, Atlanta, GA USA. [Kawwass, Jennifer F.; Monsour, Michael; Crawford, Sara; Kissin, Dmitry M.; Kulkarni, Aniket D.; Jamieson, Denise J.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Reprod Hlth, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0029-7828 EI 1533-9866 J9 OBSTET GYNECOL SURV JI Obstet. Gynecol. Surv. PD APR PY 2014 VL 69 IS 4 BP 189 EP 191 DI 10.1097/01.ogx.0000446903.17513.fd PG 3 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA AG4NQ UT WOS:000335397400004 ER PT J AU Adamu, H Petros, B Zhang, GQ Kassa, H Amer, S Ye, JB Feng, YY Xiao, LH AF Adamu, Haileeyesus Petros, Beyene Zhang, Guoqing Kassa, Hailu Amer, Said Ye, Jianbin Feng, Yaoyu Xiao, Lihua TI Distribution and Clinical Manifestations of Cryptosporidium Species and Subtypes in HIV/AIDS Patients in Ethiopia SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID SP APICOMPLEXA CRYPTOSPORIDIIDAE; ACTIVE ANTIRETROVIRAL THERAPY; NORTH-WEST ETHIOPIA; CHRONIC DIARRHEA; AIDS PATIENTS; INFECTIONS; PARASITES; CHILDREN; EPIDEMIOLOGY; PREVALENCE AB Author Summary The disease burden of Cryptosporidium parvum and role of zoonotic transmission in cryptosporidiosis epidemiology are poorly understood in developing countries. In this study, we examined the distribution and clinical manifestations of Cryptosporidium species and subtypes in HIV/AIDS patients in Addis Ababa, Ethiopia. Using molecular diagnostic tools, we detected Cryptosporidium infection in 26.9% of 520 HIV/AIDS patients studied. We have shown a very high diversity of Cryptosporidium species and subtypes in these patients, but unlike in other developing countries, C. parvum is overwhelmingly the dominant species in the study community, responsible for similar to 65% Cryptosporidium infections. The common occurrence of C. parvum zoonotic subtype family IIa, combined with calf contact as a significant risk factor, suggest that zoonotic transmission is important in cryptosporidiosis epidemiology in HIV/AIDS patients in Ethiopia. We have also shown that different Cryptosporidium species and subtypes are linked to different clinical manifestations. Improved hygiene and avoidance of calf contact should be advocated to reduce cryptosporidiosis transmission in HIV/AIDS patients in the study setting. Background Cryptosporidiosis is an important cause for chronic diarrhea and death in HIV/AIDS patients. Among common Cryptosporidium species in humans, C. parvum is responsible for most zoonotic infections in industrialized nations. Nevertheless, the clinical significance of C. parvum and role of zoonotic transmission in cryptosporidiosis epidemiology in developing countries remain unclear. Methodology/Principal Findings In this cross-sectional study, 520 HIV/AIDS patients were examined for Cryptosporidium presence in stool samples using genotyping and subtyping techniques. Altogether, 140 (26.9%) patients were positive for Cryptosporidium spp. by PCR-RFLP analysis of the small subunit rRNA gene, belonging to C. parvum (92 patients), C. hominis (25 patients), C. viatorum (10 patients), C. felis (5 patients), C. meleagridis (3 patients), C. canis (2 patients), C. xiaoi (2 patients), and mixture of C. parvum and C. hominis (1 patient). Sequence analyses of the 60 kDa glycoprotein gene revealed a high genetic diversity within the 82 C. parvum and 19 C. hominis specimens subtyped, including C. parvum zoonotic subtype families IIa (71) and IId (5) and anthroponotic subtype families IIc (2), IIb (1), IIe (1) and If-like (2), and C. hominis subtype families Id (13), Ie (5), and Ib (1). Overall, Cryptosporidium infection was associated with the occurrence of diarrhea and vomiting. Diarrhea was attributable mostly to C. parvum subtype family IIa and C. hominis, whereas vomiting was largely attributable to C. hominis and rare Cryptosporidium species. Calf contact was identified as a significant risk factor for infection with Cryptosporidium spp., especially C. parvum subtype family IIa. Conclusions/Significance Results of the study indicate that C. parvum is a major cause of cryptosporidiosis in HIV-positive patients and zoonotic transmission is important in cryptosporidiosis epidemiology in Ethiopia. In addition, they confirm that different Cryptosporidium species and subtypes are linked to different clinical manifestations. C1 [Adamu, Haileeyesus; Amer, Said; Ye, Jianbin; Xiao, Lihua] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30333 USA. [Adamu, Haileeyesus; Petros, Beyene] Univ Addis Ababa, Addis Ababa, Ethiopia. [Zhang, Guoqing] Ctr Dis Control & Prevent, Div Global HIV AIDS, Atlanta, GA USA. [Kassa, Hailu] Bowling Green State Univ, Dept Publ & Allied Hlth, Bowling Green, OH 43403 USA. [Amer, Said] Kafr El Sheikh Univ, Dept Zool, Fac Sci, Kafe El Sheikh, Egypt. [Ye, Jianbin; Feng, Yaoyu] E China Univ Sci & Technol, State Key Lab Bioreactor Engn, Sch Resources & Environm Engn, Shanghai 200237, Peoples R China. RP Adamu, H (reprint author), Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30333 USA. EM yyfeng@ecust.edu.cn; lxiao@cdc.gov RI Xiao, Lihua/B-1704-2013; Feng, Yaoyu/B-3076-2014; OI Xiao, Lihua/0000-0001-8532-2727; Adamu, Haileeyesus/0000-0003-2998-5977 FU Centers for Disease Control and Prevention (CDC); Addis Ababa University; National Natural Science Foundation of China [31110103901]; American Society for Microbiology (ASM); CDC FX This study was supported in part by funds from the Centers for Disease Control and Prevention (CDC), Addis Ababa University, and National Natural Science Foundation of China (No. 31110103901), and a postdoctoral fellowship from the American Society for Microbiology (ASM) and CDC. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 38 TC 18 Z9 19 U1 2 U2 16 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD APR PY 2014 VL 8 IS 4 DI 10.1371/journal.pntd.0002831 PG 10 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA AG3TK UT WOS:000335342400032 PM 24743521 ER PT J AU Mbopi-Keou, FX Belec, L Milleliri, JM Teo, CG AF Mbopi-Keou, Francois-Xavier Belec, Laurent Milleliri, Jean-Marie Teo, Chong-Gee TI The Legacies of Eugene Jamot and La Jamotique SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID MOBILE UNITS; AFRICA; THERAPY C1 [Mbopi-Keou, Francois-Xavier] Univ Yaounde I, Minist Publ Hlth, Dept Labs & Blood Safety, Yaounde, Cameroon. [Belec, Laurent] Univ Paris 05, Hop Europeen Georges Pompidou, Virol Lab, Paris, France. [Belec, Laurent] Univ Paris 05, Fac Med Paris Descartes, Paris, France. [Milleliri, Jean-Marie] UNAIDS, Dakar, Senegal. [Teo, Chong-Gee] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA USA. RP Mbopi-Keou, FX (reprint author), Univ Yaounde I, Minist Publ Hlth, Dept Labs & Blood Safety, Yaounde, Cameroon. EM fxmkeou@hotmail.com NR 14 TC 2 Z9 2 U1 1 U2 1 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD APR PY 2014 VL 8 IS 4 DI 10.1371/journal.pntd.0002635 PG 3 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA AG3TK UT WOS:000335342400025 PM 24762970 ER PT J AU Vesper, HW Botelho, JC Vidal, ML Rahmani, Y Thienpont, LM Caudill, SP AF Vesper, Hubert W. Botelho, Julianne C. Vidal, Meghan L. Rahmani, Yasamin Thienpont, Linda M. Caudill, Samuel P. TI High variability in serum estradiol measurements in men and women SO STEROIDS LA English DT Article DE Estradiol; Assay comparison; Analytical variability ID BREAST-CANCER RISK; POSTMENOPAUSAL WOMEN; MASS-SPECTROMETRY; POSITION STATEMENT; CHROMATOGRAPHY; IMMUNOASSAYS; CHALLENGES; ESTROGENS; HORMONES; COHORT AB To reduce the variability in estradiol (E2) testing and to assure better patient care, standardization of E2 measurements has been recommended. This study aims to assess the accuracy and variability of E2 measurements performed by 11 routine immunological methods and 6 mass spectrometry methods using single donor serum materials and to compare the results to a reference method. The contribution of calibration bias, specificity or matrix effects, and imprecision on the overall variability of individual assays was evaluated. This study showed substantial variability in serum E2 measurements in samples from men and pre- and post-menopausal women. The mean bias across all samples, for each participant, ranged between -2.4% and 235%, with 3 participants having a mean bias of over 100%. The data suggest that calibration bias is the major contributor to the overall variability for nine assays. The analytical performances of most assays measuring E2 concentrations do not meet current needs in research and patient care. Three out of 17 assays would meet performance criteria derived from biological variability of +/- 12.5% bias at concentrations >= 20 pg/mL, and a maximum allowable bias of +/- 2.5 pg/mL at concentrations <20 pg/mL. The sensitivity differs highly between assays. Most assays are not able to measure E2 levels below 10 pg/mL. Standardization, specifically calibration to a common standard by using panels of individual patient samples, can reduce the observed variability and improve the utility of E2 levels in clinical settings. Published by Elsevier Inc. C1 [Vesper, Hubert W.; Botelho, Julianne C.; Vidal, Meghan L.; Rahmani, Yasamin; Caudill, Samuel P.] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. [Thienpont, Linda M.] Univ Ghent, B-9000 Ghent, Belgium. RP Vesper, HW (reprint author), Ctr Dis Control & Prevent, 4770 Buford Highway,NE F25, Atlanta, GA 30341 USA. EM HVesper@cdc.gov NR 28 TC 9 Z9 9 U1 0 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0039-128X EI 1878-5867 J9 STEROIDS JI Steroids PD APR PY 2014 VL 82 BP 7 EP 13 DI 10.1016/j.steroids.2013.12.005 PG 7 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA AG6QT UT WOS:000335544200002 PM 24407040 ER PT J AU Penman-Aguilar, A Macaluso, M Peacock, N Snead, MC Posner, SF AF Penman-Aguilar, Ana Macaluso, Maurizio Peacock, Nadine Snead, M. Christine Posner, Samuel F. TI A NOVEL APPROACH TO MIXING QUALITATIVE AND QUANTITATIVE METHODS IN HIV AND STI PREVENTION RESEARCH SO AIDS EDUCATION AND PREVENTION LA English DT Article ID SEXUALLY-TRANSMITTED-DISEASE; FEMALE CONDOM; INTERVENTION; TRIALS AB Mixed-method designs are increasingly used in sexually transmitted infection (STI) and HIV prevention research. The authors designed a mixed-method approach and applied it to estimate and evaluate a predictor of continued female condom use (6+ uses, among those who used it at least once) in a 6-month prospective cohort study. The analysis included 402 women who received an intervention promoting use of female and male condoms for STI prevention and completed monthly quantitative surveys; 33 also completed a semistructured qualitative interview. The authors identified a qualitative theme (couples' female condom enjoyment [CFCE]), applied discriminant analysis techniques to estimate CFCE for all participants, and added CFCE to a multivariable logistic regression model of continued female condom use. CFCE related to comfort, naturalness, pleasure, feeling protected, playfulness, ease of use, intimacy, and feeling in control of protection. CFCE was associated with continued female condom use (adjusted odds ratio: 2.8, 95% confidence interval: 1.4-5.6) and significantly improved model fit (p < .001). CFCE predicted continued female condom use. Mixed-method approaches for "scaling up" qualitative findings from small samples to larger numbers of participants can benefit HIV and STI prevention research. C1 [Penman-Aguilar, Ana; Snead, M. Christine; Posner, Samuel F.] Ctr Dis Control & Prevent, CDC, Atlanta, GA 30333 USA. [Macaluso, Maurizio] Cincinnati Childrens Hosp, Med Ctr, Div Biostat & Epidemiol, Cincinnati, OH USA. [Peacock, Nadine] Univ Illinois, Sch Publ Hlth, Dept Community Hlth Sci, Chicago, IL USA. RP Penman-Aguilar, A (reprint author), Ctr Dis Control & Prevent, Off Director, Off Minor Hlth & Hlth Equ, 4770 Buford Highway NE,Mailstop K77, Atlanta, GA 30333 USA. EM bpv4@cdc.gov RI Macaluso, Maurizio/J-2076-2015; OI Macaluso, Maurizio/0000-0002-2977-9690; Posner, Samuel/0000-0003-1574-585X FU NICHD NIH HHS [N01-HD-1-3135]; PHS HHS [U48/CCU 409679-02] NR 21 TC 0 Z9 0 U1 0 U2 5 PU GUILFORD PUBLICATIONS INC PI NEW YORK PA 72 SPRING STREET, NEW YORK, NY 10012 USA SN 0899-9546 EI 1943-2755 J9 AIDS EDUC PREV JI Aids Educ. Prev. PD APR PY 2014 VL 26 IS 2 BP 95 EP 108 PG 14 WC Education & Educational Research; Public, Environmental & Occupational Health SC Education & Educational Research; Public, Environmental & Occupational Health GA AF1MK UT WOS:000334477800001 PM 24694324 ER PT J AU Nelson, KM Thiede, H Jenkins, RA Carey, JW Hutcheson, R Golden, MR AF Nelson, Kimberly M. Thiede, Hanne Jenkins, Richard A. Carey, James W. Hutcheson, Rebecca Golden, Matthew R. TI PERSONAL AND CONTEXTUAL FACTORS RELATED TO DELAYED HIV DIAGNOSIS AMONG MEN WHO HAVE SEX WITH MEN SO AIDS EDUCATION AND PREVENTION LA English DT Article ID ACTIVE ANTIRETROVIRAL THERAPY; UNITED-STATES; CARE; INTERCOURSE; PREVENTION; MORTALITY; INFECTION; DISEASE; COST; RISK AB Delayed HIV diagnosis among men who have sex with men (MSM) in the United States continues to be a significant personal and public health issue. Using qualitative and quantitative data from 75 recently tested, HIV-sero-positive MSM (38 delayed and 37 nondelayed testers), the authors sought to further elucidate potential personal and contextual factors that may contribute to delayed HIV diagnosis among MSM. Findings indicate that MSM who experience multiple life stressors, whether personal or contextual, have an increased likelihood of delaying HIV diagnosis. Furthermore, MSM who experience multiple life stressors without the scaffolding of social support, stable mental health, and self-efficacy to engage in protective health behaviors may be particularly vulnerable to delaying diagnosis. Interventions targeting these factors as well as structural interventions targeting physiological and safety concerns are needed to help MSM handle their life stressors more effectively and seek HIV testing in a timelier manner. C1 [Nelson, Kimberly M.] Univ Washington, Dept Psychol, Seattle, WA 98195 USA. [Thiede, Hanne; Golden, Matthew R.] Publ Hlth Seattle & King Cty, Seattle, WA USA. [Jenkins, Richard A.] Natl Inst Drug Abuse, Bethesda, MD USA. [Carey, James W.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. [Golden, Matthew R.] Univ Washington, Sch Publ Hlth & Community Med, Seattle, WA 98195 USA. [Golden, Matthew R.] Univ Washington, Sch Med, Seattle, WA USA. RP Nelson, KM (reprint author), Univ Washington, Dept Psychol, Box 351525, Seattle, WA 98195 USA. EM knelson6@uw.edu FU NIMH NIH HHS [F31 MH088851, F31MH088851]; PHS HHS [U64/CCU019523] NR 30 TC 3 Z9 3 U1 1 U2 4 PU GUILFORD PUBLICATIONS INC PI NEW YORK PA 72 SPRING STREET, NEW YORK, NY 10012 USA SN 0899-9546 EI 1943-2755 J9 AIDS EDUC PREV JI Aids Educ. Prev. PD APR PY 2014 VL 26 IS 2 BP 122 EP 133 PG 12 WC Education & Educational Research; Public, Environmental & Occupational Health SC Education & Educational Research; Public, Environmental & Occupational Health GA AF1MK UT WOS:000334477800003 PM 24694326 ER PT J AU Groome, MJ Moon, SS Velasquez, D Jones, S Koen, A van Niekerk, N Jiang, BM Parashar, UD Madhi, SA AF Groome, Michelle J. Moon, Sung-Sil Velasquez, Daniel Jones, Stephanie Koen, Anthonet van Niekerk, Nadia Jiang, Baoming Parashar, Umesh D. Madhi, Shabir A. TI Effect of breastfeeding on immunogenicity of oral live-attenuated human rotavirus vaccine: a randomized trial in HIV-uninfected infants in Soweto, South Africa SO BULLETIN OF THE WORLD HEALTH ORGANIZATION LA English DT Article ID POLIOVIRUS VACCINE; EFFICACY; MILK; CHILDREN; SEROCONVERSION; SURVEILLANCE; METAANALYSIS; COUNTRIES; ANTIBODY; MOTHERS AB Objective To investigate the effect of abstention from breastfeeding, for an hour before and after each vaccination, on the immune responses of infants to two doses of rotavirus vaccine. Methods In Soweto, South Africa, mother infant pairs who were uninfected with human immunodeficiency virus (HIV) were enrolled as they presented for the "6-week" immunizations of the infants. Each infant was randomly assigned to Group 1 in which breastfeeding was deferred for at least 1 h before and after each dose of rotavirus vaccine or Group 2 in which unrestricted breastfeeding was encouraged. Enzyme-linked immunosorbent assays were used to evaluate the titres of rotavirus-specific IgA in samples of serum collected from each infant immediately. before each vaccine dose and 1 month after the second dose. Among the infants, a fourfold or greater increase in titres of rotavirus-specific IgA following vaccination was considered indicative of seroconversion. Findings The evaluable infants in Group 1 (n = 98) were similar to those in Group 2 (n = 106) in their baseline demographic characteristics and their pre-vaccination titres of anti-rotavirus IgA. After the second vaccine doses, geometric mean titres of anti-rotavirus IgA in the sera of Group-1 infants were similar to those in the sera of Group-2 infants (P=0.685) and the frequency of seroconversion in the Group-1 infants was similar to that in the Group-2 infants (P=0.485). Conclusion Among HIV-uninfected South African infants, abstention from breastfeeding for at least 1 h before and after each vaccination dose had no significant effect on the infants' immune response to a rotavirus vaccine. C1 [Groome, Michelle J.; Jones, Stephanie; Koen, Anthonet; van Niekerk, Nadia; Madhi, Shabir A.] Univ Witwatersrand, Dept Sci & Technol, Natl Res Fdn, ZA-2013 Bertsham, Gauteng, South Africa. [Moon, Sung-Sil; Velasquez, Daniel; Jiang, Baoming; Parashar, Umesh D.] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA USA. RP Groome, MJ (reprint author), Univ Witwatersrand, Dept Sci & Technol, Natl Res Fdn, POB 90753, ZA-2013 Bertsham, Gauteng, South Africa. EM groomem@rmpru.co.za FU Respiratory and Meningeal Pathogens Research Unit, University of the Witwatersrand; United States Centers for Disease Control and Prevention FX This work was supported by the Respiratory and Meningeal Pathogens Research Unit, University of the Witwatersrand and the United States Centers for Disease Control and Prevention. NR 26 TC 20 Z9 20 U1 0 U2 8 PU WORLD HEALTH ORGANIZATION PI GENEVA 27 PA MARKETING AND DISSEMINATION, CH-1211 GENEVA 27, SWITZERLAND SN 0042-9686 EI 1564-0604 J9 B WORLD HEALTH ORGAN JI Bull. World Health Organ. PD APR PY 2014 VL 92 IS 4 BP 238 EP 245 DI 10.2471/BLT.13.128066 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AF4BM UT WOS:000334656400011 PM 24700991 ER PT J AU Townsend, JS Stormo, AR Roland, KB Buenconsejo-Lum, L White, S Saraiya, M AF Townsend, Julie S. Stormo, Analia Romina Roland, Katherine B. Buenconsejo-Lum, Lee White, Susan Saraiya, Mona TI Current Cervical Cancer Screening Knowledge, Awareness, and Practices Among US Affiliated Pacific Island Providers: Opportunities and Challenges SO ONCOLOGIST LA English DT Article DE Uterine cervical neoplasms; Cancer screening; Pacific Islands; Female; Early detection of cancer; Papillomavirus infections; Diagnosis; Prevention and control ID RANDOMIZED CONTROLLED-TRIAL; LOW-RESOURCE SETTINGS; LIQUID-BASED CYTOLOGY; SERVICES TASK-FORCE; HUMAN-PAPILLOMAVIRUS; VISUAL INSPECTION; SELF-COLLECTION; LATIN-AMERICA; ACETIC-ACID; PREVENTION AB Background. Cervical cancer is a leading cause of cancer mortality in nearly all U.S. Affiliated Pacific Island Jurisdictions (USAPIJ); however, most jurisdictions are financially and geographically limited in their capacity to deliver routine screening. Methods. We conducted a cross-sectional survey of 72 health care providers from five of the six USAPIJ in 2011 to assess knowledge, beliefs, practices, and perceived barriers regarding routine cervical cancer screening. We compared the responses of providers from jurisdictions that were funded by the Centers for Disease Control and Prevention's National Breast and Cervical Cancer Early Detection Program (NBCCEDP) with those that were not funded. Results. Most providers reported cervical cancer prevention as a priority in their clinical practices (90.3%) and use the Papanicolaou test for screening (86.1%). Many providers reported knowledge of screening guidelines (76.4%); however, more than half reported that annual screening is most effective (56.9%). Providers in non-NBCCEDP-funded jurisdictions reported greater acceptance of visual inspection with acetic acid (93.9%) and self-sampling for human papillomavirus testing (48.5%) compared with NBCCEDP-funded jurisdictions (15.4% and 30.8% respectively). Providers from non-NBCCEDP-funded jurisdictions reported inadequate technological resources for screening women (42.4%), and approximately 25% of providers in both groups believed that screening was cost- prohibitive. Conclusion. Although cervical cancer screening is a priority in clinical practice, beliefs about annual screening, costs associated with screening, and varying levels of support for alternative screening tests pose barriers to providers throughout the USAPIJ. Further exploration of using evidence-based, lower cost, and sustainable screening technologies is warranted in addition to emphasizing timely follow-up of all positive cases. C1 [Townsend, Julie S.; Stormo, Analia Romina; Roland, Katherine B.; White, Susan; Saraiya, Mona] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA USA. [Buenconsejo-Lum, Lee] Univ Hawaii, John A Burns Sch Med, Dept Family Med & Community Hlth, Honolulu, HI 96822 USA. RP Townsend, JS (reprint author), 4770 Buford Highway NE,MS F76, Chamblee, GA 30341 USA. EM jtownsend@cdc.gov OI Buenconsejo-Lum, Lee/0000-0001-8939-7646 FU Centers for Disease Control and Prevention cooperative agreement, Federated States of Micronesia National Comprehensive Cancer Control Program [U58 DP000779] FX We thank the Cancer Council of the Pacific Islands, health care providers and public health programs in the U. S. Affiliated Pacific Island Jurisdictions for their participation and assistance in our assessment of cervical cancer screening practices in the U. S. Affiliated Pacific Island Jurisdictions. We also thank Dr. Tom Richards for producing a regional map for us. This work was supported through a Centers for Disease Control and Prevention cooperative agreement, U58 DP000779 Federated States of Micronesia National Comprehensive Cancer Control Program. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. Furthermore, the use of any product names, trade names, images, or commercial sources is for identification only and does not imply endorsement or government sanction by the U.S. Department of Health and Human Services. NR 55 TC 2 Z9 2 U1 2 U2 8 PU ALPHAMED PRESS PI DURHAM PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701-2884 USA SN 1083-7159 EI 1549-490X J9 ONCOLOGIST JI Oncologist PD APR PY 2014 VL 19 IS 4 BP 383 EP 393 DI 10.1634/theoncologist.2013-0340 PG 11 WC Oncology SC Oncology GA AF0JY UT WOS:000334401300016 PM 24668335 ER PT J AU Perrine, CG Cogswell, ME Swanson, CA Sullivan, KM Chen, TC Carriquiry, AL Dodd, KW Caldwell, KL Wang, CY AF Perrine, Cria G. Cogswell, Mary E. Swanson, Christine A. Sullivan, Kevin M. Chen, Te-Ching Carriquiry, Alicia L. Dodd, Kevin W. Caldwell, Kathleen L. Wang, Chia-Yih TI Comparison of Population Iodine Estimates from 24-Hour Urine and Timed-Spot Urine Samples SO THYROID LA English DT Article ID UNITED-STATES; CREATININE CONCENTRATIONS; IODINE/CREATININE RATIO; EXCRETION; NUTRITION; SODIUM; ADULTS; DEFICIENCY; ADJUSTMENT; POTASSIUM AB Background: Median urine iodine concentration (UIC; mu g/L) in spot urine samples is recommended for monitoring population iodine status. Other common measures are iodine:creatinine ratio (I/Cr; mu g/g) and estimated 24-hour urine iodine excretion (UIE; I/Crxpredicted 24-hour Cr; mu g/day). Despite different units, these measures are often used interchangeably, and it is unclear how they compare with the reference standard 24-hour UIE. Methods: Volunteers aged 18-39 years collected all their urine samples for 24 hours (n=400). Voids from morning, afternoon, evening, overnight, and a composite 24-hour sample were analyzed for iodine. We calculated median observed 24-hour UIE and 24-hour UIC, and spot UIC, I/Cr, and two measures of estimated UIE calculated using predicted 24-hour Cr from published estimates by Kesteloot and Joosens (varies by age and sex) and published equations by Mage et al. (varies by age, sex, race, and anthropometric measures). We examined mean differences and relative difference across iodine excretion levels using Bland-Altman plots. Results: Median 24-hour UIE was 173.6 mu g/day and 24-hour UIC was 144.8 mu g/L. From timed-spot urine samples, estimates were: UIC 147.3-156.2 mu g/L; I/Cr 103.6-114.3 mu g/g, estimated 24-hour UIE (Kesteloot and Joosens) 145.7-163.3 mu g/day; and estimated 24-hour UIE (Mage) 176.5-187.7 mu g/day. Iodine measures did not vary consistently by timing of spot urine collection. Compared with observed 24-hour UIE, on average, estimated (Mage) 24-hour UIE was not significantly different, while estimated 24-hour UIE (Kesteloot and Joosens) was significantly different for some ethnicity/sex groups. Compared with 24-hour UIC, on average, spot UIC did not differ. Conclusions: Estimates of UIC, I/Cr, and estimated 24-hour UIE (I/Crxpredicted 24-hour Cr) from spot urine samples should not be used interchangeably. Estimated 24-hour UIE, where predicted 24-hour Cr varies by age, sex, ethnicity, and anthropometric measures and was calculated with prediction equations using data from the sample, was more comparable to observed 24-hour UIE than when predicted 24-hour Cr was from published estimates from a different population. However, currently no cutoffs exist to interpret population estimated 24-hour UIE values. C1 [Perrine, Cria G.; Dodd, Kevin W.] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Atlanta, GA 30333 USA. [Cogswell, Mary E.] Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Atlanta, GA 30333 USA. [Chen, Te-Ching; Wang, Chia-Yih] Ctr Dis Control & Prevent, Div Hlth & Nutr Examinat Surveys, Atlanta, GA 30333 USA. [Caldwell, Kathleen L.] Ctr Dis Control & Prevent, Div Sci Lab, Atlanta, GA 30333 USA. [Swanson, Christine A.] NCI, Off Dietary Supplements, NIH, Bethesda, MD 20892 USA. [Dodd, Kevin W.] NCI, NIH, Bethesda, MD 20892 USA. [Sullivan, Kevin M.] Emory Univ, Dept Epidemiol, Atlanta, GA 30322 USA. [Carriquiry, Alicia L.] Iowa State Univ, Dept Stat, Ames, IA USA. RP Perrine, CG (reprint author), Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, 1600 Clifton Rd, Atlanta, GA 30333 USA. EM cperrine@cdc.gov FU NIDDK NIH HHS [T32 DK007734] NR 32 TC 11 Z9 12 U1 0 U2 8 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1050-7256 EI 1557-9077 J9 THYROID JI Thyroid PD APR 1 PY 2014 VL 24 IS 4 BP 748 EP 757 DI 10.1089/thy.2013.0404 PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA AE6NN UT WOS:000334110700017 PM 24308769 ER PT J AU Vichinsky, E Neumayr, L Trimble, S Giardina, PJ Cohen, AR Coates, T Boudreaux, J Neufeld, EJ Kenney, K Grant, A Thompson, AA AF Vichinsky, Elliott Neumayr, Lynne Trimble, Sean Giardina, Patricia J. Cohen, Alan R. Coates, Thomas Boudreaux, Jeanne Neufeld, Ellis J. Kenney, Kristy Grant, Althea Thompson, Alexis A. CA CDC Thalassemia Investigators TI Transfusion complications in thalassemia patients: a report from the Centers for Disease Control and Prevention SO TRANSFUSION LA English DT Article ID SICKLE-CELL-DISEASE; BLOOD-TRANSFUSION; SERIOUS HAZARDS; DEPENDENT THALASSEMIA; HEMOLYTIC-ANEMIA; UNITED-STATES; NORTH-AMERICA; ALLOIMMUNIZATION; RISK; ALLOANTIBODIES AB BackgroundTransfusions are the primary therapy for thalassemia but have significant cumulative risks. In 2004, the Centers for Disease Control and Prevention (CDC) established a national blood safety monitoring program for thalassemia. This report summarizes the population and their previous nonimmune and immune transfusion complications. Study Design and MethodsThe CDC Thalassemia Blood Safety Network is a consortium of centers longitudinally following patients. Enrollment occurred from 2004 through 2012. Demographics, transfusion history, infectious exposures, and transfusion and nontransfusion complications were summarized. Logistic regression analyses of factors associated with allo- and autoimmunization were employed. ResultsThe race/ethnicity of these 407 thalassemia patients was predominantly Asian or Caucasian. The mean SD age was 22.3 +/- 13.2 years and patients had received a mean +/- SD total number of 149 +/- 103.4 units of red blood cells (RBCs). Multiorgan dysfunction was common despite chelation. Twenty-four percent of transfused patients had previous exposure to possible transfusion-associated pathogens including one case of babesia. As 27% were immigrants, the infection source cannot be unequivocally linked to transfusion. Transfusion reactions occurred in 48%, including allergic, febrile, and hemolytic; 19% were alloimmunized. Common antigens were E, Kell, and C. Years of transfusion was the strongest predictor of alloimmunization. Autoantibodies occurred in 6.5% and were associated with alloimmunization (p<0.0001). Local institutional policies, not patient characteristics, were major determinants of blood preparation and transfusion practices. ConclusionHemosiderosis, transfusion reactions, and infections continue to be major problems in thalassemia. New pathogens were noted. National guidelines for RBC phenotyping and preparation are needed to decrease transfusion-related morbidity. C1 Childrens Hosp Oakland, Oakland, CA USA. Ctr Dis Control & Prevent, Atlanta, GA USA. Cornell Univ, Weill Med Coll, New York, NY 10021 USA. Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA. Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA. Childrens Healthcare Atlanta Scottish Rite, Atlanta, GA USA. Boston Childrens Hosp, Boston, MA USA. Ann & Robert H Lurie Childrens Hosp Chicago, Chicago, IL USA. RP Vichinsky, E (reprint author), Childrens Hosp & Res Ctr Oakland, Dept Hematol Oncol, 747 52nd St, Oakland, CA 94609 USA. EM evichinsky@mail.cho.org FU Centers for Disease Control and Prevention (CDC) [5U01DD000310-05, U01-DD00306, U01-DD00309, U01-DD000308-05, U01-DD0003075, U01-DD000311-05]; NCRR [M01-RR02172] FX This study was supported by the Centers for Disease Control and Prevention (CDC): 5U01DD000310-05 to Children's Hospital & Research Center Oakland, U01-DD00306 to Children's Hospital Philadelphia, U01-DD00309 to Children's Hospital Los Angeles, U01-DD000308-05 to Boston Children's Hospital, U01-DD0003075 to Ann & Robert H. Lurie Children's Hospital of Chicago, and U01-DD000311-05 to Weill Medical College of Cornell University. In addition, Boston Children's Hospital was supported by NCRR Grant M01-RR02172. NR 65 TC 20 Z9 20 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0041-1132 EI 1537-2995 J9 TRANSFUSION JI Transfusion PD APR PY 2014 VL 54 IS 4 BP 972 EP 981 DI 10.1111/trf.12348 PG 10 WC Hematology SC Hematology GA AE7DF UT WOS:000334156200005 PM 23889533 ER PT J AU Shibeshi, ME Masresha, BG Smit, SB Biellik, RJ Nicholson, JL Muitherero, C Shivute, N Walker, O Reggis, K Goodson, JL AF Shibeshi, Messeret E. Masresha, Balcha G. Smit, Sheilagh B. Biellik, Robin J. Nicholson, Jennifer L. Muitherero, Charles Shivute, Nestor Walker, Oladapo Reggis, Katsande Goodson, James L. TI Measles resurgence in southern Africa: Challenges to measles elimination SO VACCINE LA English DT Article DE Measles; Elimination; Africa; Immunization; Vaccination ID CONGENITAL-RUBELLA SYNDROME; GLOBAL MEASLES; AMERICA; ERADICATION; INFANTS; EPIDEMIOLOGY; VACCINATION; OUTBREAK; CHILDREN; LESSONS AB Introduction: In seven southern African countries (Botswana, Lesotho, Malawi, Namibia, South Africa, Swaziland and Zimbabwe), following implementation of a measles mortality reduction strategy starting in 1996, the number of annually reported measles cases decreased sharply to less than one per million population during 2006-2008. However, during 2009-2010, large outbreaks occurred in these countries. In 2011, a goal for measles elimination by 2020 was set in the World Health Organization (WHO) African Region (AFR). We reviewed the implementation of the measles control strategy and measles epidemiology during the resurgence in the seven southern African countries. Methods: Estimated coverage with routine measles vaccination, supplemental immunization activities (SIA), annually reported measles cases by country, and measles surveillance and laboratory data were analyzed using descriptive analysis. Results: In the seven countries, coverage with the routine first dose of measles-containing vaccine (MCV1) decreased from 80% to 65% during 1996-2004, then increased to 84% in 2011; during 1996-2011, 79,696,523 people were reached with measles vaccination during 45 SIAs. Annually reported measles cases decreased from 61,160 cases to 60 cases and measles incidence decreased to <1 case per million during 1996-2008. During 2009-2010, large outbreaks that included cases among older children and adults were reported in all seven countries, starting in South Africa and Namibia in mid-2009 and in the other five countries by early 2010. The measles virus genotype detected was predominantly genotype B3. Conclusion: The measles resurgence highlighted challenges to achieving measles elimination in AFR by 2020. To achieve this goal, high two-dose measles vaccine coverage by strengthening routine immunization systems and conducting timely SIAs targeting expanded age groups, potentially including young adults, and maintaining outbreak preparedness to rapidly respond to outbreaks will be needed. Published by Elsevier Ltd. C1 [Shibeshi, Messeret E.; Muitherero, Charles; Shivute, Nestor] WHO, East & South Africa Inter Country Support Team, Harare, Zimbabwe. [Masresha, Balcha G.; Reggis, Katsande] WHO, African Reg Off, Harare, Zimbabwe. [Smit, Sheilagh B.] Natl Inst Communicable Dis, Measles & Rubella Reg Reference Lab, Johannesburg, South Africa. [Biellik, Robin J.] Consultant Epidemiologist, Geneva, Switzerland. [Nicholson, Jennifer L.] Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA 30322 USA. [Nicholson, Jennifer L.] Emory Univ, Laney Grad Sch, Atlanta, GA 30322 USA. [Walker, Oladapo] WHO, West Africa Inter Country Support Team, Ouagadougou, Burkina Faso. [Goodson, James L.] WHO, West Africa Inter Country Support Team, Ouagadougou, Burkina Faso. RP Goodson, JL (reprint author), US Ctr Dis Control & Prevent, Global Immunizat Div, Atlanta, GA 30333 USA. EM JGoodson@cdc.gov FU Measles & Rubella Initiative FX The authors gratefully acknowledge the work of all immunization officers, surveillance medical officers, and measles laboratory personnel across AFR involved in the implementation of the strategies for measles control. We also thank the Measles & Rubella Initiative for providing financial and technical assistance to member states for strategy implementation and efforts to achieve measles elimination in AFR. NR 43 TC 16 Z9 18 U1 0 U2 11 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD APR 1 PY 2014 VL 32 IS 16 BP 1798 EP 1807 DI 10.1016/j.vaccine.2014.01.089 PG 10 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA AF1OP UT WOS:000334483500006 PM 24530936 ER PT J AU Malosh, R Ohmit, SE Petrie, JG Thompson, MG Aiello, AE Monto, AS AF Malosh, Ryan Ohmit, Suzanne E. Petrie, Joshua G. Thompson, Mark G. Aiello, Allison E. Monto, Arnold S. TI Factors associated with influenza vaccine receipt in community dwelling adults and their children SO VACCINE LA English DT Article DE Influenza vaccination; Household vaccination; Attitudes ID A H1N1 VACCINATION; PARENTAL PERSPECTIVES; YOUNG-CHILDREN; UNITED-STATES; CARE; IMMUNIZATION; COVERAGE; DETERMINANTS; POPULATION; ACCEPTANCE AB Background: Factors associated with influenza vaccine receipt are well studied in healthcare personnel, pregnant women, and the elderly. There has been substantially less research in community dwelling adults and children, and none among entire households. Many studies determine vaccination status by self-report or behavioral intention, outcomes susceptible to misclassification. Given that vaccine is recommended for everyone over six months, re-evaluating these factors is warranted. Methods: The Household Influenza Vaccine Effectiveness (HIVE) study is a prospective cohort of households with children. In 2010-2011,549 adults representing 312 households completed surveys evaluating knowledge, attitudes, and practices regarding influenza vaccination for themselves and their children. Using the health belief model (HBM) as a framework, we examined factors associated with documented seasonal influenza vaccine receipt using log-binomial regression models. Results: In multivariate models, cues to action such as doctor recommendation, (RR 1.62, 95% CI: 1.25-2.10), perceived benefits (RR 1.25,95% CI: 1.04-1.50), and perceived susceptibility (RR 1.21,95% CI: 1.03-1.42) were significantly associated with increased likelihood of vaccine receipt among adults while high perceived barriers were associated with decreased likelihood (RR 0.38, 95% Cl: 0.25-0.59). Similarly, parents reporting higher barriers were less likely (RR 0.58,95% Cl: 0.42-0.79) and those perceiving greater benefits (RR 4.16, 95% CI: 2.28-7.59) and severity (RR 1.13, 95% CI: 1.00-1.27 were more likely to vaccinate their children. The observed effects of perceptions of susceptibility, severity, and benefits were more pronounced at low cues to action for children, as were the effects of perceptions of barriers and severity among adults. Conclusion: Perceived benefits and barriers are most strongly associated with vaccine receipt. However, the effects of various factors were most pronounced in the absence of cues to action, which may be an important component of targeted interventions. (c) 2014 Elsevier Ltd. All rights reserved. C1 [Malosh, Ryan; Ohmit, Suzanne E.; Petrie, Joshua G.; Aiello, Allison E.; Monto, Arnold S.] Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA. [Thompson, Mark G.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30333 USA. RP Malosh, R (reprint author), Univ Michigan, Sch Publ Hlth, Dept Epidemiol, 1415 Washington Hts, Ann Arbor, MI 48109 USA. EM rmalosh@umich.edu FU Centers for Disease Control and Prevention through a cooperative agreement with the University of Michigan [U01 IP000170] FX This work was supported by the Centers for Disease Control and Prevention through a cooperative agreement with the University of Michigan (U01 IP000170). NR 33 TC 12 Z9 12 U1 1 U2 4 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD APR 1 PY 2014 VL 32 IS 16 BP 1841 EP 1847 DI 10.1016/j.vaccine.2014.01.075 PG 7 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA AF1OP UT WOS:000334483500012 PM 24530926 ER PT J AU Norman, JJ Arya, JM McClain, MA Frew, PM Meltzer, MI Prausnitz, MR AF Norman, James J. Arya, Jaya M. McClain, Maxine A. Frew, Paula M. Meltzer, Martin I. Prausnitz, Mark R. TI Microneedle patches: Usability and acceptability for self-vaccination against influenza SO VACCINE LA English DT Article DE Microneedle, Human study; Usability; Acceptability; Influenza ID HEAT-LABILE ENTEROTOXIN; ADULTS; IMMUNIZATION; SAFETY; SKIN; IMMUNOGENICITY; ACCEPTANCE; INSERTION; OPINIONS; DELIVERY AB While therapeutic drugs are routinely self-administered by patients, there is little precedent for self-vaccination. Convenient self-vaccination may expand vaccination coverage and reduce administration costs. Microneedle patches are in development for many vaccines, but no reports exist on usability or acceptability. We hypothesized that naive patients could apply patches and that self-administered patches would improve stated intent to receive an influenza vaccine. We conducted a randomized, repeated measures study with 91 venue-recruited adults. To simulate vaccination, subjects received placebo microneedle patches given three times by self-administration and once by the investigator, as well as an intramuscular injection of saline. Seventy participants inserted patches with thumb pressure alone and the remainder used snap-based devices that closed shut at a certain force. Usability was assessed by skin staining and acceptability was measured with an adaptive-choice analysis. The best usability was seen with the snap device, with users inserting a median value of 93-96% of microneedles over three repetitions. When a self-administered microneedle patch was offered, intent to vaccinate increased from 44% to 65% (CI: 55-74%). The majority of those intending vaccination would prefer to self-vaccinate: 64% (CI: 51-75%). There were no serious adverse events associated with use of microneedle patches. The findings from this initial study indicate that microneedle patches for self-vaccination against influenza are usable and may lead to improved vaccination coverage. (c) 2014 Elsevier Ltd. All rights reserved. C1 [Norman, James J.; Arya, Jaya M.; McClain, Maxine A.; Prausnitz, Mark R.] Georgia Inst Technol, Sch Chem & Biomol Engn, Atlanta, GA 30332 USA. [Frew, Paula M.] Emory Univ, Sch Med, Div Infect Dis, Atlanta, GA 30322 USA. [Frew, Paula M.] Emory Univ, Rollins Sch Publ Hlth, Dept Behav Sci & Hlth Educ, Atlanta, GA 30332 USA. [Meltzer, Martin I.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. RP Prausnitz, MR (reprint author), Georgia Inst Technol, Sch Chem & Biomol Engn, 311 Ferst Dr, Atlanta, GA 30332 USA. EM jnorman3@gatech.edu; jarya3@gatech.edu; mx.mcclain@gmail.com; pfrew@emory.edu; qzm4@cdc.gov; prausnitz@gatech.edu OI Frew, Paula/0000-0002-3078-9124 FU NIBIB NIH HHS [U01 EB012495] NR 39 TC 52 Z9 52 U1 1 U2 41 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD APR 1 PY 2014 VL 32 IS 16 BP 1856 EP 1862 DI 10.1016/j.vaccine.2014.01.076 PG 7 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA AF1OP UT WOS:000334483500014 PM 24530146 ER PT J AU Lu, XH Liu, F Zeng, H Sheu, T Achenbach, JE Veguilla, V Gubareva, LV Garten, R Smith, C Yang, H Stevens, J Xu, XY Katz, JM Tumpey, TM AF Lu, Xiuhua Liu, Feng Zeng, Hui Sheu, Tiffany Achenbach, Jenna E. Veguilla, Vic Gubareva, Larisa V. Garten, Rebecca Smith, Catherine Yang, Hua Stevens, James Xu, Xiyan Katz, Jacqueline M. Tumpey, Terrence M. TI Evaluation of the antigenic relatedness and cross-protective immunity of the neuraminidase between human influenza A (H1N1) virus and highly pathogenic avian influenza A (H5N1) virus SO VIROLOGY LA English DT Article DE Influenza virus; Anti-neuraminidase antibodies; Antigenic and genetic analyses; Passive immunization; BALB/c mice; Cross-protective immunity ID 3-DIMENSIONAL STRUCTURE; LETHAL INFLUENZA; UNITED-STATES; VIRAL NEURAMINIDASE; ANTIBODY-RESPONSES; CRYSTAL-STRUCTURES; NATURAL INFECTION; B NEURAMINIDASE; VACCINE; HEMAGGLUTININ AB To determine the genetic and antigenic relatedness as well as the cross-protective immunity of human HI NI and avian H5N1 influenza virus neuraminidase (NA), we immunized rabbits with either a baculovirus-expressed recombinant NA from A/Beijing/262/95 (BJ/262) H1N1 or A/Hong Kong/483/97 (HK/483) H5N1 virus. Cross-reactive antibody responses were evaluated by multiple serological assays and cross-protection against H5N1 virus challenge was evaluated in mice. In a neuraminidase inhibition (NI) test, the antisera exhibited substantial inhibition of NA activity of the homologous virus, but failed to inhibit the NA activity of heterologous virus. However, these antisera exhibited low levels of cross-reactivity measured by plaque size reduction, replication inhibition, single radial hemolysis, and ELISA assays. Passive immunization with HK/483 NA-specific antisera significantly reduced virus replication and disease, and afforded almost complete protection against lethal homologous virus challenge in mice. However, passive immunization with BJ/262 (H1N1) NA-specific antisera was ineffective at providing cross-protection against lethal H5N1 virus challenge and only slightly reduced weight loss. Substantial amino acid variation among the NA antigenic sites was observed between BJ/262 and HK/483 virus, which was consistent with the lack of cross-reactive NI activity by the antibody and limited cross-protective immunity in mice. These results show a strong correlation between the lack of cross-protective immunity and low structural similarities of NA from a human seasonal HI NI virus and an avian H5N1 influenza virus. Published by Elsevier Inc C1 [Lu, Xiuhua; Liu, Feng; Zeng, Hui; Sheu, Tiffany; Achenbach, Jenna E.; Veguilla, Vic; Gubareva, Larisa V.; Garten, Rebecca; Smith, Catherine; Yang, Hua; Stevens, James; Xu, Xiyan; Katz, Jacqueline M.; Tumpey, Terrence M.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Influenza Div, Atlanta, GA 30333 USA. RP Tumpey, TM (reprint author), Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Influenza Div, Atlanta, GA 30333 USA. EM TTumpey@cdc.gov NR 70 TC 3 Z9 3 U1 0 U2 6 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0042-6822 J9 VIROLOGY JI Virology PD APR PY 2014 VL 454 BP 169 EP 175 DI 10.1016/j.virol.2014.02.011 PG 7 WC Virology SC Virology GA AF4AY UT WOS:000334655000018 PM 24725943 ER PT J AU McCann, RS Ochomo, E Bayoh, MN Vulule, JM Hamel, MJ Gimnig, JE Hawley, WA Walker, ED AF McCann, Robert S. Ochomo, Eric Bayoh, M. Nabie Vulule, John M. Hamel, Mary J. Gimnig, John E. Hawley, William A. Walker, Edward D. TI Reemergence of Anopheles funestus as a Vector of Plasmodium falciparum in Western Kenya after Long-Term Implementation of Insecticide-Treated Bed Nets SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID MALARIA TRANSMISSION; CHILD-MORTALITY; GAMBIAE S.S.; RESISTANCE; CULICIDAE; MOSQUITOS; DIPTERA; BEDNETS; IMPACT; SUSCEPTIBILITY AB Historically, the malaria vectors in western Kenya have been Anopheles funestus, Anopheles gambiae s.s., and Anopheles arabiensis. Of these species, An. funestus populations declined the most after the introduction of insecticide-treated bed nets (ITNs) in the 1990s in Asembo, and collections of An. funestus in the region remained low until at least 2008. Contrary to findings during the early years of ITN use in Asembo, the majority of the Anopheles collected here in 2010 and 2011 were An. funestus. Female An. funestus had characteristically high Plasmodium falciparum sporozoite rates and showed nearly 100% anthropophily. Female An. funestus were found more often indoors than outdoors and had relatively low mortality rates during insecticide bioassays. Together, these results are of serious concern for public health in the region, indicating that An. fimestus may once again be contributing significantly to the transmission of malaria in this region despite the widespread use of ITNs/long-lasting insecticidal nets (LLINs). C1 [McCann, Robert S.] Michigan State Univ, Dept Entomol, E Lansing, MI 48824 USA. Maseno Univ, Sch Publ Hlth & Community Dev, Dept Biomed Sci & Technol, Maseno, Kenya. Ctr Dis Control & Prevent, Kenya Med Res Inst, Ctr Global Hlth Res, Kisumu, Kenya. Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA USA. [Walker, Edward D.] Michigan State Univ, Dept Microbiol & Mol Genet, E Lansing, MI 48824 USA. [Ochomo, Eric; Bayoh, M. Nabie] Ctr Dis Control & Prevent, Res & Publ Hlth Collaborat, Kenya Med Res Inst, Kisumu, Kenya. [Vulule, John M.] Kenya Govt Med Res Ctr, Ctr Global Hlth Res, Kisumu, Kenya. [Hamel, Mary J.; Gimnig, John E.; Hawley, William A.] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA USA. RP McCann, RS (reprint author), Michigan State Univ, Dept Entomol, Biomed & Phys Sci Bldg,567 Wilson Rd,Room 6170, E Lansing, MI 48824 USA. EM mccannr3@msu.edu; eochomo@kemricdc.org; nbayoh@kemricdc.org; jvulule@kemricdc.org; mhamel@cdc.gov; jgimnig@cdc.gov; whawley@cdc.gov; walker@msu.edu FU National Science Foundation Ecology of Infectious Diseases grant [EF-0723770]; NIAID [U01AI0508542]; Rhodes Thompson Memorial Fellowship Fund FX This study was supported by a National Science Foundation Ecology of Infectious Diseases grant (grant no. EF-0723770) and NIAID Grant U01AI0508542 with additional support from the Rhodes Thompson Memorial Fellowship Fund. NR 37 TC 21 Z9 21 U1 0 U2 12 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 EI 1476-1645 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD APR PY 2014 VL 90 IS 4 BP 597 EP 604 DI 10.4269/ajtmh.13-0614 PG 8 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA AE6HS UT WOS:000334091800005 PM 24470562 ER PT J AU Musuva, RM Awiti, A Omedo, M Ogutu, M Secor, WE Montgomery, SP Alaii, J Mwinzi, PNM AF Musuva, Rosemary M. Awiti, Alphonce Omedo, Martin Ogutu, Michael Secor, W. Evan Montgomery, Susan P. Alaii, Jane Mwinzi, Pauline N. M. TI Community Knowledge, Attitudes and Practices on Schistosomiasis in Western Kenya-The SCORE Project SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID SOIL-TRANSMITTED HELMINTHS; NEGLECTED-TROPICAL-DISEASES; HEALTH-EDUCATION; SEEKING BEHAVIOR; MASS TREATMENT; COTE-DIVOIRE; INFECTIONS; CHILDREN; TANZANIA; MANSONI AB In an effort to improve intervention strategies, community knowledge, attitudes, and practices on schistosomiasis were evaluated using focus group discussions involving 237 participants, in eight Schistosoma mansoni high prevalence districts in rural Nyanza Province, Kenya. The majority of participants reported having heard about schistosomiasis through schools, posters, radio announcements, and community gatherings. Participants had a variety of beliefs about contracting schistosomiasis, including associating it with dirty drinking water and uncooked or contaminated food. Avenues for seeking treatment included health centers, spiritual intervention, herbal treatments, and medicine shops, with health centers receiving the most mention. Barriers to schistosomiasis control included attitudes of community members toward the infection, especially misconceptions that lead to stigma and the perception that diagnosis and treatment are expensive. Schools were the most common avenue for receiving information, suggesting that the existing education infrastructure can be used for health education and improved sensitization about schistosomiasis control programs. C1 [Musuva, Rosemary M.; Awiti, Alphonce; Omedo, Martin; Ogutu, Michael; Mwinzi, Pauline N. M.] Kenya Govt Med Res Ctr, Ctr Global Hlth Res, Neglected Trop Dis Branch, Kisumu, Kenya. [Secor, W. Evan; Montgomery, Susan P.] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA 30341 USA. [Alaii, Jane] ContextFACTOR Solut, Nairobi, Kenya. RP Secor, WE (reprint author), Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, 1600 Clifton Rd, Atlanta, GA 30341 USA. EM RMusuva@kemricdc.org; AAwiti@kemricdc.org; martowino007@yahoo.com; michaelogutu06@yahoo.com; was4@cdc.gov; zqu6@cdc.gov; alaiij@yahoo.co.uk; PMwinzi@kemricdc.org FU University of Georgia Research Foundation, Inc.; Bill and Melinda Gates Foundation FX The study was funded by the University of Georgia Research Foundation, Inc., which is funded by the Bill and Melinda Gates Foundation. NR 35 TC 11 Z9 12 U1 0 U2 12 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 EI 1476-1645 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD APR PY 2014 VL 90 IS 4 BP 646 EP 652 DI 10.4269/ajtmh.13-0488 PG 7 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA AE6HS UT WOS:000334091800014 PM 24534810 ER PT J AU Moss, DM Priest, JW Hamlin, K Derado, G Herbein, J Petri, WA Lammie, PJ AF Moss, Delynn M. Priest, Jeffrey W. Hamlin, Kathy Derado, Gordana Herbein, Joel Petri, William A., Jr. Lammie, Patrick J. TI Longitudinal Evaluation of Enteric Protozoa in Haitian Children by Stool Exam and Multiplex Serologic Assay SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID NEGLECTED TROPICAL DISEASES; TRANSMITTED HELMINTH INFECTIONS; SRI-LANKA; PREVENTIVE CHEMOTHERAPY; BEHAVIORAL-FACTORS; PROGRAMS; FILARIASIS; IMPLEMENTATION; TRANSMISSION; INTEGRATION AB Haitian children were monitored longitudinally in a filariasis study. Included were stool samples examined for Giardia intestinalis and Entamoeba histolytica cysts, and serum specimens analyzed for irnmunoglobulin G (IgG) responses to eight recombinant antigens from G. intestinalis (variant-specific surface protein [VSP1-VSP5]), E. histolytica (lectin adhesion molecule [LecA]), and Cryptosporidium parvum (17- and 27-kDa) using a multiplex bead assay. The IgG responses to VSP antigens peaked at 2 years of age and then diminished and were significantly lower (P < 0.002) in children > 4.5 years than in children < 4.5 years. The IgG responses to Cryptosporidium tended to increase with age. The IgG responses to LecA and VSP antigens and the prevalence of stools positive for cysts were significantly higher (P < 0.037 and P < 0.035, respectively) in the rainy season than in the dry season. The multiplex bead assay provides a powerful tool for analyzing serologic responses to multiple pathogens. C1 Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Div Parasit Dis & Malaria,Natl Ctr Global Hlth, Atlanta, GA 30329 USA. Univ Virginia, Dept Med, Blacksburg, VA USA. Univ Virginia, Dept Microbiol, Blacksburg, VA USA. Univ Virginia, Dept Pathol, Blacksburg, VA USA. [Herbein, Joel] TECHLAB Inc, Blacksburg, VA USA. RP Moss, DM (reprint author), Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, 1600 Clifton Rd, Atlanta, GA 30329 USA. EM dmm3@cdc.gov; jip8@cdc.gov; kl.hamlin28@gmail.com; uwx8@cdc.gov; jherbein@techlab.com; wap3q@virginia.edu; pjl1@cdc.gov FU National Institutes of Health (NIH); CDC; UNDP/World Bank/WHO Special Program for Research and Training in Tropical Diseases [920528, 940441]; CDC/APHL Emerging Infectious Disease Fellowship; NIH [R01 AI043596] FX We appreciate the financial support of the National Institutes of Health (NIH), CDC, and the UNDP/World Bank/WHO Special Program for Research and Training in Tropical Diseases (grant nos. 920528 and 940441). Katy Hamlin was supported by a CDC/APHL Emerging Infectious Disease Fellowship. Support for the production and purification of the LecA antigen was provided by NIH, grant R01 AI043596. NR 31 TC 12 Z9 13 U1 0 U2 4 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 EI 1476-1645 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD APR PY 2014 VL 90 IS 4 BP 653 EP 660 DI 10.4269/ajtmh.13-0545 PG 8 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA AE6HS UT WOS:000334091800015 PM 24591430 ER PT J AU Mehal, JM Holman, RC Vora, NM Blanton, J Gordon, PH Cheek, JE AF Mehal, Jason M. Holman, Robert C. Vora, Neil M. Blanton, Jesse Gordon, Paul H. Cheek, James E. TI Encephalitis-Associated Hospitalizations among American Indians and Alaska Natives SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID UNITED-STATES; INFECTIOUS-DISEASES; MANAGEMENT; MORTALITY; TRENDS AB Encephalitis produces considerable morbidity in the United States, but morbidity rates among American Indian/Alaska Native (AI/AN) people have not been described. Hospitalization records listing an encephalitis diagnosis were analyzed by using Indian Health Service direct/contract inpatient data. For 1998-2010, there were 436 encephalitis-associated hospitalizations among AI/AN people, an average annual age-adjusted hospitalization rate of 3.1/100,000 population. The rate for infants (11.9) was more than double that for any other age group. Death occurred for 4.1% of hospitalizations. Consistent with reports for the general U.S. population, the rate was high among infants and most (53.9%) hospitalizations were of unexplained etiology. The average annual rate during the study period appeared lower than for the general U.S. population, due particularly to lower rates in the elderly. Future community-based surveillance and mortality studies are needed to confirm these findings and examine reasons underlying the low rates of encephalitis in AI/AN people. C1 [Mehal, Jason M.] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Cheek, James E.] Univ New Mexico, Dept Family & Community Med, Hlth Sci Ctr, Publ Hlth Program, Albuquerque, NM 87131 USA. [Gordon, Paul H.] Indian Hlth Serv, Northern Navajo Med Ctr, Shiprock, NM USA. [Mehal, Jason M.; Holman, Robert C.; Vora, Neil M.; Blanton, Jesse] Ctr Dis Control & Prevent Atlanta, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. RP Mehal, JM (reprint author), Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. EM jmehal@cdc.gov; rholman@cdc.gov; wii8@cdc.gov; asi5@cdc.gov; paul.gordon@ihs.gov; jcheek@salud.unm.edu OI Gordon, Paul/0000-0001-5714-9875 NR 34 TC 1 Z9 1 U1 0 U2 3 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 EI 1476-1645 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD APR PY 2014 VL 90 IS 4 BP 755 EP 759 DI 10.4269/ajtmh.13-0420 PG 5 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA AE6HS UT WOS:000334091800030 PM 24515941 ER PT J AU Kalb, SR Baudys, J Smith, TJ Smith, LA Barr, JR AF Kalb, Suzanne R. Baudys, Jakub Smith, Theresa J. Smith, Leonard A. Barr, John R. TI Three Enzymatically Active Neurotoxins of Clostridium botulinum Strain Af84: BoNT/A2, /F4, and /F5 SO ANALYTICAL CHEMISTRY LA English DT Article ID TOXIN PROTEOMICS; ENDOPEP-MS; SEROTYPE-A; SNAP-25; IDENTIFICATION; CLEAVAGE; GROWTH; PH; VAMP/SYNAPTOBREVIN; PROTEOLYSIS AB Botulinum neurotoxins (BoNTs) are produced by various species of clostridia and are potent neurotoxins which cause the disease botulism, by cleaving proteins needed for successful nerve transmission. There are currently seven confirmed serotypes of BoNTs, labeled A-G, and toxin-producing clostridia typically only produce one serotype of BoNT. There are a few strains (bivalent strains) which are known to produce more than one serotype of BoNT, producing either both BoNT/A and /B, BoNT/A and /F, or BoNT/B and /F, designated as Ab, Ba, Af, or BE Recently, it was reported that Clostridium botulinum strain Af84 has three neurotoxin gene clusters: bont/A2, bont/F4, and bont/F5. This was the first report of a clostridial organism containing more than two neurotoxin gene clusters. Using a mass spectrometry based proteomics approach, we report here that all three neurotoxins, BoNT/A2, /F4, and /F5, are produced by C. botulinum Af84. Label free MSE quantification of the three toxins indicated that toxin composition is 88% BoNT/A2, 1% BoNT/F4, and 11% BoNT/F5. The enzymatic activity of all three neurotoxins was assessed by examining the enzymatic activity of the neurotoxins upon peptide substrates, which mimic the toxins' natural targets, and monitoring cleavage of the substrates by mass spectrometry. We determined that all three neurotoxins are enzymatically active. This is the first report of three enzymatically active neurotoxins produced in a single strain of Clostridium botulinum. C1 [Kalb, Suzanne R.; Baudys, Jakub; Barr, John R.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Sci Lab, Atlanta, GA 30341 USA. [Smith, Theresa J.] US Army Med Res Inst Infect Dis, Ft Detrick, MD 21702 USA. [Smith, Leonard A.] Med Res & Mat Command, Off Chief Scientist, Ft Detrick, MD 21702 USA. RP Barr, JR (reprint author), Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Sci Lab, 4770 Buford Hwy, Atlanta, GA 30341 USA. EM jbarr@cdc.gov OI Kalb, Suzanne/0000-0002-8067-136X FU Intramural CDC HHS [CC999999] NR 30 TC 10 Z9 10 U1 0 U2 8 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0003-2700 EI 1520-6882 J9 ANAL CHEM JI Anal. Chem. PD APR 1 PY 2014 VL 86 IS 7 BP 3254 EP 3262 DI 10.1021/ac5001509 PG 9 WC Chemistry, Analytical SC Chemistry GA AE2AV UT WOS:000333776600003 PM 24605815 ER PT J AU Weiner, ZP Ernst, SM Boyer, AE Gallegos-Candela, M Barr, JR Glomski, IJ AF Weiner, Zachary P. Ernst, Stephen M. Boyer, Anne E. Gallegos-Candela, Maribel Barr, John R. Glomski, Ian J. TI Circulating lethal toxin decreases the ability of neutrophils to respond to Bacillus anthracis SO CELLULAR MICROBIOLOGY LA English DT Article ID ACTIN-BASED MOTILITY; POLYMORPHONUCLEAR LEUKOCYTE; INHALATIONAL ANTHRAX; ADAPTIVE IMMUNITY; EDEMA TOXIN; CHEMOTAXIS; MODEL; MICE; MACROPHAGES; COMPONENTS AB Polymorphonuclear leucocytes (PMNs) play a protective role during Bacillus anthracis infection. However, B.anthracis is able to subvert the PMN response effectively as evidenced by the high mortality rates of anthrax. One major virulence factor produced by B.anthracis, lethal toxin (LT), is necessary for dissemination in the BSL2 model of mouse infection. While human and mouse PMNs kill vegetative B.anthracis, short in vitro half-lives of PMNs have made it difficult to determine how or if LT alters their bactericidal function. Additionally, the role of LT intoxication on PMN's ability to migrate to inflammatory signals remains controversial. LF concentrations in both serum and major organs were determined from mice infected with B.anthracisSterne strain at defined stages of infection to guide subsequent administration of purified toxin. Bactericidal activity of PMNs assessed using ex vivo cell culture assays showed significant defects in killing B.anthracis. In vivoPMN recruitment to inflammatory stimuli was significantly impaired at 24h as assessed by real-time analysis of light-producing PMNs within the mouse. The observations described above suggest that LT serves dual functions; it both attenuates accumulation of PMNs at sites of inflammation and impairs PMNs bactericidal activity against vegetative B.anthracis. C1 [Weiner, Zachary P.; Ernst, Stephen M.; Glomski, Ian J.] Univ Virginia, Dept Microbiol Immunol & Canc Biol, Charlottesville, VA 22903 USA. [Boyer, Anne E.; Gallegos-Candela, Maribel; Barr, John R.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. RP Glomski, IJ (reprint author), Univ Virginia, Dept Microbiol Immunol & Canc Biol, Charlottesville, VA 22903 USA. EM iglomski@virginia.edu NR 56 TC 2 Z9 2 U1 0 U2 10 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1462-5814 EI 1462-5822 J9 CELL MICROBIOL JI Cell Microbiol. PD APR PY 2014 VL 16 IS 4 BP 504 EP 518 DI 10.1111/cmi.12232 PG 15 WC Cell Biology; Microbiology SC Cell Biology; Microbiology GA AD0UR UT WOS:000332950100006 PM 24152301 ER PT J AU Ye, XY Wong, LY Zhou, XL Calafat, AM AF Ye, Xiaoyun Wong, Lee-Yang Zhou, Xiaoliu Calafat, Antonia M. TI Urinary Concentrations of 2,4-Dichlorophenol and 2,5-Dichlorophenol in the US Population (National Health and Nutrition Examination Survey, 2003-2010): Trends and Predictors SO ENVIRONMENTAL HEALTH PERSPECTIVES LA English DT Article ID SECONDHAND SMOKE; EXPOSURE; PHENOLS; CHLOROPHENOLS; PESTICIDES; BIRTH; RATS AB BACKGROUND: 2,4-Dichlorophenol (2,4-DCP), 2,5-dichlorophenol (2,5-DCP), and their precursors are widely used in industry and in consumer products. Urinary concentrations of these dichlorophenols (DCPs) have been measured as part of four National Health and Nutrition Examination Survey (NHANES) cycles in order to assess the exposure to these compounds or their precursors among the general U.S. population. OBJECTIVES: We identified predictors and evaluated trends in DCP concentrations according to race/ethnicity, age, sex, family income, and housing type. METHODS: We used analysis of covariance to examine associations of various demographic parameters and survey cycle with urinary concentrations of DCPs during NHANES 2003-2010. We also conducted weighted logistic regressions to estimate associations of DCP concentrations above the 95th percentile with housing type, race/ethnicity, and income. RESULTS: We detected DCPs in at least 81% of participants. Geometric mean (GM) urinary concentrations were higher for 2,5-DCP (6.1-12.9 mu g/L) than 2,4-DCP (0.8-1.0 mu g/L) throughout 2003-2010. Adjusted GM concentrations of the DCPs among children (6-11 years of age) and adults > 60 years of age were higher than among adolescents and other adults. Adjusted GM concentrations among non-Hispanic whites were lower than among non-Hispanic blacks and Mexican Americans, although differences according to race/ethnicity were less pronounced among participants in high-income households. Among non-Hispanic blacks and Mexican Americans, adjusted GM concentrations were lowest among high-income participants relative to other income groups, with a monotonic decrease with increasing income among Mexican Americans. Type of housing and race/ethnicity were significant predictors of DCP urinary concentrations above the 95th percentile. Furthermore, urinary DCP concentrations have showed a downward trend since 2003. CONCLUSIONS: Exposure to DCPs and their precursors was prevalent in the general U. S. population in 2003-2010. We identified age and race/ethnicity, family income, and housing type as predictors of exposure to these compounds. C1 [Ye, Xiaoyun; Wong, Lee-Yang; Zhou, Xiaoliu; Calafat, Antonia M.] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. RP Ye, XY (reprint author), Ctr Dis Control & Prevent, 4770 Buford Hwy,Mailstop F53, Atlanta, GA 30341 USA. EM xay5@cdc.gov NR 30 TC 5 Z9 5 U1 1 U2 11 PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE PI RES TRIANGLE PK PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA SN 0091-6765 EI 1552-9924 J9 ENVIRON HEALTH PERSP JI Environ. Health Perspect. PD APR PY 2014 VL 122 IS 4 BP 351 EP 355 DI 10.1289/ehp.1306816 PG 5 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA AE5ZY UT WOS:000334069100017 PM 24451842 ER PT J AU Auld, AF Tuho, MZ Ekra, KA Kouakou, J Shiraishi, RW Adjorlolo-Johnson, G Marlink, R Ellerbrock, TV AF Auld, A. F. Tuho, M. Z. Ekra, K. A. Kouakou, J. Shiraishi, R. W. Adjorlolo-Johnson, G. Marlink, R. Ellerbrock, T. V. TI Tuberculosis in human immunodeficiency virus-infected children starting antiretroviral therapy in Cote d'Ivoire SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE LA English DT Article DE pediatric; incident tuberculosis; tuberculosis screening; Ivory Coast ID AFRICAN CHILDREN; SOUTH-AFRICA; HIV-INFECTION; COMMUNITY; IMPACT; COHORT AB SETTING: In Cote d'Ivoire, more than 2000 human immunodeficiency virus (HIV) infected children aged <15 years were started on antiretroviral therapy (ART) during 2004-2008. OBJECTIVES: To estimate tuberculosis (TB) incidence and determinants among ART enrollees. DESIGN: A nationally representative retrospective cohort study among 2110 children starting ART during 2004-2008 at 29 facilities. RESULTS: At ART initiation, the median age was 5.1 years; 82% had World Health Organization Stage III/IV, median CD4% was 11%, 42% were severely undernourished (weight-for-age Z-score [WAZ] <-3), and 150 (7%) were taking anti-tuberculosis treatment. Documentation of TB screening before ART declined from 63% to 46% during 2004-2008. Children taking anti-tuberculosis treatment at ART enrollment had a lower median CD4% (9.0% vs. 11.0%, P = 0.037) and a higher prevalence of WAZ <-3 (59% vs. 40%, P < 0.001). Among children considered TB-free at ART enrollment, TB incidence was 6.28/100 child-years during days 0-90 of ART, declining to 0.56/100 childyears after 180 days. Children with one unit higher WAZ at ART enrollment had 13% lower TB incidence (adjusted HR 0.87, 95 %CI 0.77-1.00, P = 0.047). CONCLUSIONS: Ensuring clinician compliance with TB screening before ART and ensuring earlier ART initiation before children suffer from advanced HIV disease and nutritional compromise might reduce TB morbidity during ART. C1 [Auld, A. F.; Shiraishi, R. W.; Ellerbrock, T. V.] Ctr Dis Control & Prevent CDC, Div Global HIV AIDS, Atlanta, GA USA. [Tuho, M. Z.] Natl Programme Med Care Persons Living HIVAIDS, Minist Hlth, Abidjan, Cote Ivoire. [Ekra, K. A.; Kouakou, J.] CDC, Div Global HIV AIDS, Abidjan, Cote Ivoire. [Adjorlolo-Johnson, G.; Marlink, R.] Elizabeth Glaser Pediat AIDS Fdn, Los Angeles, CA USA. RP Auld, AF (reprint author), US Ctr Dis Control & Prevent CDC, HIV Care & Treatment Team, Div Global HIVAIDS DGHA, Ctr Global Hlth CGH, 1600 Clifton Rd,Mailstop E04, Atlanta, GA 30333 USA. EM aauld@cdc.gov OI Auld, Andrew/0000-0001-5089-9163 FU President's Emergency Plan for AIDS Relief (PEPFAR) through the US Centers for Disease Control and Prevention (CDC) FX This research has been supported by the President's Emergency Plan for AIDS Relief (PEPFAR) through the US Centers for Disease Control and Prevention (CDC). NR 28 TC 7 Z9 7 U1 0 U2 0 PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D) PI PARIS PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE SN 1027-3719 EI 1815-7920 J9 INT J TUBERC LUNG D JI Int. J. Tuberc. Lung Dis. PD APR PY 2014 VL 18 IS 4 BP 381 EP 387 DI 10.5588/ijtld.13.0395 PG 7 WC Infectious Diseases; Respiratory System SC Infectious Diseases; Respiratory System GA AE7AV UT WOS:000334150000003 PM 24670690 ER PT J AU Fiske, CT Yan, FX Hirsch-Moverman, Y Sterling, TR Reichler, MR AF Fiske, C. T. Yan, F-X. Hirsch-Moverman, Y. Sterling, T. R. Reichler, M. R. CA TB Epidemiologic Studies Consortiu TI Risk factors for treatment default in close contacts with latent tuberculous infection SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE LA English DT Article DE LTBI; treatment non-completion; treatment effectiveness ID ISONIAZID PREVENTIVE THERAPY; HUMAN-IMMUNODEFICIENCY-VIRUS; TREATMENT COMPLETION; UNITED-STATES; CONTROLLED TRIAL; HIV-INFECTION; JAIL INMATES; RIFAMPIN; ADULTS; ENHANCEMENT AB OBJECTIVE: 1) To characterize risk factors for non-completion of latent tuberculous infection treatment (LTBIT), and 2) to assess the impact of LTBIT regimens on subsequent risk of tuberculosis (TB). METHODS: Close contacts of adults aged >= 15 years with pulmonary TB were prospectively enrolled in a multi-center study in the United States and Canada from January 2002 to December 2006. Close contacts of TB patients were screened and cross-matched with TB registries to identify those who developed active TB. RESULTS: Of 3238 contacts screened, 1714 (53%) were diagnosed with LTBI. Preventive treatment was recommended in 1371 (80%); 1147 (84%) initiated treatment, of whom 723 (63%) completed it. In multivariate analysis, study site, initial interview sites other than a home or health care setting and isoniazid preventive treatment (IPT) were significantly associated with non-completion of LTBIT. Fourteen TB cases were identified in contacts, all of whom initiated IPT: two TB cases among persons who received >= 6 months of IPT (66 cases/100 000 person-years [py]), and nine among those who received 0-5 months (median 2 months) of IPT (792 cases/100 000 py, P < 0.001); data on duration of IPT were not available for three cases. CONCLUSION: Only 53% (723/1371) of close contacts for whom IPT was recommended actually completed treatment. Close contacts were significantly less likely to complete LTBIT if they took IPT. Less than 6 months of IPT was associated with increased risk of active TB. C1 [Fiske, C. T.; Sterling, T. R.] Vanderbilt Univ, Dept Med, Div Infect Dis, Sch Med, Nashville, TN 37232 USA. [Yan, F-X.; Reichler, M. R.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Hirsch-Moverman, Y.] Columbia Univ, Charles P Felton Natl TB Ctr, Int Ctr AIDS Care & Treatment Programs, Mailman Sch Publ Hlth, New York, NY USA. RP Fiske, CT (reprint author), Vanderbilt Univ, Dept Med, Div Infect Dis, Sch Med, A2200 MCN,1161 21 Ave S, Nashville, TN 37232 USA. EM christina.fiske@vanderbilt.edu FU Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA [K24 AI065298, K23 AI091692-01] FX Funding was provided by the Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA [K24 AI065298 (TRS); K23 AI091692-01 (CTF)]. NR 31 TC 7 Z9 8 U1 0 U2 4 PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D) PI PARIS PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE SN 1027-3719 EI 1815-7920 J9 INT J TUBERC LUNG D JI Int. J. Tuberc. Lung Dis. PD APR PY 2014 VL 18 IS 4 BP 421 EP 427 DI 10.5588/ijtld.13.0688 PG 7 WC Infectious Diseases; Respiratory System SC Infectious Diseases; Respiratory System GA AE7AV UT WOS:000334150000009 PM 24670696 ER PT J AU Holub, CK Lobelo, F Mehta, SM Romero, LMS Arredondo, EM Elder, JP AF Holub, Christina K. Lobelo, Felipe Mehta, Setoo M. Sanchez Romero, Luz M. Arredondo, Elva M. Elder, John P. TI School-Wide Programs Aimed at Obesity Among Latino Youth in the United States: A Review of the Evidence SO JOURNAL OF SCHOOL HEALTH LA English DT Article DE childhood obesity; Latino; school-based interventions; review ID RANDOMIZED CONTROLLED-TRIAL; PRESCHOOL-CHILDREN; PREVENTION PROGRAM; HIP-HOP; OVERWEIGHT; WEIGHT; HEALTH; RISK; RECOMMENDATIONS; INTERVENTIONS AB BACKGROUNDIn the past 30years, childhood obesity rates have tripled, disproportionately affecting Latino children. From 2003 to 2006, 43.0% of Mexican-American children were classified as overweight compared with 36.9% of non-Hispanic Whites. Obesity interventions targeting children can have a significant impact in the school setting. METHODSWe conducted a systematic review of evidence-based, obesity-related interventions in the school setting. Inclusion criteria included: having 50% or more Latino children in the study, and usage of obesity-related outcomes (eg, body mass index [BMI] z-score, weight, and waist circumference, and body fat). RESULTSThe majority of identified studies included interventions that targeted both nutrition and physical activity. The most successful interventions were randomized, controlled trials or quasi-experimental controlled studies and had few limitations in execution in the study; however, overall results were mixed. There are promising results for interventions targeting Latino children who are already overweight or obese, but evidence of effectiveness is sparse. CONCLUSIONSThis review is the first to gather evidence-based research systematically aimed at obesity-related interventions in the school setting that are specifically focused on Latino children. Results of the review are promising and timely, given the exigency of the needed evidence, and the current state of childhood obesity in the United States. C1 [Holub, Christina K.; Mehta, Setoo M.; Arredondo, Elva M.; Elder, John P.] San Diego State Univ, Inst Behav & Community Hlth, San Diego, CA 92123 USA. [Lobelo, Felipe] Ctr Dis Control & Prevent, Global Hlth Promot Off, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Sanchez Romero, Luz M.] Natl Inst Publ Hlth, Ctr Nutr & Hlth, Res Dept Nutr Policies & Programs, Cuernavaca 62100, Morelos, Mexico. RP Holub, CK (reprint author), San Diego State Univ, Inst Behav & Community Hlth, 9245 Sky Pk Court,Suite 221, San Diego, CA 92123 USA. EM cholub@mail.sdsu.edu; rlobelo@cdc.gov; setoome@gmail.com; luz.sanchez@insp.mx; earredondo@mail.sdsu.edu; jelder@mail.sdsu.edu OI Lobelo, Felipe/0000-0003-4185-7193 FU NCCDPHP CDC HHS [1U48 DP001917] NR 32 TC 5 Z9 5 U1 1 U2 18 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0022-4391 EI 1746-1561 J9 J SCHOOL HEALTH JI J. Sch. Health PD APR PY 2014 VL 84 IS 4 BP 239 EP 246 DI 10.1111/josh.12144 PG 8 WC Education & Educational Research; Education, Scientific Disciplines; Health Care Sciences & Services; Public, Environmental & Occupational Health SC Education & Educational Research; Health Care Sciences & Services; Public, Environmental & Occupational Health GA AF0PC UT WOS:000334415500003 PM 24617907 ER PT J AU Arnold, BF Priest, JW Hamlin, KL Moss, DM Colford, JM Lammie, PJ AF Arnold, Benjamin F. Priest, Jeffrey W. Hamlin, Katy L. Moss, Delynn M. Colford, John M., Jr. Lammie, Patrick J. TI Serological Measures of Malaria Transmission in Haiti: Comparison of Longitudinal and Cross-Sectional Methods SO PLOS ONE LA English DT Article ID PLASMODIUM-FALCIPARUM; WUCHERERIA-BANCROFTI; LYMPHATIC FILARIASIS; ANTIBODIES; INFECTION; EXPOSURE; CHILDREN; RATES; AREA AB Background: Efforts to monitor malaria transmission increasingly use cross-sectional surveys to estimate transmission intensity from seroprevalence data using malarial antibodies. To date, seroconversion rates estimated from cross-sectional surveys have not been compared to rates estimated in prospective cohorts. Our objective was to compare seroconversion rates estimated in a prospective cohort with those from a cross-sectional survey in a low-transmission population. Methods and Findings: The analysis included two studies from Haiti: a prospective cohort of 142 children ages <= 11 years followed for up to 9 years, and a concurrent cross-sectional survey of 383 individuals ages 0-90 years old. From all individuals, we analyzed 1,154 blood spot specimens for the malaria antibody MSP-1(19) using a multiplex bead antigen assay. We classified individuals as positive for malaria using a cutoff derived from the mean plus 3 standard deviations in antibody responses from a negative control set of unexposed individuals. We estimated prospective seroconversion rates from the longitudinal cohort based on 13 incident seroconversions among 646 person-years at risk. We also estimated seroconversion rates from the cross-sectional survey using a reversible catalytic model fit with maximum likelihood. We found the two approaches provided consistent results: the seroconversion rate for ages <= 11 years was 0.020 ( 0.010, 0.032) estimated prospectively versus 0.023 ( 0.001, 0.052) in the cross-sectional survey. Conclusions: The estimation of seroconversion rates using cross-sectional data is a widespread and generalizable problem for many infectious diseases that can be measured using antibody titers. The consistency between these two estimates lends credibility to model-based estimates of malaria seroconversion rates using cross-sectional surveys. This study also demonstrates the utility of including malaria antibody measures in multiplex assays alongside targets for vaccine coverage and other neglected tropical diseases, which together could comprise an integrated, large-scale serological surveillance platform. C1 [Arnold, Benjamin F.; Colford, John M., Jr.] Univ Calif Berkeley, Sch Publ Hlth, Dept Epidemiol, Berkeley, CA 94720 USA. [Priest, Jeffrey W.; Moss, Delynn M.] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA USA. [Hamlin, Katy L.; Lammie, Patrick J.] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA USA. RP Arnold, BF (reprint author), Univ Calif Berkeley, Sch Publ Hlth, Dept Epidemiol, Berkeley, CA 94720 USA. EM benarnold@berkeley.edu FU National Institutes of Health; CDC; UNDP/World Bank/WHO Special Program for Research and Training in Tropical Diseases [920528, 940441]; CDC/APHL Emerging Infectious Disease Fellowship FX The authors appreciate the financial support of the National Institutes of Health, CDC and the UNDP/World Bank/WHO Special Program for Research and Training in Tropical Diseases (grants #920528 and #940441). Katy Hamlin was supported by a CDC/APHL Emerging Infectious Disease Fellowship. Besides the CDC, the funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Use of trade names is for identification only and does not imply endorsement by the Public Health Service of by the U. S. Department of Health and Human Services. The findings and conclusions in this report do not represent the official position of the Centers for Disease Control and Prevention. NR 21 TC 20 Z9 21 U1 0 U2 9 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD APR 1 PY 2014 VL 9 IS 4 AR e93684 DI 10.1371/journal.pone.0093684 PG 8 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA AE6KM UT WOS:000334101100126 PM 24691467 ER PT J AU Gordon, SC Butala, JH Carter, JM Elder, A Gordon, T Gray, G Sayre, PG Schulte, PA Tsai, CS West, J AF Gordon, Steven C. Butala, John H. Carter, Janet M. Elder, Alison Gordon, Terry Gray, George Sayre, Philip G. Schulte, Paul A. Tsai, Candace S. West, Jay TI Workshop report: Strategies for setting occupational exposure limits for engineered nanomaterials SO REGULATORY TOXICOLOGY AND PHARMACOLOGY LA English DT Article DE Occupational exposure limit; Engineered nanomaterial; OEL; ENM; Workshop; Strategies; Alternatives ID WALLED CARBON NANOTUBES; RISK-ASSESSMENT; NANOPARTICLES; DEPOSITION; MODEL; PARTICLES; DOSIMETRY; TOXICITY; HUMANS; LUNG AB Occupational exposure limits (OELs) are important tools for managing worker exposures to chemicals; however, hazard data for many engineered nanomaterials (ENMs) are insufficient for deriving OELs by traditional methods. Technical challenges and questions about how best to measure worker exposures to ENMs also pose barriers to implementing OELs. New varieties of ENMs are being developed and introduced into commerce at a rapid pace, further compounding the issue of OEL development for ENMs. A Workshop on Strategies for Setting Occupational Exposure Limits for Engineered Nanomaterials, held in September 2012, provided an opportunity for occupational health experts from various stakeholder groups to discuss possible alternative approaches for setting OELs for ENMs and issues related to their implementation. This report summarizes the workshop proceedings and findings, identifies areas for additional research, and suggests potential avenues for further progress on this important topic. (C) 2014 The Authors. Published by Elsevier Inc. C1 [Gordon, Steven C.] 3M Co, Toxicol Assessment & Compliance Assurance, St Paul, MN 55144 USA. [Butala, John H.] Toxicol Consultants Inc, Gibsonia, PA 15044 USA. [Carter, Janet M.] US Dept Labor, Washington, DC 20210 USA. [Elder, Alison] Univ Rochester, Sch Med & Dent, Dept Environm Med, Rochester, NY 14642 USA. [Gordon, Terry] NYU, Sch Med, Dept Environm Med, Tuxedo Pk, NY 10987 USA. [Gray, George] George Washington Univ, Sch Publ Hlth & Hlth Serv, Dept Environm & Occupat Hlth, Washington, DC 20037 USA. [Gray, George] George Washington Univ, Sch Publ Hlth & Hlth Serv, Ctr Risk Sci & Publ Hlth, Washington, DC 20037 USA. [Sayre, Philip G.] US EPA, Washington, DC 20460 USA. [Schulte, Paul A.] NIOSH, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. [Tsai, Candace S.] Purdue Univ, Sch Hlth Sci, W Lafayette, IN 47907 USA. [West, Jay] Amer Chem Council, Nanotechnol Panel, Washington, DC 20002 USA. RP Gordon, SC (reprint author), 3M Co, Toxicol Assessment & Compliance Assurance, 3M Ctr,Bldg 220-6E-03, St Paul, MN 55144 USA. EM scgordon@mmm.com; butala@jhbutala.com; carter.janet@dol.gov; alison_elder@urmc.rochester.edu; terry.gordon@nyumc.org; gmgray@gwu.edu; sayre.phil@epa.gov; pas4@cdc.gov; tsai51@purdue.edu; jay_west@americanchemistry.com FU National Institute for Occupational Safety and Health [R13 OH010337]; American Chemistry Council Nanotechnology Panel; National Science Foundation [123634] FX The authors wish to thank the workshop speakers and participants for their valuable contributions to the discussions and results of the workshop. We also thank the National Institute for Occupational Safety and Health (Grant R13 OH010337) and the American Chemistry Council Nanotechnology Panel for their financial support; The George Washington University School of Public Health and Health Services for hosting the workshop; Mary Butow, Julie Goodnight, Mary Popovech, Eric Saunders, and Chia Thach for serving as note takers; and Jessica Knutson, Andrew MacCachran, and Schubert Fabros of the American Chemistry Council for handling the many logistical details. This material is based upon work supported by the National Science Foundation under Grant Number 123634. NR 37 TC 14 Z9 14 U1 2 U2 15 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0273-2300 EI 1096-0295 J9 REGUL TOXICOL PHARM JI Regul. Toxicol. Pharmacol. PD APR PY 2014 VL 68 IS 3 BP 305 EP 311 DI 10.1016/j.yrtph.2014.01.005 PG 7 WC Medicine, Legal; Pharmacology & Pharmacy; Toxicology SC Legal Medicine; Pharmacology & Pharmacy; Toxicology GA AE6YY UT WOS:000334145100001 PM 24462629 ER PT J AU Kauffman, CA Freifeld, AG Andes, DR Baddley, JW Herwaldt, L Walker, RC Alexander, BD Anaissie, EJ Benedict, K Ito, JI Knapp, KM Lyon, GM Marr, KA Morrison, VA Park, BJ Patterson, TF Schuster, MG Chiller, TM Pappas, PG AF Kauffman, C. A. Freifeld, A. G. Andes, D. R. Baddley, J. W. Herwaldt, L. Walker, R. C. Alexander, B. D. Anaissie, E. J. Benedict, K. Ito, J. I. Knapp, K. M. Lyon, G. M. Marr, K. A. Morrison, V. A. Park, B. J. Patterson, T. F. Schuster, M. G. Chiller, T. M. Pappas, P. G. TI Endemic fungal infections in solid organ and hematopoietic cell transplant recipients enrolled in the Transplant-Associated Infection Surveillance Network (TRANSNET) SO TRANSPLANT INFECTIOUS DISEASE LA English DT Article DE solid organ transplant; hematopoietic cell transplant; histoplasmosis; blastomycosis; coccidioidomycosis ID CLINICAL-PRACTICE GUIDELINES; SOCIETY-OF-AMERICA; COCCIDIOIDOMYCOSIS; HISTOPLASMOSIS; BLASTOMYCOSIS; TRANSMISSION; MANAGEMENT; UPDATE AB BackgroundInvasive fungal infections are a major cause of morbidity and mortality among solid organ transplant (SOT) and hematopoietic cell transplant (HCT) recipients, but few data have been reported on the epidemiology of endemic fungal infections in these populations. MethodsFifteen institutions belonging to the Transplant-Associated Infection Surveillance Network prospectively enrolled SOT and HCT recipients with histoplasmosis, blastomycosis, or coccidioidomycosis occurring between March 2001 and March 2006. ResultsA total of 70 patients (64 SOT recipients and 6 HCT recipients) had infection with an endemic mycosis, including 52 with histoplasmosis, 9 with blastomycosis, and 9 with coccidioidomycosis. The 12-month cumulative incidence rate among SOT recipients for histoplasmosis was 0.102%. Occurrence of infection was bimodal; 28 (40%) infections occurred in the first 6months post transplantation, and 24 (34%) occurred between 2 and 11years post transplantation. Three patients were documented to have acquired infection from the donor organ. Seven SOT recipients with histoplasmosis and 3 with coccidioidomycosis died (16%); no HCT recipient died. ConclusionsThis 5-year multicenter prospective surveillance study found that endemic mycoses occur uncommonly in SOT and HCT recipients, and that the period at risk extends for years after transplantation. C1 [Kauffman, C. A.] Univ Michigan, Ann Arbor, MI 48109 USA. [Kauffman, C. A.] Vet Affairs Ann Arbor Healthcare Syst, Ann Arbor, MI USA. [Freifeld, A. G.] Univ Nebraska Med Ctr, Omaha, NE USA. [Andes, D. R.] Univ Wisconsin, Madison, WI USA. [Baddley, J. W.; Pappas, P. G.] Univ Alabama Birmingham, Med Ctr, Birmingham, AL 35294 USA. [Baddley, J. W.; Pappas, P. G.] Vet Affairs Med Ctr, Birmingham, AL USA. [Herwaldt, L.] Univ Iowa, Carver Coll Med, Iowa City, IA USA. [Herwaldt, L.] Univ Iowa Hosp & Clin, Iowa City, IA 52242 USA. [Walker, R. C.] Mayo Clin, Rochester, MN USA. [Alexander, B. D.] Duke Univ, Med Ctr, Durham, NC USA. [Anaissie, E. J.] Univ Arkansas Med Sci, Little Rock, AR 72205 USA. [Benedict, K.; Park, B. J.; Chiller, T. M.] Ctr Dis Control & Prevent, Mycot Dis Branch, Atlanta, GA USA. [Ito, J. I.] City Hope Comprehens Canc Ctr, Duarte, CA USA. [Knapp, K. M.] St Jude Childrens Res Hosp, Memphis, TN 38105 USA. [Lyon, G. M.] Emory Univ, Sch Med, Atlanta, GA USA. [Marr, K. A.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Morrison, V. A.] Univ Minnesota, Minneapolis, MN USA. [Morrison, V. A.] Vet Affairs Med Ctr, Minneapolis, MN USA. [Patterson, T. F.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Patterson, T. F.] South Texas Vet Healthcare Syst, San Antonio, TX USA. [Schuster, M. G.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. RP Kauffman, CA (reprint author), VA Ann Arbor Healthcare Syst, Infect Dis Sect, 2215 Fuller Rd, Ann Arbor, MI 48105 USA. EM ckauff@umich.edu FU CDC Grant [5U01CI000286-05]; Merck Co., Inc.; Astellas US, Inc.; Pfizer, Inc.; Schering-Plough Research Institute; Enzon Pharmaceuticals, Inc.; Merck; Pfizer; Astellas; T2 Biosystems; Gilead; Sigma Tau; Charles River Laboratories FX Support: This study was supported through CDC Grant 5U01CI000286-05 and grants from Merck & Co., Inc.; Astellas US, Inc.; Pfizer, Inc.; Schering-Plough Research Institute; and Enzon Pharmaceuticals, Inc.; Potential conflicts of interest: P.G.P.: Research grants: Merck, Pfizer, Astellas, T2 Biosystems, Gilead; Ad hoc Advisory Committees: Merck, Astellas, Gilead, and T2 Biosystems. C.A.K.: Data Safety Committee: Merck; Data Review Committee: New England Research Institute. A.G.F.: Data Safety Committee: Astellas; Consultant: Merck. T.F.P.: Research grants: Merck, Pfizer, Astellas; Consultant or received honoraria: Merck, Pfizer, Astellas, Toyoma, Viamet. V.A.M.: Data Safety Committee: Celgene; Data Review Committee: Merck; Speakers Bureaus: Amgen, Celgene, Genentech. J.W.B.: Data Review Committees: Astellas, Pfizer; Consultant: Merck, Mayne Pharma. J.I.I.: Speakers Bureaus: Astellas, Merck, Sigma Tau. K.A.M.: Research grants: Astellas, Merck, Pfizer, Sigma Tau; Consultant/Advisory Boards: Astellas, Merck, Pfizer, Optimer. G.M.L.: Research grants: Astellas, T2 Biosystems. D.R.A.: Research grants: Merck, Astellas; Consultant: Merck, Astellas. B.D.A.: Research grants: Pfizer, Astellas, Charles River Laboratories. All others author: No conflicts. NR 25 TC 19 Z9 19 U1 0 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1398-2273 EI 1399-3062 J9 TRANSPL INFECT DIS JI Transpl. Infect. Dis. PD APR PY 2014 VL 16 IS 2 BP 213 EP 224 DI 10.1111/tid.12186 PG 12 WC Immunology; Infectious Diseases; Transplantation SC Immunology; Infectious Diseases; Transplantation GA AE4RC UT WOS:000333969500005 PM 24589027 ER PT J AU Woodhall, DM Mkwanda, S Dembele, M Lwanga, H Drexler, N Dubray, C Harris, J Worrell, C Mathieu, E AF Woodhall, Dana M. Mkwanda, Square Dembele, Massitan Lwanga, Harriet Drexler, Naomi Dubray, Christine Harris, Jennifer Worrell, Caitlin Mathieu, Els TI Exploring innovative ways to conduct coverage surveys for neglected tropical diseases in Malawi, Mali, and Uganda SO ACTA TROPICA LA English DT Article DE Neglected tropical diseases; Drug coverage survey ID DRUG COVERAGE; COMMUNITY; PREVALENCE; PROGRAMS; MARKET AB Currently, a 30-cluster survey to monitor drug coverage after mass drug administration for neglected tropical diseases is the most common methodology used by control programs. We investigated alternative survey methodologies that could potentially provide an estimation of drug coverage. Three alternative survey methods (market, village chief, and religious leader) were conducted and compared to the 30-cluster method in Malawi, Mali, and Uganda. In Malawi, drug coverage for the 30-cluster, market, village chief, and religious leader methods were 66.8% (95% CI 60.3-73.4), 74.3%, 76.3%, and 77.8%, respectively. In Mali, results for round 1 were 62.6% (95% Cl 54.4-70.7), 56.1%, 74.8%, and 83.2%, and 57.2% (95% CI 49.0-65.4), 54.5%, 72.2%, and 73.3%, respectively, for round 2. Uganda survey results were 65.7% (59.4-72.0),43.7%, 67.2%, and 77.6% respectively. Further research is needed to test different coverage survey methodologies to determine which survey methods are the most scientifically rigorous and resource efficient. Published by Elsevier B.V. C1 [Woodhall, Dana M.; Drexler, Naomi; Dubray, Christine; Harris, Jennifer; Worrell, Caitlin; Mathieu, Els] Ctr Dis Control & Prevent, Parasit Dis Branch, Atlanta, GA 30333 USA. [Mkwanda, Square] Minist Hlth, Capital City 3, Lilongwe, Malawi. [Dembele, Massitan] Minist Sante, Bamako, Mali. [Lwanga, Harriet] RTI Uganda, Kampala, Uganda. RP Woodhall, DM (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,MS A-06, Atlanta, GA 30333 USA. EM dqw6@cdc.gov; smkwanda@yahoo.com; masdembele@yahoo.fr; harrietlwanga@ymail.com NR 18 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0001-706X EI 1873-6254 J9 ACTA TROP JI Acta Trop. PD APR PY 2014 VL 132 BP 119 EP 124 DI 10.1016/j.actatropica.2014.01.001 PG 6 WC Parasitology; Tropical Medicine SC Parasitology; Tropical Medicine GA AE5AV UT WOS:000334001100016 PM 24462795 ER PT J AU Cohen, BL Zoega, H Shah, SA LeLeiko, N Lidofsky, S Bright, R Flowers, N Law, M Moniz, H Merrick, M Sands, BE AF Cohen, B. L. Zoega, H. Shah, S. A. LeLeiko, N. Lidofsky, S. Bright, R. Flowers, N. Law, M. Moniz, H. Merrick, M. Sands, B. E. TI Fatigue is highly associated with poor health-related quality of life, disability and depression in newly-diagnosed patients with inflammatory bowel disease, independent of disease activity SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS LA English DT Article ID FUNCTIONAL ASSESSMENT; CROHNS-DISEASE; WORK PRODUCTIVITY; RHEUMATOID-ARTHRITIS; REPORTED OUTCOMES; SURVEY SF-36; VALIDITY; RELIABILITY; POPULATION; VALIDATION AB Background Fatigue is common in Crohn's disease (CD) and ulcerative colitis (UC). Data on fatigue in newly diagnosed patients are unavailable. Aim To report prevalence of fatigue in newly diagnosed CD and UC patients and examine its association with health-related quality of life (HRQOL), depression and disability. Methods The Ocean State Crohn's and Colitis Area Registry (OSCCAR) is a statewide cohort of newly diagnosed inflammatory bowel disease patients in Rhode Island. Fatigue was assessed using the Functional Assessment of Chronic Illness Therapy-Fatigue Scale. Patients were administered instruments measuring HRQOL, overall disability and work impairment, and depression. Results Fatigue was prevalent in 26.4% of 220 subjects. Cohen's d effect sizes for fatigue were large: Short-Form 36 Health Survey mental health component (CD 1.5, UC 1.4) and physical health component (CD 1.4, UC 1.4), EuroQol-5D valuation of current health state (CD 1.2, UC 1.0), Inflammatory Bowel Disease Questionnaire (CD 1.9, UC 1.6) and Patient Health Questionnaire depression scale (CD 1.8, UC 1.7). Fatigued patients reported more work impairment (Score difference: CD 29.5%, UC 23.8%) and activity impairment (score difference: CD 32.3%, UC 25.7%) on the Work Productivity and Activity Impairment Questionnaire. Fatigue's association with all scores remained highly significant despite controlling for disease activity. Conclusions Fatigue is strongly associated with poor HRQOL, disability and depression similarly in CD and UC even when controlling for disease activity. Fatigue's association with a wide range of patient-reported outcome measures suggests that monitoring fatigue is a simple way to screen for overall disruption in patient life. C1 [Cohen, B. L.; Zoega, H.; Sands, B. E.] Icahn Sch Med Mt Sinai, Div Gastroenterol, New York, NY 10029 USA. [Zoega, H.] Univ Iceland, Fac Med, Ctr Publ Hlth Sci, Reykjavik, Iceland. [Shah, S. A.; Lidofsky, S.] Brown Univ, Gastroenterol Associates Inc, Warren Alpert Med Sch, Providence, RI USA. [LeLeiko, N.] Brown Univ, Rhode Isl Hosp, Div Pediat Gastroenterol Nutr & Liver Dis, Hasbro Childrens Hospital,Warren Alpert Med Sch, Providence, RI 02903 USA. [Bright, R.; Law, M.; Moniz, H.] Rhode Isl Hosp, Div Gastroenterol, Providence, RI USA. [Flowers, N.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Merrick, M.] Crohns & Colitis Fdn Amer, New York, NY USA. RP Sands, BE (reprint author), Icahn Sch Med Mt Sinai, Div Gastroenterol, One Gustave L Levy Pl,Box 1069, New York, NY 10029 USA. EM bruce.sands@mssm.edu RI Zoega, Helga/M-1968-2015; OI leleiko, neal/0000-0001-7699-1400 FU Center for Disease Control and Prevention (CDC) [5U01DP000340, 3U01DP002676]; Crohn's and Colitis Foundation of America (CCFA) FX The Ocean State Crohn's and Colitis Area Registry (OSCCAR) is supported by grants from the Center for Disease Control and Prevention (CDC) (5U01DP000340 and 3U01DP002676) and the Crohn's and Colitis Foundation of America (CCFA). NR 57 TC 23 Z9 24 U1 0 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0269-2813 EI 1365-2036 J9 ALIMENT PHARM THER JI Aliment. Pharmacol. Ther. PD APR PY 2014 VL 39 IS 8 BP 811 EP 822 DI 10.1111/apt.12659 PG 12 WC Gastroenterology & Hepatology; Pharmacology & Pharmacy SC Gastroenterology & Hepatology; Pharmacology & Pharmacy GA AC8PO UT WOS:000332796200007 PM 24612278 ER PT J AU Naleway, AL Henkle, EM Ball, S Bozeman, S Gaglani, MJ Kennedy, ED Thompson, MG AF Naleway, Allison L. Henkle, Emily M. Ball, Sarah Bozeman, Sam Gaglani, Manjusha J. Kennedy, Erin D. Thompson, Mark G. TI Barriers and facilitators to influenza vaccination and vaccine coverage in a cohort of health care personnel SO AMERICAN JOURNAL OF INFECTION CONTROL LA English DT Article DE Vaccination coverage; Vaccination mandate; Employee health ID UNITED-STATES; WORKERS; RATES; ATTITUDES; MANDATES; SEASON AB Background: Annual influenza vaccination is recommended for health care personnel (HCP). We describe influenza vaccination coverage among HCP during the 2010-2011 season and present reported facilitators of and barriers to vaccination. Methods: We enrolled HCP 18 to 65 years of age, working full time, with direct patient contact. Participants completed an Internet-based survey at enrollment and the end of influenza season. In addition to self-reported data, we collected information about the 2010-2011 influenza vaccine from electronic employee health and medical records. Results: Vaccination coverage was 77% (1,307/1,701). Factors associated with higher vaccination coverage include older age, being married or partnered, working as a physician or dentist, prior history of influenza vaccination, more years in patient care, and higher job satisfaction. Personal protection was reported as the most important reason for vaccination followed closely by convenience, protection of patients, and protection of family and friends. Concerns about perceived vaccine safety and effectiveness and low perceived susceptibility to influenza were the most commonly reported barriers to vaccination. About half of the unvaccinated HCP said they would have been vaccinated if required by their employer. Conclusion: Influenza vaccination in this cohort was relatively high but still fell short of the recommended target of 90% coverage for HCP. Addressing concerns about vaccine safety and effectiveness are possible areas for future education or intervention to improve coverage among HCP. Copyright (C) 2014 by the Association for Professionals in Infection Control and Epidemiology, Inc. Published by Elsevier Inc. All rights reserved. C1 [Naleway, Allison L.; Henkle, Emily M.] Kaiser Permanente Northwest, Ctr Hlth Res, Portland, OR 97227 USA. [Ball, Sarah; Bozeman, Sam] Abt Associates Inc, Cambridge, MA USA. [Gaglani, Manjusha J.] Scott & White Healthcare, Temple, TX USA. [Kennedy, Erin D.] Ctr Dis Control & Prevent, Immunizat Serv Div, Atlanta, GA USA. [Thompson, Mark G.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. RP Naleway, AL (reprint author), Kaiser Permanente Northwest, Ctr Hlth Res, 3800 North Interstate Ave, Portland, OR 97227 USA. EM allison.naleway@kpchr.org OI Naleway, Allison/0000-0001-5747-4643 FU Centers for Disease Control and Prevention [200-2010-F-33396] FX Supported by the Centers for Disease Control and Prevention (contract 200-2010-F-33396 to Abt Associates, Inc). NR 24 TC 10 Z9 10 U1 1 U2 11 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-6553 EI 1527-3296 J9 AM J INFECT CONTROL JI Am. J. Infect. Control PD APR PY 2014 VL 42 IS 4 BP 371 EP 375 DI 10.1016/j.ajic.2013.11.003 PG 5 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA AD8OI UT WOS:000333525100008 PM 24679562 ER PT J AU Nguyen, DB Gupta, N Abou-Daoud, A KleKamp, BG Rhone, C Winston, T Hedberg, T Scuteri, A Evans, C Jensen, B Moulton-Meissner, H Torok, T Berrios-Torres, SI Noble-Wang, J Kallen, A AF Nguyen, Duc B. Gupta, Neil Abou-Daoud, Alison KleKamp, Benjamin G. Rhone, Chaz Winston, Tiffany Hedberg, Trevor Scuteri, Ana Evans, Charlotte Jensen, Bette Moulton-Meissner, Heather Toeroek, Thomas Berrios-Torres, Sandra I. Noble-Wang, Judith Kallen, Alexander TI A polymicrobial outbreak of surgical site infections following cardiac surgery at a community hospital in Florida, 2011-2012 SO AMERICAN JOURNAL OF INFECTION CONTROL LA English DT Article DE Gordonia; Environmental contamination; Infection control ID GORDONIA AB We describe an outbreak of 22 sternal surgical site infections following cardiac surgery, including 4 Gordonia infections. Possible operation room environmental contamination and suboptimal infection control practices regarding scrub attire may have contributed to the outbreak. Published by Elsevier Inc. on behalf of the Association for Professionals in Infection Control and Epidemiology, Inc. C1 [Nguyen, Duc B.; Gupta, Neil; Jensen, Bette; Moulton-Meissner, Heather; Berrios-Torres, Sandra I.; Noble-Wang, Judith; Kallen, Alexander] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA USA. [Nguyen, Duc B.; Gupta, Neil; Abou-Daoud, Alison] Ctr Dis Control & Prevent, Sci Educ & Profess Dev Program Off, Atlanta, GA USA. [KleKamp, Benjamin G.; Rhone, Chaz; Winston, Tiffany; Hedberg, Trevor; Scuteri, Ana; Toeroek, Thomas] Florida Dept Hlth, Tallahassee, FL USA. [Evans, Charlotte] Hosp Corp Amer, Gainesville, FL USA. RP Nguyen, DB (reprint author), 1600 Clifton Rd NE,MS-A35, Atlanta, GA 30333 USA. EM vif8@cdc.gov FU Hospital Corporation of America FX The authors thank all hospital staff for their great support and cooperation, colleagues from the Florida Department of Health and Hospital Corporation of America for their support and valuable comments to the paper, and Ms Shaneka Wright and her team for sharing experience from their investigation. NR 13 TC 1 Z9 3 U1 1 U2 3 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-6553 EI 1527-3296 J9 AM J INFECT CONTROL JI Am. J. Infect. Control PD APR PY 2014 VL 42 IS 4 BP 432 EP 435 DI 10.1016/j.ajic.2013.11.021 PG 4 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA AD8OI UT WOS:000333525100022 PM 24679572 ER PT J AU de Perio, MA Wiegand, DM Brueck, SE AF de Perio, Marie A. Wiegand, Douglas M. Brueck, Scott E. TI Influenza-like illness and presenteeism among school employees SO AMERICAN JOURNAL OF INFECTION CONTROL LA English DT Article DE ILI; Teachers AB We determined the prevalence of influenza-like illness (ILI) among employees of a suburban Ohio school district. In a survey of 412 of 841 employees (49%), 120 (29%) reported ILI symptoms during the school year, and 92 (77%) reported working while ill. Age >= 50 years and asthma were significantly associated with reporting of ILI symptoms. Encouraging school employees to receive the seasonal influenza vaccine and to stay home when ill should be part of a comprehensive influenza prevention strategy. Published by Elsevier Inc. on behalf of the Association for Professionals in Infection Control and Epidemiology, Inc. C1 [de Perio, Marie A.; Wiegand, Douglas M.; Brueck, Scott E.] NIOSH, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. RP de Perio, MA (reprint author), NIOSH, Ctr Dis Control & Prevent, 4676 Columbia Pkwy,R-10, Cincinnati, OH 45226 USA. EM mdeperio@cdc.gov FU Intramural CDC HHS [CC999999] NR 10 TC 5 Z9 5 U1 1 U2 10 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-6553 EI 1527-3296 J9 AM J INFECT CONTROL JI Am. J. Infect. Control PD APR PY 2014 VL 42 IS 4 BP 450 EP 452 DI 10.1016/j.ajic.2013.11.012 PG 3 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA AD8OI UT WOS:000333525100028 PM 24679576 ER PT J AU Akinsanya-Beysolow, I AF Akinsanya-Beysolow, Iyabode CA ACIP ACIP Child Adolescent Immunization TI Advisory Committee on Immunization Practices Recommended Immunization Schedules for Persons Aged 0 Through 18 YearsUnited States, 2014 SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Reprint AB The 2014 pediatric immunization guideline changes are highlighted in these recommendations. C1 [Akinsanya-Beysolow, Iyabode] CDC, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Akinsanya-Beysolow, I (reprint author), CDC, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM htr5@cdc.gov NR 1 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD APR PY 2014 VL 14 IS 4 BP 972 EP 973 DI 10.1111/ajt.12730 PG 2 WC Surgery; Transplantation SC Surgery; Transplantation GA AD5UN UT WOS:000333318800029 ER PT J AU Bukreyev, AA Chandran, K Dolnik, O Dye, JM Ebihara, H Leroy, EM Muhlberger, E Netesov, SV Patterson, JL Paweska, JT Saphire, EO Smither, SJ Takada, A Towner, JS Volchkov, VE Warren, TK Kuhn, JH AF Bukreyev, Alexander A. Chandran, Kartik Dolnik, Olga Dye, John M. Ebihara, Hideki Leroy, Eric M. Muehlberger, Elke Netesov, Sergey V. Patterson, Jean L. Paweska, Janusz T. Saphire, Erica Ollmann Smither, Sophie J. Takada, Ayato Towner, Jonathan S. Volchkov, Viktor E. Warren, Travis K. Kuhn, Jens H. TI Discussions and decisions of the 2012-2014 International Committee on Taxonomy of Viruses (ICTV) Filoviridae Study Group, January 2012-June 2013 SO ARCHIVES OF VIROLOGY LA English DT Article ID FAMILY FILOVIRIDAE; STANDARDIZED NOMENCLATURE; SPECIES LEVEL; CLASSIFICATION; FILOVIRUSES; VARIANTS; PROPOSAL; NAMES AB The International Committee on Taxonomy of Viruses (ICTV) Filoviridae Study Group prepares proposals on the classification and nomenclature of filoviruses to reflect current knowledge or to correct disagreements with the International Code of Virus Classification and Nomenclature (ICVCN). In recent years, filovirus taxonomy has been corrected and updated, but parts of it remain controversial, and several topics remain to be debated. This article summarizes the decisions and discussion of the currently acting ICTV Filoviridae Study Group since its inauguration in January 2012. C1 [Bukreyev, Alexander A.] Univ Texas Med Branch, Dept Pathol, Galveston, TX 77555 USA. [Bukreyev, Alexander A.] Univ Texas Med Branch, Galveston Natl Lab, Galveston, TX 77555 USA. [Chandran, Kartik] Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10467 USA. [Dolnik, Olga] Univ Marburg, Inst Virol, D-35032 Marburg, Germany. [Dye, John M.; Warren, Travis K.] US Army Med Res Inst Infect Dis, Frederick, MD USA. [Ebihara, Hideki] NIAID, Rocky Mt Labs, Integrated Res Facil, NIH, Hamilton, MT 59840 USA. [Leroy, Eric M.] IRD, Ctr Int Rech Med Franceville, Franceville, Gabon. [Muehlberger, Elke] Boston Univ, Sch Med, Dept Microbiol, Boston, MA 02118 USA. [Muehlberger, Elke] Boston Univ, Sch Med, Natl Emerging Infect Dis Lab, Boston, MA 02118 USA. [Netesov, Sergey V.] Novosibirsk State Univ, Novosibirsk 630090, Novosibirsk Obl, Russia. [Patterson, Jean L.] Texas Biomed Res Inst, Dept Virol & Immunol, San Antonio, TX USA. [Paweska, Janusz T.] Natl Hlth Lab Serv, Natl Inst Communicable Dis, Ctr Emerging & Zoonot Dis, Johannesburg, Gauteng, South Africa. [Saphire, Erica Ollmann] Scripps Res Inst, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA. [Saphire, Erica Ollmann] Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA. [Smither, Sophie J.] DSTL, Dept Biomed Sci, Salisbury, Wilts, England. [Takada, Ayato] Hokkaido Univ, Div Global Epidemiol, Res Ctr Zoonosis Control, Sapporo, Hokkaido, Japan. [Towner, Jonathan S.] Ctr Dis Control & Prevent, Viral Special Pathogens Branch, Div High Consequence Pathogens Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Volchkov, Viktor E.] Univ Lyon, UCB Lyon 1, Ecole Normale Super Lyon, INSERM,U758,Lab Filovirus, Lyon, France. [Kuhn, Jens H.] NIAID, Integrated Res Facil Ft Detrick IRF Frederick, DCR, NIH, Frederick, MD 21702 USA. RP Kuhn, JH (reprint author), NIAID, Integrated Res Facil Ft Detrick IRF Frederick, DCR, NIH, B-8200 Res Plaza, Frederick, MD 21702 USA. EM kuhnjens@mail.nih.gov RI Volchkov, Viktor/M-7846-2014; Kuhn, Jens H./B-7615-2011; Netesov, Sergey/A-3751-2013; LEROY, Eric/I-4347-2016 OI Volchkov, Viktor/0000-0001-7896-8706; Kuhn, Jens H./0000-0002-7800-6045; Netesov, Sergey/0000-0002-7786-2464; LEROY, Eric/0000-0003-0022-0890 FU NIAID [HHSN272200700016I] FX The content of this publication does not necessarily reflect the views or policies of the US Department of the Army, the US Department of Defense or the US Department of Health and Human Services or of the institutions and companies affiliated with the authors. JHK performed this work as an employee of Tunnell Consulting, Inc., a subcontractor to Battelle Memorial Institute under its prime contract with NIAID, under Contract No. HHSN272200700016I. NR 17 TC 25 Z9 28 U1 0 U2 11 PU SPRINGER WIEN PI WIEN PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA SN 0304-8608 EI 1432-8798 J9 ARCH VIROL JI Arch. Virol. PD APR PY 2014 VL 159 IS 4 BP 821 EP 830 DI 10.1007/s00705-013-1846-9 PG 10 WC Virology SC Virology GA AE5UQ UT WOS:000334055200025 PM 24122154 ER PT J AU Grigorescu, V Zhang, YJ Kissin, DM Sauber-Schatz, E Sunderam, M Kirby, RS Diop, H McKane, P Jamieson, DJ AF Grigorescu, Violanda Zhang, Yujia Kissin, Dmitry M. Sauber-Schatz, Erin Sunderam, Mithi Kirby, Russell S. Diop, Hafsatou McKane, Patricia Jamieson, Denise J. TI Maternal characteristics and pregnancy outcomes after assisted reproductive technology by infertility diagnosis: ovulatory dysfunction versus tubal obstruction SO FERTILITY AND STERILITY LA English DT Article DE Ovulatory dysfunction (OD); polycystic ovary syndrome (PCOS); tubal obstruction (TO); assisted reproductive technology (ART); Apgar score ID POLYCYSTIC-OVARY-SYNDROME; APGAR SCORE; SYNDROME PCOS; LIFE-SPAN; HEALTH; WOMEN; PREVALENCE; CRITERIA; METAANALYSIS; POPULATION AB Objective: To examine differences in maternal characteristics and pregnancy outcomes between women with ovulatory dysfunction (OD) and women with tubal obstruction (TO) who underwent assisted reproductive technology (ART). Design: Retrospective cohort study. Setting: Centers for Disease Control and Prevention. Patient(s): Exposed and nonexposed groups were selected from the 2000-2006 National ART Surveillance System linked with livebirth certificates from three states: Florida, Massachusetts, and Michigan. Intervention(s): None. Main Outcome Measure(s): Maternal characteristics and pregnancy outcomes, including newborn's health status right after delivery (Apgar score,< 7 vs. >= 7) as the study outcome of interest, were assessed among women with OD/polycystic ovary syndrome (PCOS) and TO who used ART. Result(s): A significantly higher prevalence of women with OD/PCOS were younger (< 35 years of age; 65.7% vs. 48.9%), were white (85.4% vs. 74.4%), had higher education (29.4% vs. 15.6%), and experienced diabetes (8.8% vs. 5.3%) compared with those having TO. The odds of having a lower (< 7) Apgar score at 5 minutes were almost twice as high among newborns of women with OD/PCOS compared with those with TO (crude odds ratio, 1.86; 95% confidence interval [CI], 1.31, 2.64; adjusted odds ratio, 1.90; 95% CI, 1.30, 2.77). Conclusion(s): Women with OD/PCOS who underwent ART have different characteristics and health issues (higher prevalence of diabetes) and infant outcomes (lower Apgar score) compared with women with TO. (C)2014 by American Society for Reproductive Medicine.) C1 [Grigorescu, Violanda; Zhang, Yujia; Kissin, Dmitry M.; Sauber-Schatz, Erin; Sunderam, Mithi; Jamieson, Denise J.] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. [Kirby, Russell S.] Univ S Florida, Coll Publ Hlth, Tampa, FL USA. [Diop, Hafsatou] Massachusetts Dept Publ Hlth, Boston, MA USA. [McKane, Patricia] Michigan Dept Community Hlth, Lansing, MI USA. RP Grigorescu, V (reprint author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Reprod Hlth, 4770 Buford Highway NE,Mailstop F74, Atlanta, GA 30341 USA. EM vgrigorescu@cdc.gov FU Centers for Disease Control and Prevention, the state of Florida; March of Dimes FX V.G. has nothing to disclose. Y.Z. has nothing to disclose. D. M. K. has nothing to disclose. E.S.-S. has nothing to disclose. M. S. has nothing to disclose. R. S. K. is a board member of the Perinatal Foundation (Wisconsin); a member of the pregnancy exposure registry scientific advisory committee of Amgen Corp.; and the primary investigator on several projects through the USF Birth Defects Surveillance Program, funded through the Centers for Disease Control and Prevention, the state of Florida, and the March of Dimes. H.D. has nothing to disclose. P.M. has nothing to disclose. D.J.J. has nothing to disclose. NR 39 TC 7 Z9 7 U1 0 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0015-0282 EI 1556-5653 J9 FERTIL STERIL JI Fertil. Steril. PD APR PY 2014 VL 101 IS 4 BP 1019 EP 1025 DI 10.1016/j.fertnstert.2013.12.030 PG 7 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA AE2LR UT WOS:000333805000033 PM 24484993 ER PT J AU Martin, MY Evans, MB Kratt, P Pollack, LA Smith, JL Oster, R Dignan, M Prayor-Patterson, H Watson, C Houston, P Andrews, S Liwo, A Tseng, TS Hullett, S Oliver, J Pisu, M AF Martin, Michelle Y. Evans, Mary B. Kratt, Polly Pollack, Lori A. Smith, Judith Lee Oster, Robert Dignan, Mark Prayor-Patterson, Heather Watson, Christopher Houston, Peter Andrews, Shiquina Liwo, Amandiy Tseng, Tung Sung Hullett, Sandral Oliver, Joann Pisu, Maria TI Meeting the Information Needs of Lower Income Cancer Survivors: Results of a Randomized Control Trial Evaluating the American Cancer Society's "I Can Cope" SO JOURNAL OF HEALTH COMMUNICATION LA English DT Article ID SEEKING BEHAVIORS; DISPARITIES; SUPPORT; HEALTH AB The American Cancer Society is a leader in the development of cancer survivorship resources. One resource of the American Cancer Society is the I Can Cope program, an educational program for cancer survivors and their families. Evaluations of this program indicate that cancer patients highly rate its objectives. Yet, there are gaps in the understanding of the full impact of the program on diverse cancer survivors. In this study, the authors used a randomized trial to evaluate the program. Participants included 140 low-income survivors (79% Black; 38% breast cancer) from community hospitals who were randomized to 4 sessions of I Can Cope (learning about cancer; understanding cancer treatments; relieving cancer pain; and keeping well in mind and body) or 4 sessions of a wellness intervention (humor, meditation, relaxation, and music therapy). The authors' primary outcome was "met information needs." After controlling for covariates, their analysis indicated that I Can Cope was no more effective than the wellness intervention in addressing survivor information needs relative to the learning objectives. Participants provided high overall ratings for both interventions. Self-efficacy for obtaining advice about cancer, age, education, and income were associated with information needs. Educational programs tailored to levels of self-efficacy and patient demographics may be needed. C1 [Martin, Michelle Y.; Kratt, Polly; Oster, Robert; Houston, Peter; Andrews, Shiquina; Liwo, Amandiy; Pisu, Maria] Univ Alabama Birmingham, Div Prevent Med, Dept Med, Birmingham, AL 35128 USA. [Evans, Mary B.] Univ Alabama Birmingham, UAB Ctr Study Community Hlth, Birmingham, AL 35128 USA. [Pollack, Lori A.; Smith, Judith Lee] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA USA. [Dignan, Mark] Univ Kentucky, Dept Internal Med Oncol, Lexington, KY USA. [Prayor-Patterson, Heather] Cleveland Clin, Dept Psychiat & Psychol, Cleveland, OH 44106 USA. [Watson, Christopher] Meharry Med Coll, Nashville, TN 37208 USA. [Tseng, Tung Sung] Louisiana State Univ, Hlth Sci Ctr, Sch Publ Hlth, New Orleans, LA USA. [Hullett, Sandral] Cooper Green Mercy Hosp, Birmingham, AL USA. [Oliver, Joann] Univ Alabama, Capstone Coll Nursing, Tuscaloosa, AL USA. RP Martin, MY (reprint author), Univ Alabama Birmingham, Div Prevent Med, 1717 11th Ave South,MT 617, Birmingham, AL 35128 USA. EM mymartin@uab.edu FU Intramural CDC HHS [CC999999]; NCCDPHP CDC HHS [U48/DP000567-1]; NCI NIH HHS [U54 CA118948]; NIA NIH HHS [P30 AG031054] NR 26 TC 2 Z9 2 U1 2 U2 21 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1081-0730 EI 1087-0415 J9 J HEALTH COMMUN JI J. Health Commun. PD APR 1 PY 2014 VL 19 IS 4 BP 441 EP 459 DI 10.1080/10810730.2013.821557 PG 19 WC Communication; Information Science & Library Science SC Communication; Information Science & Library Science GA AE3IU UT WOS:000333871000004 PM 24433231 ER PT J AU Jiang, BJ Ryan, KA Hamedani, A Cheng, YC Sparks, MJ Koontz, D Bean, CJ Gallagher, M Hooper, WC McArdle, PF O'Connell, JR Stine, OC Wozniak, MA Stern, BJ Mitchell, BD Kittner, SJ Cole, JW AF Jiang, Baijia Ryan, Kathleen A. Hamedani, Ali Cheng, Yuching Sparks, Mary J. Koontz, Deborah Bean, Christopher J. Gallagher, Margaret Hooper, W. Craig McArdle, Patrick F. O'Connell, Jeffrey R. Stine, O. Colin Wozniak, Marcella A. Stern, Barney J. Mitchell, Braxton D. Kittner, Steven J. Cole, John W. TI Prothrombin G20210A Mutation Is Associated With Young-Onset Stroke The Genetics of Early-Onset Stroke Study and Meta-Analysis SO STROKE LA English DT Article DE genetics; risk factors ID FACTOR-V-LEIDEN; ISCHEMIC-STROKE; RISK-FACTOR; CRYPTOGENIC STROKE; ADULTS; THROMBOPHILIA; DISEASE; VARIANT; CLASSIFICATION; PREGNANCY AB Background and Purpose Although the prothrombin G20210A mutation has been implicated as a risk factor for venous thrombosis, its role in arterial ischemic stroke is unclear, particularly among young adults. To address this issue, we examined the association between prothrombin G20210A and ischemic stroke in a white case-control population and additionally performed a meta-analysis. Methods From the population-based Genetics of Early Onset Stroke (GEOS) study, we identified 397 individuals of European ancestry aged 15 to 49 years with first-ever ischemic stroke and 426 matched controls. Logistic regression was used to calculate odds ratios (ORs) in the entire population and for subgroups stratified by sex, age, oral contraceptive use, migraine, and smoking status. A meta-analysis of 17 case-control studies (n=2305 cases <55 years) was also performed with and without GEOS data. Results Within GEOS, the association of the prothrombin G20210A mutation with ischemic stroke did not achieve statistical significance (OR=2.5; 95% confidence interval [CI]=0.9-6.5; P=0.07). However, among adults aged 15 to 42 years (younger than median age), cases were significantly more likely than controls to have the mutation (OR=5.9; 95% CI=1.2-28.1; P=0.03), whereas adults aged 42 to 49 years were not (OR=1.4; 95% CI=0.4-5.1; P=0.94). In our meta-analysis, the mutation was associated with significantly increased stroke risk in adults 55 years (OR=1.4; 95% CI=1.1-1.9; P=0.02), with significance increasing with addition of the GEOS results (OR=1.5; 95% CI=1.1-2.0; P=0.005). Conclusions The prothrombin G20210A mutation is associated with ischemic stroke in young adults and may have an even stronger association among those with earlier onset strokes. Our finding of a stronger association in the younger young adult population requires replication. C1 [Jiang, Baijia; Hamedani, Ali; Sparks, Mary J.; Wozniak, Marcella A.; Stern, Barney J.; Kittner, Steven J.; Cole, John W.] Univ Maryland, Sch Med, Dept Neurol, Baltimore, MD 21201 USA. [Ryan, Kathleen A.; Cheng, Yuching; McArdle, Patrick F.; O'Connell, Jeffrey R.; Mitchell, Braxton D.] Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA. [Stine, O. Colin] Univ Maryland, Sch Med, Dept Epidemiol & Publ Hlth, Baltimore, MD 21201 USA. [Koontz, Deborah; Bean, Christopher J.; Gallagher, Margaret; Hooper, W. Craig] Ctr Dis Control & Prevent, Atlanta, GA USA. [Cheng, Yuching; Wozniak, Marcella A.; Stern, Barney J.; Kittner, Steven J.; Cole, John W.] Vet Affairs Med Ctr, Dept Vet Affairs, Baltimore, MD USA. [Mitchell, Braxton D.; Kittner, Steven J.] Geriatr Res Educ & Clin Ctr, Dept Vet Affairs, Baltimore, MD USA. [Mitchell, Braxton D.; Kittner, Steven J.] Geriatr Res Educ & Clin Ctr, Vet Affairs Med Ctr Baltimore, Baltimore, MD USA. RP Cole, JW (reprint author), Univ Maryland, Sch Med, Dept Neurol, Maryland Stroke Ctr, Bressler Res Bldg,Room 12-006,655 W Baltimore St, Baltimore, MD 21201 USA. EM jcole@som.umaryland.edu OI Mitchell, Braxton/0000-0003-4920-4744 FU Department of Veterans Affairs, Baltimore, Office of Research and Development, Medical Research Service; Department of Veterans Affairs Stroke Research Enhancement Award Program; Department of Veterans Affairs, Baltimore, Geriatrics Research, Education, and Clinical Center of Excellence; National Institute of Neurological Disorders and Stroke [U01 NS069208-01, R01 NS39987]; National Institutes of Health Office of Research on Women's Health [R01 NS45012]; National Human Genome Research Institute [U01 HG004436] FX This work was supported, in part, by the Department of Veterans Affairs, Baltimore, Office of Research and Development, Medical Research Service; the Department of Veterans Affairs Stroke Research Enhancement Award Program; the Department of Veterans Affairs, Baltimore, Geriatrics Research, Education, and Clinical Center of Excellence; the National Institute of Neurological Disorders and Stroke (grants U01 NS069208-01 and R01 NS39987); the National Institutes of Health Office of Research on Women's Health (grant R01 NS45012); the National Human Genome Research Institute (grant U01 HG004436). The Centers for Disease Control and Prevention partially supported data collection and genotyping. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the article. There was no additional external funding received for this study. NR 31 TC 8 Z9 8 U1 0 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 EI 1524-4628 J9 STROKE JI Stroke PD APR PY 2014 VL 45 IS 4 BP 961 EP 967 DI 10.1161/STROKEAHA.113.004063 PG 7 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA AD5OS UT WOS:000333303400016 PM 24619398 ER PT J AU Robbins, CL Hutchings, Y Dietz, PM Kuklina, EV Callaghan, WM AF Robbins, Cheryl L. Hutchings, Yalonda Dietz, Patricia M. Kuklina, Elena V. Callaghan, William M. TI History of preterm birth and subsequent cardiovascular disease: a systematic review SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY LA English DT Review DE cardiovascular disease; death; preterm birth ID ISCHEMIC-HEART-DISEASE; PREGNANCY COMPLICATIONS; RETROSPECTIVE COHORT; MATERNAL RISK; FETAL-GROWTH; MORTALITY; DELIVERY; MOTHERS; EPIDEMIOLOGY; PREECLAMPSIA AB A history of preterm birth (PTB) may be an important lifetime risk factor for cardiovascular disease (CVD) in women. We identified all peer-reviewed journal articles that met study criteria (English language, human studies, female, and adults >= 19 years old), that were found in the PubMed/MEDLINE databases, and that were published between Jan. 1, 1995, and Sept. 17, 2012. We summarized 10 studies that assessed the association between having a history of PTB and subsequent CVD morbidity or death. Compared with women who had term deliveries, women with any history of PTB had increased risk of CVD morbidity (variously defined; adjusted hazard ratio [aHR] ranged from 1.2-2.9; 2 studies), ischemic heart disease (aHR, 1.3-2.1; 3 studies), stroke (aHR, 1.7; 1 study), and atherosclerosis (aHR, 4.1; 1 study). Four of 5 studies that examined death showed that women with a history of PTB have twice the risk of CVD death compared with women who had term births. Two studies reported statistically significant higher risk of CVD-related morbidity and death outcomes (variously defined) among women with >= 2 pregnancies that ended in PTBs compared with women who had at least 2 births but which ended in only 1 PTB. Future research is needed to understand the potential impact of enhanced monitoring of CVD risk factors in women with a history of PTB on risk of future CVD risk. C1 [Robbins, Cheryl L.; Hutchings, Yalonda; Dietz, Patricia M.; Callaghan, William M.] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Kuklina, Elena V.] Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. RP Robbins, CL (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. FU Intramural CDC HHS [CC999999] NR 33 TC 15 Z9 15 U1 0 U2 4 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9378 EI 1097-6868 J9 AM J OBSTET GYNECOL JI Am. J. Obstet. Gynecol. PD APR PY 2014 VL 210 IS 4 BP 285 EP 297 DI 10.1016/j.ajog.2013.09.020 PG 13 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA AD6WM UT WOS:000333401900001 PM 24055578 ER PT J AU Jones, HE Deppen, K Hudak, ML Leffert, L McClelland, C Sahin, L Starer, J Terplan, M Thorp, JM Walsh, J Creanga, AA AF Jones, Hendree E. Deppen, Krisanna Hudak, Mark L. Leffert, Lisa McClelland, Carol Sahin, Leyla Starer, Jacquelyn Terplan, Mishka Thorp, John M., Jr. Walsh, James Creanga, Andreea A. TI Clinical care for opioid-using pregnant and postpartum women: the role of obstetric providers SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY LA English DT Article DE opioid-agonist; opioid use; substance use ID NEONATAL ABSTINENCE SYNDROME; OPIATE WITHDRAWAL; ALCOHOL-USE; METHADONE; BUPRENORPHINE; OUTCOMES; EMPATHY; ISSUES AB We review clinical care issues that are related to illicit and therapeutic opioid use among pregnant women and women in the postpartum period and outline the major responsibilities of obstetrics providers who care for these patients during the antepartum, intrapartum, and postpartum periods. Selected patient treatment issues are highlighted, and case examples are provided. Securing a strong rapport and trust with these patients is crucial for success in delivering high-quality obstetric care and in coordinating services with other specialists as needed. Obstetrics providers have an ethical obligation to screen, assess, and provide brief interventions and referral to specialized treatment for patients with drug use disorders. Opioid-dependent pregnant women often can be treated effectively with methadone or buprenorphine. These medications are classified as pregnancy category C medications by the Food and Drug Administration, and their use in the treatment of opioid-dependent pregnant patients should not be considered "off-label." Except in rare special circumstances, medication-assisted withdrawal during pregnancy should be discouraged because of a high relapse rate. Acute pain management in this population deserves special consideration because patients who use opioids can be hypersensitive to pain and because the use of mixed opioid-agonist/antagonists can precipitate opioid withdrawal. In the absence of other indications, pregnant women who use opioids do not require more intense medical care than other pregnant patients to ensure adequate treatment and the best possible outcomes. Together with specialists in pain and addiction medicine, obstetricians can coordinate comprehensive care for pregnant women who use opioids and women who use opioids in the postpartum period. C1 [Jones, Hendree E.; McClelland, Carol; Thorp, John M., Jr.] Univ North Carolina Chapel Hill, UNC Sch Med, Dept Obstet & Gynecol, UNC Horizons Program, Carrboro, NC USA. [Deppen, Krisanna] Grant Med Ctr, Dept Family Med, Columbus, OH USA. [Hudak, Mark L.] Univ Florida, Coll Med Jacksonville, Dept Pediat, Gainesville, FL 32611 USA. [Leffert, Lisa] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA. [Sahin, Leyla] US FDA, Maternal Hlth Team, Off New Drugs, Silver Spring, MD USA. [Starer, Jacquelyn] Brigham & Womens Faulkner Hosp, Addict Recovery Program, Boston, MA USA. [Terplan, Mishka] Univ Maryland, Sch Med, Dept Epidemiol & Publ Hlth, Dept Obstet Gynecol & Reprod Sci, Baltimore, MD 21201 USA. [Walsh, James] Swedish Med Ctr, Addict Recovery Serv, Seattle, WA USA. [Creanga, Andreea A.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA USA. RP Jones, HE (reprint author), UNC Horizons, 400 Roberson St, Carrboro, NC 27510 USA. EM hendree_jones@med.unc.edu NR 46 TC 17 Z9 17 U1 0 U2 15 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9378 EI 1097-6868 J9 AM J OBSTET GYNECOL JI Am. J. Obstet. Gynecol. PD APR PY 2014 VL 210 IS 4 BP 302 EP 310 DI 10.1016/j.ajog.2013.10.010 PG 9 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA AD6WM UT WOS:000333401900003 PM 24120973 ER PT J AU Dietz, PM Bombard, JM Hutchings, YL Gauthier, JP Gambatese, MA Ko, JY Martin, JA Callaghan, WM AF Dietz, Patricia M. Bombard, Jennifer M. Hutchings, Yalonda L. Gauthier, John P. Gambatese, Melissa A. Ko, Jean Y. Martin, Joyce A. Callaghan, William M. TI Validation of obstetric estimate of gestational age on US birth certificates SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY LA English DT Article DE birth certificates; gestational age; preterm; validation ID RECORDS AB OBJECTIVE: The birth certificate variable obstetric estimate of gestational age (GA) has not been previously validated against GA based on estimated date of delivery from medical records. STUDY DESIGN: We estimated sensitivity, specificity, positive predictive value, negative predictive value and the corresponding 95% confidence intervals (CIs) for preterm delivery (<37 weeks' gestation) based on obstetric estimate using estimated date of delivery-based GA as the gold standard. Trained abstractors obtained the estimated date of delivery from the prenatal record (64.8% in New York City, and 94.6% in Vermont), or, when not available, from the hospital delivery record for 2 population-based samples: 586 live births delivered in New York City and 649 live births delivered in Vermont during 2009. Weights were applied to account for nonresponse and sampling design. RESULTS: In New York City, the preterm delivery rate based on estimated date of delivery was 9.7% (95% CI, 7.6-12.4) and 8.2% (95% CI, 6.3-10.6) based on obstetric estimate; in Vermont, it was 6.8% (95% CI, 5.4-8.4) based on estimated date of delivery and 6.3% (95% CI, 5.1-7.8) based on obstetric estimate. In New York City, sensitivity of obstetric estimate-based preterm delivery was 82.5% (95% CI, 69.4-90.8), specificity 98.1% (95% CI, 96.4-99.1), positive predictive value 98.0% (95% CI, 95.2-99.2), and negative predictive value 98.8% (95% CI, 99.6-99.9). In Vermont, sensitivity of obstetric estimate-based preterm delivery was 93.8% (95% CI, 81.8-98.1), specificity 99.6% (95% CI, 98.5-99.9), positive predictive value 100%, and negative predictive value 100%. CONCLUSION: Obstetric estimate-based preterm delivery had excellent specificity, positive predictive value and negative predictive value. Sensitivity was moderate in New York City and excellent in Vermont. These results suggest obstetric estimate-based preterm delivery from the birth certificate is useful for the surveillance of preterm delivery. C1 [Dietz, Patricia M.; Bombard, Jennifer M.; Hutchings, Yalonda L.; Ko, Jean Y.; Callaghan, William M.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Gambatese, Melissa A.] Gotham Ctr, New York City Dept Hlth & Mental Hyg, Queens, NY USA. [Gauthier, John P.] Vermont Dept Hlth, Agcy Human Serv, Burlington, VT 05402 USA. [Martin, Joyce A.] Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. RP Dietz, PM (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. FU Centers for Disease Control and Prevention [3UR6DP000467-05W1]; New York City Department of Health and Mental Hygiene [3UR6DP000484-05W1]; Agency of Human Services, Vermont Department of Health FX This project was funded by the Centers for Disease Control and Prevention under cooperative agreement number 3UR6DP000467-05W1 with the New York City Department of Health and Mental Hygiene and under agreement number 3UR6DP000484-05W1 with the Agency of Human Services, Vermont Department of Health. NR 7 TC 1 Z9 1 U1 0 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9378 EI 1097-6868 J9 AM J OBSTET GYNECOL JI Am. J. Obstet. Gynecol. PD APR PY 2014 VL 210 IS 4 AR 335.e1 DI 10.1016/j.ajog.2013.10.875 PG 5 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA AD6WM UT WOS:000333401900014 PM 24184397 ER PT J AU Razzaghi, H Tinker, SC Crider, K AF Razzaghi, Hilda Tinker, Sarah C. Crider, Krista TI Blood mercury concentrations in pregnant and nonpregnant women in the United States: National Health and Nutrition Examination Survey 1999-2006 SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY LA English DT Article DE mercury; NHANES; pregnant; seafood ID FISH CONSUMPTION; METHYLMERCURY EXPOSURE; METHYL MERCURY; PRENATAL EXPOSURE; CHILDBEARING AGE; US CHILDREN; COHORT; LEAD; ASSOCIATION; PERFORMANCE AB BACKGROUND: Prenatal exposure to methylmercury is associated with adverse neurologic development in children. We examined total blood mercury concentrations and predictors of higher blood mercury concentrations in pregnant and nonpregnant women. METHODS: We analyzed data from 1183 pregnant and 5587 nonpregnant women aged 16-49 years from the 1999-2006 National Health and Nutrition Examination Survey (NHANES). We estimated geometric mean blood mercury concentrations and characteristics associated with higher mercury concentrations (>= 3.5 mu g/L) in crude and adjusted linear and logistic regression models. RESULTS: After adjusting for age and race/ethnicity, geometric mean blood mercury concentrations were clinically similar but significantly lower for pregnant (0.81 mu g/L; 95% confidence interval [CI], 0.71-0.91) and nonpregnant women of childbearing age (0.93 mu g/L; 95% CI, 0.87-0.99); 94% of pregnant and 89% of nonpregnant women had blood mercury concentrations below 3.5 mu g/L. The most significant predictor of higher blood mercury concentrations for both pregnant and nonpregnant women was any seafood consumption vs no consumption in the last 30 days (odds ratio, 18.7; 95% CI, 4.9-71.1; odds ratio, 15.5; 95% CI, 7.5-32.1, respectively). Other characteristics associated with >= 3.5 mu g/L blood mercury concentrations were older age (>= 35 years), higher education (greater than high school), and higher family income to poverty ratio (3.501+) for both pregnant and nonpregnant women. CONCLUSION: Pregnancy status was not strongly associated with blood mercury concentrations in women of childbearing age and blood mercury concentrations above the 3.5 mu g/L cut were uncommon. C1 [Razzaghi, Hilda; Tinker, Sarah C.; Crider, Krista] Ctr Dis Control & Prevent CDC, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Razzaghi, Hilda] Oak Ridge Inst Sci & Educ, Oak Ridge, TN USA. RP Razzaghi, H (reprint author), Mail Stop E86,1600 Clifton Rd, Atlanta, GA 30333 USA. EM hir2JO@cdc.gov FU Research Participation program for the CDC FX The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the CDC. H.R. was supported by an appointment to the Research Participation program for the CDC administered by the Oak Ridge Institute for Science and Education through an agreement between the Department of Energy and CDC. H.R. and S.C.T. conducted the analysis. H.R., S.C.T., and K.C. developed the manuscript. NR 40 TC 2 Z9 2 U1 0 U2 9 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9378 EI 1097-6868 J9 AM J OBSTET GYNECOL JI Am. J. Obstet. Gynecol. PD APR PY 2014 VL 210 IS 4 AR 357.e1 DI 10.1016/j.ajog.2013.10.884 PG 9 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA AD6WM UT WOS:000333401900022 PM 24189168 ER PT J AU Schieve, LA Tian, LH Baio, J Rankin, K Rosenberg, D Wiggins, L Maenner, MJ Yeargin-Allsopp, M Durkin, M Rice, C King, L Kirby, RS Wingate, MS Devine, O AF Schieve, Laura A. Tian, Lin H. Baio, Jon Rankin, Kristin Rosenberg, Deborah Wiggins, Lisa Maenner, Matthew J. Yeargin-Allsopp, Marshalyn Durkin, Maureen Rice, Catherine King, Lydia Kirby, Russell S. Wingate, Martha S. Devine, Owen TI Population attributable fractions for three perinatal risk factors for autism spectrum disorders, 2002 and 2008 autism and developmental disabilities monitoring network SO ANNALS OF EPIDEMIOLOGY LA English DT Article DE Autism; Birth weight; Cesarean section; Population; Premature birth; Risk factors ID PREVALENCE; CHILDREN; ADULTS AB Purpose: Numerous studies establish associations between adverse perinatal outcomes/complications and autism spectrum disorder (ASD). There has been little assessment of population attributable fractions (PAFs). Methods: We estimated average ASD PAFs for preterm birth (PTB), small for gestational age (SGA), and Cesarean delivery (CD) in a U.S. population. Average PAF methodology accounts for risk factor co-occurrence. ASD cases were singleton non-Hispanic white, non-Hispanic black, and Hispanic children born in 1994 (n = 703) or 2000 (n = 1339) who resided in 48 U.S. counties included within eight Autism and Developmental Disabilities Monitoring Network sites. Cases were matched on birth year, sex, and maternal county of residence, race-ethnicity, age, and education to 20 controls from U.S. natality files. Results: For the 1994 cohort, average PAFs were 4.2%, 0.9%, and 7.9% for PTB, SGA, and CD, respectively. The summary PAF was 13.0% (1.7%-19.5%). For the 2000 cohort, average PAFs were 2.0%, 3.1%, and 6.7% for PTB, SGA, and CD, respectively, with a summary PAF of 11.8% (7.5%-15.9%). Conclusions: Three perinatal risk factors notably contribute to ASD risk in a U.S. population. Because each factor represents multiple etiologic pathways, PAF estimates are best interpreted as the proportion of ASD attributable to having a suboptimal perinatal environment resulting in PTB, SGA, and/or CD. Published by Elsevier Inc. C1 [Schieve, Laura A.; Tian, Lin H.; Baio, Jon; Wiggins, Lisa; Yeargin-Allsopp, Marshalyn; Rice, Catherine; Devine, Owen] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Rankin, Kristin; Rosenberg, Deborah] Univ Illinois, Sch Publ Hlth, Chicago, IL USA. [Maenner, Matthew J.; Durkin, Maureen] Univ Wisconsin Madison, Waisman Ctr, Madison, WI USA. [King, Lydia] Med Univ S Carolina, Charleston, SC USA. [Kirby, Russell S.] Univ S Florida, Sch Publ Hlth, Tampa, FL USA. [Wingate, Martha S.] Univ Alabama Birmingham, Coll Publ Hlth, Birmingham, AL USA. RP Schieve, LA (reprint author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, MS E-86,1600 Clifton Rd, Atlanta, GA 30333 USA. EM LSchieve@cdc.gov RI Durkin, Maureen/B-7834-2015; Rice, Catherine/D-6305-2016 FU Intramural CDC HHS [CC999999] NR 27 TC 13 Z9 13 U1 0 U2 11 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1047-2797 EI 1873-2585 J9 ANN EPIDEMIOL JI Ann. Epidemiol. PD APR PY 2014 VL 24 IS 4 BP 260 EP 266 DI 10.1016/j.annepidem.2013.12.014 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AD7IE UT WOS:000333436500004 PM 24529515 ER PT J AU Friedman, SR West, BS Tempalski, B Morton, CM Cleland, CM Des Jarlais, DC Hall, HI Cooper, HLF AF Friedman, Samuel R. West, Brooke S. Tempalski, Barbara Morton, Cory M. Cleland, Charles M. Des Jarlais, Don C. Hall, H. Irene Cooper, Hannah L. F. TI Do metropolitan HIV epidemic histories and programs for people who inject drugs and Men who have sex with men predict AIDS incidence and mortality among heterosexuals? SO ANNALS OF EPIDEMIOLOGY LA English DT Article DE Urban health; Metropolitan areas; HIV/AIDS; Bridging; Heterosexuals; People who inject drugs; IDU; Men who have sex with men; MSM; Epidemics ID SYRINGE EXCHANGE PROGRAMS; RACIAL RESIDENTIAL SEGREGATION; UNITED-STATES; METHAMPHETAMINE USE; NEEDLE-EXCHANGE; TREATMENT COVERAGE; AFRICAN-AMERICANS; SOCIAL-CONTEXT; GAY MEN; USERS AB Purpose: We focus on a little-researched issue how human immunodeficiency virus (HIV) epidemics and programs in key populations in metropolitan areas affect epidemics in other key populations. We consider (1) How are earlier epidemics among people who inject drugs (PWID) and men who have sex with men (MSM) related to later AIDS incidence and mortality among heterosexuals?; (2) Were prevention programs targeting PWID or MSM associated with lower AIDS incidence and mortality among heterosexuals?; and (3) Was the size of the potential bridge population of noninjecting drug users (NIDUs) in a metropolitan area associated with later AIDS incidence and mortality among heterosexuals? Methods: Using data for 96 large U.S. metropolitan areas, Poisson regression assessed associations of population prevalences of HIV-infected PWID and MSM (1992); NIDU population prevalence (1992-1994); drug use treatment coverage for PWID (1993); HIV counseling and testing coverage for MSM and for PWID (1992); and syringe exchange presence (2000) with CDC data on AIDS incidence and mortality among heterosexuals in 2006-2008, with appropriate socioeconomic controls. Results: Population density of HIV+ PWID and of NIDUs were positively related, and prevention programs for PWID negatively related to later AIDS incidence among heterosexuals and later mortality among heterosexuals living with AIDS. HIV+ MSM population density and prevention programs for MSM were not associated with these outcomes. Conclusions: Efforts to reduce HIV transmission among PWID and NIDUs may reduce AIDS and AIDS-related mortality among heterosexuals. More research is needed at metropolitan area, network, and individual levels into HIV bridging across key populations and how interventions in one key population affect HIV epidemics in other key populations. (C) 2014 Elsevier Inc. All rights reserved. C1 [Friedman, Samuel R.; West, Brooke S.; Tempalski, Barbara; Morton, Cory M.] Natl Dev & Res Inst Inc, Inst Infect Dis Res, New York, NY 10010 USA. [Friedman, Samuel R.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. [Cleland, Charles M.] NYU, Coll Nursing, New York, NY USA. [Des Jarlais, Don C.] Beth Israel Deaconess Med Ctr, New York, NY 10003 USA. [Hall, H. Irene] Ctr Dis Control & Prevent, Div HIVAIDS Prevent, Natl Ctr HIVAIDS Viral Hepatitis STD & TB Prevent, Atlanta, GA USA. [Cooper, Hannah L. F.] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. RP Friedman, SR (reprint author), Natl Dev & Res Inst Inc, Inst Infect Dis Res, New York, NY 10010 USA. EM friedman@ndri.org OI Tempalski, Barbara/0000-0002-6128-2510 FU National Institute of Drug Abuse [R01 DA013336, R01 DA 003574, 5T32 DA007233]; Public Health Solutions and National Development and Research Institutes FX This work was supported by National Institute of Drug Abuse grants #R01 DA013336 (Community Vulnerability and Responses to Drug-User-Related HIV/AIDS), R01 DA 003574 (Risk Factors for AIDS among Intravenous Drug Users), and 5T32 DA007233 (Behavioral Sciences Training in Drug Abuse Research program sponsored by Public Health Solutions and National Development and Research Institutes). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 94 TC 5 Z9 6 U1 1 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1047-2797 EI 1873-2585 J9 ANN EPIDEMIOL JI Ann. Epidemiol. PD APR PY 2014 VL 24 IS 4 BP 304 EP 311 DI 10.1016/j.annepidem.2014.01.008 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AD7IE UT WOS:000333436500011 PM 24529517 ER PT J AU Flegal, KM AF Flegal, Katherine M. TI Metabolically Healthy Overweight and Obesity SO ANNALS OF INTERNAL MEDICINE LA English DT Letter ID EVENTS C1 Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. RP Flegal, KM (reprint author), Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. NR 5 TC 0 Z9 0 U1 0 U2 5 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD APR 1 PY 2014 VL 160 IS 7 BP 515 EP 516 DI 10.7326/L14-5007-6 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA AE6IL UT WOS:000334093800018 PM 24687079 ER PT J AU Espinel-Ingroff, A Pfaller, MA Bustamante, B Canton, E Fothergill, A Fuller, J Gonzalez, GM Lass-Florl, C Lockhart, SR Martin-Mazuelos, E Meis, JF Melhem, MSC Ostrosky-Zeichner, L Pelaez, T Szeszs, MW St-Germain, G Bonefietti, LX Guarro, J Turnidge, J AF Espinel-Ingroff, A. Pfaller, M. A. Bustamante, B. Canton, E. Fothergill, A. Fuller, J. Gonzalez, G. M. Lass-Floerl, C. Lockhart, S. R. Martin-Mazuelos, E. Meis, J. F. Melhem, M. S. C. Ostrosky-Zeichner, L. Pelaez, T. Szeszs, M. W. St-Germain, G. Bonefietti, L. X. Guarro, J. Turnidge, J. TI Multilaboratory Study of Epidemiological Cutoff Values for Detection of Resistance in Eight Candida Species to Fluconazole, Posaconazole, and Voriconazole SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID BROTH MICRODILUTION METHOD; AZOLE RESISTANCE; IN-VITRO; MIC DISTRIBUTIONS; ANTIFUNGAL AGENTS; AMPHOTERICIN-B; WILD-TYPE; SUSCEPTIBILITY; MECHANISMS; ITRACONAZOLE AB Although epidemiological cutoff values (ECVs) have been established for Candida spp. and the triazoles, they are based on MIC data from a single laboratory. We have established ECVs for eight Candida species and fluconazole, posaconazole, and voriconazole based on wild-type (WT) MIC distributions for isolates of C. albicans (n = 11,241 isolates), C. glabrata (7,538), C. parapsilosis (6,023), C. tropicalis (3,748), C. krusei (1,073), C. lusitaniae (574), C. guilliermondii (373), and C. dubliniensis (162). The 24-h CLSI broth microdilution MICs were collated from multiple laboratories (in Canada, Brazil, Europe, Mexico, Peru, and the United States). The ECVs for distributions originating from >= 6 laboratories, which included >= 95% of the modeled WT population, for fluconazole, posaconazole, and voriconazole were, respectively, 0.5, 0.06 and 0.03 mu g/ml for C. albicans, 0.5, 0.25, and 0.03 mu g/ml for C. dubliniensis, 8, 1, and 0.25 mu g/ml for C. glabrata, 8, 0.5, and 0.12 mu g/ml for C. guilliermondii, 32, 0.5, and 0.25 mu g/ml for C. krusei, 1, 0.06, and 0.06 mu g/ml for C. lusitaniae, 1, 0.25, and 0.03 mu g/ml for C. parapsilosis, and 1, 0.12, and 0.06 mu g/ml for C. tropicalis. The low number of MICs (<100) for other less prevalent species (C. famata, C. kefyr, C. orthopsilosis, C. rugosa) precluded ECV definition, but their MIC distributions are documented. Evaluation of our ECVs for some species/agent combinations using published individual MICs for 136 isolates (harboring mutations in or upregulation of ERG11, MDR1, CDR1, or CDR2) and 64 WT isolates indicated that our ECVs may be useful in distinguishing WT from non-WT isolates. C1 [Espinel-Ingroff, A.] VCU Med Ctr, Richmond, VA USA. [Pfaller, M. A.] JMI Labs, North Liberty, IA USA. [Pfaller, M. A.] Univ Iowa, Coll Med, Iowa City, IA USA. [Bustamante, B.] Univ Peruana Cayetano Heredia, Inst Med Trop Alexander Von Humboldt, Lima, Peru. [Canton, E.] Hosp Univ La Fe, Ctr Invest, Unidad Microbiol Expt, Valencia, Spain. [Fothergill, A.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Fuller, J.] Univ Alberta, Edmonton, AB, Canada. [Gonzalez, G. M.] Univ Autonoma Nuevo Leon, Monterrey, Nuevo Leon, Mexico. [Lass-Floerl, C.] Med Univ Innsbruck, Div Hyg & Med Microbiol, A-6020 Innsbruck, Austria. [Lockhart, S. R.] Ctr Dis Control & Prevent, Mycot Dis Branch, Atlanta, GA USA. [Martin-Mazuelos, E.] Hosp Univ Valme, Seville, Spain. [Meis, J. F.] Canisius Wilhelmina Hosp, Nijmegen, Netherlands. [Meis, J. F.] Radboud Univ Nijmegen, NL-6525 ED Nijmegen, Netherlands. [Melhem, M. S. C.] Adolfo Lutz Inst, Fungal Taxon Labs, Sao Paulo, Brazil. [Ostrosky-Zeichner, L.] Univ Texas Hlth Sci Ctr Houston, Houston, TX 77030 USA. [Pelaez, T.] Univ Complutense, Fac Med, Hosp Gen Univ Gregorio Maranon, E-28040 Madrid, Spain. [Szeszs, M. W.] Adolfo Lutz Inst, Dept Mycol, Sao Paulo, Brazil. [St-Germain, G.] Inst Natl Sante Publ Quebec, Lab Sante Publ Quebec, Quebec City, PQ, Canada. [Bonefietti, L. X.] Adolfo Lutz Inst, Aracatuba City, Brazil. [Guarro, J.] IISPV, Fac Med, Reus, Spain. [Turnidge, J.] Univ Adelaide, Adelaide, SA, Australia. RP Espinel-Ingroff, A (reprint author), VCU Med Ctr, Richmond, VA USA. EM avingrof@vcu.edu RI MELHEM, MARCIA/D-4477-2012; OI MELHEM, MARCIA/0000-0002-1335-8808; Martin Mazuelos, Estrella/0000-0003-2632-2246 FU Pfizer; Merck; Astellas FX L. Ostrosky-Zeichner has received research grants from and is a consultant and/or speaker for Pfizer, Merck, and Astellas. NR 41 TC 34 Z9 35 U1 1 U2 9 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 EI 1098-6596 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD APR PY 2014 VL 58 IS 4 BP 2006 EP 2012 DI 10.1128/AAC.02615-13 PG 7 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA AD9SU UT WOS:000333605600021 PM 24419346 ER PT J AU Sleeman, K Mishin, VP Guo, Z Garten, RJ Balish, A Fry, AM Villanueva, J Stevens, J Gubareva, LV AF Sleeman, K. Mishin, V. P. Guo, Z. Garten, R. J. Balish, A. Fry, A. M. Villanueva, J. Stevens, J. Gubareva, L. V. TI Antiviral Susceptibility of Variant Influenza A(H3N2)v Viruses Isolated in the United States from 2011 to 2013 SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID NEURAMINIDASE INHIBITOR RESISTANCE; A(H1N1) VIRUSES; A VIRUSES; TRANSMISSION; INFECTIONS; FERRETS; PROTEIN; DAS181; MODEL AB Since 2011, outbreaks caused by influenza A(H3N2) variant [A(H3N2) v] viruses have become a public health concern in the United States. The A(H3N2) v viruses share the A(H1N1)pdm09 M gene containing the marker of M2 blocker resistance, S31N, but do not contain any known molecular markers associated with resistance to neuraminidase (NA) inhibitors (NAIs). Using a fluorescent NA inhibition (NI) assay, the susceptibilities of recovered A(H3N2)v viruses (n = 168) to FDA-approved (oseltamivir and zanamivir) and other (peramivir, laninamivir, and A-315675) NAIs were assessed. All A(H3N2)v viruses tested, with the exception of a single virus strain, A/Ohio/88/2012, isolated from an untreated patient, were susceptible to the NAIs tested. The A/Ohio/88/2012 virus contained two rare substitutions, S245N and S247P, in the NA and demonstrated reduced inhibition by oseltamivir (31-fold) and zanamivir (66-fold) in the NI assay. Using recombinant NA (recNA) proteins, S247P was shown to be responsible for the observed altered NAI susceptibility, in addition to an approximately 60% reduction in NA enzymatic activity. The S247P substitution has not been previously reported as a molecular marker of reduced susceptibility to the NAIs. Using cell culture assays, the investigational antiviral drugs nitazoxanide, favipiravir, and fludase were shown to inhibit the replication of A(H3N2)v viruses, including the virus with the S247P substitution in the NA. This report demonstrates the importance of continuous monitoring of susceptibility of zoonotic influenza viruses to available and investigational antiviral drugs. C1 [Sleeman, K.; Mishin, V. P.; Guo, Z.; Garten, R. J.; Balish, A.; Villanueva, J.; Stevens, J.; Gubareva, L. V.] Ctr Dis Control & Prevent, Virol Surveillance & Diag Branch, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Fry, A. M.] Ctr Dis Control & Prevent, Epidemiol & Prevent Branch, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. RP Gubareva, LV (reprint author), Ctr Dis Control & Prevent, Virol Surveillance & Diag Branch, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM LGubareva@cdc.gov NR 37 TC 7 Z9 7 U1 0 U2 5 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 EI 1098-6596 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD APR PY 2014 VL 58 IS 4 BP 2045 EP 2051 DI 10.1128/AAC.02556-13 PG 7 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA AD9SU UT WOS:000333605600026 PM 24449767 ER PT J AU Dong, W Chochua, S McGee, L Jackson, D Klugman, KP Vidal, JE AF Dong, W. Chochua, S. McGee, L. Jackson, D. Klugman, K. P. Vidal, J. E. TI Mutations within the rplD Gene of Linezolid-Nonsusceptible Streptococcus pneumoniae Strains Isolated in the United States SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID RESISTANT STAPHYLOCOCCUS-AUREUS; RIBOSOMAL-PROTEIN L4; SURVEILLANCE PROGRAM; IN-VITRO; 1ST REPORT; LEADER PROGRAM; CFR; MECHANISM; CHLORAMPHENICOL; SPECTRUM AB Three invasive Streptococcus pneumoniae strains nonsusceptible to linezolid were isolated in the United States between 2001 and 2012 from the CDC's Active Bacterial Core surveillance. Linezolid binds ribosomal proteins where structural changes within its target site may confer resistance. Our study identified mutations and deletions near the linezolid binding pocket of two of these strains within the rplD gene, which encodes ribosomal protein L4. Mutations in the 23S rRNA alleles or the rplV gene were not detected. C1 [Dong, W.; Chochua, S.; Klugman, K. P.; Vidal, J. E.] Emory Univ, Hubert Dept Global Hlth, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [McGee, L.; Jackson, D.] Ctr Dis Control & Prevent, Resp Dis Branch, Atlanta, GA USA. RP Vidal, JE (reprint author), Emory Univ, Hubert Dept Global Hlth, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. EM jvidalg@emory.edu NR 32 TC 3 Z9 3 U1 0 U2 2 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 EI 1098-6596 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD APR PY 2014 VL 58 IS 4 BP 2459 EP 2462 DI 10.1128/AAC.02630-13 PG 4 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA AD9SU UT WOS:000333605600084 PM 24492357 ER PT J AU Brandt, KS Patton, TG Allard, AS Caimano, MJ Radolf, JD Gilmore, RD AF Brandt, Kevin S. Patton, Toni G. Allard, Anna S. Caimano, Melissa J. Radolf, Justin D. Gilmore, Robert D. TI Evaluation of the Borrelia burgdorferi BBA64 Protein as a Protective Immunogen in Mice SO CLINICAL AND VACCINE IMMUNOLOGY LA English DT Article ID OUTER-SURFACE PROTEIN; LYME-DISEASE VACCINE; MAMMALIAN INFECTION; GENE-EXPRESSION; TICK BITE; OSPC; TRANSMISSION; TEMPERATURE; IDENTIFICATION; IMMUNIZATION AB The Borrelia burgdorferi bba64 gene product is a surface-localized lipoprotein synthesized within mammalian and tick hosts and is involved in vector transmission of disease. These properties suggest that BBA64 may be a vaccine candidate against Lyme borreliosis. In this study, protective immunity against B. burgdorferi challenge was assessed in mice immunized with the BBA64 protein. Mice developed a high-titer antibody response following immunization with soluble recombinant BBA64 but were not protected when challenged by needle inoculation of culture-grown spirochetes. Likewise, mice passively immunized with an anti-BBA64 monoclonal antibody were not protected against needle-inoculated organisms. BBA64-immunized mice were subjected to B. burgdorferi challenge by the natural route of a tick bite, but these trials did not demonstrate significant protective immunity in either outbred or inbred strains of mice. Lipidated recombinant BBA64 produced in Escherichia coli was assessed for possible improved elicitation of a protective immune response. Although inoculation with this antigen produced a high-titer antibody response, the lipidated BBA64 also was unsuccessful in protecting mice from B. burgdorferi challenge by tick bites. Anti-BBA64 antibodies raised in rats eradicated the organisms, as evidenced by in vitro borreliacidal assays, thus demonstrating the potential for BBA64 to be effective as a protective immunogen. However, passive immunization with the same monospecific rat anti-BBA64 polyclonal serum failed to provide protection against tick bite-administered challenge. These results reveal the challenges faced in not only identifying B. burgdorferi proteins with potential protective capability but also in producing recombinant antigens conducive to preventive therapies against Lyme borreliosis. C1 [Brandt, Kevin S.; Patton, Toni G.; Gilmore, Robert D.] Ctr Dis Control & Prevent, Bacterial Dis Branch, Div Vector Borne Dis, Ft Collins, CO USA. [Allard, Anna S.; Caimano, Melissa J.; Radolf, Justin D.] Univ Connecticut, Ctr Hlth, Dept Med, Farmington, CT USA. [Caimano, Melissa J.; Radolf, Justin D.] Univ Connecticut, Ctr Hlth, Dept Pediat, Farmington, CT USA. [Radolf, Justin D.] Univ Connecticut, Ctr Hlth, Dept Immunol, Farmington, CT USA. [Radolf, Justin D.] Univ Connecticut, Ctr Hlth, Dept Genet & Dev Biol, Farmington, CT USA. [Radolf, Justin D.] Univ Connecticut, Ctr Hlth, Dept Mol Biol & Biophys, Farmington, CT USA. RP Gilmore, RD (reprint author), Ctr Dis Control & Prevent, Bacterial Dis Branch, Div Vector Borne Dis, Ft Collins, CO USA. EM rbg9@cdc.gov FU NIH/NIAID [AI29735, AI85248] FX This work was supported by NIH/NIAID grants AI29735 (to M.J.C. and J.D.R.) and AI85248 (to M.J.C.). NR 45 TC 1 Z9 1 U1 4 U2 10 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 1556-6811 EI 1556-679X J9 CLIN VACCINE IMMUNOL JI Clin. Vaccine Immunol. PD APR PY 2014 VL 21 IS 4 BP 526 EP 533 DI 10.1128/CVI.00824-13 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA AE0TG UT WOS:000333678500010 PM 24501342 ER PT J AU Bardenheier, BH Gregg, EW Zhuo, XH Cheng, YLJ Geiss, LS AF Bardenheier, Barbara H. Gregg, Edward W. Zhuo, Xiaohui Cheng, Yiling J. Geiss, Linda S. TI Association of Functional Decline With Subsequent Diabetes Incidence in U.S. Adults Aged 51 Years and Older: The Health and Retirement Study 1998-2010 SO DIABETES CARE LA English DT Article ID INSULIN-RESISTANCE; OBESE ADULTS; US ADULTS; DISABILITY; RISK; LIFE AB OBJECTIVE We assessed whether functional decline and physical disability increase the subsequent risk of diabetes. RESEARCH DESIGN AND METHODS We used a subsample of adults aged 51 years and older with no diabetes at baseline who were followed up to 12 years (1998-2010) in the Health and Retirement Study, an observational study of a nationally representative survey. We assessed baseline disability status and incident disability with subsequent risk of diabetes, accounting for death as a competing risk and controlling for BMI, age, sex, race/ethnicity, net wealth, mother's level of education, respondents' level of education, and time of follow-up. Disability was defined as none, mild, moderate, and severe, based on a validated scale of mobility measures. Diabetes was identified by self-report of a diagnosis from a doctor. Population attributable fraction (PAF) was calculated to assess the percentage of diabetes cases that were attributable to mobility disability. RESULTS The sample included 22,878 adults with an average of 8.7 years of follow-up; 9,649 (41.2%) reported some level of disability at baseline, and 8,175 (35.7%) additional participants developed disability during follow-up; 3,546 (15.5%) participants developed diabetes; and 5,869 (25.6%) died. Regression analyses found a statistically significant dose-response relationship of increased risk of diabetes (28-95%) among those with any level of functional decline, prevalent or incident. Among the subanalytic sample, including incident disability only, the PAF was 6.9% (CI 4.2-9.5). CONCLUSIONS Our findings suggest those who become disabled, even mildly, are at increased risk of developing diabetes. This finding raises the possibility that approaches to prevent disability in older adults could also reduce diabetes incidence. C1 [Bardenheier, Barbara H.; Gregg, Edward W.; Zhuo, Xiaohui; Cheng, Yiling J.; Geiss, Linda S.] Ctr Dis Control & Prevent, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP Bardenheier, BH (reprint author), Ctr Dis Control & Prevent, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM bfb7@cdc.gov NR 25 TC 2 Z9 2 U1 1 U2 4 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 EI 1935-5548 J9 DIABETES CARE JI Diabetes Care PD APR PY 2014 VL 37 IS 4 BP 1032 EP 1038 DI 10.2337/dc13-2216 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA AD7BB UT WOS:000333414700034 PM 24550218 ER PT J AU Marcello, RK Papadouka, V Misener, M Wake, E Mandell, R Zucker, JR AF Marcello, Roopa Kalyanaraman Papadouka, Vikki Misener, Mark Wake, Edward Mandell, Rebecca Zucker, Jane R. TI Distribution of Pandemic Influenza Vaccine and Reporting of Doses Administered, New York, New York, USA SO EMERGING INFECTIOUS DISEASES LA English DT Article ID A H1N1 VIRUS AB In 2009, the New York City Department of Health and Mental Hygiene delivered influenza A(H1N1)pdm09 (pH1N1) vaccine to health care providers, who were required to report all administered doses to the Citywide Immunization Registry. Using data from this registry and a provider survey, we estimated the number of all pH1N1 vaccine doses administered. Of 2.8 million doses distributed during October 1, 2009 March 4, 2010, a total of 988,298 doses were administered and reported; another 172,289 doses were administered but not reported, for a total of 1,160,587 doses administered during this period. Reported doses represented an estimated 80%-85% of actual doses administered. Reporting by a wide range of provider types was feasible during a pandemic. Pediatric-care providers had the highest reporting rate (93%). Other private-care providers who routinely did not report vaccinations indicated that they had few, if any, problems, thereby suggesting that mandatory reporting of all vaccines would be feasible. C1 [Marcello, Roopa Kalyanaraman; Papadouka, Vikki; Misener, Mark; Wake, Edward; Mandell, Rebecca; Zucker, Jane R.] New York City Dept Hlth & Mental Hyg, Queens, NY 11101 USA. [Wake, Edward; Zucker, Jane R.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Zucker, JR (reprint author), New York City Dept Hlth & Mental Hyg, Bur Immunizat, 42-09 28th St,Room 5-97, Queens, NY 11101 USA. EM jzucker@health.nyc.gov NR 12 TC 1 Z9 1 U1 2 U2 5 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD APR PY 2014 VL 20 IS 4 BP 525 EP 531 DI 10.3201/eid2004.131114 PG 7 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA AD8GO UT WOS:000333504700001 PM 24656328 ER PT J AU Mendelson, M Han, PV Vincent, P von Sonnenburg, F Cramer, JP Loutan, L Kain, KC Parola, P Hagmann, S Gkrania-Klotsas, E Sotir, M Schlagenhauf, P AF Mendelson, Marc Han, Pauline V. Vincent, Peter von Sonnenburg, Frank Cramer, Jakob P. Loutan, Louis Kain, Kevin C. Parola, Philippe Hagmann, Stefan Gkrania-Klotsas, Effrossyni Sotir, Mark Schlagenhauf, Patricia CA GeoSentinel Surveillance Network TI Regional Variation in Travel-related Illness acquired in Africa, March 1997-May 2011 SO EMERGING INFECTIOUS DISEASES LA English DT Article ID GEOSENTINEL SURVEILLANCE NETWORK; HEALTH KNOWLEDGE; ATTITUDES; TROPICS; RISK; SPECTRUM; DISEASES; CHILDREN; MALARIA AB To understand geographic variation in travel-related illness acquired in distinct African regions, we used the Geo Sentinel Surveillance Network database to analyze records for 16,893 ill travelers returning from Africa over a 14-year period. Travelers to northern Africa most commonly reported gastrointestinal illnesses and dog bites. Febrile illnesses were more common in travelers returning from sub-Saharan countries. Eleven travelers died, 9 of malaria; these deaths occurred mainly among male business travelers to sub-Saharan Africa. The profile of illness varied substantially by region: malaria predominated in travelers returning from Central and Western Africa; schistosomiasis, strongyloidiasis, and dengue from Eastern and Western Africa; and loaisis from Central Africa. There were few reports of vaccine-preventable infections, HIV infection, and tuberculosis. Geographic profiling of illness acquired during travel to Africa guides targeted pretravel advice, expedites diagnosis in ill returning travelers, and may influence destination choices in tourism. C1 [Mendelson, Marc] Univ Cape Town, Groote Schuur Hosp, ZA-7925 Cape Town, South Africa. [Han, Pauline V.; Sotir, Mark] Ctr Dis Control & Prevent, Atlanta, GA USA. [Vincent, Peter] Tokai Medicross Travel Clin, Cape Town, South Africa. [von Sonnenburg, Frank] Univ Munich, Munich, Germany. [Cramer, Jakob P.] Univ Med Ctr, Hamburg, Germany. [Loutan, Louis] Univ Geneva, Geneva, Switzerland. [Kain, Kevin C.] Univ Toronto, Toronto, ON, Canada. [Parola, Philippe] North Univ Hosp, Assistance Publ Hop Marseille, Marseille, France. [Hagmann, Stefan] Yeshiva Univ, Bronx Lebanon Hosp Ctr, Bronx, NY USA. [Gkrania-Klotsas, Effrossyni] Cambridge Univ Hosp Natl Hlth Serv Trust, Cambridge, England. [Schlagenhauf, Patricia] Univ Zurich, Ctr Travel Med, Zurich, Switzerland. RP Mendelson, M (reprint author), Univ Cape Town, Dept Med, Div Infect Dis & HIV Med, G16-68 Groote Schuur Hosp, ZA-7925 Cape Town, South Africa. EM marc.mendelson@uct.ac.za RI Matteelli, Alberto/M-8784-2015; OI Matteelli, Alberto/0000-0001-5109-9248; Klion, Amy/0000-0002-4986-5326; Ursing, Johan/0000-0002-5508-9327; Leder, Karin/0000-0003-1368-1039; Gkrania-Klotsas, Effrossyni/0000-0002-0930-8330; Asgeirsson, Hilmir/0000-0003-3869-8021 FU Canada Research Chair in Molecular Parasitology; Canadian Institutes of Health Research [MOP-115160, MOP-13721]; National Institute of Health Research Cambridge Biomedical Research Center FX K.C.K. was supported by a Canada Research Chair in Molecular Parasitology and by the Canadian Institutes of Health Research (grants MOP-115160 and MOP-13721). E.G.K. was supported by the National Institute of Health Research Cambridge Biomedical Research Center. NR 24 TC 14 Z9 14 U1 0 U2 7 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD APR PY 2014 VL 20 IS 4 BP 532 EP 541 DI 10.3201/eid2004.131128 PG 10 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA AD8GO UT WOS:000333504700002 PM 24655358 ER PT J AU Saha, S Dean, B Teutsch, S Borse, RH Meltzer, MI Bagwell, D Plough, A Fielding, J AF Saha, Shubhayu Dean, Brandon Teutsch, Steven Borse, Rebekah H. Meltzer, Martin I. Bagwell, DeeAnn Plough, Alonzo Fielding, Jonathan TI Efficiency of Points of Dispensing for Influenza A(H1N1)pdm09 Vaccination, Los Angeles County, California, USA, 2009 SO EMERGING INFECTIOUS DISEASES LA English DT Article ID INFORMATION-SYSTEMS GIS; MASS VACCINATION; PRIMARY-CARE AB During October 23 December 8, 2009, the Los Angeles County Department of Public Health used points of dispensing (PODs) to improve access to and increase the number of vaccinations against influenza A(H1N1)pdm09. We assessed the efficiency of these units and access to vaccines among ethnic groups. An average of 251 persons per hour (SE 65) were vaccinated at the PODs; a 10% increase in use of live-attenuated monovalent vaccines reduced that rate by 23 persons per hour (SE 7). Vaccination rates were highest for Asians (257/10,000 persons), followed by Hispanics (114/10,000), whites (75/100,000), and African Americans (37/10,000). Average distance traveled to a POD was highest for whites (6.6 miles; SD 6.5) and lowest for Hispanics (4.7 miles; SD +/-5.3). Placing PODs in areas of high population density could be an effective strategy to reach large numbers of persons for mass vaccination, but additional PODs may be needed to improve coverage for specific populations. C1 [Saha, Shubhayu; Borse, Rebekah H.; Meltzer, Martin I.] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. [Dean, Brandon; Teutsch, Steven; Bagwell, DeeAnn; Plough, Alonzo; Fielding, Jonathan] Los Angeles Cty Dept Publ Hlth, Los Angeles, CA USA. RP Saha, S (reprint author), Ctr Dis Control & Prevent, 4770 Buford Hwy,Mailstop F59, Atlanta, GA 30341 USA. EM ssaha@cdc.gov NR 17 TC 4 Z9 4 U1 0 U2 3 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD APR PY 2014 VL 20 IS 4 BP 590 EP 595 DI 10.3201/eid2004.130725 PG 6 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA AD8GO UT WOS:000333504700008 PM 24656212 ER PT J AU Chesson, HW Kirkcaldy, RD Gift, TL Owusu-Edusei, K Weinstock, HS AF Chesson, Harrell W. Kirkcaldy, Robert D. Gift, Thomas L. Owusu-Edusei, Kwame, Jr. Weinstock, Hillard S. TI Ciprofloxacin Resistance and Gonorrhea Incidence Rates in 17 Cities, United States, 1991-2006 SO EMERGING INFECTIOUS DISEASES LA English DT Article ID SEXUALLY-TRANSMITTED INFECTIONS; DISEASES-TREATMENT-GUIDELINES; NEISSERIA-GONORRHOEAE; ANTIMICROBIAL RESISTANCE; GONOCOCCAL INFECTIONS; NO LONGER; IMPACT; CEFTRIAXONE; MUTATIONS; UPDATE AB Antimicrobial drug resistance can hinder gonorrhea prevention and control efforts. In this study, we analyzed historical ciprofloxacin resistance data and gonorrhea incidence data to examine the possible effect of antimicrobial drug resistance on gonorrhea incidence at the population level. We analyzed data from the Gonococcal Isolate Surveillance Project and city-level gonorrhea incidence rates from surveillance data for 17 cities during 1991-2006. We found a strong positive association between ciprofloxacin resistance and gonorrhea incidence rates at the city level during this period. Their association was consistent with predictions of mathematical models in which resistance to treatment can increase gonorrhea incidence rates through factors such as increased duration of infection. These findings highlight the possibility of future increases in gonorrhea incidence Caused by emerging cephalosporin resistance. C1 [Chesson, Harrell W.; Kirkcaldy, Robert D.; Gift, Thomas L.; Owusu-Edusei, Kwame, Jr.; Weinstock, Hillard S.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Chesson, HW (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop E80, Atlanta, GA 30333 USA. EM hbc7@cdc.gov NR 25 TC 1 Z9 1 U1 1 U2 8 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD APR PY 2014 VL 20 IS 4 BP 612 EP 619 DI 10.3201/eid2004.131288 PG 8 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA AD8GO UT WOS:000333504700011 PM 24655615 ER PT J AU Dharmayanti, NLPI Hartawan, R Pudjiatmoko Wibawa, H Hardiman Balish, A Donis, R Davis, CT Samaan, G AF Dharmayanti, Ni Luh Putu Indi Hartawan, Risza Pudjiatmoko Wibawa, Hendra Hardiman Balish, Amanda Donis, Ruben Davis, C. Todd Samaan, Gina TI Genetic Characterization of Clade 2.3.2.1 Avian Influenza A(H5N1) Viruses, Indonesia, 2012 SO EMERGING INFECTIOUS DISEASES LA English DT Article AB After reports of unusually high mortality rates among ducks on farms in Java Island, Indonesia, in September 2012, influenza A(H5N1) viruses were detected and characterized. Sequence analyses revealed all genes clustered with contemporary clade 2.3.2.1 viruses, rather than enzootic clade 2.1.3 viruses, indicating the introduction of an exotic H5N1 clade into Indonesia. C1 [Dharmayanti, Ni Luh Putu Indi; Hartawan, Risza; Hardiman] Indonesian Res Ctr Vet Sci, Bogor 16114, Indonesia. [Pudjiatmoko] Minist Agr, Jakarta, Indonesia. [Wibawa, Hendra] Dis Invest Ctr Wates, Yogyakarta, Indonesia. [Balish, Amanda; Donis, Ruben; Davis, C. Todd] Ctr Dis Control & Prevent, Atlanta, GA USA. [Samaan, Gina] Ctr Dis Control & Prevent, Jakarta, Indonesia. RP Dharmayanti, NLPI (reprint author), Indonesian Res Ctr Vet Sci, Dept Virol, Jalan RE Martadinata 30, Bogor 16114, Indonesia. EM nlpdharmayanti@yahoo.com NR 15 TC 7 Z9 7 U1 0 U2 5 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD APR PY 2014 VL 20 IS 4 BP 671 EP 674 DI 10.3201/eid2004.130517 PG 4 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA AD8GO UT WOS:000333504700020 PM 24656213 ER PT J AU Gee, JE Allender, CJ Tuanyok, A Elrod, MG Hoffmaster, AR AF Gee, Jay E. Allender, Christopher J. Tuanyok, Apichai Elrod, Mindy G. Hoffmaster, Alex R. TI Burkholderia pseudomallei Type G in Western Hemisphere SO EMERGING INFECTIOUS DISEASES LA English DT Article ID GENE-TRANSFER; MELIOIDOSIS AB Burkholderia pseudomallei isolates from the Western Hemisphere are difficult to differentiate from those from regions in which melioidosis is traditionally endemic. We used internal transcribed spacer typing to determine that B. pseudomallei isolates from the Western Hemisphere are consistently type G. Knowledge of this relationship might be useful for epidemiologic investigations. C1 [Gee, Jay E.; Elrod, Mindy G.; Hoffmaster, Alex R.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Allender, Christopher J.; Tuanyok, Apichai] No Arizona Univ, Flagstaff, AZ 86011 USA. RP Gee, JE (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop G34, Atlanta, GA 30333 USA. EM xzg4@cdc.gov FU United States Department of Homeland Security [HSHQDC-10-C-00135]; Wellcome Trust FX A.T. is supported by the United States Department of Homeland Security grant no. HSHQDC-10-C-00135. This study used the Multi Locus Sequence Typing website (www.mlst.net) at Imperial College London, developed by David Aanensen and funded by the Wellcome Trust. NR 6 TC 12 Z9 12 U1 0 U2 3 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD APR PY 2014 VL 20 IS 4 BP 682 EP 684 DI 10.3201/eid2004.130960 PG 3 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA AD8GO UT WOS:000333504700023 PM 24655932 ER PT J AU Shimabukuro, TT Redd, SC AF Shimabukuro, Tom T. Redd, Stephen C. TI Incorporating Research and Evaluation into Pandemic Influenza Vaccination Preparedness and Response SO EMERGING INFECTIOUS DISEASES LA English DT Editorial Material ID LESSONS C1 [Shimabukuro, Tom T.; Redd, Stephen C.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Shimabukuro, TT (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop D26, Atlanta, GA 30333 USA. EM tshimabukuro@cdc.gov NR 11 TC 0 Z9 0 U1 0 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD APR PY 2014 VL 20 IS 4 BP 713 EP 714 DI 10.3201/eid2004.0224.140224 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA AD8GO UT WOS:000333504700031 PM 24795933 ER PT J AU Bloom, S Weeks, EM AF Bloom, Sharon Weeks, Emily M. TI Truth in the Details SO EMERGING INFECTIOUS DISEASES LA English DT Editorial Material C1 [Bloom, Sharon] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Bloom, S (reprint author), Ctr Dis Control & Prevent, Ctr Global Hlth, 1600 Clifton Rd NE,Mailstop E41, Atlanta, GA 30333 USA. EM sbloom@cdc.gov NR 4 TC 0 Z9 0 U1 0 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD APR PY 2014 VL 20 IS 4 BP 734 EP 735 DI 10.3201/eid2004.AC2004 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA AD8GO UT WOS:000333504700042 ER PT J AU Folster, JP Tolar, B Pecic, G Sheehan, D Rickert, R Hise, K Zhao, SH Fedorka-Cray, PJ McDermott, P Whichard, JM AF Folster, Jason P. Tolar, Beth Pecic, Gary Sheehan, Deborah Rickert, Regan Hise, Kelley Zhao, Shaohua Fedorka-Cray, Paula J. McDermott, Patrick Whichard, Jean M. TI Characterization of bla(CMY) Plasmids and Their Possible Role in Source Attribution of Salmonella enterica Serotype Typhimurium Infections SO FOODBORNE PATHOGENS AND DISEASE LA English DT Article ID FIELD GEL-ELECTROPHORESIS; ESCHERICHIA-COLI; UNITED-STATES; BETA-LACTAMASES; INCI1 PLASMIDS; INCA/C PLASMID; FOOD ANIMALS; SUSCEPTIBILITY; RESISTANCE; PATHOGENS AB Salmonella is an important cause of foodborne illness; however, identifying the source of these infections can be difficult. This is especially true for Salmonella serotype Typhimurium, which is found in diverse agricultural niches. Extended-spectrum cephalosporins (ESC) are one of the primary treatment choices for complicated Salmonella infections. In Salmonella, ESC resistance in the United States is mainly mediated by bla(CMY) genes carried on various plasmids. In this study, we examined whether the characterization of bla(CMY) plasmids, along with additional information, can help us identify potential sources of infection by Salmonella, and used serotype Typhimurium as a model. In the United States, monitoring of retail meat, food animals, and ill persons for antimicrobial-resistant Salmonella is conducted by the National Antimicrobial Resistance Monitoring System. In 2008, 70 isolates (70/581; 12.0%) (34 isolates from retail meat, 23 food animal, and 13 human) were resistant to ceftriaxone and amoxicillin/clavulanic acid. All were polymerase chain reaction (PCR)-positive for bla(CMY) and 59/70 (84.3%) of these genes were plasmid encoded. PCR-based replicon typing identified 42/59 (71.2%) IncI1-bla(CMY) plasmids and 17/59 (28.8%) IncA/C-bla(CMY) plasmids. Isolates from chickens or chicken products with bla(CMY) plasmids primarily had IncI1-bla(CMY) plasmids (37/40; 92.5%), while all isolates from cattle had IncA/C-bla(CMY) plasmids. Isolates from humans had either IncA/C- bla(CMY) (n=8/12; [66.7%]) or IncI1- bla(CMY) (n=4/12 [33.3%]) plasmids. All of the IncI1-bla(CMY) plasmids were ST12 or were closely related to ST12. Antimicrobial susceptibility patterns (AST) and pulsed-field gel electrophoresis (PFGE) patterns of the isolates were also compared and differences were identified between isolate sources. When the source of a Typhimurium outbreak or sporadic illness is unknown, characterizing the outbreak isolate's bla(CMY) plasmids, AST, and PFGE patterns may help identify it. C1 [Folster, Jason P.; Tolar, Beth; Pecic, Gary; Sheehan, Deborah; Rickert, Regan; Hise, Kelley; Whichard, Jean M.] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30329 USA. [Pecic, Gary] IHRC, Atlanta, GA USA. [Zhao, Shaohua; McDermott, Patrick] US FDA, Div Anim & Food Microbiol, Res Off, Ctr Vet Med, Laurel, MD USA. [Fedorka-Cray, Paula J.] ARS, Bacterial Epidemiol & Antimicrobial Resistance Re, USDA, Athens, GA USA. RP Folster, JP (reprint author), Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, 1600 Clifton Rd NE,MS G29, Atlanta, GA 30329 USA. EM gux8@cdc.gov FU CDC; USDA; FDA Center for Veterinary Medicine FX We thank the NARMS participating public health laboratories for submitting the isolates, Anne Whitney for DNA sequencing, and Alessandra Carattoli for the plasmid incompatibility typing control strains. This work was partially supported by an interagency agreement between CDC, USDA, and the FDA Center for Veterinary Medicine. NR 28 TC 5 Z9 5 U1 1 U2 4 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1535-3141 EI 1556-7125 J9 FOODBORNE PATHOG DIS JI Foodborne Pathog. Dis. PD APR 1 PY 2014 VL 11 IS 4 BP 301 EP 306 DI 10.1089/fpd.2013.1670 PG 6 WC Food Science & Technology SC Food Science & Technology GA AD9RR UT WOS:000333602700007 PM 24484290 ER PT J AU Glidewell, J Reefhuis, J Rasmussen, SA Woomert, A Hobbs, C Romitti, PA Crider, KS AF Glidewell, Jill Reefhuis, Jennita Rasmussen, Sonja A. Woomert, Alison Hobbs, Charlotte Romitti, Paul A. Crider, Krista S. TI Factors affecting maternal participation in the genetic component of the National Birth Defects Prevention Study-United States, 1997-2007 SO GENETICS IN MEDICINE LA English DT Article DE birth defects; data collection; epidemiologic methods; ethnic groups; risk factors ID GENERAL-POPULATION; RACIAL-DIFFERENCES; DNA COLLECTION; CONSENT; WILLINGNESS; HEALTH; INCENTIVES; EXPERIENCE; SELECTION; DISTRUST AB Purpose: As epidemiological studies expand to examine gene environment interaction effects, it is important to identify factors associated with participation in genetic studies. The National Birth Defects Prevention Study is a multisite case-control study designed to investigate environmental and genetic risk factors for major birth defects. The National Birth Defects Prevention Study includes maternal telephone interviews and mailed buccal cell self-collection kits. Because subjects can participate in the interview, independent of buccal cell collection, detailed analysis of factors associated with participation in buccal cell collection was possible. Methods: Multivariable logistic regression models were used to identify the factors associated with participation in the genetic component of the study. Results: Buccal cell participation rates varied by race/ethnicity (non-Hispanic whites, 66.9%; Hispanics, 60.4%; and non-Hispanic blacks, 47.3%) and study site (50.2-74.2%). Additional monetary incentive following return of buccal cell kit and shorter interval between infant's estimated date of delivery and interview were associated with increased participation across all racial/ethnic groups. Higher education and delivering an infant with a birth defect were associated with increased participation among non-Hispanic whites and Hispanics. Conclusion: Factors associated with participation varied by race/ethnicity. Improved understanding of factors associated with participation may facilitate strategies to increase participation, thereby improving generalizability of study findings. C1 [Glidewell, Jill; Reefhuis, Jennita; Crider, Krista S.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Glidewell, Jill] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. [Rasmussen, Sonja A.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Woomert, Alison] Univ N Carolina, Dept Epidemiol, Gillings Sch Global Publ Hlth, Chapel Hill, NC USA. [Hobbs, Charlotte] Univ Arkansas Med Sci, Coll Med, Dept Pediat, Little Rock, AR 72205 USA. [Romitti, Paul A.] Univ Iowa, Dept Epidemiol, Coll Publ Hlth, Iowa City, IA USA. RP Glidewell, J (reprint author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. EM jill.glidewell@cdc.hhs.gov FU Intramural CDC HHS [CC999999]; NIEHS NIH HHS [P30 ES005605] NR 27 TC 2 Z9 2 U1 0 U2 6 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1098-3600 EI 1530-0366 J9 GENET MED JI Genet. Med. PD APR PY 2014 VL 16 IS 4 BP 329 EP 337 DI 10.1038/gim.2013.143 PG 9 WC Genetics & Heredity SC Genetics & Heredity GA AE2BZ UT WOS:000333779600007 PM 24071796 ER PT J AU Sabry, A Hauk, PJ Jing, H Su, HC Stence, NV Mirsky, DM Nagel, MA Abbott, JK Dragone, LL Armstrong-Wells, J Curtis, DJ Cohrs, R Schmid, DS Gilden, D Gelfand, EW AF Sabry, Angela Hauk, Pia J. Jing, Huie Su, Helen C. Stence, Nicholas V. Mirsky, David M. Nagel, Maria A. Abbott, Jordan K. Dragone, Leonard L. Armstrong-Wells, Jennifer Curtis, Donna J. Cohrs, Randall Schmid, D. Scott Gilden, Don Gelfand, Erwin W. TI Vaccine strain varicella- zoster virus- induced central nervous system vasculopathy as the presenting feature of DOCK8 deficiency SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Letter ID CLINICAL-MANIFESTATIONS C1 [Sabry, Angela; Hauk, Pia J.; Abbott, Jordan K.; Dragone, Leonard L.; Gelfand, Erwin W.] Natl Jewish Hlth, Dept Pediat, Div Allergy Immunol, Denver, CO 80206 USA. [Sabry, Angela; Hauk, Pia J.; Abbott, Jordan K.; Dragone, Leonard L.; Gelfand, Erwin W.] Natl Jewish Hlth, Div Cell Biol, Denver, CO USA. [Jing, Huie; Su, Helen C.] NIAID, NIH, Bethesda, MD 20892 USA. [Stence, Nicholas V.; Mirsky, David M.; Armstrong-Wells, Jennifer; Curtis, Donna J.; Cohrs, Randall; Gilden, Don] Univ Colorado, Sch Med, Aurora, CO USA. [Stence, Nicholas V.; Mirsky, David M.; Nagel, Maria A.; Armstrong-Wells, Jennifer; Curtis, Donna J.] Childrens Hosp Colorado, Aurora, CO USA. [Schmid, D. Scott] Ctr Dis Control & Prevent, Div Viral Dis, Herpesvirus Team, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. RP Sabry, A (reprint author), Natl Jewish Hlth, Dept Pediat, Div Allergy Immunol, Denver, CO 80206 USA. EM gelfande@njhealth.org RI Su, Helen/H-9541-2015; Abbott, Jordan/P-2509-2016 OI Su, Helen/0000-0002-5582-9110; Abbott, Jordan/0000-0001-6334-5266 FU NIAID NIH HHS [R01 AI077609] NR 12 TC 13 Z9 14 U1 0 U2 5 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 EI 1097-6825 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD APR PY 2014 VL 133 IS 4 BP 1225 EP 1227 DI 10.1016/j.jaci.2013.11.031 PG 14 WC Allergy; Immunology SC Allergy; Immunology GA AD8QW UT WOS:000333531700040 PM 24418481 ER PT J AU Smith, JL AF Smith, Judith Lee TI Capsule Commentary on Davis et al., Improving Mammography Screening among the Medically Underserved SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material C1 Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. RP Smith, JL (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. EM JLeeSmith@cdc.gov NR 5 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2014 VL 29 IS 4 BP 652 EP 652 DI 10.1007/s11606-013-2761-1 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AD8RF UT WOS:000333532600025 PM 24464284 ER PT J AU Jandacek, RJ Heubi, JE Buckley, DD Khoury, JC Turner, WE Sjodin, A Olson, JR Shelton, C Helms, K Bailey, TD Carter, S Tso, P Pavuk, M AF Jandacek, Ronald J. Heubi, James E. Buckley, Donna D. Khoury, Jane C. Turner, Wayman E. Sjoedin, Andreas Olson, James R. Shelton, Christie Helms, Kim Bailey, Tina D. Carter, Shirley Tso, Patrick Pavuk, Marian TI Reduction of the body burden of PCBs and DDE by dietary intervention in a randomized trial SO JOURNAL OF NUTRITIONAL BIOCHEMISTRY LA English DT Article DE PCBs DDE; Olestra; Dietary intervention ID SUCROSE POLYESTER; ADIPOSE-TISSUE; POLYCHLORINATED-BIPHENYLS; HYPERCHOLESTEROLEMIC OUTPATIENTS; CALORIC RESTRICTION; HUMAN SERUM; FAT; SUBSTITUTION; ELIMINATION; OLESTRA AB Serum polychlorinated biphenyls (PCBs) in Anniston, AL, residents have been associated with hypertension and diabetes. There have been no systematic interventions to reduce PCB body burdens in Anniston or other populations. Our objective was to determine the efficacy of 15 g/day of dietary olestra to reduce PCBs in Anniston residents. Blood PCBs and 1,1-bis-(4-chlorophenyl)-2,2-dichloroethene were measured at baseline and 4-month intervals in a double-blind, placebo-controlled, 1-year trial. Participants with elevated serum PCBs were randomized into two groups of 14 and received potato crisps made with olestra or vegetable oil (VO). Elimination rates during the study period were compared with 5-year prestudy rates. Eleven participants in the olestra group and 12 in the VO group completed the study. Except for one participant in the VO group, reasons for dropout were unrelated to treatments. The elimination rate of 37 non-coplanar PCB congeners during the 1-year trial was faster during olestra consumption compared to the pretrial period (-0.0829 +/- 0.0357 and -0.00864 +/- 0.0116 year(-1), respectively; P=.04), but not during VO consumption (-0.0413 +/- 0.0408 and -0.0283 +/- 0.0096 year(-1), respectively; P=.27). The concentration of PCBs in two olestra group participants decreased by 27% and 25% during the trial. There was no significant time by group interaction in change from baseline. However, group main effects for total PCBs and PCB 153 were of borderline significance. This pilot study has demonstrated that olestra can safely reduce body burdens of PCBs and supports a larger intervention trial that may also determine whether reduction in PCBs will reduce the risk of hypertension and diabetes. (C) 2014 Elsevier Inc. All rights reserved. C1 [Jandacek, Ronald J.; Carter, Shirley] Univ Cincinnati, Cincinnati, OH 45237 USA. [Heubi, James E.; Buckley, Donna D.; Khoury, Jane C.; Bailey, Tina D.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA. [Turner, Wayman E.; Sjoedin, Andreas; Pavuk, Marian] Ctr Dis Control & Prevent, Atlanta, GA USA. [Olson, James R.] SUNY Buffalo, Buffalo, NY 14260 USA. [Shelton, Christie; Helms, Kim; Tso, Patrick] Jacksonville State Univ, Jacksonville, AL 36265 USA. RP Jandacek, RJ (reprint author), Univ Cincinnati, 2120 E Galbraith Rd, Cincinnati, OH 45237 USA. EM Ronald.Jandacek@uc.edu RI Sjodin, Andreas/F-2464-2010; Khoury, Jane/O-2068-2015 FU National Institutes for Environmental Health Science [R21 ES019206]; National Center for Research Resources; National Center for Advancing Translational Sciences, National Institutes of Health (NIH) [8 UL1 TR00007] FX The study was supported by the National Institutes for Environmental Health Science (R21 ES019206) and the National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health (NIH), through grant 8 UL1 TR00007. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or the Center for Disease Control and Prevention. NR 23 TC 9 Z9 9 U1 2 U2 18 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0955-2863 EI 1873-4847 J9 J NUTR BIOCHEM JI J. Nutr. Biochem. PD APR PY 2014 VL 25 IS 4 BP 483 EP 488 DI 10.1016/j.jnutbio.2014.01.002 PG 6 WC Biochemistry & Molecular Biology; Nutrition & Dietetics SC Biochemistry & Molecular Biology; Nutrition & Dietetics GA AD8JU UT WOS:000333513100014 PM 24629911 ER PT J AU Kim, JH Powell, JB Roberge, RJ Shepherd, A Coca, A AF Kim, Jung-Hyun Powell, Jeffery B. Roberge, Raymond J. Shepherd, Angie Coca, Aitor TI Evaluation of Protective Ensemble Thermal Characteristics Through Sweating Hot Plate, Sweating Thermal Manikin, and Human Tests SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL HYGIENE LA English DT Article DE total heat loss; thermal resistance; vapor permeability; core temperature; evaporative heat loss ID UNCOMPENSABLE HEAT-STRESS; EXERCISE; TOLERANCE; POROSITY; STRAIN AB The purpose of this study was to evaluate the predictive capability of fabric Total Heat Loss (THL) values on thermal stress that Personal Protective Equipment (PPE) ensemble wearers may encounter while performing work. A series of three tests, consisting of the Sweating Hot Plate (SHP) test on two sample fabrics and the Sweating Thermal Manikin (STM) and human performance tests on two single-layer encapsulating ensembles (fabric/ensemble A = low THL and B = high THL), was conducted to compare THL values between SHP and STM methods along with human thermophysiological responses to wearing the ensembles. In human testing, ten male subjects performed a treadmill exercise at 4.8km and 3% incline for 60min in two environmental conditions (mild = 22 degrees C, 50% relative humidity (RH) and hot/humid = 35 degrees C, 65% RH). The thermal and evaporative resistances were significantly higher on a fabric level as measured in the SHP test than on the ensemble level as measured in the STM test. Consequently the THL values were also significantly different for both fabric types (SHP vs. STM: 191.3vs. 81.5W/m(2) in fabric/ensemble A, and 909.3vs. 149.9W/m(2) in fabric/ensemble B (p < 0.001). Body temperature and heart rate response between ensembles A and B were consistently different in both environmental conditions (p < 0.001), which is attributed to significantly higher sweat evaporation in ensemble B than in A (p < 0.05), despite a greater sweat production in ensemble A (p < 0.001) in both environmental conditions. Further, elevation of microclimate temperature (p < 0.001) and humidity (p < 0.01) was significantly greater in ensemble A than in B. It was concluded that: (1) SHP test determined THL values are significantly different from the actual THL potential of the PPE ensemble tested on STM, (2) physiological benefits from wearing a more breathable PPE ensemble may not be feasible with incremental THL values (SHP test) less than approximately 150-200Wm(2), and (3) the effects of thermal environments on a level of heat stress in PPE ensemble wearers are greater than ensemble thermal characteristics. C1 [Kim, Jung-Hyun; Powell, Jeffery B.; Roberge, Raymond J.; Shepherd, Angie; Coca, Aitor] NIOSH, Natl Personal Protect Technol Lab, Ctr Dis Control & Prevent, Pittsburgh, PA 15236 USA. RP Coca, A (reprint author), NIOSH, Natl Personal Protect Technol Lab, NPPTL, CDC, 626 Cochrans Mill Rd,B29-107, Pittsburgh, PA 15236 USA. EM esq6@cdc.gov NR 28 TC 3 Z9 3 U1 2 U2 15 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 520 CHESTNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1545-9624 EI 1545-9632 J9 J OCCUP ENVIRON HYG JI J. Occup. Environ. Hyg. PD APR 1 PY 2014 VL 11 IS 4 BP 259 EP 267 DI 10.1080/15459624.2013.858820 PG 9 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA AD7ZC UT WOS:000333485000007 PM 24579755 ER PT J AU Field, N Cohen, T Struelens, MJ Palm, D Cookson, B Glynn, JR Gallo, V Ramsay, M Sonnenberg, P MacCannell, D Charlett, A Egger, M Green, J Vineis, P Abubakar, I AF Field, Nigel Cohen, Ted Struelens, Marc J. Palm, Daniel Cookson, Barry Glynn, Judith R. Gallo, Valentina Ramsay, Mary Sonnenberg, Pam MacCannell, Duncan Charlett, Andre Egger, Matthias Green, Jonathan Vineis, Paolo Abubakar, Ibrahim TI Strengthening the Reporting of Molecular Epidemiology for Infectious Diseases (STROME-ID): an extension of the STROBE statement SO LANCET INFECTIOUS DISEASES LA English DT Review ID HEMOLYTIC-UREMIC SYNDROME; MYCOBACTERIUM-TUBERCULOSIS; PHYLOGENETIC ANALYSIS; STRAIN INFECTIONS; HIV TRANSMISSION; HEPATITIS-B; OUTBREAK; BIAS; GENOME; GUIDELINES AB Molecular data are now widely used in epidemiological studies to investigate the transmission, distribution, biology, and diversity of pathogens. Our objective was to establish recommendations to support good scientific reporting of molecular epidemiological studies to encourage authors to consider specific threats to valid inference. The statement Strengthening the Reporting of Molecular Epidemiology for Infectious Diseases (STROME-ID) builds upon the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) initiative. The STROME-ID statement was developed by a working group of epidemiologists, statisticians, bioinformaticians, virologists, and microbiologists with expertise in control of infection and communicable diseases. The statement focuses on issues relating to the reporting of epidemiological studies of infectious diseases using molecular data that were not addressed by STROBE. STROME-ID addresses terminology, measures of genetic diversity within pathogen populations, laboratory methods, sample collection, use of molecular markers, molecular clocks, timeframe, multiple-strain infections, non-independence of infectious-disease data, missing data, ascertainment bias, consistency between molecular and epidemiological data, and ethical considerations with respect to infectiousdisease research. In total, 20 items were added to the 22 item STROBE checklist. When used, the STROME-ID recommendations should advance the quality and transparency of scientific reporting, with clear benefits for evidence reviews and health-policy decision making. C1 [Field, Nigel; Sonnenberg, Pam; Abubakar, Ibrahim] UCL, Dept Infect & Populat Hlth, London WC1E 6JB, England. [Cohen, Ted] Brigham & Womens Hosp, Div Global Hlth Equ, Boston, MA 02115 USA. [Struelens, Marc J.; Palm, Daniel] European Ctr Dis Prevent & Control, Microbiol Coordinat Sect, Stockholm, Sweden. [Cookson, Barry] Ctr Infect Dis Surveillance & Control, Publ Hlth England, Lab Healthcare Associated Infect, London, England. [Charlett, Andre] Ctr Infect Dis Surveillance & Control, Publ Hlth England, Modelling & Econ Dept, London, England. [Green, Jonathan] Ctr Infect Dis Surveillance & Control, Publ Hlth England, Bioinformat Unit, London, England. [Glynn, Judith R.] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London WC1, England. [Gallo, Valentina] Queen Marys Univ, Ctr Primary Care & Publ Hlth, London, England. [MacCannell, Duncan] Natl Ctr Emerging & Zoonot Infect Dis, Ctr Dis Control & Prevent, Atlanta, GA USA. [Egger, Matthias] Univ Bern, Inst Social & Prevent Med, Bern, Switzerland. [Vineis, Paolo] Imperial Coll London, Sch Publ Hlth, London, England. RP Abubakar, I (reprint author), UCL, Inst Epidemiol & Hlth, Fac Populat Hlth Sci, London WC1E 6JB, England. EM i.abubakar@ucl.ac.uk RI Christ Angotti, Melisa/H-6077-2016; Beletini, Lucimara Fatima/H-6083-2016; OI Abubakar, Ibrahim/0000-0002-0370-1430; Sonnenberg, Pam/0000-0002-1067-1583 FU National Institute for Health Research Academic Clinical Lectureship; National Institute for Health Research Senior Research Fellowship FX We thank Mike Catchpole (Health Protection Agency, Centre for Infections, UK), who set up the Centre for Infections, Epidemiology and Surveillance Governance Group, through which this work was initiated. NF is supported by a National Institute for Health Research Academic Clinical Lectureship. IA is supported by a National Institute for Health Research Senior Research Fellowship. NR 81 TC 24 Z9 27 U1 1 U2 16 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1473-3099 EI 1474-4457 J9 LANCET INFECT DIS JI Lancet Infect. Dis. PD APR PY 2014 VL 14 IS 4 BP 341 EP 352 DI 10.1016/S1473-3099(13)70324-4 PG 12 WC Infectious Diseases SC Infectious Diseases GA AD8FJ UT WOS:000333501600023 PM 24631223 ER PT J AU Lakhani, NA Saraiya, M Thompson, TD King, SC Guy, GP AF Lakhani, Naheed A. Saraiya, Mona Thompson, Trevor D. King, Sallyann Coleman Guy, Gery P., Jr. TI Total body skin examination for skin cancer screening among US adults from 2000 to 2010 SO PREVENTIVE MEDICINE LA English DT Article DE Skin cancer; Cancer screening; Early diagnosis of cancer; Melanoma ID UNITED-STATES; AMERICAN-ACADEMY; MELANOMA; PROGRAM AB Objective. Melanoma incidence and mortality are increasing among United States adults. At present, routine skin cancer screening via total body skin examinations (TBSEs) by a physician is not recommended by the United States Preventive Services Task Force (USPSTF); while organizations such as the American Cancer Society recommend screening. Currently, there are limited data on the prevalence, correlates, and trends of TBSE among United States adults. Methods. We analyzed data by race/ethnicity, age, and skin cancer risk level, among other characteristics from three different National Health Interview Survey (NHIS) cancer control supplements conducted every five years since 2000 in random United States households. High-risk status and middle-risk status were defined based on the USPSTF criteria (age, race, sunburn, and family history). Results. Prevalence of having at least one TBSE increased from 14.5 in 2000 to 16.5 in 2005 to 19.8 in 2010 (P < 0.0001). In 2010, screening rates were higher among the elderly, the fair-skinned, those reporting sunburn(s), and individuals with a family history of skin cancer. Approximately 104.7 million (51.1%) U.S. adults are at high-risk for developing melanoma, of which 24.0% had at least one TBSE. Conclusions. TBSE rates have been increasing since 2000 both overall and among higher-risk groups. Data on screening trends could help tailor future prevention strategies. Published by Elsevier Inc. C1 [Lakhani, Naheed A.] Emory Univ, Sch Med, Atlanta, GA 30322 USA. [Saraiya, Mona; Thompson, Trevor D.; King, Sallyann Coleman; Guy, Gery P., Jr.] Natl Ctr Chron Dis Prevent & Hlth Promot, Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA USA. RP Saraiya, M (reprint author), 4770 Buford Highway MS K-76, Atlanta, GA 30341 USA. EM Naheeda786@gmail.com; yzs2@cdc.gov; tkt25@cdc.gov; fjq9@cdc.gov; irm2@cdc.gov FU Intramural CDC HHS [CC999999] NR 17 TC 8 Z9 8 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0091-7435 EI 1096-0260 J9 PREV MED JI Prev. Med. PD APR PY 2014 VL 61 BP 75 EP 80 DI 10.1016/j.ypmed.2014.01.003 PG 6 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA AD8WB UT WOS:000333545300013 PM 24418263 ER PT J AU Menon, R Bhat, G Saade, GR Spratt, H AF Menon, Ramkumar Bhat, Geeta Saade, George R. Spratt, Heidi TI Multivariate adaptive regression splines analysis to predict biomarkers of spontaneous preterm birth SO ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA LA English DT Article DE Prediction model; biomarkers; cytokines; preterm birth; interactions; inflammation ID AMNIOTIC-FLUID; RACIAL DISPARITY; RECEPTORS; PROTEOMICS; GENES; ALPHA; WOMEN AB ObjectiveTo develop classification models of demographic/clinical factors and biomarker data from spontaneous preterm birth in African Americans and Caucasians. DesignSecondary analysis of biomarker data using multivariate adaptive regression splines (MARS), a supervised machine learning algorithm method. SettingAnalysis of data on 36 biomarkers from 191 women was reduced by MARS to develop predictive models for preterm birth in African Americans and Caucasians. SamplesMaternal plasma, cord plasma collected at admission for preterm or term labor and amniotic fluid at delivery. MethodsData were partitioned into training and testing sets. Variable importance, a relative indicator (0-100%) and area under the receiver operating characteristic curve (AUC) characterized results. ResultsMultivariate adaptive regression splines generated models for combined and racially stratified biomarker data. Clinical and demographic data did not contribute to the model. Racial stratification of data produced distinct models in all three compartments. In African Americans maternal plasma samples IL-1RA, TNF-, angiopoietin 2, TNFRI, IL-5, MIP1, IL-1 and TGF- modeled preterm birth (AUC train: 0.98, AUC test: 0.86). In Caucasians TNFR1, ICAM-1 and IL-1RA contributed to the model (AUC train: 0.84, AUC test: 0.68). African Americans cord plasma samples produced IL-12P70, IL-8 (AUC train: 0.82, AUC test: 0.66). Cord plasma in Caucasians modeled IGFII, PDGFBB, TGF-(1), IL-12P70, and TIMP1 (AUC train: 0.99, AUC test: 0.82). Amniotic fluid in African Americans modeled FasL, TNFRII, RANTES, KGF, IGFI (AUC train: 0.95, AUC test: 0.89) and in Caucasians, TNF-, MCP3, TGF-(3), TNFR1 and angiopoietin 2 (AUC train: 0.94 AUC test: 0.79). ConclusionsMultivariate adaptive regression splines models multiple biomarkers associated with preterm birth and demonstrated racial disparity. C1 [Menon, Ramkumar; Bhat, Geeta; Saade, George R.] Univ Texas Med Branch, Dept Obstet & Gynecol, Div Maternal Fetal Med Perinatal Res, Galveston, TX 77555 USA. [Menon, Ramkumar; Bhat, Geeta; Saade, George R.] CDC, Atlanta, GA 30333 USA. [Spratt, Heidi] Univ Texas Med Branch, Dept Epidemiol & Biostat, Galveston, TX 77555 USA. RP Menon, R (reprint author), MRB, 301 Univ Blvd,Room 11-138, Galveston, TX 77555 USA. EM ram.menon@utmb.edu FU March of Dimes Perinatal Research Initiative [21-FY08-594] FX This study is supported by March of Dimes Perinatal Research Initiative Grants to Dr Menon (no. 21-FY08-594). NR 24 TC 10 Z9 11 U1 0 U2 10 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0001-6349 EI 1600-0412 J9 ACTA OBSTET GYN SCAN JI Acta Obstet. Gynecol. Scand. PD APR PY 2014 VL 93 IS 4 BP 382 EP 391 DI 10.1111/aogs.12344 PG 10 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA AD3MR UT WOS:000333150700009 PM 24461165 ER PT J AU Flax, VL Bentley, ME Combs, GF Chasela, CS Kayira, D Tegha, G Kamwendo, D Daza, EJ Fokar, A Kourtis, AP Jamieson, DJ van der Horst, CM Adair, LS AF Flax, Valerie L. Bentley, Margaret E. Combs, Gerald F., Jr. Chasela, Charles S. Kayira, Dumbani Tegha, Gerald Kamwendo, Debbie Daza, Eric J. Fokar, Ali Kourtis, Athena P. Jamieson, Denise J. van der Horst, Charles M. Adair, Linda S. TI Plasma and breast-milk selenium in HIV-infected Malawian mothers are positively associated with infant selenium status but are not associated with maternal supplementation: results of the Breastfeeding, Antiretrovirals, and Nutrition study SO AMERICAN JOURNAL OF CLINICAL NUTRITION LA English DT Article ID GLUTATHIONE-PEROXIDASE ACTIVITY; PREGNANT-WOMEN; GENITAL-TRACT; BLOOD; ZINC; TUBERCULOSIS; DEFICIENCY; LACTATION; MORTALITY; CHILDREN AB Background: Selenium is found in soils and is essential for human antioxidant defense and immune function. In Malawi, low soil selenium and dietary intakes coupled with low plasma selenium concentrations in HIV infection could have negative consequences for the health of HIV-infected mothers and their exclusively breastfed infants. Objective: We tested the effects of lipid-based nutrient supplements (LNS) that contained 1.3 times the Recommended Dietary Allowance of sodium selenite and antiretroviral drugs (ARV) on maternal plasma and breast-milk selenium concentrations. Design: HIV-infected Malawian mothers in the Breastfeeding, Antiretrovirals, and Nutrition study were randomly assigned at delivery to receive: LNS, ARV, LNS and ARV, or a control. In a subsample of 526 mothers and their uninfected infants, we measured plasma and breast-milk selenium concentrations at 2 or 6 (depending on the availability of infant samples) and 24 wk postpartum. Results: Overall, mean (+/- SD) maternal (range: 81.2 6 20.4 to 86.2 6 19.9 mu g/ L) and infant (55.6 +/- 16.3 to 61.0 +/- 15.4 mu g/L) plasma selenium concentrations increased, whereas breast-milk selenium concentrations declined (14.3 +/- 11.5 to 9.8 +/- 7.3 mu g/L) from 2 or 6 to 24 wk postpartum (all P < 0.001). Compared with the highest baseline selenium tertile, low and middle tertiles were positively associated with a change in maternal plasma or breast-milk selenium from 2 or 6 to 24 wk postpartum (both P < 0.001). With the use of linear regression, we showed that LNS that contained selenium and ARV were not associated with changes in maternal plasma and breast-milk selenium, but maternal selenium concentrations were positively associated with infant plasma selenium at 2 or 6 and 24 wk postpartum (P < 0.001) regardless of the study arm. Conclusions: Selenite supplementation of HIV-infected Malawian women was not associated with a change in their plasma or breast-milk selenium concentrations. Future research should examine effects of more readily incorporated forms of selenium (ie, selenomethionine) in HIV-infected breastfeeding women. This trial was registered at clinicaltrials. gov as NCT00164736. C1 [Flax, Valerie L.; Bentley, Margaret E.; Daza, Eric J.; Adair, Linda S.] Univ N Carolina, Carolina Populat Ctr, Sch Med, Chapel Hill, NC 27516 USA. [Flax, Valerie L.; Bentley, Margaret E.; Adair, Linda S.] Univ N Carolina, Dept Nutr, Sch Med, Chapel Hill, NC 27516 USA. [Daza, Eric J.] Univ N Carolina, Dept Biostat, Sch Med, Chapel Hill, NC 27516 USA. [Fokar, Ali; van der Horst, Charles M.] Univ N Carolina, Div Infect Dis, Sch Med, Chapel Hill, NC 27516 USA. [Combs, Gerald F., Jr.] ARS, USDA, Grand Forks Human Nutr Res Ctr, Grand Forks, ND USA. [Chasela, Charles S.; Kayira, Dumbani; Tegha, Gerald; Kamwendo, Debbie] Univ North Carolina Project, Lilongwe, Malawi. [Chasela, Charles S.] Univ Witwatersrand, Sch Publ Hlth, Div Epidemiol & Biostat, Parktown, South Africa. [Kourtis, Athena P.; Jamieson, Denise J.] US CDC, Atlanta, GA USA. RP Flax, VL (reprint author), Univ N Carolina, Carolina Populat Ctr, Campus Box 8120, Chapel Hill, NC 27516 USA. EM flax@unc.edu OI Flax, Valerie/0000-0003-0200-3355 FU Bill & Melinda Gates Foundation [OPP53107]; National Institute of Allergy and Infectious Diseases; University of North Carolina Center for AIDS Research [P30-AI50410]; Carolina Population Center [R24 HD050924]; NIH Fogarty AIDS International Training and Research Program (DHHS/NIH/FIC) [2-D43 TW001039, R24TW007988]; Elizabeth Glaser Pediatric AIDS Foundation; United Nations Children's Fund; World Food Program; Malawi Ministry of Health and Population; Johnson Johnson; US Agency for International Development; Prevention Research Centers Special Interest Project of the CDC [SIP 13-01 U48-CCU409660-09, SIP 26-04 U48-DP000059-01, SIP 22-09 U48-DP001944-01] FX The Breastfeeding, Antiretrovirals, and Nutrition (BAN) study was supported by grants from the Prevention Research Centers Special Interest Project of the CDC (SIP 13-01 U48-CCU409660-09, SIP 26-04 U48-DP000059-01, and SIP 22-09 U48-DP001944-01), the Bill & Melinda Gates Foundation (OPP53107), the National Institute of Allergy and Infectious Diseases, the University of North Carolina Center for AIDS Research (P30-AI50410), the Carolina Population Center (R24 HD050924), and the NIH Fogarty AIDS International Training and Research Program (DHHS/NIH/FIC 2-D43 TW001039 and R24TW007988; the American Recovery and Reinvestment Act). The Call to Action Prevention of Mother-To-Child Transmission program, from which BAN mothers were recruited, was supported by the Elizabeth Glaser Pediatric AIDS Foundation, the United Nations Children's Fund, the World Food Program, the Malawi Ministry of Health and Population, Johnson & Johnson, and the US Agency for International Development. Antiretrovirals used in the BAN study were donated by Abbott Laboratories, GlaxoSmithKline, Boehringer Ingelheim, Roche Pharmaceuticals, and Bristol-Myers Squibb. NR 47 TC 1 Z9 1 U1 0 U2 12 PU AMER SOC NUTRITION-ASN PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0002-9165 EI 1938-3207 J9 AM J CLIN NUTR JI Am. J. Clin. Nutr. PD APR PY 2014 VL 99 IS 4 BP 950 EP 956 DI 10.3945/ajcn.113.073833 PG 7 WC Nutrition & Dietetics SC Nutrition & Dietetics GA AD3VA UT WOS:000333173100023 PM 24500152 ER PT J AU Boothe, VL Boehmer, TK Wendel, AM Yip, FY AF Boothe, Vickie L. Boehmer, Tegan K. Wendel, Arthur M. Yip, Fuyuen Y. TI Residential Traffic Exposure and Childhood Leukemia A Systematic Review and Meta-analysis SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Review ID ACUTE LYMPHOBLASTIC-LEUKEMIA; HAZARDOUS AIR-POLLUTANTS; CANCER INCIDENCE; SOCIOECONOMIC-STATUS; PARENTAL EXPOSURE; PUBLICATION BIAS; RISK-FACTOR; HEALTH; DENSITY; POLLUTION AB Context: Exposure to elevated concentrations of traffic-related air pollutants in the near-road environment is associated with numerous adverse human health effects, including childhood cancer, which has been increasing since 1975. Results of individual epidemiologic studies have been inconsistent. Therefore, a meta-analysis was performed to examine the association between residential traffic exposure and childhood cancer. Evidence acquisition: Studies published between January 1980 and July 2011 were retrieved from a systematic search of 18 bibliographic databases. Nine studies meeting the inclusion criteria were identified. Weighted summary ORs were calculated using a random effects model for outcomes with four or more studies. Subgroup and sensitivity analyses were performed. Evidence synthesis: Childhood leukemia was positively associated (summary OR=1.53, 95% CI=1.12, 2.10) with residential traffic exposure among seven studies using a postnatal exposure window (e.g., childhood period or diagnosis address) and there was no association (summary OR=0.92, 95% CI=0.78, 1.09) among four studies using a prenatal exposure window (e.g., pregnancy period or birth address). There were too few studies to analyze other childhood cancer outcomes. Conclusions: Current evidence suggests that childhood leukemia is associated with residential traffic exposure during the postnatal period, but not during the prenatal period. Additional well-designed epidemiologic studies that use complete residential history to estimate traffic exposure, examine leukemia subtypes, and control for potential confounding factors are needed to confirm these findings. As many people reside near busy roads, especially in urban areas, precautionary public health messages and interventions designed to reduce population exposure to traffic might be warranted. Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Boothe, Vickie L.] CDC, Off Publ Hlth Sci Serv, Div Epidemiol Anal & Lib Serv, Analyt Tools & Methods Branch, Atlanta, GA 30333 USA. [Boehmer, Tegan K.; Yip, Fuyuen Y.] CDC, Natl Ctr Environm Hlth, Div Environm Hazards & Hlth Effects, Air Pollut & Resp Hlth Branch, Atlanta, GA 30333 USA. [Wendel, Arthur M.] CDC, Natl Ctr Environm Hlth, Div Emergency & Environm Hlth Serv, Hlth Community Design Initiat, Atlanta, GA 30333 USA. RP Boothe, VL (reprint author), CDC, 1600 Clifton Rd NE,MS E-33, Atlanta, GA 30333 USA. EM veb6@cdc.gov NR 68 TC 23 Z9 23 U1 5 U2 29 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD APR PY 2014 VL 46 IS 4 BP 413 EP 422 DI 10.1016/j.amepre.2013.11.004 PG 10 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA AD4YM UT WOS:000333257900012 PM 24650845 ER PT J AU McMahon, BJ Bulkow, L Simons, B Zhang, YH Negus, S Homan, C Spradling, P Teshale, E Lau, D Snowball, M Livingston, SE AF McMahon, Brian J. Bulkow, Lisa Simons, Brenna Zhang, Yuhong Negus, Susan Homan, Chriss Spradling, Philip Teshale, Eyasu Lau, Daryl Snowball, Mary Livingston, Stephen E. TI Relationship Between Level of Hepatitis B Virus DNA and Liver Disease: A Population-based Study of Hepatitis B e Antigen-Negative Persons With Hepatitis B SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY LA English DT Article DE HBV Genotype; Liver Biopsy; HBsAg ID SURFACE-ANTIGEN; GENOTYPE-D; INFECTION; AMINOTRANSFERASE; MANAGEMENT; CLEARANCE; CARRIERS; UPDATE; COHORT AB BACKGROUND & AIMS: There is little information on the proportion of persons with chronic hepatitis B virus (HBV) infection with active hepatitis. We aimed to determine the proportion of persons with hepatitis B e antigen-negative chronic HBV infection who develop immune-active HBV infection over time and the relationship between demographic and viral factors on severity of disease on liver biopsy. METHODS: We performed a longitudinal population-based cohort study of 754 Alaska Native patients with chronic HBV infection. Levels of alanine aminotransferase (ALT) were measured every 6 months, and levels of HBV DNA were measured at study entry and whenever ALT levels exceeded the upper limit of normal (ULN). Immune-active chronic HBV infection was defined as levels of ALT >= 30 U/L in men and > 20 U/L in women and levels of HBV DNA > 2000 IU/mL at 1 or more time points from 2001-2008. Liver biopsies were scored by using the modified histology activity index score of Knodell and the Ishak fibrosis score. RESULTS: Of the study participants, 186 (25%) met the criteria for immune-active HBV, 56% of these initially and 44% later during follow up. Of the 38 patients with liver biopsy results, only 1 of 16 with ALT levels consistently below twice the ULN and 1 of 19 with HBV DNA between 2000 and 20,000 IU/mL, vs 12 of 22 (55%) with ALT > twice ULN (P = .002) and 11 of 18 (61%) with 1 or more measurements of HBV DNA > 20,000 IU/mL (P < .001), had moderate or severe hepatitis or fibrosis. CONCLUSIONS: In a cohort of Alaska Natives with chronic HBV infection, 25% met criteria for immune-active HBV. There is a low probability of advanced fibrosis if levels of HBV DNA never exceed 20,000 IU/mL. C1 [McMahon, Brian J.; Simons, Brenna; Negus, Susan; Homan, Chriss; Snowball, Mary; Livingston, Stephen E.] Alaska Nat Tribal Hlth Consortium, Liver Dis & Hepatitis Program, Anchorage, AK 99508 USA. [McMahon, Brian J.; Bulkow, Lisa] CDC, Natl Ctr Emerging & Zoonot Infect Dis, Div Preparedness & Emerging Infect, Arct Invest Program, Anchorage, AK USA. [Zhang, Yuhong; Lau, Daryl] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Gastroenterol,Liver Ctr, Boston, MA USA. [Spradling, Philip; Teshale, Eyasu] CDC, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preve, Atlanta, GA USA. RP Livingston, SE (reprint author), Alaska Nat Tribal Hlth Consortium, Liver Dis & Hepatitis Program, 4315 Diplomacy Dr, Anchorage, AK 99508 USA. EM slivings@anthc.org FU National Institutes of Health Native American Research Centers for Health [1 U26 94 00005]; Centers for Disease Control and Prevention [U50 CCU022279, U0I PS001097]; Alaska Native Tribal Health Consortium; Arctic Investigations Program, CDC, Anchorage, Alaska FX Supported by National Institutes of Health Native American Research Centers for Health grant 1 U26 94 00005, Centers for Disease Control and Prevention grants U50 CCU022279 and U0I PS001097, and additional support from the Alaska Native Tribal Health Consortium and the Arctic Investigations Program, CDC, Anchorage, Alaska. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 14 TC 5 Z9 6 U1 1 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1542-3565 EI 1542-7714 J9 CLIN GASTROENTEROL H JI Clin. Gastroenterol. Hepatol. PD APR PY 2014 VL 12 IS 4 BP 701 EP + DI 10.1016/j.cgh.2013.09.005 PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AD2IF UT WOS:000333057500031 PM 24035774 ER PT J AU Dotson, WD Douglas, MP Kolor, K Stewart, AC Bowen, MS Gwinn, M Wulf, A Anders, HM Chang, CQ Clyne, M Lam, TK Schully, SD Marrone, M Feero, WG Khoury, MJ AF Dotson, W. D. Douglas, M. P. Kolor, K. Stewart, A. C. Bowen, M. S. Gwinn, M. Wulf, A. Anders, H. M. Chang, C. Q. Clyne, M. Lam, T. K. Schully, S. D. Marrone, M. Feero, W. G. Khoury, M. J. TI Prioritizing Genomic Applications for Action by Level of Evidence: A Horizon-Scanning Method SO CLINICAL PHARMACOLOGY & THERAPEUTICS LA English DT Review ID PHARMACOGENETICS IMPLEMENTATION CONSORTIUM; EGAPP-WORKING-GROUP; THIOPURINE METHYLTRANSFERASE GENOTYPE; SEROTONIN REUPTAKE INHIBITORS; IMPROVE HEALTH OUTCOMES; HLA-B GENOTYPE; CLINICAL PHARMACOGENETICS; NONPSYCHOTIC DEPRESSION; CLOPIDOGREL THERAPY; INCIDENTAL FINDINGS AB As evidence accumulates on the use of genomic tests and other health-related applications of genomic technologies, decision makers may increasingly seek support in identifying which applications have sufficiently robust evidence to suggest they might be considered for action. As an interim working process to provide such support, we developed a horizon-scanning method that assigns genomic applications to tiers defined by availability of synthesized evidence. We illustrate an application of the method to pharmacogenomics tests. C1 [Dotson, W. D.; Douglas, M. P.; Kolor, K.; Stewart, A. C.; Bowen, M. S.; Gwinn, M.; Wulf, A.; Anders, H. M.; Khoury, M. J.] Ctr Dis Control & Prevent, Off Publ Hlth Genom, Atlanta, GA 30333 USA. [Douglas, M. P.; Stewart, A. C.; Gwinn, M.; Anders, H. M.] McKing Consulting Corp, Atlanta, GA USA. [Wulf, A.] Cadence Grp, Atlanta, GA USA. [Chang, C. Q.; Clyne, M.; Lam, T. K.; Schully, S. D.; Khoury, M. J.] NCI, Epidemiol & Genom Res Program, Bethesda, MD 20892 USA. [Clyne, M.] Kelly Serv, Troy, MI USA. [Marrone, M.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Feero, W. G.] Maine Dartmouth Family Med Residency Program, Augusta, ME USA. RP Dotson, WD (reprint author), Ctr Dis Control & Prevent, Off Publ Hlth Genom, Atlanta, GA 30333 USA. EM wdotson@cdc.gov OI Dotson, William David/0000-0002-9606-6594 FU Intramural CDC HHS [CC999999] NR 70 TC 8 Z9 8 U1 4 U2 9 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0009-9236 EI 1532-6535 J9 CLIN PHARMACOL THER JI Clin. Pharmacol. Ther. PD APR PY 2014 VL 95 IS 4 BP 394 EP 402 DI 10.1038/clpt.2013.226 PG 9 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA AD4ZP UT WOS:000333261200013 PM 24398597 ER PT J AU Weissman, DN AF Weissman, David N. TI Medical surveillance for the emerging occupational and environmental respiratory diseases SO CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Review DE constrictive bronchiolitis; medical surveillance; respiratory disease; spirometry; World Trade Center ID LUNG-DISEASE; CONSTRICTIVE BRONCHIOLITIS; OBLITERATIVE BRONCHIOLITIS; MANUFACTURING WORKERS; CALIFORNIA; INDUSTRY AB Purpose of reviewTo highlight the important issues to consider in deciding whether to pursue and how to conduct medical surveillance for the emerging occupational and environmental respiratory diseases. It provides several recent examples illustrating implementation and usefulness of medical surveillance and the lessons learned from these experiences.Recent findingsMedical surveillance conducted after sentinel outbreaks of constrictive bronchiolitis in microwave popcorn and flavoring production plants have shown the usefulness of this approach in documenting the burden of disease, identifying particular problem areas as targets for preventive interventions, and in tracking the progress. They have also identified the usefulness of longitudinal spirometry, which allows comparison of the individuals' results to their own previous tests. The importance of recognizing a sentinel outbreak needing greater investigation is demonstrated by the cluster of cases of constrictive bronchiolitis recognized in military veterans returning from Iraq and Afghanistan. The World Trade Center disaster has demonstrated the importance of having baseline lung function data for future comparison and the importance of rapidly identifying exposed populations at greatest risk for health effects, and thus potentially having the greatest benefit from medical surveillance.SummaryWhen used appropriately, medical surveillance is a useful tool in addressing the emerging occupational and environmental respiratory diseases by facilitating improvements in primary prevention and enabling interventions to help individuals through secondary prevention. C1 [Weissman, David N.] NIOSH, Div Resp Dis Studies, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA. RP Weissman, DN (reprint author), NIOSH, 1095 Willowdale Rd, Morgantown, WV 26505 USA. EM DWeissman@cdc.gov FU Intramural CDC HHS [CC999999] NR 19 TC 2 Z9 2 U1 1 U2 15 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1528-4050 EI 1473-6322 J9 CURR OPIN ALLERGY CL JI Curr. Opin. Allergy Clin. Immunol. PD APR PY 2014 VL 14 IS 2 BP 119 EP 125 DI 10.1097/ACI.0000000000000033 PG 7 WC Allergy; Immunology SC Allergy; Immunology GA AD4XX UT WOS:000333256200007 PM 24500294 ER PT J AU Robson, MJ Turner, RC Naser, ZJ McCurdy, CR O'Callaghan, JP Huber, JD Matsumoto, RR AF Robson, Matthew J. Turner, Ryan C. Naser, Zachary J. McCurdy, Christopher R. O'Callaghan, James P. Huber, Jason D. Matsumoto, Rae R. TI SN79, a sigma receptor antagonist, attenuates methamphetamine-induced astrogliosis through a blockade of OSMR/gp130 signaling and STAT3 phosphorylation SO EXPERIMENTAL NEUROLOGY LA English DT Article DE Sigma receptor; Methamphetamine neurotoxicity; Glia; Astrocyte; Neuroinflammation ID TRAUMATIC BRAIN-INJURY; IN-VIVO; UP-REGULATION; ONCOSTATIN-M; FLUORO-JADE; PHARMACOLOGICAL EVALUATION; INTERLEUKIN-6 EXPRESSION; PROTEIN-PHOSPHORYLATION; MICROGLIAL ACTIVATION; INDUCED NEUROTOXICITY AB Methamphetamine (METH) exposure results in dopaminergic neurotoxicity in striatal regions of the brain, an effect that has been linked to an increased risk of Parkinson's disease. Various aspects of neuroinflammation, including astrogliosis, are believed to be contributory factors in METH neurotoxicity. METH interacts with sigma receptors at physiologically relevant concentrations and treatment with sigma receptor antagonists has been shown to mitigate METH-induced neurotoxicity in rodent models. Whether these compounds alter the responses of glial cells within the central nervous system to METH however has yet to be determined. Therefore, the purpose of the current study was to determine whether the sigma receptor antagonist, SN79, mitigates METH-induced striatal reactive astrogliosis. Male, Swiss Webster mice treated with a neurotoxic regimen of METH exhibited time-dependent increases in striatal gfap mRNA and concomitant increases in GFAP protein, indicative of astrogliosis. This is the first report that similar to other neurotoxicants that induce astrogliosis through the activation of JAK2/STAT3 signaling by stimulating gp-130-linked cytokine signaling resulting from neuroinflammation, METH treatment also increases astrocytic oncostatin m receptor (OSMR) expression and the phosphorylation of STAT3 (Tyr-705) in vivo. Pretreatment with SN79 blocked METH-induced increases in OSMR, STAT3 phosphorylation and astrocyte activation within the striatum. Additionally, METH treatment resulted in striatal cellular degeneration as measured by Fluoro-Jade B, an effect that was mitigated by SN79. The current study provides evidence that sigma receptor antagonists attenuate METH-induced astrocyte activation through a pathway believed to be shared by various neurotoxicants. (c) 2014 Elsevier Inc. All rights reserved. C1 [Robson, Matthew J.; Huber, Jason D.; Matsumoto, Rae R.] W Virginia Univ, Sch Pharm, Dept Basic Pharmaceut Sci, Hlth Sci Ctr, Morgantown, WV 26506 USA. [Robson, Matthew J.] Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA. [Turner, Ryan C.; Naser, Zachary J.] W Virginia Univ, Sch Med, Dept Neurosurg, Hlth Sci Ctr, Morgantown, WV 26506 USA. [Turner, Ryan C.; Huber, Jason D.; Matsumoto, Rae R.] W Virginia Univ, Sch Med, Ctr Neurosci, Hlth Sci Ctr, Morgantown, WV 26506 USA. [McCurdy, Christopher R.] Univ Mississippi, Sch Pharm, Dept Med Chem, University, MS 38677 USA. [McCurdy, Christopher R.] Univ Mississippi, Sch Pharm, Dept Pharmacol, University, MS 38677 USA. [O'Callaghan, James P.] Ctr Dis Control & Prevent, Hlth Effects Lab Div, NIOSH, Morgantown, WV 26505 USA. RP Matsumoto, RR (reprint author), W Virginia Univ, Sch Pharm, 1 Med Ctr Dr, Morgantown, WV 26506 USA. EM rmatsumoto@hsc.wvu.edu RI Robson, Matthew/H-3127-2013; OI Robson, Matthew/0000-0002-3277-3062; Turner, Ryan/0000-0001-5523-0645 FU National Institutes of Health [DA013978, DA023205, NS061954, T32 NS007491, T32 GM081741] FX This research was supported by grants from the National Institutes of Health (DA013978, DA023205, and NS061954). Matthew J. Robson was supported by a grant from the National Institutes of Health (T32 NS007491). Ryan C. Turner was supported by a grant from the National Institutes of Health (T32 GM081741). NR 77 TC 14 Z9 14 U1 1 U2 4 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0014-4886 EI 1090-2430 J9 EXP NEUROL JI Exp. Neurol. PD APR PY 2014 VL 254 BP 180 EP 189 DI 10.1016/j.expneurol.2014.01.020 PG 10 WC Neurosciences SC Neurosciences & Neurology GA AD5VM UT WOS:000333321300019 PM 24508558 ER PT J AU Singh, R Gupta, P Sharma, PK Ades, EW Hollingshead, SK Singh, S Lillard, JW AF Singh, Rajesh Gupta, Pranav Sharma, Praveen K. Ades, Edwin W. Hollingshead, Susan K. Singh, Shailesh Lillard, James W. TI Prediction and characterization of helper T-cell epitopes from pneumococcal surface adhesin A SO IMMUNOLOGY LA English DT Article DE MHC; peptide vaccine; Streptococcus pneumoniae; T helper type 1; 2 cytokine ID STREPTOCOCCUS-PNEUMONIAE; PEPTIDE BINDING; WALL POLYSACCHARIDE; INVARIANT CHAIN; MHC MOLECULES; HOST-DEFENSE; ANTIGEN; MICE; PSAA; PROTEIN AB Pneumococcal surface adhesin A (PsaA) is a multifunctional lipoprotein known to bind nasopharyngeal epithelial cells, and is significantly involved in bacterial adherence and virulence. Identification of PsaA peptides that optimally bind human leucocyte antigen (HLA) and elicit a potent immune response would be of great importance to vaccine development. However, this is hindered by the multitude of HLA polymorphisms in humans. To identify the conserved immunodominant epitopes, we used an experimental dataset of 28 PsaA synthetic peptides and in silico methods to predict specific peptide-binding to HLA and murine MHC class II molecules. We also characterized spleen and cervical lymph node (CLN) -derived T helper (Th) lymphocyte cytokine responses to these peptides after Streptococcus pneumoniae strain EF3030 challenge in mice. Individual, yet overlapping, peptides 15 amino acids in length revealed residues of PsaA that consistently caused the highest interferon-, interleukin-2 (IL-2), IL-5 and IL-17 responses and proliferation as well as moderate IL-10 and IL-4 responses by ex vivo re-stimulated splenic and CLN CD4(+) T cells isolated from S.pneumoniae strain EF3030-challenged F-1 (B6x BALB/c) mice. In silico analysis revealed that peptides from PsaA may interact with a broad range of HLA-DP, -DQ and -DR alleles, due in part to regions lacking -turns and asparagine endopeptidase sites. These data suggest that Th cell peptides (7, 19, 20, 22, 23 and 24) screened for secondary structures and MHC class II peptide-binding affinities can elicit T helper cytokine and proliferative responses to PsaA peptides. C1 [Singh, Rajesh; Gupta, Pranav; Singh, Shailesh; Lillard, James W.] Morehouse Sch Med, Dept Microbiol Biochem & Immunol, Atlanta, GA 30310 USA. [Sharma, Praveen K.] Cent Univ Jharkhand, Sch Nat Sci, Ctr Life Sci, Ranchi, Bihar, India. [Ades, Edwin W.] Ctr Dis Control & Prevent, Div Bacterial Dis, Atlanta, GA USA. [Hollingshead, Susan K.] Univ Alabama Birmingham, Sch Med, Dept Microbiol, Birmingham, AL 35294 USA. RP Lillard, JW (reprint author), Morehouse Sch Med, Dept Microbiol Biochem & Immunol, 720 Westview Dr SW, Atlanta, GA 30310 USA. EM jlillard@msm.edu RI Sharma, Praveen/M-2810-2014 OI Sharma, Praveen/0000-0002-7020-3570 FU National Institute of Health [AI057808, MD007602, RR03034] FX This study was supported by funds from the National Institute of Health Grants AI057808, MD007602, and RR03034. The contents of this manuscript benefitted from many fruitful conversations with colleagues at Morehouse School of Medicine and the University of Alabama at Birmingham. NR 51 TC 2 Z9 3 U1 1 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0019-2805 EI 1365-2567 J9 IMMUNOLOGY JI Immunology PD APR PY 2014 VL 141 IS 4 BP 514 EP 530 DI 10.1111/imm.12194 PG 17 WC Immunology SC Immunology GA AC4EQ UT WOS:000332474100005 PM 24138116 ER PT J AU Sutton, MY Lasswell, SM Lanier, Y Miller, KS AF Sutton, Madeline Y. Lasswell, Sarah M. Lanier, Yzette Miller, Kim S. TI Impact of Parent-Child Communication Interventions on Sex Behaviors and Cognitive Outcomes for Black/African-American and Hispanic/Latino Youth: A Systematic Review, 1988-2012 SO JOURNAL OF ADOLESCENT HEALTH LA English DT Review DE Youth; Black/African-American; Hispanic/Latino; Parent-child communication; Sex outcomes; Disparities ID SEXUALLY-TRANSMITTED-DISEASES; PREGNANCY PREVENTION PROGRAM; AFRICAN-AMERICAN; HIV PREVENTION; RISK BEHAVIORS; RANDOMIZED-TRIAL; MONITORING INTERVENTION; ADOLESCENT PREGNANCY; FAMILIES PROGRAM; REDUCTION AB Purpose: We reviewed human immunodeficiency virus (HIV) and sexually transmitted infection (STI)- behavioral interventions implemented with disproportionately affected black/African-American and Hispanic/Latino youth and designed to improve parent-child communications about sex. We compared their effectiveness in improving sex-related behavior or cognitive outcomes. Methods: A search of electronic databases identified peer-reviewed studies published between 1988 and 2012. Eligible studies were U. S.-based parent-child communication interventions with active parent components, experimental and quasiexperimental designs, measurement of youth sexual health outcomes, and enrollment of >= 50% black/African-American or Hispanic/Latino youth. We conducted systematic, primary reviews of eligible papers to abstract data on study characteristics and youth outcomes. Results: Fifteen studies evaluating 14 interventions were eligible. Although youth outcome measures and follow-up times varied, 13 of 15 studies (87%) showed at least one significantly improved youth sexual health outcome compared with controls (p < .05). Common components of effective interventions included joint parent and child session attendance, promotion of parent/family involvement, sexuality education for parents, developmental and/or cultural tailoring, and opportunities for parents to practice new communication skills with their youth. Conclusions: Parent-child communication interventions that include parents of youth disproportionately affected by HIV/STIs can effectively reduce sexual risk for youth. These interventions may help reduce HIV/STI-related health disparities and improve sexual health outcomes. Published by Elsevier Inc. on behalf of Society for Adolescent Health and Medicine. C1 [Sutton, Madeline Y.; Lasswell, Sarah M.; Lanier, Yzette; Miller, Kim S.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. [Lanier, Yzette] Univ Penn, Sch Nursing, Ctr Global Womens Hlth, Philadelphia, PA 19104 USA. [Lanier, Yzette] Ctr Hlth Equ Res, Philadelphia, PA USA. RP Sutton, MY (reprint author), DHAP NCHHSTP CDC, 1600 Clifton Rd NE MS E-45, Atlanta, GA 30333 USA. EM msutton@cdc.gov NR 74 TC 11 Z9 11 U1 4 U2 31 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X EI 1879-1972 J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD APR PY 2014 VL 54 IS 4 BP 369 EP 384 DI 10.1016/j.jadohealth.2013.11.004 PG 16 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA AD4YT UT WOS:000333258700003 PM 24388108 ER PT J AU Walsh, K Latzman, NE Latzman, RD AF Walsh, Kate Latzman, Natasha E. Latzman, Robert D. TI Pathway From Child Sexual and Physical Abuse to Risky Sex Among Emerging Adults: The Role of Trauma-Related Intrusions and Alcohol Problems SO JOURNAL OF ADOLESCENT HEALTH LA English DT Article DE Child abuse; Sexual risk behavior; Traumatic intrusions; Alcohol problems ID POSTTRAUMATIC-STRESS-DISORDER; TRANSMITTED-DISEASES; COLLEGE-STUDENTS; BEHAVIOR; WOMEN; VALIDATION; HIV; CONSEQUENCES; DRINKING; IDAS AB Purpose: Some evidence suggests that risk reduction programming for sexual risk behaviors (SRB) has been minimally effective, which emphasized the need for research on etiological and mechanistic factors that can be addressed in prevention and intervention programming. Childhood sexual and physical abuse have been linked with SRB among older adolescents and emerging adults; however, pathways to SRB remain unclear. This study adds to the literature by testing a model specifying that traumatic intrusions after early abuse may increase risk for alcohol problems, which in turn may increase the likelihood of engaging in various types of SRB. Methods: Participants were 1,169 racially diverse college students (72.9% female, 37.6% black/African-American, and 33.6% white) who completed anonymous questionnaires assessing child abuse, traumatic intrusions, alcohol problems, and sexual risk behavior. Results: The hypothesized path model specifying that traumatic intrusions and alcohol problems account for associations between child abuse and several aspects of SRB was a good fit for the data; however, for men, stronger associations emerged between physical abuse and traumatic intrusions and between traumatic intrusions and alcohol problems, whereas for women, alcohol problems were more strongly associated with intent to engage in risky sex. Conclusions: Findings highlight the role of traumatic intrusions and alcohol problems in explaining paths from childhood abuse to SRB in emerging adulthood, and suggest that risk reduction programs may benefit from an integrated focus on traumatic intrusions, alcohol problems, and SRB for individuals with abuse experiences. (C) 2014 Society for Adolescent Health and Medicine. All rights reserved. C1 [Walsh, Kate] Columbia Univ, Dept Epidemiol, New York, NY USA. [Latzman, Natasha E.] Ctr Dis Control & Prevent, Div Violence Prevent, Natl Ctr Injury Control & Prevent, Atlanta, GA USA. [Latzman, Robert D.] Georgia State Univ, Dept Psychol, Atlanta, GA 30303 USA. RP Walsh, K (reprint author), 722 West 168th St,Room 520, New York, NY 10032 USA. EM klw2153@columbia.edu FU National Institutes of Health, National Institute on Drug Abuse [T32DA031099] FX Manuscript preparation was partially supported by Grant T32DA031099 from the National Institutes of Health, National Institute on Drug Abuse (to K.W.). NR 39 TC 11 Z9 11 U1 0 U2 19 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X EI 1879-1972 J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD APR PY 2014 VL 54 IS 4 BP 442 EP 448 DI 10.1016/j.jadohealth.2013.09.020 PG 7 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA AD4YT UT WOS:000333258700012 PM 24268710 ER PT J AU Farrelly, MC Loomis, BR Kuiper, N Han, B Gfroerer, J Caraballo, RS Pechacek, TF Couzens, GL AF Farrelly, Matthew C. Loomis, Brett R. Kuiper, Nicole Han, Beth Gfroerer, Joseph Caraballo, Ralph S. Pechacek, Terry F. Couzens, G. Lance TI Are Tobacco Control Policies Effective in Reducing Young Adult Smoking? SO JOURNAL OF ADOLESCENT HEALTH LA English DT Article DE Smoking; Young adults; Smoke-free air laws; Cigarette prices; Tobacco control programs ID CONTROL PROGRAMS; PUBLIC-POLICY; UNITED-STATES; PROMOTIONS; IMPACT; ADOLESCENT; CIGARETTES; DOCUMENTS; TAX; BAR AB Purpose: We examined the influence of tobacco control program funding, smoke-free air laws, and cigarette prices on young adult smoking outcomes. Methods: We use a natural experimental design approach that uses the variation in tobacco control policies across states and over time to understand their influence on tobacco outcomes. We combine individual outcome data with annual state-level policy data to conduct multivariable logistic regression models, controlling for an extensive set of sociodemographic factors. The participants are 18- to 25-year-olds from the 2002-2009 National Surveys on Drug Use and Health. The three main outcomes are past-year smoking initiation, and current and established smoking. A current smoker was one who had smoked on at least 1 day in the past 30 days. An established smoker was one who had smoked 1 or more cigarettes in the past 30 days and smoked at least 100 cigarettes in his or her lifetime. Results: Higher levels of tobacco control program funding and greater smoke-free-air law coverage were both associated with declines in current and established smoking (p < .01). Greater coverage of smoke-free air laws was associated with lower past year initiation with marginal significance (p = .058). Higher cigarette prices were not associated with smoking outcomes. Had smoke-free-air law coverage and cumulative tobacco control funding remained at 2002 levels, current and established smoking would have been 5%-7% higher in 2009. Conclusions: Smoke-free air laws and state tobacco control programs are effective strategies for curbing young adult smoking. (C) 2014 Society for Adolescent Health and Medicine. All rights reserved. C1 [Farrelly, Matthew C.; Loomis, Brett R.; Caraballo, Ralph S.; Pechacek, Terry F.; Couzens, G. Lance] RTI Int, Res Triangle Pk, NC 27709 USA. [Kuiper, Nicole] Ctr Dis Control & Prevent, Off Smoking & Hlth, Atlanta, GA USA. [Han, Beth; Gfroerer, Joseph] Ctr Behav Hlth Stat & Qual, Substance Abuse & Mental Hlth Serv Adm, Rockville, MD USA. RP Farrelly, MC (reprint author), RTI Int, 3040 Cornwallis Rd,POB 12194, Res Triangle Pk, NC 27709 USA. EM mcf@rti.org FU Office on Smoking and Health at the Centers for Disease Control and Prevention FX This work was supported by the Office on Smoking and Health at the Centers for Disease Control and Prevention. NR 27 TC 5 Z9 5 U1 0 U2 8 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X EI 1879-1972 J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD APR PY 2014 VL 54 IS 4 BP 481 EP 486 DI 10.1016/j.jadohealth.2013.09.015 PG 6 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA AD4YT UT WOS:000333258700018 PM 24268360 ER PT J AU Weiner, M Egelund, EF Engle, M Kiser, M Prihoda, TJ Gelfond, JAL Mac Kenzie, W Peloquin, CA AF Weiner, Marc Egelund, Eric F. Engle, Melissa Kiser, Melissa Prihoda, Thomas J. Gelfond, Jonathan A. L. Mac Kenzie, William Peloquin, Charles A. TI Pharmacokinetic interaction of rifapentine and raltegravir in healthy volunteers SO JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY LA English DT Article DE rifamycin; latent tuberculosis infection; antiretroviral therapy; integrase strand transfer inhibitor; HIV ID HIV-INFECTED PATIENTS; PLASMA-CONCENTRATIONS; LATENT TUBERCULOSIS; RIFAMPIN; VARIABILITY; METABOLISM; INHIBITOR; REGIMENS; ATORVASTATIN; INDUCTION AB Latent tuberculosis infection and tuberculosis disease are prevalent worldwide. However, antimycobacterial rifamycins have drug interactions with many antiretroviral drugs. We evaluated the effect of rifapentine on the pharmacokinetic properties of raltegravir. In this open-label, fixed-sequence, three-period study, 21 healthy volunteers were given: raltegravir alone (400 mg every 12 h for 4 days) on days 14 of Period 1; rifapentine (900 mg once weekly for 3 weeks) on days 1, 8 and 15 of Period 2 and raltegravir (400 mg every 12 h for 4 days) on days 1215 of Period 2; and rifapentine (600 mg once daily for 10 scheduled doses) on days 1, 48 and 1114 of Period 3 and raltegravir (400 mg every 12 h for 4 days) on days 1114 of Period 3. Plasma raltegravir concentrations were measured. ClinicalTrials.gov database: NCT00809718. In 16 subjects who completed the study, coadministration of raltegravir with rifapentine (900 mg once weekly; Period 2) compared with raltegravir alone resulted in the geometric mean of the raltegravir AUC from 0 to 12 h (AUC(012)) being increased by 71; the peak concentration increased by 89 and the trough concentration decreased by 12. Coadministration of raltegravir with rifapentine in Period 3 did not change the geometric mean of the raltegravir AUC(012) or the peak concentration, but it decreased the trough concentration by 41. Raltegravir coadministered with rifapentine was generally well tolerated. The increased raltegravir exposure observed with once-weekly rifapentine was safe and tolerable. Once-weekly rifapentine can be used with raltegravir to treat latent tuberculosis infection in patients who are infected with HIV. C1 [Weiner, Marc] Dept Vet Affairs Med Ctr, Med Serv, San Antonio, TX 78229 USA. [Weiner, Marc; Engle, Melissa] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Egelund, Eric F.; Peloquin, Charles A.] Univ Florida, Coll Pharm, Gainesville, FL USA. [Kiser, Melissa] Bioanalyt Syst Inc, Mcminnville, OR USA. [Prihoda, Thomas J.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. [Gelfond, Jonathan A. L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA. [Mac Kenzie, William] Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA USA. RP Weiner, M (reprint author), Dept Vet Affairs Med Ctr, Med Serv, San Antonio, TX 78229 USA. EM weiner@uthscsa.edu FU Investigator-Initiated Studies Program of Merck Co., Inc.; Veterans Administration, United States Centers for Disease Control and Prevention (Tuberculosis Trials Consortium); National Center for Advancing Translational Sciences [8UL1TR000149] FX This study was supported in part by a research grant from the Investigator-Initiated Studies Program of Merck & Co., Inc. Support was also provided by the Veterans Administration, United States Centers for Disease Control and Prevention (Tuberculosis Trials Consortium), and National Center for Advancing Translational Sciences, through Grant 8UL1TR000149. NR 40 TC 7 Z9 7 U1 0 U2 3 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0305-7453 EI 1460-2091 J9 J ANTIMICROB CHEMOTH JI J. Antimicrob. Chemother. PD APR PY 2014 VL 69 IS 4 BP 1079 EP 1085 DI 10.1093/jac/dkt483 PG 7 WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy GA AD5EQ UT WOS:000333275000031 PM 24343893 ER PT J AU Geretti, AM Conibear, T Hill, A Johnson, JA Tambuyzer, L Thys, K Vingerhoets, J Van Delft, Y AF Geretti, Anna Maria Conibear, Tim Hill, Andrew Johnson, Jeffrey A. Tambuyzer, Lotke Thys, Kim Vingerhoets, Johan Van Delft, Yvon CA SENSE Study Grp TI Sensitive testing of plasma HIV-1 RNA and Sanger sequencing of cellular HIV-1 DNA for the detection of drug resistance prior to starting first-line antiretroviral therapy with etravirine or efavirenz SO JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY LA English DT Article DE ART; HIV; genotyping ID TRANSCRIPTASE INHIBITOR RESISTANCE; TREATMENT-NAIVE PATIENTS; REVERSE-TRANSCRIPTASE; GENOTYPIC-RESISTANCE; VIRAL VARIANTS; MUTATIONS; INFECTION; IMPACT; SURVEILLANCE; TRANSMISSION AB This study investigated strategies that may increase the yield of drug resistance testing prior to starting antiretroviral therapy (ART), and whether transmitted and polymorphic resistance-associated mutations (RAMs) correlated with virological outcomes. We carried out retrospective testing of baseline samples from patients entering the SENSE trial of first-line ART in Europe, Russia and Israel. Prior to randomization to etravirine or efavirenz plus two nucleos(t)ide reverse transcriptase inhibitors (NRTIs), plasma samples underwent routine Sanger sequencing of HIV-1 RT and protease (plasmaSS) in order to exclude patients with transmitted RAMs. Retrospectively, Sanger sequencing was repeated with HIV-1 DNA from baseline peripheral blood mononuclear cells (PBMCSS); baseline plasma samples were retested by allele-specific PCR targeting seven RT RAMs (AS-PCR) and ultra-deep RT sequencing (UDS). By plasmaSS, 16/193 (8.3) patients showed 1 transmitted RAM affecting the NRTIs (10/193, 5.2), non-nucleoside reverse transcriptase inhibitors (4/193, 2.1) or protease inhibitors (2/193, 1.0). No additional RAMs were detected by AS-PCR (n152) and UDS (n24); PBMCSS (n91) yielded two additional samples with one RAM each. Over 48 weeks, 4/79 (5.1) patients on etravirine and 7/78 (9.0) on efavirenz experienced virological failure; none had baseline RAMs. Conversely, 11/79 (13.9) patients randomized to etravirine had one polymorphic RAM from the etravirine score in baseline plasma (V90I, V106I or E138A), without any impact on virological outcomes. The detection of resistance increased marginally with PBMC testing but did not increase with sensitive plasma testing. A careful consideration is required of the cost-effectiveness of different strategies for baseline HIV drug resistance testing. C1 [Geretti, Anna Maria] Univ Liverpool, Inst Infect & Global Hlth, Liverpool L69 3BX, Merseyside, England. [Conibear, Tim] Royal Free Hampstead Fdn Trust, Dept Virol, London, England. [Hill, Andrew] Janssen, High Wycombe, Bucks, England. [Johnson, Jeffrey A.] Ctr Dis Control & Prevent, Natl Ctr HIV Prevent, Atlanta, GA USA. [Tambuyzer, Lotke; Thys, Kim; Vingerhoets, Johan] Janssen Infect Dis BVBA, Beerse, Belgium. [Van Delft, Yvon] Janssen, Tilburg, Netherlands. RP Geretti, AM (reprint author), Univ Liverpool, Inst Infect & Global Hlth, Liverpool L69 3BX, Merseyside, England. EM geretti@liverpool.ac.uk RI Arribas, Jose/A-1595-2015; Greil, Richard/C-7673-2017; OI Arribas, Jose/0000-0002-7410-9450; Greil, Richard/0000-0002-4462-3694; van Delft, Yvon/0000-0002-2965-6156; Andreoni, Massimo/0000-0002-3205-9758 FU Janssen EMEA Medical Affairs, a division of Janssen International N.V. FX The SENSE trial was designed and conducted by Janssen EMEA Medical Affairs, a division of Janssen International N.V., which acted as the study sponsor. NR 42 TC 7 Z9 7 U1 0 U2 5 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0305-7453 EI 1460-2091 J9 J ANTIMICROB CHEMOTH JI J. Antimicrob. Chemother. PD APR PY 2014 VL 69 IS 4 BP 1090 EP 1097 DI 10.1093/jac/dkt474 PG 8 WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy GA AD5EQ UT WOS:000333275000033 PM 24284781 ER PT J AU Chen, DS Locarnini, S Wait, S Bae, SH Chen, PJ Fung, JYY Kim, HS Lu, SN Sung, J Tanaka, J Wakita, T Ward, J Wallace, J AF Chen, Ding-Shinn Locarnini, Stephen Wait, Suzanne Bae, Si-Hyun Chen, Pei-Jer Fung, James Y. Y. Kim, Hong Soo Lu, Sheng-Nan Sung, Joseph Tanaka, Junko Wakita, Takaji Ward, John Wallace, Jack CA CEVHAP North Asia Workshop Viral TI Report from a Viral Hepatitis Policy Forum on implementing the WHO framework for global action on viral hepatitis in North Asia (vol 59, pg 1073, 2013) SO JOURNAL OF HEPATOLOGY LA English DT Correction ID VIRUS-INFECTION C1 [Chen, Ding-Shinn] Natl Taiwan Univ, Coll Med, Taipei 10764, Taiwan. [Locarnini, Stephen] Victorian Infect Dis Reference Lab, North Melbourne, Australia. [Wait, Suzanne] SHW Hlth Ltd, London, England. [Bae, Si-Hyun] Catholic Univ, Seoul St Mary Hosp, Coll Med, Dept Internal Med, Seoul, South Korea. [Chen, Pei-Jer] Natl Taiwan Univ & Hosp, Hepatitis Res Ctr, Taipei, Taiwan. [Fung, James Y. Y.] Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China. [Kim, Hong Soo] SoonChunHyang Univ Hosp, Dept Internal Med, Div Gastroenterol, Cheonan, South Korea. [Lu, Sheng-Nan] Kaohsiung Chang Gung Mem Hosp, Dept Internal Med, Div Hepatogastroenterol, Kaohsiung, Taiwan. [Sung, Joseph] Chinese Univ Hong Kong, Shatin, Hong Kong, Peoples R China. [Tanaka, Junko] Hiroshima Univ, Inst Biomed & Hlth Sci, Dept Epidemiol Infect Dis Control & Prevent, Hiroshima, Japan. [Wakita, Takaji] Natl Inst Infect Dis, Dept Virol 2, Tokyo, Japan. [Ward, John] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div Viral Hepatitis, Atlanta, GA USA. [Wallace, Jack] La Trobe Univ, Australian Res Ctr Sex Hlth & Soc, Melbourne, Vic, Australia. RP Locarnini, S (reprint author), WHO, Reg Reference Lab Hepatitis B, 10 Wreckyn St, North Melbourne, Vic 3051, Australia. EM Stephen.Locarnini@mh.org..au RI Li, Lien/I-9223-2014; OI CHEN, DING-SHINN/0000-0001-7791-6154 NR 5 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-8278 EI 1600-0641 J9 J HEPATOL JI J. Hepatol. PD APR PY 2014 VL 60 IS 4 BP 902 EP 903 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AD2ZR UT WOS:000333106600035 ER PT J AU Mourich, DV Oda, SK Schnell, FJ Crumley, SL Hauck, LL Moentenich, CA Marshall, NB Hinrichs, DJ Iversen, PL AF Mourich, Dan V. Oda, Shannon K. Schnell, Frederick J. Crumley, Stacy L. Hauck, Laura L. Moentenich, Carla A. Marshall, Nikki B. Hinrichs, Dave J. Iversen, Patrick L. TI Alternative Splice Forms of CTLA-4 Induced by Antisense Mediated Splice-Switching Influences Autoimmune Diabetes Susceptibility in NOD Mice SO NUCLEIC ACID THERAPEUTICS LA English DT Article ID T-CELL-ACTIVATION; SOLUBLE COSTIMULATORY MOLECULES; DYSTROPHIC PATHOLOGY; INCREASED EXPRESSION; ABERRANT REGULATION; GENE REGION; IN-VIVO; DISEASE; RNA; MORPHOLINO AB Activated and regulatory T cells express the negative co-stimulatory molecule cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) that binds B7 on antigen-presenting cells to mediate cellular responses. Single nucleotide polymorphisms in the CTLA-4 gene have been found to affect alternative splicing and are linked to autoimmune disease susceptibility or resistance. Increased expression of a soluble splice form (sCTLA-4), lacking the transmembrane domain encoded by exon 3, has been shown to accelerate autoimmune pathology. In contrast, an exon 2-deficient form lacking the B7 ligand binding domain (liCTLA-4), expressed by diabetes resistant mouse strains has been shown to be protective when expressed as a transgene in diabetes susceptible non-obese diabetic (NOD) mice. We sought to employ an antisense-targeted splice-switching approach to independently produce these CTLA-4 splice forms in NOD mouse T cells and observe their relative impact on spontaneous autoimmune diabetes susceptibility. In vitro antisense targeting of the splice acceptor site for exon 2 produced liCTLA-4 while targeting exon 3 produced the sCTLA-4 form in NOD T cells. The liCTLA-4 expressing T cells exhibited reduced activation, proliferation and increased adhesion to intercellular adhesion molecule-1 (ICAM-1) similar to treatment with agonist alpha-CTLA-4. Mice treated to produce liCTLA-4 at the time of elevated blood glucose levels exhibited a significant reduction in the incidence of insulitis and diabetes, whereas a marked increase in the incidence of both was observed in animals treated to produce sCTLA-4. These findings provide further support that alternative splice forms of CTLA-4 affects diabetes susceptibility in NOD mice and demonstrates the therapeutic utility of antisense mediated splice-switching for modulating immune responses. C1 [Mourich, Dan V.; Schnell, Frederick J.; Crumley, Stacy L.; Iversen, Patrick L.] Sarepta Therapeut, Corvallis, OR 97333 USA. [Oda, Shannon K.] Univ Colorado, Natl Jewish Hlth, Dept Immunol, Denver, CO 80202 USA. [Hauck, Laura L.] Oregon State Univ, Biomed Sci Coll Vet Med, Corvallis, OR 97331 USA. [Moentenich, Carla A.] Portland Community Coll, Dept Biosci Technol, Portland, OR USA. [Marshall, Nikki B.] Ctr Dis Control & Prevent, Natl Inst Occupat Safety & Hlth, Hlth Effects Lab Div, Allergy & Clin Immunol Branch, Morgantown, WV USA. [Hinrichs, Dave J.] Oregon Hlth & Sci Univ, Vet Affairs Med Ctr, Portland, OR 97201 USA. RP Mourich, DV (reprint author), Sarepta Therapeut, Discovery Res Biol, 4575 SW Res Way,Suite 200, Corvallis, OR 97333 USA. EM dmourich@sarepta.com FU Sarepta Therapeutics, Inc. FX DVM, FJS, SLC, PLI have received employment compensation in the form of wages and benefits from Sarepta Therapeutics, Inc. All work conducted and reported herein was funded by Sarepta Therapeutics, Inc. NR 51 TC 6 Z9 6 U1 0 U2 5 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 2159-3337 EI 2159-3345 J9 NUCLEIC ACID THER JI Nucl. Acid Ther. PD APR 1 PY 2014 VL 24 IS 2 BP 114 EP 126 DI 10.1089/nat.2013.0449 PG 13 WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Medicine, Research & Experimental SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Research & Experimental Medicine GA AD4TG UT WOS:000333242900002 PM 24494586 ER PT J AU Tobin, KE Yang, C Sun, C Spikes, P Latkin, CA AF Tobin, Karin Elizabeth Yang, Cui Sun, Christina Spikes, Pilgrim Latkin, Carl Asher TI Discrepancies Between HIV Prevention Communication Attitudes and Actual Conversations About HIV Testing Within Social and Sexual Networks of African American Men Who Have Sex With Men SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID INJECTION-DRUG USERS; CONDOM USE; RISK; INTERVENTION; PARTNERS; EFFICACY; METAANALYSIS; ADOLESCENTS; BALTIMORE; MARYLAND AB Background Promoting communication among African American men who have sex with men (AA MSM) and their social networks about HIV testing is an avenue for altering HIV prevention social norms. This study examined the attitudes of AA MSM on talking with peers about HIV testing and characteristics of their network members with whom they have these conversations. Methods Data came from a cross-sectional survey of 226 AA MSM who were 18 years or older and self-reported sex with another male in the prior 90 days. Participants completed an inventory to characterize network members with whom they had conversations about HIV testing and HIV status. Results Most of the sample reported that it was important/very important to talk to male friends about HIV (85%) and that they were comfortable/very comfortable talking with their friends about sexual behaviors (84%). However, a small proportion of the social network had been talked to by the participant about HIV testing (14%). Among sexual networks, 58% had been talked to about their HIV status, and this was positively associated with main and casual partner type compared with partners with whom money or drugs were exchanged. Conclusions Findings suggest that positive attitudes about communication may be necessary but not sufficient for actual conversations to occur. Designing interventions that increase communication with social networks is warranted. C1 [Tobin, Karin Elizabeth; Yang, Cui; Sun, Christina; Latkin, Carl Asher] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Behav & Soc, Baltimore, MD 21205 USA. [Spikes, Pilgrim] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Prevent Res Branch, Atlanta, GA USA. RP Tobin, KE (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Behav & Soc, 2213 McElderry St,Second Floor, Baltimore, MD 21205 USA. EM ktobin@jhsph.edu OI Sun, Christina J./0000-0001-5656-7055 FU Centers for Disease Control and Prevention [1UR6PS000355]; Eunice Kennedy Shriver National Institute of Child Health and Human Development [1K01HD061269] FX This research was funded through a grant from the Centers for Disease Control and Prevention (1UR6PS000355) and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (1K01HD061269). NR 29 TC 4 Z9 4 U1 2 U2 18 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD APR PY 2014 VL 41 IS 4 BP 221 EP 226 DI 10.1097/OLQ.0000000000000112 PG 6 WC Infectious Diseases SC Infectious Diseases GA AD3VO UT WOS:000333174500001 PM 24622631 ER PT J AU Oster, AM Sternberg, M Nebenzahl, S Broz, D Xu, FJ Hariri, S Miles, I Paz-Bailey, G AF Oster, Alexandra M. Sternberg, Maya Nebenzahl, Samara Broz, Dita Xu, Fujie Hariri, Susan Miles, Isa Paz-Bailey, Gabriela TI Prevalence of HIV, Sexually Transmitted Infections, and Viral Hepatitis by Urbanicity, Among Men Who Have Sex With Men, Injection Drug Users, and Heterosexuals in the United States SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID C VIRUS-INFECTION; HEALTH; RECOMMENDATIONS; IDENTIFICATION; CITIES; WOMEN; RISK AB Background Men who have sex with men (MSM), injection drug users (IDUs), and certain subgroups of heterosexuals are disproportionately affected by the syndemics of HIV, other sexually transmitted infections, and viral hepatitis. Although understanding the burden of these infections in these populations by urbanicity (the degree to which a geographic area is urban) is critical to targeting prevention programs, few studies have done so. Methods We analyzed nationally representative 1999 to 2010 data from the National Health and Nutrition Examination Survey on persons aged 18 to 59 years. We estimated the weighted prevalence of HIV, herpes simplex virus type 2 (HSV-2), human papillomavirus, chlamydia, hepatitis B, and hepatitis C, stratified by urbanicity level, for the overall sample, MSM, IDUs, and heterosexuals. Geographic areas with population at least million are classified into large central and large fringe metropolitan counties. Results Overall, large central metropolitan areas had a higher prevalence of HIV, HSV-2, and hepatitis B. HIV prevalence among MSM was elevated in large central and large fringe metro areas (14.5% and 16.9%, respectively). Among heterosexuals, large central metropolitan areas had elevated prevalence of HSV-2, chlamydia, and hepatitis B. Human papillomavirus and hepatitis C prevalence did not vary significantly by urbanicity for any population, including IDUs. Conclusions Infections with higher prevalence in urban areas merit a geographically focused approach to screening and prevention programs, whereas those with uniform prevalence across levels of urbanicity would benefit from a generalized prevention approach. These nationally representative, population-based data allow for more effective planning for prevention programs. C1 [Oster, Alexandra M.; Nebenzahl, Samara; Broz, Dita; Miles, Isa; Paz-Bailey, Gabriela] CDC, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Sternberg, Maya] CDC, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. [Xu, Fujie] CDC, Div Viral Hepatitis, NCHHSTP, Atlanta, GA 30333 USA. [Hariri, Susan] CDC, Div STD Prevent, NCHHSTP, Atlanta, GA 30333 USA. RP Oster, AM (reprint author), CDC, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, 1600 Clifton Rd NE,MS E-47, Atlanta, GA 30333 USA. EM AOster@cdc.gov NR 23 TC 16 Z9 16 U1 2 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD APR PY 2014 VL 41 IS 4 BP 272 EP 279 DI 10.1097/OLQ.0000000000000110 PG 8 WC Infectious Diseases SC Infectious Diseases GA AD3VO UT WOS:000333174500011 PM 24622641 ER PT J AU Koblin, BA Mansergh, G Chesney, M Coates, T AF Koblin, Beryl A. Mansergh, Gordon Chesney, Margaret Coates, Thomas TI Moving the Bar to the Right Place: Positioning Interventions in HIV Prevention SO AIDS AND BEHAVIOR LA English DT Editorial Material DE HIV prevention; Combination strategies; Antiretroviral treatment; PrEP; Condoms; Interventions; Trials ID HIV/STI BEHAVIORAL INTERVENTIONS; UNITED-STATES; ANTIRETROVIRAL PROPHYLAXIS; AFRICAN-AMERICANS; SEXUAL RISK; INFECTION; METAANALYSIS; EFFICACY; MEN; TRIALS C1 [Koblin, Beryl A.] New York Blood Ctr, Lab Infect Dis Prevent, New York, NY 10065 USA. [Mansergh, Gordon] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. [Chesney, Margaret] Univ Calif San Francisco, Osher Ctr Integrat Med, San Francisco, CA 94143 USA. [Coates, Thomas] Univ Calif Los Angeles, David Geffen Sch Med, UCLA Ctr World Hlth, UC Global Hlth Inst, Los Angeles, CA 90095 USA. [Coates, Thomas] Univ Calif Los Angeles, UCLA Hlth, Los Angeles, CA USA. RP Koblin, BA (reprint author), New York Blood Ctr, Lab Infect Dis Prevent, 310 E 67th St, New York, NY 10065 USA. EM bkoblin@nybloodcenter.org FU NCI NIH HHS [N01 CA035176]; NIAID NIH HHS [U01AI48040, U01 AI048040, U01 AI048016, U01 AI047995, N01 AI045200, 5 U01AI46749, U01AI47995, U01AI48016, N01 AI35176, U01 AI047981, U01AI47981, N01 AI45200, U01 AI046749] NR 31 TC 0 Z9 0 U1 2 U2 5 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1090-7165 EI 1573-3254 J9 AIDS BEHAV JI AIDS Behav. PD APR PY 2014 VL 18 IS 4 BP 634 EP 637 DI 10.1007/s10461-013-0607-9 PG 4 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA AD4ED UT WOS:000333198900002 PM 24057930 ER PT J AU Charania, MR Marshall, KJ Lyles, CM Crepaz, N Kay, LS Koenig, LJ Weidle, PJ Purcell, DW AF Charania, Mahnaz R. Marshall, Khiya J. Lyles, Cynthia M. Crepaz, Nicole Kay, Linda S. Koenig, Linda J. Weidle, Paul J. Purcell, David W. CA HIV AIDS Prevention Res Synth PRS TI Identification of Evidence-Based Interventions for Promoting HIV Medication Adherence: Findings from a Systematic Review of US-Based Studies, 1996-2011 SO AIDS AND BEHAVIOR LA English DT Review DE HIV/AIDS; Intervention; Medication adherence; Evidence-based; Antiretroviral therapy ID RANDOMIZED CONTROLLED-TRIAL; ACTIVE ANTIRETROVIRAL THERAPY; COGNITIVE-BEHAVIORAL INTERVENTION; RISK REDUCTION INTERVENTION; INJECTION-DRUG USERS; CLINICAL-TRIAL; IMPROVE ADHERENCE; INFECTED PATIENTS; VIRAL LOAD; MANAGEMENT INTERVENTION AB A systematic review was conducted to identify evidence-based interventions (EBIs) for increasing HIV medication adherence behavior or decreasing HIV viral load among persons living with HIV (PLWH). We conducted automated searches of electronic databases (i.e., MEDLINE, EMBASE, PsycINFO, CINAHL) and manual searches of journals, reference lists, and listservs. Interventions were eligible for the review if they were U.S.-based, published between 1996 and 2011, intended to improve HIV medication adherence behaviors of PLWH, evaluated the intervention using a comparison group, and reported outcome data on adherence behaviors or HIV viral load. Each intervention was evaluated on the quality of study design, implementation, analysis, and strength of findings. Of the 65 eligible interventions, 10 are EBIs. The remaining 55 interventions failed to meet the efficacy criteria primarily due to null findings, small sample sizes, or low retention rates. Research gaps and future directions for development of adherence EBIs are discussed. C1 [Charania, Mahnaz R.; Marshall, Khiya J.; Lyles, Cynthia M.; Crepaz, Nicole; Kay, Linda S.; Koenig, Linda J.; Weidle, Paul J.; Purcell, David W.] Ctr Dis Control & Prevent, HIV AIDS Prevent Res Synth PRS Team, Div HIV AIDS Prevent, Natl Ctr HIV STD & TB Prevent, Atlanta, GA 30333 USA. RP Lyles, CM (reprint author), Ctr Dis Control & Prevent, HIV AIDS Prevent Res Synth PRS Team, Div HIV AIDS Prevent, Natl Ctr HIV STD & TB Prevent, 1600 Clifton Rd,Mailstop E-37, Atlanta, GA 30333 USA. EM clyles@cdc.gov; ncrepaz@cdc.gov OI Purcell, David/0000-0001-8125-5168 FU Intramural CDC HHS [CC999999] NR 107 TC 11 Z9 11 U1 6 U2 23 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1090-7165 EI 1573-3254 J9 AIDS BEHAV JI AIDS Behav. PD APR PY 2014 VL 18 IS 4 BP 646 EP 660 DI 10.1007/s10461-013-0594-x PG 15 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA AD4ED UT WOS:000333198900006 PM 24043269 ER PT J AU Seth, P Wingood, GM Robinson, LS DiClemente, RJ AF Seth, Puja Wingood, Gina M. Robinson, LaShun S. DiClemente, Ralph J. TI The Impact of Alcohol Use on HIV/STI Intervention Efficacy in Predicting Sexually Transmitted Infections Among Young African-American Women SO AIDS AND BEHAVIOR LA English DT Article DE Alcohol; Sexually transmitted infections; African-American; Women; HIV; Intervention ID BEHAVIOR PATTERNS; HIGH-RISK; HIV; VIOLENCE AB The impact of alcohol use on the efficacy of an HIV/STI intervention designed for young African-American women in predicting STIs was examined. Eight hundred forty-eight African-American women, 18-29 years, were randomly assigned to either the HIV/STI intervention or a control condition. Participants were assessed on alcohol use and provided two vaginal swab specimens for STI testing. Women in the intervention who consumed alcohol were less likely to test STI-positive than women in the control and abstainers (AOR = 2.47, 95 % CI = 1.01-6.22). STI risk factors may vary across different populations. Further research on heavy drinking and HIV intervention efficacy is needed. C1 [Seth, Puja; Wingood, Gina M.; Robinson, LaShun S.; DiClemente, Ralph J.] Emory Univ, Rollins Sch Publ Hlth, Dept Behav Sci & Hlth Educ, Atlanta, GA 30333 USA. [Seth, Puja; Wingood, Gina M.; DiClemente, Ralph J.] Emory Ctr AIDS Res, Prevent Sci Core, Atlanta, GA USA. [DiClemente, Ralph J.] Emory Univ, Sch Med, Dept Pediat, Div Infect Dis Epidemiol & Immunol, Atlanta, GA USA. RP Seth, P (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. EM pseth@cdc.gov FU NIMH NIH HHS [R01-MH062717, R01 MH062717] NR 12 TC 0 Z9 0 U1 0 U2 2 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1090-7165 EI 1573-3254 J9 AIDS BEHAV JI AIDS Behav. PD APR PY 2014 VL 18 IS 4 BP 747 EP 751 DI 10.1007/s10461-013-0555-4 PG 5 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA AD4ED UT WOS:000333198900015 PM 23979497 ER PT J AU O'Donnell, L Stueve, A Joseph, HA Flores, S AF O'Donnell, Lydia Stueve, Ann Joseph, Heather A. Flores, Stephen TI Adapting the VOICES HIV Behavioral Intervention for Latino Men Who Have Sex with Men SO AIDS AND BEHAVIOR LA English DT Article DE HIV prevention; Gay men; Latino health ID RANDOMIZED CONTROLLED-TRIAL; PREVENTION INTERVENTIONS; CONDOM ACQUISITION; PATIENT EDUCATION; AFRICAN-AMERICAN; RISK BEHAVIORS; WHITE MEN; INFECTION; PREVALENCE; ADOLESCENT AB Latino men who have sex with men (MSM) are disproportionately impacted by HIV/AIDS, but few behavioral interventions address their prevention needs. Adaptation of evidence-based interventions is a pragmatic strategy that builds upon lessons learned and has the potential to fill gaps in prevention programming. Yet there are few reports of how transfers are executed and whether effectiveness is achieved. This research reports on the adaptation of VOICES/VOICES, a single-session intervention designed for heterosexual adults, into No Excuses/Sin buscar excuses for Latino MSM. To test the adapted intervention, 370 at-risk Latino MSM were enrolled in a randomized trial. At a three-month follow-up, there was a sharper decrease in unprotected intercourse in the intervention group compared to controls (59 % vs. 39 %, ANOVA p < 0.05, F = 4.10). Intervention participants also reported more condom use at last intercourse (AOR = 1.69; 95 % CI 1.02-2.81, p < 02). Findings support use of adapted models for meeting prevention needs of high-priority populations. C1 [O'Donnell, Lydia; Stueve, Ann] Educ Dev Ctr, Waltham, MA USA. [Joseph, Heather A.; Flores, Stephen] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. RP O'Donnell, L (reprint author), Educ Dev Ctr, Waltham, MA USA. EM lodonnell@edc.org FU NCHHSTP CDC HHS [5UR6PS0004250] NR 28 TC 3 Z9 3 U1 0 U2 5 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1090-7165 EI 1573-3254 J9 AIDS BEHAV JI AIDS Behav. PD APR PY 2014 VL 18 IS 4 BP 767 EP 775 DI 10.1007/s10461-013-0653-3 PG 9 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA AD4ED UT WOS:000333198900017 PM 24419993 ER PT J AU Gonzalez-Escalona, N Timme, R Raphael, BH Zink, D Sharma, SK AF Gonzalez-Escalona, Narjol Timme, Ruth Raphael, Brian H. Zink, Donald Sharma, Shashi K. TI Whole-Genome Single-Nucleotide-Polymorphism Analysis for Discrimination of Clostridium botulinum Group I Strains SO APPLIED AND ENVIRONMENTAL MICROBIOLOGY LA English DT Article ID SEROTYPE-A SUBTYPES; TOXIN; CLUSTERS; GENES; NEUROTOXINS; DIVERSITY; PLASMIDS; OUTBREAK; SEQUENCE; ORGANISM AB Clostridium botulinum is a genetically diverse Gram-positive bacterium producing extremely potent neurotoxins (botulinum neurotoxins A through G [BoNT/A-G]). The complete genome sequences of three strains harboring only the BoNT/A1 nucleotide sequence are publicly available. Although these strains contain a toxin cluster (HA(+) OrfX(-)) associated with hemagglutinin genes, little is known about the genomes of subtype A1 strains (termed HA(-) OrfX(+)) that lack hemagglutinin genes in the toxin gene cluster. We sequenced the genomes of three BoNT/A1-producing C. botulinum strains: two strains with the HA(+) OrfX(-) cluster (69A and 32A) and one strain with the HA(-) OrfX(+) cluster (CDC297). Whole-genome phylogenic single-nucleotide-polymorphism (SNP) analysis of these strains along with other publicly available C. botulinum group I strains revealed five distinct lineages. Strains 69A and 32A clustered with the C. botulinum type A1 Hall group, and strain CDC297 clustered with the C. botulinum type Ba4 strain 657. This study reports the use of whole-genome SNP sequence analysis for discrimination of C. botulinum group I strains and demonstrates the utility of this analysis in quickly differentiating C. botulinum strains harboring identical toxin gene subtypes. This analysis further supports previous work showing that strains CDC297 and 657 likely evolved from a common ancestor and independently acquired separate BoNT/A1 toxin gene clusters at distinct genomic locations. C1 [Gonzalez-Escalona, Narjol; Timme, Ruth; Sharma, Shashi K.] US FDA, Div Microbiol, Off Regulatory Sci, Ctr Food Safety & Appl Nutr, College Pk, MD USA. [Zink, Donald] US FDA, Off Ctr Director, Ctr Food Safety & Appl Nutr, College Pk, MD USA. [Raphael, Brian H.] Ctr Dis Control & Prevent, Enter Dis Lab Branch, Atlanta, GA USA. RP Gonzalez-Escalona, N (reprint author), US FDA, Div Microbiol, Off Regulatory Sci, Ctr Food Safety & Appl Nutr, College Pk, MD USA. EM narjol.gonzalez-escalona@fda.hhs.gov OI Raphael, Brian/0000-0003-2778-2623; Gonzalez-Escalona, Narjol/0000-0003-4568-0022 FU FDA Foods Program intramural funds FX This project was supported by FDA Foods Program intramural funds. NR 37 TC 12 Z9 12 U1 0 U2 10 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0099-2240 EI 1098-5336 J9 APPL ENVIRON MICROB JI Appl. Environ. Microbiol. PD APR PY 2014 VL 80 IS 7 BP 2125 EP 2132 DI 10.1128/AEM.03934-13 PG 8 WC Biotechnology & Applied Microbiology; Microbiology SC Biotechnology & Applied Microbiology; Microbiology GA AC9FV UT WOS:000332840700010 PM 24463972 ER PT J AU Wang, GJ Fang, J Ayala, C AF Wang, Guijing Fang, Jing Ayala, Carma TI Hypertension-associated hospitalizations and costs in the United States, 1979-2006 SO BLOOD PRESSURE LA English DT Article DE Economic cost; hospitalization; hypertension; trends; United States ID CORONARY-HEART-DISEASE; BLOOD-PRESSURE; COMORBIDITY INDEX; CARE; PREVALENCE; MORTALITY; BURDEN; TRENDS; COMPLICATIONS; EXPENDITURES AB Background and objective. In the USA, the prevalence of hypertension has been high and increasing in recent decades. Even so, little is known about the changes over time in hospitalizations and the economic burden associated with this epidemic. We examined hypertension-associated hospitalizations and costs from 1979 to 2006. Methods. Using the National Hospital Discharge Survey and the costs of community hospitals in the USA, we analyzed the changes in hypertension-associated hospitalizations and costs over time. We included those hospitalizations with a primary or secondary diagnosis of hypertension among patients aged 25 years and above. We examined changes in costs by adjusting them into year 2008 dollars. The costs included hospital expenses of payroll, employee benefits, professional fees and supplies. Results. From 1979-1982 to 2003-2006, the proportion of hospitalizations that were associated with hypertension (primary or secondary diagnosis) increased from 1.9% to 5.4%. Among all hypertension-associated hospitalizations, the proportion with a secondary diagnosis of hypertension increased from 81.8% to 95.1%. In 2008 dollars, annual costs for hypertension-related hospitalizations increased from US $40 billion (5.1% of total hospital costs) during 1979-1982 to US $113 billion (15.1% of total hospital costs) during 2003-2006. Conclusions. Both the proportions of hospitalizations that were associated with hypertension and the adjusted annual costs of such hospitalizations nearly tripled over the past 28 years. The increases were in substantial measure due to the greatly increasing proportion of hospitalizations in which hypertension was listed as a secondary diagnosis. Interventions for the management of hypertension as a secondary diagnosis might be potentially cost-effective. C1 [Wang, Guijing; Fang, Jing; Ayala, Carma] Ctr Dis Control & Prevent CDC, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. RP Wang, GJ (reprint author), 4770 Buford Hwy NE,MS F-72, Atlanta, GA 30341 USA. EM gbw9@cdc.gov FU Intramural CDC HHS [CC999999] NR 38 TC 2 Z9 3 U1 1 U2 4 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0803-7051 EI 1651-1999 J9 BLOOD PRESSURE JI Blood Pressure PD APR PY 2014 VL 23 IS 2 BP 126 EP 133 DI 10.3109/08037051.2013.814751 PG 8 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA AD2EE UT WOS:000333045500008 PM 23885763 ER PT J AU Pillai, SK Beekmann, SE Santibanez, S Polgreen, PM AF Pillai, Satish K. Beekmann, Susan E. Santibanez, Scott Polgreen, Philip M. TI The Infectious Diseases Society of America Emerging Infections Network: Bridging the Gap Between Clinical Infectious Diseases and Public Health SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE public health; emerging infectious diseases; infectious diseases physicians ID CARE WORKERS; MANAGEMENT; PHYSICIANS; SPECIALISTS AB In 1995, the Centers for Disease Control and Prevention granted a Cooperative Agreement Program award to the Infectious Diseases Society of America to develop a provider-based emerging infections sentinel network, the Emerging Infections Network (EIN). Over the past 17 years, the EIN has evolved into a flexible, nationwide network with membership representing a broad cross-section of infectious disease physicians. The EIN has an active electronic mail conference (listserv) that facilitates communication among infectious disease providers and the public health community, and also sends members periodic queries (short surveys on infectious disease topics) that have addressed numerous topics relevant to both clinical infectious diseases and public health practice. The article reviews how the various functions of EIN contribute to clinical care and public health, identifies opportunities to further link clinical medicine and public health, and describes future directions for the EIN. C1 [Pillai, Satish K.; Santibanez, Scott] Ctr Dis Control & Prevent, Div Preparedness & Emerging Infect, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Beekmann, Susan E.; Polgreen, Philip M.] Univ Iowa, Emerging Infect Network, Iowa City, IA 52242 USA. RP Polgreen, PM (reprint author), Univ Iowa, Carver Coll Med, Dept Internal Med, Iowa City, IA 52242 USA. EM philip-polgreen@uiowa.edu FU CDC [1U50CK000187] FX Financial support. This work was supported by the CDC (Cooperative Agreement Number 1U50CK000187). NR 26 TC 16 Z9 16 U1 0 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD APR 1 PY 2014 VL 58 IS 7 BP 991 EP 996 DI 10.1093/cid/cit932 PG 6 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA AD2HM UT WOS:000333055400016 PM 24403542 ER PT J AU Hahn, MB Epstein, JH Gurley, ES Islam, MS Luby, SP Daszak, P Patz, JA AF Hahn, Micah B. Epstein, Jonathan H. Gurley, Emily S. Islam, Mohammad S. Luby, Stephen P. Daszak, Peter Patz, Jonathan A. TI Roosting behaviour and habitat selection of Pteropus giganteus reveal potential links to Nipah virus epidemiology SO JOURNAL OF APPLIED ECOLOGY LA English DT Article DE Bangladesh; conservation medicine; ecological niche model; habitat selection; Indian flying fox; Maxent; Nipah virus; One Health; Pteropus giganteus; zoonotic disease ID FLYING-FOXES; EMERGING VIRUSES; HOME-RANGE; OLD-WORLD; BATS; BANGLADESH; LANDSCAPE; VAMPYRUS; DISTRIBUTIONS; TRANSMISSION AB 1. Flying foxes Pteropus spp. play a key role in forest regeneration as seed dispersers and are also the reservoir of many viruses, including Nipah virus in Bangladesh. Little is known about their habitat requirements, particularly in South Asia. Identifying Pteropus habitat preferences could assist in understanding the risk of zoonotic disease transmission broadly and, in Bangladesh, could help explain the spatial distribution of human Nipah virus cases. 2. We analysed characteristics of Pteropus giganteus roosts and constructed an ecological niche model to identify suitable habitat in Bangladesh. We also assessed the distribution of suitable habitat in relation to the location of human Nipah virus cases. 3. Compared to non-roost trees, P.giganteus roost trees are taller with larger diameters and are more frequently canopy trees. Colony size was larger in densely forested regions and smaller in flood-affected areas. Roosts were located in areas with lower annual precipitation and higher human population density than non-roost sites. 4. We predicted that 2-17% of Bangladesh's land area is suitable roosting habitat. Nipah virus outbreak villages were 2.6 times more likely to be located in areas predicted as highly suitable habitat for P. giganteus compared to non-outbreak villages. 5. Synthesis and applications. Habitat suitability modelling may help identify previously undocumented Nipah outbreak locations and improve our understanding of Nipah virus ecology by highlighting regions where there is suitable bat habitat but no reported human Nipah virus. Conservation and public health education is a key component of P.giganteus management in Bangladesh due to the general misunderstanding and fear of bats that are a reservoir of Nipah virus. Affiliation between Old World fruit bats (Pteropodidae) and people is common throughout their range, and in order to conserve these keystone bat species and prevent emergence of zoonotic viruses, it is imperative that we continue to improve our understanding of Pteropus resource requirements and routes of virus transmission from bats to people. Results presented here can be utilized to develop land management strategies and conservation policies that simultaneously protect fruit bats and public health. C1 [Hahn, Micah B.; Patz, Jonathan A.] Univ Wisconsin, SAGE Ctr Sustainabil & Global Environm, Nelson Inst, Madison, WI 53706 USA. [Hahn, Micah B.; Patz, Jonathan A.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Populat Hlth Sci, Madison, WI USA. [Epstein, Jonathan H.; Daszak, Peter] EcoHlth Alliance, New York, NY USA. [Gurley, Emily S.; Luby, Stephen P.] Int Ctr Diarrheal Dis Res, Dhaka, Bangladesh. [Islam, Mohammad S.] Ctr Environm & Geog Informat Serv, Dhaka, Bangladesh. [Luby, Stephen P.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Hahn, MB (reprint author), Univ Wisconsin, SAGE Ctr Sustainabil & Global Environm, Nelson Inst, Madison, WI 53706 USA. EM micah.hahn@gmail.com; epstein@ecohealthalliance.org RI Gurley, Emily/B-7903-2010 OI Gurley, Emily/0000-0002-8648-9403 FU NSF/NIH Ecology and Evolution of Infectious Diseases Grant [2R01-TW005869]; NSF IGERT Grant [0549407] FX Hossain M.S. Sazzad, Golam Dostogir Harun, A.K.M. Dawlat Khan and Sonia Hegde provided logistical support for the field component of this research. We would like to extend our gratitude to the icddr,b field staff for their dedication to collecting accurate and complete data. We also thank Tony Goldberg, Monica Turner and Ron Gangnon for their helpful comments that greatly improved the article. Funding was received from the NSF/NIH Ecology and Evolution of Infectious Diseases Grant 2R01-TW005869 (Fogarty International Center) and the NSF IGERT Grant 0549407: CHANGE-IGERT in the Nelson Institute for Environmental Studies at the University of Wisconsin-Madison. NR 44 TC 9 Z9 10 U1 5 U2 72 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0021-8901 EI 1365-2664 J9 J APPL ECOL JI J. Appl. Ecol. PD APR PY 2014 VL 51 IS 2 BP 376 EP 387 DI 10.1111/1365-2664.12212 PG 12 WC Biodiversity Conservation; Ecology SC Biodiversity & Conservation; Environmental Sciences & Ecology GA AC9DX UT WOS:000332835600011 PM 24778457 ER PT J AU Price, M Kearns, M Houry, D Rothbaum, BO AF Price, Matthew Kearns, Megan Houry, Debra Rothbaum, Barbara O. TI Emergency Department Predictors of Posttraumatic Stress Reduction for Trauma-Exposed Individuals With and Without an Early Intervention SO JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY LA English DT Article ID CHILD-ABUSE; DISORDER; PTSD; SYMPTOMS; THERAPY; RELIABILITY; VALIDITY AB Objective: Recent data have supported the use of an early exposure intervention to promote a reduction in acute stress and posttraumatic stress disorder (PTSD) symptoms after trauma exposure. The present study explored a comprehensive predictive model that included history of trauma exposure, dissociation at the time of the trauma and early intervention, and physiological responses (cortisol and heart rate) to determine which variables were most indicative of reduced PTSD symptoms for an early intervention or treatment as usual. Method: Participants (n = 137) were randomly assigned to the early intervention condition (n = 68) or assessment-only condition (n = 69) while receiving care at the emergency department of a Level 1 trauma center. Follow-up assessments occurred at 4 and 12 weeks posttrauma. Results: Findings suggested that dissociation at the time of the 1st treatment session was associated with reduced response to the early intervention. No other predictors were associated with treatment response. For treatment as usual, cortisol levels at the time of acute care and dissociation at the time of the traumatic event were positively associated with PTSD symptoms. Conclusions: Dissociation at the time at which treatment starts may indicate poorer response to early intervention for PTSD. Similarly, dissociation at the time of the event was positively related to PTSD symptoms in those who received treatment as usual. C1 [Price, Matthew] Univ Vermont, Dept Psychol, Burlington, VT 05405 USA. [Kearns, Megan] Ctr Dis Control & Prevent, Atlanta, GA USA. [Kearns, Megan; Rothbaum, Barbara O.] Emory Univ, Sch Med, Dept Psychiat & Behav Sci, Atlanta, GA 30322 USA. [Houry, Debra] Emory Univ, Sch Med, Dept Emergency Med, Atlanta, GA 30322 USA. RP Price, M (reprint author), Univ Vermont, Dept Psychol, Burlington, VT 05405 USA. EM matthew.price@uvm.edu FU NCIPC CDC HHS [5R49CE001494, R49 CE001494]; NIMH NIH HHS [R34MH083078, R34 MH083078] NR 30 TC 12 Z9 12 U1 3 U2 11 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0022-006X EI 1939-2117 J9 J CONSULT CLIN PSYCH JI J. Consult. Clin. Psychol. PD APR PY 2014 VL 82 IS 2 BP 336 EP 341 DI 10.1037/a0035537 PG 6 WC Psychology, Clinical SC Psychology GA AD7RR UT WOS:000333463400014 PM 24491070 ER PT J AU Corral, I Landrine, H Zhao, LH AF Corral, Irma Landrine, Hope Zhao, Luhua TI Residential segregation and obesity among a national sample of Hispanic adults SO JOURNAL OF HEALTH PSYCHOLOGY LA English DT Article DE Latinos; Hispanics; segregation; neighborhoods; obesity ID MULTILEVEL LOGISTIC-REGRESSION; US METROPOLITAN-AREAS; BODY-MASS INDEX; PHYSICAL-ACTIVITY; UNITED-STATES; WEIGHT STATUS; NEIGHBORHOOD CHARACTERISTICS; RECREATIONAL RESOURCES; SOCIOECONOMIC-STATUS; HEALTH DISPARITIES AB We explored the role of residential segregation in obesity among a national sample of Hispanics for the first time. Data on the 8785 Hispanic adults in the 2000 Behavioral Risk Factor Surveillance System were linked to 2000 census data on the segregation of 290 metropolitan statistical areas. Multilevel modeling revealed that after controlling for individual-level variables, the odds of being obese for Hispanics residing in high-segregated metropolitan statistical areas were 26.4 percent higher than for those residing in low-segregated metropolitan statistical areas. This segregation effect might be mediated by the obesogenic features (e.g. paucity of recreational facilities and abundance of fast-food outlets) of segregated Hispanic neighborhoods. C1 [Corral, Irma; Landrine, Hope] E Carolina Univ, Greenville, NC 27834 USA. [Zhao, Luhua] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Landrine, H (reprint author), E Carolina Univ, Ctr Hlth Dispar, 1800 W 5th St,Med Pavilion Suite 6, Greenville, NC 27834 USA. EM landrineh@ecu.edu OI Corral, Irma/0000-0003-3840-9269 NR 38 TC 3 Z9 3 U1 2 U2 10 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1359-1053 EI 1461-7277 J9 J HEALTH PSYCHOL JI J. Health Psychol. PD APR PY 2014 VL 19 IS 4 BP 503 EP 508 DI 10.1177/1359105312474912 PG 6 WC Psychology, Clinical SC Psychology GA AD5WN UT WOS:000333324000005 PM 23460679 ER PT J AU Buskirk, AD Templeton, SP Nayak, AP Hettick, JM Law, BF Green, BJ Beezhold, DH AF Buskirk, Amanda D. Templeton, Steven P. Nayak, Ajay P. Hettick, Justin M. Law, Brandon F. Green, Brett J. Beezhold, Donald H. TI Pulmonary immune responses to Aspergillus fumigatus in an immunocompetent mouse model of repeated exposures SO JOURNAL OF IMMUNOTOXICOLOGY LA English DT Article DE Aspergillus fumigatus; immune response; melanin; Tc17 cells ID CONIDIAL PIGMENT BIOSYNTHESIS; CD8 T-CELLS; CRYPTOCOCCUS-NEOFORMANS; FUNGAL SPORES; VIRULENCE; MELANIN; TC17; ASTHMA; MICE; GENE AB Aspergillus fumigatus is a filamentous fungus that produces abundant pigmented conidia. Several fungal components have been identified as virulence factors, including melanin; however, the impact of these factors in a repeated exposure model resembling natural environmental exposures remains unknown. This study examined the role of fungal melanin in the stimulation of pulmonary immune responses using immunocompetent BALB/c mice in a multiple exposure model. It compared conidia from wild-type A. fumigatus to two melanin mutants of the same strain, Delta arp2 (tan) or Delta alb1 (white). Mass spectrometry-based analysis of conidial extracts demonstrated that there was little difference in the protein fingerprint profiles between the three strains. Field emission scanning electron microscopy demonstrated that the immunologically inert Rodlet A layer remained intact in melanin-deficient conidia. Thus, the primary difference between the strains was the extent of melanization. Histopathology indicated that each A. fumigatus strain induced lung inflammation, regardless of the extent of melanization. In mice exposed to Delta alb1 conidia, an increase in airway eosinophils and a decrease in neutrophils and CD8(+) IL-17(+) (Tc17) cells were observed. Additionally, it was shown that melanin mutant conidia were more rapidly cleared from the lungs than wild-type conidia. These data suggest that the presence of fungal melanin may modulate the pulmonary immune response in a mouse model of repeated exposures to A. fumigatus conidia. C1 [Buskirk, Amanda D.; Templeton, Steven P.; Nayak, Ajay P.; Hettick, Justin M.; Law, Brandon F.; Green, Brett J.; Beezhold, Donald H.] NIOSH, Allergy & Clin Immunol Branch, Hlth Effects Lab Div, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA. [Buskirk, Amanda D.] W Virginia Univ, Dept Microbiol Immunol & Cell Biol, Morgantown, WV 26506 USA. [Templeton, Steven P.] Indiana Univ Sch Med, Dept Microbiol & Immunol, Terre Haute, IN USA. RP Beezhold, DH (reprint author), NIOSH, Allergy & Clin Immunol Branch, Ctr Dis Control & Prevent, 1095 Willowdale Road, Morgantown, WV 26505 USA. EM zec1@cdc.gov FU National Institute of Environmental Health Sciences (CDC IAA) [12-NS12-01] FX This work was supported in part by an interagency agreement with the National Institute of Environmental Health Sciences (CDC IAA#12-NS12-01). NR 53 TC 5 Z9 5 U1 0 U2 2 PU INFORMA HEALTHCARE PI NEW YORK PA 52 VANDERBILT AVE, NEW YORK, NY 10017 USA SN 1547-691X EI 1547-6901 J9 J IMMUNOTOXICOL JI J. Immunotoxicol. PD APR-JUN PY 2014 VL 11 IS 2 BP 180 EP 189 DI 10.3109/1547691X.2013.819054 PG 10 WC Toxicology SC Toxicology GA AD2VG UT WOS:000333093200011 PM 23919459 ER PT J AU Clark, TA AF Clark, Thomas A. TI Changing Pertussis Epidemiology: Everything Old is New Again SO JOURNAL OF INFECTIOUS DISEASES LA English DT Editorial Material DE Whooping cough; vaccination; epidemiology; Bordetella pertussis; immunization; public health ID BORDETELLA-PERTUSSIS; UNITED-STATES; WHOLE-CELL; VACCINE; PERTACTIN; PROTECTION; CALIFORNIA; CHILDREN; INFANTS; TDAP AB Before vaccination, pertussis was a universal disease of early childhood. Although apparent control of the disease in the United States and other countries was achieved through vaccination, pertussis is resurgent. Though acellular vaccines have been in use for 20 years, new data are emerging on their effectiveness and durability of protection and the contribution of these characteristics to the resurgence of pertussis. C1 Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Clark, TA (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,Mailstop C-25, Atlanta, GA 30333 USA. EM tnc4@cdc.gov NR 23 TC 66 Z9 67 U1 0 U2 16 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD APR 1 PY 2014 VL 209 IS 7 BP 978 EP 981 DI 10.1093/infdis/jiu001 PG 4 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA AD2TI UT WOS:000333087900002 PM 24626532 ER PT J AU Hewlett, EL Burns, DL Cotter, PA Harvill, ET Merkel, TJ Quinn, CP Stibitz, ES AF Hewlett, Erik L. Burns, Drusilla L. Cotter, Peggy A. Harvill, Eric T. Merkel, Tod J. Quinn, Conrad P. Stibitz, E. Scott TI Pertussis Pathogenesis-What We Know and What We Don't Know SO JOURNAL OF INFECTIOUS DISEASES LA English DT Editorial Material DE Bordetella pertussis; pertussis; pathogenesis; virulence factors; whooping cough ID BORDETELLA-PERTUSSIS; INFECTION; TOXIN AB Pertussis is a worldwide public health threat. Bordetella pertussis produces multiple virulence factors that have been studied individually, and many have recently been found to have additional biological activities. Nevertheless, how they interact to cause the disease pertussis remains unknown. New animal models, particularly the infection of infant baboons with B. pertussis, are enabling longstanding questions about pertussis pathogenesis to be answered and new ones to be asked. Enhancing our understanding of pathogenesis will enable new approaches to the prevention and control of pertussis. C1 [Hewlett, Erik L.] Univ Virginia, Sch Med, Dept Med, Charlottesville, VA 22908 USA. [Hewlett, Erik L.] Univ Virginia, Sch Med, Dept Microbiol Immunol & Canc Biol, Charlottesville, VA 22908 USA. [Burns, Drusilla L.; Merkel, Tod J.; Stibitz, E. Scott] US FDA, Ctr Biol Evaluat & Res, Bethesda, MD USA. [Cotter, Peggy A.] Univ N Carolina, Sch Med, Dept Microbiol & Immunol, Chapel Hill, NC USA. [Harvill, Eric T.] Penn State Univ, University Pk, PA 16802 USA. [Quinn, Conrad P.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. RP Hewlett, EL (reprint author), Univ Virginia, Sch Med, Box 800419, Charlottesville, VA 22908 USA. EM eh2v@virginia.edu FU NIAID NIH HHS [R01 AI094991, R01 AI018000, R01 AI18000]; NIGMS NIH HHS [R01 GM083113, R01 GM113681]; NIH HHS [P40 OD010988] NR 15 TC 21 Z9 23 U1 1 U2 17 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD APR 1 PY 2014 VL 209 IS 7 BP 982 EP 985 DI 10.1093/infdis/jit639 PG 4 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA AD2TI UT WOS:000333087900003 PM 24626533 ER PT J AU Zhong, WM Reed, C Blair, PJ Katz, JM Hancock, K AF Zhong, Weimin Reed, Carrie Blair, Patrick J. Katz, Jacqueline M. Hancock, Kathy CA Influenza Serology Working Grp TI Serum Antibody Response to Matrix Protein 2 Following Natural Infection With 2009 Pandemic Influenza A(H1N1) Virus in Humans SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE Influenza A virus; Matrix protein 2; Antibody; Human ID A-VIRUS; M2 PROTEIN; H1N1 INFLUENZA; MONOCLONAL-ANTIBODY; EXTRACELLULAR DOMAIN; CROSS-PROTECTION; UNITED-STATES; VACCINATION; ECTODOMAIN; MICE AB Natural infection-induced humoral immunity to matrix protein 2 (M2) of influenza A viruses in humans is not fully understood. Evidence suggests that anti-M2 antibody responses following influenza A virus infection are weak and/or transient. We show that the seroprevalence of anti-M2 antibodies increased with age in 317 serum samples from healthy individuals in the United States in 2007-2008. Infection with 2009 pandemic H1N1 influenza A virus (A[H1N1]pdm09) elicited a recall serum antibody response to M2 protein of A(H1N1)pdm09 in 47% of the affected 118 individuals tested. Anti-M2 antibody responses were more robust among individuals with preexisting antibodies to M2 protein. Moreover, the antibodies induced as a result of infection with A(H1N1)pdm09 were cross-reactive with M2 protein of seasonal influenza A viruses. These results emphasize the need to further investigate the possible roles of anti-M2 antibodies in human influenza A virus infection. C1 [Zhong, Weimin; Reed, Carrie; Katz, Jacqueline M.; Hancock, Kathy] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Blair, Patrick J.] Naval Hlth Res Ctr, San Diego, CA USA. RP Zhong, WM (reprint author), Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd, Atlanta, GA 30333 USA. EM wzhong@cdc.gov FU Centers for Disease Control and Prevention; Naval Health Research Center FX This work was supported by the Centers for Disease Control and Prevention and the Naval Health Research Center. NR 41 TC 11 Z9 11 U1 0 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD APR 1 PY 2014 VL 209 IS 7 BP 986 EP 994 DI 10.1093/infdis/jit811 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA AD2TI UT WOS:000333087900004 PM 24325965 ER PT J AU Burns, DL Meade, BD Messionnier, NE AF Burns, Drusilla L. Meade, Bruce D. Messionnier, Nancy E. TI Pertussis Resurgence: Perspectives From the Working Group Meeting on Pertussis on the Causes, Possible Paths Forward, and Gaps in Our Knowledge SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE pertussis; pertussis vaccines; vaccine effectiveness ID BORDETELLA-PERTUSSIS; WHOLE-CELL; UNITED-STATES; VACCINE; CHILDREN; APPEARANCE; PERTACTIN; RESPONSES; IMMUNITY; STRAINS C1 [Burns, Drusilla L.] US FDA, CBER, Bethesda, MD 20892 USA. [Meade, Bruce D.] Meade Biol, Hillsborough, NC USA. [Messionnier, Nancy E.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Burns, DL (reprint author), US FDA, CBER, HFM-434,8800 Rockville Pike, Bethesda, MD 20892 USA. EM drusilla.burns@fda.hhs.gov FU Food and Drug and Administration; Centers for Disease Control and Prevention FX This work was supported by the Food and Drug and Administration and Centers for Disease Control and Prevention. NR 25 TC 30 Z9 30 U1 0 U2 5 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD APR 1 PY 2014 VL 209 SU 1 BP S32 EP S35 DI 10.1093/infdis/jit491 PG 4 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA AD2TN UT WOS:000333088400008 PM 24626870 ER PT J AU Dennis, AF McDonald, SM Payne, DC Mijatovic-Rustempasic, S Esona, MD Edwards, KM Chappell, JD Patton, JT AF Dennis, Allison F. McDonald, Sarah M. Payne, Daniel C. Mijatovic-Rustempasic, Slavica Esona, Mathew D. Edwards, Kathryn M. Chappell, James D. Patton, John T. TI Molecular Epidemiology of Contemporary G2P[4] Human Rotaviruses Cocirculating in a Single US Community: Footprints of a Globally Transitioning Genotype SO JOURNAL OF VIROLOGY LA English DT Article ID GROUP-A ROTAVIRUS; IMMUNIZATION PRACTICES ACIP; LINKED-IMMUNOSORBENT-ASSAY; PHYLOGENETIC ANALYSIS; ADVISORY-COMMITTEE; UNITED-STATES; STRAINS; GASTROENTERITIS; CHILDREN; VACCINATION AB Group A rotaviruses (RVs) remain a leading cause of childhood gastroenteritis worldwide. Although the G/P types of locally circulating RVs can vary from year to year and differ depending upon geographical location, those with G1P[8], G2P[4], G3P[8], G4P[8], G9P[8], and G12P[8] specificities typically dominate. Little is known about the evolution and diversity of G2P[4] RVs and the possible role that widespread vaccine use has had on their increased frequency of detection. To address these issues, we analyzed the 12 G2P[4] RV isolates associated with a rise in RV gastroenteritis cases at Vanderbilt University Medical Center (VUMC) during the 2010-2011 winter season. Full-genome sequencing revealed that the isolates had genotype 2 constellations typical of DS-1-like viruses (G2P[4]-I2-R2-C2-M2-A2-N2-T2-E2-H2). Phylogenetic analyses showed that the genome segments of the isolates were comprised of two or three different subgenotype alleles; this enabled recognition of three distinct clades of G2P[4] viruses that caused disease at VUMC in the 2010-2011 season. Although the three clades cocirculated in the same community, there was no evidence of interclade reassortment. Bayesian analysis of 328 VP7 genes of G2 viruses isolated in the last 39 years indicate that existing G2 VP7 gene lineages continue to evolve and that novel lineages, as represented by the VUMC isolates, are constantly being formed. Moreover, G2 lineages are characteristically shaped by lineage turnover events that introduce new globally dominant strains every 7 years, on average. The ongoing evolution of G2 VP7 lineages may give rise to antigenic changes that undermine vaccine effectiveness in the long term. C1 [Dennis, Allison F.; McDonald, Sarah M.; Patton, John T.] NIAID, Infect Dis Lab, NIH, Bethesda, MD 20892 USA. [Payne, Daniel C.; Mijatovic-Rustempasic, Slavica; Esona, Mathew D.] Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Edwards, Kathryn M.; Chappell, James D.] Vanderbilt Univ, Sch Med, Dept Pediat, Nashville, TN 37212 USA. [Chappell, James D.] Vanderbilt Univ, Sch Med, Dept Pathol Microbiol & Immunol, Nashville, TN 37212 USA. RP Patton, JT (reprint author), NIAID, Infect Dis Lab, NIH, Bethesda, MD 20892 USA. EM jpatton@niaid.nih.gov RI Patton, John/P-1390-2014 FU Intramural Research Program of the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) FX A.F.D., S.M.M., and J.T.P. were supported by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). NR 68 TC 25 Z9 25 U1 1 U2 7 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X EI 1098-5514 J9 J VIROL JI J. Virol. PD APR PY 2014 VL 88 IS 7 BP 3789 EP 3801 DI 10.1128/JVI.03516-13 PG 13 WC Virology SC Virology GA AC6IH UT WOS:000332624700015 PM 24429371 ER PT J AU Kim, SY England, LJ Shapiro-Mendoza, CK Wilson, HG Klejka, J Tucker, M Lewis, C Kendrick, JS AF Kim, Shin Y. England, Lucinda J. Shapiro-Mendoza, Carrie K. Wilson, Hoyt G. Klejka, Joseph Tucker, Myra Lewis, Claire Kendrick, Juliette S. TI Community and Federal Collaboration to Assess Pregnancy Outcomes in Alaska Native Women, 1997-2005 SO MATERNAL AND CHILD HEALTH JOURNAL LA English DT Article DE Alaska Native; Pregnancy; Collaboration ID GESTATIONAL DIABETES-MELLITUS AB The objectives are to report the estimated prevalence of pregnancy complications and adverse pregnancy outcomes in a defined population of Alaska Native women and also examine factors contributing to an intensive and successful collaboration between a tribal health center and the Centers for Disease Control and Prevention. Investigators abstracted medical record data from a random sample of singleton deliveries to residents of the study region occurring between 1997 and 2005. We used descriptive statistics to estimate the prevalence and 95 % confidence intervals of selected pregnancy complications and adverse pregnancy outcomes. Records were examined for 505 pregnancies ending in a singleton delivery to 469 women. Pregnancy complication rates were 5.9 % (95 % CI 4.0, 8.4) for gestational diabetes mellitus, 6.1 % (95 % CI 4.2, 8.6 %) for maternal chronic hypertension and 11.5 % (95 % CI 8.8, 14.6) for pregnancy associated hypertension, and 22.9 % (95 % CI 19.2-26.5 %) for anemia. The cesarean section rate was 5.5 % (95 % CI 3.5, 7.5) and 3.8 % (95 % CI 2.3, 5.8) of newborns weighed > 4,500 g. Few previous studies reported pregnancy outcomes among Alaska Native women in a specific geographic region of Alaska and regarding the health needs in this population. We highlight components of our collaboration that contributed to the success of the study. Studies focusing on special populations such as Alaska Native women are feasible and can provide important information on health indicators at the local level. C1 [Kim, Shin Y.; England, Lucinda J.; Shapiro-Mendoza, Carrie K.; Wilson, Hoyt G.; Tucker, Myra; Kendrick, Juliette S.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Reprod Hlth, Atlanta, GA 30341 USA. [Klejka, Joseph; Lewis, Claire] Yukon Kuskokwim Hlth Corp, Bethel, AK USA. RP Kim, SY (reprint author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Reprod Hlth, 4770 Buford Hwy NE,MS K-23, Atlanta, GA 30341 USA. EM skim1@cdc.gov FU Intramural CDC HHS [CC999999] NR 10 TC 0 Z9 0 U1 0 U2 2 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1092-7875 EI 1573-6628 J9 MATERN CHILD HLTH J JI Matern. Child Health J. PD APR PY 2014 VL 18 IS 3 BP 634 EP 639 DI 10.1007/s10995-013-1287-9 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AD1XI UT WOS:000333026600014 PM 23775248 ER PT J AU Harris, LFF Taylor, AW Zhang, F Borkowf, CB Arthur, BC Jacques-Carroll, L Wang, SA Nesheim, SR AF Harris, Lauren F. Fitz Taylor, Allan W. Zhang, Fan Borkowf, Craig B. Arthur, Bayo C. Jacques-Carroll, Lisa Wang, Susan A. Nesheim, Steven R. TI Factors Associated with Human Immunodeficiency Virus Screening of Women During Pregnancy, Labor and Delivery, United States, 2005-2006 SO MATERNAL AND CHILD HEALTH JOURNAL LA English DT Article DE HIV; Perinatal; Pregnancy; Screening ID FOR-DISEASE-CONTROL; PRENATAL-CARE; TESTING RECOMMENDATIONS; PERINATAL TRANSMISSION; HIV; PREVENTION; CONSENT; RATES AB The purpose of this study was to estimate prenatal human immunodeficiency virus (HIV) screening rates prior to and on admission to labor and delivery (L&D) and to examine factors associated with HIV screening, including hospital policies, with a comparison of HIV and hepatitis B prenatal screening practices and hospital policies. In March 2006, a survey of hospitals (n = 190) and review of paired maternal and infant medical records (n = 4,762) were conducted in 50 US states, DC, and Puerto Rico. Data from the survey and medical record review were analyzed using SAS software v9.2 (SAS Institute, Cary, NC). HIV testing before delivery occurred among 3,438 women (73.9 %); African American and Hispanic women were more likely to be tested than white women [aOR 2.22, 95 % CI (1.6-3.1) and aOR 1.55, 95 % CI (1.1-2.2), respectively]. Among women without previous HIV testing, 138 (16.6 %) were tested after admission to labor and delivery. Policies to test women with undocumented HIV status in at delivery were present in 65 (36.3 %) hospitals. HIV testing after admission to L&D was more likely in hospitals with policies to test women with undocumented HIV status [aOR 5.91, 95 % CI (2.0-17.8)]. Overall, policies and screening practices for HIV were consistently less prevalent than those for hepatitis B. Many women are not being routinely screened for HIV before or at delivery. Women with unknown HIV status were more likely to be tested in L&D in hospitals with testing policies. C1 [Harris, Lauren F. Fitz] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, ICF Int, Atlanta, GA 30333 USA. [Harris, Lauren F. Fitz] Assoc Sch Publ Hlth, Washington, DC USA. [Taylor, Allan W.; Nesheim, Steven R.] Ctr Dis Control & Prevent CDC, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div HIV AIDS Prevent, Epidemiol Branch, Atlanta, GA USA. [Zhang, Fan; Arthur, Bayo C.; Jacques-Carroll, Lisa] CDC, Natl Ctr Immunizat & Resp Dis, Immunizat Serv Div, Hlth Serv Res & Evaluat Branch, Atlanta, GA 30333 USA. [Borkowf, Craig B.] CDC, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div HIV AIDS Prevent, Quantitat Sci & Data Management Branch, Atlanta, GA 30333 USA. [Wang, Susan A.] CDC, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div Viral Hepatitis, Prevent Branch, Atlanta, GA 30333 USA. RP Harris, LFF (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, ICF Int, 1600 Clifton Rd,MS E-45, Atlanta, GA 30333 USA. EM LFitzharris@cdc.gov NR 25 TC 1 Z9 1 U1 0 U2 3 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1092-7875 EI 1573-6628 J9 MATERN CHILD HLTH J JI Matern. Child Health J. PD APR PY 2014 VL 18 IS 3 BP 648 EP 656 DI 10.1007/s10995-013-1289-7 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AD1XI UT WOS:000333026600016 ER PT J AU Kim, C Kim, SY Sappenfield, W Wilson, HG Salihu, HM Sharma, AJ AF Kim, Catherine Kim, Shin Y. Sappenfield, William Wilson, Hoyt G. Salihu, Hamisu M. Sharma, Andrea J. TI Are Gestational Diabetes Mellitus and Preconception Diabetes Mellitus Less Common in Non-Hispanic Black Women than in Non-Hispanic White Women? SO MATERNAL AND CHILD HEALTH JOURNAL LA English DT Article DE Race; Ethnicity; Birth certificates; Prenatal; Gestational diabetes; Diabetes mellitus; Type 2 diabetes mellitus ID BODY-MASS INDEX; RACIAL/ETHNIC DISPARITIES; PREVALENCE; RISK; WEIGHT; BIRTH; POPULATION; GLUCOSE; OBESITY; IMPACT AB Based on their higher risk of type 2 diabetes, non-Hispanic blacks (NHBs) would be expected to have higher gestational diabetes mellitus (GDM) risk compared to non-Hispanic whites (NHWs). However, previous studies have reported lower GDM risk in NHBs versus NHWs. We examined whether GDM risk was lower in NHBs and NHWs, and whether this disparity differed by age group. The cohort consisted of 462,296 live singleton births linked by birth certificate and hospital discharge data from 2004 to 2007 in Florida. Using multivariable regression models, we examined GDM risk stratified by age and adjusted for body mass index (BMI) and other covariates. Overall, NHBs had a lower prevalence of GDM (2.5 vs. 3.1 %, p < 0.01) and a higher proportion of preconception DM births (0.5 vs. 0.3 %, p a parts per thousand currency sign 0.01) than NHWs. Among women in their teens (risk ratio 0.56, p < 0.01) and 20-29 years of age (risk ratio 0.85, p < 0.01), GDM risk was lower in NHBs than NHWs. These patterns did not change with adjustment for BMI and other covariates. Among women 30-39 years (risk ratio 1.18, p < 0.01) and a parts per thousand yen40 years (risk ratio 1.22, p < 0.01), GDM risk was higher in NHBs than NHWs, but risk was higher in NHWs after adjustment for BMI. Associations between BMI and GDM risk did not vary by race/ethnicity or age group. NHBs have lower risk of GDM than NHWs at younger ages, regardless of BMI. NHBs had higher risk than NHWs at older ages, largely due to racial/ethnic disparities in overweight/obesity at older ages. C1 [Kim, Catherine] Univ Michigan, Dept Med, Ann Arbor, MI 48109 USA. [Kim, Catherine] Univ Michigan, Dept Obstet & Gynecol, Ann Arbor, MI 48109 USA. [Kim, Shin Y.; Wilson, Hoyt G.; Sharma, Andrea J.] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Sappenfield, William; Salihu, Hamisu M.] Univ S Florida, Dept Publ Hlth, Tampa, FL USA. [Sappenfield, William; Salihu, Hamisu M.] Univ S Florida, Coll Med, Tampa, FL USA. RP Kim, C (reprint author), Univ Michigan, Dept Med, 2800 Plymouth Rd,Bldg 16,Room 430W, Ann Arbor, MI 48109 USA. EM cathkim@umich.edu OI Sharma, Andrea/0000-0003-0385-0011 FU NIDDK NIH HHS [R01 DK083297, K23 DK071552, P30 DK020572, R03 DK083332] NR 29 TC 1 Z9 1 U1 0 U2 1 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1092-7875 EI 1573-6628 J9 MATERN CHILD HLTH J JI Matern. Child Health J. PD APR PY 2014 VL 18 IS 3 BP 698 EP 706 DI 10.1007/s10995-013-1295-9 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AD1XI UT WOS:000333026600022 PM 23793482 ER PT J AU Jackson, BR Kucerova, Z Roy, SL Aguirre, G Weiss, J Sriram, R Yoder, J Foelber, R Baty, S Derado, G Stramer, SL Winkelman, V Visvesvara, GS AF Jackson, Brendan R. Kucerova, Zuzana Roy, Sharon L. Aguirre, Glenda Weiss, Joli Sriram, Rama Yoder, Jonathan Foelber, Rebecca Baty, Steven Derado, Gordana Stramer, Susan L. Winkelman, Valerie Visvesvara, Govinda S. TI Serologic survey for exposure following fatal Balamuthia mandrillaris infection SO PARASITOLOGY RESEARCH LA English DT Article ID FREE-LIVING AMEBAS; SERUM ANTIBODIES; ENCEPHALITIS; AGENT AB Granulomatous amebic encephalitis (GAE) from Balamuthia mandrillaris, a free-living ameba, has a case fatality rate exceeding 90 % among recognized cases in the USA. In August 2010, a GAE cluster occurred following transplantation of infected organs from a previously healthy landscaper in Tucson, AZ, USA, who died from a suspected stroke. As B. mandrillaris is thought to be transmitted through soil, a serologic survey of landscapers and a comparison group of blood donors in southern Arizona was performed. Three (3.6 %) of 83 serum samples from landscapers and 11 (2.5 %) of 441 serum samples from blood donors were seropositive (p = 0.47). On multivariable analysis, county of residence was associated with seropositivity, whereas age, sex, and ethnicity were not. Exposure to B. mandrillaris, previously unexamined in North America, appears to be far more common than GAE in Southern Arizona. Risk factors for disease progression and the ameba's geographic range should be examined. C1 [Jackson, Brendan R.; Kucerova, Zuzana; Roy, Sharon L.; Sriram, Rama; Yoder, Jonathan; Baty, Steven; Derado, Gordana; Visvesvara, Govinda S.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Aguirre, Glenda] Pima Cty Hlth Dept, Tucson, AZ USA. [Weiss, Joli; Baty, Steven] Arizona Dept Hlth Serv, Phoenix, AZ 85007 USA. [Foelber, Rebecca] Tufts Sch Vet Med, North Grafton, MA USA. [Stramer, Susan L.] Amer Red Cross, Gaithersburg, MD USA. [Winkelman, Valerie] Creat Testing Solut, Tempe, AZ USA. RP Jackson, BR (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM iyn0@cdc.gov FU Intramural CDC HHS [CC999999] NR 23 TC 6 Z9 6 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0932-0113 EI 1432-1955 J9 PARASITOL RES JI Parasitol. Res. PD APR PY 2014 VL 113 IS 4 BP 1305 EP 1311 DI 10.1007/s00436-014-3769-0 PG 7 WC Parasitology SC Parasitology GA AD1YO UT WOS:000333029800007 PM 24458652 ER PT J AU Carreon, T Hein, MJ Hanley, KW Viet, SM Ruder, AM AF Carreon, Tania Hein, Misty J. Hanley, Kevin W. Viet, Susan M. Ruder, Avima M. TI Coronary Artery Disease and Cancer Mortality in a Cohort of Workers Exposed to Vinyl Chloride, Carbon Disulfide, Rotating Shift Work, and o- Toluidine at a Chemical Manufacturing Plant SO AMERICAN JOURNAL OF INDUSTRIAL MEDICINE LA English DT Article DE cohort mortality; chemical manufacturing; vinyl chloride; carbon disulfide; o-toluidine; shift work; cancer; coronary artery disease ID TABLE ANALYSIS SYSTEM; CARDIOVASCULAR-DISEASE; EPIDEMIOLOGIC EVIDENCE; HEART-DISEASE; RISK-FACTORS; METAANALYSIS; ANILINE; SMOKING; UPDATE; EXCESS AB BackgroundWe updated through 2007 the mortality experience of 1,874 workers employed at a New York State chemical manufacturing plant between 1946 and 2006. MethodsReassessed exposures to vinyl chloride, carbon disulfide, and shift work and categories of o-toluidine exposure were based on year, department and job title. Standardized mortality ratios (SMR) compared mortality to that of the US population. Internal comparisons used directly standardized rate ratios. ResultsHepatobiliary cancer mortality was elevated among workers ever exposed to vinyl chloride (SMR=3.80, 95% confidence interval 1.89-6.80); directly standardized rates increased with increasing vinyl chloride exposure duration. No increase in non-Hodgkin lymphoma mortality was observed with vinyl chloride and shift work exposures. Internal comparisons showed increased coronary artery disease mortality among long-term workers exposed to carbon disulfide and shift work for 4 years or more. ConclusionsExcess coronary artery disease mortality confirms earlier results; further investigation is needed to understand risk factors. Am. J. Ind. Med. 57:398-411, 2014. (c) 2014 Wiley Periodicals, Inc. C1 [Carreon, Tania; Hein, Misty J.; Hanley, Kevin W.; Ruder, Avima M.] NIOSH, Div Surveillance Hazard Evaluat & Field Studies, Cincinnati, OH 45226 USA. [Viet, Susan M.] Westat Corp, Rockville, MD USA. RP Carreon, T (reprint author), NIOSH, Div Surveillance Hazard Evaluat & Field Studies, Cincinnati, OH 45226 USA. EM tcarreonvalencia@cdc.gov FU NIOSH Operating Funds FX Contract grant sponsor: NIOSH Operating Funds. NR 41 TC 0 Z9 0 U1 1 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0271-3586 EI 1097-0274 J9 AM J IND MED JI Am. J. Ind. Med. PD APR PY 2014 VL 57 IS 4 BP 398 EP 411 DI 10.1002/ajim.22299 PG 14 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AC0XD UT WOS:000332217900002 PM 24464642 ER PT J AU Silver, SR Pinkerton, LE Fleming, DA Jones, JH Allee, S Luo, L Bertke, SJ AF Silver, Sharon R. Pinkerton, Lynne E. Fleming, Donald A. Jones, James H. Allee, Steven Luo, Lian Bertke, Stephen J. TI Retrospective Cohort Study of a Microelectronics and Business Machine Facility SO AMERICAN JOURNAL OF INDUSTRIAL MEDICINE LA English DT Article DE occupation; cancer; chemicals ID TABLE ANALYSIS SYSTEM; CANCER; SEMICONDUCTOR; MORTALITY; WORKERS; TRICHLOROETHYLENE; EXPOSURE; UPDATE; RISK AB ObjectivesWe examined health outcomes among 34,494 workers employed at a microelectronics and business machine facility 1969-2001. MethodsStandardized mortality ratio (SMR) and standardized incidence ratios were used to evaluate health outcomes in the cohort and Cox regression modeling to evaluate relations between scores for occupational exposures and outcomes of a priori interest. ResultsJust over 17% of the cohort (5,966 people) had died through 2009. All cause, all cancer, and many cause-specific SMRs showed statistically significant deficits. In hourly males, SMRs were significantly elevated for non-Hodgkin's lymphoma and rectal cancer. Salaried males had excess testicular cancer incidence. Pleural cancer and mesothelioma excesses were observed in workers hired before 1969, but no available records substantiate use of asbestos in manufacturing processes. A positive, statistically significant relation was observed between exposure scores for tetrachloroethylene and nervous system diseases. ConclusionsFew significant exposure-outcome relations were observed, but risks from occupational exposures cannot be ruled out due to data limitations and the relative youth of the cohort. Am. J. Ind. Med. 57:412-424, 2014. (c) 2013 Wiley Periodicals, Inc. C1 [Silver, Sharon R.; Pinkerton, Lynne E.; Fleming, Donald A.; Bertke, Stephen J.] NIOSH, Div Surveillance Hazard Assessment & Field Studie, Cincinnati, OH 45226 USA. [Jones, James H.] Jones Ind Hyg Serv LLC, Cincinnati, OH USA. [Allee, Steven; Luo, Lian] Emergint Technol, Cincinnati, OH USA. RP Silver, SR (reprint author), NIOSH, Div Surveillance Hazard Assessment & Field Studie, 4676 Columbia Pkwy,Mailstop R-15, Cincinnati, OH 45226 USA. EM ssilver@cdc.gov OI Silver, Sharon/0000-0002-7679-5028 FU National Institute for Occupational Safety and Health (NIOSH) FX Contract grant sponsor: National Institute for Occupational Safety and Health (NIOSH). NR 27 TC 3 Z9 3 U1 2 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0271-3586 EI 1097-0274 J9 AM J IND MED JI Am. J. Ind. Med. PD APR PY 2014 VL 57 IS 4 BP 412 EP 424 DI 10.1002/ajim.22288 PG 13 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AC0XD UT WOS:000332217900003 PM 24375784 ER PT J AU Ma, CC Burchfiel, CM Charles, LE Dorn, JM Andrew, ME Gu, JK Joseph, PN Fekedulegn, D Slaven, JE Hartley, TA Mnatsakanova, A Violanti, JM AF Ma, Claudia C. Burchfiel, Cecil M. Charles, Luenda E. Dorn, Joan M. Andrew, Michael E. Gu, Ja Kook Joseph, Parveen Nedra Fekedulegn, Desta Slaven, James E. Hartley, Tara A. Mnatsakanova, Anna Violanti, John M. TI Authors' Response to the Letter to the Editor: " Definition of Sleep Duration and Carotid Artery Intima Media Thickness: Caution for Risk Assessment" SO AMERICAN JOURNAL OF INDUSTRIAL MEDICINE LA English DT Letter C1 [Ma, Claudia C.; Burchfiel, Cecil M.; Charles, Luenda E.; Andrew, Michael E.; Gu, Ja Kook; Joseph, Parveen Nedra; Fekedulegn, Desta; Slaven, James E.; Hartley, Tara A.; Mnatsakanova, Anna] NIOSH, Hlth Effects Lab Div, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA. [Dorn, Joan M.; Violanti, John M.] SUNY Buffalo, Sch Publ Hlth & Hlth Profess, Dept Social & Prevent Med, Buffalo, NY 14260 USA. [Dorn, Joan M.] Natl Ctr Chron Dis Prevent & Hlth Promot, Off Noncommunicable Dis, Ctr Dis Control & Prevent, Atlanta, GA USA. [Joseph, Parveen Nedra] Univ Chicago, Ctr Comprehens Canc, Epidemiol & Res Recruitment Core, Chicago, IL 60637 USA. [Slaven, James E.] Indiana Univ, Sch Med, Dept Biostat, Indianapolis, IN USA. RP Ma, CC (reprint author), NIOSH, HELD, MSL 4050,1095Willowdale Rd, Morgantown, WV 26505 USA. EM iia4@cdc.gov NR 7 TC 0 Z9 0 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0271-3586 EI 1097-0274 J9 AM J IND MED JI Am. J. Ind. Med. PD APR PY 2014 VL 57 IS 4 BP 490 EP 491 DI 10.1002/ajim.22295 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AC0XD UT WOS:000332217900012 PM 24415485 ER PT J AU Stanley, SL Thomas, CC King, JB Richardson, LC AF Stanley, Sandte L. Thomas, Cheryll C. King, Jessica B. Richardson, Lisa C. TI Predictors of Never Being Screened for Cervical Cancer by Metropolitan Area SO JOURNAL OF COMMUNITY HEALTH LA English DT Article DE Cervical cancer screening; Never screened; Health disparities; Metropolitan area; Health belief model ID UNITED-STATES; ASIAN-AMERICAN; SOCIOECONOMIC-STATUS; HEALTH LITERACY; WHITE WOMEN; BREAST; US; TRENDS; CARE; POPULATIONS AB Previous studies have shown an association between cervical cancer screening and racial/ethnic minority status, no usual source of care, and lower socioeconomic status. This study describes the demographics and health beliefs of women who report never being screened for cervical cancer by area of residence. Data from the 2010 Behavioral Risk Factor Surveillance System were used to study women aged 21-65 years who reported never being screened for cervical cancer. Multivariate logistic regression modeling was used to calculate predicted marginals to examine associations between never being screened and demographic characteristics and health belief model (HBM) constructs by metropolitan statistical area (MSA). After adjusting for all demographics and HBM constructs, prevalence of never being screened was higher for the following women: non-Hispanic Asians/Native Hawaiians/Pacific Islanders (16.5 %, 95 % CI = 13.7 %, 19.8 %) who live in MSAs; those with only a high school diploma who live in MSAs (5.5 %, 95 % CI = 4.7 %, 6.5 %); those living in non-MSAs who reported "fair or poor" general health (4.1 %, 95 % CI = 3.1 %, 5.4 %); and those living in either MSAs and non-MSAs unable to see a doctor within the past 12 months because of cost (MSA: 4.4 %, 95 % CI = 4.0 %, 4.8 %; non-MSA: 3.4 %, 95 % CI = 2.9 %, 3.9 %). The Affordable Care Act will expand access to insurance coverage for cervical cancer screening, without cost sharing for millions of women, essentially eliminating insurance costs as a barrier. Future interventions for women who have never been screened should focus on promoting the importance of screening and reaching non-Hispanic Asians/Native Hawaiians/Pacific Islanders who live in MSAs. C1 [Stanley, Sandte L.; Thomas, Cheryll C.; King, Jessica B.; Richardson, Lisa C.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Richardson, LC (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,E 64, Atlanta, GA 30333 USA. EM lrichardson@cdc.gov FU Intramural CDC HHS [CC999999] NR 44 TC 3 Z9 3 U1 1 U2 8 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0094-5145 EI 1573-3610 J9 J COMMUN HEALTH JI J. Community Health PD APR PY 2014 VL 39 IS 2 BP 400 EP 408 DI 10.1007/s10900-013-9778-6 PG 9 WC Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA AC4IM UT WOS:000332484600026 PM 24162857 ER PT J AU Streja, L Crespi, CM Bastani, R Wong, GC Jones, CA Bernert, JT Tashkin, D Hammond, SK Berman, BA AF Streja, Leanne Crespi, Catherine M. Bastani, Roshan Wong, Glenn C. Jones, Craig A. Bernert, John T. Tashkin, Donald Hammond, S. Katharine Berman, Barbara A. TI Can a Minimal Intervention Reduce Secondhand Smoke Exposure Among Children with Asthma from Low Income Minority Families? Results of a Randomized Trial SO JOURNAL OF IMMIGRANT AND MINORITY HEALTH LA English DT Article DE SHS exposure; Behavioral modification; Environmental tobacco smoke; Childhood asthma; Household smoking restrictions ID ENVIRONMENTAL TOBACCO-SMOKE; PASSIVE SMOKING; LATINO CHILDREN; ETS EXPOSURE; PARENTAL REPORTS; UNITED-STATES; HOME; HEALTH; RESTRICTIONS; DISPARITIES AB We report on the results of a low-intensity behavioral intervention to reduce second hand smoke (SHS) exposure of children with asthma from low income minority households in Los Angeles, California. In this study, 242 child/adult dyads were randomized to a behavioral intervention (video, workbook, minimal counseling) or control condition (brochure). Main outcome measures included child's urine cotinine and parental reports of child's hours of SHS exposure and number of household cigarettes smoked. Implementation of household bans was also considered. No differences in outcomes were detected between intervention and control groups at follow-up. Limitations included high attrition and low rates of collection of objective measures (few children with urine cotinine samples). There continues to be a need for effective culturally and linguistically appropriate strategies that support reduction of household SHS exposure among children with asthma in low income, minority households. C1 [Streja, Leanne; Crespi, Catherine M.; Bastani, Roshan; Berman, Barbara A.] Univ Calif Los Angeles, Div Canc Prevent & Control Res, Los Angeles, CA USA. [Streja, Leanne; Crespi, Catherine M.; Bastani, Roshan; Berman, Barbara A.] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA. [Streja, Leanne; Crespi, Catherine M.; Bastani, Roshan; Berman, Barbara A.] Univ Calif Los Angeles, Jonathan & Karin Fielding Sch Publ Hlth, Los Angeles, CA USA. [Streja, Leanne] City Hope Natl Med Ctr, Div Biostat, Dept Informat Sci, Duarte, CA 91010 USA. [Streja, Leanne] City Hope Natl Med Ctr, Dept Informat Sci, Duarte, CA 91010 USA. [Wong, Glenn C.] GW Graph Works, Los Angeles, CA USA. [Jones, Craig A.] Agcy Adm, Vermont Blueprint Hlth, Montpelier, VT USA. [Bernert, John T.] Ctr Dis Control & Prevent, Emergency Response & Air Toxicants Branch, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA USA. [Tashkin, Donald] Univ Calif Los Angeles, David Geffen Sch Med, Div Pulm & Crit Care Med, Los Angeles, CA 90095 USA. [Hammond, S. Katharine] Univ Calif Berkeley, Sch Publ Hlth, Div Environm Hlth Sci, Berkeley, CA 94720 USA. RP Streja, L (reprint author), City Hope Natl Med Ctr, Dept Informat Sci, 1500 Duarte Rd, Duarte, CA 91010 USA. EM leanne.streja@gmail.com FU NCATS NIH HHS [UL1 TR000124]; NCI NIH HHS [P30 CA016042, CA16042]; NHLBI NIH HHS [HL53957] NR 48 TC 5 Z9 5 U1 3 U2 15 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1557-1912 EI 1557-1920 J9 J IMMIGR MINOR HEALT JI J. Immigr. Minor. Health PD APR PY 2014 VL 16 IS 2 BP 256 EP 264 DI 10.1007/s10903-012-9713-4 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AC6RR UT WOS:000332652800010 PM 22945813 ER PT J AU Nyakarahuka, L Knust, B Schafer, I Nzietchueng, S Wamala, J Shoemaker, T AF Nyakarahuka, L. Knust, B. Schafer, I. Nzietchueng, S. Wamala, J. Shoemaker, T. TI Using network analysis technique to describe the spread of Marburg hemorrhagic fever outbreak in Uganda, 2012 SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES LA English DT Meeting Abstract C1 [Nyakarahuka, L.] Makerere Univ, Uganda Virus Res Inst, Kampala, Uganda. [Knust, B.; Schafer, I.] CDC, Atlanta, GA 30333 USA. [Nzietchueng, S.] Univ Minnesota, Minneapolis, MN USA. [Wamala, J.] Minist Hlth, Kampala, Uganda. [Shoemaker, T.] Uganda Virus Inst, Entebbe, Uganda. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1201-9712 EI 1878-3511 J9 INT J INFECT DIS JI Int. J. Infect. Dis. PD APR PY 2014 VL 21 SU 1 MA Pre.003 BP 2 EP 2 DI 10.1016/j.ijid.2014.03.410 PG 1 WC Infectious Diseases SC Infectious Diseases GA V43TP UT WOS:000209704000004 ER PT J AU Ossai, O Idris, SA Abonyi, G Turkur, D Dankoli, R Ekwueme, O Nwagbo, D Ezeanolue, E Nwanyanwu, O Nwodo, CC Nguku, P Nsubuga, P Ogbuabor, D AF Ossai, O. Idris, S. A. Abonyi, G. Turkur, D. Dankoli, R. Ekwueme, O. Nwagbo, D. Ezeanolue, E. Nwanyanwu, O. Nwodo, C. C. Nguku, P. Nsubuga, P. Ogbuabor, D. TI Bacteriuria and urinary schistosomiasis in primary school children in rural communities in Enugu State, Nigeria, 2012 SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES LA English DT Meeting Abstract C1 [Ossai, O.; Dankoli, R.; Nwodo, C. C.] NFELTP, Abuja, Nigeria. [Idris, S. A.; Turkur, D.] Ahmadu Bello Univ, Zaria, Nigeria. [Abonyi, G.] Enugu State Minist Hlth, Enugu, Nigeria. [Ekwueme, O.; Nwagbo, D.; Ogbuabor, D.] Univ Nigeria, Enugu, Nigeria. [Ezeanolue, E.] Las Vegas Univ, Las Vegas, NV USA. [Nwanyanwu, O.] CDC, Abuja, Nigeria. [Nguku, P.] FELTP, Abuja, FCT, Nigeria. [Nsubuga, P.] US Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1201-9712 EI 1878-3511 J9 INT J INFECT DIS JI Int. J. Infect. Dis. PD APR PY 2014 VL 21 SU 1 MA Pre.007 BP 4 EP 4 DI 10.1016/j.ijid.2014.03.414 PG 1 WC Infectious Diseases SC Infectious Diseases GA V43TP UT WOS:000209704000008 ER PT J AU Pillay, A Katz, S Chi, KH Kool, J Danavall, D Taleo, F Nachamkin, E Tun, Y Asiedu, K Ballard, R Chen, CY AF Pillay, A. Katz, S. Chi, K. -H. Kool, J. Danavall, D. Taleo, F. Nachamkin, E. Tun, Y. Asiedu, K. Ballard, R. Chen, C. Y. TI Molecular characterization of T-pallidum subsp pertenue, the etiologic agent of yaws SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES LA English DT Meeting Abstract C1 [Pillay, A.; Katz, S.; Chi, K. -H.; Danavall, D.; Nachamkin, E.; Chen, C. Y.] Ctr Dis Control & Prevent CDC, Atlanta, GA USA. [Kool, J.] WHO, Port Vila, Vanuatu. [Taleo, F.] Minist Hlth, Port Vila, Vanuatu. [Tun, Y.; Ballard, R.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Asiedu, K.] WHO, CH-1211 Geneva, Switzerland. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1201-9712 EI 1878-3511 J9 INT J INFECT DIS JI Int. J. Infect. Dis. PD APR PY 2014 VL 21 SU 1 MA 21.003 BP 45 EP 46 DI 10.1016/j.ijid.2014.03.512 PG 2 WC Infectious Diseases SC Infectious Diseases GA V43TP UT WOS:000209704000100 ER PT J AU Schwitters, A Kaggwa, M Omiel, P Nagadya, G Kisa, N Dalal, S AF Schwitters, A. Kaggwa, M. Omiel, P. Nagadya, G. Kisa, N. Dalal, S. TI Tracking transfers: TB treatment completion among Ugandan prisoners SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES LA English DT Meeting Abstract C1 [Schwitters, A.] US Ctr Dis Control & Prevent, Atlanta, GA USA. [Kaggwa, M.; Kisa, N.] Uganda Prisons Serv, Kampala, Uganda. [Omiel, P.; Nagadya, G.; Dalal, S.] CDC Uganda, Entebbe, Uganda. NR 0 TC 0 Z9 0 U1 3 U2 3 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1201-9712 EI 1878-3511 J9 INT J INFECT DIS JI Int. J. Infect. Dis. PD APR PY 2014 VL 21 SU 1 MA 27.008 BP 60 EP 60 DI 10.1016/j.ijid.2014.03.544 PG 1 WC Infectious Diseases SC Infectious Diseases GA V43TP UT WOS:000209704000132 ER PT J AU Carroll, S Kirkcaldy, R Fox, J Kubin, G Trees, D AF Carroll, S. Kirkcaldy, R. Fox, J. Kubin, G. Trees, D. TI Decreased susceptibility to ceftriaxone in Neisseria gonorrhoeae in the absence of a mosaic penicillin-binding protein 2 (PenA) allele SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES LA English DT Meeting Abstract C1 [Carroll, S.; Kirkcaldy, R.; Trees, D.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Fox, J.] Oklahoma Dept Hlth, Oklahoma City, OK USA. [Kubin, G.] Texas Dept State Hlth Serv, Austin, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1201-9712 EI 1878-3511 J9 INT J INFECT DIS JI Int. J. Infect. Dis. PD APR PY 2014 VL 21 SU 1 MA 40.049 BP 102 EP 102 DI 10.1016/j.ijid.2014.03.639 PG 1 WC Infectious Diseases SC Infectious Diseases GA V43TP UT WOS:000209704000224 ER PT J AU Ribeiro, A Cheng, PY Mirza, S Palomeque, F Zanetta, DMT Widdowson, MA AF Ribeiro, A. Cheng, P. -Y. Mirza, S. Palomeque, F. Zanetta, D. M. T. Widdowson, M. -A. TI The Impact of seasonal influenza vaccination among persons 60 years and older, on rates of influenza-associated mortality and hospitalization from 1994 to 2009 in Sao Paulo State, Brazil SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES LA English DT Meeting Abstract C1 [Ribeiro, A.] Epidemiol Surveillance Ctr, Sao Paulo, Brazil. [Cheng, P. -Y.; Mirza, S.; Palomeque, F.; Widdowson, M. -A.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Zanetta, D. M. T.] Sch Publ Hlth, Sao Paulo, Brazil. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1201-9712 EI 1878-3511 J9 INT J INFECT DIS JI Int. J. Infect. Dis. PD APR PY 2014 VL 21 SU 1 MA 41.004 BP 104 EP 105 DI 10.1016/j.ijid.2014.03.644 PG 2 WC Infectious Diseases SC Infectious Diseases GA V43TP UT WOS:000209704000229 ER PT J AU Asaku, ST Apangu, T Mead, P AF Asaku, S. T. Apangu, T. Mead, P. TI Surveillance and response: Integrated indigenous health systems-based sentinel detection of human plague in a plague endemic West Nile region of Uganda (2008-2013) SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES LA English DT Meeting Abstract C1 [Asaku, S. T.] Uganda Virus Res Inst, Kampala, Uganda. [Apangu, T.] Uganda Virus Res Inst, Kampla, Uganda. [Mead, P.] Ctr Dis Control & Prevent, Ft Collins, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1201-9712 EI 1878-3511 J9 INT J INFECT DIS JI Int. J. Infect. Dis. PD APR PY 2014 VL 21 SU 1 MA 43.011 BP 141 EP 141 DI 10.1016/j.ijid.2014.03.718 PG 1 WC Infectious Diseases SC Infectious Diseases GA V43TP UT WOS:000209704000303 ER PT J AU McCollum, A Nakazawa, Y Ndongala, GM Pukuta, E Karhemere, S Lushima, RS Ilunga, BK Kabamba, J Li, Y Damon, I Carroll, D Reynolds, M Malekani, J Tamfum, JJM AF McCollum, A. Nakazawa, Y. Ndongala, G. Mutombo Pukuta, E. Karhemere, S. Lushima, R. Shongo Ilunga, B. Kebela Kabamba, J. Li, Y. Damon, I. Carroll, D. Reynolds, M. Malekani, J. Tamfum, J. -J. Muyembe TI Human monkeypox in the Kivus, a conflict region of The Democratic Republic of the Congo SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES LA English DT Meeting Abstract C1 [McCollum, A.; Nakazawa, Y.; Li, Y.; Damon, I.; Carroll, D.; Reynolds, M.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Ndongala, G. Mutombo] Minist Hlth, Goma, Congo. [Pukuta, E.; Karhemere, S.; Tamfum, J. -J. Muyembe] INRB, Kinshasa, Congo. [Lushima, R. Shongo; Ilunga, B. Kebela] Minist Hlth, Kinshasa, Congo. [Kabamba, J.] CDC Kinshasa, Kinshasa, Congo. [Malekani, J.] Univ Kinshasa, Kinshasa, Zaire. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1201-9712 EI 1878-3511 J9 INT J INFECT DIS JI Int. J. Infect. Dis. PD APR PY 2014 VL 21 SU 1 MA 47.033 BP 192 EP 192 DI 10.1016/j.ijid.2014.03.820 PG 1 WC Infectious Diseases SC Infectious Diseases GA V43TP UT WOS:000209704000405 ER PT J AU Tapia, EDLN Tinoco, YO Carcamo, C Azziz-Baumgartner, E Montgomery, JM AF Tapia, E. D. L. N. Tinoco, Y. O. Carcamo, C. Azziz-Baumgartner, E. Montgomery, J. M. TI Healthcare seeking behavior in Individuals with Influenza-like Illness (ILI) during the influenza pandemic of 2009 compared to posterior years in Peru SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES LA English DT Meeting Abstract C1 [Tapia, E. D. L. N.] Naval Med Res Unit 6, Callao, Peru. [Tinoco, Y. O.] Naval Med Res Unit 6, Lima, Callao, Peru. [Carcamo, C.] Univ Cayetano, Lima, Peru. [Azziz-Baumgartner, E.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Montgomery, J. M.] Ctr Dis Control & Prevent Kenya CDC K, Nairobi, Kenya. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1201-9712 EI 1878-3511 J9 INT J INFECT DIS JI Int. J. Infect. Dis. PD APR PY 2014 VL 21 SU 1 MA 51.002 BP 215 EP 215 DI 10.1016/j.ijid.2014.03.870 PG 1 WC Infectious Diseases SC Infectious Diseases GA V43TP UT WOS:000209704000454 ER PT J AU Bhengsri, S Baggett, HC Edouard, S Dowell, SF Watt, G Raoult, D Parola, P AF Bhengsri, S. Baggett, H. C. Edouard, S. Dowell, S. F. Watt, G. Raoult, D. Parola, P. TI Spotted fever group, typhus group rickettsioses and sennetsu neorickettsiosis in rural Thailand SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES LA English DT Meeting Abstract C1 [Bhengsri, S.; Watt, G.] Thailand MOPH US CDC Collaborat, Global Dis Detect Reg Ctr, Int Emerging Infect Program, Nonthaburi, Thailand. [Baggett, H. C.] CDC, Global Dis Detect Branch, Div Global Hlth Protect, Ctr Global Hlth, Atlanta, GA 30333 USA. [Edouard, S.; Raoult, D.; Parola, P.] Fac Mediterranee, Marseilles, France. [Dowell, S. F.] CDC, Ctr Global Hlth, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1201-9712 EI 1878-3511 J9 INT J INFECT DIS JI Int. J. Infect. Dis. PD APR PY 2014 VL 21 SU 1 MA 51.034 BP 231 EP 231 DI 10.1016/j.ijid.2014.03.902 PG 1 WC Infectious Diseases SC Infectious Diseases GA V43TP UT WOS:000209704000486 ER PT J AU Reynolds, M Malekani, J Damon, I Monroe, B Kabamba, J Lushima, RS Nguete, B Karhemere, S Pukuta, E Tack, D McCollum, A Bass, J Wemakoy, O AF Reynolds, M. Malekani, J. Damon, I. Monroe, B. Kabamba, J. Lushima, R. Shongo Nguete, B. Karhemere, S. Pukuta, E. Tack, D. McCollum, A. Bass, J. Wemakoy, O. TI Training health workers for enhanced monkeypox surveillance, Democratic Republic of the Congo SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES LA English DT Meeting Abstract C1 [Reynolds, M.; Damon, I.; Monroe, B.; McCollum, A.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Malekani, J.] Univ Kinshasa, Kinshasa, Congo. [Kabamba, J.] CDC Kinshasa, Kinshasa, Congo. [Lushima, R. Shongo] Minist Hlth, Kinshasa, Congo. [Nguete, B.; Wemakoy, O.] Kinshasa Sch Publ Hlth, Kinshasa, Zaire. [Karhemere, S.; Pukuta, E.] INRB, Kinshasa, Congo. [Tack, D.] US Ctr Dis Control, Atlanta, GA USA. [Bass, J.] Univ Michigan, Ann Arbor, MI 48109 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1201-9712 EI 1878-3511 J9 INT J INFECT DIS JI Int. J. Infect. Dis. PD APR PY 2014 VL 21 SU 1 MA 53.031 BP 274 EP 275 DI 10.1016/j.ijid.2014.03.990 PG 2 WC Infectious Diseases SC Infectious Diseases GA V43TP UT WOS:000209704000574 ER PT J AU Hughes, C McCollum, A Pukuta, E Karhemere, S Nguete, B Lushima, RS Kabamba, J Balilo, M Tamfum, JJM Wemakoy, O Malekani, J Monroe, B Damon, I Reynolds, M AF Hughes, C. McCollum, A. Pukuta, E. Karhemere, S. Nguete, B. Lushima, R. Shongo Kabamba, J. Balilo, M. Tamfum, J. -J. Muyembe Wemakoy, O. Malekani, J. Monroe, B. Damon, I. Reynolds, M. TI Ocular complications associated with acute monkeypox virus infection, DRC SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES LA English DT Meeting Abstract C1 [Hughes, C.] US Ctr Dis Control & Prevent, Atlanta, GA USA. [McCollum, A.; Monroe, B.; Damon, I.; Reynolds, M.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Pukuta, E.; Karhemere, S.; Tamfum, J. -J. Muyembe] INRB, Kinshasa, Congo. [Nguete, B.; Wemakoy, O.] Kinshasa Sch Publ Hlth, Kinshasa, Congo. [Lushima, R. Shongo; Balilo, M.] Minist Hlth, Kinshasa, Congo. [Kabamba, J.] CDC Kinshasa, Kinshasa, Congo. [Malekani, J.] Univ Kinshasa, Kinshasa, Congo. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1201-9712 EI 1878-3511 J9 INT J INFECT DIS JI Int. J. Infect. Dis. PD APR PY 2014 VL 21 SU 1 MA 53.035 BP 276 EP 277 DI 10.1016/j.ijid.2014.03.994 PG 2 WC Infectious Diseases SC Infectious Diseases GA V43TP UT WOS:000209704000578 ER PT J AU Iyengar, PJ von Mollendorf, C Martinson, N Chhagan, M Variava, E Tempia, S McMorrow, M Gambhir, M Cauchemez, S Cohen, A Cohen, C AF Iyengar, P. J. von Mollendorf, C. Martinson, N. Chhagan, M. Variava, E. Tempia, S. McMorrow, M. Gambhir, M. Cauchemez, S. Cohen, A. Cohen, C. TI Household transmission of influenza in a developing country setting-South Africa, 2013 SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES LA English DT Meeting Abstract C1 [Iyengar, P. J.; McMorrow, M.; Gambhir, M.] Ctr Dis Control & Prevent, Atlanta, GA USA. [von Mollendorf, C.] Natl Inst Communicable Dis, Johannesburg, South Africa. [Martinson, N.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [Chhagan, M.] Univ KwaZulu Natal, Durban, South Africa. [Variava, E.] Klerksdorp Tshepong Hosp, Klerksdorp, North West Prov, South Africa. [Tempia, S.] Ctr Dis Control & Prevent, Pretoria, South Africa. [Cauchemez, S.] Univ London Imperial Coll Sci Technol & Med, London, England. [Cohen, A.] CDC, Atlanta, South Africa. [Cohen, C.] Natl Inst Communicable Dis, Johannesburg, South Africa. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1201-9712 EI 1878-3511 J9 INT J INFECT DIS JI Int. J. Infect. Dis. PD APR PY 2014 VL 21 SU 1 MA 57.030 BP 325 EP 325 DI 10.1016/j.ijid.2014.03.1091 PG 1 WC Infectious Diseases SC Infectious Diseases GA V43TP UT WOS:000209704000674 ER PT J AU Goodwin, R Bernstein, D Atmar, RL Lyon, GM Treanor, JJ Chen, WH Frenck, RW Jiang, X Vinje, J Al-Ibrahim, MS Barrett, J Graham, DY Borkowski, A Clemens, R Mendelman, PM AF Goodwin, R. Bernstein, D. Atmar, R. L. Lyon, G. M. Treanor, J. J. Chen, W. H. Frenck, R. W. Jiang, X. Vinje, J. Al-Ibrahim, M. S. Barrett, J. Graham, D. Y. Borkowski, A. Clemens, R. Mendelman, P. M. TI Reduction in vomiting associated with norovirus vaccination in a live norovirus human challenge study SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES LA English DT Meeting Abstract C1 [Goodwin, R.; Mendelman, P. M.] Takeda Vaccines, Bozeman, MT USA. [Bernstein, D.; Frenck, R. W.; Jiang, X.] Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH USA. [Atmar, R. L.; Graham, D. Y.] Baylor Coll Med, Houston, TX 77030 USA. [Lyon, G. M.] Emory Univ, Sch Med, Atlanta, GA USA. [Treanor, J. J.] Univ Rochester, Med Ctr, Rochester, NY 14627 USA. [Chen, W. H.] Univ Maryland, Sch Med, Baltimore, MD 21201 USA. [Vinje, J.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Al-Ibrahim, M. S.] Shin Nippon Biomed Labs, Baltimore, MD USA. [Barrett, J.] EMMES Corp, Rockville, MD USA. [Borkowski, A.; Clemens, R.] Takeda Vaccines, Zurich, Switzerland. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1201-9712 EI 1878-3511 J9 INT J INFECT DIS JI Int. J. Infect. Dis. PD APR PY 2014 VL 21 SU 1 MA 63.011 BP 434 EP 435 DI 10.1016/j.ijid.2014.03.1316 PG 2 WC Infectious Diseases SC Infectious Diseases GA V43TP UT WOS:000209704000897 ER PT J AU Doyle, JS Hunt, D Aspinall, EJ Hutchinson, SJ Goldberg, DJ Nguyen, T Falck-Ytter, Y Morgan, RL Smith, B Stoove, M Lutchers, S Thompson, AJ Wiktor, SZ Hellard, ME AF Doyle, J. S. Hunt, D. Aspinall, E. J. Hutchinson, S. J. Goldberg, D. J. Nguyen, T. Falck-Ytter, Y. Morgan, R. L. Smith, B. Stoove, M. Lutchers, S. Thompson, A. J. Wiktor, S. Z. Hellard, M. E. TI A SYSTEMATIC REVIEW OF INTERVENTIONS TO REDUCE ALCOHOL CONSUMPTION AMONG INDIVIDUALS WITH CHRONIC HCV INFECTION SO JOURNAL OF HEPATOLOGY LA English DT Meeting Abstract CT 49th Annual International Liver Congress of the European-Association-for-the-Study-of-the-Liver CY APR 09-13, 2014 CL London, ENGLAND SP European Assoc Study Liver C1 [Doyle, J. S.; Hunt, D.; Stoove, M.; Hellard, M. E.] Burnet Inst, Ctr Populat Hlth, Melbourne, Vic, Australia. [Doyle, J. S.; Hellard, M. E.] Alfred & Monash Univ, Dept Infect Dis, Melbourne, Vic, Australia. [Doyle, J. S.; Hellard, M. E.] Monash Univ, Dept Epidemiol & Preventat Med, Melbourne, Vic 3004, Australia. [Aspinall, E. J.; Hutchinson, S. J.] Glasgow Caledonian Univ, Sch Hlth & Life Sci, Glasgow G4 0BA, Lanark, Scotland. [Aspinall, E. J.; Hutchinson, S. J.; Goldberg, D. J.] Hlth Protect Scotland, Glasgow, Lanark, Scotland. [Nguyen, T.; Wiktor, S. Z.] WHO, Global Hepatitis Programme, CH-1211 Geneva, Switzerland. [Falck-Ytter, Y.] Case Western Reserve Univ, Case & VA Med Ctr, Cleveland, OH 44106 USA. [Morgan, R. L.; Smith, B.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Lutchers, S.] Burnet Inst, Ctr Int Hlth, Melbourne, Vic, Australia. [Thompson, A. J.] St Vincents Hosp, Dept Gastroenterol, Melbourne, Vic, Australia. [Thompson, A. J.] Victorian Infect Dis Reference Lab, Melbourne, Vic, Australia. EM j.doyle@burnet.edu.au NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-8278 EI 1600-0641 J9 J HEPATOL JI J. Hepatol. PD APR PY 2014 VL 60 IS 1 SU S MA P734 BP S314 EP S315 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CT5DT UT WOS:000362828600151 ER PT J AU Gordon, SC Lamerato, L Rupp, LB Holmberg, SD Moorman, AC Spradling, PR Teshale, E Vijayadeva, V Boscarino, JA Schmidt, MA Nerenz, D Oja-Tebbe, N Lu, M AF Gordon, S. C. Lamerato, L. Rupp, L. B. Holmberg, S. D. Moorman, A. C. Spradling, P. R. Teshale, E. Vijayadeva, V. Boscarino, J. A. Schmidt, M. A. Nerenz, D. Oja-Tebbe, N. Lu, M. CA CHeCS Investigators TI ESTIMATED PREVALENCE OF HCV CIRRHOSIS IN THE CHRONIC HEPATITIS COHORT STUDY (CHECS) SO JOURNAL OF HEPATOLOGY LA English DT Meeting Abstract CT 49th Annual International Liver Congress of the European-Association-for-the-Study-of-the-Liver CY APR 09-13, 2014 CL London, ENGLAND SP European Assoc Study Liver C1 [Gordon, S. C.] Henry Ford Hlth Syst, Gastroenterol & Hepatol, Detroit, MI USA. [Lamerato, L.; Oja-Tebbe, N.; Lu, M.] Henry Ford Hlth Syst, Publ Hlth Sci, Detroit, MI USA. [Rupp, L. B.; Nerenz, D.] Henry Ford Hlth Syst, Ctr Hlth Policy & Hlth Serv Res, Detroit, MI USA. [Holmberg, S. D.; Moorman, A. C.; Spradling, P. R.; Teshale, E.] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA USA. [Vijayadeva, V.] Kaiser Permante Hawaii, Ctr Hlth Res, Honolulu, HI USA. [Boscarino, J. A.] Weis Ctr Res, Geisinger Clin, Ctr Hlth Res, Danville, PA 17822 USA. [Schmidt, M. A.] Kaiser Permanente Northwest, Ctr Hlth Res, Portland, OR USA. EM sgordon3@hfhs.org NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-8278 EI 1600-0641 J9 J HEPATOL JI J. Hepatol. PD APR PY 2014 VL 60 IS 1 SU S MA P1034 BP S419 EP S420 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CT5DT UT WOS:000362828600450 ER PT J AU Rein, DB Stevens, G Flaxman, A Wittenborn, JS Timothy, N Wiktor, SZ Wiersma, ST AF Rein, D. B. Stevens, G. Flaxman, A. Wittenborn, J. S. Timothy, N. Wiktor, S. Z. Wiersma, S. T. TI THE GLOBAL BURDEN OF HEPATITIS A VIRUS IN 1990 AND 2005 SO JOURNAL OF HEPATOLOGY LA English DT Meeting Abstract CT 49th Annual International Liver Congress of the European-Association-for-the-Study-of-the-Liver CY APR 09-13, 2014 CL London, ENGLAND SP European Assoc Study Liver C1 [Rein, D. B.; Wittenborn, J. S.] Univ Chicago, NORC, Dept Publ Hlth, Atlanta, GA USA. [Stevens, G.] WHO, Dept Hlth Stat & Informat Syst, CH-1211 Geneva, Switzerland. [Flaxman, A.] Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98195 USA. [Timothy, N.; Wiktor, S. Z.] WHO, Global Hepatitis Programme, CH-1211 Geneva, Switzerland. [Wiersma, S. T.] US Ctr Dis Control & Prevent, Atlanta, GA USA. EM rein-david@norc.org NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-8278 EI 1600-0641 J9 J HEPATOL JI J. Hepatol. PD APR PY 2014 VL 60 IS 1 SU S MA P703 BP S303 EP S303 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CT5DT UT WOS:000362828600121 ER PT J AU Zeremski, M Dimova, RB Zavala, R Kritz, S Lin, M Smith, BD Zibbell, J Talal, AH AF Zeremski, M. Dimova, R. B. Zavala, R. Kritz, S. Lin, M. Smith, B. D. Zibbell, J. Talal, A. H. TI HEPATITIS C VIRUS (HCV) RELATED KNOWLEDGE AND WILLINGNESS TO RECEIVE TREATMENT AMONG PATIENTS ON METHADONE MAINTENANCE SO JOURNAL OF HEPATOLOGY LA English DT Meeting Abstract CT 49th Annual International Liver Congress of the European-Association-for-the-Study-of-the-Liver CY APR 09-13, 2014 CL London, ENGLAND SP European Assoc Study Liver C1 [Zeremski, M.] Weill Cornell Med Coll, Med, New York, NY USA. [Dimova, R. B.] SUNY Buffalo, Biostat, Buffalo, NY 14260 USA. [Zavala, R.; Kritz, S.; Lin, M.] START Treatment & Recovery Ctr, Brooklyn, NY USA. [Smith, B. D.; Zibbell, J.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Talal, A. H.] SUNY Buffalo, Med, Buffalo, NY 14260 USA. EM ahtalal@buffalo.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-8278 EI 1600-0641 J9 J HEPATOL JI J. Hepatol. PD APR PY 2014 VL 60 IS 1 SU S MA P1192 BP S483 EP S484 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CT5DT UT WOS:000362828600608 ER PT J AU Sinclair, RC Cunningham, TR AF Sinclair, Raymond C. Cunningham, Thomas R. TI Safety activities in small businesses SO SAFETY SCIENCE LA English DT Article DE Small business; Workplace monitoring; Safety practices; Work-related injuries ID OCCUPATIONAL-HEALTH; SMALL ENTERPRISES; OSHA ENFORCEMENT; INJURY RATES; SIZE; IMPACT; INTERVENTION; PERFORMANCE; PREVENTION; MANAGEMENT AB Background: Workplace injuries occur at higher rates in smaller firms than in larger firms, and the number of workplace safety activities appear to be inversely associated with those rates. Predictors of safety activities are rarely studied. Methods: This study uses data from a national random survey of firms (n = 722) with less than 250 employees conducted in 2002. Results: We found that, regardless of firm size or industry, safety activities were more common in 2002 than they were in a similar 1983 study. Having had an OSHA inspection in the last five years and firm size were stronger predictors of safety activities than industry hazardousness and manager's perceptions of hazardousness. All four variables were significant predictors (beta range .19 to .28; R-2 = .27). Conclusions: Further progress in the prevention of injuries in small firms will require attention to factors likely subsumed within the firm size variable, especially the relative lack of slack resources that might be devoted to safety activities. Published by Elsevier Ltd. C1 [Sinclair, Raymond C.; Cunningham, Thomas R.] NIOSH, Cincinnati, OH 45243 USA. RP Sinclair, RC (reprint author), NIOSH, 4676 Columbia Pkwy, Cincinnati, OH 45243 USA. EM Rsinclair@cdc.gov; Tcunningham@cdc.gov FU Intramural CDC HHS [CC999999] NR 42 TC 8 Z9 8 U1 1 U2 25 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0925-7535 EI 1879-1042 J9 SAFETY SCI JI Saf. Sci. PD APR PY 2014 VL 64 BP 32 EP 38 DI 10.1016/j.ssci.2013.11.022 PG 7 WC Engineering, Industrial; Operations Research & Management Science SC Engineering; Operations Research & Management Science GA AB0MB UT WOS:000331485300004 PM 26339124 ER PT J AU Mezal, EH Sabol, A Khan, MA Ali, N Stefanova, R Khan, AA AF Mezal, Ezat H. Sabol, Ashley Khan, Mariam A. Ali, Nawab Stefanova, Rossina Khan, Ashraf A. TI Isolation and molecular characterization of Salmonella enterica serovar Enteritidis from poultry house and clinical samples during 2010 SO FOOD MICROBIOLOGY LA English DT Article DE Salmonella Enteritidis; MLVA; Pulsed-field gel electrophoresis; Plasmid ID FIELD GEL-ELECTROPHORESIS; UNITED-STATES; IMPORTED SEAFOOD; SEROTYPE ENTERITIDIS; ESCHERICHIA-COLI; VARIABLE-NUMBER; RESISTANCE; FOOD; PCR; IDENTIFICATION AB A total of 60 Salmonella enterica serovar (ser.) Enteritidis isolates, 28 from poultry houses and 32 from clinical samples, were isolated during 2010. These isolates were subjected to testing and analyzed for antibiotic resistance, virulence genes, plasmids and plasmid replicon types. To assess genetic diversity, pulsed-field gel electrophoresis (PFGE) fingerprinting, using the Xbal restriction enzyme, Multiple-Locus Variable-Number Tandem Repeat Analysis (MLVA) and plasmid profiles were performed. All isolates from poultry, and 10 out of 32 clinical isolates were sensitive to ampicillin, chloramphenicol, gentamicin, kanamycin, nalidixic acid, sulfisoxazole, streptomycin, and tetracycline. Twenty-one of thirty-two clinical isolates were resistant to ampicillin and tetracycline, and one isolate was resistant to nalidixic acid. PFGE typing of sixty ser. Enteritidis isolates by Xbal resulted in 10-12 bands and grouped into six clusters each with similarity from 95% to 81%. The MLVA analysis of sixty isolates gave 18 allele profiles with the majority of isolates displayed in three groups, and two clinical isolates found to be new in the PulseNet national MLVA database. All isolates were positive for 12 or more of the 17 virulence genes mostly found in S. enterica (spvB, spiA, pagC, msgA, invA, sipB, prgH, spaN, orgA, tolC, iroN, sitC, lpfC, sifA, sopB, and pefA) and negative for one gene (cdtB). All isolates carried a typical 58 kb plasmid, type Inc/FIIA. Three poultry isolates and one clinical isolate carried small plasmids with 3.8, 6, 7.6 and 11.5 kb. Ten of the clinical isolates carried plasmids, with sizes 36 and 38 kb, types IncL/M and IncN, and one isolate carried an 81 kb plasmid, type Incl. Southern hybridization of a plasmid with an Inc/FIIA gene probe hybridized one large 58 kb plasmid in all isolates. Several large and small plasmids from poultry isolates were not typed by our PCR-based method. These results confirmed that PFGE fingerprinting has limited discriminatory power for ser. Enteritidis in both poultry and clinical sources. However, the plasmid and MLVA allele profiles were a useful and important epidemiology tool to discriminate outbreak strains of set. Enteritidis from poultry and clinical samples. Published by Elsevier Ltd. C1 [Mezal, Ezat H.; Khan, Ashraf A.] US FDA, Natl Ctr Toxicol Res, Div Microbiol, Jefferson, AR 72079 USA. [Mezal, Ezat H.; Ali, Nawab] Univ Arkansas, Little Rock, AR 72205 USA. [Sabol, Ashley] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Khan, Mariam A.] Univ Cent Arkansas, Conway, AR USA. [Stefanova, Rossina] Arkansas Dept Hlth, Little Rock, AR 72205 USA. [Mezal, Ezat H.] Univ Thi Qar, Coll Sci, Dept Biol, Thi Qar, Iraq. RP Khan, AA (reprint author), US FDA, Natl Ctr Toxicol Res, Div Microbiol, Jefferson, AR 72079 USA. EM ashraf.khan@hotmail.com NR 39 TC 12 Z9 14 U1 1 U2 89 PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 0740-0020 EI 1095-9998 J9 FOOD MICROBIOL JI Food Microbiol. PD APR PY 2014 VL 38 BP 67 EP 74 DI 10.1016/j.fm.2013.08.003 PG 8 WC Biotechnology & Applied Microbiology; Food Science & Technology; Microbiology SC Biotechnology & Applied Microbiology; Food Science & Technology; Microbiology GA 275EZ UT WOS:000328660400010 PM 24290628 ER PT J AU He, YL Selck, F Normand, SLT AF He, Yulei Selck, Frederic Normand, Sharon-Lise T. TI On the accuracy of classifying hospitals on their performance measures SO STATISTICS IN MEDICINE LA English DT Article DE Bayesian; hospital compare data; hospital profiling; mixture distribution; National Hospital Ambulatory Medical Care Survey; sensitivity; specificity ID EMPIRICAL BAYES METHODS; INSTITUTIONAL PERFORMANCE; HIERARCHICAL-MODELS; REGRESSION-MODELS; CARE; QUALITY; RISK; RANKING; ISSUES AB The evaluation, comparison, and public report of health care provider performance is essential to improving the quality of health care. Hospitals, as one type of provider, are often classified into quality tiers (e.g., top or suboptimal) based on their performance data for various purposes. However, potential misclassification might lead to detrimental effects for both consumers and payers. Although such risk has been highlighted by applied health services researchers, a systematic investigation of statistical approaches has been lacking. We assess and compare the expected accuracy of several commonly used classification methods: unadjusted hospital-level averages, shrinkage estimators under a random-effects model accommodating between-hospital variation, and two others based on posterior probabilities. Assuming that performance data follow a classic one-way random-effects model with unequal sample size per hospital, we derive accuracy formulae for these classification approaches and gain insight into how the misclassification might be affected by various factors such as reliability of the data, hospital-level sample size distribution, and cutoff values between quality tiers. The case of binary performance data is also explored using Monte Carlo simulation strategies. We apply the methods to real data and discuss the practical implications. Copyright (c) 2013 John Wiley & Sons, Ltd. C1 [He, Yulei] Ctr Dis Control & Prevent, Off Res & Methodol, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. [Selck, Frederic] Ctr Dis Control & Prevent, Off Anal & Epidemiol, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. [Normand, Sharon-Lise T.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA. RP He, YL (reprint author), Ctr Dis Control & Prevent, Off Res & Methodol, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. EM wdq7@cdc.gov NR 51 TC 5 Z9 5 U1 1 U2 13 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0277-6715 EI 1097-0258 J9 STAT MED JI Stat. Med. PD MAR 30 PY 2014 VL 33 IS 7 BP 1081 EP 1103 DI 10.1002/sim.6012 PG 23 WC Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Medicine, Research & Experimental; Statistics & Probability SC Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Research & Experimental Medicine; Mathematics GA AD1RQ UT WOS:000333011600001 PM 24122879 ER PT J AU Sami, S Williams, HA Krause, S Onyango, MA Burton, A Tomczyk, B AF Sami, Samira Williams, Holly A. Krause, Sandra Onyango, Monica A. Burton, Ann Tomczyk, Barbara TI Responding to the Syrian crisis: the needs of women and girls SO LANCET LA English DT Editorial Material ID REPRODUCTIVE HEALTH; COMPLEX EMERGENCIES C1 [Sami, Samira; Williams, Holly A.; Tomczyk, Barbara] US Ctr Dis Control & Prevent, Emergency Response & Recovery Branch, Atlanta, GA 30341 USA. [Krause, Sandra] Womens Refugee Commiss, New York, NY USA. [Onyango, Monica A.] Boston Univ, Sch Publ Hlth, Dept Int Hlth, Boston, MA USA. [Burton, Ann] UN High Commissioner Refugees, Amman, Jordan. RP Tomczyk, B (reprint author), US Ctr Dis Control & Prevent, Emergency Response & Recovery Branch, Atlanta, GA 30341 USA. EM bet8@cdc.gov NR 19 TC 3 Z9 3 U1 1 U2 19 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0140-6736 EI 1474-547X J9 LANCET JI Lancet PD MAR 29 PY 2014 VL 383 IS 9923 BP 1179 EP 1181 DI 10.1016/S0140-6736(13)62034-6 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA AE4MH UT WOS:000333956000037 PM 24211044 ER PT J AU Wingate, M Kirby, RS Pettygrove, S Cunniff, C Schulz, E Ghosh, T Robinson, C Lee, LC Landa, R Constantino, J Fitzgerald, R Zahorodny, W Daniels, J Nicholas, J Charles, J McMahon, W Bilder, D Durkin, M Baio, J Christensen, D Van, K Braun, N Clayton, H Goodman, A Doernberg, N Yeargin-Allsopp, M AF Wingate, Martha Kirby, Russell S. Pettygrove, Sydney Cunniff, Chris Schulz, Eldon Ghosh, Tista Robinson, Cordelia Lee, Li-Ching Landa, Rebecca Constantino, John Fitzgerald, Robert Zahorodny, Walter Daniels, Julie Nicholas, Joyce Charles, Jane McMahon, William Bilder, Deborah Durkin, Maureen Baio, Jon Christensen, Deborah Van, Kim Braun, Naarden Clayton, Heather Goodman, Alyson Doernberg, Nancy Yeargin-Allsopp, Marshalyn CA Autism Dev Disabilities Monitoring TI Prevalence of Autism Spectrum Disorder Among Children Aged 8 Years - Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2010 SO MMWR SURVEILLANCE SUMMARIES LA English DT Article ID IDENTIFICATION; PREDICTORS; HEALTH; RISK AB Problem/Condition: Autism spectrum disorder (ASD). Period Covered: 2010. Description of System: The Autism and Developmental Disabilities Monitoring (ADDM) Network is an active surveillance system in the United States that provides estimates of the prevalence of ASD and other characteristics among children aged 8 years whose parents or guardians live in 11 ADDM sites in the United States. ADDM surveillance is conducted in two phases. The first phase consists of screening and abstracting comprehensive evaluations performed by professional providers in the community. Multiple data sources for these evaluations include general pediatric health clinics and specialized programs for children with developmental disabilities. In addition, most ADDM Network sites also review and abstract records of children receiving special education services in public schools. The second phase involves review of all abstracted evaluations by trained clinicians to determine ASD surveillance case status. A child meets the surveillance case definition for ASD if a comprehensive evaluation of that child completed by a qualified professional describes behaviors consistent with the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) diagnostic criteria for any of the following conditions: autistic disorder, pervasive developmental disorder-not otherwise specified (including atypical autism), or Asperger disorder. This report provides updated prevalence estimates for ASD from the 2010 surveillance year. In addition to prevalence estimates, characteristics of the population of children with ASD are described. Results: For 2010, the overall prevalence of ASD among the ADDM sites was 14.7 per 1,000 (one in 68) children aged 8 years. Overall ASD prevalence estimates varied among sites from 5.7 to 21.9 per 1,000 children aged 8 years. ASD prevalence estimates also varied by sex and racial/ethnic group. Approximately one in 42 boys and one in 189 girls living in the ADDM Network communities were identified as having ASD. Non-Hispanic white children were approximately 30% more likely to be identified with ASD than non-Hispanic black children and were almost 50% more likely to be identified with ASD than Hispanic children. Among the seven sites with sufficient data on intellectual ability, 31% of children with ASD were classified as having IQ scores in the range of intellectual disability (IQ <= 70), 23% in the borderline range (IQ = 71-85), and 46% in the average or above average range of intellectual ability (IQ > 85). The proportion of children classified in the range of intellectual disability differed by race/ethnicity. Approximately 48% of non-Hispanic black children with ASD were classified in the range of intellectual disability compared with 38% of Hispanic children and 25% of non-Hispanic white children. The median age of earliest known ASD diagnosis was 53 months and did not differ significantly by sex or race/ethnicity. Interpretation: These findings from CDC's ADDM Network, which are based on 2010 data reported from 11 sites, provide updated population-based estimates of the prevalence of ASD in multiple communities in the United States. Because the ADDM Network sites do not provide a representative sample of the entire United States, the combined prevalence estimates presented in this report cannot be generalized to all children aged 8 years in the United States population. Consistent with previous reports from the ADDM Network, findings from the 2010 surveillance year were marked by significant variations in ASD prevalence by geographic area, sex, race/ethnicity, and level of intellectual ability. The extent to which this variation might be attributable to diagnostic practices, underrecognition of ASD symptoms in some racial/ethnic groups, socioeconomic disparities in access to services, and regional differences in clinical or school-based practices that might influence the findings in this report is unclear. Public Health Action: ADDM Network investigators will continue to monitor the prevalence of ASD in select communities, with a focus on exploring changes within these communities that might affect both the observed prevalence of ASD and population-based characteristics of children identified with ASD. Although ASD is sometimes diagnosed by 2 years of age, the median age of the first ASD diagnosis remains older than age 4 years in the ADDM Network communities. Recommendations from the ADDM Network include enhancing strategies to address the need for 1) standardized, widely adopted measures to document ASD severity and functional limitations associated with ASD diagnosis; 2) improved recognition and documentation of symptoms of ASD, particularly among both boys and girls, children without intellectual disability, and children in all racial/ethnic groups; and 3) decreasing the age when children receive their first evaluation for and a diagnosis of ASD and are enrolled in community-based support systems. C1 [Wingate, Martha] Univ Alabama, Tuscaloosa, AL 35487 USA. [Kirby, Russell S.] Univ S Florida, Tampa, FL USA. [Pettygrove, Sydney; Cunniff, Chris] Univ Arizona, Tucson, AZ USA. [Schulz, Eldon] Univ Arkansas Med Sci, Little Rock, AR 72205 USA. [Ghosh, Tista] Colorado Dept Publ Hlth & Environm, Denver, CO USA. [Robinson, Cordelia] Univ Colorado Denver, Denver, CO USA. [Lee, Li-Ching] Johns Hopkins Univ, Baltimore, MD USA. [Landa, Rebecca] Kennedy Krieger Inst, Baltimore, MD USA. [Constantino, John; Fitzgerald, Robert] Washington Univ, St Louis, MO 63130 USA. [Zahorodny, Walter] Rutgers State Univ, New Jersey Med Sch, Newark, NJ USA. [Daniels, Julie] Univ N Carolina, Chapel Hill, NC USA. [Nicholas, Joyce; Charles, Jane] Med Univ S Carolina, Charleston, SC USA. [McMahon, William; Bilder, Deborah] Univ Utah, Salt Lake City, UT USA. [Durkin, Maureen] Univ Wisconsin, Madison, WI 53706 USA. [Baio, Jon; Christensen, Deborah; Van, Kim; Braun, Naarden; Clayton, Heather; Goodman, Alyson; Doernberg, Nancy; Yeargin-Allsopp, Marshalyn] CDC, Natl Ctr Birth Defects & Dev Disabil, Div Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. RP Baio, J (reprint author), CDC, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. EM jbaio@cdc.gov RI Durkin, Maureen/B-7834-2015 NR 26 TC 24 Z9 24 U1 8 U2 79 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 1545-8636 J9 MMWR SURVEILL SUMM JI MMWR Surv. Summ. PD MAR 28 PY 2014 VL 63 IS 2 PG 22 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AE9TI UT WOS:000334352600001 ER PT J AU Henley, SJ Singh, S King, J Wilson, R Ryerson, B AF Henley, S. Jane Singh, Simple King, Jessica Wilson, Reda Ryerson, Blythe TI Invasive Cancer Incidence - United States, 2010 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID HEALTH C1 [Henley, S. Jane; Singh, Simple; King, Jessica; Wilson, Reda; Ryerson, Blythe] CDC, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP Henley, SJ (reprint author), CDC, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM shenley@cdc.gov NR 10 TC 7 Z9 7 U1 0 U2 1 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAR 28 PY 2014 VL 63 IS 12 BP 253 EP 259 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AE1TC UT WOS:000333751900001 PM 24670926 ER PT J AU Saul, J Valle, LA Mercy, JA Turner, S Kaufmann, R Popovic, T AF Saul, Janet Valle, Linda A. Mercy, James A. Turner, Shairi Kaufmann, Rachel Popovic, Tanja TI CDC Grand Rounds: Creating a Healthier Future Through Prevention of Child Maltreatment SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID OF-THE-LITERATURE; EXPERIENCES; ABUSE; RISK C1 [Saul, Janet; Valle, Linda A.; Mercy, James A.] CDC, Div Violence Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA. [Turner, Shairi] Florida Dept Hlth, Hollywood, FL USA. [Kaufmann, Rachel] CDC, Ctr Surveillance Epidemiol & Lab Serv, Atlanta, GA 30333 USA. [Popovic, Tanja] CDC, Off Director, Atlanta, GA 30333 USA. RP Valle, LA (reprint author), CDC, Atlanta, GA 30333 USA. EM lvalle@cdc.gov NR 16 TC 6 Z9 6 U1 1 U2 2 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAR 28 PY 2014 VL 63 IS 12 BP 260 EP 263 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AE1TC UT WOS:000333751900002 PM 24670927 ER PT J AU Singleterry, J Jump, Z Lancet, E Babb, S MacNeil, A Zhang, L AF Singleterry, Jennifer Jump, Zach Lancet, Elizabeth Babb, Stephen MacNeil, Allison Zhang, Lei TI State Medicaid Coverage for Tobacco Cessation Treatments and Barriers to Coverage - United States, 2008-2014 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID DEPENDENCE TREATMENTS; SMOKING; IMPACT C1 [Singleterry, Jennifer; Jump, Zach; Lancet, Elizabeth] Amer Lung Assoc, New York, NY 10019 USA. [Babb, Stephen; MacNeil, Allison; Zhang, Lei] CDC, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP Babb, S (reprint author), CDC, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM sbabb@cdc.gov NR 10 TC 16 Z9 16 U1 0 U2 0 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAR 28 PY 2014 VL 63 IS 12 BP 264 EP 269 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AE1TC UT WOS:000333751900003 PM 24670928 ER PT J AU Pastula, DM Turabelidze, G Yates, KF Jones, TF Lambert, AJ Panella, AJ Kosoy, OI Velez, JO Fischer, M Staples, JE AF Pastula, Daniel M. Turabelidze, George Yates, Karen F. Jones, Timothy F. Lambert, Amy J. Panella, Amanda J. Kosoy, Olga I. Velez, Jason O. Fischer, Marc Staples, J. Erin TI Heartland Virus Disease - United States, 2012-2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID PHLEBOVIRUS C1 [Pastula, Daniel M.] CDC, Atlanta, GA 30333 USA. [Turabelidze, George; Yates, Karen F.] Missouri Dept Hlth & Sr Serv, Jefferson City, MO USA. [Jones, Timothy F.] Tennessee Dept Hlth, Nashville, TN USA. [Lambert, Amy J.; Panella, Amanda J.; Kosoy, Olga I.; Velez, Jason O.; Fischer, Marc; Staples, J. Erin] CDC, Arboviral Dis Branch, Natl Ctr Emerging & Zoonot Dis, Atlanta, GA 30333 USA. RP Pastula, DM (reprint author), CDC, Atlanta, GA 30333 USA. EM dpastula@cdc.gov NR 3 TC 22 Z9 22 U1 0 U2 11 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAR 28 PY 2014 VL 63 IS 12 BP 270 EP 271 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AE1TC UT WOS:000333751900004 PM 24670929 ER PT J AU Magill, SS Edwards, JR Bamberg, W Beldavs, ZG Dumyati, G Kainer, MA Lynfield, R Maloney, M McAllister-Hollod, L Nadle, J Ray, SM Thompson, DL Wilson, LE Fridkin, SK AF Magill, Shelley S. Edwards, Jonathan R. Bamberg, Wendy Beldavs, Zintars G. Dumyati, Ghinwa Kainer, Marion A. Lynfield, Ruth Maloney, Meghan McAllister-Hollod, Laura Nadle, Joelle Ray, Susan M. Thompson, Deborah L. Wilson, Lucy E. Fridkin, Scott K. CA Emerging Infect Program Healthcare TI Multistate Point- Prevalence Survey of Health Care- Associated Infections SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID HOSPITAL-ACQUIRED INFECTIONS; CLOSTRIDIUM-DIFFICILE INFECTIONS; BLOOD-STREAM INFECTIONS; NOSOCOMIAL INFECTIONS; ANTIMICROBIAL USE; RISK-FACTORS; SURVEILLANCE; MULTICENTER; PREVENTION; BURDEN AB BackgroundCurrently, no single U.S. surveillance system can provide estimates of the burden of all types of health care-associated infections across acute care patient populations. We conducted a prevalence survey in 10 geographically diverse states to determine the prevalence of health care-associated infections in acute care hospitals and generate updated estimates of the national burden of such infections. MethodsWe defined health care-associated infections with the use of National Healthcare Safety Network criteria. One-day surveys of randomly selected inpatients were performed in participating hospitals. Hospital personnel collected demographic and limited clinical data. Trained data collectors reviewed medical records retrospectively to identify health care-associated infections active at the time of the survey. Survey data and 2010 Nationwide Inpatient Sample data, stratified according to patient age and length of hospital stay, were used to estimate the total numbers of health care-associated infections and of inpatients with such infections in U.S. acute care hospitals in 2011. ResultsSurveys were conducted in 183 hospitals. Of 11,282 patients, 452 had 1 or more health care-associated infections (4.0%; 95% confidence interval, 3.7 to 4.4). Of 504 such infections, the most common types were pneumonia (21.8%), surgical-site infections (21.8%), and gastrointestinal infections (17.1%). Clostridium difficile was the most commonly reported pathogen (causing 12.1% of health care-associated infections). Device-associated infections (i.e., central-catheter-associated bloodstream infection, catheter-associated urinary tract infection, and ventilator-associated pneumonia), which have traditionally been the focus of programs to prevent health care-associated infections, accounted for 25.6% of such infections. We estimated that there were 648,000 patients with 721,800 health care-associated infections in U.S. acute care hospitals in 2011. ConclusionsResults of this multistate prevalence survey of health care-associated infections indicate that public health surveillance and prevention activities should continue to address C. difficile infections. As device- and procedure-associated infections decrease, consideration should be given to expanding surveillance and prevention activities to include other health care-associated infections. Hospital-acquired infections cause substantial morbidity in inpatient settings. On the basis of a 1-day point-prevalence survey, CDC investigators report the burden and types of health care-associated infection in 183 hospitals across 10 geographically diverse states. Elimination of health care-associated infections is a priority of the Department of Health and Human Services.(1) Considerable success in prevention has been reported for some infections, particularly central-catheter-associated bloodstream infections.(2)-(5) Continued improvements in patient safety depend on maintaining a comprehensive understanding of the epidemiology of health care-associated infections. Currently, no single U.S. surveillance system can provide estimates of the burden of all types of such infections across acute care patient populations. The most recent estimate produced by the Centers for Disease Control and Prevention (CDC) and published in 2007 1.7 million health care-associated infections per year relied ... C1 [Magill, Shelley S.; Edwards, Jonathan R.; McAllister-Hollod, Laura; Fridkin, Scott K.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Ray, Susan M.] Emory Univ, Sch Med, Atlanta, GA USA. [Bamberg, Wendy] Colorado Dept Publ Hlth & Environm, Denver, CO USA. [Beldavs, Zintars G.] Oregon Publ Hlth Author, Portland, OR USA. [Dumyati, Ghinwa] New York Rochester Emerging Infect Program, Rochester, NY USA. [Dumyati, Ghinwa] Univ Rochester, Rochester, NY 14627 USA. [Kainer, Marion A.] Tennessee Dept Hlth, Nashville, TN USA. [Lynfield, Ruth] Minnesota Dept Hlth, St Paul, MN USA. [Maloney, Meghan] Connecticut Dept Publ Hlth, Hartford, CT USA. [Nadle, Joelle] Calif Emerging Infect Program, Oakland, CA USA. [Ray, Susan M.] Georgia Emerging Infect Program, Decatur, GA USA. [Ray, Susan M.] Atlanta Vet Affairs Med Ctr, Decatur, GA USA. [Thompson, Deborah L.] New Mexico Dept Hlth, Santa Fe, NM USA. [Wilson, Lucy E.] Maryland Dept Hlth & Mental Hyg, Baltimore, MD USA. RP Magill, SS (reprint author), Ctr Dis Control & Prevent, Div Healthcare Qual Promot, 1600 Clifton Rd,MS A-24, Atlanta, GA 30333 USA. EM smagill@cdc.gov RI Chiang, Vincent, Ming-Hsien/D-4312-2016 OI Chiang, Vincent, Ming-Hsien/0000-0002-2029-7863 FU Infectious Disease Consulting Corporation FX Dr. Kainer reports receiving consulting, lecture, and board membership fees from and owning stock in the Infectious Disease Consulting Corporation. Dr. Lynfield reports receiving travel support from Parexel. No other potential conflict of interest relevant to this article was reported. NR 44 TC 531 Z9 549 U1 18 U2 86 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD MAR 27 PY 2014 VL 370 IS 13 BP 1198 EP 1208 DI 10.1056/NEJMoa1306801 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA AD7EW UT WOS:000333426000007 PM 24670166 ER PT J AU Pickering, AJ Blum, AG Breiman, RF Ram, PK Davis, J AF Pickering, Amy J. Blum, Annalise G. Breiman, Robert F. Ram, Pavani K. Davis, Jennifer TI Video Surveillance Captures Student Hand Hygiene Behavior, Reactivity to Observation, and Peer Influence in Kenyan Primary Schools SO PLOS ONE LA English DT Article ID INTENSIVE-CARE-UNIT; QUESTIONNAIRES; SOAP AB Background: In-person structured observation is considered the best approach for measuring hand hygiene behavior, yet is expensive, time consuming, and may alter behavior. Video surveillance could be a useful tool for objectively monitoring hand hygiene behavior if validated against current methods. Methods: Student hand cleaning behavior was monitored with video surveillance and in-person structured observation, both simultaneously and separately, at four primary schools in urban Kenya over a study period of 8 weeks. Findings: Video surveillance and in-person observation captured similar rates of hand cleaning (absolute difference <5%, p = 0.74). Video surveillance documented higher hand cleaning rates (71%) when at least one other person was present at the hand cleaning station, compared to when a student was alone (48%; rate ratio = 1.14 [95% CI 1.01-1.28]). Students increased hand cleaning rates during simultaneous video and in-person monitoring as compared to single-method monitoring, suggesting reactivity to each method of monitoring. This trend was documented at schools receiving a handwashing with soap intervention, but not at schools receiving a sanitizer intervention. Conclusion: Video surveillance of hand hygiene behavior yields results comparable to in-person observation among schools in a resource-constrained setting. Video surveillance also has certain advantages over in-person observation, including rapid data processing and the capability to capture new behavioral insights. Peer influence can significantly improve student hand cleaning behavior and, when possible, should be exploited in the design and implementation of school hand hygiene programs. C1 [Pickering, Amy J.; Davis, Jennifer] Stanford Univ, Woods Inst Environm, Stanford, CA 94305 USA. [Pickering, Amy J.; Blum, Annalise G.; Davis, Jennifer] Stanford Univ, Stanford, CA 94305 USA. [Breiman, Robert F.] Ctr Dis Control & Prevent, Kenya Off, Global Dis Detect Program, Nairobi, Kenya. [Ram, Pavani K.] SUNY Buffalo, Buffalo, NY 14260 USA. [Breiman, Robert F.] Ctr Dis Control & Prevent, Global Dis Detect Branch, Div Global Hlth Protect, Ctr Global Hlth, Atlanta, GA USA. RP Pickering, AJ (reprint author), Stanford Univ, Woods Inst Environm, Stanford, CA 94305 USA. EM amyjanel@stanford.edu FU CDC-Kenya/KEMRI; Freeman Spogli Institute for International Studies at Stanford University FX This study was funded by CDC-Kenya/KEMRI (http://www.cdc.gov/globalhealth/countries/kenya/), and the Freeman Spogli Institute for International Studies at Stanford University (http://fsi.stanford.edu/). The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 22 TC 3 Z9 3 U1 0 U2 7 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAR 27 PY 2014 VL 9 IS 3 AR e92571 DI 10.1371/journal.pone.0092571 PG 7 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA AE0SW UT WOS:000333677500025 PM 24676389 ER PT J AU Baker, JV Hullsiek, KH Singh, A Wilson, E Henry, K Lichtenstein, K Onen, N Kojic, E Patel, P Brooks, JT Hodis, HN Budoff, M Sereti, I AF Baker, Jason V. Hullsiek, Katherine Huppler Singh, Amrit Wilson, Eleanor Henry, Keith Lichtenstein, Ken Onen, Nur Kojic, Erna Patel, Pragna Brooks, John T. Hodis, Howard N. Budoff, Matt Sereti, Irini CA CDC SUN Study Investigators TI Immunologic predictors of coronary artery calcium progression in a contemporary HIV cohort SO AIDS LA English DT Article DE cardiovascular disease; coronary artery calcium; HIV; immune activation; inflammation; monocyte activation ID T-CELL-ACTIVATION; CARDIOVASCULAR-DISEASE EVENTS; ACUTE MYOCARDIAL-INFARCTION; COMPUTED-TOMOGRAPHY; IMMUNE ACTIVATION; INFECTED WOMEN; RISK-FACTORS; MICROBIAL TRANSLOCATION; ANTIRETROVIRAL DRUGS; MONOCYTE ACTIVATION AB Background:Identifying immunologic mechanisms that contribute to premature cardiovascular disease (CVD) among HIV-positive patients will inform prevention strategies.Methods:Coronary artery calcium (CAC) progression was studied in an HIV cohort. Immunophenotypes were measured on baseline cryopreserved peripheral blood mononuclear cells using multicolor flow cytometry. Logistic regression identified predictors of CAC progression after adjusting for traditional and HIV-related risk factors.Results:Baseline characteristics for the analysis cohort (n=436) were median age 42 years, median CD4(+) cell count 481cells/l, and 78% receiving antiretroviral therapy. Higher frequencies of CD16(+) monocytes were associated with greater likelihood of CAC progression, after adjusting for traditional and HIV risk factors [odds ratio per doubling was 1.66 for CD14(+)/CD16(+) (P=0.02), 1.36 for CD14(dim)/CD16(+) (P=0.06), and 1.69 for CD14(var)/CD16(+) (P=0.01)]. Associations for CD16(+) monocytes persisted when restricted to participants with viral suppression. We found no significant associations for CAC progression with other cellular phenotypes, including T-cell activation and senescence markers.Conclusion:Circulating CD16(+) monocytes, potentially reflecting a more pro-atherogenic subpopulation, independently predicted greater CAC progression among HIV-infected persons at low risk for AIDS. In contrast to T-cell abnormalities classically associated with AIDS-related disease progression, these data highlight the potential role of monocyte activation in HIV-related CVD risk. C1 [Baker, Jason V.; Henry, Keith] Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA. [Baker, Jason V.; Henry, Keith] Univ Minnesota, Hennepin Cty Med Ctr, Div Infect Dis, Minneapolis, MN 55415 USA. [Hullsiek, Katherine Huppler] Univ Minnesota, Div Biostat, Minneapolis, MN USA. [Singh, Amrit; Wilson, Eleanor; Sereti, Irini] NIAID, NIH, Bethesda, MD 20892 USA. [Lichtenstein, Ken] Natl Jewish Med & Res Ctr, Denver, CO USA. [Onen, Nur] Washington Univ, Sch Med, St Louis, MO USA. [Kojic, Erna] Miriam Hosp, Providence, RI 02906 USA. [Patel, Pragna; Brooks, John T.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. [Hodis, Howard N.] Univ So Calif, Atherosclerosis Res Unit, Los Angeles, CA USA. [Budoff, Matt] Harbor UCLA, Los Angeles Biomed Res Inst, Los Angeles, CA USA. RP Baker, JV (reprint author), 701 Pk Ave MC G5, Minneapolis, MN 55415 USA. EM baker459@umn.edu OI Wilson, Eleanor/0000-0002-4855-514X FU Centers for Disease Control and Prevention [200-2002-00610, 200-2002-00611, 200-2002-00612, 200-2002-00613, 200-2007-23633, 200-2007-23634, 200-2007-23635,, 200-2007-23636]; NIH [1KL2RR033182-01]; NIAID FX The study received financial support from Centers for Disease Control and Prevention contract numbers 200-2002-00610, 200-2002-00611, 200-2002-00612, 200-2002-00613, 200-2007-23633, 200-2007-23634, 200-2007-23635, and 200-2007-23636. Additional support was provided by the NIH 1KL2RR033182-01. The work of E.W., A.S., and I.S. was supported by the intramural program of NIAID. NR 52 TC 33 Z9 33 U1 0 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0269-9370 EI 1473-5571 J9 AIDS JI Aids PD MAR 27 PY 2014 VL 28 IS 6 BP 831 EP 840 DI 10.1097/QAD.0000000000000145 PG 10 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA AD5MH UT WOS:000333296600004 PM 24370480 ER PT J AU Green, BJ Beezhold, DH Gallinger, Z Barron, CS Melvin, R Bledsoe, TA Kashon, ML Sussman, GL AF Green, Brett J. Beezhold, Donald H. Gallinger, Zane Barron, Carly S. Melvin, Rochelle Bledsoe, Toni A. Kashon, Michael L. Sussman, Gordon L. TI Allergic sensitization in Canadian chronic rhinosinusitis patients SO ALLERGY ASTHMA AND CLINICAL IMMUNOLOGY LA English DT Article DE Allergic rhinitis; Allergic sensitization; Chronic rhinosinusitis; Perennial allergens ID NASAL EXPLANT MODEL; FUNGAL SINUSITIS; ASTHMA; PATHOPHYSIOLOGY; EXPRESSION; RESPONSES; RHINITIS; PROTEIN; HEALTH; RISK AB Background: Chronic rhinosinusitis (CRS) is a societal burden and cause of morbidity in Canada; however, the prevalence of allergic sensitization in Canadian CRS patients has remained poorly characterized. Objective: In this study, we used skin prick test (SPT) and specific immunoglobulin E (sIgE) and G (sIgG) titers to regionally relevant allergen sources in order to determine whether allergic sensitization is more prevalent in CRS patients compared to chronic idiopathic urticaria (CIU) control patients. Methods: One hundred and fifty eight subjects (19-70 years of age) were recruited into the study. 101 subjects had a confirmed diagnostic history of CRS and 57 subjects with a clinical diagnosis of CIU were recruited as controls. Enrolled subjects underwent SPT to a panel of perennial and seasonal allergens and sIgE titers were quantified to selected environmental allergen mixes (grass, mold, and tree species) using Phadia ImmunoCAP. sIgG was additionally quantified to Alternaria alternata, Aspergillus versicolor, Cladosporium herbarum, and Stachybotrys atra. Differences between CRS and control CIU patient SPT and serological data were examined by chi-squared analysis and analysis of variance. Results: Reactivity to at least one SPT extract occurred in 73% of CRS patients. Positive SPT reactivity to A. alternata (odds ratio (OR): 4.34, 95% confidence interval: 1.57, 12.02), cat (OR: 3.23, 95% CI: 1.16, 9.02), and ragweed (OR: 2.31, 95% CI: 1.02, 5.19) extracts were more prevalent in patients with CRS (p < 0.05). Although dust mite and timothy grass sensitization approached statistical significance in the chi-squared analysis of SPT data, other common perennial and seasonal allergens were not associated with CRS. No statistically significant differences were observed between mean sIgE and sIgG titers in CRS and control patients. Conclusions: This study supports previous data that suggests A. alternata sensitization is associated with CRS; however, these findings additionally highlight the contribution of other regionally important allergens including cat and ragweed. C1 [Green, Brett J.; Beezhold, Donald H.; Bledsoe, Toni A.] NIOSH, Allergy & Clin Immunol Branch, Hlth Effects Lab Div, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA. [Gallinger, Zane; Barron, Carly S.; Melvin, Rochelle; Sussman, Gordon L.] Gordon Sussman Clinical Res Inc, Allergy & Clin Immunol, Toronto, ON, Canada. [Kashon, Michael L.] NIOSH, Biostat & Epidemiol Branch, Hlth Effects Lab Div, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA. RP Beezhold, DH (reprint author), NIOSH, Allergy & Clin Immunol Branch, Hlth Effects Lab Div, Ctr Dis Control & Prevent, 1095 Willowdale Rd,M-S L-4020, Morgantown, WV 26505 USA. EM zec1@cdc.gov FU NIEHS IAA [AES 12007-00100000] FX The findings and the conclusions in this report are those of the authors and do not necessarily represent the views of the National Institute for Occupational Safety and Health. This study was supported in part by an interagency agreement with NIEHS IAA#AES 12007-00100000. NR 36 TC 3 Z9 3 U1 0 U2 5 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1710-1484 EI 1710-1492 J9 ALLERGY ASTHMA CL IM JI Allerg Asthma Clin. Immunol. PD MAR 25 PY 2014 VL 10 AR 15 DI 10.1186/1710-1492-10-15 PG 7 WC Allergy; Immunology SC Allergy; Immunology GA AF1DM UT WOS:000334454600001 PM 24666655 ER PT J AU Emukule, GO McMorrow, M Ulloa, C Khagayi, S Njuguna, HN Burton, D Montgomery, JM Muthoka, P Katz, MA Breiman, RF Mott, JA AF Emukule, Gideon O. McMorrow, Meredith Ulloa, Chulie Khagayi, Sammy Njuguna, Henry N. Burton, Deron Montgomery, Joel M. Muthoka, Philip Katz, Mark A. Breiman, Robert F. Mott, Joshua A. TI Predicting Mortality among Hospitalized Children with Respiratory Illness in Western Kenya, 2009-2012 SO PLOS ONE LA English DT Article ID INFECTIONS; BURDEN; MANAGEMENT; PNEUMONIA; MALARIA AB Background: Pediatric respiratory disease is a major cause of morbidity and mortality in the developing world. We evaluated a modified respiratory index of severity in children (mRISC) scoring system as a standard tool to identify children at greater risk of death from respiratory illness in Kenya. Materials and Methods: We analyzed data from children,5 years old who were hospitalized with respiratory illness at Siaya District Hospital from 2009-2012. We used a multivariable logistic regression model to identify patient characteristics predictive for in-hospital mortality. Model discrimination was evaluated using the concordance statistic. Using bootstrap samples, we re-estimated the coefficients and the optimism of the model. The mRISC score for each child was developed by adding up the points assigned to each factor associated with mortality based on the coefficients in the multivariable model. Results: We analyzed data from 3,581 children hospitalized with respiratory illness; including 218 (6%) who died. Low weight-for-age [adjusted odds ratio (aOR) = 2.1; 95% CI 1.3-3.2], very low weight-for-age (aOR = 3.8; 95% CI 2.7-5.4), caretaker-reported history of unconsciousness (aOR = 2.3; 95% CI 1.6-3.4), inability to drink or breastfeed (aOR = 1.8; 95% CI 1.2-2.8), chest wall in-drawing (aOR = 2.2; 95% CI 1.5-3.1), and being not fully conscious on physical exam (aOR = 8.0; 95% CI 5.1-12.6) were independently associated with mortality. The positive predictive value for mortality increased with increasing mRISC scores. Conclusions: A modified RISC scoring system based on a set of easily measurable clinical features at admission was able to identify children at greater risk of death from respiratory illness in Kenya. C1 [Emukule, Gideon O.; Khagayi, Sammy; Njuguna, Henry N.; Burton, Deron; Montgomery, Joel M.; Mott, Joshua A.] Kenya Govt Med Res Ctr, Ctr Dis Control & Prevent Kenya, KEMRI, CDC, Nairobi, Kenya. [Emukule, Gideon O.; Khagayi, Sammy; Njuguna, Henry N.; Burton, Deron; Montgomery, Joel M.; Mott, Joshua A.] Kenya Govt Med Res Ctr, Ctr Dis Control & Prevent Kenya, KEMRI, CDC, Kisumu, Kenya. [McMorrow, Meredith] US Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Ulloa, Chulie] Stanford Univ, Sch Med, Stanford, CA 94305 USA. [Muthoka, Philip] Minist Publ Hlth & Sanitat, Div Dis Surveillance & Response, Nairobi, Kenya. [Katz, Mark A.] Ctr Dis Control & Prevent, Port Au Prince, Haiti. [Breiman, Robert F.] Emory Univ, Atlanta, GA 30322 USA. RP Emukule, GO (reprint author), Kenya Govt Med Res Ctr, Ctr Dis Control & Prevent Kenya, KEMRI, CDC, Nairobi, Kenya. EM GEmukule@ke.cdc.gov FU Core Funding of the Global Disease Detection Division of CDC FX The funding for this project is from Core Funding of the Global Disease Detection Division of CDC. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 30 TC 2 Z9 2 U1 0 U2 2 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAR 25 PY 2014 VL 9 IS 3 AR e92968 DI 10.1371/journal.pone.0092968 PG 8 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA AE0SD UT WOS:000333675600111 PM 24667695 ER PT J AU Martin, M Vanichseni, S Suntharasamai, P Sangkum, U Mock, PA Leethochawalit, M Chiamwongpaet, S Gvetadze, RJ Kittimunkong, S Curlin, ME Worrajittanon, D McNicholl, JM Paxton, LA Choopanya, K AF Martin, Michael Vanichseni, Suphak Suntharasamai, Pravan Sangkum, Udomsak Mock, Philip A. Leethochawalit, Manoj Chiamwongpaet, Sithisat Gvetadze, Roman J. Kittimunkong, Somyot Curlin, Marcel E. Worrajittanon, Dararat McNicholl, Janet M. Paxton, Lynn A. Choopanya, Kachit CA Bangkok Tenofovir Study Grp TI Risk Behaviors and Risk Factors for HIV Infection among Participants in the Bangkok Tenofovir Study, an HIV Pre-Exposure Prophylaxis Trial among People Who Inject Drugs SO PLOS ONE LA English DT Article ID ANTIRETROVIRAL PROPHYLAXIS; VACCINE TRIAL; DOUBLE-BLIND; THAILAND; USERS; PRISON; INCARCERATION; TRANSMISSION; PREVENTION; NUMBER AB Introduction: HIV spread rapidly among people who inject drugs in Bangkok in the late 1980s. In recent years, changes in drug use and HIV-associated risk behaviors have been reported. We examined data from the Bangkok Tenofovir Study, an HIV pre-exposure prophylaxis trial conducted among people who inject drugs, to assess participant risk behavior and drug use, and to identify risk factors for HIV infection. Methods: The Bangkok Tenofovir Study was a randomized, double-blind, placebo-controlled trial. HIV status was assessed monthly and risk behavior every 3 months. We used generalized estimating equations logistic regression to model trends of injecting, needle sharing, drugs injected, incarceration, and sexual activity reported at follow-up visits; and proportional hazards models to evaluate demographic characteristics, sexual activities, incarceration, drug injection practices, and drugs injected during follow-up as predictors of HIV infection. Results: The proportion of participants injecting drugs, sharing needles, and reporting sex with more than one partner declined during follow-up (p<0.001). Among participants who reported injecting at enrollment, 801 (53.2%) injected methamphetamine, 559 (37.1%) midazolam, and 527 (35.0%) heroin. In multivariable analysis, young age (i.e., 20-29 years) (p = 0.02), sharing needles (p<0.001), and incarceration in prison (p = 0.002) were associated with incident HIV infection. Participants reporting sex with an opposite sex partner, live-in partner, casual partner, or men reporting sex with male partners were not at a significantly higher risk of HIV infection compared to those who did not report these behaviors. Conclusion: Reports of HIV-associated risk behavior declined significantly during the trial. Young age, needle sharing, and incarceration were independently associated with HIV infection. Sexual activity was not associated with HIV infection, suggesting that the reduction in HIV incidence among participants taking daily oral tenofovir compared to those taking placebo was due to a decrease in parenteral HIV transmission. C1 [Martin, Michael; Mock, Philip A.; Curlin, Marcel E.; Worrajittanon, Dararat] Thailand MOPH US CDC Collaborat, Nonthaburi, Thailand. [Martin, Michael; Gvetadze, Roman J.; Curlin, Marcel E.; McNicholl, Janet M.; Paxton, Lynn A.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Vanichseni, Suphak; Suntharasamai, Pravan; Sangkum, Udomsak; Choopanya, Kachit] Bangkok Tenofovir Study Grp, Bangkok, Thailand. [Leethochawalit, Manoj; Chiamwongpaet, Sithisat] Bangkok Metropolitan Adm, Bangkok, Thailand. [Kittimunkong, Somyot] Thailand Minist Publ Hlth, Nonthaburi, Thailand. RP Martin, M (reprint author), Thailand MOPH US CDC Collaborat, Nonthaburi, Thailand. EM Znd9@cdc.gov RI Hendrix, Craig/G-4182-2014 OI Hendrix, Craig/0000-0002-5696-8665 FU Bangkok Metropolitan Administration; U.S. Centers for Disease Control and Prevention FX The study was funded and supported by the Bangkok Metropolitan Administration and U.S. Centers for Disease Control and Prevention. The funders had a role in study design, data collection and analysis, and the decision to publish the manuscript. NR 32 TC 8 Z9 8 U1 0 U2 4 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAR 25 PY 2014 VL 9 IS 3 AR e92809 DI 10.1371/journal.pone.0092809 PG 7 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA AE0SD UT WOS:000333675600079 PM 24667938 ER PT J AU Patel, RB Mathur, MB Gould, M Uyeki, TM Bhattacharya, J Xiao, Y Khazeni, N AF Patel, Rita B. Mathur, Maya B. Gould, Michael Uyeki, Timothy M. Bhattacharya, Jay Xiao, Yang Khazeni, Nayer TI Demographic and Clinical Predictors of Mortality from Highly Pathogenic Avian Influenza A (H5N1) Virus Infection: CART Analysis of International Cases SO PLOS ONE LA English DT Article ID UNITED-STATES; HUMANS METAANALYSIS; PUBLIC-HEALTH; HOST GENETICS; SUSCEPTIBILITY; SEROEVIDENCE; MORBIDITY; INDONESIA; CHILDREN; DEATHS AB Background: Human infections with highly pathogenic avian influenza (HPAI) A (H5N1) viruses have occurred in 15 countries, with high mortality to date. Determining risk factors for morbidity and mortality from HPAI H5N1 can inform preventive and therapeutic interventions. Methods: We included all cases of human HPAI H5N1 reported in World Health Organization Global Alert and Response updates and those identified through a systematic search of multiple databases (PubMed, Scopus, and Google Scholar), including articles in all languages. We abstracted predefined clinical and demographic predictors and mortality and used bivariate logistic regression analyses to examine the relationship of each candidate predictor with mortality. We developed and pruned a decision tree using nonparametric Classification and Regression Tree methods to create risk strata for mortality. Findings: We identified 617 human cases of HPAI H5N1 occurring between December 1997 and April 2013. The median age of subjects was 18 years (interquartile range 6-29 years) and 54% were female. HPAI H5N1 case-fatality proportion was 59%. The final decision tree for mortality included age, country, per capita government health expenditure, and delay from symptom onset to hospitalization, with an area under the receiver operator characteristic (ROC) curve of 0.81 (95% CI: 0.76-0.86). Interpretation: A model defined by four clinical and demographic predictors successfully estimated the probability of mortality from HPAI H5N1 illness. These parameters highlight the importance of early diagnosis and treatment and may enable early, targeted pharmaceutical therapy and supportive care for symptomatic patients with HPAI H5N1 virus infection. C1 [Patel, Rita B.; Mathur, Maya B.; Khazeni, Nayer] Stanford Univ, Med Ctr, Div Pulm & Crit Care Med, Stanford, CA 94305 USA. [Gould, Michael] Kaiser Permanente So Calif, Pasadena, CA 91101 USA. [Uyeki, Timothy M.] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Bhattacharya, Jay; Khazeni, Nayer] Stanford Univ, Ctr Hlth Policy, Stanford, CA 94305 USA. [Bhattacharya, Jay; Khazeni, Nayer] Stanford Univ, Ctr Primary Care & Outcomes Res, Stanford, CA 94305 USA. [Xiao, Yang] Univ S Carolina, Dept Languages Literatures & Cultures, Columbia, SC 29208 USA. RP Mathur, MB (reprint author), Stanford Univ, Med Ctr, Div Pulm & Crit Care Med, Stanford, CA 94305 USA. EM mmathur@stanford.edu OI Xiao-Desai, Yang/0000-0002-3609-2758 FU Agency for Healthcare Research and Quality [1 K08 HS019816] FX This research was supported by the Agency for Healthcare Research and Quality (1 K08 HS019816, Dr. Khazeni). See http://www.ahrq.gov/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 47 TC 8 Z9 8 U1 1 U2 7 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAR 25 PY 2014 VL 9 IS 3 AR e91630 DI 10.1371/journal.pone.0091630 PG 10 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA AE0SD UT WOS:000333675600011 PM 24667532 ER PT J AU Escoffery, C Rodgers, KC Kegler, MC Haardorfer, R Howard, DH Liang, S Pinsker, E Roland, KB Allen, JD Ory, MG Bastani, R Fernandez, ME Risendal, BC Byrd, TL Coronado, GD AF Escoffery, Cam Rodgers, Kirsten C. Kegler, Michelle C. Haardoerfer, Regine Howard, David H. Liang, Shuting Pinsker, Erika Roland, Katherine B. Allen, Jennifer D. Ory, Marcia G. Bastani, Roshan Fernandez, Maria E. Risendal, Betsy C. Byrd, Theresa L. Coronado, Gloria D. TI A systematic review of special events to promote breast, cervical and colorectal cancer screening in the United States SO BMC PUBLIC HEALTH LA English DT Article DE Cancer screening; Early detection of cancer; Health promotion; Community health education; Breast neoplasms; Cervical neoplasms; Colorectal neoplasms ID CLIENT-DIRECTED INTERVENTIONS; SERVICES TASK-FORCE; PREVENTIVE SERVICES; HEALTH FAIRS; RISK-FACTORS; NATION; ACCESS AB Background: Special events are common community-based strategies for health promotion. This paper presents findings from a systematic literature review on the impact of special events to promote breast, cervical or colorectal cancer education and screening. Methods: Articles in English that focused on special events involving breast, cervical, and/or colorectal cancer conducted in the U. S. and published between January 1990 and December 2011 were identified from seven databases: Ovid, Web of Science, CINAHL, PsycINFO, Sociological Abstract, Cochrane Libraries, and EconLit. Study inclusion and data extraction were independently validated by two researchers. Results: Of the 20 articles selected for screening out of 1,409, ten articles on special events reported outcome data. Five types of special events were found: health fairs, parties, cultural events, special days, and plays. Many focused on breast cancer only, or in combination with other cancers. Reach ranged from 50-1732 participants. All special events used at least one evidence-based strategy suggested by the Community Guide to Preventive Services, such as small media, one-on-one education, and reducing structural barriers. For cancer screening as an outcome of the events, mammography screening rates ranged from 4.8% to 88%, Pap testing was 3.9%, and clinical breast exams ranged from 9.1% to 100%. For colorectal screening, FOBT ranged from 29.4% to 76%, and sigmoidoscopy was 100% at one event. Outcome measures included intentions to get screened, scheduled appointments, uptake of clinical exams, and participation in cancer screening. Conclusions: Special events found in the review varied and used evidence-based strategies. Screening data suggest that some special events can lead to increases in cancer screening, especially if they provide onsite screening services. However, there is insufficient evidence to demonstrate that special events are effective in increasing cancer screening. The heterogeneity of populations served, event activities, outcome variables assessed, and the reliance on self- report to measure screening limit conclusions. This study highlights the need for further research to determine the effectiveness of special events to increase cancer screening. C1 [Escoffery, Cam; Rodgers, Kirsten C.; Kegler, Michelle C.; Haardoerfer, Regine; Liang, Shuting] Rollins Sch Publ Hlth, Dept Behav Sci & Hlth Educ, Atlanta, GA 30322 USA. [Howard, David H.] Rollins Sch Publ Hlth, Dept Hlth Policy & Management, Atlanta, GA USA. [Pinsker, Erika] Univ Minnesota, Div Epidemiol & Community Hlth, Minneapolis, MN USA. [Roland, Katherine B.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Epidemiol & Appl Res Branch, Atlanta, GA USA. [Allen, Jennifer D.] Tufts Univ, Medford, MA 02155 USA. [Ory, Marcia G.] Texas A&M Univ, Sch Rural Publ Hlth, Dept Social & Behav Hlth, College Stn, TX USA. [Bastani, Roshan] Univ Calif Los Angeles, Dept Hlth Policy & Management, Los Angeles, CA USA. [Fernandez, Maria E.] Univ Texas Houston, Dept Behav Sci, Houston, TX USA. [Risendal, Betsy C.] Univ Colorado, Dept Community & Behav Hlth, Aurora, CO USA. [Byrd, Theresa L.] Texas Tech Paul L Foster Sch Med, El Paso, TX USA. [Coronado, Gloria D.] Kaiser Permanente, Ctr Canc Res, Portland, OR USA. RP Escoffery, C (reprint author), Rollins Sch Publ Hlth, Dept Behav Sci & Hlth Educ, 1518 Clifton Rd, Atlanta, GA 30322 USA. EM cescoff@emory.edu RI Allen, Jennifer/M-2113-2015 FU Centers for Disease Control and Prevention (CDC); National Cancer Institute through the Cancer Prevention and Control Research Network FX This publication was supported by the Centers for Disease Control and Prevention (CDC) and the National Cancer Institute through the Cancer Prevention and Control Research Network, a network within the CDC's Prevention Research Centers Program (Emory University, U48DP001909, SIP 10-030; Harvard University, U48D001946; University of California at Los Angeles, U48 DP001934; University of Colorado, U48DP001938; Texas A & M University, U48DP001924; University of Texas at Houston, U48DP001949). The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 40 TC 10 Z9 10 U1 1 U2 15 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2458 J9 BMC PUBLIC HEALTH JI BMC Public Health PD MAR 24 PY 2014 VL 14 AR 274 DI 10.1186/1471-2458-14-274 PG 13 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AG3WZ UT WOS:000335351900001 PM 24661503 ER PT J AU Do, AN Rosenberg, ES Sullivan, PS Beer, L Strine, TW Schulden, JD Fagan, JL Freedman, MS Skarbinski, J AF Do, Ann N. Rosenberg, Eli S. Sullivan, Patrick S. Beer, Linda Strine, Tara W. Schulden, Jeffrey D. Fagan, Jennifer L. Freedman, Mark S. Skarbinski, Jacek TI Excess Burden of Depression among HIV-Infected Persons Receiving Medical Care in the United States: Data from the Medical Monitoring Project and the Behavioral Risk Factor Surveillance System SO PLOS ONE LA English DT Article ID PATIENT HEALTH QUESTIONNAIRE; HUMAN-IMMUNODEFICIENCY-VIRUS; ACTIVE ANTIRETROVIRAL THERAPY; INJECTION-DRUG USERS; PSYCHIATRIC-DISORDERS; PUBLIC-HEALTH; POSITIVE PATIENTS; SUBSTANCE-ABUSE; IMMUNE FUNCTION; MOOD DISORDERS AB Background: With increased life expectancy for HIV-infected persons, there is concern regarding comorbid depression because of its common occurrence and association with behaviors that may facilitate HIV transmission. Our objectives were to estimate the prevalence of current depression among HIV-infected persons receiving care and assess the burden of major depression, relative to that in the general population. Methods and Findings: We used data from the Medical Monitoring Project (MMP) and the Behavioral Risk Factors Surveillance System (BRFSS). The eight-item Patient Health Questionnaire was used to identify depression. To assess the burden of major depression among HIV-infected persons receiving care, we compared the prevalence of current major depression between the MMP and BRFSS populations using stratified analyses that simultaneously controlled for gender and, in turn, each of the potentially confounding demographic factors of age, race/ethnicity, education, and income. Each unadjusted comparison was summarized as a prevalence ratio (PR), and each of the adjusted comparisons was summarized as a standardized prevalence ratio (SPR). Among HIV-infected persons receiving care, the prevalence of a current episode of major depression and other depression, respectively, was 12.4% (95% CI: 11.2, 13.7) and 13.2% (95% CI: 12.0%, 14.4%). Overall, the PR comparing the prevalence of current major depression between HIV-infected persons receiving care and the general population was 3.1. When controlling for gender and each of the factors age, race/ethnicity, and education, the SPR (3.3, 3.0, and 2.9, respectively) was similar to the PR. However, when controlling for gender and annual household income, the SPR decreased to 1.5. Conclusions: Depression remains a common comorbidity among HIV-infected persons. The overall excess burden among HIV-infected persons receiving care is about three-times that among the general population and is associated with differences in annual household income between the two populations. Relevant efforts are needed to reduce this burden. C1 [Do, Ann N.; Beer, Linda; Fagan, Jennifer L.; Freedman, Mark S.; Skarbinski, Jacek] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. [Rosenberg, Eli S.; Sullivan, Patrick S.] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Strine, Tara W.] Ctr Dis Control & Prevent, Off Publ Hlth Preparedness & Response, Atlanta, GA USA. [Schulden, Jeffrey D.] NIDA, Rockville, MD USA. RP Do, AN (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. EM aad9@cdc.gov FU Centers for Disease Control and Prevention FX Funding was exclusively provided by the Centers for Disease Control and Prevention, which conceived the project, developed project-associated materials including data collection instruments, provided oversight of implementation, conducted analytic procedures, and developed this report. NR 93 TC 21 Z9 21 U1 8 U2 21 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAR 24 PY 2014 VL 9 IS 3 AR e92842 DI 10.1371/journal.pone.0092842 PG 10 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA AD7QO UT WOS:000333459900124 PM 24663122 ER PT J AU Alami, NN Yuen, CM Miramontes, R Pratt, R Price, SF Navin, TR AF Alami, Negar Niki Yuen, Courtney M. Miramontes, Roque Pratt, Robert Price, Sandy F. Navin, Thomas R. TI Trends in Tuberculosis - United States, 2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID HOMELESS; COUNTY C1 [Alami, Negar Niki; Yuen, Courtney M.] CDC, Atlanta, GA 30333 USA. [Miramontes, Roque; Pratt, Robert; Price, Sandy F.; Navin, Thomas R.] CDC, Div TB Eliminat, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. RP Alami, NN (reprint author), CDC, Atlanta, GA 30333 USA. EM nalami@cdc.gov NR 8 TC 26 Z9 26 U1 0 U2 4 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAR 21 PY 2014 VL 63 IS 11 BP 229 EP 233 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AD7NJ UT WOS:000333450600001 PM 24647398 ER PT J AU Posey, DL Naughton, MP Willacy, EA Russell, M Olson, CK Godwin, CM McSpadden, PS White, ZA Comans, TW Ortega, LS Guterbock, M Weinberg, MS Cetron, MS AF Posey, Drew L. Naughton, Mary P. Willacy, Erika A. Russell, Michelle Olson, Christine K. Godwin, Courtney M. McSpadden, Pamela S. White, Zachary A. Comans, Terry W. Ortega, Luis S. Guterbock, Michael Weinberg, Michelle S. Cetron, Martin S. TI Implementation of New TB Screening Requirements for US-Bound Immigrants and Refugees-2007-2014 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID TUBERCULOSIS C1 [Posey, Drew L.; Naughton, Mary P.; Willacy, Erika A.; Russell, Michelle; Olson, Christine K.; Godwin, Courtney M.; McSpadden, Pamela S.; White, Zachary A.; Comans, Terry W.; Ortega, Luis S.; Guterbock, Michael; Weinberg, Michelle S.; Cetron, Martin S.] CDC, Div Global Migrat & Quarantine, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. RP Posey, DL (reprint author), CDC, Div Global Migrat & Quarantine, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. EM dposey@cdc.gov NR 10 TC 12 Z9 12 U1 0 U2 4 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAR 21 PY 2014 VL 63 IS 11 BP 234 EP 236 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AD7NJ UT WOS:000333450600003 PM 24647399 ER PT J AU Sheikh, MA Makokha, F Hussein, MA Mohamed, G Mach, O Humayun, K Okiror, S Abrar, L Nasibov, O Burton, J Unshur, A Wannemuehler, K Estivariz, CF AF Sheikh, Mohamed A. Makokha, Frederick Hussein, M. Abdullahi Mohamed, Gedi Mach, Ondrej Humayun, Kabir Okiror, Samuel Abrar, Leila Nasibov, Orkhan Burton, John Unshur, Ahmed Wannemuehler, Kathleen Estivariz, Concepcion F. TI Combined Use of Inactivated and Oral Poliovirus Vaccines in Refugee Camps and Surrounding Communities - Kenya, December 2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID IMMUNOGENICITY C1 [Mohamed, Gedi] World Hlth Org WHO Country Off, Nairobi, Kenya. [Mach, Ondrej; Humayun, Kabir] WHO, Polio Eradicat, CH-1211 Geneva, Switzerland. [Okiror, Samuel] WHO, Inter Country Support Team, Harare, Zimbabwe. [Abrar, Leila] UNICEF Kenya Off, Hlth Sect, Nairobi, Kenya. [Unshur, Ahmed] CDC, Kenya Med Res Inst, Refugee Hlth Program, Atlanta, GA 30333 USA. [Wannemuehler, Kathleen; Estivariz, Concepcion F.] CDC, Global Immunizat Div, Ctr Global Hlth, Atlanta, GA 30333 USA. RP Estivariz, CF (reprint author), CDC, Global Immunizat Div, Ctr Global Hlth, Atlanta, GA 30333 USA. EM cestivariz@cdc.gov NR 10 TC 6 Z9 6 U1 0 U2 3 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAR 21 PY 2014 VL 63 IS 11 BP 237 EP 241 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AD7NJ UT WOS:000333450600004 PM 24647400 ER PT J AU Diop, OM Burns, CC Wassilak, SG Kew, OM AF Diop, Ousmane M. Burns, Cara C. Wassilak, Steven G. Kew, Olen M. TI Update on Vaccine-Derived Polioviruses - Worldwide, July 2012-December 2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID TYPE-2 C1 [Diop, Ousmane M.] WHO, Dept Immunizat Vaccines & Biol, CH-1211 Geneva, Switzerland. [Burns, Cara C.; Kew, Olen M.] Natl Ctr Immunizat & Resp Dis, Div Viral Dis, Atlanta, GA 30333 USA. [Wassilak, Steven G.] CDC, Ctr Global Hlth, Global Immunizat Div, Atlanta, GA 30333 USA. RP Kew, OM (reprint author), Natl Ctr Immunizat & Resp Dis, Div Viral Dis, Atlanta, GA 30333 USA. EM okew@cdc.gov NR 10 TC 20 Z9 21 U1 0 U2 4 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAR 21 PY 2014 VL 63 IS 11 BP 242 EP 248 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AD7NJ UT WOS:000333450600005 PM 24647401 ER PT J AU Schafer, IJ Miller, R Stroher, U Knust, B Nichol, ST Rollin, PE AF Schafer, Ilana J. Miller, Rachel Stroeher, Ute Knust, Barbara Nichol, Stuart T. Rollin, Pierre E. TI A Cluster of Lymphocytic Choriomeningitis Virus Infections Transmitted Through Organ Transplantation - Iowa, 2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Schafer, Ilana J.] CDC, Atlanta, GA 30333 USA. [Miller, Rachel] Univ Iowa, Carver Coll Med, Iowa City, IA 52242 USA. [Stroeher, Ute; Knust, Barbara; Nichol, Stuart T.; Rollin, Pierre E.] CDC, Natl Ctr Emerging & Zoonot Infect, Viral Special Pathogens Branch, Atlanta, GA 30333 USA. RP Schafer, IJ (reprint author), CDC, Atlanta, GA 30333 USA. EM ischafer@cdc.gov NR 3 TC 5 Z9 5 U1 0 U2 0 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAR 21 PY 2014 VL 63 IS 11 BP 249 EP 249 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AD7NJ UT WOS:000333450600006 PM 24647402 ER PT J AU Gottlieb, SL Low, N Newman, LM Bolan, G Kamb, M Broutet, N AF Gottlieb, Sami L. Low, Nicola Newman, Lori M. Bolan, Gail Kamb, Mary Broutet, Nathalie TI Toward global prevention of sexually transmitted infections (STIs): The need for STI vaccines SO VACCINE LA English DT Article DE Sexually transmitted diseases; Vaccines; Prevention and control ID HERPES-SIMPLEX-VIRUS; TRACHOMATIS GENITAL-INFECTION; PELVIC-INFLAMMATORY-DISEASE; HUMAN-PAPILLOMAVIRUS INFECTION; RANDOMIZED CONTROLLED-TRIALS; HUMAN-IMMUNODEFICIENCY-VIRUS; SUB-SAHARAN AFRICA; OF-THE-LITERATURE; CHLAMYDIA-TRACHOMATIS; UNITED-STATES AB An estimated 499 million curable sexually transmitted infections (STIs; gonorrhea, chlamydia, syphilis, and trichomoniasis) occurred globally in 2008. In addition, well over 500 million people are estimated to have a viral STI such as herpes simplex virus type 2 (HSV-2) or human papillomavirus (HPV) at any point in time. STIs result in a large global burden of sexual, reproductive, and maternal-child health consequences, including genital symptoms, pregnancy complications, cancer, infertility, and enhanced HIV transmission, as well as important psychosocial consequences and financial costs. STI control strategies based primarily on behavioral primary prevention and STI case management have had clear successes, but gains have not been universal. Current STI control is hampered or threatened by several behavioral, biological, and implementation challenges, including a large proportion of asymptomatic infections, lack of feasible diagnostic tests globally, antimicrobial resistance, repeat infections, and barriers to intervention access, availability, and scale-up. Vaccines against HPV and hepatitis B virus offer a new paradigm for STI control. Challenges to existing STI prevention efforts provide important reasons for working toward additional STI vaccines. We summarize the global epidemiology of STIs and STI-associated complications, examine challenges to existing STI prevention efforts, and discuss the need for new STI vaccines for future prevention efforts. (C) 2014 Elsevier Ltd. All rights reserved. C1 [Gottlieb, Sami L.; Newman, Lori M.; Broutet, Nathalie] WHO, Dept Reprod Hlth & Res, CH-1211 Geneva 27, Switzerland. [Low, Nicola] Univ Bern, Dept Social & Prevent Med, Bern, Switzerland. [Bolan, Gail; Kamb, Mary] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. RP Gottlieb, SL (reprint author), WHO, Dept Reprod Hlth & Res, Ave Appia 20, CH-1211 Geneva 27, Switzerland. EM gottliebs@who.int OI Low, Nicola/0000-0003-4817-8986 FU World Health Organization [001] NR 108 TC 38 Z9 38 U1 6 U2 31 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD MAR 20 PY 2014 VL 32 IS 14 SI SI BP 1527 EP 1535 DI 10.1016/j.vaccine.2013.07.087 PG 9 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA AE2HM UT WOS:000333793900003 PM 24581979 ER PT J AU Fonjungo, PN Kalish, ML Schaefer, A Rayfield, M Mika, J Rose, LE Heslop, O Soudre, R Pieniazek, D AF Fonjungo, Peter N. Kalish, Marcia L. Schaefer, Amanda Rayfield, Mark Mika, Jennifer Rose, Laura E. Heslop, Orville Soudre, Robert Pieniazek, Danuta TI Recombinant Viruses Initiated the Early HIV-1 Epidemic in Burkina Faso SO PLOS ONE LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; WEST CENTRAL-AFRICA; GROUP-N; HIGHLY DIVERGENT; GROUP-O; GENETIC DIVERSITY; TYPE-1 SUBTYPE; GUINEA-BISSAU; GENOME SEQUENCES; ANTIBODY-BINDING AB We analyzed genetic diversity and phylogenetic relationships among 124 HIV-1 and 19 HIV-2 strains in sera collected in 1986 from patients of the state hospital in Ouagadougou, Burkina Faso. Phylogenetic analysis of the HIV-1 env gp41 region of 65 sequences characterized 37 (56.9%) as CRF06_cpx strains, 25 (38.5%) as CRF02_AG, 2 (3.1%) as CRF09_cpx, and 1 (1.5%) as subtype A. Similarly, phylogenetic analysis of the protease (PR) gene region of 73 sequences identified 52 (71.2%) as CRF06_cpx, 15 (20.5%) as CRF02_AG, 5 (6.8%) as subtype A, and 1 (1.4%) was a unique strain that clustered along the B/D lineage but basal to the node connecting the two lineages. HIV-2 PR or integrase (INT) groups A (n = 17 [89.5%]) and B (n = 2 [10.5%]) were found in both monotypic (n = 11) and heterotypic HIV-1/HIV-2 (n = 8) infections, with few HIV-2 group B infections. Based on limited available sampling, evidence suggests two recombinant viruses, CRF06_cpx and CRF02_AG, appear to have driven the beginning of the mid-1980s HIV-1 epidemic in Burkina Faso. C1 [Fonjungo, Peter N.; Kalish, Marcia L.; Schaefer, Amanda; Rayfield, Mark; Mika, Jennifer; Rose, Laura E.; Heslop, Orville; Pieniazek, Danuta] Ctr Dis Control, Natl Ctr Infect Dis, HIV & Retrovirol Branch, Div AIDS STD & TB Lab Res, Atlanta, GA 30333 USA. [Fonjungo, Peter N.] Ctr Dis Control & Prevent, Div Global HIV AIDS, Ctr Global Hlth, Atlanta, GA USA. [Soudre, Robert] Univ Ouagadougou, Unite Format & Rech Sci Sante UFR SDS, Ouagadougou, Burkina Faso. RP Fonjungo, PN (reprint author), Ctr Dis Control, Natl Ctr Infect Dis, HIV & Retrovirol Branch, Div AIDS STD & TB Lab Res, Atlanta, GA 30333 USA. EM Pfonjungo@cdc.gov FU Centers for Disease Control and Prevention FX The work was funded by the Centers for Disease Control and Prevention. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 82 TC 3 Z9 3 U1 0 U2 2 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAR 19 PY 2014 VL 9 IS 3 AR e92423 DI 10.1371/journal.pone.0092423 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA AD6ER UT WOS:000333348500129 PM 24647246 ER PT J AU Shcherbik, SV Pearce, NC Levine, ML Klimov, AI Villanueva, JM Bousse, TL AF Shcherbik, Svetlana V. Pearce, Nicholas C. Levine, Marnie L. Klimov, Alexander I. Villanueva, Julie M. Bousse, Tatiana L. TI Rapid Strategy for Screening by Pyrosequencing of Influenza Virus Reassortants - Candidates for Live Attenuated Vaccines SO PLOS ONE LA English DT Article ID A H7N9 VIRUS; GENOME COMPOSITION; WILD-TYPE; INACTIVATED VACCINES; RESTRICTION ANALYSIS; PANDEMIC INFLUENZA; H3N2 VIRUSES; B VIRUS; STRAINS; PCR AB Background: Live attenuated influenza vaccine viruses (LAIVs) can be generated by classical reassortment of gene segments between a cold adapted, temperature sensitive and attenuated Master Donor Virus (MDV) and a seasonal wild-type (wt) virus. The vaccine candidates contain hemagglutinin (HA) and neuraminidase (NA) genes derived from the circulating wt viruses and the remaining six genes derived from the MDV strains. Rapid, efficient selection of the viruses with 6: 2 genome compositions from the large number of genetically different viruses generated during reassortment is essential for the biannual production schedule of vaccine viruses. Methodology/Principal Findings: This manuscript describes a new approach for the genotypic analysis of LAIV reassortant virus clones based on pyrosequencing. LAIV candidate viruses were created by classical reassortment of seasonal influenza A (H3N2) (A/Victoria/361/2011, A/Ohio/02/2012, A/Texas/50/2012) or influenza A (H7N9) (A/Anhui/1/2013) wt viruses with the MDV A/Leningrad/134/17/57(H2N2). Using strain-specific pyrosequencing assays, mixed gene variations were detected in the allantoic progenies during the cloning procedure. The pyrosequencing analysis also allowed for estimation of the relative abundance of segment variants in mixed populations. This semi-quantitative approach was used for selecting specific clones for the subsequent cloning procedures. Conclusions/Significance: The present study demonstrates that pyrosequencing analysis is a useful technique for rapid and reliable genotyping of reassortants and intermediate clones during the preparation of LAIV candidates, and can expedite the selection of vaccine virus candidates. C1 [Shcherbik, Svetlana V.; Pearce, Nicholas C.; Levine, Marnie L.; Klimov, Alexander I.; Villanueva, Julie M.; Bousse, Tatiana L.] Ctr Dis Control & Prevent, Virol Surveillance & Diag Branch, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Shcherbik, Svetlana V.; Pearce, Nicholas C.; Levine, Marnie L.] Battelle Mem Inst, Atlanta, GA USA. RP Bousse, TL (reprint author), Ctr Dis Control & Prevent, Virol Surveillance & Diag Branch, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM tbousse@cdc.gov OI Pearce, Neil/0000-0002-9938-7852 FU U.S. Department of Health and Human Services Biomedical Advanced Research and Development Authority (HHS BARDA) FX The research study was supported by U.S. Department of Health and Human Services Biomedical Advanced Research and Development Authority (HHS BARDA). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 51 TC 5 Z9 6 U1 0 U2 9 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAR 19 PY 2014 VL 9 IS 3 AR e92580 DI 10.1371/journal.pone.0092580 PG 11 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA AD6ER UT WOS:000333348500147 PM 24647786 ER PT J AU Vindigni, SM Riley, PL Kimani, F Willy, R Warutere, P Sabatier, JF Kiriinya, R Friedman, M Osumba, M Waudo, AN Rakuom, C Rogers, M AF Vindigni, Stephen M. Riley, Patricia L. Kimani, Francis Willy, Rankesh Warutere, Patrick Sabatier, Jennifer F. Kiriinya, Rose Friedman, Michael Osumba, Martin Waudo, Agnes N. Rakuom, Chris Rogers, Martha TI Kenya's emergency-hire nursing programme: a pilot evaluation of health service delivery in two districts SO HUMAN RESOURCES FOR HEALTH LA English DT Article DE Emergency-hire programme; Human resources for health; Human resource information systems; Health management information systems; Kenya; Nursing; Primary care ID HUMAN-RESOURCES; RURAL-AREAS; NURSES; SHORTAGE; SYSTEMS; AFRICA; CRISIS AB Objective: To assess the feasibility of utilizing a small-scale, low-cost, pilot evaluation in assessing the short-term impact of Kenya's emergency-hire nursing programme (EHP) on the delivery of health services (outpatient visits and maternal-child health indicators) in two underserved health districts with high HIV/AIDS prevalence. Methods: Six primary outcomes were assessed through the collection of data from facility-level health management forms-total general outpatient visits, vaginal deliveries, caesarean sections, antenatal care (ANC) attendance, ANC clients tested for HIV, and deliveries to HIV-positive women. Data on outcome measures were assessed both pre-and post-emergency-hire nurse placement. Informal discussions were also conducted to obtain supporting qualitative data. Findings: The majority of EHP nurses were placed in Suba (15.5%) and Siaya (13%) districts. At the time of the intervention, we describe an increase in total general outpatient visits, vaginal deliveries and caesarean sections within both districts. Similar significant increases were seen with ANC attendance and deliveries to HIV-positive women. Despite increases in the quantity of health services immediately following nurse placement, these levels were often not sustained. We identify several factors that challenge the long-term sustainability of these staffing enhancements. Conclusions: There are multiple factors beyond increasing the supply of nurses that affect the delivery of health services. We believe this pilot evaluation sets the foundation for future, larger and more comprehensive studies further elaborating on the interface between interventions to alleviate nursing shortages and promote enhanced health service delivery. We also stress the importance of strong national and local relationships in conducting future studies. C1 [Vindigni, Stephen M.] Univ Washington, Sch Med, Seattle, WA 98195 USA. [Vindigni, Stephen M.; Riley, Patricia L.; Sabatier, Jennifer F.; Friedman, Michael] Ctr Dis Control & Prevent, Div Global HIV AIDS, Ctr Global Hlth, Atlanta, GA 30333 USA. [Kimani, Francis] Kenya Minist Med Serv, Off Director Med Serv, Nairobi, Kenya. [Willy, Rankesh; Rakuom, Chris] Kenya Minist Med Serv, Off Chief Nursing Officer, Nairobi, Kenya. [Warutere, Patrick; Osumba, Martin] Minist Med Serv, Off Hlth Management Informat Syst, Nairobi, Kenya. [Kiriinya, Rose; Waudo, Agnes N.] Kenya Hlth Workforce Project, Nairobi, Kenya. [Rogers, Martha] Emory Univ, Nell Hodgson Woodruff Sch Nursing, Lillian Carter Ctr Int Nursing, Atlanta, GA 30322 USA. RP Vindigni, SM (reprint author), Univ Washington, Sch Med, 1959 NE Pacific St,Box 356421, Seattle, WA 98195 USA. EM stephen.vindigni@gmail.com NR 19 TC 2 Z9 2 U1 2 U2 5 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1478-4491 J9 HUM RESOUR HEALTH JI Hum. Resour. Health PD MAR 17 PY 2014 VL 12 AR 16 DI 10.1186/1478-4491-12-16 PG 11 WC Health Policy & Services; Industrial Relations & Labor SC Health Care Sciences & Services; Business & Economics GA AF4XF UT WOS:000334717100001 PM 24636052 ER PT J AU Pagnotti, VS Feng, JN Wang, LQ Blount, B AF Pagnotti, Vincent S. Feng, June Wang, Lanqing Blount, Benjamin TI Toward addressing the role of menthol in tobacco use and cessation: A LC/MS/MS method SO ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY LA English DT Meeting Abstract CT 247th National Spring Meeting of the American-Chemical-Society (ACS) CY MAR 16-20, 2014 CL Dallas, TX SP Amer Chem Soc C1 [Pagnotti, Vincent S.; Feng, June; Wang, Lanqing; Blount, Benjamin] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. EM vpagnotti@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0065-7727 J9 ABSTR PAP AM CHEM S JI Abstr. Pap. Am. Chem. Soc. PD MAR 16 PY 2014 VL 247 MA 213-ANYL PG 1 WC Chemistry, Multidisciplinary SC Chemistry GA AZ8HD UT WOS:000348455200322 ER PT J AU Raines, GC Schleicher, R Powers, C Momin, S AF Raines, Grace C. Schleicher, Rosemary Powers, Carissa Momin, Shazhad TI GC/MS analysis of fatty acid concentrations in whole blood compared to serum and plasma SO ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY LA English DT Meeting Abstract CT 247th National Spring Meeting of the American-Chemical-Society (ACS) CY MAR 16-20, 2014 CL Dallas, TX SP Amer Chem Soc C1 [Raines, Grace C.] The Citadel, Dept Chem, Charleston, SC 29409 USA. [Schleicher, Rosemary; Powers, Carissa; Momin, Shazhad] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. EM graines@citadel.edu NR 0 TC 0 Z9 0 U1 2 U2 2 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0065-7727 J9 ABSTR PAP AM CHEM S JI Abstr. Pap. Am. Chem. Soc. PD MAR 16 PY 2014 VL 247 MA 524-CHED PG 1 WC Chemistry, Multidisciplinary SC Chemistry GA AZ8HD UT WOS:000348455202430 ER PT J AU Lapinski, MK Anderson, J Shugart, A Todd, E AF Lapinski, Maria Knight Anderson, Jenn Shugart, Alicia Todd, Ewen TI Social Influence in Child Care Centers: A Test of the Theory of Normative Social Behavior SO HEALTH COMMUNICATION LA English DT Article ID DESCRIPTIVE NORMS; HAND HYGIENE; FOCUS THEORY; HEALTH; COMMUNICATION; ENVIRONMENT; ATTITUDES; IDENTITY; ALCOHOL; CONDUCT AB Child care centers are a unique context for studying communication about the social and personal expectations about health behaviors. The theory of normative social behavior (TNSB; Rimal & Real, 2005) provides a framework for testing the role of social and psychological influences on handwashing behaviors among child care workers. A cross-sectional survey of child care workers in 21 centers indicates that outcome expectations and group identity increase the strength of the relationship between descriptive norms and handwashing behavior. Injunctive norms also moderate the effect of descriptive norms on handwashing behavior such that when strong injunctive norms are reported, descriptive norms are positively related to handwashing, but when weak injunctive norms are reported, descriptive norms are negatively related to handwashing. The findings suggest that communication interventions in child care centers can focus on strengthening injunctive norms in order to increase handwashing behaviors in child care centers. The findings also suggest that the theory of normative social behavior can be useful in organizational contexts. C1 [Lapinski, Maria Knight] Michigan State Univ, Dept Commun, E Lansing, MI 48824 USA. [Anderson, Jenn] Ctr Dis Control & Prevent, Prevent & Response Branch, Div Healthcare Qual Promot, Atlanta, GA USA. [Shugart, Alicia] S Dakota State Univ, Brookings, SD USA. [Todd, Ewen] Ewen Todd Consulting, Glasgow, Lanark, Scotland. RP Lapinski, MK (reprint author), Michigan State Univ, Dept Commun, 297 Commun Arts & Sci Bldg, E Lansing, MI 48824 USA. EM lapinsk3@msu.edu OI Todd, Ewen/0000-0001-7266-279X NR 45 TC 6 Z9 6 U1 0 U2 8 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1041-0236 EI 1532-7027 J9 HEALTH COMMUN JI Health Commun. PD MAR 16 PY 2014 VL 29 IS 3 BP 219 EP 232 DI 10.1080/10410236.2012.738322 PG 14 WC Communication; Health Policy & Services SC Communication; Health Care Sciences & Services GA AH2DT UT WOS:000335931600003 PM 23682754 ER PT J AU Oster, ME Kim, CH Kusano, AS Cragan, JD Dressler, P Hales, AR Mahle, WT Correa, A AF Oster, Matthew E. Kim, Christopher H. Kusano, Aaron S. Cragan, Janet D. Dressler, Paul Hales, Alice R. Mahle, William T. Correa, Adolfo TI A Population-Based Study of the Association of Prenatal Diagnosis With Survival Rate for Infants With Congenital Heart Defects SO AMERICAN JOURNAL OF CARDIOLOGY LA English DT Article ID FETAL ECHOCARDIOGRAPHY; GREAT-ARTERIES; DISEASE; OUTCOMES; IMPACT; MORBIDITY; TRENDS; TRANSPOSITION; MORTALITY; ATLANTA AB Prenatal diagnosis has been shown to improve preoperative morbidity in newborns with congenital heart defects (CRDs), but there are conflicting data as to the association with mortality. We performed a population-based, retrospective, cohort study of infants with prenatally versus postnatally diagnosed CHDs from 1994 to 2005 as ascertained by the Metropolitan Atlanta Congenital Defects Program. Among infants with isolated CHDs, we estimated 1-year Kaplan-Meier survival probabilities for prenatal versus postnatal diagnosis and estimated Cox proportional hazard ratios adjusted for critical CHD status, gestational age, and maternal race/ethnicity. Of 539,519 live births, 4,348 infants had CHDs (411 prenatally diagnosed). Compared with those with noncritical defects, those with critical defects were more likely to be prenatally diagnosed (58% vs 20%, respectively, p <0.001). Of the 3,146 infants with isolated CHDs, 1-year survival rate was 77% for those prenatally diagnosed (n = 207) versus 96% for those postnatally diagnosed (n = 2,939, p <0.001). Comparing 1-year survival rate among those with noncritical CHDs alone (n = 2,455) showed no difference between prenatal and postnatal diagnoses (96% vs 98%, respectively, p = 0.26), whereas among those with critical CHDs (n = 691), prenatally diagnosed infants had significantly lower survival rate (71% vs 86%, respectively, p <0.001). Among infants with critical CHDs, the adjusted hazard ratio for 1-year mortality rate for those prenatally versus postnatally (reference) diagnosed was 2.51 (95% confidence interval 1.72 to 3.66). In conclusion, prenatal diagnosis is associated with lower 1-year survival rate for infants with isolated critical CHDs but shows no change for those with isolated noncritical CHDs. More severe disease among the critical CRD sOtypes diagnosed prenatally might explain these findings. Published by Elsevier Inc. C1 [Oster, Matthew E.; Kim, Christopher H.; Kusano, Aaron S.; Cragan, Janet D.; Dressler, Paul; Correa, Adolfo] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Oster, Matthew E.; Kim, Christopher H.; Dressler, Paul; Hales, Alice R.; Mahle, William T.] Emory Univ, Childrens Healthcare Atlanta, Atlanta, GA 30322 USA. [Kusano, Aaron S.] Univ Washington, Dept Radiat Oncol, Seattle, WA 98195 USA. [Correa, Adolfo] Univ Mississippi, Med Ctr, Dept Med, Jackson, MS 39216 USA. RP Oster, ME (reprint author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. EM osterm@kidsheart.com FU Intramural CDC HHS [CC999999] NR 26 TC 14 Z9 14 U1 0 U2 4 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 0002-9149 EI 1879-1913 J9 AM J CARDIOL JI Am. J. Cardiol. PD MAR 15 PY 2014 VL 113 IS 6 BP 1036 EP 1040 DI 10.1016/j.amjcard.2013.11.066 PG 5 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA AD7WD UT WOS:000333476700022 PM 24472597 ER PT J AU Nankoberanyi, S Mbogo, GW LeClair, NP Conrad, MD Tumwebaze, P Tukwasibwe, S Kamya, MR Tappero, J Nsobya, SL Rosenthal, PJ AF Nankoberanyi, Sheila Mbogo, George W. LeClair, Norbert P. Conrad, Melissa D. Tumwebaze, Patrick Tukwasibwe, Stephen Kamya, Moses R. Tappero, Jordan Nsobya, Samuel L. Rosenthal, Philip J. TI Validation of the ligase detection reaction fluorescent microsphere assay for the detection of Plasmodium falciparum resistance mediating polymorphisms in Uganda SO MALARIA JOURNAL LA English DT Article DE Plasmodium falciparum; Malaria; Fluorescent microsphere assay; Drug resistance; Polymorphisms ID SINGLE-NUCLEOTIDE POLYMORPHISMS; REAL-TIME PCR; DRUG-RESISTANCE; DIHYDROFOLATE-REDUCTASE; ARTEMETHER-LUMEFANTRINE; CHLOROQUINE-RESISTANCE; LONG ROAD; MALARIA; MUTATIONS; AMODIAQUINE AB Background: Malaria remains a major public health problem, and its control has been hampered by drug resistance. For a number of drugs, Plasmodium falciparum single nucleotide polymorphisms (SNPs) are associated with altered drug sensitivity and can be used as markers of drug resistance. Several techniques have been studied to assess resistance markers. The most widely used methodology is restriction fragment length polymorphism (RFLP) analysis. The ligase detection reaction fluorescent microsphere (LDR-FM) assay was recently shown to provide high throughput assessment of P. falciparum SNPs associated with drug resistance. The aim of this study was to validate the reliability and accuracy of the LDR-FM assay in a field setting. Methods: For 223 samples from a clinical trial in Tororo, Uganda in which P. falciparum was identified by blood smear, DNA was extracted from dried blood spots, genes of interest were amplified by PCR, amplicons were analysed by both RFLP and LDR-FM assays, and results were compared. Results: SNP prevalence (wild type/mixed/mutant) with RFLP analysis was 8/5/87% for pfcrt K76T, 34/37/29% for pfmdr1 N86Y, 64/17/19% for pfmdr1 Y184F, and 42/21/37% for pfmdr1 D1246Y. These prevalences with the LDR-FM assay were 7/5/88%, 31/24/45%, 62/20/18%, and 48/19/33% for the four SNPs, respectively. Combining mixed and mutant outcomes for analysis, agreement between the assays was 97% (K = 0.77) for pfcrt K76T, 79% (K = 0.55) for pfmdr1 N86Y, 83% (K = 0.65) for pfmdr1 Y184F, and 91% (K = 0.82) for pfmdr1 D1246Y, with most disagreements due to discrepant readings of mixed genotypes. Conclusion: The LDR-FM assay provides a high throughput, relatively inexpensive and accurate assay for the surveillance of P. falciparum SNPs associated with drug resistance in resource-limited countries. C1 [Nankoberanyi, Sheila; Mbogo, George W.; Tumwebaze, Patrick; Tukwasibwe, Stephen; Kamya, Moses R.; Nsobya, Samuel L.] Infect Dis Res Collaborat, Kampala, Uganda. [LeClair, Norbert P.; Conrad, Melissa D.; Rosenthal, Philip J.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Nankoberanyi, Sheila; Mbogo, George W.; Tumwebaze, Patrick; Tukwasibwe, Stephen; Kamya, Moses R.; Nsobya, Samuel L.] Makerere Univ, Kampala, Uganda. [Tappero, Jordan] Ctr Dis Control & Prevent, Ctr Global Hlth, Atlanta, GA USA. RP Rosenthal, PJ (reprint author), Univ Calif San Francisco, Dept Med, Box 0811, San Francisco, CA 94143 USA. EM prosenthal@medsfgh.ucsf.edu FU International Center of Excellence in Malaria Research, National Institutes of Health [AI089674]; Fogarty International Center, National Institutes of Health [TW007375]; Centers for Disease Control and Prevention; Doris Duke Charitable Foundation FX We thank the children studied in the clinical trial that provided samples for our analyses, their parents or guardians, the study personnel and the molecular biology team in Kampala for their assistance during the study. This study was funded by an International Center of Excellence in Malaria Research grant (AI089674) and a Fogarty International Center training grant (TW007375), both from the National Institutes of Health. The clinical trial that provided samples for this study was funded by the Centers for Disease Control and Prevention and the Doris Duke Charitable Foundation. NR 29 TC 7 Z9 7 U1 0 U2 3 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1475-2875 J9 MALARIA J JI Malar. J. PD MAR 14 PY 2014 VL 13 AR 95 DI 10.1186/1475-2875-13-95 PG 5 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA AF6CS UT WOS:000334802600001 PM 24629020 ER PT J AU Papp, JR Schachter, J Gaydos, CA Van der Pol, B AF Papp, John R. Schachter, Julius Gaydos, Charlotte A. Van der Pol, Barbara TI Recommendations for the Laboratory-Based Detection of Chlamydia trachomatis and Neisseria gonorrhoeae-2014 SO MMWR RECOMMENDATIONS AND REPORTS LA English DT Article ID ACID AMPLIFICATION TESTS; PELVIC-INFLAMMATORY-DISEASE; POLYMERASE-CHAIN-REACTION; SEXUALLY-TRANSMITTED INFECTIONS; COLLECTED VAGINAL SWABS; FAMILY-PLANNING CLINICS; AMPLICOR CT/NG TESTS; NEISSERIA-GONORRHOEAE; LYMPHOGRANULOMA-VENEREUM; URINE SPECIMENS AB This report updates CDC's 2002 recommendations regarding screening tests to detect Chlamydia trachomatis and Neisseria gonorrhoeae infections (CDC. Screening tests to detect Chlamydia trachomatis and Neisseria gonorrhoeae infections-2002. MMWR 2002; 51[No. RR-15]) and provides new recommendations regarding optimal specimen types, the use of tests to detect rectal and oropharyngeal C. trachomatis and N. gonorrhoeae infections, and circumstances when supplemental testing is indicated. The recommendations in this report are intended for use by clinical laboratory directors, laboratory staff, clinicians, and disease control personnel who must choose among the multiple available tests, establish standard operating procedures for collecting and processing specimens, interpret test results for laboratory reporting, and counsel and treat patients. The performance of nucleic acid amplification tests (NAATs) with respect to overall sensitivity, specificity, and ease of specimen transport is better than that of any of the other tests available for the diagnosis of chlamydial and gonococcal infections. Laboratories should use NAATs to detect chlamydia and gonorrhea except in cases of child sexual assault involving boys and rectal and oropharyngeal infections in prepubescent girls and when evaluating a potential gonorrhea treatment failure, in which case culture and susceptibility testing might be required. NAATs that have been cleared by the Food and Drug Administration (FDA) for the detection of C. trachomatis and N. gonorrhoeae infections are recommended as screening or diagnostic tests because they have been evaluated in patients with and without symptoms. Maintaining the capability to culture for both N. gonorrhoeae and C. trachomatis in laboratories throughout the country is important because data are insufficient to recommend nonculture tests in cases of sexual assault in prepubescent boys and extragenital anatomic site exposure in prepubescent girls. N. gonorrhoeae culture is required to evaluate suspected cases of gonorrhea treatment failure and to monitor developing resistance to current treatment regimens. Chlamydia culture also should be maintained in some laboratories to monitor future changes in antibiotic susceptibility and to support surveillance and research activities such as detection of lymphogranuloma venereum or rare infections caused by variant or mutated C. trachomatis. C1 [Papp, John R.] CDC, Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Schachter, Julius] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Gaydos, Charlotte A.] Johns Hopkins Univ, Baltimore, MD USA. [Van der Pol, Barbara] Univ Alabama Birmingham, Sch Med, Birmingham, AL USA. RP Papp, JR (reprint author), CDC, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. EM jwp6@cdc.gov NR 116 TC 46 Z9 48 U1 0 U2 18 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 1057-5987 EI 1545-8601 J9 MMWR RECOMM REP JI MMWR Recomm. Rep. PD MAR 14 PY 2014 VL 63 IS 2 BP 1 EP 19 PG 19 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AE1TF UT WOS:000333752400001 ER PT J AU Chan, SK Thornton, LR Chronister, KJ Meyer, J Wolverton, M Johnson, CK Arafat, RR Joyce, MP Switzer, WM Heneine, W Shankar, A Granade, T Owen, SM Sprinkle, P Sullivan, V AF Chan, Shirley K. Thornton, Lupita R. Chronister, Karen J. Meyer, Jeffrey Wolverton, Marcia Johnson, Cynthia K. Arafat, Raouf R. Joyce, M. Patricia Switzer, William M. Heneine, Walid Shankar, Anupama Granade, Timothy Owen, S. Michele Sprinkle, Patrick Sullivan, Vickie TI Likely Female-to-Female Sexual Transmission of HIV - Texas, 2012 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID UNITED-STATES; EPIDEMIOLOGY; LESBIANS; WOMEN; AIDS C1 [Chan, Shirley K.; Thornton, Lupita R.; Chronister, Karen J.; Meyer, Jeffrey; Wolverton, Marcia; Johnson, Cynthia K.; Arafat, Raouf R.] Houston Dept Hlth & Human Serv, Houston, TX USA. [Joyce, M. Patricia; Switzer, William M.; Heneine, Walid; Shankar, Anupama; Granade, Timothy; Owen, S. Michele; Sprinkle, Patrick; Sullivan, Vickie] CDC, Div HIV & AIDS Prevent, Natl Ctr HIV Hepatitis STD & TB Prevent, Atlanta, GA 30333 USA. RP Joyce, MP (reprint author), CDC, Div HIV & AIDS Prevent, Natl Ctr HIV Hepatitis STD & TB Prevent, Atlanta, GA 30333 USA. EM pjoyce@cdc.gov NR 10 TC 13 Z9 14 U1 0 U2 3 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAR 14 PY 2014 VL 63 IS 10 BP 209 EP 212 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AD0QW UT WOS:000332940200001 PM 24622284 ER PT J AU Gonzales, K Roeber, J Kanny, D Tran, A Saiki, C Johnson, H Yeoman, K Safranek, T Creppage, K Lepp, A Miller, T Tarkhashvili, N Lynch, KE Watson, JR Henderson, D Christenson, M Geiger, SD AF Gonzales, Katherine Roeber, Jim Kanny, Dafna Annie Tran Saiki, Cathy Johnson, Hal Yeoman, Kristin Safranek, Tom Creppage, Kathleen Lepp, Alicia Miller, Tracy Tarkhashvili, Nato Lynch, Kristine E. Watson, Joanna R. Henderson, Danielle Christenson, Megan Geiger, Sarah Dee TI Alcohol-Attributable Deaths and Years of Potential Life Lost-11 States, 2006-2010 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID UNITED-STATES; CONSUMPTION; US C1 [Gonzales, Katherine] Michigan Dept Community Hlth, Lansing Charter Township, MI 48933 USA. [Roeber, Jim] New Mexico Dept Hlth, Albuquerque, NM 87125 USA. [Kanny, Dafna] CDC, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Saiki, Cathy] Calif Dept Publ Hlth, Sacramento, CA 95814 USA. [Johnson, Hal] Florida Dept Children & Families, Opa Locka, FL 33054 USA. [Yeoman, Kristin; Safranek, Tom] Nebraska Dept Hlth & Human Serv, Lincoln, NE 68508 USA. [Creppage, Kathleen] North Carolina Div Publ Hlth, Raleigh, NC 27609 USA. [Lepp, Alicia; Miller, Tracy] North Dakota Dept Hlth, Bismarck, ND 58505 USA. [Tarkhashvili, Nato] South Dakota Dept Hlth, Off Publ Hlth Preparedness & Response, Pierre, SD 57501 USA. [Lynch, Kristine E.; Watson, Joanna R.] Utah Dept Hlth, Salt Lake City, UT 84116 USA. [Henderson, Danielle] Virginia Dept Hlth, Fairfax, VA 22035 USA. [Christenson, Megan; Geiger, Sarah Dee] Wisconsin Div Publ Hlth, Green Bay, WI 54301 USA. RP Gonzales, K (reprint author), Michigan Dept Community Hlth, Lansing Charter Township, MI 48933 USA. EM gonzalesk2@michigan.gov OI Watson, Joanna/0000-0002-2532-2423 NR 10 TC 14 Z9 14 U1 1 U2 3 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAR 14 PY 2014 VL 63 IS 10 BP 213 EP 216 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AD0QW UT WOS:000332940200002 PM 24622285 ER PT J AU Luckhaupt, SE Calvert, GM Li, J Sweeney, M Santibanez, TA AF Luckhaupt, Sara E. Calvert, Geoffrey M. Li, Jia Sweeney, Marie Santibanez, Tammy A. TI Prevalence of Influenza-Like Illness and Seasonal and Pandemic H1N1 Influenza Vaccination Coverage Among Workers - United States, 2009-10 Influenza Season SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Luckhaupt, Sara E.; Calvert, Geoffrey M.; Li, Jia; Sweeney, Marie] NIOSH, Div Surveillance Hazard Evaluat & Field Studies, CDC, Washington, DC USA. [Santibanez, Tammy A.] CDC, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Luckhaupt, SE (reprint author), NIOSH, Div Surveillance Hazard Evaluat & Field Studies, CDC, Washington, DC USA. EM pks8@cdc.gov NR 6 TC 1 Z9 1 U1 0 U2 2 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAR 14 PY 2014 VL 63 IS 10 BP 217 EP 221 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AD0QW UT WOS:000332940200003 PM 24622286 ER PT J AU Basler, C Forshey, TM Machesky, K Erdman, CM Gomez, TM Nguyen, TA Behravesh, CB AF Basler, Colin Forshey, Tony M. Machesky, Kimberly Erdman, C. Matthew Gomez, Thomas M. Thai-An Nguyen Behravesh, Casey Barton TI Multistate Outbreak of Human Salmonella Infections Linked to Live Poultry from a Mail-Order Hatchery in Ohio - March-September 2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Basler, Colin] CDC, Atlanta, GA 30333 USA. [Forshey, Tony M.] Ohio Dept Agr, Reynoldsburg, OH 43068 USA. [Machesky, Kimberly] Ohio Dept Hlth, Columbus, OH 43266 USA. [Erdman, C. Matthew] USDA, Washington, DC 20250 USA. [Thai-An Nguyen; Behravesh, Casey Barton] CDC, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. RP Basler, C (reprint author), CDC, Atlanta, GA 30333 USA. EM cbasler@cdc.gov NR 3 TC 8 Z9 8 U1 0 U2 5 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAR 14 PY 2014 VL 63 IS 10 BP 222 EP 222 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AD0QW UT WOS:000332940200004 PM 24622287 ER PT J AU Crepaz, N Tungol-Ashmon, MV Higa, DH Vosburgh, W Mullins, MM Barham, T Adegbite, A DeLuca, JB Sipe, TA White, CM Baack, BN Lyles, CM AF Crepaz, Nicole Tungol-Ashmon, Malu V. Higa, Darrel H. Vosburgh, Waverly Mullins, Mary M. Barham, Terrika Adegbite, Adebukola DeLuca, Julia B. Sipe, Theresa A. White, Christina M. Baack, Brittney N. Lyles, Cynthia M. TI A systematic review of interventions for reducing HIV risk behaviors among people living with HIV in the United States, 1988-2012 SO AIDS LA English DT Review DE risk reduction; systematic review; evidence-based intervention; people living with HIV; HIV prevention ID RANDOMIZED CONTROLLED-TRIAL; CLINICAL CARE SETTINGS; INJECTION-DRUG USERS; CHILDHOOD SEXUAL-ABUSE; SAFER-SEX; REDUCTION INTERVENTION; PREVENTION INTERVENTIONS; INFECTED PATIENTS; AFRICAN-AMERICAN; MULTICLINIC ASSESSMENT AB Objective: To conduct a systematic review to examine interventions for reducing HIV risk behaviors among people living with HIV (PLWH) in the United States. Methods: Systematic searches included electronic databases from 1988 to 2012, hand searches of journals, reference lists of articles, and HIV/AIDS Internet listservs. Each eligible study was evaluated against the established criteria on study design, implementation, analysis, and strength of findings to assess the risk of bias and intervention effects. Results: Forty-eight studies were evaluated. Fourteen studies (29%) with both low risk of bias and significant positive intervention effects in reducing HIV transmission risk behaviors were classified as evidence-based interventions (EBIs). Thirty-four studies were classified as non-EBIs due to high risk of bias or nonsignificant positive intervention effects. EBIs varied in delivery from brief prevention messages to intensive multisession interventions. The key components of EBIs included addressing HIV risk reduction behaviors, motivation for behavioral change, misconception about HIV, and issues related to mental health, medication adherence, and HIV transmission risk behavior. Conclusion: Moving evidence-based prevention for PLWH into practice is an important step in making a greater impact on the HIV epidemic. Efficacious EBIs can serve as model programs for providers in healthcare and nonhealthcare settings looking to implement evidence-based HIV prevention. Clinics and public health agencies at the state, local, and federal levels can use the results of this review as a resource when making decisions that meet the needs of PLWH to achieve the greatest impact on the HIV epidemic. C1 [Crepaz, Nicole; Tungol-Ashmon, Malu V.; Higa, Darrel H.; Vosburgh, Waverly; Mullins, Mary M.; DeLuca, Julia B.; Sipe, Theresa A.; Baack, Brittney N.; Lyles, Cynthia M.] US Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Prevent Res Branch, Atlanta, GA 30333 USA. [Barham, Terrika; Adegbite, Adebukola; White, Christina M.] ICF Int Inc, Atlanta, GA USA. RP Crepaz, N (reprint author), US Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Prevent Res Branch, 1600 Clifton Rd,Mailstop E-37, Atlanta, GA 30333 USA. EM ncrepaz@cdc.gov FU Prevention Research Branch, Division of HIV/AIDS Prevention at the US Centers for Disease Control and Prevention FX This work was supported by the Prevention Research Branch, Division of HIV/AIDS Prevention at the US Centers for Disease Control and Prevention and was not funded by any other organization. NR 98 TC 14 Z9 14 U1 6 U2 17 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0269-9370 EI 1473-5571 J9 AIDS JI Aids PD MAR 13 PY 2014 VL 28 IS 5 BP 633 EP 656 DI 10.1097/QAD.0000000000000108 PG 24 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA AD6QU UT WOS:000333386700002 PM 24983541 ER PT J AU Kulkarni, AD Kissin, DM AF Kulkarni, Aniket D. Kissin, Dmitry M. TI Fertility Treatments and Multiple Births in the United States Reply SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Letter C1 [Kulkarni, Aniket D.; Kissin, Dmitry M.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Kulkarni, AD (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. EM eof0@cdc.gov NR 3 TC 2 Z9 2 U1 2 U2 2 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD MAR 13 PY 2014 VL 370 IS 11 BP 1070 EP 1071 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA AC7ED UT WOS:000332689100024 PM 24620876 ER PT J AU Kasonde, M Niska, RW Rose, C Henderson, FL Segolodi, TM Turner, K Smith, DK Thigpen, MC Paxton, LA AF Kasonde, Michael Niska, Richard W. Rose, Charles Henderson, Faith L. Segolodi, Tebogo M. Turner, Kyle Smith, Dawn K. Thigpen, Michael C. Paxton, Lynn A. TI Bone Mineral Density Changes among HIV-Uninfected Young Adults in a Randomised Trial of Pre-Exposure Prophylaxis with Tenofovir-Emtricitabine or Placebo in Botswana SO PLOS ONE LA English DT Article ID CALCIUM SUPPLEMENTATION; MEN; LAMIVUDINE; EFAVIRENZ; WOMEN; BLACK; AGE; DF AB Background: Tenofovir-emtricitabine (TDF-FTC) pre-exposure prophylaxis (PrEP) has been found to be effective for prevention of HIV infection in several clinical trials. Two studies of TDF PrEP among men who have sex with men showed slight bone mineral density (BMD) loss. We investigated the effect of TDF and the interaction of TDF and hormonal contraception on BMD among HIV-uninfected African men and women. Method: We evaluated the effects on BMD of using daily oral TDF-FTC compared to placebo among heterosexual men and women aged 18-29 years enrolled in the Botswana TDF2 PrEP study. Participants had BMD measurements at baseline and thereafter at 6-month intervals with dual-energy X-ray absorptiometry (DXA) scans at the hip, spine, and forearm. Results: A total of 220 participants (108 TDF-FTC, 112 placebo) had baseline DXA BMD measurements at three anatomic sites. Fifteen (6.8%) participants had low baseline BMD (z-score of <-22.0 at any anatomic site), including 3/114 women (2.6%) and 12/106 men (11.3%) (p = 0.02). Low baseline BMD was associated with being underweight (p = 0.02), having high blood urea nitrogen (p = 0.02) or high alkaline phosphatase (p = 0.03), and low creatinine clearance (p = 0.04). BMD losses of >3.0% at any anatomic site at any time after baseline were significantly greater for the TDF-FTC treatment group [34/68 (50.0%) TDF-FTC vs. 26/79 (32.9%) placebo; p = 0.04]. There was a small but significant difference in the mean percent change in BMD from baseline for TDF-FTC versus placebo at all three sites at month 30 [forearm 20.84% (p = 0.01), spine -1.62% (p = 0.0002), hip -1.51% (p = 0.003)]. Conclusion: Use of TDF-FTC was associated with a small but statistically significant decrease in BMD at the forearm, hip and lumbar spine. A high percentage (6.8%) of healthy Batswana young adults had abnormal baseline BMD Further evaluation is needed of the longer-term use of TDF in HIV-uninfected persons. C1 [Kasonde, Michael; Henderson, Faith L.; Segolodi, Tebogo M.] Ctr Dis Control & Prevent Botswana, HIV Prevent Res Unit, Gaborone, Botswana. [Niska, Richard W.; Rose, Charles; Turner, Kyle; Smith, Dawn K.; Thigpen, Michael C.; Paxton, Lynn A.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. RP Kasonde, M (reprint author), Ctr Dis Control & Prevent Botswana, HIV Prevent Res Unit, Gaborone, Botswana. EM kasondem@bw.cdc.gov FU Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention; Division of AIDS, National Institutes of Health FX The study was supported by the Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, and the Division of AIDS, National Institutes of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 27 TC 20 Z9 20 U1 1 U2 7 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAR 13 PY 2014 VL 9 IS 3 AR e90111 DI 10.1371/journal.pone.0090111 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA AC9JS UT WOS:000332851300014 PM 24625530 ER PT J AU Dobard, C Sharma, S Parikh, UM West, R Taylor, A Martin, A Pau, CP Hanson, DL Lipscomb, J Smith, J Novembre, F Hazuda, D Garcia-Lerma, JG Heneine, W AF Dobard, Charles Sharma, Sunita Parikh, Urvi M. West, Rolieria Taylor, Andrew Martin, Amy Pau, Chou-Pong Hanson, Debra L. Lipscomb, Jonathan Smith, James Novembre, Francis Hazuda, Daria Garcia-Lerma, J. Gerardo Heneine, Walid TI Postexposure Protection of Macaques from Vaginal SHIV Infection by Topical Integrase Inhibitors SO SCIENCE TRANSLATIONAL MEDICINE LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; TENOFOVIR DISOPROXIL FUMARATE; HIV-1 INTEGRASE; RHESUS MACAQUES; TRANSMISSION; PROPHYLAXIS; RALTEGRAVIR; PREVENTION; GEL; SUSCEPTIBILITY AB Coitally delivered microbicide gels containing antiretroviral drugs are important for HIV prevention. However, to date, microbicides have contained entry or reverse transcriptase inhibitors that block early steps in virus infection and thus need to be given as a preexposure dose that interferes with sexual practices and may limit compliance. Integrase inhibitors block late steps after virus infection and therefore are more suitable for post-coital dosing. We first determined the kinetics of strand transfer in vitro and confirmed that integration begins about 6 hours after infection. We then used a repeat-challenge macaque model to assess efficacy of vaginal gels containing integrase strand transfer inhibitors when applied before or after simian/human immunodeficiency virus (SHIV) challenge. We showed that gel containing the strand transfer inhibitor L-870812 protected two of three macaques when applied 30 min before SHIV challenge. We next evaluated the efficacy of 1% raltegravir gel and demonstrated its ability to protect macaques when applied 3 hours after SHIV exposure (five of six protected; P < 0.05, Fisher's exact test). Breakthrough infections showed no evidence of drug resistance in plasma or vaginal secretions despite continued gel dosing after infection. We documented rapid vaginal absorption reflecting a short pharmacological lag time and noted that vaginal, but not plasma, virus load was substantially reduced in the breakthrough infection after raltegravir gel treatment. We provide a proof of concept that topically applied integrase inhibitors protect against vaginal SHIV infection when administered shortly before or 3 hours after virus exposure. C1 [Dobard, Charles; Sharma, Sunita; Parikh, Urvi M.; West, Rolieria; Taylor, Andrew; Martin, Amy; Pau, Chou-Pong; Lipscomb, Jonathan; Smith, James; Garcia-Lerma, J. Gerardo; Heneine, Walid] Ctr Dis Control & Prevent, Branch Lab, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. [Hanson, Debra L.] Ctr Dis Control & Prevent, Quantitat Sci & Data Management Branch, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. [Novembre, Francis] Emory Univ, Yerkes Primate Ctr, Atlanta, GA 30322 USA. [Hazuda, Daria] Merck Res Labs, West Point, PA 19486 USA. RP Heneine, W (reprint author), Ctr Dis Control & Prevent, Branch Lab, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. EM wmh2@cdc.gov FU CDC [Y1-AI0681-02]; NIH [Y1-AI0681-02] FX Partially supported by Interagency Agreement Y1-AI0681-02 between CDC and NIH. NR 38 TC 7 Z9 7 U1 1 U2 4 PU AMER ASSOC ADVANCEMENT SCIENCE PI WASHINGTON PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA SN 1946-6234 EI 1946-6242 J9 SCI TRANSL MED JI Sci. Transl. Med. PD MAR 12 PY 2014 VL 6 IS 227 AR 227ra35 DI 10.1126/scitranslmed.3007701 PG 9 WC Cell Biology; Medicine, Research & Experimental SC Cell Biology; Research & Experimental Medicine GA AC6KD UT WOS:000332630500008 PM 24622515 ER PT J AU Whitfield, GP Gabriel, KKP Rahbar, MH Kohl, HW AF Whitfield, Geoffrey P. Gabriel, Kelley K. Pettee Rahbar, Mohammad H. Kohl, Harold W., III TI Application of the American Heart Association/American College of Sports Medicine Adult Preparticipation Screening Checklist to a Nationally Representative Sample of US Adults Aged >= 40 Years From the National Health and Nutrition Examination Survey 2001 to 2004 SO CIRCULATION LA English DT Article DE epidemiology; exercise; health surveys; mass screening ID PHYSICAL-ACTIVITY; QUESTIONNAIRE; FITNESS AB Background-Although the American Heart Association/American College of Sports Medicine's Preparticipation Questionnaire (AAPQ) is a recommended preexercise cardiovascular screening tool, it has never been systematically evaluated. The purpose of this research is to provide preliminary evidence of its effectiveness among adults aged >= 40 years. Methods and Results-Under the assumption that participants would respond to AAPQ items as they responded to a general health survey, we calculated the sex-and age-specific proportions of adult participants in the National Health and Nutrition Examination Survey 2001 to 2004 who would receive a recommendation for physician consultation based on AAPQ referral criteria. Additionally, we compared recommended AAPQ referrals to a similar assessment using the Physical Activity Readiness Questionnaire in the study sample. AAPQ referral proportions were higher with older age. Across all age groups >= 40 years, 95.5% (94.3% to 96.8%) of women and 93.5% (92.2% to 94.7%) of men in the United States would be advised to consult a physician before exercise. Prescription medication use and age were the most commonly selected items. When referral based on AAPQ was compared with that of the Physical Activity Readiness Questionnaire, the 2 screening tools produced similar results for 72.4% of respondents. Conclusions-These results suggest that >90% of US adults aged >= 40 years would receive a recommendation for physician consultation by the AAPQ. Excessive referral may present an unnecessary barrier to exercise adoption and stress the healthcare infrastructure. C1 [Whitfield, Geoffrey P.; Gabriel, Kelley K. Pettee; Rahbar, Mohammad H.; Kohl, Harold W., III] Univ Texas Sch Publ Hlth, Div Epidemiol Human Genet & Environm Sci, Austin, TX USA. [Rahbar, Mohammad H.] Univ Texas Hlth Sci Ctr Houston, Ctr Clin & Translat Sci, Houston, TX 77030 USA. [Kohl, Harold W., III] Univ Texas Austin, Dept Kinesiol & Hlth Educ, Austin, TX 78712 USA. RP Whitfield, GP (reprint author), Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, 4770 Buford Highway, Atlanta, GA 30034 USA. EM xdh5@cdc.gov FU Cancer Education and Career Development Program at the University of Texas School of Public Health, National Cancer Institute/National Institutes of Health [2 R25 CA57712] FX Dr Whitfield was partially supported by the Cancer Education and Career Development Program at the University of Texas School of Public Health, National Cancer Institute/National Institutes of Health Grant 2 R25 CA57712. NR 23 TC 10 Z9 10 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD MAR 11 PY 2014 VL 129 IS 10 BP 1113 EP U120 DI 10.1161/CIRCULATIONAHA.113.004160 PG 15 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA AI2ZH UT WOS:000336727200013 PM 24421370 ER PT J AU Berzkalns, A Bates, J Ye, W Mukasa, L France, AM Patil, N Yang, ZH AF Berzkalns, Anna Bates, Joseph Ye, Wen Mukasa, Leonard France, Anne Marie Patil, Naveen Yang, Zhenhua TI The Road to Tuberculosis (Mycobacterium tuberculosis) Elimination in Arkansas; a Re-Examination of Risk Groups SO PLOS ONE LA English DT Article ID MOLECULAR EPIDEMIOLOGIC ANALYSIS; UNITED-STATES; RURAL-COMMUNITY; POPULATION; SURVEILLANCE; TRENDS AB Objectives: This study was conducted to generate knowledge useful for developing public health interventions for more effective tuberculosis control in Arkansas. Methods: The study population included 429 culture-confirmed reported cases (January 1, 2004-December 31, 2010). Mycobacterium tuberculosis genotyping data were used to identify cases likely due to recent transmission (clustered) versus reactivation (non-clustered). Poisson regression models estimated average decline rate in incidence over time and assessed the significance of differences between subpopulations. A multinomial logistic model examined differences between clustered and non-clustered incidence. Results: A significant average annual percent decline was found for the overall incidence of culture-confirmed (9%; 95% CI: 5.5%, 16.9%), clustered (6%; 95% CI: 0.5%, 11.6%), and non-clustered tuberculosis cases (12%; 95% CI: 7.6%, 15.9%). However, declines varied among demographic groups. Significant declines in clustered incidence were only observed in males, non-Hispanic blacks, 65 years and older, and the rural population. Conclusions: These findings suggest that the Arkansas tuberculosis control program must target both traditional and non-traditional risk groups for successful tuberculosis elimination. The present study also demonstrates that a thorough analysis of TB trends in different population subgroups of a given geographic region or state can lead to the identification of non-traditional risk factors for TB transmission. Similar studies in other low incidence populations would provide beneficial data for how to control and eventually eliminate TB in the U.S. C1 [Berzkalns, Anna; Yang, Zhenhua] Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA. [Bates, Joseph; Mukasa, Leonard; Patil, Naveen] Arkansas Dept Hlth, Little Rock, AR 72205 USA. [Bates, Joseph; Mukasa, Leonard] Univ Arkansas Med Sci, Fay W Boozman Coll Publ Hlth, Dept Epidemiol, Little Rock, AR 72205 USA. [Ye, Wen] Univ Michigan, Sch Publ Hlth, Dept Biostat, Ann Arbor, MI 48109 USA. [France, Anne Marie] Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA USA. [Patil, Naveen] Univ Arkansas Med Sci, Coll Med, Little Rock, AR 72205 USA. RP Yang, ZH (reprint author), Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA. EM zhenhua@umich.edu NR 32 TC 2 Z9 2 U1 0 U2 0 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAR 11 PY 2014 VL 9 IS 3 AR e90664 DI 10.1371/journal.pone.0090664 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA AC9GM UT WOS:000332842400024 PM 24618839 ER PT J AU Smieszek, T Barclay, VC Seeni, I Rainey, JJ Gao, HJ Uzicanin, A Salathe, M AF Smieszek, Timo Barclay, Victoria C. Seeni, Indulaxmi Rainey, Jeanette J. Gao, Hongjiang Uzicanin, Amra Salathe, Marcel TI How should social mixing be measured: comparing web-based survey and sensor-based methods SO BMC INFECTIOUS DISEASES LA English DT Article DE Contact networks; Social network; Proximity network; Droplet transmission; Contact survey; Wireless sensor network ID SEXUALLY-TRANSMITTED INFECTIONS; CONTACT NETWORKS; INFLUENZA-A; DISEASE TRANSMISSION; AEROSOL TRANSMISSION; PANDEMIC INFLUENZA; SPREAD; MODEL; VIRUS; INDIVIDUALS AB Background: Contact surveys and diaries have conventionally been used to measure contact networks in different settings for elucidating infectious disease transmission dynamics of respiratory infections. More recently, technological advances have permitted the use of wireless sensor devices, which can be worn by individuals interacting in a particular social context to record high resolution mixing patterns. To date, a direct comparison of these two different methods for collecting contact data has not been performed. Methods: We studied the contact network at a United States high school in the spring of 2012. All school members (i.e., students, teachers, and other staff) were invited to wear wireless sensor devices for a single school day, and asked to remember and report the name and duration of all of their close proximity conversational contacts for that day in an online contact survey. We compared the two methods in terms of the resulting network densities, nodal degrees, and degree distributions. We also assessed the correspondence between the methods at the dyadic and individual levels. Results: We found limited congruence in recorded contact data between the online contact survey and wireless sensors. In particular, there was only negligible correlation between the two methods for nodal degree, and the degree distribution differed substantially between both methods. We found that survey underreporting was a significant source of the difference between the two methods, and that this difference could be improved by excluding individuals who reported only a few contact partners. Additionally, survey reporting was more accurate for contacts of longer duration, and very inaccurate for contacts of shorter duration. Finally, female participants tended to report more accurately than male participants. Conclusions: Online contact surveys and wireless sensor devices collected incongruent network data from an identical setting. This finding suggests that these two methods cannot be used interchangeably for informing models of infectious disease dynamics. C1 [Smieszek, Timo; Barclay, Victoria C.; Seeni, Indulaxmi; Salathe, Marcel] Penn State Univ, Dept Biol, Ctr Infect Dis Dynam, University Pk, PA 16802 USA. [Rainey, Jeanette J.; Gao, Hongjiang; Uzicanin, Amra] Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, Atlanta, GA 30333 USA. RP Smieszek, T (reprint author), Publ Hlth England, Modelling & Econ Unit, London NW9 5EQ, England. EM timo.smieszek@phe.gov.uk OI Smieszek, Timo/0000-0003-1681-9777 FU Centers for Disease Control and Prevention [U01 CK000178-01]; German Academic Exchange Service DAAD [D/10/52328]; NIH RAPIDD; Society in Science: Branco Weiss fellowship FX We thank members of the high school who made this project possible. This research was supported by the Centers for Disease Control and Prevention through grant U01 CK000178-01 (to MS), a fellowship from the German Academic Exchange Service DAAD through grant D/10/52328 (to TS), a Society in Science: Branco Weiss fellowship (to MS), and NIH RAPIDD support (to MS). We thank Devon Brewer for his elaborated comments that helped to improve the quality of this paper and Ellsworth Campbell for his valuable contribution to Figure 1. Finally, we thank the five reviewers for their insightful and knowledgeable suggestions. NR 59 TC 20 Z9 20 U1 0 U2 11 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2334 J9 BMC INFECT DIS JI BMC Infect. Dis. PD MAR 10 PY 2014 VL 14 AR 136 DI 10.1186/1471-2334-14-136 PG 13 WC Infectious Diseases SC Infectious Diseases GA AD9NY UT WOS:000333593000001 PM 24612900 ER PT J AU Iliyasu, Z Nwaze, E Verma, H Mustapha, AO Weldegebriel, G Gasasira, A Wannemuehler, KA Pallansch, MA Gajida, AU Pate, M Sutter, RW AF Iliyasu, Zubairu Nwaze, Eric Verma, Harish Mustapha, Asani O. Weldegebriel, Goitom Gasasira, Alex Wannemuehler, Kathleen A. Pallansch, Mark A. Gajida, Auwalu U. Pate, Muhammad Sutter, Roland W. TI Survey of poliovirus antibodies in Kano, Northern Nigeria SO VACCINE LA English DT Article DE Poliomyelitis; Seroprevalence; Kano; Nigeria; Oral poliovirus vaccine ID VACCINE-DERIVED POLIOVIRUS; NEUTRALIZING ANTIBODIES; CONTROLLED-TRIAL; CHILDREN; IMMUNOGENICITY; INDIA AB Introduction: In 1988, the World Health Assembly resolved to eradicate poliomyelitis. Since then, much progress towards this goal has been made, but three countries including Nigeria remain polio-endemic as of end 2012. To assess the immunity level against poliomyelitis in young children in Northern Nigeria, we conducted a seroprevalence survey in the Kano Metropolitan Area (KMA) in May 2011. Methods: Parents or guardians of infants aged 6-9 months or children aged 36-47 months presenting to the outpatient department of Murtala Mohammad Specialist Hospital were approached for participation, screened for eligibility and were asked to provide informed consent. After that, a questionnaire was administered and blood was collected for neutralization assay. Results: A total of 327 subjects were enrolled. Of these, 313 (96%) met the study requirements and were analyzed (161 [51%] aged 6-9 months and 152 [49%] aged 36-47 months). Among subjects aged 6-9 months, seroprevalence was 81% (95% confidence interval [CI] 75-87%) to poliovirus type 1,76% (95% CI 68-81%) to poliovirus type 2, and 73% (95% CI 67-80%) to poliovirus type 3. Among subjects aged 36-47 months, the seroprevalence was 91% (95% CI 86-95%) to poliovirus type 1,87% (95% CI 82-92%) for poliovirus type 2, and 86% (95% CI 80-91%) to poliovirus type 3. Seroprevalence was associated with history of oral poliovirus vaccine (OPV) doses, maternal education and gender. Conclusions: Seroprevalence is lower than required levels for poliovirus interruption in the KMA. Persistence of immunity gaps in the 36-47 months group is a big concern. Since higher number of vaccine doses is associated with higher seroprevalence, it implies that failure-to-vaccinate and not vaccine failure accounts for the suboptimal seroprevalence. Intensified efforts are necessary to administer polio vaccines to all target children and surpass the threshold levels for herd immunity. Published by Elsevier Ltd. C1 [Iliyasu, Zubairu; Gajida, Auwalu U.] Aminu Kano Teaching Hosp, Dept Community Med, Kano, Nigeria. [Iliyasu, Zubairu; Mustapha, Asani O.; Gajida, Auwalu U.] Bayero Univ, Kano, Nigeria. [Nwaze, Eric; Pate, Muhammad] Natl Primary Hlth Care Dev Agcy, Abuja, Nigeria. [Verma, Harish; Sutter, Roland W.] WHO, CH-1211 Geneva 27, Switzerland. [Mustapha, Asani O.] Aminu Kano Teaching Hosp, Dept Pediat, Kano, Nigeria. [Weldegebriel, Goitom; Gasasira, Alex] WHO, Abuja, Nigeria. [Wannemuehler, Kathleen A.; Pallansch, Mark A.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Pate, Muhammad] Duke Univ, Duke Global Hlth Inst, Durham, NC 27706 USA. RP Sutter, RW (reprint author), WHO, Polio Eradicat Initiat, 20 Ave Appia, CH-1211 Geneva 27, Switzerland. EM sutterr@who.int OI Iliyasu, Zubairu/0000-0002-8669-1863 FU World Health Organization FX Provided by the World Health Organization. NR 24 TC 6 Z9 6 U1 0 U2 7 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD MAR 10 PY 2014 VL 32 IS 12 BP 1414 EP 1420 DI 10.1016/j.vaccine.2013.08.060 PG 7 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA AD8JP UT WOS:000333512600014 PM 24041545 ER PT J AU Hadler, JL Yousey-Hindes, K Kudish, K Kennedy, ED Sacco, V Cartter, ML AF Hadler, James L. Yousey-Hindes, Kimberly Kudish, Kathy Kennedy, Erin D. Sacco, Vincent Cartter, Matthew L. TI Impact of Requiring Influenza Vaccination for Children in Licensed Child Care or Preschool Programs - Connecticut, 2012-13 Influenza Season SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Hadler, James L.; Yousey-Hindes, Kimberly] Yale Univ, Sch Publ Hlth, Connecticut Emerging Infect Program, New Haven, CT 06520 USA. [Kudish, Kathy; Sacco, Vincent; Cartter, Matthew L.] CDC, Connecticut Dept Publ Hlth, Atlanta, GA 30333 USA. [Kennedy, Erin D.] CDC, Div Immunizat Serv, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Hadler, JL (reprint author), Yale Univ, Sch Publ Hlth, Connecticut Emerging Infect Program, New Haven, CT 06520 USA. EM hadler-epi@att.net OI Yousey-Hindes, Kimberly/0000-0002-9418-575X NR 10 TC 9 Z9 11 U1 0 U2 1 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAR 7 PY 2014 VL 63 IS 9 BP 181 EP 185 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AC3GJ UT WOS:000332404000001 PM 24598593 ER PT J AU Burrows, NR Hora, I Williams, DE Geiss, LS AF Burrows, Nilka Rios Hora, Israel Williams, Desmond E. Geiss, Linda S. TI Trends in Incidence of End-Stage Renal Disease Among Persons With Diagnosed Diabetes - Puerto Rico, 1996-2010 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Burrows, Nilka Rios; Hora, Israel; Williams, Desmond E.; Geiss, Linda S.] CDC, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP Burrows, NR (reprint author), CDC, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM nrios@cdc.gov NR 9 TC 1 Z9 1 U1 0 U2 3 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAR 7 PY 2014 VL 63 IS 9 BP 186 EP 189 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AC3GJ UT WOS:000332404000002 PM 24598594 ER PT J AU Streiff, MB Brady, PJ Grant, AM Grosse, SD Wong, B Popovic, T AF Streiff, Michael B. Brady, P. Jeffrey Grant, Althea M. Grosse, Scott D. Wong, Betty Popovic, Tanja TI CDC Grand Rounds: Preventing Hospital-Associated Venous Thromboembolism SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID POSTTHROMBOTIC SYNDROME; THROMBOSIS; VTE; GUIDELINES; EVENTS; RISK; CARE C1 [Streiff, Michael B.] Johns Hopkins Med Inst, Anticoagulat Management Serv, Baltimore, MD USA. [Brady, P. Jeffrey] Agcy Healthcare Res & Qual, Ctr Qual Improvement & Patient Safety, Rockville, MD USA. [Grant, Althea M.; Grosse, Scott D.] CDC, Div Blood Disorders, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Wong, Betty; Popovic, Tanja] CDC, Off Director, Atlanta, GA 30333 USA. RP Grosse, SD (reprint author), CDC, Div Blood Disorders, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. EM sgrosse@cdc.gov NR 23 TC 6 Z9 7 U1 0 U2 3 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAR 7 PY 2014 VL 63 IS 9 BP 190 EP 193 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AC3GJ UT WOS:000332404000003 PM 24598595 ER PT J AU Fridkin, S Baggs, J Fagan, R Magill, S Pollack, LA Malpiedi, P Slayton, R Khader, K Rubin, MA Jones, M Samore, MH Dumyati, G Dodds-Ashley, E Meek, J Yousey-Hindes, K Jernigan, J Shehab, N Herrera, R McDonald, LC Schneider, A Srinivasan, A AF Fridkin, Scott Baggs, James Fagan, Ryan Magill, Shelley Pollack, Lori A. Malpiedi, Paul Slayton, Rachel Khader, Karim Rubin, Michael A. Jones, Makoto Samore, Matthew H. Dumyati, Ghinwa Dodds-Ashley, Elizabeth Meek, James Yousey-Hindes, Kimberly Jernigan, John Shehab, Nadine Herrera, Rosa McDonald, L. Clifford Schneider, Amy Srinivasan, Arjun TI Vital Signs: Improving Antibiotic Use Among Hospitalized Patients SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID ANTIMICROBIAL STEWARDSHIP; CARE AB Background: Antibiotics are essential to effectively treat many hospitalized patients. However, when antibiotics are prescribed incorrectly, they offer little benefit to patients and potentially expose them to risks for complications, including Clostridium difficile infection (CDI) and antibiotic-resistant infections. Information is needed on the frequency of incorrect prescribing in hospitals and how improved prescribing will benefit patients. Methods: A national administrative database (MarketScan Hospital Drug Database) and CDC's Emerging Infections Program (EIP) data were analyzed to assess the potential for improvement of inpatient antibiotic prescribing. Variability in days of therapy for selected antibiotics reported to the National Healthcare Safety Network (NHSN) antimicrobial use option was computed. The impact of reducing inpatient antibiotic exposure on incidence of CDI was modeled using data from two U. S. hospitals. Results: In 2010, 55.7% of patients discharged from 323 hospitals received antibiotics during their hospitalization. EIP reviewed patients' records from 183 hospitals to describe inpatient antibiotic use; antibiotic prescribing potentially could be improved in 37.2% of the most common prescription scenarios reviewed. There were threefold differences in usage rates among 26 medical/surgical wards reporting to NHSN. Models estimate that the total direct and indirect effects from a 30% reduction in use of broad-spectrum antibiotics will result in a 26% reduction in CDI. Conclusions: Antibiotic prescribing for inpatients is common, and there is ample opportunity to improve use and patient safety by reducing incorrect antibiotic prescribing. Implications for Public Health: Hospital administrators and health-care providers can reduce potential harm and risk for antibiotic resistance by implementing formal programs to improve antibiotic prescribing in hospitals. C1 [Fridkin, Scott; Baggs, James; Fagan, Ryan; Magill, Shelley; Pollack, Lori A.; Malpiedi, Paul; Slayton, Rachel; Jones, Makoto; Jernigan, John; Shehab, Nadine; Herrera, Rosa; McDonald, L. Clifford; Schneider, Amy; Srinivasan, Arjun] CDC, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Khader, Karim; Rubin, Michael A.; Samore, Matthew H.] Univ Utah, Salt Lake City, UT 84112 USA. [Khader, Karim; Rubin, Michael A.; Samore, Matthew H.] VA Salt Lake City Hlth Syst, Salt Lake City, UT USA. [Dumyati, Ghinwa; Dodds-Ashley, Elizabeth] Univ Rochester, Med Ctr, Rochester, NY 14627 USA. [Meek, James; Yousey-Hindes, Kimberly] Yale Univ, Sch Publ Hlth, Connecticut Emerging Infect Program, New Haven, CT 06520 USA. RP Fridkin, S (reprint author), CDC, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. EM sfridkin@cdc.gov OI Yousey-Hindes, Kimberly/0000-0002-9418-575X; Baggs, James/0000-0003-0757-4683; Slayton, Rachel/0000-0003-4699-8040 NR 15 TC 78 Z9 80 U1 3 U2 12 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAR 7 PY 2014 VL 63 IS 9 BP 194 EP 200 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AC3GJ UT WOS:000332404000004 PM 24598596 ER PT J AU Schnabel, D Gaines, J Nguyen, DB Esposito, DH Ridpath, A Yacisin, K Poy, JA Mullins, J Burns, R Lijewski, V McElroy, NP Ahmad, N Harrison, C Parinelli, EJ Beaudoin, AL Posivak-Khouly, L Pritchard, PS Jensen, BJ Toney, NC Moulton-Meissner, HA Nyangoma, EN Barry, MA Feldman, KA Blythe, D Perz, JF Morgan, OW Kozarsky, P Brunette, GW Sotir, M AF Schnabel, David Gaines, Joanna Nguyen, Duc B. Esposito, Douglas H. Ridpath, Alison Yacisin, Kari Poy, Jose A. Mullins, Jocelyn Burns, Rachel Lijewski, Virginia McElroy, Nora P. Ahmad, Nina Harrison, Cassandra Parinelli, Ellen J. Beaudoin, Amanda L. Posivak-Khouly, Leah Pritchard, P. Scott Jensen, Bette J. Toney, Nadege C. Moulton-Meissner, Heather A. Nyangoma, Edith N. Barry, M. Anita Feldman, Katherine A. Blythe, David Perz, Joseph F. Morgan, Oliver W. Kozarsky, Phyllis Brunette, Gary W. Sotir, Mark TI Rapidly Growing Nontuberculous Mycobacterium Wound Infections Among Medical Tourists Undergoing Cosmetic Surgeries in the Dominican Republic - Multiple States, March 2013-February 2014 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID ABSCESSUS C1 [Schnabel, David; Nguyen, Duc B.; Feldman, Katherine A.] CDC, Maryland Dept Hlth & Mental Hyg, Baltimore, MD 21201 USA. [Gaines, Joanna; Esposito, Douglas H.; Nyangoma, Edith N.; Kozarsky, Phyllis; Brunette, Gary W.; Sotir, Mark] CDC, Div Global Migrat & Quarantine, Natl Ctr Emerging & Zoonot Infect Dis, New York, NY USA. [Nguyen, Duc B.; Jensen, Bette J.; Toney, Nadege C.; Moulton-Meissner, Heather A.; Perz, Joseph F.] CDC, Div Healthcare Qual & Promot, Natl Ctr Emerging & Zoonot Infect Dis, New York, NY USA. [Ridpath, Alison; Yacisin, Kari; Poy, Jose A.] NYU, Dept Hlth & Mental Hyg, New York, NY USA. [Mullins, Jocelyn] Connecticut Dept Publ Hlth, Norristown, PA USA. [Burns, Rachel; Lijewski, Virginia; McElroy, Nora P.] Massachusetts Dept Publ Hlth, Norristown, PA USA. [Ahmad, Nina] New York State Dept Hlth, Norristown, PA USA. [Harrison, Cassandra] New York State Metropolitan Area Reg Off, Norristown, PA USA. [Parinelli, Ellen J.] New York State Orange Cty Hlth Dept, Norristown, PA USA. [Beaudoin, Amanda L.] Penn Dept Hlth, Norristown, PA USA. [Posivak-Khouly, Leah] Montgomery Cty Hlth Dept, Norristown, PA USA. [Pritchard, P. Scott] Florida Dept Hlth, Boston, MA USA. [Barry, M. Anita] Boston Publ Hlth Commiss, Boston, MA USA. [Morgan, Oliver W.] CDC, Dominican Republ Country Off, Ctr Global Hlth, New York, NY USA. RP Schnabel, D (reprint author), CDC, Maryland Dept Hlth & Mental Hyg, Baltimore, MD 21201 USA. EM dschnabel@cdc.gov NR 5 TC 5 Z9 6 U1 0 U2 3 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAR 7 PY 2014 VL 63 IS 9 BP 201 EP 202 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AC3GJ UT WOS:000332404000005 PM 24598597 ER PT J AU Anshebo, GY Graves, PM Smith, SC Wills, AB Damte, M Endeshaw, T Shargie, EB Gebre, T Mosher, AW Patterson, AE Emerson, PM AF Anshebo, Gedeon Yohannes Graves, Patricia M. Smith, Stephen C. Wills, Aprielle B. Damte, Mesele Endeshaw, Tekola Shargie, Estifanos Biru Gebre, Teshome Mosher, Aryc W. Patterson, Amy E. Emerson, Paul M. TI Estimation of insecticide persistence, biological activity and mosquito resistance to PermaNet (R) 2 long-lasting insecticidal nets over three to 32 months of use in Ethiopia SO MALARIA JOURNAL LA English DT Article ID EXPERIMENTAL HUT TRIALS; VISCERAL LEISHMANIASIS; ANOPHELES-ARABIENSIS; HOUSEHOLD USE; TREATED NETS; BEDNETS; FIELD; DELTAMETHRIN; BIOEFFICACY; TANZANIA AB Background: Information is needed on the expected durability of insecticidal nets under operational conditions. The persistence of insecticidal efficacy is important to estimate the median serviceable life of nets under field conditions and to plan for net replacement. Methods: Deltamethrin residue levels were evaluated by the proxy method of X-ray fluorescence spectrometry on 189 nets used for three to six months from nine sites, 220 nets used for 14-20 months from 11 sites, and 200 nets used for 26-32 months from ten sites in Ethiopia. A random sample of 16.5-20% of nets from each time period (total 112 of 609 nets) were tested by bioassay with susceptible mosquitoes, and nets used for 14-20 months and 26-32 months were also tested with wild caught mosquitoes. Results: Mean insecticide levels estimated by X-ray fluorescence declined by 25.9% from baseline of 66.2 (SD 14.6) mg/m(2) at three to six months to 44.1 (SD 21.2) mg/m(2) at 14-20 months and by 30.8% to 41.1 (SD 18.9) mg/m(2) at 26-32 months. More than 95% of nets retained greater than 10 mg/m2 of deltamethrin and over 79% had at least 25 mg/m2 at all time periods. By bioassay with susceptible Anopheles, mortality averaged 89.0% on 28 nets tested at three to six months, 93.3% on 44 nets at 14-20 months and 94.1% on 40 nets at 26-32 months. With wild caught mosquitoes, mortality averaged 85.4% (range 79.1 to 91.7%) at 14-20 months but had dropped significantly to 47.2% (39.8 to 54.7%) at 26-32 months. Conclusions: Insecticide residue level, as estimated by X-ray fluorescence, declined by about one third between three and six months and 14-20 months, but remained relatively stable and above minimum requirements thereafter up to 26-32 months. The insecticidal activity of PermaNet (R) 2.0 long-lasting insecticidal nets in the specified study area may be considered effective to susceptible mosquitoes at least for the duration indicated in this study (32 months). However, results indicated that resistance in the wild population is already rendering nets with optimum insecticide concentrations less effective in practice. C1 [Anshebo, Gedeon Yohannes; Damte, Mesele; Endeshaw, Tekola; Shargie, Estifanos Biru; Gebre, Teshome] Carter Ctr, Addis Ababa, Ethiopia. [Graves, Patricia M.; Wills, Aprielle B.; Mosher, Aryc W.; Patterson, Amy E.; Emerson, Paul M.] Emory Univ, Carter Ctr, Atlanta, GA 30322 USA. [Smith, Stephen C.] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA USA. RP Graves, PM (reprint author), James Cook Univ, Sch Publ Hlth Trop Med & Rehabil Sci, POB 6811, Cairns, Qld, Australia. EM pgraves.work@gmail.com RI Graves, Patricia/J-8691-2014 OI Graves, Patricia/0000-0002-5215-3901 FU The Carter Center FX Funding for these studies was provided by The Carter Center. We are grateful to Mulat Zerihun, Ambaye Areru and Tesfaye Getachew for assistance with net collections in the field, and to John Gimnig, Frank Richards and Greg Noland for advice and discussions. NR 26 TC 3 Z9 3 U1 0 U2 6 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1475-2875 J9 MALARIA J JI Malar. J. PD MAR 6 PY 2014 VL 13 AR 80 DI 10.1186/1475-2875-13-80 PG 14 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA AF6BI UT WOS:000334799000001 PM 24602340 ER PT J AU Ortega-Sanchez, IR Vijayaraghavan, M Barskey, AE Wallace, GS AF Ortega-Sanchez, Ismael R. Vijayaraghavan, Maya Barskey, Albert E. Wallace, Gregory S. TI The economic burden of sixteen measles outbreaks on United States public health departments in 2011 SO VACCINE LA English DT Article DE Measles outbreak; Costs; Public health ID AUGUST-SEPTEMBER 2011; SAN-DIEGO; CALIFORNIA; TRANSMISSION; REFUGEE; INDIANA AB Background: Despite vaccination efforts and documentation of elimination of indigenous measles in 2000, the United States (US) experienced a marked increase in imported cases and outbreaks of measles in 2011. Due to the high infectiousness and potential severity of measles, these outbreaks require a vigorous response from public health institutions. The effort and resources required to respond to these outbreaks are likely to impose a significant economic burden on these institutions. Objective: To estimate the economic burden of measles outbreaks (defined as >= 3 epidemiologically linked cases) on the local and state public health institutions in the US in 2011. Methods: From the perspective of local and state public health institutions, we estimated personnel time and resources allocated to measles outbreak response in local and state public health departments, and estimated the corresponding costs associated with these outbreaks in the US in 2011. We used cost and resource utilization data from previous studies on measles outbreaks in the US and, relying on outbreak size classification based on a case-day index, we estimated costs incurred by local and state public health institutions. Results: In 2011, the US experienced 16 outbreaks with 107 confirmed cases. The average duration of an outbreak was 22 days (range: 5-68). The total estimated number of identified contacts to measles cases ranged from 8936 to 17,450, requiring from 42,635 to 83,133 personnel hours. Overall, the total economic burden on local and state public health institutions that dealt with measles outbreaks during 2011 ranged from an estimated $2.7 million to $5.3 million US dollars. Conclusion: Investigating and responding to measles outbreaks imposes a significant economic burden on local and state health institutions. Such impact is compounded by the duration of the outbreak and the number of potentially susceptible contacts. (C) 2013 The Authors. Published by Elsevier Ltd. All rights reserved. C1 [Ortega-Sanchez, Ismael R.; Vijayaraghavan, Maya; Barskey, Albert E.; Wallace, Gregory S.] Ctr Dis Control & Prevent CDC, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Ortega-Sanchez, IR (reprint author), Ctr Dis Control & Prevent CDC, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd,Ne MS A-34, Atlanta, GA 30333 USA. EM IOrtegaSanchez@cdc.gov NR 25 TC 22 Z9 22 U1 1 U2 4 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD MAR 5 PY 2014 VL 32 IS 11 BP 1311 EP 1317 DI 10.1016/j.vaccine.2013.10.012 PG 7 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA AD0FF UT WOS:000332909200014 PM 24135574 ER PT J AU Denniston, MM Jiles, RB Drobeniuc, J Klevens, RM Ward, JW McQuillan, GM Holmberg, SD AF Denniston, Maxine M. Jiles, Ruth B. Drobeniuc, Jan Klevens, R. Monina Ward, John W. McQuillan, Geraldine M. Holmberg, Scott D. TI Chronic Hepatitis C Virus Infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010 SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID MORTALITY; PREVALENCE; TRANSMISSION; DISEASE; BURDEN; TYPE-2 AB Background: Knowledge of the number of persons with chronic hepatitis C virus (HCV) infection in the United States is critical for public health and policy planning. Objective: To estimate the prevalence of chronic HCV infection between 2003 and 2010 and to identify factors associated with this condition. Design: Nationally representative household survey. Setting: U.S. noninstitutionalized civilian population. Participants: 30 074 NHANES (National Health and Nutrition Examination Survey) participants between 2003 and 2010. Measurements: Interviews to ascertain demographic characteristics and possible risks and exposures for HCV infection. Serum samples from participants aged 6 years or older were tested for antibody to HCV; if results were positive or indeterminate, the samples were tested for HCV RNA, which indicates current chronic infection. Results: Based on 273 participants who tested positive for HCV RNA, the estimated prevalence of HCV infection was 1.0% (95% CI, 0.8% to 1.2%), corresponding to 2.7 million chronically infected persons (CI, 2.2 to 3.2 million persons) in the U. S. noninstitutionalized civilian population. Infected persons were more likely to be aged 40 to 59 years, male, and non-Hispanic black and to have less education and lower family income. Factors significantly associated with chronic HCV infection were illicit drug use (including injection drugs) and receipt of a blood transfusion before 1992; 49% of persons with HCV infection did not report either risk factor. Limitation: Incarcerated and homeless persons were not surveyed. Conclusion: This analysis estimated that approximately 2.7 million U. S. residents in the population sampled by NHANES have chronic HCV infection, about 500 000 fewer than estimated in a similar analysis between 1999 and 2002. These data underscore the urgency of identifying the millions of persons who remain infected and linking them to appropriate care and treatment. C1 Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. RP Holmberg, SD (reprint author), 1600 Clifton Rd NE,Mail Stop G37, Atlanta, GA 30333 USA. EM sdh1@cdc.gov FU Intramural CDC HHS [CC999999] NR 21 TC 180 Z9 183 U1 7 U2 14 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD MAR 4 PY 2014 VL 160 IS 5 BP 293 EP + DI 10.7326/M13-1133 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA AC8OT UT WOS:000332793900001 PM 24737271 ER PT J AU Tsai, RJ Luckhaupt, SE Sweeney, MH Calvert, GM AF Tsai, Rebecca J. Luckhaupt, Sara E. Sweeney, Marie Haring Calvert, Geoffrey M. TI Shift Work and Cancer Screening: Do Females Who Work Alternative Shifts Undergo Recommended Cancer Screening? SO AMERICAN JOURNAL OF INDUSTRIAL MEDICINE LA English DT Article DE industry; occupation; shift work; cancer screening recommendations; breast cancer; cervical cancer; colorectal cancer ID HEALTH INTERVIEW SURVEY; BREAST-CANCER; NURSES HEALTH; RISK; PREVALENCE; MECHANISMS; STATEMENT AB Background Alternative shift work is classified as a probable human carcinogen. Certain cancer screening tests reduce cancer mortality. Methods The 2010 National Health Interview Survey was used to examine associations between adherence to breast, cervical, and colon cancer screening recommendations and alternative shift work among female workers. Results Workers on alternative shifts, compared to workers on daytime shifts, were more likely to be non-adherent to screening recommendations for breast (34% vs. 23%) and colorectal (55% vs. 48%) cancer (P < 0.05). Workers on alternative shifts in two industries ("Manufacturing" and "Accommodation/Food Services") and three occupations ("Food Preparation/Serving," "Personal Care Services," and "Production") were more likely to be non-adherent to screening recommendations for at least two cancers (P < 0.05). Conclusions The Affordable Care Act eliminates out-of-pocket screening expenses for these three cancers. Greater efforts are needed to promote this benefit, particularly among workers with demonstrated non-adherence. 2014. Published 2013. This article is a U.S. Government work and is in the public domain in the USA. C1 [Tsai, Rebecca J.; Luckhaupt, Sara E.; Sweeney, Marie Haring; Calvert, Geoffrey M.] Ctr Dis Control & Prevent, Div Surveillance Hazard Evaluat & Field Studies, NIOSH, Cincinnati, OH USA. RP Tsai, RJ (reprint author), NIOSH, 4676 Columbia Pkwy,R-17, Cincinnati, OH 45226 USA. EM rtsai@cdc.gov OI Tsai, Rebecca/0000-0001-8656-9836 FU U.S. Government FX Contract grant sponsor: U.S. Government. NR 27 TC 1 Z9 1 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0271-3586 EI 1097-0274 J9 AM J IND MED JI Am. J. Ind. Med. PD MAR PY 2014 VL 57 IS 3 BP 265 EP 275 DI 10.1002/ajim.22285 PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AX0SE UT WOS:000346661300002 PM 24488817 ER PT J AU Ustrup, M Ngwira, B Stockman, LJ Deming, M Nyasulu, P Bowie, C Msyamboza, K Meyrowitsch, DW Cunliffe, NA Bresee, J Fischer, TK AF Ustrup, Marte Ngwira, Bagrey Stockman, Lauren J. Deming, Michael Nyasulu, Peter Bowie, Cameron Msyamboza, Kelias Meyrowitsch, Dan W. Cunliffe, Nigel A. Bresee, Joseph Fischer, Thea K. TI Potential Barriers to Healthcare in Malawi for Under-five Children with Cough and Fever: A National Household Survey SO JOURNAL OF HEALTH POPULATION AND NUTRITION LA English DT Article DE Healthcare surveys; Health expenditure; Health services accessibility; Malaria; Pneumonia; Malawi ID MIDDLE-INCOME COUNTRIES; CHILDHOOD FEVERS; MORTALITY; TANZANIA; SERVICES; DISTRICT; EQUITY; KENYA; GHANA AB Failure to access healthcare is an important contributor to child mortality in many developing countries. In a national household survey in Malawi, we explored demographic and socioeconomic barriers to healthcare for childhood illnesses and assessed the direct and indirect costs of seeking care. Using a cluster-sample design, we selected 2,697 households and interviewed 1,669 caretakers. The main reason for households not being surveyed was the absence of a primary caretaker in the household. Among 2,077 children aged less than five years, 504 episodes of cough and fever during the previous two weeks were reported. A trained healthcare provider was visited for 48.0% of illness episodes. A multivariate regression model showed that children from the poorest households (p=0.02) and children aged >12 months (p=0.02) were less likely to seek care when ill compared to those living in wealthier households and children of higher age-group respectively. Families from rural households spent more time travelling compared to urban households (68.9 vs 14.1 minutes; p<0.001). In addition, visiting a trained healthcare provider was associated with longer travel time (p<0.001) and higher direct costs (p<0.001) compared to visiting an untrained provider. Thus, several barriers to accessing healthcare in Malawi for childhood illnesses exist. Continued efforts to reduce these barriers are needed to narrow the gap in the health and healthcare equity in Malawi. C1 [Ustrup, Marte; Meyrowitsch, Dan W.] Univ Copenhagen, Fac Hlth Sci, Dept Publ Hlth, DK-1014 Copenhagen, Denmark. [Ngwira, Bagrey; Bowie, Cameron; Msyamboza, Kelias] Univ Malawi, Coll Med, Dept Community Hlth, Blantyre, Malawi. [Stockman, Lauren J.; Deming, Michael; Bresee, Joseph; Fischer, Thea K.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Nyasulu, Peter] Univ Witwatersrand, Fac Hlth Sci, Sch Publ Hlth, Div Epidemiol & Biostat, Johannesburg, South Africa. [Cunliffe, Nigel A.] Univ Liverpool, Inst Infect & Global Hlth, Dept Clin Infect Microbiol & Immunol, Liverpool L69 3BX, Merseyside, England. RP Ustrup, M (reprint author), Univ Copenhagen, Fac Hlth Sci, Dept Publ Hlth, Oester Farimagsgade 5, DK-1014 Copenhagen, Denmark. EM marte@ustrup.net OI Cunliffe, Nigel/0000-0002-5449-4988 NR 43 TC 3 Z9 3 U1 1 U2 9 PU ICDDR B PI DHAKA PA MOHAKHALI, 1212 DHAKA, BANGLADESH SN 1606-0997 EI 2072-1315 J9 J HEALTH POPUL NUTR JI J. Heatlh Popul. Nutr. PD MAR PY 2014 VL 32 IS 1 BP 68 EP 78 PG 11 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA AR7GA UT WOS:000343746300009 PM 24847595 ER PT J AU Liu, Y Njai, RS Greenlund, KJ Chapman, DP Croft, JB AF Liu, Yong Njai, Rashid S. Greenlund, Kurt J. Chapman, Daniel P. Croft, Janet B. TI Relationships Between Housing and Food Insecurity, Frequent Mental Distress, and Insufficient Sleep Among Adults in 12 US States, 20309 SO PREVENTING CHRONIC DISEASE LA English DT Article ID PUBLIC-HEALTH ACTION; QUALITY-OF-LIFE; ASSOCIATION; BEHAVIORS; SYSTEM; WOMEN; CARE AB Introduction Housing insecurity and food insecurity may be psychological stressors associated with insufficient sleep. Frequent mental distress may mediate the relationships between these variables. The objective of this study was to examine the relationships between housing insecurity and food insecurity, frequent mental distress, and insufficient sleep. Methods We analyzed data from the 2009 Behavioral Risk Factor Surveillance System in 12 states. Housing insecurity and food insecurity were defined as being worried or stressed "sometimes," "usually," or "always" during the previous 12 months about having enough money to pay rent or mortgage or to buy nutritious meals. Results Of 68,111 respondents, 26.4% reported frequent insufficient sleep, 28.5% reported housing insecurity, 19.3% reported food insecurity, and 10.8% reported frequent mental distress. The prevalence of frequent insufficient sleep was significantly greater among those who reported housing insecurity (37.7% vs 21.6%) or food insecurity (41.1% vs 22.9%) than among those who did not. The prevalence of frequent mental distress was also significantly greater among those reporting housing insecurity (20.1% vs 6.8%) and food insecurity (23.5% vs 7.7%) than those who did not. The association between housing insecurity or food insecurity and frequent insufficient sleep remained significant after adjustment for other sociodemographic variables and frequent mental distress. Conclusion Sleep health and mental health are embedded in the social context. Research is needed to assess whether interventions that reduce housing insecurity and food insecurity will also improve sleep health and mental health. C1 [Liu, Yong] Ctr Dis Control & Prevent, Div Populat Hlth, Atlanta, GA 30341 USA. [Njai, Rashid S.; Greenlund, Kurt J.; Chapman, Daniel P.; Croft, Janet B.] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. RP Liu, Y (reprint author), Ctr Dis Control & Prevent, Div Populat Hlth, 4770 Buford Hwy NE,AS F-78, Atlanta, GA 30341 USA. EM ikd8@cdc.gov NR 42 TC 4 Z9 4 U1 1 U2 7 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD MAR PY 2014 VL 11 DI 10.5888/pcd11.130334 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AR3XF UT WOS:000343521800020 ER PT J AU Zhou, H Siegel, PZ Barile, J Njai, RS Thompson, WW Kent, C Liao, YL AF Zhou, Hong Siegel, Paul Z. Barile, John Njai, Rashid S. Thompson, William W. Kent, Charlotte Liao, Youlian TI Models for Count Data With an Application to Healthy Days Measures: Are You Driving in Screws With a Hammer? SO PREVENTING CHRONIC DISEASE LA English DT Article ID QUALITY-OF-LIFE; REGRESSION-ANALYSES; ASSOCIATIONS AB Introduction Count data are often collected in chronic disease research, and sometimes these data have a skewed distribution. The number of unhealthy days reported in the Behavioral Risk Factor Surveillance System (BRFSS) is an example of such data: most respondents report zero days. Studies have either categorized the Healthy Days measure or used linear regression models. We used alternative regression models for these count data and examined the effect on statistical inference. Methods Using responses from participants aged 35 years or older from 12 states that included a homeownership question in their 2009 BRFSS, we compared 5 multivariate regression models logistic, linear, Poisson, negative binomial, and zero-inflated negative binomial with respect to 1) how well the modeled data fit the observed data and 2) how model selections affect inferences. Results Most respondents (66.8%) reported zero mentally unhealthy days. The distribution was highly skewed (variance = 58.7, mean = 3.3 d). Zero-inflated negative binomial regression provided the best-fitting model, followed by negative binomial regression. A significant independent association between homeownership and number of mentally unhealthy days was not found in the logistic, linear, or Poisson regression model but was found in the negative binomial model. The zero-inflated negative binomial model showed that homeowners were 24% more likely than nonhomeowners to have excess zero mentally unhealthy days (adjusted odds ratio, 1.24; 95% confidence interval, 1.08 - 1.43), but it did not show an association between homeownership and the number of unhealthy days. Conclusion Our comparison of regression models indicates the importance of examining data distribution and selecting models with appropriate assumptions. Otherwise, statistical inferences might be misleading. C1 [Siegel, Paul Z.; Njai, Rashid S.; Thompson, William W.; Kent, Charlotte; Liao, Youlian] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Barile, John] Univ Hawaii Manoa, Manoa, HI USA. RP Zhou, H (reprint author), Ctr Dis Control & Prevent, Div Hlth Informat Surveillance, Ctr Surveillance Epidemiol & Lab Serv, 1600 Clifton Rd NE,Mailstop E91, Atlanta, GA 30333 USA. EM HZou1@cdc.gov RI Barile, John/F-9456-2015 OI Barile, John/0000-0003-4098-0640 NR 26 TC 1 Z9 1 U1 0 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD MAR PY 2014 VL 11 DI 10.5888/pcd11.130252 PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AR3XF UT WOS:000343521800010 ER PT J AU Smith, SG Fowler, KA Niolon, PH AF Smith, Sharon G. Fowler, Katherine A. Niolon, Phyllis H. TI Intimate Partner Homicide and Corollary Victims in 16 States: National Violent Death Reporting System, 2003-2009 SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID SAFE DATES; PREVENTION PROGRAM; SUICIDE; RISK; INTERVENTION; FEMICIDE; FAMILY; INJURY AB Objectives. We estimated the frequency and examined the characteristics of intimate partner homicide and related deaths in 16 US states participating in the National Violent Death Reporting System (NVDRS), a state-based surveillance system. Methods. We used a combination of quantitative and qualitative methods to analyze NVDRS data from 2003 to 2009. We selected deaths linked to intimate partner violence for analysis. Results. Our sample comprised 4470 persons who died in the course of 3350 intimate partner violence-related homicide incidents. Intimate partners and corollary victims represented 80% and 20% of homicide victims, respectively. Corollary homicide victims included family members, new intimate partners, friends, acquaintances, police officers, and strangers. Conclusions. Our findings, from the first multiple-state study of intimate partner homicide and corollary homicides, demonstrate that the burden of intimate partner violence extends beyond the couple involved. Systems (e.g., criminal justice, medical care, and shelters) whose representatives routinely interact with victims of intimate partner violence can help assess the potential for lethal danger, which may prevent intimate partner and corollary victims from harm. C1 [Smith, Sharon G.; Fowler, Katherine A.; Niolon, Phyllis H.] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. RP Smith, SG (reprint author), Ctr Dis Control & Prevent, Div Violence Prevent, Natl Ctr Injury Prevent & Control, 4770 Buford Hwy NE,MS F-64, Atlanta, GA 30341 USA. EM ssmith4@cdc.gov NR 35 TC 8 Z9 9 U1 0 U2 5 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD MAR PY 2014 VL 104 IS 3 BP 461 EP 466 DI 10.2105/AJPH.2013.301582 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AP0LP UT WOS:000341753300038 PM 24432943 ER PT J AU Jemmott, JB Jemmott, LS O'Leary, A Ngwane, Z Icard, LD Heeren, A Mtose, X Carty, C AF Jemmott, John B., III Jemmott, Loretta S. O'Leary, Ann Ngwane, Zolani Icard, Larry D. Heeren, Anita Mtose, Xoliswa Carty, Craig TI Cluster-Randomized Controlled Trial of an HIV/Sexually Transmitted Infection Risk-Reduction Intervention for South African Men SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID HIV PREVENTION INTERVENTIONS; SEXUAL-BEHAVIOR; CAPE-TOWN; TRANSMISSION; VIOLENCE; GENDER; METAANALYSIS; PREVALENCE; PARTNERS; DISEASES AB Objectives. We tested the efficacy of a sexual risk-reduction intervention for men in South Africa, where heterosexual exposure is the main mode of HIV transmission. Methods. Matched-pairs of neighborhoods in Eastern Cape Province, South Africa, were randomly selected and within pairs randomized to 1 of 2 interventions based on social cognitive theory and qualitative research: HIV/sexually transmitted infection (STI) risk-reduction, targeting condom use, or attention-matched control, targeting health issues unrelated to sexual risks. Sexually active men aged 18 to 45 years were eligible. The primary outcome was consistent condom use in the past 3 months. Results. Of 1181 participants, 1106 (93.6%) completed the 12-month follow-up. HIV and STI risk-reduction participants had higher odds of reporting consistent condom use (odds ratio [OR] = 1.32; 95% confidence interval [CI] = 1.03, 1.71) and condom use at last vaginal intercourse (OR = 1.40; 95% CI = 1.08, 1.82) than did attention-control participants, adjusting for baseline prevalence. No differences were observed on unprotected intercourse or multiple partnerships. Findings did not differ for sex with steady as opposed to casual partners. Conclusions. Behavioral interventions specifically targeting men can contribute to efforts to reduce sexual risk behaviors in South Africa. C1 [Jemmott, John B., III; Heeren, Anita; Carty, Craig] Univ Penn, Perelman Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. [Jemmott, John B., III] Univ Penn, Annenberg Sch Commun, Philadelphia, PA 19104 USA. [Jemmott, Loretta S.] Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA. [O'Leary, Ann] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. [Ngwane, Zolani] Haverford Coll, Dept Anthropol, Haverford, PA 19041 USA. [Icard, Larry D.] Temple Univ, Coll Hlth Profess & Social Work, Philadelphia, PA 19122 USA. [Mtose, Xoliswa] Univ Ft Hare, Fac Educ, East London, South Africa. RP Jemmott, JB (reprint author), Univ Penn, Annenberg Sch Commun, 3535 Market St,Suite 520, Philadelphia, PA 19104 USA. EM jjemmott@asc.upenn.edu OI Carty, Craig Raymond/0000-0003-0767-3382 FU National Institutes of Health [1 R01 HD053270] FX This study was funded by the National Institutes of Health (grant 1 R01 HD053270). NR 45 TC 10 Z9 10 U1 3 U2 6 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD MAR PY 2014 VL 104 IS 3 BP 467 EP 473 DI 10.2105/AJPH.2013.301578 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AP0LP UT WOS:000341753300039 PM 24432923 ER PT J AU Smith, BD Beckett, GA Yartel, A Holtzman, D Patel, N Ward, JW AF Smith, Bryce D. Beckett, Geoff A. Yartel, Anthony Holtzman, Deborah Patel, Nita Ward, John W. TI Previous Exposure to HCV Among Persons Born During 1945-1965: Prevalence and Predictors, United States, 1999-2008 SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID HEPATITIS-C VIRUS; SUSTAINED VIROLOGICAL RESPONSE; PRIMARY-CARE PHYSICIANS; SERVICES-TASK-FORCE; VIRAL-HEPATITIS; HEPATOCELLULAR-CARCINOMA; ALCOHOL-CONSUMPTION; PLUS RIBAVIRIN; INFECTION; MORTALITY AB Objectives. We examined HCV exposure prevalence and predictors among persons in the United States born during 1945-1965. Methods. With data from the 1999-2008 National Health and Nutrition Examination Survey, we calculated the proportion of persons born during 1945-1965 who tested positive for HCV antibody (anti-HCV) and analyzed the prevalence by sociodemographic and behavioral risk factors. Results. Anti-HCV prevalence in the 1945-1965 birth cohort was 3.2% (95% confidence interval [CI] = 2.8%, 3.8%), substantially higher than among other adults (0.9%). Within the cohort, anti-HCV prevalence was higher among non-Hispanic Blacks (6.4%; 95% CI = 5.3%, 7.7%), persons with injection drug use histories (56.8%; 95% CI = 48.4%, 64.8%), and persons with elevated alanine aminotransferase levels (12.7%; 95% CI = 10.7%, 15.1%). Injection drug use (adjusted odds ratio = 98.4; 95% CI = 58.8, 164.5) was the strongest anti-HCV prevalence predictor. Among anti-HCV-positive persons, 57.8% reported having 2 or more alcoholic drinks daily. Conclusions. With the high prevalence of HCV among persons born during 1945-1965, the increasing morbidity and mortality associated with HCV, and reductions in liver cancer and HCV-related mortality when HCV is eradicated, it is critically important to identify persons with HCV and link them to appropriate care. C1 [Smith, Bryce D.; Beckett, Geoff A.; Holtzman, Deborah; Ward, John W.] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA USA. [Yartel, Anthony; Patel, Nita] Ctr Dis Control & Prevent Fdn, Atlanta, GA USA. RP Smith, BD (reprint author), 1600 Clifton Rd,MS G-37, Atlanta, GA 30333 USA. EM bsmith6@cdc.gov OI Yartel, Anthony/0000-0001-6586-9362 NR 49 TC 13 Z9 14 U1 0 U2 0 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD MAR PY 2014 VL 104 IS 3 BP 474 EP 481 DI 10.2105/AJPH.2013.301549 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AP0LP UT WOS:000341753300040 PM 24432883 ER PT J AU Klevens, RM Liu, S Roberts, H Jiles, RB Holmberg, SD AF Klevens, R. Monina Liu, Stephen Roberts, Henry Jiles, Ruth B. Holmberg, Scott D. TI Estimating Acute Viral Hepatitis Infections From Nationally Reported Cases SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID B-VIRUS INFECTION; INJECTION-DRUG USERS; ASSISTED LIVING FACILITIES; C VIRUS; UNITED-STATES; EVOLVING EPIDEMIOLOGY; BLOOD-GLUCOSE; NEW-YORK; OUTBREAK; SURVEILLANCE AB Objectives. Because only a fraction of patients with acute viral hepatitis A, B, and C are reported through national surveillance to the Centers for Disease Control and Prevention, we estimated the true numbers. Methods. We applied a simple probabilistic model to estimate the fraction of patients with acute hepatitis A, hepatitis B, and hepatitis C who would have been symptomatic, would have sought health care tests, and would have been reported to health officials in 2011. Results. For hepatitis A, the frequencies of symptoms (85%), care seeking (88%), and reporting (69%) yielded an estimate of 2730 infections (2.0 infections per reported case). For hepatitis B, the frequencies of symptoms (39%), care seeking (88%), and reporting (45%) indicated 18 730 infections (6.5 infections per reported case). For hepatitis C, the frequency of symptoms among injection drug users (13%) and those infected otherwise (48%), proportion seeking care (88%), and percentage reported (53%) indicated 17 100 infections (12.3 infections per reported case). Conclusions. These adjustment factors will allow state and local health authorities to estimate acute hepatitis infections locally and plan prevention activities accordingly. C1 [Klevens, R. Monina; Liu, Stephen; Roberts, Henry; Jiles, Ruth B.; Holmberg, Scott D.] Ctr Dis Control & Prevent, Div Viral Hepatitis, Natl Ctr HIV AIDS Viral Hepatitis STDs & TB Preve, Atlanta, GA USA. RP Klevens, RM (reprint author), 1600 Clifton Rd,Mail Stop G-37, Atlanta, GA 30333 USA. EM rmk2@cdc.gov NR 55 TC 11 Z9 11 U1 1 U2 3 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD MAR PY 2014 VL 104 IS 3 BP 482 EP 487 DI 10.2105/AJPH.2013.301601 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AP0LP UT WOS:000341753300041 PM 24432918 ER PT J AU Hess, JJ Schramm, PJ Luber, G AF Hess, Jeremy J. Schramm, Paul J. Luber, George TI Public Health and Climate Change Adaptation at the Federal Level: One Agency's Response to Executive Order 13514 SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Editorial Material ID UNITED-STATES; ADAPTIVE MANAGEMENT; VULNERABILITY; IMPACTS; RESILIENCE; BARRIERS; OPTIONS; RISKS AB Climate change will likely have adverse human health effects that require federal agency involvement in adaptation activities. In 2009, President Obama issued Executive Order 13514, Federal Leadership in Environmental, Energy, and Economic Performance. The order required federal agencies to develop and implement climate change adaptation plans. The Centers for Disease Control and Prevention (CDC), as part of a larger Department of Health and Human Services response to climate change, is developing such plans. We provide background on Executive Orders, outline tenets of climate change adaptation, discuss public health adaptation planning at both the Department of Health and Human Services and the CDC, and outline possible future CDC efforts. We also consider how these activities may be better integrated with other adaptation activities that manage emerging health threats posed by climate change. C1 [Hess, Jeremy J.; Schramm, Paul J.; Luber, George] Ctr Dis Control & Prevent, Climate & Hlth Program, Div Environm Hazards & Hlth Effects, Natl Ctr Environm Hlth, Atlanta, GA USA. [Hess, Jeremy J.] Emory Univ, Sch Med, Dept Emergency Med, Atlanta, GA USA. RP Hess, JJ (reprint author), Ctr Dis Control & Prevent, Climate & Hlth Program, Natl Ctr Environm Hlth, 4770 Buford Highway,MS F-59, Chamblee, GA 30341 USA. EM aso1@cdc.gov NR 55 TC 5 Z9 5 U1 2 U2 10 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD MAR PY 2014 VL 104 IS 3 BP E22 EP E30 DI 10.2105/AJPH.2013.301796 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AP0LP UT WOS:000341753300014 PM 24432931 ER PT J AU Siddaramappa, S Challacombe, JF Petersen, JM Pillai, S Kuske, CR AF Siddaramappa, Shivakumara Challacombe, Jean F. Petersen, Jeannine M. Pillai, Segaran Kuske, Cheryl R. TI Comparative analyses of a putative Francisella conjugative element SO GENOME LA English DT Article DE Francisella; plasmid; conjugal transfer proteins; theta replication ID ENVIRONMENTAL-SAMPLES; TULARENSIS; PLASMIDS; IDENTIFICATION; PHILOMIRAGIA; REPLICATION; BACTEREMIA; SEQUENCE; STRAINS; DISEASE AB A large circular plasmid detected in Francisella novicida-like strain PA10-7858, designated pFNPA10, was sequenced completely and analyzed. This 41 013-bp plasmid showed no homology to any of the previously sequenced Francisella plasmids and was 8-10 times larger in size than them. A total of 57 ORFs were identified within pFNPA10 and at least 9 of them encoded putative proteins with homology to different conjugal transfer proteins. The presence of iteron-like direct repeats and an ORF encoding a putative replication protein within pFNPA10 suggested that it replicated by the theta mode. Phylogenetic analyses indicated that pFNPA10 had no near neighbors in the databases and that it may have originated within an environmental Francisella lineage. Based on its features, pFNPA10 appears to be a novel extra-chromosomal genetic element within the genus Francisella. The suitability of pFNPA10 as a vector for transformation of species of Francisella by conjugation remains to be explored. C1 [Siddaramappa, Shivakumara] Inst Bioinformat & Appl Biotechnol, Bengaluru 560100, India. [Challacombe, Jean F.; Kuske, Cheryl R.] Los Alamos Natl Lab, Biosci Div, Los Alamos, NM 87545 USA. [Petersen, Jeannine M.] Ctr Dis Control & Prevent, Div Vector Borne Infect Dis, Ft Collins, CO 80521 USA. [Pillai, Segaran] Dept Homeland Secur, Sci & Technol Directorate, Chem & Biol Div, Washington, DC USA. RP Kuske, CR (reprint author), Los Alamos Natl Lab, Biosci Div, POB 1663, Los Alamos, NM 87545 USA. EM kuske@lanl.gov FU United States Department of Homeland Security, Science and Technology Directorate, Homeland Security Advanced Research Projects Agency; Centers for Disease Control and Prevention FX This study was funded by the United States Department of Homeland Security, Science and Technology Directorate, Homeland Security Advanced Research Projects Agency, and the Centers for Disease Control and Prevention. The authors wish to thank members of the Genome Sequencing and Finishing Team, Joint Genome Institute at the Los Alamos National Laboratory for help with DNA sequencing. This is Los Alamos National Laboratory unclassified document number LA-UR-13-28060. NR 38 TC 2 Z9 2 U1 0 U2 0 PU CANADIAN SCIENCE PUBLISHING, NRC RESEARCH PRESS PI OTTAWA PA 65 AURIGA DR, SUITE 203, OTTAWA, ON K2E 7W6, CANADA SN 0831-2796 EI 1480-3321 J9 GENOME JI Genome PD MAR PY 2014 VL 57 IS 3 BP 137 EP 144 DI 10.1139/gen-2013-0231 PG 8 WC Biotechnology & Applied Microbiology; Genetics & Heredity SC Biotechnology & Applied Microbiology; Genetics & Heredity GA AP1JN UT WOS:000341825300002 PM 24884689 ER PT J AU Merkle, S AF Merkle, Sarah TI Food Safety Tools and Products for Environmental Health Practitioners SO JOURNAL OF ENVIRONMENTAL HEALTH LA English DT Editorial Material C1 CDC, Div Emergency & Environm Hlth Serv, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. RP Merkle, S (reprint author), CDC, Div Emergency & Environm Hlth Serv, Natl Ctr Environm Hlth, 4770 Buford Highway NE,Mailstop F-58, Atlanta, GA 30341 USA. EM smerkle@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 2 PU NATL ENVIRON HEALTH ASSOC PI DENVER PA 720 S COLORADO BLVD SUITE 970, SOUTH TOWER, DENVER, CO 80246 USA SN 0022-0892 J9 J ENVIRON HEALTH JI J. Environ. Health PD MAR PY 2014 VL 76 IS 7 BP 44 EP 46 PG 3 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA AO7NR UT WOS:000341540400007 PM 24683939 ER PT J AU Balluz, LS AF Balluz, Lina S. TI CDC's Environmental Public Health Tracking Network: An Innovative Dynamic Surveillance System for You SO JOURNAL OF ENVIRONMENTAL HEALTH LA English DT Editorial Material C1 CDC, Environm Hlth Tracking Branch, Div Environm Hazards & Hlth Effects, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. RP Balluz, LS (reprint author), CDC, Environm Hlth Tracking Branch, Div Environm Hazards & Hlth Effects, Natl Ctr Environm Hlth, 4770 Buford Highway NE,Mailstop F-60, Atlanta, GA 30341 USA. EM lballuz@cdc.gov NR 0 TC 2 Z9 2 U1 0 U2 1 PU NATL ENVIRON HEALTH ASSOC PI DENVER PA 720 S COLORADO BLVD SUITE 970, SOUTH TOWER, DENVER, CO 80246 USA SN 0022-0892 J9 J ENVIRON HEALTH JI J. Environ. Health PD MAR PY 2014 VL 76 IS 7 BP 48 EP 50 PG 3 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA AO7NR UT WOS:000341540400008 PM 24683940 ER PT J AU Goodwin, DJ Mazurek, GH Campbell, BH Bohanon, J West, KB Bell, JJ Powell, R Toney, S Morris, JA Yamane, GK Sjoberg, PA AF Goodwin, Donald J. Mazurek, Gerald H. Campbell, Brandon H. Bohanon, Jamaria West, Kevin B. Bell, James J. Powell, Richard Toney, Sean Morris, John A. Yamane, Grover K. Sjoberg, Paul A. TI Automation of an Interferon-gamma Release Assay and Comparison to the Tuberculin Skin Test for Screening Basic Military Trainees for Mycobacterium tuberculosis Infection SO MILITARY MEDICINE LA English DT Article ID UNITED-STATES; CROSS-REACTIVITY; HOMOLOG; PROTEIN; LEPRAE; HEALTH AB We automated portions of the QuantiFERON-TB Gold In-Tube test (QFT-GIT) and assessed its quality when performed concurrently with the tuberculin skin test (TST) among U.S. Air Force basic military trainees (BMTs). The volume of blood collected for QFT-GIT was monitored. At least one of the three tubes required for QFT-GIT had blood volume outside the recommended 0.8- to 1.2-mL range for 688 (29.0%) of 2,373 subjects who had their blood collected. Of the 2,124 subjects who had TST and QFT-GIT completed, TST was positive for 0.6%; QFT-GIT was positive for 0.3% and indeterminate for 2.0%. Among 2,081 subjects with completed TST and determinate QFT-GIT results, overall agreement was 99.5% but positive agreement was 5.6%. Specificity among the 1,546 low-risk BMTs was identical (99.7%). Indeterminate QFT-GIT results were 2.7 times more likely when mitogen tubes contained >1.2 mL blood than when containing 0.8- to 1.2-mL blood. Automation can facilitate QFT-GIT completion, especially if the recommended volume of blood is collected. Mycobacterium tuberculosis infection prevalence among BMTs based on TST and QFT-GIT is similar and low. Selectively testing those with significant risk may be more appropriate than universal testing of all recruits. C1 [Goodwin, Donald J.; Bohanon, Jamaria; Bell, James J.; Yamane, Grover K.; Sjoberg, Paul A.] US Air Force, Sch Aerosp Med, Epidemiol Consult Serv, Wright Patterson AFB, OH 45433 USA. [Mazurek, Gerald H.; Campbell, Brandon H.; Powell, Richard; Toney, Sean] Ctr Dis Control & Prevent CDC, Div TB Eliminat, Atlanta, GA 30333 USA. [West, Kevin B.] Wilford Hall USAF Med Ctr, Reid Clin, Dept Occupat Med TB Prevent Deployment Med, Lackland AFB, TX 78236 USA. [Morris, John A.] Grifols USA LLC, Div Diagnost, Doral, FL 33172 USA. RP Goodwin, DJ (reprint author), US Air Force, Sch Aerosp Med, Epidemiol Consult Serv, 2510 Fifth St,Bldg 840,W318K, Wright Patterson AFB, OH 45433 USA. FU USAF FX The USAF provided funding for the study. The USAF also provided access to USAF BMTs while undergoing medical assessment at Reid Clinic; office and laboratory space; and administrative, laboratory, computer, and staff support through USAFSAM's Epidemiology Consult Services. CDC and the CDC Foundation provided technical expertise, procedure manuals, training and oversight of study staff, and computer programming support. Grifols USA provided two Triturus automated ELISA workstations for use in the trial, as well as maintenance and staff training during the trial. At the completion of the trial, the Triturus instruments were returned to Grifols USA. Cellestis provided the QuantiFERON-TB Gold In-Tube kits used in the trial. Cooperative Research and Development Agreements facilitated sharing of equipment, materials, and findings. The USAF and CDC retained control of the study, data, analyses, and results dissemination. NR 19 TC 2 Z9 2 U1 0 U2 1 PU ASSOC MILITARY SURG US PI BETHESDA PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA SN 0026-4075 EI 1930-613X J9 MIL MED JI Milit. Med. PD MAR PY 2014 VL 179 IS 3 BP 333 EP 341 DI 10.7205/MILMED-D-13-00364 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA AN7UJ UT WOS:000340806200021 PM 24594471 ER PT J AU Steele, CB Townsend, JS Tai, E Thomas, CC AF Steele, C. Brooke Townsend, Julie S. Tai, Eric Thomas, Cheryll C. TI Physician visits and preventive care among Asian American and Pacific Islander long-term survivors of colorectal cancer, USA, 1996-2006 SO JOURNAL OF CANCER SURVIVORSHIP LA English DT Article DE Cancer survivors; Colorectal cancer; Preventive care; Physician specialty ID MEDICARE BENEFICIARIES; UNITED-STATES; TUMOR CHARACTERISTICS; CLAIMS DATA; FOLLOW-UP; BREAST; DISPARITIES; QUALITY; WOMEN; SERVICES AB Purpose Published literature on receipt of preventive healthcare services among Asian American and Pacific Islander (API) cancer survivors is scarce. We describe patterns in receipt of preventive services among API long-term colorectal cancer (CRC) survivors. Methods Surveillance, Epidemiology, and End Results registry-Medicare data were used to identify 9,737 API and white patients who were diagnosed with CRC during 19962000 and who survived 5 or more years beyond their diagnoses. We examined receipt of vaccines, mammography (females), bone densitometry (females), and cholesterol screening among the survivors and how the physician specialties they visited for follow-up care correlated to services received. Results APIs were less likely than whites to receive mammography (52.0 vs. 69.3 %, respectively; P<0.0001) but more likely to receive influenza vaccine, cholesterol screening, and bone densitometry. These findings remained significant in our multivariable model, except for receipt of bone densitometry. APIs visited PCPs only and both PCPs and oncologists more frequently than whites (P<0.0001). Women who visited both PCPs and oncologists compared with PCPs only were more likely to receive mammography (odds ratio=1.40; 95 % confidence interval, 1.05-1.86). Conclusions Visits to both PCPs and oncologists were associated with increased use of mammography. Although API survivors visited these specialties more frequently than white survivors, API women may need culturally appropriate outreach to increase their use of this test. Implications for Cancer Survivors Long-term cancer survivors need to be aware of recommended preventive healthcare services, as well as who will manage their primary care and cancer surveillance follow-up. C1 [Steele, C. Brooke; Townsend, Julie S.; Tai, Eric; Thomas, Cheryll C.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA 30333 USA. RP Steele, CB (reprint author), Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA 30333 USA. EM BSteele1@cdc.gov FU Intramural CDC HHS [CC999999] NR 48 TC 2 Z9 2 U1 1 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1932-2259 EI 1932-2267 J9 J CANCER SURVIV JI J. Cancer Surviv.-Res. Pract. PD MAR PY 2014 VL 8 IS 1 BP 70 EP 79 DI 10.1007/s11764-013-0319-1 PG 10 WC Oncology; Social Sciences, Biomedical SC Oncology; Biomedical Social Sciences GA AM9WP UT WOS:000340232000008 PM 24190589 ER PT J AU Stevens, JA Voukelatos, A Ehrenreich, H AF Stevens, Judy A. Voukelatos, Alexander Ehrenreich, Heidi TI Preventing falls with Tai Ji Quan: A public health perspective SO JOURNAL OF SPORT AND HEALTH SCIENCE LA English DT Review DE Elderly; Falls; Falls prevention; Older adults; Tai Chi; Tai Ji Quan ID RANDOMIZED CLINICAL-TRIAL; OLDER-ADULTS; PHYSICAL-ACTIVITY; ELDERLY-PEOPLE; CHI-CHUAN; RISK-FACTORS; COMMUNITY; EXERCISE; BALANCE; INTERVENTION AB Falls among people aged 65 and older are a significant public health problem and one that is expected to increase as the population ages. Randomized controlled trials have demonstrated that Tai Ji Quan can reduce falls and associated injuries among older adults. In this paper, we describe how Tai Ji Quan community programs are being utilized by public health and aging services organizations to reduce older adult falls. We conclude that, to have a population-level impact on reducing falls and improving the health of older adults, Tai Ji Quan interventions must be translated into community programs that meet the needs and abilities of older adults. These programs must be adapted to fit into existing community structures, disseminated through multiple delivery channels, adopted and implemented broadly by organizations, and institutionalized to ensure sustainability. Copyright (C) 2014, Shanghai University of Sport. Production and hosting by Elsevier B. V. All rights reserved. C1 [Stevens, Judy A.; Ehrenreich, Heidi] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA. [Voukelatos, Alexander] Univ New S Wales, Sch Publ Hlth & Community Med, Sydney, NSW 2052, Australia. RP Stevens, JA (reprint author), Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA. EM jas2@cdc.gov FU Centers for Disease Control and Prevention (CDC); US Department of Energy FX We would like to thank Dr. Tamara Haegerich for her thoughtful comments and helpful suggestions. This work was supported by the Centers for Disease Control and Prevention (CDC) through intramural funding and supported in part by an appointment to the Research Participation Program at the Centers for Disease Control and Prevention administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the US Department of Energy and CDC. NR 53 TC 6 Z9 6 U1 2 U2 16 PU SHANGHAI UNIV SPORT PI SHANGHAI PA EDITORIAL BOARD, 650 QINGYUANHUAN RD, SHANGHAI, 200438, PEOPLES R CHINA SN 2095-2546 EI 2213-2961 J9 J SPORT HEALTH SCI JI J. Sport Health Sci. PD MAR PY 2014 VL 3 IS 1 SI SI BP 21 EP 26 DI 10.1016/j.jshs.2013.10.002 PG 6 WC Hospitality, Leisure, Sport & Tourism; Sport Sciences SC Social Sciences - Other Topics; Sport Sciences GA AM7GX UT WOS:000340034600005 PM 26744633 ER PT J AU Sleet, DA Baldwin, GT AF Sleet, David A. Baldwin, Grant T. TI Can an evidence-based fall prevention program be translated for use in culturally diverse communities? SO JOURNAL OF SPORT AND HEALTH SCIENCE LA English DT Editorial Material ID RE-AIM FRAMEWORK; INTERVENTION C1 [Sleet, David A.; Baldwin, Grant T.] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. RP Sleet, DA (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. EM dds6@cdc.gov NR 14 TC 1 Z9 1 U1 1 U2 2 PU SHANGHAI UNIV SPORT PI SHANGHAI PA EDITORIAL BOARD, 650 QINGYUANHUAN RD, SHANGHAI, 200438, PEOPLES R CHINA SN 2095-2546 EI 2213-2961 J9 J SPORT HEALTH SCI JI J. Sport Health Sci. PD MAR PY 2014 VL 3 IS 1 SI SI BP 32 EP 33 DI 10.1016/j.jshs.2013.11.001 PG 2 WC Hospitality, Leisure, Sport & Tourism; Sport Sciences SC Social Sciences - Other Topics; Sport Sciences GA AM7GX UT WOS:000340034600007 ER PT J AU Almeida, MAB Cardoso, JD dos Santos, E da Fonseca, DF Cruz, LL Faraco, FJC Bercini, MA Vettorello, KC Porto, MA Mohrdieck, R Ranieri, TMS Schermann, MT Sperb, AF Paz, FZ Nunes, ZMA Romano, APM Costa, ZG Gomes, SL Flannery, B AF Almeida, Marco A. B. Cardoso, Jader da C. dos Santos, Edmilson da Fonseca, Daltro F. Cruz, Laura L. Faraco, Fernando J. C. Bercini, Marilina A. Vettorello, Katia C. Porto, Mariana A. Mohrdieck, Renate Ranieri, Tani M. S. Schermann, Maria T. Sperb, Alethea F. Paz, Francisco Z. Nunes, Zenaida M. A. Romano, Alessandro P. M. Costa, Zouraide G. Gomes, Silvana L. Flannery, Brendan TI Surveillance for Yellow Fever Virus in Non-Human Primates in Southern Brazil, 2001-2011: A Tool for Prioritizing Human Populations for Vaccination SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID ANTIGENS; LIVER AB In Brazil, epizootics among New World monkey species may indicate circulation of yellow fever (YF) virus and provide early warning of risk to humans. Between 1999 and 2001, the southern Brazilian state of Rio Grande do Sul initiated surveillance for epizootics of YF in non-human primates to inform vaccination of human populations. Following a YF outbreak, we analyzed epizootic surveillance data and assessed YF vaccine coverage, timeliness of implementation of vaccination in unvaccinated human populations. From October 2008 through June 2009, circulation of YF virus was confirmed in 67 municipalities in Rio Grande do Sul State; vaccination was recommended in 23 (34%) prior to the outbreak and in 16 (24%) within two weeks of first epizootic report. In 28 (42%) municipalities, vaccination began more than two weeks after first epizootic report. Eleven (52%) of 21 laboratory-confirmed human YF cases occurred in two municipalities with delayed vaccination. By 2010, municipalities with confirmed YF epizootics reported higher vaccine coverage than other municipalities that began vaccination. In unvaccinated human populations timely response to epizootic events is critical to prevent human yellow fever cases. C1 [Almeida, Marco A. B.; Cardoso, Jader da C.; dos Santos, Edmilson; da Fonseca, Daltro F.; Cruz, Laura L.] Rio Grande do Sul State Hlth Dept, Div Environm Hlth Surveillance, Porto Alegre, RS, Brazil. [Cardoso, Jader da C.] La Salle Univ, Canoas, RS, Brazil. [Faraco, Fernando J. C.; Bercini, Marilina A.; Vettorello, Katia C.; Porto, Mariana A.; Mohrdieck, Renate; Ranieri, Tani M. S.; Schermann, Maria T.] Rio Grande do Sul State Hlth Dept, Div Epidemiol Surveillance, Porto Alegre, RS, Brazil. [Sperb, Alethea F.; Paz, Francisco Z.] Rio Grande do Sul State Hlth Dept, Porto Alegre, RS, Brazil. [Nunes, Zenaida M. A.] Rio Grande do Sul State Hlth Dept, Cent State Publ Hlth Lab, Porto Alegre, RS, Brazil. [Romano, Alessandro P. M.; Costa, Zouraide G.; Gomes, Silvana L.] Brazilian Minist Hlth, Secretariat Hlth Surveillance, Brasilia, DF, Brazil. [Flannery, Brendan] Pan Amer Hlth Org, Brasilia, DF, Brazil. [Flannery, Brendan] US Ctr Dis Control & Prevent, Global Immunizat Div, Ctr Global Hlth, Atlanta, GA USA. RP Almeida, MAB (reprint author), Rio Grande do Sul State Hlth Dept, Div Environm Hlth Surveillance, Porto Alegre, RS, Brazil. EM mabalmeida@gmail.com FU Rio Grande do Sul State Health Department; Brazilian Ministry of Health FX Yellow fever surveillance activities were funded by the Rio Grande do Sul State Health Department and the Brazilian Ministry of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 23 TC 6 Z9 6 U1 0 U2 2 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD MAR PY 2014 VL 8 IS 3 AR e2741 DI 10.1371/journal.pntd.0002741 PG 7 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA AJ0MU UT WOS:000337348800025 PM 24625681 ER PT J AU Houghton, RL Reed, DE Hubbard, MA Dillon, MJ Chen, HJ Currie, BJ Mayo, M Sarovich, DS Theobald, V Limmathurotsakul, D Wongsuvan, G Chantratita, N Peacock, SJ Hoffmaster, AR Duval, B Brett, PJ Burtnick, MN AuCoin, DP AF Houghton, Raymond L. Reed, Dana E. Hubbard, Mark A. Dillon, Michael J. Chen, Hongjing Currie, Bart J. Mayo, Mark Sarovich, Derek S. Theobald, Vanessa Limmathurotsakul, Direk Wongsuvan, Gumphol Chantratita, Narisara Peacock, Sharon J. Hoffmaster, Alex R. Duval, Brea Brett, Paul J. Burtnick, Mary N. AuCoin, David P. TI Development of a Prototype Lateral Flow Immunoassay (LFI) for the Rapid Diagnosis of Melioidosis SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID COMMUNITY-ACQUIRED SEPTICEMIA; BURKHOLDERIA-PSEUDOMALLEI; PSEUDOMONAS-PSEUDOMALLEI; CLINICAL SPECIMENS; NORTHEAST THAILAND; IMMUNOFLUORESCENCE MICROSCOPY; IDENTIFICATION; BLOOD; ASSAY; AGGLUTINATION AB Burkholderia pseudomallei is a soil-dwelling bacterium and the causative agent of melioidosis. Isolation of B. pseudomallei from clinical samples is the "gold standard'' for the diagnosis of melioidosis; results can take 3-7 days to produce. Alternatively, antibody-based tests have low specificity due to a high percentage of seropositive individuals in endemic areas. There is a clear need to develop a rapid point-of-care antigen detection assay for the diagnosis of melioidosis. Previously, we employed In vivo Microbial Antigen Discovery (InMAD) to identify potential B. pseudomallei diagnostic biomarkers. The B. pseudomallei capsular polysaccharide (CPS) and numerous protein antigens were identified as potential candidates. Here, we describe the development of a diagnostic immunoassay based on the detection of CPS. Following production of a CPS-specific monoclonal antibody (mAb), an antigen-capture immunoassay was developed to determine the concentration of CPS within a panel of melioidosis patient serum and urine samples. The same mAb was used to produce a prototype Active Melioidosis Detect Lateral Flow Immunoassay (AMD LFI); the limit of detection of the LFI for CPS is comparable to the antigen-capture immunoassay (similar to 0.2 ng/ml). The analytical reactivity (inclusivity) of the AMD LFI was 98.7% (76/77) when tested against a large panel of B. pseudomallei isolates. Analytical specificity (cross-reactivity) testing determined that 97.2% of B. pseudomallei near neighbor species (35/36) were not reactive. The non-reactive B. pseudomallei strain and the reactive near neighbor strain can be explained through genetic sequence analysis. Importantly, we show the AMD LFI is capable of detecting CPS in a variety of patient samples. The LFI is currently being evaluated in Thailand and Australia; the focus is to optimize and validate testing procedures on melioidosis patient samples prior to initiation of a large, multisite pre-clinical evaluation. C1 [Houghton, Raymond L.; Chen, Hongjing] InBios Int Inc, Seattle, WA 98104 USA. [Reed, Dana E.; Hubbard, Mark A.; Dillon, Michael J.; AuCoin, David P.] Univ Nevada, Sch Med, Dept Microbiol & Immunol, Reno, NV 89557 USA. [Currie, Bart J.; Mayo, Mark; Sarovich, Derek S.; Theobald, Vanessa] Royal Darwin Hosp, Menzies Sch Hlth Res, Darwin, NT, Australia. [Currie, Bart J.; Mayo, Mark; Sarovich, Derek S.; Theobald, Vanessa] Royal Darwin Hosp, Northern Terr Clin Sch, Darwin, NT, Australia. [Limmathurotsakul, Direk] Mahidol Univ, Fac Trop Med, Dept Trop Hyg, Mahidol Oxford Trop Med Res Unit, Bangkok, Thailand. [Wongsuvan, Gumphol] Sappasithiprasong Hosp, Dept Clin Pathol, Ubon Ratchathani, Thailand. [Chantratita, Narisara] Mahidol Univ, Fac Trop Med, Dept Microbiol & Immunol, Bangkok, Thailand. [Chantratita, Narisara] Mahidol Univ, Fac Trop Med, Mahidol Oxford Trop Med Res Unit, Bangkok, Thailand. [Peacock, Sharon J.] Mahidol Univ, Fac Trop Med, Mahidol Oxford Trop Med Res Unit, Dept Microbiol & Immunol, Bangkok, Thailand. [Peacock, Sharon J.] Univ Cambridge, Addenbrookes Hosp, Dept Med, Cambridge CB2 2QQ, England. [Hoffmaster, Alex R.; Duval, Brea] Ctr Dis Control & Prevent, Bacterial Special Pathogens Branch, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Brett, Paul J.; Burtnick, Mary N.] Univ S Alabama, Dept Microbiol & Immunol, Mobile, AL 36688 USA. RP Houghton, RL (reprint author), InBios Int Inc, Seattle, WA 98104 USA. EM daucoin@medicine.nevada.edu OI Dillon, Michael/0000-0001-6751-7678; Sarovich, Derek/0000-0002-6944-3980 FU National Institute of Allergy and Infectious Diseases [U54AI065359, 1R41AI102482] FX Funding for this study was through grant U54AI065359 (DPA) and 1R41AI102482 (DPA and RLH) from the National Institute of Allergy and Infectious Diseases. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 38 TC 13 Z9 14 U1 3 U2 14 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD MAR PY 2014 VL 8 IS 3 AR e2727 DI 10.1371/journal.pntd.0002727 PG 10 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA AJ0MU UT WOS:000337348800012 PM 24651568 ER PT J AU Romano, APM Costa, ZGA Ramos, DG Andrade, MA Jayme, VD de Almeida, MAB Vettorello, KC Mascheretti, M Flannery, B AF Martins Romano, Alessandro Pecego Antunes Costa, Zouraide Guerra Ramos, Daniel Garkauskas Andrade, Maria Auxiliadora Jayme, Valeria de Sa Barreto de Almeida, Marco Antonio Vettorello, Katia Campomar Mascheretti, Melissa Flannery, Brendan TI Yellow Fever Outbreaks in Unvaccinated Populations, Brazil, 2008-2009 SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID SERIOUS ADVERSE EVENTS; VACCINE VIRUS; 17DD VACCINE; RISK; DENGUE; TRANSMISSION; STATE AB Due to the risk of severe vaccine-associated adverse events, yellow fever vaccination in Brazil is only recommended in areas considered at risk for disease. From September 2008 through June 2009, two outbreaks of yellow fever in previously unvaccinated populations resulted in 21 confirmed cases with 9 deaths (case-fatality, 43%) in the southern state of Rio Grande do Sul and 28 cases with 11 deaths (39%) in Sao Paulo state. Epizootic deaths of non-human primates were reported before and during the outbreak. Over 5.5 million doses of yellow fever vaccine were administered in the two most affected states. Vaccine-associated adverse events were associated with six deaths due to acute viscerotropic disease (0.8 deaths per million doses administered) and 45 cases of acute neurotropic disease (5.6 per million doses administered). Yellow fever vaccine recommendations were revised to include areas in Brazil previously not considered at risk for yellow fever. C1 [Martins Romano, Alessandro Pecego; Antunes Costa, Zouraide Guerra; Ramos, Daniel Garkauskas] Brazilian Minist Hlth, Secretariat Hlth Surveillance, Brasilia, DF, Brazil. [Martins Romano, Alessandro Pecego; Andrade, Maria Auxiliadora; Jayme, Valeria de Sa] Univ Fed Goias, Dept Anim Sci, Goiania, Go, Brazil. [Barreto de Almeida, Marco Antonio; Vettorello, Katia Campomar] Rio Grande do Sul State Hlth Dept, Hlth Surveillance Ctr, Porto Alegre, RS, Brazil. [Mascheretti, Melissa] Sao Paulo State Hlth Dept, Epidemiol Surveillance Ctr, Sao Paulo, Brazil. [Flannery, Brendan] Pan Amer Hlth Org, Brasilia, DF, Brazil. [Flannery, Brendan] US Ctr Dis Control & Prevent, Global Immunizat Div, Ctr Global Hlth, Atlanta, GA USA. RP Romano, APM (reprint author), Brazilian Minist Hlth, Secretariat Hlth Surveillance, Brasilia, DF, Brazil. EM alessandro.romano@saude.gov.br FU Brazilian Ministry of Health FX This manuscript presents surveillance data from routine surveillance activities wholly funded by the Brazilian Ministry of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 41 TC 13 Z9 13 U1 0 U2 6 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD MAR PY 2014 VL 8 IS 3 AR e2740 DI 10.1371/journal.pntd.0002740 PG 8 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA AJ0MU UT WOS:000337348800024 PM 24625634 ER PT J AU Walters, MS Routh, J Mikoleit, M Kadivane, S Ouma, C Mubiru, D Mbusa, B Murangi, A Ejoku, E Rwantangle, A Kule, U Lule, J Garrett, N Halpin, J Maxwell, N Kagirita, A Mulabya, F Makumbi, I Freeman, M Joyce, K Hill, V Downing, R Mintz, E AF Walters, Maroya Spalding Routh, Janell Mikoleit, Matthew Kadivane, Samuel Ouma, Caroline Mubiru, Denis Mbusa, Ben Murangi, Amos Ejoku, Emmanuel Rwantangle, Absalom Kule, Uziah Lule, John Garrett, Nancy Halpin, Jessica Maxwell, Nikki Kagirita, Atek Mulabya, Fred Makumbi, Issa Freeman, Molly Joyce, Kevin Hill, Vince Downing, Robert Mintz, Eric TI Shifts in Geographic Distribution and Antimicrobial Resistance during a Prolonged Typhoid Fever Outbreak - Bundibugyo and Kasese Districts, Uganda, 2009-2011 SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID RAPID DIAGNOSTIC-TESTS; USE WATER-TREATMENT; INTESTINAL PERFORATION; SALMONELLA-TYPHI; INFECTIONS; MALAWI AB Background: Salmonella enterica serovar Typhi is transmitted by fecally contaminated food and water and causes approximately 22 million typhoid fever infections worldwide each year. Most cases occur in developing countries, where approximately 4% of patients develop intestinal perforation (IP). In Kasese District, Uganda, a typhoid fever outbreak notable for a high IP rate began in 2008. We report that this outbreak continued through 2011, when it spread to the neighboring district of Bundibugyo. Methodology/Principal Findings: A suspected typhoid fever case was defined as IP or symptoms of fever, abdominal pain, and >= 1 of the following: gastrointestinal disruptions, body weakness, joint pain, headache, clinically suspected IP, or non-responsiveness to antimalarial medications. Cases were identified retrospectively via medical record reviews and prospectively through laboratory-enhanced case finding. Among Kasese residents, 709 cases were identified from August 1, 2009-December 31, 2011; of these, 149 were identified during the prospective period beginning November 1, 2011. Among Bundibugyo residents, 333 cases were identified from January 1-December 31, 2011, including 128 cases identified during the prospective period beginning October 28, 2011. IP was reported for 507 (82%) and 59 (20%) of Kasese and Bundibugyo cases, respectively. Blood and stool cultures performed for 154 patients during the prospective period yielded isolates from 24 (16%) patients. Three pulsed-field gel electrophoresis pattern combinations, including one observed in a Kasese isolate in 2009, were shared among Kasese and Bundibugyo isolates. Antimicrobial susceptibility was assessed for 18 isolates; among these 15 (83%) were multidrug-resistant (MDR), compared to 5% of 2009 isolates. Conclusions/Significance: Molecular and epidemiological evidence suggest that during a prolonged outbreak, typhoid spread from Kasese to Bundibugyo. MDR strains became prevalent. Lasting interventions, such as typhoid vaccination and improvements in drinking water infrastructure, should be considered to minimize the risk of prolonged outbreaks in the future. C1 [Walters, Maroya Spalding; Routh, Janell; Mikoleit, Matthew; Garrett, Nancy; Halpin, Jessica; Maxwell, Nikki; Freeman, Molly; Joyce, Kevin; Hill, Vince; Mintz, Eric] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30333 USA. [Walters, Maroya Spalding; Routh, Janell] Ctr Dis Control & Prevent, Atlanta, GA USA. [Kadivane, Samuel] Kenya Field Epidemiol Training Program, Nairobi, Kenya. [Ouma, Caroline] CDC Kenya, Kisumu, Kenya. [Mubiru, Denis; Kagirita, Atek] Uganda Cent Publ Hlth Lab, Kampala, Uganda. [Mbusa, Ben] Bundibugyo Dist Hlth Off, Bundibugyo, Uganda. [Murangi, Amos] Kasese Dist Hlth Off, Kasese, Uganda. [Ejoku, Emmanuel] Bundibugyo Hosp, Bundibugyo, Uganda. [Rwantangle, Absalom] Kagando Hosp, Kagando, Uganda. [Kule, Uziah] St Pauls Hlth Ctr, Kasese, Uganda. [Lule, John; Downing, Robert] CDC Uganda, Entebbe, Uganda. [Mulabya, Fred; Makumbi, Issa] Uganda Minist Hlth, Kampala, Uganda. RP Walters, MS (reprint author), Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30333 USA. EM MSWalters@cdc.gov RI Hill, Vincent/G-1789-2012 OI Hill, Vincent/0000-0001-7069-7737 FU CDC Global Disease Detection Operations Center Outbreak Response Contingency Fund FX Financial support was provided by the CDC Global Disease Detection Operations Center Outbreak Response Contingency Fund. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 30 TC 5 Z9 5 U1 1 U2 5 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD MAR PY 2014 VL 8 IS 3 AR e2726 DI 10.1371/journal.pntd.0002726 PG 11 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA AJ0MU UT WOS:000337348800011 PM 24603860 ER PT J AU Rimi, NA Sultana, R Ishtiak-Ahmed, K Khan, SU Sharker, MAY Zaman, RU Azziz-Baumgartner, E Gurley, ES Nahar, N Luby, SP AF Rimi, Nadia Ali Sultana, Rebeca Ishtiak-Ahmed, Kazi Khan, Salah Uddin Sharker, M. A. Yushuf Zaman, Rashid Uz Azziz-Baumgartner, Eduardo Gurley, Emily S. Nahar, Nazmun Luby, Stephen P. TI Poultry Slaughtering Practices in Rural Communities of Bangladesh and Risk of Avian Influenza Transmission: A Qualitative Study SO ECOHEALTH LA English DT Article DE Avian influenza; Bangladesh; poultry slaughtering; qualitative research; focused ethnography ID A H5N1 VIRUS; HUMAN INFECTION; ZOONOTIC TRANSMISSION; RESOURCE; BEHAVIOR; CAMBODIA; CONTACT; HUMANS; ACCESS; HEALTH AB Slaughtering sick poultry is a risk factor for human infection with highly pathogenic avian influenza and is a common practice in Bangladesh. This paper describes human exposures to poultry during slaughtering process and the customs and rituals influencing these practices in two Bangladeshi rural communities. In 2009, we conducted 30 observations to observe slaughtering practices and 110 in-depth and short interviews and 36 group discussions to explore reasons behind those practices. The villagers reported slaughtering 103 poultry, including 20 sick poultry during 2 months. During different stages of slaughtering, humans, the environment, healthy poultry, and other animals were exposed to poultry blood and body parts. Women performed most of the slaughtering tasks, including evisceration. Defeathering required the most time and involved several persons. During festivals, ceremonies, and rituals, many people gathered and participated in the slaughtering of poultry. Exposure to poultry slaughtering created numerous opportunities for potential avian influenza transmission. Strategies that can be further tested to determine if they reduce the risk of transmission include skinning the carcasses of sick poultry, using hot water for defeathering and cleaning, using a bucket to contain slaughtering blood and carcass, burying the offal and encouraging handwashing. C1 [Rimi, Nadia Ali; Sultana, Rebeca; Ishtiak-Ahmed, Kazi; Khan, Salah Uddin; Sharker, M. A. Yushuf; Zaman, Rashid Uz; Gurley, Emily S.; Nahar, Nazmun; Luby, Stephen P.] Icddrb, CCD, Dhaka 1212, Bangladesh. [Azziz-Baumgartner, Eduardo; Luby, Stephen P.] Ctr Dis Control & Prevent CDC, Atlanta, GA USA. RP Rimi, NA (reprint author), Icddrb, CCD, 68 Shaheed Tajuddin Ahmed Sharani,GPO Box 128, Dhaka 1212, Bangladesh. EM nadiarimi@icddrb.org RI Gurley, Emily/B-7903-2010; OI Gurley, Emily/0000-0002-8648-9403; Luby, Stephen/0000-0001-5385-899X FU Centers of Disease Control and Prevention (CDC) [5-U51-CI000298] FX This research was funded by the Centers of Disease Control and Prevention (CDC) under the agreement of CoAg Grant 5-U51-CI000298. icddr,b acknowledges the commitment of CDC to its research efforts with gratitude. We are grateful to our study participants for their time and invaluable information. We thank Marufa Hasin, Afroza Khanam Roza, and Md. Zahidur Rahman for their valuable contribution in data collection, Shamim Azad for his contribution to data organizing and Kamal Hossain for preparing the map. We also thank Dorothy Southern for her guidance in writing and Andrea Mikolon, Najmul Haider, and Meghan Scott for reviewing the manuscript. NR 53 TC 4 Z9 4 U1 0 U2 7 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1612-9202 EI 1612-9210 J9 ECOHEALTH JI EcoHealth PD MAR PY 2014 VL 11 IS 1 BP 83 EP 93 DI 10.1007/s10393-013-0885-8 PG 11 WC Biodiversity Conservation; Ecology; Environmental Sciences SC Biodiversity & Conservation; Environmental Sciences & Ecology GA AI7MP UT WOS:000337076000011 PM 24306550 ER PT J AU Gautam, R Esona, MD Mijatovic-Rustempasic, S Tam, KI Gentsch, JR Bowen, MD AF Gautam, Rashi Esona, Mathew D. Mijatovic-Rustempasic, Slavica Tam, Ka Ian Gentsch, Jon R. Bowen, Michael D. TI Real-time RT-PCR assays to differentiate wild-type group A rotavirus strains from Rotarix (R) and RotaTeq (R) vaccine strains in stool samples SO HUMAN VACCINES & IMMUNOTHERAPEUTICS LA English DT Article DE rotavirus vaccine; acute gastroenteritis; Rotarix (R); RotaTeq (R); qRT-PCR ID SEVERE COMBINED IMMUNODEFICIENCY; POLYMERASE-CHAIN-REACTION; REASSORTANT ROTAVIRUS; NUCLEIC-ACID; INFANTS; GASTROENTERITIS; TRANSMISSION; INFECTION; GENOTYPE; CHILDREN AB Group A rotaviruses (RVA) are the leading cause of severe diarrhea in young children worldwide. Two live-attenuated RVA vaccines, Rotarix (R) and RotaTeq (R) are recommended by World Health Organization (WHO) for routine immunization of all infants. Rotarix (R) and RotaTeq (R) vaccines have substantially reduced RVA associated mortality but occasionally have been associated with acute gastroenteritis (AGE) cases identified in vaccinees and their contacts. High-throughput assays are needed to monitor the prevalence of vaccine strains in AGE cases and emergence of new vaccine-derived strains following RVA vaccine introduction. In this study, we have developed quantitative real-time RT-PCR (qRT-PCR) assays for detection of Rotarix (R) and RotaTeq (R) vaccine components in stool samples. Real-time RT-PCR assays were designed for vaccine specific targets in the genomes of Rotarix (R) (NSP2, VP4) and RotaTeq (R) (VP6, VP3-WC3, VP3-human) and validated on sequence confirmed stool samples containing vaccine strains, wild-type RVA strains, and RVA-negative stools. For quantification, standard curves were generated using dsRNA transcripts derived from RVA gene segments. Rotarix (R) NSP2 and VP4 qRT-PCR assays exhibited 92-100% sensitivity, 99-100% specificity, 94-105% efficiency, and a limit of detection of 2-3 copies per reaction. RotaTeq (R) VP6, VP3-WC3, and VP3-human qRT-PCR assays displayed 100% sensitivity, 94-100% specificity, 91-102% efficiency and limits of detection of 1 copy, 2 copies, and 140 copies, respectively. These assays permit rapid identification of Rotarix (R) and RotaTeq (R) vaccine components in stool samples from clinical and surveillance studies and will be helpful in determining the frequency of vaccine strain-associated AGE. C1 [Gautam, Rashi; Esona, Mathew D.; Mijatovic-Rustempasic, Slavica; Tam, Ka Ian; Gentsch, Jon R.; Bowen, Michael D.] Ctr Dis Control & Prevent, Gastroenteritis & Resp Viruses Lab Branch, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Bowen, MD (reprint author), Ctr Dis Control & Prevent, Gastroenteritis & Resp Viruses Lab Branch, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM mkb6@cdc.gov FU CDC Core Activity Funds FX CDC Core Activity Funds NR 42 TC 6 Z9 7 U1 0 U2 3 PU LANDES BIOSCIENCE PI AUSTIN PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA SN 2164-5515 EI 2164-554X J9 HUM VACC IMMUNOTHER JI Human Vaccines Immunother. PD MAR PY 2014 VL 10 IS 3 BP 767 EP 777 DI 10.4161/hv.27388 PG 11 WC Biotechnology & Applied Microbiology; Immunology SC Biotechnology & Applied Microbiology; Immunology GA AI1ZF UT WOS:000336653800044 PM 24342877 ER PT J AU Moro, PL AF Moro, Pedro L. TI Safety of Influenza A (H1N1) 2009 Live Attenuated Monovalent Vaccine in Pregnant Women In Reply SO OBSTETRICS AND GYNECOLOGY LA English DT Letter C1 Ctr Dis Control & Prevent, Immunizat Safety Off, Div Healthcare Qual Promot, NCEZID, Atlanta, GA 30333 USA. RP Moro, PL (reprint author), Ctr Dis Control & Prevent, Immunizat Safety Off, Div Healthcare Qual Promot, NCEZID, Atlanta, GA 30333 USA. NR 5 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0029-7844 J9 OBSTET GYNECOL JI Obstet. Gynecol. PD MAR PY 2014 VL 123 IS 3 BP 666 EP 666 PG 1 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA AI4BA UT WOS:000336809100030 PM 24553157 ER PT J AU Rha, B Tate, JE Payne, DC Cortese, MM Lopman, BA Curns, AT Parashar, UD AF Rha, Brian Tate, Jacqueline E. Payne, Daniel C. Cortese, Margaret M. Lopman, Benjamin A. Curns, Aaron T. Parashar, Umesh D. TI Effectiveness and impact of rotavirus vaccines in the United States-2006-2012 SO EXPERT REVIEW OF VACCINES LA English DT Review DE gastroenteritis; rotavirus; rotavirus disease; rotavirus vaccines; vaccines ID NATIONAL IMMUNIZATION PROGRAM; CHILDREN LESS-THAN-5 YEARS; US CHILDREN; GASTROENTERITIS HOSPITALIZATIONS; STATES CHILDREN; INTUSSUSCEPTION RISK; PROVIDES PROTECTION; ADVISORY-COMMITTEE; OLDER CHILDREN; DISEASE BURDEN AB Prior to the introduction of rotavirus vaccines in 2006, rotavirus was the leading cause of severe gastroenteritis among US children <5 years of age. In the first 7 years of vaccine use, both recommended rotavirus vaccines (RotaTeq [RV5] and Rotarix [RV1]) have been shown to be highly effective in preventing outcomes of severe disease in US children in a variety of settings. In addition, substantial decreases in severe diarrheal disease in US children, exceeding the level expected based on vaccine coverage, as well as the extension of benefits to older age groups ineligible for vaccination have demonstrated both the direct and indirect impacts of vaccination in the USA. C1 [Rha, Brian; Tate, Jacqueline E.; Payne, Daniel C.; Cortese, Margaret M.; Lopman, Benjamin A.; Curns, Aaron T.; Parashar, Umesh D.] Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Rha, Brian] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. RP Rha, B (reprint author), Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM wif8@cdc.gov NR 56 TC 26 Z9 26 U1 0 U2 9 PU EXPERT REVIEWS PI LONDON PA UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB, ENGLAND SN 1476-0584 EI 1744-8395 J9 EXPERT REV VACCINES JI Expert Rev. Vaccines PD MAR PY 2014 VL 13 IS 3 BP 365 EP 376 DI 10.1586/14760584.2014.877846 PG 12 WC Immunology SC Immunology GA AG3MV UT WOS:000335324500006 PM 24392657 ER PT J AU Sutton, MY Patel, R Frazier, EL AF Sutton, Madeline Y. Patel, Roshni Frazier, Emma L. TI Unplanned Pregnancies Among HIV-Infected Women in Care-United States SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE family planning; HIV; clinical care; pregnancy; AIDS; women ID UNINTENDED PREGNANCY; DISPARITIES; CHALLENGES; INTENTIONS; FERTILITY; DESIRES AB Objective: To examine the prevalence of unplanned pregnancies among HIV-infected women in care in the United States. Methods: We used the 2007-2008 cycles of the Medical Monitoring Project, which collected data on HIV-infected adults in care. Women were included if they had an HIV diagnosis before 45 years of age and responded to questions about pregnancies and pregnancy planning after HIV diagnosis. Logistic regression was used to calculate unadjusted and adjusted odds ratios (AORs) and 95% confidence intervals (CIs) for correlates of unplanned pregnancies among women with >= 1 pregnancy at or after an HIV diagnosis. Results: Of 1492 women, 382 (25.6%) reported >= 1 pregnancy after HIV diagnosis (median diagnosis age = 25.0 years; interquartile range = 21.0-30.0); 58% were non-Hispanic black, 22% Hispanic, and 15% non-Hispanic white. Of those, 326 (85.3%) reported >= 1 unplanned pregnancy; 124 (32.5%) reported recent unprotected vaginal and/or anal sex with a male partner with either negative or unknown HIV status. Unplanned pregnancies were more likely among women who reported nadir CD4 cell counts <200 cells/mu L (AOR = 2.3; 95% CI: 1.2 to 4.8) or did not report nadir CD4 cell counts (AOR = 4.3; 95% CI: 1.9 to 10.5) compared with women who reported nadir CD4 cell counts >= 200 cells/mu L; and who received public assistance in the most recent year before Medical Monitoring Project interview (AOR = 2.1; 95% CI: 1.1 to 3.8) compared with women who did not receive assistance. Conclusions: Unplanned pregnancies were prevalent among our sample. To avoid unplanned pregnancies, HIV-infected women need access to effective family planning services and risk reduction discussions during routine care visits. C1 [Sutton, Madeline Y.; Patel, Roshni; Frazier, Emma L.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Atlanta, GA 30333 USA. [Patel, Roshni] ICF Int, Atlanta, GA USA. RP Sutton, MY (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, 1600 Clifton Rd NE MS E-45, Atlanta, GA 30333 USA. EM msutton@cdc.gov NR 39 TC 13 Z9 13 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 EI 1077-9450 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD MAR 1 PY 2014 VL 65 IS 3 BP 350 EP 358 DI 10.1097/QAI.0000000000000054 PG 9 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA AH0DL UT WOS:000335789200026 PM 24189153 ER PT J AU Holtgrave, DR Hall, HI Des Jarlais, DC Mizuno, Y Purcell, DW AF Holtgrave, David R. Hall, H. Irene Des Jarlais, Don C. Mizuno, Yuko Purcell, David W. TI Estimating Number Diagnosed Persons Living With HIV in the United States Engaged in Unprotected Serodiscordant Risk Behavior With Unsuppressed Viral Load SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Letter ID TRANSMISSION C1 [Holtgrave, David R.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Behav & Soc, Baltimore, MD 21205 USA. [Hall, H. Irene] Ctr Dis Control & Prevent, HIV Incidence & Case Surveillance Branch, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. [Des Jarlais, Don C.] Beth Israel Deaconess Med Ctr, New York, NY 10003 USA. [Mizuno, Yuko; Purcell, David W.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. RP Holtgrave, DR (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Behav & Soc, 624 N Broadway, Baltimore, MD 21205 USA. EM dholtgra@jhsph.edu FU NIDA NIH HHS [R01 DA 003574] NR 9 TC 1 Z9 1 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 EI 1077-9450 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD MAR 1 PY 2014 VL 65 IS 3 BP E125 EP E128 DI 10.1097/QAI.0b013e3182a8ef0e PG 4 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA AH0DL UT WOS:000335789200008 PM 23978998 ER PT J AU Dang, BN Dowell, CH AF Dang, Bich N. Dowell, Chad H. TI Factors Associated With Heat Strain Among Workers at an Aluminum Smelter in Texas SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE LA English DT Article AB Objectives: To determine the prevalence of heat strain and factors associated with heat strain among workers at an aluminum smelter in Texas. Methods: Continuous core body temperature (T-c), heart rate, and pre- and postshift serum electrolytes, and urine specific gravity were measured, and symptom questionnaires were administered. Results: Most participants (54%) had 1 or more signs of heat strain. Unacclimatized participants were significantly more likely to exceed the American Conference of Governmental Industrial Hygienists-recommended T-c than acclimatized participants (88% vs 20%; P < 0.01). Participants who exceeded the T-c for their acclimatization status and/or exceeded the recommended sustained peak HR had a significantly lower body mass index than those who did not (27.6 vs 31.8 and 28.4 vs 32.4, respectively; P = 0.01). Conclusions: Employees and management need to strictly adhere to a heat stress management program to minimize heat stress and strain. C1 [Dang, Bich N.; Dowell, Chad H.] NIOSH, Ctr Dis Control & Prevent, Div Surveillance Hazard Evaluat & Field Studies, Cincinnati, OH 45226 USA. RP Dowell, CH (reprint author), NIOSH, Ctr Dis Control & Prevent, 1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM cdowell@cdc.gov FU Intramural CDC HHS [CC999999] NR 7 TC 1 Z9 1 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1076-2752 EI 1536-5948 J9 J OCCUP ENVIRON MED JI J. Occup. Environ. Med. PD MAR PY 2014 VL 56 IS 3 BP 313 EP 318 DI 10.1097/JOM.0000000000000095 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AH1SC UT WOS:000335900200013 PM 24458134 ER PT J AU Singleton, CM DeBastiani, S Rose, D Kahn, EB AF Singleton, Christa-Marie DeBastiani, Summer Rose, Dale Kahn, Emily B. TI An Analysis of Root Cause Identification and Continuous Quality Improvement in Public Health H1N1 After-Action Reports SO JOURNAL OF PUBLIC HEALTH MANAGEMENT AND PRACTICE LA English DT Article DE after action report; corrective action; root cause analysis; quality improvement; emergency preparedness AB Objective: To identify the extent to which the Homeland Security Exercise and Evaluation Program's (HSEEP) After Action Report/Improvement Plan (AAR/IP) template was followed by public health entities and facilitated the identification of detailed corrective actions and continuous improvement. Design: Data were drawn from the US H1N1 Public Health Emergency Response (PHER) federal grant awardees (n = 62). After action report/improvement plan text was examined to identify the presence of AAR/IP HSEEP elements and characterized as "minimally complete," "partially complete," or "complete." Corrective actions (CA) and recommendations within the IP focusing on performance deficits were coded as specific, measurable, and time-bound, and whether they were associated with a problem that met root cause criteria and whether the CA/recommendation was intended to address or fix the root cause. Main Outcome Measures: A total of 2619 CA/recommendations were identified. More than half (n = 1480, 57%) addressed root causes. Corrective actions/recommendations associated with complete AARs more frequently addressed root cause (58% vs 51%, chi(2) = 9.1, P < 0.003) and were more specific (34% vs 23%, chi(2) = 32.3, P < 0.0001), measurable (30% vs 18%, chi(2) = 37.9, P < 0.0001), and time-bound (38% vs 15%, chi(2) = 115.5, P < 0.0001) than partially complete AARs. The same pattern was not observed with completeness of IPs. Corrective actions and recommendations were similarly specific and measurable. Recommendations significantly addressed root cause more than CAs. Conclusions: Our analysis indicates a possible lack of awardee distinction between CA and recommendations in AARs. As HSEEP adapts to align with the 2011 National Preparedness Goal and National Preparedness System, future HSEEP documents should emphasize the importance of root cause analysis as a required element within AAR documents and templates in the exercise and real incident environment, as well as the need for specific and measurable CAs. C1 [Singleton, Christa-Marie; DeBastiani, Summer; Rose, Dale; Kahn, Emily B.] Ctr Dis Control & Prevent, Off Publ Hlth Preparedness & Response, Div State & Local Readiness, Atlanta, GA 30333 USA. RP Singleton, CM (reprint author), Ctr Dis Control & Prevent, Off Publ Hlth Preparedness & Response, Div State & Local Readiness, 1600 Clifton Rd,Bldg 21,Mailstop D-29, Atlanta, GA 30333 USA. EM ZBI9@cdc.gov OI Kahn, Emily/0000-0001-7812-7958 NR 13 TC 4 Z9 4 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1078-4659 EI 1550-5022 J9 J PUBLIC HEALTH MAN JI J. Public Health Manag. Pract. PD MAR-APR PY 2014 VL 20 IS 2 BP 197 EP 204 DI 10.1097/PHH.0b013e31829ddd21 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AG7DV UT WOS:000335579200008 PM 23838895 ER PT J AU Yasmin, S Pogreba-Brown, K Stewart, J Sunenshine, R AF Yasmin, Seema Pogreba-Brown, Kristen Stewart, Jennifer Sunenshine, Rebecca TI Use of an Online Survey During an Outbreak of Clostridium perfringens in a Retirement Community-Arizona, 2012 SO JOURNAL OF PUBLIC HEALTH MANAGEMENT AND PRACTICE LA English DT Article DE foodborne diseases; Clostridium perfringens; disease outbreaks AB Context: An outbreak of gastrointestinal (GI) illness among retirement community residents was reported to the Maricopa County Department of Public Health. Online surveys can be useful for rapid investigation of disease outbreaks, especially when local health departments lack time and resources to perform telephone interviews. Online survey utility among older populations, which may lack computer access or literacy, has not been defined. Objective: To investigate and implement prevention measures for a GI outbreak and assess the utility of an online survey among retirement community residents. Design: A retrospective cohort investigation was conducted using an online survey distributed through the retirement community e-mail listserv; a follow-up telephone survey was conducted to assess computer literacy and Internet access. A case was defined as any GI illness occurring among residents during March 1-14, 2012. Setting: A barbecue in a retirement community of 3000 residents. Participants: Retirement community residents. Intervention: Residents were directed to discard leftover food and seek health care for symptoms. A telephone survey was conducted to assess the utility of online surveys in this population. Main Outcome Measures: Computer literacy and Internet access of retirement community residents. Results: Of 1000 residents on the listserv, 370 (37%) completed the online survey (mean age, 69.7 years; 60.6% women); 66 residents (17.8%) reported a GI illness after the barbecue, 63 (95.5%) reported diarrhea, and 5 (7.6%) reported vomiting. Leftover beef from an attendee's refrigerator grew Clostridium perfringens. Of 552 residents contacted by telephone, 113 completed the telephone survey (mean age, 71.3 years; 63.3% women), 101 (89.4%) reported the ability to send e-mail, 82 (81.2%) checked e-mail daily, and 28 (27.7%) checked e-mail on a handheld device. The attack rate was 17.8% for online versus 2.7% for telephone respondents (P < .001). Conclusions: This outbreak demonstrated the utility of an online survey to rapidly collect information and implement prevention measures among an older demographic. C1 [Yasmin, Seema] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Sunenshine, Rebecca] Ctr Dis Control & Prevent, Off Publ Hlth Preparedness & Response, Atlanta, GA 30333 USA. [Pogreba-Brown, Kristen] Univ Arizona, Coll Publ Hlth, Tucson, AZ USA. [Yasmin, Seema; Stewart, Jennifer; Sunenshine, Rebecca] Maricopa Cty Dept Publ Hlth, Phoenix, AZ USA. RP Yasmin, S (reprint author), Ctr Dis Control & Prevent, Epidem Intelligence Serv, 1600 Clifton Rd, Atlanta, GA 30333 USA. EM syasmin@cdc.gov NR 9 TC 2 Z9 2 U1 0 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1078-4659 EI 1550-5022 J9 J PUBLIC HEALTH MAN JI J. Public Health Manag. Pract. PD MAR-APR PY 2014 VL 20 IS 2 BP 205 EP 209 DI 10.1097/PHH.0b013e31829a2cf5 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AG7DV UT WOS:000335579200009 PM 23760307 ER PT J AU Alam, S Gaffney, M Eichwald, J AF Alam, Suhana Gaffney, Marcus Eichwald, John TI Improved Newborn Hearing Screening Follow-up Results in More Infants Identified SO JOURNAL OF PUBLIC HEALTH MANAGEMENT AND PRACTICE LA English DT Article DE follow-up; diagnostic evaluation; hearing screening; hearing loss; lost to documentation; audiology; lost to follow-up; EHDI; intervention ID INTERVENTION PROGRAMS; STATEMENT; SERVICES AB Longitudinal research suggests that efforts at the national, state, and local levels are leading to improved follow-up and data reporting. Data now support the assumption that the number of deaf or hard-of-hearing infants identified through newborn hearing screening increases with a reduction in the number of infants lost to follow-up. Documenting the receipt of services has made a noticeable impact on reducing lost to follow-up rates and early identification of infants with hearing loss; however, continued improvement and monitoring of services are still needed. C1 [Alam, Suhana] Oak Ridge Inst Sci & Educ, Oak Ridge, TN USA. [Gaffney, Marcus; Eichwald, John] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Alam, S (reprint author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, 1600 Clifton Rd NE,MS E-88, Atlanta, GA 30333 USA. EM SAlam1@cdc.gov FU Intramural CDC HHS [CC999999] NR 8 TC 1 Z9 1 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1078-4659 EI 1550-5022 J9 J PUBLIC HEALTH MAN JI J. Public Health Manag. Pract. PD MAR-APR PY 2014 VL 20 IS 2 BP 220 EP 223 DI 10.1097/PHH.0b013e31829d7b57 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AG7DV UT WOS:000335579200011 PM 23803975 ER PT J AU Groom, HC Zhang, F Fisher, AK Wortley, PM AF Groom, Holly C. Zhang, Fan Fisher, Allison Kennedy Wortley, Pascale M. TI Differences in Adult Influenza Vaccine-Seeking Behavior: The Roles of Race and Attitudes SO JOURNAL OF PUBLIC HEALTH MANAGEMENT AND PRACTICE LA English DT Article DE influenza; adult; disparities ID RACIAL/ETHNIC DIFFERENCES; UNITED-STATES; DISPARITIES; IMMUNIZATION; BELIEFS; CARE AB Background: Racial/ethnic disparities in influenza vaccination among adults are longstanding, and research suggests they result from multiple factors. Influenza vaccine-seeking behavior may be an important aspect to consider when evaluating disparities in vaccination coverage. Objective: To determine whether there are differences between blacks and whites in influenza vaccine-seeking behavior among adults 65 years and older. Methods: Data were analyzed from a national sample of 3138 adults 65 years and older collected through the adult module of the 2007 National Immunization Survey, a random digit dialing telephone survey, which included an oversample of non-Hispanic blacks. Analysis included influenza vaccination rate, location of vaccination, and whether vaccinated individuals specifically went to the location to receive the vaccine (vaccine seekers) by race. The relationship between attitudes about influenza vaccination and vaccine-seeking behavior by race was also examined. Results: White adults 65 years and older were significantly more likely to receive influenza vaccine than blacks, during the 2006-2007 influenza season (68% +/- 4% vs 54% +/- 3%, respectively), and a significantly higher proportion of vaccinated whites reported seeking out the vaccine than vaccinated blacks (66% +/- 4% vs 47% +/- 4%, respectively). Blacks were less likely to be vaccine seekers, regardless of education or poverty levels. Among persons vaccinated in a doctor's office, 52% of whites specifically went there to get vaccinated, compared with 37% of blacks. Among persons who believe the vaccine is very effective, 66% +/- 5% of whites versus 50% +/- 6% of blacks were vaccine seekers. Conclusions: This study points to the importance of improving our understanding of what factors, in addition to beliefs about vaccination, lead to vaccine seeking and reinforces the need for systematically offering vaccine. C1 Ctr Dis Control & Prevent, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Groom, Holly C.] Kaiser Permanente Northwest, Ctr Hlth Res, Portland, OR 97217 USA. RP Groom, HC (reprint author), Kaiser Permanente Northwest, Ctr Hlth Res, 3550 N,Interstate Ave, Portland, OR 97217 USA. EM holly.c.groom@kpchr.org OI Groom, Holly/0000-0003-2866-9788 NR 19 TC 9 Z9 9 U1 3 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1078-4659 EI 1550-5022 J9 J PUBLIC HEALTH MAN JI J. Public Health Manag. Pract. PD MAR-APR PY 2014 VL 20 IS 2 BP 246 EP 250 DI 10.1097/PHH.0b013e318298bd88 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AG7DV UT WOS:000335579200015 PM 23715220 ER PT J AU Benard, VB Saraiya, M Greek, A Hawkins, NA Roland, KB Manninen, D Ekwueme, DU Miller, JW Unger, ER AF Benard, Vicki B. Saraiya, Mona Greek, April Hawkins, Nikki A. Roland, Katherine B. Manninen, Diane Ekwueme, Donatus U. Miller, Jacqueline W. Unger, Elizabeth R. TI Overview of the CDC Cervical Cancer (Cx3) Study: An Educational Intervention of HPV Testing for Cervical Cancer Screening SO JOURNAL OF WOMENS HEALTH LA English DT Article ID QUALIFIED HEALTH CENTERS; HUMAN-PAPILLOMAVIRUS DNA; COST-EFFECTIVENESS; RECOMMENDATION; GUIDELINES; INTERVALS; CYTOLOGY; BELIEFS; WOMEN AB Background: The recommended screening interval when using the Papanicolaou (Pap) and human papillomavirus (HPV) test (co-testing) is 5 years. However because providers are reluctant to extend the screening interval, we launched a study to identify barriers to appropriate use of the co-test and to implement an educational intervention to promote evidence-based screening practices. This article provides an overview of the study including the multi-component intervention and participant demographics. Methods: The study was conducted in 15 clinics associated with 6 Federally Qualified Health Centers (FQHCs) in Illinois. Each clinic received HPV tests to administer with routine Pap tests among enrolled patients (n=2,246) and was assigned to a study arm: intervention arm (n=7) received a multi-component educational intervention (small media, academic detailing, and website) for providers and printed educational materials for patients, and control arm (n=8) received printed copies of general guidelines. Clinic coordinators (n=15), providers (n=98), and patients (n=984) completed baseline surveys to assess screening practices. Results: Providers reported an average age of 41.3 years and were predominately female, non-Hispanic, and white. Patients reported an average age of 45.0 years and nearly two-thirds were Hispanic or black. Of the 2,246 patients, 89% had a normal co-test. Lessons learned from the study included the importance of buy-in at a high level in the organization, a champion provider, and a clinical coordinator devoted to the study. Conclusion: Materials from this study can be adapted to educate providers and patients on appropriate use of the co-test and encourage extended screening intervals as a safe and effective practice. C1 [Benard, Vicki B.; Saraiya, Mona; Hawkins, Nikki A.; Roland, Katherine B.; Ekwueme, Donatus U.; Miller, Jacqueline W.; Unger, Elizabeth R.] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. [Greek, April; Manninen, Diane] Battelle Mem Inst, Hlth & Analyt, Seattle, WA USA. RP Benard, VB (reprint author), Ctr Dis Control & Prevent, Div Canc Prevent & Control, 4770 Buford Hwy Northeast,MS K-55, Atlanta, GA 30341 USA. EM vdb9@cdc.gov FU United States Government [200-2002-00573] FX The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. This manuscript was written in the course of employment by the United States Government under a contract with Battelle (200-2002-00573, Task Order No. 0006) and it is not subject to copyright in the United States. NR 23 TC 5 Z9 5 U1 0 U2 7 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 EI 1931-843X J9 J WOMENS HEALTH JI J. Womens Health PD MAR 1 PY 2014 VL 23 IS 3 BP 197 EP 203 DI 10.1089/jwh.2013.4655 PG 7 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA AC4BQ UT WOS:000332466000003 PM 24380501 ER PT J AU Roberts, RK Grubb, PL AF Roberts, Rashaun K. Grubb, Paula L. TI The Consequences of Nursing Stress and Need for Integrated Solutions SO REHABILITATION NURSING LA English DT Article DE Job stress; literature review; nurses; organization-focused stress prevention strategies; person-focused stress prevention strategies; psychosocial issues ID JOB STRAIN; PSYCHOLOGICAL DISTRESS; PSYCHOSOCIAL FACTORS; OCCUPATIONAL STRESS; SICKNESS ABSENCE; SOCIAL SUPPORT; DEATH ANXIETY; BACK-PAIN; NURSES; WORK AB PurposeIn a 2011 survey sponsored by the American Nurses Association (ANA), nurses identified the acute and chronic effects of stress and overwork as one of their two top safety and health concerns. Design/MethodsA review of the literature was conducted to investigate the impact that job stress has on the health and safety of nursing professionals and the role that working conditions and job characteristics play in fostering job stress. FindingsStrong evidence supporting links between job stress, safety and health in general and within different types of nursing populations exists. Working conditions also contribute to the development of job stress. ConclusionCombining and integrating person-focused strategies designed to build nurses' ability to manage stress at the individual level with organization-focused strategies that eliminate stressful working conditions is critical to the reduction and prevention of job stress among nursing professionals. C1 [Roberts, Rashaun K.; Grubb, Paula L.] NIOSH, Cincinnati, OH 45226 USA. RP Roberts, RK (reprint author), NIOSH, 4676 Columbia Pkwy,MS C24, Cincinnati, OH 45226 USA. EM rsr3@cdc.gov FU Intramural CDC HHS [CC999999] NR 89 TC 2 Z9 2 U1 7 U2 28 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0278-4807 EI 2048-7940 J9 REHABIL NURS JI Rehabil. Nurs. PD MAR PY 2014 VL 39 IS 2 BP 62 EP 69 DI 10.1002/rnj.97 PG 8 WC Nursing; Rehabilitation SC Nursing; Rehabilitation GA AC3DH UT WOS:000332394700002 PM 23696492 ER PT J AU Kingry, LC Petersen, JM AF Kingry, Luke C. Petersen, Jeannine M. TI Comparative review of Francisella tularensis and Francisella novicida SO FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY LA English DT Review DE tularemia; Francisella tularensis; Francisella novicida; intracellular pathogen; virulence ID LIPOPOLYSACCHARIDE O-ANTIGEN; IN-VITRO SUSCEPTIBILITY; COMPLETE GENOME SEQUENCE; SCHU S4; SUBSPECIES TULARENSIS; PATHOGENICITY ISLAND; ACARI-IXODIDAE; OROPHARYNGEAL TULAREMIA; INFLAMMATORY RESPONSES; ENVIRONMENTAL-SAMPLES AB Francisella tularensis is the causative agent of the acute disease tularemia. Due to its extreme infectivity and ability to cause disease upon inhalation, F tularensis has been classified as a biothreat agent. Two subspecies of F tularensis, tularensis and holarctica, are responsible for tularemia in humans. In comparison, the closely related species novicida very rarely causes human illness and cases that do occur are associated with patients who are immune compromised or have other underlying health problems. Virulence between F tularensis and F novicida also differs in laboratory animals. Despite this varying capacity to cause disease, the two species share similar to 97% nucleotide identity, with F novicida commonly used as a laboratory surrogate for F tularensis. As the F novicida U112 strain is exempt from U.S. select agent regulations, research studies can be carried out in non-registered laboratories lacking specialized containment facilities required for work with virulent F tularensis strains. This review is designed to highlight phenotypic (clinical, ecological, virulence, and pathogenic) and genomic differences between F tularensis and F novicida that warrant maintaining F novicida and F tularensis as separate species. Standardized nomenclature for F novicida is critical for accurate interpretation of experimental results, limiting clinical confusion between F novicida and F tularensis and ensuring treatment efficacy studies utilize virulent F tularensis strains. C1 [Kingry, Luke C.; Petersen, Jeannine M.] Ctr Dis Control & Prevent, Bacterial Dis Branch, Div Vector Borne Dis, Ft Collins, CO 80523 USA. RP Petersen, JM (reprint author), Ctr Dis Control & Prevent, Bacterial Dis Branch, Div Vector Borne Dis, 3150 Rampart Rd, Ft Collins, CO 80523 USA. EM nzp0@cdc.gov OI Kingry, Luke/0000-0002-5724-2575 NR 148 TC 24 Z9 24 U1 0 U2 22 PU FRONTIERS RESEARCH FOUNDATION PI LAUSANNE PA PO BOX 110, LAUSANNE, 1015, SWITZERLAND SN 2235-2988 J9 FRONT CELL INFECT MI JI Front. Cell. Infect. Microbiol. PD MAR PY 2014 VL 4 AR 35 DI 10.3389/fcimb.2014.00035 PG 12 WC Immunology; Microbiology SC Immunology; Microbiology GA AH4TC UT WOS:000336120000012 PM 24660164 ER PT J AU Soucie, JM Miller, CH Kelly, FM Payne, AB Creary, M Bockenstedt, PL Kempton, CL Manco-Johnson, MJ Neff, AT AF Soucie, J. M. Miller, C. H. Kelly, F. M. Payne, A. B. Creary, M. Bockenstedt, P. L. Kempton, C. L. Manco-Johnson, M. J. Neff, A. T. CA Haemophilia Inhibitor Res Study TI A study of prospective surveillance for inhibitors among persons with haemophilia in the United States SO HAEMOPHILIA LA English DT Article ID HEALTH-CARE EXPENDITURES; FACTOR-VIII; MALES C1 [Soucie, J. M.; Miller, C. H.; Kelly, F. M.; Payne, A. B.; Creary, M.] Ctr Dis Control & Prevent, Div Blood Disorders, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Bockenstedt, P. L.] Univ Michigan Haemophilia & Coagulat Disorders, Ann Arbor, MI USA. [Kempton, C. L.] Emory Univ, Atlanta, GA 30322 USA. [Manco-Johnson, M. J.] Univ Colorado, Mt States Reg Haemophilia & Thrombosis Ctr, Aurora, CO USA. [Manco-Johnson, M. J.] Childrens Hosp, Aurora, CO USA. [Neff, A. T.] Vanderbilt Univ, Med Ctr, Nashville, TN USA. RP Soucie, JM (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,MS E64, Atlanta, GA 30333 USA. EM msoucie@cdc.gov OI Miller, Connie H/0000-0002-3989-7973 FU CDC Foundation through Pfizer Inc; Baxter Healthcare; Bayer Healthcare; Novo Nordisk, Inc.; Bayer; CSL Behring; Inspiration Biopharmaceuticals FX The work was supported by the CDC Foundation through grants from Pfizer Inc and Baxter Healthcare. CLK has acted as a paid consultant for Bayer Healthcare and Inspiration Biopharmaceuticals, is a member of Baxter advisory board and received research support from Novo Nordisk, Inc. MJM received research funding from Bayer and CSL Behring and is an advisory board member for Baxter, Bayer, CSL Behring, Octapharma and Novo Nordisk, Inc. The remaining authors stated that they had no interests which might be perceived as posing a conflict or bias. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 17 TC 16 Z9 16 U1 1 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1351-8216 EI 1365-2516 J9 HAEMOPHILIA JI Haemophilia PD MAR PY 2014 VL 20 IS 2 BP 230 EP 237 PG 8 WC Hematology SC Hematology GA AB0CO UT WOS:000331459600031 PM 24261612 ER PT J AU Saha, S Zhao, YQ Shah, SA Degli Esposti, S Lidofsky, S Salih, S Bright, R Law, M Moniz, H Flowers, N Merrick, M Sands, BE AF Saha, Sumona Zhao, Ying-Qi Shah, Samir A. Degli Esposti, Silvia Lidofsky, Sheldon Salih, Sana Bright, Renee Law, Meaghan Moniz, Heather Flowers, Nicole Merrick, Marjorie Sands, Bruce E. TI Menstrual Cycle Changes in Women with Inflammatory Bowel Disease: A Study from the Ocean State Crohn's and Colitis Area Registry SO INFLAMMATORY BOWEL DISEASES LA English DT Article DE quality of life in IBD; gender studies; Crohn's disease; dysmenorrhea; menstrual cycle characteristics; ulcerative colitis ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; MENOPAUSAL TRANSITION; MANAGEMENT; DISORDERS; ADULTS; DYSMENORRHEA; HISTORY; UPDATE; HEALTH AB Background: The effect of the inflammatory bowel diseases (IBD) on menstrual function is largely unknown. The aims of this study were to determine whether changes in menstrual function occur in the year before IBD diagnosis or in the initial years after diagnosis. Methods: Women aged 18 years and older in the Ocean State Crohn's and Colitis Area Registry with at least 2 years of follow-up were eligible for this study. All patients were enrolled within 6 months of IBD diagnosis and followed prospectively. Menstrual cycle characteristics were retrospectively assessed. To assess for changes over time, general linear models for correlated data were used for continuous outcomes, and generalized estimating equations were used for discrete outcomes. Results: One hundred twenty-one patients were studied. Twenty-five percent of patients experienced a change in cycle interval in the year before IBD diagnosis and 21% experienced a change in the duration of flow. Among women with dysmenorrhea, 40% experienced a change in the intensity of their menstrual pain and 31% experienced a change in its duration. Overall cycle regularity increased over time. Quality of life was significantly lower in women without regular cycles across all time points. Conclusions: Changes in menstrual function occur frequently in the year before IBD diagnosis; therefore, screening for menstrual irregularities should be considered in women with newly diagnosed IBD. Patients can be reassured that cycles typically become more regular over time. C1 [Saha, Sumona] Univ Wisconsin, Sch Med & Publ Hlth, Div Gastroenterol & Hepatol, Madison, WI 53705 USA. [Zhao, Ying-Qi] Univ Wisconsin, Sch Med & Publ Hlth, Dept Biostat & Med Informat, Madison, WI 53705 USA. [Shah, Samir A.; Degli Esposti, Silvia; Lidofsky, Sheldon] Brown Univ, Warren Alpert Sch Med, Div Gastroenterol, Providence, RI 02912 USA. [Salih, Sana] Univ Wisconsin, Sch Med & Publ Hlth, Div Reprod Endocrinol, Madison, WI 53705 USA. [Bright, Renee; Law, Meaghan; Moniz, Heather] Rhode Isl Hosp, Dept Pediat Gastroenterol, Providence, RI USA. [Flowers, Nicole] Ctr Dis Control & Prevent, Div Community Hlth, Atlanta, GA USA. [Merrick, Marjorie] Crohns & Colitis Fdn Amer, New York, NY USA. [Sands, Bruce E.] Mt Sinai, Icahn Sch Med, Dr Henry D Janowitz Div Gastroenterol, New York, NY USA. RP Saha, S (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Div Gastroenterol & Hepatol, UW Med Fdn Centennial Bldg,1685 Highland Ave, Madison, WI 53705 USA. EM ssaha@medicine.wisc.edu FU CCFA through the Centers for Disease Control and Prevention [1 UO1 DP000340-03]; National Institutes of Health [1R21DK078555-01]; National Institute of Child Health and Human Development (NICHD) [K12HD055894] FX Supported by a grant from the CCFA through the Centers for Disease Control and Prevention (1 UO1 DP000340-03) and the National Institutes of Health (1R21DK078555-01). S. Saha was supported by Award Number K12HD055894 from the National Institute of Child Health and Human Development (NICHD). NR 32 TC 10 Z9 10 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1078-0998 EI 1536-4844 J9 INFLAMM BOWEL DIS JI Inflamm. Bowel Dis. PD MAR PY 2014 VL 20 IS 3 BP 534 EP 540 DI 10.1097/01.MIB.0000441347.94451.cf PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AG8ED UT WOS:000335650700014 PM 24451220 ER PT J AU Vivar, KL Uyeki, TM AF Vivar, Karina L. Uyeki, Timothy M. TI Influenza virus infection mimicking an acute abdomen in a female adolescent SO INFLUENZA AND OTHER RESPIRATORY VIRUSES LA English DT Article ID PEDIATRIC-PATIENTS; A VIRUSES; CHILDREN; SYMPTOMS; STOOL C1 [Vivar, Karina L.; Uyeki, Timothy M.] Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA. [Uyeki, Timothy M.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. RP Vivar, KL (reprint author), Univ Calif San Francisco, Dept Pediat, 505 Parnassus Ave M691, San Francisco, CA 94143 USA. EM vivark@peds.ucsf.edu NR 16 TC 1 Z9 1 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1750-2640 EI 1750-2659 J9 INFLUENZA OTHER RESP JI Influenza Other Respir. Viruses PD MAR PY 2014 VL 8 IS 2 BP 140 EP 141 PG 2 WC Infectious Diseases; Virology SC Infectious Diseases; Virology GA AB6BZ UT WOS:000331873800003 PM 24373432 ER PT J AU MacDonald, G Moen, AC St Louis, ME AF MacDonald, Goldie Moen, Ann C. St Louis, Michael E. TI The national inventory of core capabilities for pandemic influenza preparedness and response: an instrument for planning and evaluation SO INFLUENZA AND OTHER RESPIRATORY VIRUSES LA English DT Article C1 [MacDonald, Goldie; St Louis, Michael E.] Ctr Dis Control & Prevent, Ctr Global Hlth, Atlanta, GA 30333 USA. [Moen, Ann C.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP MacDonald, G (reprint author), Ctr Dis Control & Prevent, Ctr Global Hlth, 1600 Clifton Rd NE,MS D69, Atlanta, GA 30333 USA. EM gim2@cdc.gov NR 8 TC 1 Z9 1 U1 0 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1750-2640 EI 1750-2659 J9 INFLUENZA OTHER RESP JI Influenza Other Respir. Viruses PD MAR PY 2014 VL 8 IS 2 BP 189 EP 193 PG 5 WC Infectious Diseases; Virology SC Infectious Diseases; Virology GA AB6BZ UT WOS:000331873800009 PM 24373360 ER PT J AU Moen, A Kennedy, PJ Cheng, PY MacDonald, G AF Moen, Ann Kennedy, Pamela J. Cheng, Po-Yung MacDonald, Goldie TI National Inventory of Core Capabilities for Pandemic Influenza Preparedness and Response: Results from 36 countries with reviews in 2008 and 2010 SO INFLUENZA AND OTHER RESPIRATORY VIRUSES LA English DT Article C1 [Moen, Ann] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30329 USA. [Kennedy, Pamela J.] McKing Consulting, Atlanta, GA USA. [Cheng, Po-Yung] Battelle Mem Inst, Atlanta, GA USA. [MacDonald, Goldie] Ctr Dis Control & Prevent, Ctr Global Hlth, Atlanta, GA USA. RP Moen, A (reprint author), Ctr Dis Control & Prevent, Influenza Div, 1600 Clifton Rd MS A-20, Atlanta, GA 30329 USA. EM alc3@cdc.gov NR 9 TC 1 Z9 1 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1750-2640 EI 1750-2659 J9 INFLUENZA OTHER RESP JI Influenza Other Respir. Viruses PD MAR PY 2014 VL 8 IS 2 BP 201 EP 208 PG 8 WC Infectious Diseases; Virology SC Infectious Diseases; Virology GA AB6BZ UT WOS:000331873800011 PM 24299023 ER PT J AU Okomo-Adhiambo, M Nguyen, HT Abd Elal, A Sleeman, K Fry, AM Gubareva, LV AF Okomo-Adhiambo, Margaret Nguyen, Ha T. Abd Elal, Anwar Sleeman, Katrina Fry, Alicia M. Gubareva, Larisa V. TI Drug susceptibility surveillance of influenza viruses circulating in the United States in 2011-2012: application of the WHO antiviral working group criteria SO INFLUENZA AND OTHER RESPIRATORY VIRUSES LA English DT Article ID NEURAMINIDASE INHIBITOR RESISTANCE; PANDEMIC H1N1 2009; OSELTAMIVIR-RESISTANT; PERAMIVIR; ZANAMIVIR; ASSAYS C1 [Okomo-Adhiambo, Margaret; Sleeman, Katrina; Fry, Alicia M.; Gubareva, Larisa V.] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Nguyen, Ha T.; Abd Elal, Anwar] Battelle Mem Inst, Atlanta, GA USA. RP Gubareva, LV (reprint author), Mail Stop G-16,1600 Clifton Rd, Atlanta, GA 30333 USA. EM lgubareva@cdc.gov NR 31 TC 13 Z9 14 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1750-2640 EI 1750-2659 J9 INFLUENZA OTHER RESP JI Influenza Other Respir. Viruses PD MAR PY 2014 VL 8 IS 2 BP 258 EP 265 PG 8 WC Infectious Diseases; Virology SC Infectious Diseases; Virology GA AB6BZ UT WOS:000331873800018 PM 24299049 ER PT J AU Bart, MJ Harris, SR Advani, A Arakawa, Y Bottero, D Bouchez, V Cassiday, PK Chiang, CS Dalby, T Fry, NK Gaillard, ME van Gent, M Guiso, N Hallander, HO Harvill, ET He, QS van der Heide, HGJ Heuvelman, K Hozbor, DF Kamachi, K Karataev, GI Lan, RT Lutynska, A Maharjan, RP Mertsola, J Miyamura, T Octavia, S Preston, A Quail, MA Sintchenko, V Stefanelli, P Tondella, ML Tsang, RSW Xu, YH Yao, SM Zhang, SM Parkhill, J Mooi, FR AF Bart, Marieke J. Harris, Simon R. Advani, Abdolreza Arakawa, Yoshichika Bottero, Daniela Bouchez, Valerie Cassiday, Pamela K. Chiang, Chuen-Sheue Dalby, Tine Fry, Norman K. Gaillard, Maria Emilia van Gent, Marjolein Guiso, Nicole Hallander, Hans O. Harvill, Eric T. He, Qiushui van der Heide, Han G. J. Heuvelman, Kees Hozbor, Daniela F. Kamachi, Kazunari Karataev, Gennady I. Lan, Ruiting Lutynska, Anna Maharjan, Ram P. Mertsola, Jussi Miyamura, Tatsuo Octavia, Sophie Preston, Andrew Quail, Michael A. Sintchenko, Vitali Stefanelli, Paola Tondella, M. Lucia Tsang, Raymond S. W. Xu, Yinghua Yao, Shu-Man Zhang, Shumin Parkhill, Julian Mooi, Frits R. TI Global Population Structure and Evolution of Bordetella pertussis and Their Relationship with Vaccination SO MBIO LA English DT Article ID CLOSELY-RELATED BACTERIAL; WHOLE-CELL VACCINE; FHA PROMOTER; COMPARATIVE GENOMICS; SEQUENCE VARIATION; ESCHERICHIA-COLI; TOXIN PRODUCTION; INDUCED IMMUNITY; TEMPORAL TRENDS; WHOOPING-COUGH AB Bordetella pertussis causes pertussis, a respiratory disease that is most severe for infants. Vaccination was introduced in the 1950s, and in recent years, a resurgence of disease was observed worldwide, with significant mortality in infants. Possible causes for this include the switch from whole-cell vaccines (WCVs) to less effective acellular vaccines (ACVs), waning immunity, and pathogen adaptation. Pathogen adaptation is suggested by antigenic divergence between vaccine strains and circulating strains and by the emergence of strains with increased pertussis toxin production. We applied comparative genomics to a worldwide collection of 343 B. pertussis strains isolated between 1920 and 2010. The global phylogeny showed two deep branches; the largest of these contained 98% of all strains, and its expansion correlated temporally with the first descriptions of pertussis outbreaks in Europe in the 16th century. We found little evidence of recent geographical clustering of the strains within this lineage, suggesting rapid strain flow between countries. We observed that changes in genes encoding proteins implicated in protective immunity that are included in ACVs occurred after the introduction of WCVs but before the switch to ACVs. Furthermore, our analyses consistently suggested that virulence-associated genes and genes coding for surface-exposed proteins were involved in adaptation. However, many of the putative adaptive loci identified have a physiological role, and further studies of these loci may reveal less obvious ways in which B. pertussis and the host interact. This work provides insight into ways in which pathogens may adapt to vaccination and suggests ways to improve pertussis vaccines. IMPORTANCE Whooping cough is mainly caused by Bordetella pertussis, and current vaccines are targeted against this organism. Recently, there have been increasing outbreaks of whooping cough, even where vaccine coverage is high. Analysis of the genomes of 343 B. pertussis isolates from around the world over the last 100 years suggests that the organism has emerged within the last 500 years, consistent with historical records. We show that global transmission of new strains is very rapid and that the worldwide population of B. pertussis is evolving in response to vaccine introduction, potentially enabling vaccine escape. C1 [Bart, Marieke J.; van Gent, Marjolein; van der Heide, Han G. J.; Heuvelman, Kees; Mooi, Frits R.] Natl Inst Publ Hlth, Ctr Infect Dis Control CIb, Ctr Infect Dis Res Diagnost & Screening IDS, Bilthoven, Netherlands. [Bart, Marieke J.; van Gent, Marjolein; van der Heide, Han G. J.; Heuvelman, Kees; Parkhill, Julian] Environm RIVM, Bilthoven, Netherlands. [Bart, Marieke J.; Mooi, Frits R.] UMC St Radboud Hosp, Nijmegen, Netherlands. [Harris, Simon R.; Quail, Michael A.] Wellcome Trust Genome Campus, Wellcome Trust Sanger Inst, Cambridge, England. [Advani, Abdolreza; Hallander, Hans O.] Swedish Inst Communicable Dis Control SMI, Solna, Sweden. [Arakawa, Yoshichika; Kamachi, Kazunari; Miyamura, Tatsuo] Natl Inst Infect Dis, Shinjuku Ku, Tokyo 1628640, Japan. [Bottero, Daniela; Gaillard, Maria Emilia; Hozbor, Daniela F.] Univ Nacl La Plata, CONICET, Fac Ciencias Exactas, Lab VacSal,Inst Biotecnol & Biol Mol, La Plata, Argentina. [Bouchez, Valerie; Guiso, Nicole] Inst Pasteur, Paris, France. [Bouchez, Valerie; Guiso, Nicole] CNRS, URA 30 12, Paris, France. [Tondella, M. Lucia] Ctr Dis Control & Prevent CDC, Natl Ctr Immunizat & Resp Dis NCIRD, Atlanta, GA USA. [Chiang, Chuen-Sheue; Yao, Shu-Man] Ctr Dis Control, Taipei, Taiwan. [Dalby, Tine] Statens Serum Inst, DK-2300 Copenhagen, Denmark. [Cassiday, Pamela K.; Fry, Norman K.] Publ Hlth England Resp & Vaccine Preventable Bact, Colindale, England. [Harvill, Eric T.] Penn State Univ, Dept Vet & Biomed Sci, University Pk, PA 16802 USA. [He, Qiushui] Natl Inst Hlth & Welf, Dept Infect Dis Surveillance & Control, Helsinki, Finland. [Karataev, Gennady I.] Minist Hlth Russian Federat, Gamaleya Res Inst Epidemiol & Microbiol, Moscow, Russia. [Lan, Ruiting; Maharjan, Ram P.; Octavia, Sophie] Univ New S Wales, Sch Biotechnol & Biomol Sci, Sydney, NSW, Australia. [Lutynska, Anna] Natl Inst Hyg, Natl Inst Publ Hlth, PL-00791 Warsaw, Poland. [Mertsola, Jussi] Turku Univ Hosp, Dept Pediat, FIN-20520 Turku, Finland. [Preston, Andrew] Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England. [Sintchenko, Vitali] Westmead Hosp, Ctr Infect Dis & Microbiol Publ Hlth, Inst Clin Pathol & Med Res, Westmead, NSW 2145, Australia. [Sintchenko, Vitali] Univ Sydney, Sydney Emerging Infect Dis & Biosecur Inst, Sydney, NSW 2006, Australia. [Stefanelli, Paola] Ist Super Sanita, Dept Infect Parasit & Immune Mediated Dis, I-00161 Rome, Italy. [Tsang, Raymond S. W.] Publ Hlth Agcy Canada, Natl Microbiol Lab, Lab Syphilis Diagnost & Vaccine Preventable Bacte, Winnipeg, MB, Canada. [Xu, Yinghua; Zhang, Shumin] Natl Inst Food & Drug Control, Beijing, Peoples R China. RP Parkhill, J (reprint author), Wellcome Trust Genome Campus, Wellcome Trust Sanger Inst, Cambridge, England. EM parkhill@sanger.ac.uk RI Harris, Simon/K-1318-2013; Parkhill, Julian/G-4703-2011; Mooi, prof.F.R./L-4528-2015; Arakawa, Yoshichika/P-5997-2015; OI Harris, Simon/0000-0003-1512-6194; Parkhill, Julian/0000-0002-7069-5958; Bouchez, Valerie/0000-0002-5947-6383 FU Wellcome Trust [098051]; RIVM (SOR project) [S/230446/01/BV]; National Health and Medical Research Council of Australia FX This work was supported by the Wellcome Trust (grant number 098051), the RIVM (SOR project S/230446/01/BV), and the National Health and Medical Research Council of Australia. NR 81 TC 27 Z9 27 U1 1 U2 27 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 2150-7511 J9 MBIO JI mBio PD MAR-APR PY 2014 VL 5 IS 2 AR e01074-14 DI 10.1128/mBio.01074-14 PG 13 WC Microbiology SC Microbiology GA AH1XR UT WOS:000335915600006 PM 24757216 ER PT J AU Billeter, SA Borchert, JN Atiku, LA Mpanga, JT Gage, KL Kosoy, MY AF Billeter, Sarah A. Borchert, Jeff N. Atiku, Linda A. Mpanga, Joseph T. Gage, Kenneth L. Kosoy, Michael Y. TI Bartonella Species in Invasive Rats and Indigenous Rodents from Uganda SO VECTOR-BORNE AND ZOONOTIC DISEASES LA English DT Article DE Arvicanthis niloticus; Rattus rattus; Fleas; Bartonella; Uganda; Cricetomys gambianus ID PLAGUE-ENDEMIC REGION; INTRAVENOUS-DRUG-USERS; SMALL MAMMALS; FLEAS SIPHONAPTERA; GENETIC DIVERSITY; COMMENSAL RATS; LOS-ANGELES; PREVALENCE; IDENTIFICATION; TRANSMISSION AB The presence of bartonellae in invasive rats (Rattus rattus) and indigenous rodents (Arvicanthis niloticus and Cricetomys gambianus) from two districts in Uganda, Arua and Zombo, was examined by PCR detection and culture. Blood from a total of 228 R. rattus, 31 A. niloticus, and 5 C. gambianus was screened using genus-specific primers targeting the 16S-23S intergenic spacer region. Furthermore, rodent blood was plated on brain heart infusion blood agar, and isolates were verified as Bartonella species using citrate synthase gene- (gltA) specific primers. One hundred and four fleas recovered from R. rattus were also tested for the presence of Bartonella species using the same gltA primer set. An overall prevalence of 1.3% (three of 228) was obtained in R. rattus, whereas 61.3% of 31 A. niloticus and 60% of five C. gambianus were positive for the presence of Bartonella species. Genotypes related to Bartonella elizabethae, a known zoonotic pathogen, were detected in three R. rattus and one C. gambianus. Bartonella strains, similar to bacteria detected in indigenous rodents from other African countries, were isolated from the blood of A. niloticus. Bartonellae, similar to bacteria initially cultured from Ornithodorus sonrai (soft tick) from Senegal, were found in two C. gambianus. Interestingly, bartonellae detected in fleas from invasive rats were similar to bacteria identified in indigenous rodents and not their rat hosts, with an overall prevalence of 6.7%. These results suggest that if fleas are competent vectors of these bartonellae, humans residing in these two districts of Uganda are potentially at greater risk for exposure to Bartonella species from native rodents than from invasive rats. The low prevalence of bartonellae in R. rattus was quite surprising, in contrast, to the detection of these organisms in a large percentage of Rattus species from other geographical areas. A possible reason for this disparity is discussed. C1 [Billeter, Sarah A.; Borchert, Jeff N.; Gage, Kenneth L.; Kosoy, Michael Y.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO 80521 USA. [Borchert, Jeff N.; Atiku, Linda A.; Mpanga, Joseph T.] Uganda Virus Res Inst, Entebbe, Uganda. RP Kosoy, MY (reprint author), Ctr Dis Control & Prevent, Div Vector Borne Dis, 3156 Rampart Rd, Ft Collins, CO 80521 USA. EM mck3@cdc.gov NR 45 TC 3 Z9 3 U1 1 U2 12 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1530-3667 EI 1557-7759 J9 VECTOR-BORNE ZOONOT JI Vector-Borne Zoonotic Dis. PD MAR 1 PY 2014 VL 14 IS 3 BP 182 EP 188 DI 10.1089/vbz.2013.1375 PG 7 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA AC6DX UT WOS:000332612800002 PM 24575846 ER PT J AU O'Leary, ST Allison, MA Lindley, MC Crane, LA Hurley, LP Brtnikova, M Beaty, BL Babbel, CI Jimenez-Zambrano, A Berman, S Kempe, A AF O'Leary, Sean T. Allison, Mandy A. Lindley, Megan C. Crane, Lori A. Hurley, Laura P. Brtnikova, Michaela Beaty, Brenda L. Babbel, Christine I. Jimenez-Zambrano, Andrea Berman, Stephen Kempe, Allison TI Vaccine Financing From the Perspective of Primary Care Physicians SO PEDIATRICS LA English DT Article DE vaccines; immunizations; primary care; adolescents; children ID REIMBURSEMENT; ADOLESCENTS AB OBJECTIVES: Because of high purchase costs of newer vaccines, financial risk to private vaccination providers has increased. We assessed among pediatricians and family physicians satisfaction with insurance payment for vaccine purchase and administration by payer type, the proportion who have considered discontinuing provision of all childhood vaccines for financial reasons, and strategies used for handling uncertainty about insurance coverage when new vaccines first become available. METHODS: A national survey among private pediatricians and family physicians April to September 2011. RESULTS: Response rates were 69% (190/277) for pediatricians and 70% (181/260) for family physicians. Level of dissatisfaction varied significantly by payer type for payment for vaccine administration (Medicaid, 63%; Children's Health Insurance Program, 56%; managed care organizations, 48%; preferred provider organizations, 38%; fee for service, 37%; P < .001), but not for payment for vaccine purchase (health maintenance organization or managed care organization, 52%; Child Health Insurance Program, 47%; preferred provider organization, 45%; fee for service, 41%; P = .11). Ten percent of physicians had seriously considered discontinuing providing all childhood vaccines to privately insured patients because of cost issues. The most commonly used strategy for handling uncertainty about insurance coverage for new vaccines was to inform parents that they may be billed for the vaccine; 67% of physicians reported using 3 or more strategies to handle this uncertainty. CONCLUSIONS: Many primary care physicians are dissatisfied with payment for vaccine purchase and administration from third-party payers, particularly public insurance for vaccine administration. Physicians report a variety of strategies for dealing with the uncertainty of insurance coverage for new vaccines. C1 [O'Leary, Sean T.; Allison, Mandy A.; Crane, Lori A.; Hurley, Laura P.; Brtnikova, Michaela; Beaty, Brenda L.; Babbel, Christine I.; Jimenez-Zambrano, Andrea; Kempe, Allison] Childrens Hosp Colorado, Aurora, CO USA. [O'Leary, Sean T.; Allison, Mandy A.; Berman, Stephen; Kempe, Allison] Univ Colorado, Dept Pediat, Aurora, CO 80045 USA. [Hurley, Laura P.; Beaty, Brenda L.; Kempe, Allison] Univ Colorado, Colorado Hlth Outcomes Program, Aurora, CO 80045 USA. [Lindley, Megan C.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Crane, Lori A.] Colorado Sch Publ Hlth, Dept Community & Behav Hlth, Denver, CO USA. [Hurley, Laura P.] Denver Hlth & Hosp Author, Div Gen Internal Med, Denver, CO USA. RP O'Leary, ST (reprint author), Univ Colorado, Dept Pediat, Mail Stop F443,13199 East Montview Blvd,Suite 300, Aurora, CO 80045 USA. EM sean.o'leary@childrenscolorado.org FU Centers for Disease Control and Prevention and administered through the Rocky Mountain Prevention Research Center, University of Colorado Anschutz [5U48DP001938] FX This investigation was funded by the Centers for Disease Control and Prevention and administered through the Rocky Mountain Prevention Research Center, University of Colorado Anschutz Medical Campus (grant 5U48DP001938). NR 20 TC 9 Z9 9 U1 1 U2 7 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD MAR PY 2014 VL 133 IS 3 BP 367 EP 374 DI 10.1542/peds.2013-2637 PG 8 WC Pediatrics SC Pediatrics GA AG3PB UT WOS:000335330700003 PM 24567011 ER PT J AU Branum, AM Rossen, LM Schoendorf, KC AF Branum, Amy M. Rossen, Lauren M. Schoendorf, Kenneth C. TI Trends in Caffeine Intake Among US Children and Adolescents SO PEDIATRICS LA English DT Article DE diet; survey; children; adolescents; trends ID ENERGY DRINKS; UNITED-STATES; ADULTS; HEALTH AB BACKGROUND AND OBJECTIVE: Physicians and policy makers are increasingly interested in caffeine intake among children and adolescents in the advent of increasing energy drink sales. However, there have been no recent descriptions of caffeine or energy drink intake in the United States. We aimed to describe trends in caffeine intake over the past decade among US children and adolescents. METHODS: We assessed trends and demographic differences in mean caffeine intake among children and adolescents by using the 24-hour dietary recall data from the 1999-2010 NHANES. In addition, we described the proportion of caffeine consumption attributable to different beverages, including soda, energy drinks, and tea. RESULTS: Approximately 73% of children consumed caffeine on a given day. From 1999 to 2010, there were no significant trends in mean caffeine intake overall; however, caffeine intake decreased among 2- to 11-year-olds (P < .01) and Mexican-American children (P = .003). Soda accounted for the majority of caffeine intake, but this contribution declined from 62% to 38% (P < .001). Coffee accounted for 10% of caffeine intake in 1999-2000 but increased to nearly 24% of intake in 2009-2010 (P < .001). Energy drinks did not exist in 1999-2000 but increased to nearly 6% of caffeine intake in 2009-2010. CONCLUSIONS: Mean caffeine intake has not increased among children and adolescents in recent years. However, coffee and energy drinks represent a greater proportion of caffeine intake as soda intake has declined. These findings provide a baseline for caffeine intake among US children and young adults during a period of increasing energy drink use. C1 [Branum, Amy M.] Natl Ctr Hlth Stat, Ctr Dis Control & Prevent, Reprod Stat Branch, Div Vital Stat, Hyattsville, MD 20782 USA. [Rossen, Lauren M.; Schoendorf, Kenneth C.] Natl Ctr Hlth Stat, Ctr Dis Control & Prevent, Infant Child & Womens Hlth Stat Branch, Off Anal & Epidemiol, Hyattsville, MD 20782 USA. RP Branum, AM (reprint author), Natl Ctr Hlth Stat, 3311 Toledo Rd,Room 7418, Hyattsville, MD 20782 USA. EM ambranum@cdc.gov FU Intramural CDC HHS [CC999999] NR 18 TC 21 Z9 21 U1 3 U2 24 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD MAR PY 2014 VL 133 IS 3 BP 386 EP 393 DI 10.1542/peds.2013-2877 PG 8 WC Pediatrics SC Pediatrics GA AG3PB UT WOS:000335330700005 PM 24515508 ER PT J AU Frattarelli, DAC Galinkin, JL Green, TP Johnson, TD Neville, KA Paul, IM Van den Anker, JN Knight, M Alexander, JJ Kilpatrick, SJ Cragan, JD Rieder, MJ Robb, AS Sachs, H Zajicek, A Haro, T Koteras, RK Del Monte, M AF Frattarelli, Daniel A. C. Galinkin, Jeffrey L. Green, Thomas P. Johnson, Timothy D. Neville, Kathleen A. Paul, Ian M. Van den Anker, John N. Knight, Matthew Alexander, John J. Kilpatrick, Sarah J. Cragan, Janet D. Rieder, Michael J. Robb, Adelaide S. Sachs, Hari Zajicek, Anne Haro, Tamar Koteras, Raymond K. Del Monte, Mark CA COMM DRUGS TI Off-Label Use of Drugs in Children SO PEDIATRICS LA English DT Article DE off-label drug use; pharmaceuticals; pediatrics; infants; children; adolescents; prescribing AB The passage of the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act has collectively resulted in an improvement in rational prescribing for children, including more than 500 labeling changes. However, off-label drug use remains an important public health issue for infants, children, and adolescents, because an overwhelming number of drugs still have no information in the labeling for use in pediatrics. The purpose of off-label use is to benefit the individual patient. Practitioners use their professional judgment to determine these uses. As such, the term off-label does not imply an improper, illegal, contraindicated, or investigational use. Therapeutic decision-making must always rely on the best available evidence and the importance of the benefit for the individual patient. C1 [Alexander, John J.; Sachs, Hari] US FDA, Rockville, MD 20857 USA. [Kilpatrick, Sarah J.] Amer Coll Obstetricians & Gynecologists, Washington, DC USA. [Cragan, Janet D.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Rieder, Michael J.] Canadian Pediat Soc, Ottawa, ON, Canada. [Robb, Adelaide S.] Amer Acad Child & Adolescent Psychiat, Washington, DC USA. [Zajicek, Anne] NIH, Bethesda, MD USA. OI Paul, Ian/0000-0002-6344-8609 NR 7 TC 48 Z9 52 U1 0 U2 7 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD MAR PY 2014 VL 133 IS 3 BP 563 EP 567 DI 10.1542/peds.2013-4060 PG 5 WC Pediatrics SC Pediatrics GA AG3PB UT WOS:000335330700036 PM 24567009 ER PT J AU Blase, JL Cracco, L Schonberger, LB Maddox, RA Cohen, Y Cali, I Belay, ED AF Blase, Jennifer L. Cracco, Laura Schonberger, Lawrence B. Maddox, Ryan A. Cohen, Yvonne Cali, Ignazio Belay, Ermias D. TI Sporadic Fatal Insomnia in an Adolescent SO PEDIATRICS LA English DT Article DE adolescent; Creutzfeldt-Jakob disease; prion disease; sporadic fatal insomnia; transmissible spongiform encephalopathy ID CREUTZFELDT-JAKOB-DISEASE; HUMAN GROWTH-HORMONE; FAMILIAL INSOMNIA; CLASSIFICATION; DIAGNOSIS AB The occurrence of sporadic prion disease among adolescents is extremely rare. A prion disease was confirmed in an adolescent with disease onset at 13 years of age. Genetic, neuropathologic, and biochemical analyses of the patient's autopsy brain tissue were consistent with sporadic fatal insomnia, a type of sporadic prion disease. There was no evidence of an environmental source of infection, and this patient represents the youngest documented case of sporadic prion disease. Although rare, a prion disease diagnosis should not be discounted in adolescents exhibiting neurologic signs. Brain tissue testing is necessary for disease confirmation and is particularly beneficial in cases with an unusual clinical presentation. C1 [Blase, Jennifer L.; Schonberger, Lawrence B.; Maddox, Ryan A.; Belay, Ermias D.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Div High Consequence Pathogens & Pathol, Atlanta, GA 30333 USA. [Cracco, Laura; Cohen, Yvonne; Cali, Ignazio] Case Western Reserve Univ, Natl Prion Dis Pathol Surveillance Ctr, Cleveland, OH 44106 USA. RP Belay, ED (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,Mailstop A-30, Atlanta, GA 30333 USA. EM ebb8@cdc.gov FU Centers for Disease Control and Prevention [UR8/CCU515004]; Charles S. Britton Fund; National Institutes of Health [P01 AG-14359]; National Institutes of Health (NIH) FX The laboratory portion of this study was supported by the Centers for Disease Control and Prevention (UR8/CCU515004), the Charles S. Britton Fund, and the National Institutes of Health (P01 AG-14359). Funded by the National Institutes of Health (NIH). NR 26 TC 1 Z9 1 U1 0 U2 4 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD MAR PY 2014 VL 133 IS 3 BP E766 EP E770 DI 10.1542/peds.2013-1396 PG 5 WC Pediatrics SC Pediatrics GA AG3PB UT WOS:000335330700063 PM 24488737 ER PT J AU Pang, J Teeter, LD Katz, DJ Davidow, AL Miranda, W Wall, K Ghosh, S Stein-Hart, T Restrepo, BI Reves, R Graviss, EA AF Pang, Jenny Teeter, Larry D. Katz, Dolly J. Davidow, Amy L. Miranda, Wilson Wall, Kirsten Ghosh, Smita Stein-Hart, Trudy Restrepo, Blanca I. Reves, Randall Graviss, Edward A. CA TB Epidemiologic Studies Consortiu TI Epidemiology of Tuberculosis in Young Children in the United States SO PEDIATRICS LA English DT Article DE tuberculosis; epidemiology; young children; foreign birth ID RISK ASSESSMENT QUESTIONNAIRE; MYCOBACTERIUM-BOVIS; MEXICO BORDER; CALIFORNIA; SYMPTOMS AB OBJECTIVES:To estimate tuberculosis (TB) rates among young children in the United States by children's and parents' birth origins and describe the epidemiology of TB among young children who are foreign-born or have at least 1 foreign-born parent.METHODS:Study subjects were children <5 years old diagnosed with TB in 20 US jurisdictions during 2005-2006. TB rates were calculated from jurisdictions' TB case counts and American Community Survey population estimates. An observational study collected demographics, immigration and travel histories, and clinical and source case details from parental interviews and health department and TB surveillance records.RESULTS:Compared with TB rates among US-born children with US-born parents, rates were 32 times higher in foreign-born children and 6 times higher in US-born children with foreign-born parents. Most TB cases (53%) were among the 29% of children who were US born with foreign-born parents. In the observational study, US-born children with foreign-born parents were more likely than foreign-born children to be infants (30% vs 7%), Hispanic (73% vs 37%), diagnosed through contact tracing (40% vs 7%), and have an identified source case (61% vs 19%); two-thirds of children were exposed in the United States.CONCLUSIONS:Young children who are US born of foreign-born parents have relatively high rates of TB and account for most cases in this age group. Prompt diagnosis and treatment of adult source cases, effective contact investigations prioritizing young contacts, and targeted testing and treatment of latent TB infection are necessary to reduce TB morbidity in this population. C1 [Pang, Jenny] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Teeter, Larry D.; Graviss, Edward A.] Houston Methodist Res Inst, Ctr Mol & Translat Human Infect Dis Res, Dept Pathol & Genom Med, Houston, TX 77030 USA. [Katz, Dolly J.; Ghosh, Smita] Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA USA. [Davidow, Amy L.] Rutgers State Univ, New Jersey Med Sch, Global TB Inst, Newark, NJ 07102 USA. [Davidow, Amy L.] Rutgers State Univ, Dept Prevent Med & Community Hlth, Newark, NJ 07102 USA. [Miranda, Wilson] New York State Dept Hlth, Albany, NY USA. [Wall, Kirsten; Reves, Randall] Denver Publ Hlth Dept, Denver Metro TB Control Program, Denver, CO USA. [Stein-Hart, Trudy] Tennessee Dept Hlth, TB Eliminat Program, Nashville, TN USA. [Restrepo, Blanca I.] Univ Texas Hlth Sci Ctr Houston, Sch Publ Hlth Brownsville, Houston, TX 77030 USA. RP Teeter, LD (reprint author), Houston Methodist Res Inst, 6565 Fannin St,Mail Stn MGJ3 010, Houston, TX 77030 USA. EM ldteeter@houstonmethodist.org FU Centers for Disease Control and Prevention FX Funded by the Centers for Disease Control and Prevention. NR 35 TC 8 Z9 8 U1 0 U2 6 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD MAR PY 2014 VL 133 IS 3 BP E494 EP E504 DI 10.1542/peds.2013-2570 PG 11 WC Pediatrics SC Pediatrics GA AG3PB UT WOS:000335330700020 PM 24515517 ER PT J AU DeBastiani, SD Carroll, DD Cunningham, M Lee, S Fulton, J AF DeBastiani, Summer Dawn Carroll, Dianna D. Cunningham, Melissa Lee, Sarah Fulton, Janet TI Awareness and Knowledge of the Youth 2008 Physical Activity Guidelines for Americans SO JOURNAL OF PHYSICAL ACTIVITY & HEALTH LA English DT Article DE exercise; health; recommendations ID RANDOMIZED CONTROLLED-TRIAL; CARDIOVASCULAR HEALTH; PLANNED BEHAVIOR; REASONED ACTION; SOCIAL SUPPORT; CHILDREN; PREVENTION; IMPACT; RISK; DIET AB Background: To measure parental awareness of government physical activity guidelines and knowledge of the amount of physical activity recommended for youth (ie, 60 minutes per day, 7 days per week) as specified in the 2008 Physical Activity Guidelines for Americans. Methods: A cross-sectional national sample of adults responded to physical activity guideline questions added to the HealthStyles survey in 2009 (n = 1552). The prevalence of parents aware of government physical activity guidelines and knowledgeable of the youth physical activity guideline, specifically, was estimated overall and by parental demographic characteristics (sex, education, income level, race/ethnicity, age group, marital status) and body mass index. Results: In 2009, 34.8% of parents reported being aware of physical activity guidelines, and 9.7% were knowledgeable of the amount of physical activity recommended for youth. Conclusions: Many parents lack awareness and knowledge of the youth physical activity guidelines. The low prevalence estimates suggest the 2008 Physical Activity Guidelines for Americans has not been effectively disseminated. These results may also indicate a need for effective communication strategies to educate and inform parents, an important influencer of children's health behaviors. C1 [Carroll, Dianna D.; Lee, Sarah] Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Fulton, Janet] Ctr Dis Control & Prevent, Div Nutr & Phys Act, Atlanta, GA USA. NR 39 TC 4 Z9 4 U1 5 U2 8 PU HUMAN KINETICS PUBL INC PI CHAMPAIGN PA 1607 N MARKET ST, PO BOX 5076, CHAMPAIGN, IL 61820-2200 USA SN 1543-3080 EI 1543-5474 J9 J PHYS ACT HEALTH JI J. Phys. Act. Health PD MAR PY 2014 VL 11 IS 3 BP 495 EP 501 DI 10.1123/jpah.2012-0207 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AF8RQ UT WOS:000334983700007 PM 23493091 ER PT J AU Singleton, RJ Holman, RC Person, MK Steiner, CA Redd, JT Hennessy, TW Groom, A Holve, S Seward, JF AF Singleton, Rosalyn J. Holman, Robert C. Person, Marissa K. Steiner, Claudia A. Redd, John T. Hennessy, Thomas W. Groom, Amy Holve, Stephen Seward, Jane F. TI Impact of Varicella Vaccination on Varicella-related Hospitalizations Among American Indian/ Alaska Native People SO PEDIATRIC INFECTIOUS DISEASE JOURNAL LA English DT Article DE American Indian; Alaska Native; varicella; children; hospitalization ID UNITED-STATES; CHILDREN; INFANTS; US; IMPLEMENTATION; POPULATION; PROGRAM; DECLINE; EPIDEMIOLOGY; INFECTION AB Background: Routine childhood varicella vaccination, implemented in 1995, has resulted in significant declines in varicella-related hospitalizations in the United States. Varicella hospitalization rates among the American Indian (AI) and Alaska Native (AN) population have not been previously documented. Methods: We selected varicella-related hospitalizations, based on a published definition, from the Indian Health Service inpatient database for AI/ANs in the Alaska, Southwest and Northern Plains regions (1995-2010) and from the Nationwide Inpatient Sample for the general US population (2007-2010). We analyzed average annual hospitalization rates prevaccine (1995-1998) and postvaccine (2007-2010) for the AI/AN population, and postvaccine for the general US population. Results: From 1995-1998 to 2007-2010, the average annual varicella-related hospitalization rate for AI/ANs in the 3 regions decreased 95% (0.66-0.03/10,000 persons); the postvaccine rate appears lower than the general US rate (0.06, 95% confidence interval: 0.05-0.06). The rate declined in all AI/AN pediatric age groups. Infants experienced the highest prevaccine (14.07) and postvaccine (0.83) hospitalization rates. Adults experienced low rates in both periods. Varicella vaccination rates in 19- to 35-month-old AI/AN children during fiscal years 2008-2010 were 88.1-91.0%. Conclusions: Widespread use of varicella vaccine in AI/AN children was accompanied by substantial declines in varicella-related hospitalizations consistent with high varicella vaccine effectiveness in preventing severe varicella outcomes. C1 [Singleton, Rosalyn J.] Alaska Native Tribal Hlth Consortium, Anchorage, AK USA. [Holman, Robert C.; Person, Marissa K.] Ctr Dis Control & Prevent CDC, Div High Consequence Pathogens & Pathol, NCEZID, USDHHS, Atlanta, GA USA. [Steiner, Claudia A.] USDHHS, Healthcare Cost & Utilizat Project, Ctr Delivery Org & Markets, Agcy Healthcare Res & Qual, Rockville, MD USA. [Redd, John T.] USDHHS, IHS, Santa Fe, NM USA. [Hennessy, Thomas W.] USDHHS, Arctic Invest Program, NCEZID, CDC, Anchorage, AK USA. [Groom, Amy] USA USDHHS, Immunizat Serv Div, CDC, Atlanta, GA USA. [Holve, Stephen] USDHHS, Tuba City Reg Hlth Care, IHS, Tuba City, AZ USA. [Seward, Jane F.] CDC, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Singleton, RJ (reprint author), AIP CDC, 4055 Tudor Ctr Dr, Anchorage, AK 99508 USA. EM ris2@cdc.gov NR 31 TC 3 Z9 4 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0891-3668 EI 1532-0987 J9 PEDIATR INFECT DIS J JI Pediatr. Infect. Dis. J. PD MAR PY 2014 VL 33 IS 3 BP 276 EP 279 DI 10.1097/INF.0000000000000100 PG 4 WC Immunology; Infectious Diseases; Pediatrics SC Immunology; Infectious Diseases; Pediatrics GA AB3OB UT WOS:000331699000016 PM 24136373 ER PT J AU Chang, WC Yen, C Wu, FT Huang, YC Lin, JS Huang, FC Yu, HT Chi, CL Lin, HY Tate, JE Parashar, UD Wu, HS Hsiung, CA AF Chang, Wan-Chi Yen, Catherine Wu, Fang-Tzy Huang, Yhu-Chering Lin, Jen-Shiou Huang, Fu-Chen Yu, Hui-Tzu Chi, Cheng-Liang Lin, Han-Ying Tate, Jacqueline E. Parashar, Umesh D. Wu, Ho-Sheng Hsiung, Chao A. TI Effectiveness of 2 Rotavirus Vaccines Against Rotavirus Disease in Taiwanese Infants SO PEDIATRIC INFECTIOUS DISEASE JOURNAL LA English DT Article DE gastroenteritis; rotavirus; rotavirus vaccine; vaccine effectiveness ID MOLECULAR EPIDEMIOLOGY; GASTROENTERITIS; EFFICACY; DIARRHEA; CHILDREN; VACCINATION; SAFETY; SURVEILLANCE; MORTALITY; SPAIN AB Background: Two rotavirus (RV) vaccines (Rotarix and RotaTeq) are available on the private market in Taiwan, but are not recommended for routine use. We examined RV vaccine effectiveness (VE) against severe RV acute gastroenteritis (AGE) among Taiwanese infants to inform policymakers on the potential benefits of national RV vaccine introduction. Methods: From May 2009 to April 2011, a case-control assessment of VE against severe RV AGE was conducted at 3 hospital-based surveillance sites in Taiwan. Case-patients included children aged 8-35 months, hospitalized with laboratory-confirmed RV AGE. Controls included children age-matched within 1 month of age of the case-patient, hospitalized with RV-negative AGE or seen for non-AGE illnesses at the same hospitals. Vaccination history was confirmed through vaccination card or hospital record review. VE was calculated as (1 - odds ratio of vaccination)x100%. Results: We enrolled 184 case-patients with RV AGE, 904 RV-negative AGE and 909 non-AGE controls. Two-dose Rotarix series VE against RV gastroenteritis hospitalization was 90.4% [95% confidence interval (CI): 70.3%, 98.1%) and 92.5% (95% CI: 77.1%, 98.5%) with RV-negative AGE and non-AGE controls, respectively. Three-dose RotaTeq series VE was 96.8% (95% CI: 82.3%, 100%) and 97.1% (95% CI: 84%, 100%) with RV-negative AGE and non-AGE controls, respectively. Conclusions: Both vaccines provided excellent protection against severe RV AGE hospitalization. Addition of RV vaccination into Taiwan's National Immunization Program could substantially decrease AGE hospitalizations among children <3 years. Our findings should help inform policymakers in Taiwan and other similar Asian countries when deciding whether to include RV vaccination into their national immunization programs. C1 [Chang, Wan-Chi; Yu, Hui-Tzu; Chi, Cheng-Liang; Lin, Han-Ying; Hsiung, Chao A.] Natl Hlth Res Inst, Inst Populat Hlth Sci, Div Biostat & Bioinformat, Zhunan, Taiwan. [Yen, Catherine; Tate, Jacqueline E.; Parashar, Umesh D.] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA USA. [Wu, Fang-Tzy; Wu, Ho-Sheng] Ctr Dis Control, Dept Hlth, Res & Diagnost Ctr, Taipei, Taiwan. [Huang, Yhu-Chering] Chang Gung Mem Hosp Linkou, Div Pediat Infect Dis, Taoyuan, Taiwan. [Huang, Yhu-Chering] Chang Gung Univ, Coll Med, Taoyuan, Taiwan. [Lin, Jen-Shiou] Changhua Christian Hosp, Dept Lab Med, Changhua, Taiwan. [Huang, Fu-Chen] Kaohsiung Chang Gung Mem Hosp, Dept Pediat, Kaohsiung, Taiwan. [Huang, Fu-Chen] Chang Gung Univ, Coll Med, Kaohsiung, Taiwan. [Wu, Ho-Sheng] Taipei Med Univ, Sch Med Lab Sci & Biotechnol, Taipei, Taiwan. RP Hsiung, CA (reprint author), Natl Hlth Res Inst, Inst Populat Hlth Sci, Div Biostat & Bioinformat, 35 Keyan Rd, Zhunan Town 35053, Miaoli County, Taiwan. EM hsiung@nhri.org.tw RI Hsiung, Chao Agnes/E-3994-2010 FU Centers for Disease Control, Department of Health, Execute Yuan, Taiwan [DOH98-DC-1005] FX This study was financially supported by the following research grant: "Technology Project for Surveillance and Prevalence of Gastroenteritis in Taiwan" from Centers for Disease Control, Department of Health, Execute Yuan, Taiwan (supported grant: DOH98-DC-1005). The authors have no other funding or conflicts of interest to disclose. NR 21 TC 15 Z9 17 U1 0 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0891-3668 EI 1532-0987 J9 PEDIATR INFECT DIS J JI Pediatr. Infect. Dis. J. PD MAR PY 2014 VL 33 IS 3 BP E81 EP E86 DI 10.1097/INF.0000000000000105 PG 6 WC Immunology; Infectious Diseases; Pediatrics SC Immunology; Infectious Diseases; Pediatrics GA AB3OB UT WOS:000331699000004 PM 24569388 ER PT J AU Fradkin, C Wallander, JL Yamakawa, Y Schwebel, DC Chien, A Le, YCL Li, DH Elliott, M Schuster, M AF Fradkin, Chris Wallander, Jan L. Yamakawa, Yoshimi Schwebel, David C. Chien, Alyna Le, Yen-Chi L. Li, Dennis H. Elliott, Marc Schuster, Mark TI Quality of Life Among Asian American Youth SO ASIAN AMERICAN JOURNAL OF PSYCHOLOGY LA English DT Article DE Asian American; youth; disparities; quality of life; socioeconomic status ID GENERIC CORE SCALES; SOCIOECONOMIC-STATUS; SELF-REPORT; ADOLESCENT HEALTH; CHILDRENS HEALTH; AFRICAN-AMERICAN; MODEL MINORITY; SOCIAL ANXIETY; MENTAL-HEALTH; US CHILDREN AB The aims of the present study were to examine whether Asian American youth experience disparities in quality of life (QL) compared with Hispanic, African American, and white youth in the general population and to what extent socioeconomic status (SES) mediates any disparities among these racial/ethnic groups. Data were obtained from the Healthy Passages study, in which 4,972 Asian American (148; 3%), Hispanic (1,813; 36%), African American (1,755; 35%), and white (1,256; 25%) fifth-graders were enrolled in a population-based, cross-sectional survey conducted in three U.S. metropolitan areas. Youth reported their own QL using the PedsQL and supplemental scales. Parents reported youth's overall health status as well as parent's education and household income level. Asian American youth experienced worse status than white youth for three of 10 QL and well-being measures, better status than Hispanic youth on six measures, and better status than African American youth on three measures. However, the observed advantages for Asian American youth over Hispanic and African American youth disappeared when the marked SES differences that are also present among these racial/ethnic groups were taken into account. In contrast, the differences between Asian American and white youth remained after adjusting for SES. These findings suggest that the disparities in QL that favor white youth over Asian American youth exist independent of SES and warrant further examination. In contrast, the QL differences that favor Asian American over Hispanic and African American youth may be partly explained by SES. Interpretations are limited by the heterogeneity existing among Asian Americans. C1 [Fradkin, Chris; Wallander, Jan L.] Univ Calif, Ctr Excellence Hlth Dispar, Merced, CA USA. [Fradkin, Chris; Wallander, Jan L.] Univ Calif, Hlth Sci Res Inst, Merced, CA USA. [Yamakawa, Yoshimi] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Schwebel, David C.] Univ Alabama Birmingham, Dept Psychol, Birmingham, AL USA. [Chien, Alyna] Childrens Hosp Boston, Div Gen Pediat, Boston, MA USA. [Chien, Alyna] Harvard Univ, Sch Med, Dept Pediat, Cambridge, MA 02138 USA. [Le, Yen-Chi L.; Li, Dennis H.] Univ Texas Sch Publ Hlth, Houston, TX USA. [Elliott, Marc; Schuster, Mark] RAND Corp, Santa Monica, CA USA. [Schuster, Mark] Harvard Univ, Childrens Hosp Boston, Dept Pediat, Div Gen Pediat,Med Sch, Cambridge, MA 02138 USA. RP Wallander, JL (reprint author), UC Merced, 5200 North Lake Rd, Merced, CA 95343 USA. EM jwallander@ucmerced.edu OI Fradkin, Chris/0000-0002-8195-269X FU Intramural CDC HHS [CC999999]; NCCDPHP CDC HHS [U19 DP002663, U19 DP002664, U19 DP002665]; NCI NIH HHS [R25 CA057712]; NIDDK NIH HHS [P30 DK092949] NR 53 TC 4 Z9 4 U1 1 U2 5 PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 1948-1985 EI 1948-1993 J9 ASIAN AM J PSYCHOL JI Asian Am. J. Psychol. PD MAR PY 2014 VL 5 IS 1 SI SI BP 13 EP 21 DI 10.1037/a0029822 PG 9 WC Ethnic Studies; Psychology, Multidisciplinary SC Ethnic Studies; Psychology GA AF4OI UT WOS:000334692500003 PM 27087894 ER PT J AU Rubin, SE Schulman, RM Roszak, AR Herrmann, J Patel, A Koonin, LM AF Rubin, Sara E. Schulman, Rachel M. Roszak, Andrew R. Herrmann, Jack Patel, Anita Koonin, Lisa M. TI Leveraging Partnerships Among Community Pharmacists, Pharmacies, and Health Departments to Improve Pandemic Influenza Response SO BIOSECURITY AND BIOTERRORISM-BIODEFENSE STRATEGY PRACTICE AND SCIENCE LA English DT Article ID PUBLIC-HEALTH; EMERGENCY RESPONSE; UNITED-STATES; PREPAREDNESS; WILLINGNESS; WORKFORCE; CALL AB Response to public health emergencies requires coordination across multiple sectors and effective use of existing resources in communities. With the expanded role of community pharmacists in public health during the past decade, their participation in response to emergencies has become increasingly important. Local health departments play a lead role in local public health emergency responses, and their ability to develop and leverage partnerships has become increasingly vital given their funding and personnel shortages. This article offers insight and recommendations on how local health departments can most effectively develop and maintain relationships with community pharmacies and pharmacists that will allow for a more coordinated and resourceful public health response to emergencies, and specifically to pandemic influenza outbreaks. Additionally, state and local health departments should reach out to pharmacies in a synchronized way to incorporate them into their pandemic influenza planning and response efforts. As pharmacists continue to expand their role as part of the public health system, pharmacy staff can be active participants with public health agencies to improve community public health emergency response. C1 [Rubin, Sara E.; Schulman, Rachel M.; Roszak, Andrew R.] Natl Assoc Cty & City Hlth Officials, Washington, DC 20036 USA. [Herrmann, Jack] Natl Assoc Cty & City Hlth Officials, Publ Hlth Programs, Washington, DC 20036 USA. [Patel, Anita] Ctr Dis Control & Prevent, Div Strateg Natl Stockpile, Off Publ Hlth Preparedness & Response, Atlanta, GA USA. [Koonin, Lisa M.] Ctr Dis Control & Prevent, Influenza Coordinat Unit, Off Infect Dis, Atlanta, GA USA. RP Rubin, SE (reprint author), Natl Assoc Cty & City Hlth Officials, 1100 17th St NW, Washington, DC 20036 USA. EM srubin@naccho.org OI Roszak, Andrew/0000-0003-1344-261X NR 42 TC 6 Z9 6 U1 0 U2 4 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1538-7135 EI 1557-850X J9 BIOSECUR BIOTERROR JI Biosecur. Bioterror. PD MAR 1 PY 2014 VL 12 IS 2 BP 76 EP 84 DI 10.1089/bsp.2013.0082 PG 9 WC Public, Environmental & Occupational Health; International Relations SC Public, Environmental & Occupational Health; International Relations GA AE7LT UT WOS:000334180100003 PM 24697207 ER PT J AU Srikiatkhachorn, A Spiropoulou, CF AF Srikiatkhachorn, Anon Spiropoulou, Christina F. TI Vascular events in viral hemorrhagic fevers: a comparative study of dengue and hantaviruses SO CELL AND TISSUE RESEARCH LA English DT Review DE Endothelium; Viral hemorrhagic fevers; Dengue viruses; Hantaviruses; Permeability ID MICROVASCULAR ENDOTHELIAL-CELLS; HANTAAN VIRUS-INFECTION; CD8(+) T-CELLS; ALPHA-INDUCED ACTIVATION; INNATE IMMUNE-RESPONSES; INDUCED LETHAL DISEASE; NECROSIS-FACTOR-ALPHA; PULMONARY SYNDROME; DENDRITIC CELLS; RENAL SYNDROME AB Viral hemorrhagic diseases are a group of systemic viral infections with worldwide distribution and are significant causes of global mortality and morbidity. The hallmarks of viral hemorrhagic fevers are plasma leakage, thrombocytopenia, coagulopathy and hemorrhagic manifestations. The molecular mechanisms leading to plasma leakage in viral hemorrhagic fevers are not well understood. A common theme has emerged in which a complex interplay between pathogens, host immune response, and endothelial cells leads to the activation of endothelial cells and perturbation of barrier integrity. In this article, two clinically distinct viral hemorrhagic fevers caused by dengue viruses and hantaviruses are discussed to highlight their similarities and differences that may provide insights into the pathogenesis and therapeutic approach. C1 [Srikiatkhachorn, Anon] Univ Massachusetts, Sch Med, Dept Med, Worcester, MA 01655 USA. [Spiropoulou, Christina F.] Ctr Dis Control & Prevent, Viral Special Pathogens Branch, Div High Consequence Pathogens & Pathol, Atlanta, GA USA. RP Srikiatkhachorn, A (reprint author), Univ Massachusetts, Sch Med, Dept Med, Worcester, MA 01655 USA. EM anon.srikiatkhachorn@umassmed.edu FU National Institutes of Health [NIH-P01AI34533] FX The findings and conclusions in this report are those of the authors and do not necessarily represent those of the Centers for Disease Control and Prevention. Part of this work was supported by National Institutes of Health Grant NIH-P01AI34533. The opinions or assertions contained herein are the private ones of the authors and are not to be construed as official or reflecting the view of the US Government. The authors thank Craig Manning for help with the illustration. NR 144 TC 7 Z9 7 U1 2 U2 12 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0302-766X EI 1432-0878 J9 CELL TISSUE RES JI Cell Tissue Res. PD MAR PY 2014 VL 355 IS 3 BP 621 EP 633 DI 10.1007/s00441-014-1841-9 PG 13 WC Cell Biology SC Cell Biology GA AE7JF UT WOS:000334173000012 PM 24623445 ER PT J AU Zubkova, I Duan, HY Wells, F Mostowski, H Chang, E Pirollo, K Krawczynski, K Lanford, R Major, M AF Zubkova, Iryna Duan, Hongying Wells, Frances Mostowski, Howard Chang, Esther Pirollo, Kathleen Krawczynski, Kris Lanford, Robert Major, Marian TI Hepatitis C Virus Clearance Correlates With HLA-DR Expression on Proliferating CD8+T Cells in Immune-Primed Chimpanzees SO HEPATOLOGY LA English DT Article ID CD8(+) T-CELLS; RECOVERED CHIMPANZEES; HCV INFECTION; YELLOW-FEVER; RESPONSES; PERSISTENCE; VACCINES; DETERMINANTS; IMMUNIZATION; REPLICATION AB Vaccination of chimpanzees against hepatitis C virus (HCV) using T-cell-based vaccines targeting nonstructural proteins has not resulted in the same levels of control and clearance as those seen in animals reexposed after HCV clearance. We hypothesized that the outcome of infection depends on the different subtypes of activated T cells. We used multicolor flow cytometry to evaluate activation (CD38+/HLA-DR+) and proliferation (Ki67+/Bcl-2-low) profiles of CD4+ and CD8+ T cells in peripheral blood before and after challenge in chimpanzees vaccinated using DNA/adenovirus, mock-vaccinated, and chimpanzees that had spontaneously cleared infection (rechallenged). The frequencies of activated or proliferating CD8+ T cells peaked at 2 weeks postchallenge in the vaccinated and rechallenged animals, coinciding with reductions in viral titers. However, the magnitude of the responses did not correlate with outcome or sustained control of viral replication. In contrast, proliferation of the CD8+ T cells coexpressing HLA-DR either with or without CD38 expression was significantly higher at challenge in animals that rapidly cleared HCV and remained so throughout the follow-up period. Conclusion: Our data suggest that the appearance of proliferating HLA-DR+/CD8+ T cells can be used as a predictor of a successfully primed memory immune response against HCV and as a marker of effective vaccination in clinical trials. (Hepatology 2014;59:803-813) C1 [Zubkova, Iryna; Duan, Hongying; Wells, Frances; Major, Marian] US FDA, Lab Hepatitis Viruses, Div Viral Prod, Ctr Biol Evaluat & Res, Bethesda, MD 20014 USA. [Mostowski, Howard] US FDA, Off Cellular & Gene Therapy, Ctr Biol Evaluat & Res, Bethesda, MD 20014 USA. [Chang, Esther; Pirollo, Kathleen] Georgetown Univ, Lombardi Comprehens Canc Ctr, Dept Oncol, Washington, DC USA. [Krawczynski, Kris] Ctr Dis Control & Prevent, Div Viral Hepatitis, NCHHSTP, Atlanta, GA USA. [Lanford, Robert] SW Fdn Biomed Res, San Antonio, TX 78284 USA. RP Major, M (reprint author), Div Viral Prod, Lab Hepatitis Viruses, Bldg 29A Rm 1D10-HFM 448,8800 Rockville Pike, Bethesda, MD 20892 USA. EM marian.major@fda.hhs.gov FU CDC; FDA; U.S. Department of Energy; U.S. Food and Drug Administration FX Supported by CDC and FDA intramural research funds. The project was supported in part by the appointment of Hongying Duan to the Research Participation Program at CBER administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the U.S. Department of Energy and the U.S. Food and Drug Administration. NR 34 TC 6 Z9 6 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD MAR PY 2014 VL 59 IS 3 BP 803 EP 813 DI 10.1002/hep.26747 PG 11 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AB4VH UT WOS:000331787500013 PM 24123114 ER EF